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 Abstract 
 
Muscle pull from regular physical activity is crucial for optimal development of the 
skeleton during growth and maintenance of bone mineral density (BMD) throughout life. 
Mitochondrial Respiratory Chain Disorders (MRCD) and Cystic Fibrosis (CF) are two 
chronic diseases that exhibit reduced lean tissue mass and impaired exercise capacity, 
which negatively impacts bone health in these populations. Whole body vibration training 
(WBVT) is an emerging therapeutic modality that has been successful in improving 
BMD and muscle mass and function in heath and disease. Aim: To evaluate whether 6 
months of home-based WBVT improves BMD, muscle function, exercise capacity and 
quality of life (QoL) in people with MRCD or CF. Methods: Participants were enrolled 
for 15-18 months: 3-6 months observation; 6 months home-based WBVT (3 x 3mins 
daily at 20Hz on a Galileo® Home vibration platform); 6 months follow-up. Participants 
attended four study visits and completed: dual energy x-ray absorptiometry (DXA) and 
peripheral quantitative computed tomography (pQCT) to assess BMD; muscle function 
testing on the Leonardo Jumping Platform (LJP); 6-minute walk test (6MWT) and/or 
formal exercise testing to assess exercise capacity; and disease specific QoL 
questionnaires. Linear mixed models analysis was used to assess changes between visits. 
Results: The MRCD cohort had 23 participants (13 male) mean (SD) age 31.0 (19.8) 
years and the CF cohort, 16 participants (8 male) mean (SD) age 12.8 (3.5) years. 
Statistically significant improvements in BMD of the legs were seen in the MRCD and 
CF cohorts for both DXA and pQCT. Muscle force during hopping and co-ordination 
during the chair rise test on the LJP improved significantly post WBVT in the CF. 
 Exercise capacity did not change in the MRCD or CF cohorts after WBVT. QoL showed 
improvements in both cohorts. Conclusions: WBVT was well tolerated. WBVT improved 
BMD, aspects of muscle function, and QoL in people with MRCD or CF and may be a 
useful adjunct to physiotherapy exercise programs. 
 
 
 
 
 
 
 
 
 
 List of Figures 
 
Figure 1.1: Mitochondrial genome. .................................................................................. 89 
Figure 1.2: Mitochondrial Respiratory Chain. Source: www.bioscience.org/2009/v14/ 
af/3509/fig5.jpg. ................................................................................................................ 93 
Figure 2.1: Child on Galileo
®
 Home vibration platform (left). Pick-up frame with 
Galileo
®
 Home vibration platform (right)....................................................................... 159 
Figure 2.2: Child having total body DXA scan (left). Adult having lumbar spine DXA 
scan (right). ..................................................................................................................... 162 
Figure 2.3: pQCT scanner showing distal end (left) and proximal end (right). .............. 166 
Figure 2.4: pQCT cross-sections at the 4%, 20% and 66% site in a MRCD patient (top) 
and CF patient (bottom). ................................................................................................. 168 
Figure 2.5: Muscle function testing on the Leonardo Mechanography Ground Reaction 
Force Plate. ..................................................................................................................... 180 
Figure 2.6: Multiple one-leg jump output. ...................................................................... 181 
Figure 2.7: Single two-leg jump output. ......................................................................... 182 
Figure 2.8: Chair-rise test output. ................................................................................... 183 
Figure 2.9: Child performing CPET (left) and pulmonary function (right). ................... 187 
Figure 3.1: Flow diagram of participant recruitment. ..................................................... 196 
Figure 3.2. Standard deviation (SD) scores for anthropometric and DXA parameters in 
the paediatric cohort. Mean and 95% confidence intervals. Parameters shown in red were 
significantly different to the reference population on one-sample t-tests, p<0.05.......... 206 
Figure 3.3. Standard deviation (SD) scores for peripheral quantitative computed 
tomography (pQCT) parameters in the paediatric cohort. Mean and 95% confidence 
interval. Parameters shown in red were significantly different to the reference population 
on one-sample t-tests, p<0.05. ........................................................................................ 223 
Figure 3.4. Standard deviation (SD) scores for force plate parameters in the paediatric 
cohort. Mean and 95% confidence interval. Parameters shown in red were significantly 
different to the reference population on one-sample t-tests, p<0.05............................... 243 
Figure 4.1: Flow diagram of Participant recruitment...................................................... 271 
 Figure 4.2. Standard deviation (SD) scores for anthropometric and DXA parameters in 
the paediatric cohort. Mean and 95% confidence intervals. Parameters shown in red were 
significantly different to the reference population on one-sample t-tests, p<0.05.......... 293 
Figure 4.3. Standard deviation (SD) scores for peripheral quantitative computed 
tomography (pQCT) parameters in the paediatric cohort. Mean and 95% confidence 
interval. Parameters shown in red were significantly different to the reference population 
on one-sample t-tests, p<0.05. ........................................................................................ 317 
Figure 4.4. Total volumetric bone mineral density (vBMD) at the 4% tibial site for 
control and MRCD adult males and females. Mean and SD. PreMP, pre-menopausal; 
PostMP, post-menopausal. *** p<0.005. Graph prepared by Dr Ferretti and colleagues.
......................................................................................................................................... 318 
Figure 4.5. Cortical bone mineral content at the 20% tibial site for control and MRCD 
adult males and females. Mean and SD. **p<0.01. Graph prepared by Dr Ferretti and 
colleagues. ....................................................................................................................... 319 
Figure 4.6. Cortical bone cross sectional area at the 20% tibial site for control and MRCD 
adult males and females. Mean and SD. **p<0.01, ***p<0.005. Graph prepared by Dr 
Ferretti and colleagues. ................................................................................................... 320 
Figure 4.7. Cortical thickness at the 20% tibial site for control and MRCD adult males 
and females. Mean and SD. PreMP, pre-menopausal; PostMP, post-menopausal. *** 
p<0.005, **p<0.01. Graph prepared by Dr Ferretti and colleagues. .............................. 320 
Figure 4.8. Periosteal circumference at the 20% tibial site for control and MRCD adult 
males and females. Mean and SD.*** p<0.005. Graph prepared by Dr Ferretti and 
colleagues. ....................................................................................................................... 321 
Figure 4.9. Cortical volumetric bone mineral density (vBMD) at the 14-20% tibial site for 
control and MRCD adult males and females. Mean and SD. PreMP, pre-menopausal; 
PostMP, post-menopausal. *** p<0.005. Graph prepared by Dr Ferretti and colleagues.
......................................................................................................................................... 321 
Figure 4.10. Cortical cross-sectional area (CSA) and cortical bone mineral content 
(BMC) at the 20% tibial site for control and MRCD adult males and females. Mean and 
SD. PreMP, pre-menopausal; PostMP, post-menopausal. Dashed line represents controls 
and solid line represents the MRCD cohort. ANCOVA analysis of the two equations 
 indicated they were significantly different, p<0.0001. Graph prepared by Dr Ferretti and 
colleagues. ....................................................................................................................... 322 
Figure 4.11. Polar CSMI at the 20% tibial site for control and MRCD adult males and 
females. Mean and SD. PreMP, pre-menopausal; PostMP, post-menopausal. *** 
p<0.005, **p<0.01. Graph prepared by Dr Ferretti and colleagues. .............................. 324 
Figure 4.12. Distribution-mass curve: Cortical cross-sectional area and polar cross-
sectional moment of inertia (CSMI) at the 20% tibial site for control and MRCD adult 
males and females. PreMP, pre-menopausal; PostMP, post-menopausal. ANCOVA 
analysis found the control and MRCD equations were significantly different, p=0.04. 
Graph prepared by Dr Ferretti and colleagues. ............................................................... 325 
Figure 4.13. Distribution-mass curve: cortical bone mineral content and polar cross-
sectional moment of inertia (CSMI) at the 20% tibial site for control and MRCD adult 
males and females. PreMP, pre-menopausal; PostMP, post-menopausal. ANCOVA 
analysis found the control and MRCD equations were significantly different, p=0.009. 
Graph prepared by Dr Ferretti and colleagues. ............................................................... 326 
Figure 4.14. Distribution-quality curve: cortical volumetric bone mineral density 
(vCtBMD) and polar cross-sectional moment of inertia (CSMI) at the 20% tibial site for 
control and MRCD adult males and females. PreMP, pre-menopausal; PostMP, post-
menopausal. Graph prepared by Dr Ferretti and colleagues. .......................................... 327 
Figure 4.15. Buckling ratio at the 20% tibial site for control and MRCD adult males and 
females. Mean and SD. PreMP, pre-menopausal; PostMP, post-menopausal. *** 
p<0.005, **p<0.01. Graph prepared by Dr Ferretti and colleagues. .............................. 328 
Figure 4.16. Cortical cross-sectional area at the 66% tibial site for control and MRCD 
adult males and females. Mean and SD. PreMP, pre-menopausal; PostMP, post-
menopausal. ***p<0.005. Graph prepared by Dr Ferretti and colleagues...................... 329 
Figure 4.17. Muscle cross-sectional area at the 66% tibial site for control and MRCD 
adult males and females. Mean and SD. PreMP, pre-menopausal; PostMP, post-
menopausal. **p<0.01, *p<0.05. Graph prepared by Dr Ferretti and colleagues. ......... 330 
Figure 4.18. Muscle cross-sectional area and cortical cross-sectional area of the tibia and 
fibula at the 66% tibial site for control and MRCD adult males and females. Bands 
indicate 1, 2 and 3 standard deviation score units around either side of the regression line. 
 PreMP, pre-menopausal; PostMP, post-menopausal. Graph prepared by Dr Ferretti and 
colleagues. ....................................................................................................................... 331 
Figure 4.19. Standard deviation (SD) scores for force plate parameters in the paediatric 
cohort. Mean and 95% confidence interval. Parameters shown in red were significantly 
different to the reference population on one-sample t-tests, p<0.05............................... 355 
Figure 4.20. Standard deviation (SD) scores for force plate parameters in the adult cohort. 
Mean and 95% confidence interval. Parameters shown in red were significantly different 
to the reference population on one-sample t-tests, p<0.05. ............................................ 357 
Figure 4.21. Standard deviation (SD) scores for force plate parameters in the Leigh 
Syndrome cohort. Mean and 95% confidence interval. Parameter in blue represent one 
participant. Parameters shown in red were significantly different to the reference 
population on one-sample t-tests, p<0.05. ...................................................................... 361 
Figure 4.22. Standard deviation (SD) scores for Quality of Life Domains in the adult 
cohort. Mean and 95% confidence interval. Parameters shown in red were significantly 
different to the reference population on one-sample t-tests, p<0.05............................... 397 
 9 
List of Tables 
 
Table 1.1: CFTR gene mutation classes. ........................................................................ 134 
Table 2.1: DXA parameters, their definitions and associated coefficients of variation. 163 
Table 2.2: pQCT settings for bone and muscle parameters at the 4%, 20% and 66% tibial 
sites. ................................................................................................................................ 169 
Table 2.3: Reference ranges for bone mass, geometry, density and strength by height 
intervals for boys and girls. ............................................................................................. 172 
Table 2.4:  Bone mineral homeostasis and turnover markers, analysis methods and 
reference data used. ......................................................................................................... 174 
Table 2.5:  Force plate parameters, reference data and coefficients of variation. .......... 177 
Table 2.6: Key search terms used in search strategy. ..................................................... 192 
Table 3.1. Participant characteristics. ............................................................................. 198 
Table 3.2. Baseline anthropometric data......................................................................... 200 
Table 3.3. Baseline dual-energy x-ray absorptiometry parameters for scans of the total 
body, lumbar spine and distal femur. Mean (SD). .......................................................... 204 
Table 3.4. DXA parameters for the CF cohort at each visit, changes between visits and p 
values. *p<0.05. .............................................................................................................. 208 
Table 3.5. Baseline peripheral quantitative computed tomography parameters for the 
tibial 4%, 20% and 66% sites. Mean (SD)...................................................................... 219 
Table 3.6. pQCT parameters for the CF cohort at each visit, changes between visits and p 
values. *p<0.05. .............................................................................................................. 227 
Table 3.7. Baseline Serum Biochemistry and Bone Turnover Marker Parameters. Mean 
(SD). ................................................................................................................................ 237 
Table 3.8. Serum biochemistry and bone turn-over marker parameters for the CF cohort 
at each visit, changes between visits and p values. *p<0.05........................................... 239 
Table 3.9. Baseline force plate parameters. Mean (SD). ................................................ 241 
Table 3.10. Baseline Cardiopulmonary Exercise Test Parameters. Mean (SD). ............ 246 
Table 3.11. Cardiopulmonary exercise test parameters for the CF cohort at each visit, 
changes between visits and p values. *p<0.05. ............................................................... 252 
 10 
Table 3.12. Baseline CFQ-R Domain Scores. Mean (SD). ............................................ 258 
Table 3.13. Pulmonary function test parameters. Mean (SD)......................................... 262 
Table 3.14. Pulmonary function test parameters at each visit, changes between visits and 
p values. *p<0.05. ........................................................................................................... 263 
Table 4.1. Participant Characteristics. ............................................................................ 272 
Table 4.2. Participant diagnoses, genetic mutations and clinical manifestations. .......... 280 
Table 4.3. Baseline anthropometric data......................................................................... 287 
Table 4.4. Baseline dual-energy x-ray absorptiometry parameters for scans of the total 
body and lumbar spine. Mean (SD). ............................................................................... 289 
Table 4.5. DXA parameters for the paediatric MRCD cohort at each visit, changes 
between visits and p values. *p<0.05. ............................................................................ 296 
Table 4.6. DXA parameters for the adult MRCD cohort at each visit, changes between 
visits and p values. *p<0.05. ........................................................................................... 302 
Table 4.7. DXA parameters for the Leigh Syndrome MRCD cohort at each visit, changes 
between visits and p values. *p<0.05. ............................................................................ 303 
Table 4.8. Baseline peripheral quantitative computed tomography parameters for the 
tibial 4%, 20% and 66% sites. Mean (SD)...................................................................... 309 
Table 4.9. pQCT parameters for the paediatric cohort MRCD cohort at each visit, 
changes between visits and p values. *p<0.05 ................................................................ 334 
Table 4.10. pQCT parameters for the Leigh Syndrome cohort at each visit, changes 
between visits and p values. *p<0.05. ............................................................................ 343 
Table 4.11. pQCT parameters for the adult MRCD cohort at each visit, changes between 
visits and p values. *p<0.05. ........................................................................................... 346 
Table 4.12. Baseline Serum Biochemistry and Bone Turnover Marker Parameters. Mean 
(SD). ................................................................................................................................ 350 
Table 4.13. Bone turn-over markers and serum biochemistry parameters for the paediatric 
cohort at each visit, changes between visits and p values. *p<0.05. .............................. 351 
Table 4.14. Bone turn-over markers and serum biochemistry parameters for the Leigh 
Syndrome cohort at each visit, changes between visits and p values. *p<0.05. ............. 352 
Table 4.15. Baseline Force-plate parameters. Mean (SD). ............................................. 358 
 11 
Table 4.16. CRT parameters for the paediatric MRCD cohort at each visit, changes 
between visits and p values. *p<0.05. ............................................................................ 362 
Table 4.17. CRT parameters for the adult sub-cohort at each visit, changes between visits 
and p values. *p<0.05. .................................................................................................... 364 
Table 4.18. CRT parameters for the Leigh Syndrome cohort at each visit, changes 
between visits and p values. *p<0.05. ............................................................................ 368 
Table 4.19. Baseline 6MWT parameters. Mean (SD). ................................................... 370 
Table 4.20. Six-minute walk test parameters for the paediatric cohort at each visit, 
changes between visits and p values. *p<0.05. ............................................................... 374 
Table 4.21. 6MWT parameters for the Leigh Syndrome cohort at each visit, changes 
between visits and p values. *p<0.05. ............................................................................ 376 
Table 4.22. Baseline Cardiopulmonary Exercise Test Parameters. Mean (SD). ............ 383 
Table 4.23.  CPET parameters for the adult MRCD cohort at each visit, changes between 
visits and p values. *p<0.05. ........................................................................................... 390 
Table 4.24. Baseline Disease Scale and Quality of Life Scores for the paediatric and 
Leigh Syndrome cohorts. Mean (SD). ............................................................................ 394 
Table 4.25. Baseline Disease Scale and Quality of Life Scores for the adult cohort. Mean 
(SD). ................................................................................................................................ 396 
Table 4.26. Newcastle Paediatric Mitochondrial Disease Scale parameters for the 
paediatric cohort at each visit, changes between visits and p values. *p<0.05............... 399 
Table 4.27. Newcastle Mitochondrial Disease Adult Scale and Quality of Life parameters 
for the adult cohort at each visit, changes between visits and p values. *p<0.05. .......... 400 
Table 4.28. Newcastle Paediatric Mitochondrial Disease Scale parameters for the Leigh 
Syndrome cohort at each visit, changes between visits and p values. *p<0.05. ............. 402 
 12 
Table of Contents 
1 INTRODUCTION .............................................................................................................................. 27 
1.1 BONE STRUCTURE, FUNCTION AND BIOLOGY ................................................................................. 27 
1.2 BONE CELLS ..................................................................................................................................... 29 
1.2.1 OSTEOBLASTS .............................................................................................................................................. 29 
1.2.2 OSTEOCLASTS ............................................................................................................................................... 31 
1.2.3 OSTEOCYTES ................................................................................................................................................. 32 
1.3 BONE STRENGTH ............................................................................................................................. 37 
1.3.1 BONE REMODELLING ................................................................................................................................... 38 
1.3.2 BONE MODELLING ....................................................................................................................................... 40 
1.3.3 WOLFF’S LAW, THE MECHANOSTAT THEORY AND THE UTAH PARADIGM ....................................... 42 
1.3.4 THE FUNCTIONAL MUSCLE-BONE UNIT ................................................................................................. 45 
1.4 OPTIMISING BONE HEALTH ............................................................................................................ 47 
1.4.1 PEAK BONE MASS ........................................................................................................................................ 47 
1.4.2 NUTRITION ................................................................................................................................................... 48 
1.4.3 WEIGHT-BEARING PHYSICAL ACTIVITY .................................................................................................. 48 
1.4.4 ENDOCRINE FACTORS ................................................................................................................................. 53 
1.5 OSTEOPOROSIS ................................................................................................................................ 55 
1.6 ASSESSMENT OF BONE HEALTH ..................................................................................................... 57 
1.6.1 BONE MINERAL DENSITY AND BONE GEOMETRY ................................................................................. 57 
1.6.1.1 DXA Scans ............................................................................................................................................... 59 
1.6.1.2 pQCT scans ............................................................................................................................................. 61 
 13 
1.6.2 BONE TURNOVER MARKERS...................................................................................................................... 65 
1.7 WHOLE-BODY VIBRATION TRAINING ............................................................................................ 65 
1.7.1 HOW IT WORKS ........................................................................................................................................... 65 
1.7.2 EFFECTS ON BONE ....................................................................................................................................... 70 
1.7.3 EFFECTS ON MUSCLE .................................................................................................................................. 74 
1.7.4 EFFECTS ON FUNCTION .............................................................................................................................. 82 
1.7.5 ADVERSE EVENTS ........................................................................................................................................ 86 
1.8 MITOCHONDRIAL STRUCTURE, FUNCTION AND GENETICS ............................................................ 87 
1.8.1 MITOCHONDRIAL GENETICS ...................................................................................................................... 87 
1.8.2 MITOCHONDRIAL STRUCTURE .................................................................................................................. 91 
1.8.3 ATP GENERATION - THE MITOCHONDRIAL RESPIRATORY CHAIN .................................................... 92 
1.8.3.1 Complex I ................................................................................................................................................ 93 
1.8.3.2 Complex II .............................................................................................................................................. 94 
1.8.3.3 Complex III ............................................................................................................................................. 94 
1.8.3.4 Complex IV ............................................................................................................................................. 95 
1.8.3.5 Complex V .............................................................................................................................................. 95 
1.9 MITOCHONDRIAL RESPIRATORY CHAIN DISORDERS ................................................................... 95 
1.9.1 MUTATIONS IN MTDNA ............................................................................................................................. 96 
1.9.1.1 Large-scale deletions ......................................................................................................................... 96 
1.9.1.2 Point mutations ................................................................................................................................... 97 
1.9.2 MUTATIONS IN NDNA ................................................................................................................................ 98 
1.9.2.1 Mutations in genes encoding MRC subunits ............................................................................ 99 
1.9.2.2 Mutations in genes encoding MRC assembly or ancillary proteins................................ 99 
1.9.2.3 Mutations in genes associated with mtDNA translation .................................................. 101 
 14 
1.9.2.4 Mutations in genes involved in the structural composition of the inner 
mitochondrial membrane ............................................................................................................................... 102 
1.9.2.5 Mutations in genes affecting mitochondrial dynamics .................................................... 103 
1.9.2.6 Mutations in genes interfering with mitochondrial DNA maintenance .................... 104 
1.9.3 MRCD CLINICAL PRESENTATION.......................................................................................................... 107 
1.9.3.1 Prevalence of MRCD ........................................................................................................................ 108 
1.9.3.2 Tissue Selectivity in MRCD ........................................................................................................... 110 
1.9.3.3 Clinical Heterogeneity in MRCD ................................................................................................. 118 
1.9.3.3.1 Progressive External Opthalmoplegia (PEO) .................................................................... 121 
1.9.3.3.2 Mutations in the Nuclear Encoded POLG gene ................................................................. 121 
1.9.3.4 Mitochondrial Respiratory Chain Complex Involvement in MRCD ............................. 123 
1.9.3.5 Leigh Syndrome ................................................................................................................................ 125 
1.9.3.6 Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes 
(MELAS) Syndrome ........................................................................................................................................... 127 
1.9.3.7 Kearns-Sayre Syndrome (KSS) ................................................................................................... 129 
1.9.4 TREATMENT OF MRCD ........................................................................................................................... 130 
1.10 CYSTIC FIBROSIS .......................................................................................................................... 132 
1.10.1 CHARACTERISTICS OF CFBD ................................................................................................................ 136 
1.10.1.1 Bone Density in Cystic Fibrosis ............................................................................................... 136 
1.10.1.2 Increased risk of fragility fractures ........................................................................................ 140 
1.10.1.3 Un-coupled bone turnover ........................................................................................................ 142 
1.10.2 RISK FACTORS INVOLVED IN THE PATHOGENESIS OF CFBD ........................................................... 144 
1.10.2.1 Influence of the CFTR protein .................................................................................................. 144 
1.10.2.2 Disease severity and chronic inflammation ....................................................................... 146 
1.10.2.3 Pubertal delay and hypogonadism ......................................................................................... 149 
 15 
1.10.2.4 Nutritional factors ......................................................................................................................... 150 
1.10.2.5 Weight bearing physical activity and lean tissue ............................................................. 151 
1.11 SUMMARY ..................................................................................................................................... 152 
1.12 AIMS ............................................................................................................................................. 152 
1.13 HYPOTHESES ................................................................................................................................ 153 
2 METHODS ....................................................................................................................................... 154 
2.1 ETHICS ............................................................................................................................................ 154 
2.2 PARTICIPANT RECRUITMENT ....................................................................................................... 154 
2.3 INCLUSION CRITERIA ..................................................................................................................... 155 
2.4 EXCLUSION CRITERIA .................................................................................................................... 156 
2.5 STUDY DESIGN ............................................................................................................................... 157 
2.5.1 VISIT STRUCTURE ..................................................................................................................................... 160 
2.6 OUTCOME MEASURES .................................................................................................................... 161 
2.6.1 ANTHROPOMETRIC MEASURES .............................................................................................................. 161 
2.6.2 BONE PARAMETERS ................................................................................................................................. 161 
2.6.2.1 DXA ........................................................................................................................................................ 161 
2.6.2.2 pQCT ...................................................................................................................................................... 166 
2.6.2.3 Bone Turnover Markers ................................................................................................................ 168 
2.6.3 MUSCLE FUNCTION TESTING ................................................................................................................. 175 
2.6.3.1 Multiple One-leg Jump (M1LJ) .................................................................................................... 180 
2.6.3.2 Single Two-leg Jump (S2LJ) ......................................................................................................... 181 
2.6.3.3 Chair-rise Test (CRT) ...................................................................................................................... 182 
2.6.4 EXERCISE TESTING ................................................................................................................................... 183 
2.6.4.1 Six Minute Walk Test ...................................................................................................................... 183 
 16 
2.6.4.2 Formal Cardiopulmonary Exercise Testing .......................................................................... 184 
2.6.5 DISEASE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE ...................................................................... 188 
2.6.5.1 Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) and Newcastle 
Mitochondrial Disease Scale (NMDS) ......................................................................................................... 188 
2.6.5.2 The Cystic Fibrosis Questionnaire (CRQ-R) .......................................................................... 189 
2.6.6 ADHERENCE TO TRAINING ...................................................................................................................... 190 
2.6.7 CYSTIC FIBROSIS SPECIFIC OUTCOME MEASURES .............................................................................. 190 
2.6.7.1 Pulmonary Function Tests ........................................................................................................... 190 
2.6.8 SEARCH STRATEGY ................................................................................................................................... 191 
2.6.9 POWER CALCULATION ............................................................................................................................. 194 
2.6.10 STATISTICAL ANALYSIS ......................................................................................................................... 194 
3 CF RESULTS .................................................................................................................................... 195 
3.1 PARTICIPANTS ............................................................................................................................... 195 
3.2 ANTHROPOMETRIC PARAMETERS ................................................................................................ 197 
3.3 BONE PARAMETERS ...................................................................................................................... 201 
3.3.1 DXA ............................................................................................................................................................ 201 
3.3.1.1 Baseline ................................................................................................................................................ 201 
3.3.1.2 Observation Period ......................................................................................................................... 207 
3.3.1.3 WBVT Period ..................................................................................................................................... 214 
3.3.1.4 Follow-up Period .............................................................................................................................. 215 
3.3.2 TIBIAL PQCT ............................................................................................................................................. 217 
3.3.2.1 Baseline ................................................................................................................................................ 217 
3.3.2.2 Observation Period ......................................................................................................................... 223 
3.3.2.3 WBVT Period ..................................................................................................................................... 225 
 17 
3.3.2.4 Follow-up Period .............................................................................................................................. 236 
3.3.3 SERUM BIOCHEMISTRY AND BONE TURN-OVER MARKERS .............................................................. 237 
3.3.3.1 Baseline ................................................................................................................................................ 237 
3.3.3.2 Study Periods ..................................................................................................................................... 239 
3.4 FORCE-PLATE PARAMETERS ......................................................................................................... 240 
3.4.1 BASELINE ................................................................................................................................................... 240 
3.4.2 OBSERVATION PERIOD ............................................................................................................................ 243 
3.4.3 WBVT PERIOD ......................................................................................................................................... 244 
3.4.4 FOLLOW-UP PERIOD ................................................................................................................................ 246 
3.5 EXERCISE TESTS ............................................................................................................................ 246 
3.5.1 BASELINE ................................................................................................................................................... 250 
3.5.2 OBSERVATION PERIOD ............................................................................................................................ 256 
3.5.3 WBVT PERIOD ......................................................................................................................................... 257 
3.5.4 FOLLOW-UP PERIOD ................................................................................................................................ 257 
3.6 REVISED CYSTIC FIBROSIS QUESTIONNAIRE (CFQ-R) .............................................................. 258 
3.6.1 BASELINE ................................................................................................................................................... 258 
3.6.2 OBSERVATION PERIOD ............................................................................................................................ 260 
3.6.3 WBVT PERIOD ......................................................................................................................................... 260 
3.6.4 FOLLOW-UP PERIOD ................................................................................................................................ 261 
3.7 PULMONARY FUNCTION TESTS .................................................................................................... 261 
3.7.1 BASELINE ................................................................................................................................................... 261 
3.7.2 STUDY PERIODS ........................................................................................................................................ 261 
3.8 ADHERENCE ................................................................................................................................... 264 
3.9 SUMMARY OF FINDINGS ................................................................................................................ 264 
3.9.1 BASELINE ................................................................................................................................................... 264 
 18 
3.9.2 OBSERVATION PERIOD ............................................................................................................................ 266 
3.9.3 WBVT PERIOD ......................................................................................................................................... 267 
3.9.4 FOLLOW-UP PERIOD ................................................................................................................................ 269 
4 MRCD RESULTS ............................................................................................................................. 271 
4.1 PARTICIPANTS ............................................................................................................................... 271 
4.2 ANTHROPOMETRIC PARAMETERS ................................................................................................ 285 
4.2.1 PAEDIATRIC COHORT ............................................................................................................................... 285 
4.2.2 ADULT COHORT ........................................................................................................................................ 286 
4.2.3 LEIGH SYNDROME COHORT .................................................................................................................... 287 
4.3 BONE PARAMETERS ...................................................................................................................... 289 
4.3.1 DXA ............................................................................................................................................................ 289 
4.3.1.1 Baseline ................................................................................................................................................ 289 
4.3.1.1.1 Paediatric Cohort .......................................................................................................................... 291 
4.3.1.1.2 Adult Cohort ................................................................................................................................... 293 
4.3.1.1.3 Leigh Syndrome Cohort ............................................................................................................. 294 
4.3.1.2 Observation Period ......................................................................................................................... 294 
4.3.1.2.1 Paediatric Cohort .......................................................................................................................... 294 
4.3.1.2.2 Adult Cohort ................................................................................................................................... 301 
4.3.1.2.3 Leigh Syndrome Cohort ............................................................................................................. 301 
4.3.1.3 Whole Body Vibration Training (WBVT) Period ................................................................ 304 
4.3.1.3.1 Paediatric Cohort .......................................................................................................................... 304 
4.3.1.3.2 Adult Cohort ................................................................................................................................... 305 
4.3.1.3.3 Leigh Syndrome Cohort ............................................................................................................. 306 
4.3.1.4 Follow-up Period .............................................................................................................................. 306 
 19 
4.3.1.4.1 Paediatric Cohort .......................................................................................................................... 306 
4.3.1.4.2 Adult Cohort ................................................................................................................................... 307 
4.3.1.4.3 Leigh Syndrome Cohort ............................................................................................................. 308 
4.3.2 TIBIAL PQCT ............................................................................................................................................. 308 
4.3.2.1 Baseline ................................................................................................................................................ 308 
4.3.2.1.1 Paediatric Cohort .......................................................................................................................... 315 
4.3.2.1.2 Adult Cohort ................................................................................................................................... 317 
4.3.2.1.3 Leigh Syndrome Cohort ............................................................................................................. 331 
4.3.2.2 Whole Body Vibration Training (WBVT) Period ................................................................ 332 
4.3.2.2.1 Paediatric Cohort .......................................................................................................................... 332 
4.3.2.2.2 Adult Cohort ................................................................................................................................... 342 
4.3.2.2.3 Leigh Syndrome Cohort ............................................................................................................. 342 
4.3.2.3 Follow-up Period .............................................................................................................................. 345 
4.3.2.3.1 Paediatric Cohort .......................................................................................................................... 345 
4.3.2.3.2 Adult Cohort ................................................................................................................................... 346 
4.3.2.3.3 Leigh Syndrome Cohort ............................................................................................................. 347 
4.3.3 BONE TURNOVER MARKERS AND SERUM BIOCHEMISTRY ................................................................ 347 
4.3.3.1 Baseline ................................................................................................................................................ 347 
4.3.3.2 Study Periods ..................................................................................................................................... 349 
4.3.3.2.1 Paediatric Cohort .......................................................................................................................... 349 
4.3.3.2.2 Adult Cohort ................................................................................................................................... 349 
4.3.3.2.3 Leigh Syndrome Cohort ............................................................................................................. 351 
4.4 FORCE PLATE PARAMETERS ......................................................................................................... 353 
4.4.1 BASELINE ................................................................................................................................................... 353 
4.4.1.1 Paediatric Cohort ............................................................................................................................. 353 
 20 
4.4.1.2 Adult Cohort ....................................................................................................................................... 355 
4.4.1.3 Leigh Syndrome Cohort ................................................................................................................. 360 
4.4.2 OBSERVATION PERIOD ............................................................................................................................ 361 
4.4.3 WBVT PERIOD ......................................................................................................................................... 362 
4.4.3.1 Paediatric Cohort ............................................................................................................................. 362 
4.4.3.2 Adult Cohort ....................................................................................................................................... 363 
4.4.3.3 Leigh Syndrome Cohort ................................................................................................................. 366 
4.4.4 FOLLOW-UP PERIOD ................................................................................................................................ 366 
4.4.4.1 Paediatric Cohort ............................................................................................................................. 366 
4.4.4.2 Adult Cohort ....................................................................................................................................... 366 
4.4.4.3 Leigh Syndrome Cohort ................................................................................................................. 367 
4.5 EXERCISE PARAMETERS ................................................................................................................ 369 
4.5.1 SIX MINUTE WALK TEST (6MWT) ...................................................................................................... 369 
4.5.1.1 Baseline ................................................................................................................................................ 369 
4.5.1.1.1 Paediatric Cohort .......................................................................................................................... 369 
4.5.1.1.2 Adult Cohort ................................................................................................................................... 372 
4.5.1.1.3 Leigh Syndrome Cohort ............................................................................................................. 372 
4.5.1.2 Observation Period ......................................................................................................................... 373 
4.5.1.2.1 Paediatric Cohort .......................................................................................................................... 373 
4.5.1.2.2 Adult Cohort ................................................................................................................................... 373 
4.5.1.2.3 Leigh Syndrome Cohort ............................................................................................................. 375 
4.5.1.3 WBVT Period ..................................................................................................................................... 377 
4.5.1.3.1 Paediatric Cohort .......................................................................................................................... 377 
4.5.1.3.2 Adult Cohort ................................................................................................................................... 377 
4.5.1.3.3 Leigh Syndrome Cohort ............................................................................................................. 378 
 21 
4.5.1.4 Follow-up Period .............................................................................................................................. 378 
4.5.1.4.1 Paediatric Cohort .......................................................................................................................... 378 
4.5.1.4.2 Adult Cohort ................................................................................................................................... 379 
4.5.1.4.3 Leigh Syndrome Cohort ............................................................................................................. 379 
4.5.2 CARDIO-PULMONARY EXERCISE TESTING (CPET) ............................................................................ 379 
4.5.2.1 Baseline ................................................................................................................................................ 380 
4.5.2.2 Observation Period ......................................................................................................................... 387 
4.5.2.2.1 Adult Cohort ................................................................................................................................... 387 
4.5.2.3 WBVT Period ..................................................................................................................................... 387 
4.5.2.3.1 Adult Cohort ................................................................................................................................... 388 
4.5.2.4 Follow-up Period .............................................................................................................................. 388 
4.5.2.4.1 Adult Cohort ................................................................................................................................... 388 
4.6 DISEASE SCALE AND QUALITY OF LIFE PARAMETERS ................................................................ 394 
4.6.1 BASELINE ................................................................................................................................................... 394 
4.6.1.1 Paediatric Cohort ............................................................................................................................. 394 
4.6.1.2 Adult Cohort ....................................................................................................................................... 395 
4.6.1.3 Leigh Syndrome Cohort ................................................................................................................. 397 
4.6.2 STUDY PERIODS ........................................................................................................................................ 398 
4.6.2.1 Paediatric Cohort ............................................................................................................................. 398 
4.6.2.2 Adult Cohort ....................................................................................................................................... 400 
4.6.2.3 Leigh Syndrome Cohort ................................................................................................................. 401 
4.7 ADHERENCE ................................................................................................................................... 403 
4.8 SUMMARY OF FINDINGS ................................................................................................................ 403 
4.8.1 PAEDIATRIC COHORT ............................................................................................................................... 403 
4.8.1.1 Baseline ................................................................................................................................................ 403 
 22 
4.8.1.2 Observation Period ......................................................................................................................... 408 
4.8.1.3 WBVT Period ..................................................................................................................................... 410 
4.8.1.4 Follow-up period .............................................................................................................................. 411 
4.8.2 ADULT COHORT ........................................................................................................................................ 412 
4.8.2.1 Baseline ................................................................................................................................................ 412 
4.8.2.2 Observation Period ......................................................................................................................... 415 
4.8.2.3 WBVT Period ..................................................................................................................................... 416 
4.8.2.4 Follow-up Period .............................................................................................................................. 417 
4.8.3 LEIGH SYNDROME COHORT .................................................................................................................... 418 
4.8.3.1 Baseline ................................................................................................................................................ 418 
4.8.3.2 Observation Period ......................................................................................................................... 419 
4.8.3.3 WBVT Period ..................................................................................................................................... 419 
4.8.3.4 Follow-up Period .............................................................................................................................. 420 
5 DISCUSSION.................................................................................................................................... 422 
5.1 PAEDIATRIC PERSPECTIVE ........................................................................................................... 422 
5.1.1 EFFECT OF WBVT ON BONE AND BODY COMPOSITION PARAMETERS .......................................... 422 
5.1.1.1 WBVT Period ..................................................................................................................................... 422 
5.1.1.1.1 Trabecular Bone Compartment .............................................................................................. 422 
5.1.1.1.1.1 Bone Mass .................................................................................................................................... 423 
5.1.1.1.1.1.1 Summary .................................................................................................................................. 425 
5.1.1.1.1.2 Bone Density ............................................................................................................................... 426 
5.1.1.1.1.2.1 Summary .................................................................................................................................. 431 
5.1.1.1.2 Cortical Bone Compartment .................................................................................................... 432 
5.1.1.1.2.1 Bone Mass .................................................................................................................................... 432 
 23 
5.1.1.1.2.2 Bone Density ............................................................................................................................... 438 
5.1.1.1.2.3 Bone Area and Geometry....................................................................................................... 444 
5.1.1.1.2.4 Bone Strength ............................................................................................................................. 448 
5.1.1.1.2.5 Body composition ..................................................................................................................... 450 
5.1.1.1.2.6 Bone Biochemistry and Turnover Markers ................................................................... 454 
5.1.2 FOLLOW-UP PERIOD ................................................................................................................................ 456 
5.1.2.1 Trabecular bone compartment .................................................................................................. 456 
5.1.2.1.1 Bone Mass and Density .............................................................................................................. 456 
5.1.2.2 Cortical bone compartment ......................................................................................................... 459 
5.1.2.2.1 Bone Mass ........................................................................................................................................ 459 
5.1.2.2.2 Bone Density .................................................................................................................................. 460 
5.1.2.2.3 Bone Area and Geometry .......................................................................................................... 462 
5.1.2.2.4 Bone Strength ................................................................................................................................ 463 
5.1.2.2.5 Body Composition ........................................................................................................................ 464 
5.1.2.2.6 Bone Biochemistry and Turnover Markers ....................................................................... 465 
5.1.3 EFFECT OF WBVT ON FORCE PLATE PARAMETERS .......................................................................... 466 
5.1.3.1 WBVT Period ..................................................................................................................................... 466 
5.1.3.2 Follow-up Period .............................................................................................................................. 470 
5.1.4 EFFECT OF WBVT ON EXERCISE CAPACITY ........................................................................................ 471 
5.1.4.1 WBVT Period ..................................................................................................................................... 472 
5.1.4.2 Follow-up Period .............................................................................................................................. 474 
5.1.5 EFFECT OF WBVT ON QUALITY OF LIFE .............................................................................................. 476 
5.1.5.1 WBVT Period ..................................................................................................................................... 476 
5.1.5.2 Follow-up Period .............................................................................................................................. 477 
5.2 ADULT PERSPECTIVE..................................................................................................................... 478 
 24 
5.2.1 EFFECT OF WBVT ON BONE AND BODY COMPOSITION PARAMETERS .......................................... 478 
5.2.1.1 WBVT Period ..................................................................................................................................... 478 
5.2.1.1.1 Trabecular Bone Compartment .............................................................................................. 478 
5.2.1.1.1.1 Bone Mass .................................................................................................................................... 478 
5.2.1.1.2 Cortical Bone Compartment .................................................................................................... 482 
5.2.1.1.2.1 Bone Mass .................................................................................................................................... 482 
5.2.1.1.2.2 Bone Density ............................................................................................................................... 483 
5.2.1.1.2.3 Bone Area and Geometry....................................................................................................... 486 
5.2.1.1.2.4 Bone Strength ............................................................................................................................. 487 
5.2.1.1.2.5 Body Composition .................................................................................................................... 488 
5.2.1.1.2.6 Bone Biochemistry and Turn-over Markers .................................................................. 491 
5.2.1.2 Follow-up Period .............................................................................................................................. 496 
5.2.1.2.1 Trabecular Bone Compartment .............................................................................................. 496 
5.2.1.2.1.1 Bone Mass and Density .......................................................................................................... 496 
5.2.1.2.2 Cortical Bone Compartment .................................................................................................... 496 
5.2.1.2.2.1 Bone Mass and Density .......................................................................................................... 497 
5.2.1.2.2.2 Bone Area, Geometry and Strength ................................................................................... 498 
5.2.1.2.2.3 Body Composition .................................................................................................................... 499 
5.2.1.2.2.4 Bone Biochemistry and Turnover Markers ................................................................... 500 
5.2.2 EFFECT OF WBVT ON FORCE PLATE PARAMETERS .......................................................................... 501 
5.2.2.1 WBVT Period ..................................................................................................................................... 501 
5.2.2.1.1 Multiple One-leg Jump (M1LJ) ................................................................................................ 501 
5.2.2.1.2 Single Two-leg Jump (S2LJ) ...................................................................................................... 507 
5.2.2.1.3 Chair-rise Test (CRT) .................................................................................................................. 515 
5.2.2.1.3.1 Chair-rise Summary ................................................................................................................. 518 
 25 
5.2.2.2 Follow-up Period .............................................................................................................................. 520 
5.2.2.2.1 Multiple One-leg Jump ................................................................................................................ 520 
5.2.2.2.2 Single Two-leg Jump ................................................................................................................... 520 
5.2.2.2.3 Chair-rise Test ............................................................................................................................... 522 
5.2.3 EFFECT OF WBVT ON EXERCISE CAPACITY ........................................................................................ 523 
5.2.3.1 WBVT Period ..................................................................................................................................... 523 
5.2.3.1.1 Six-minute Walk Test (6MWT) ............................................................................................... 523 
5.2.3.1.2 Cardiopulmonary Exercise Test ............................................................................................. 526 
5.2.3.1.3 Summary .......................................................................................................................................... 526 
5.2.3.2 Follow-up Period .............................................................................................................................. 528 
5.2.3.2.1 Six-minute Walk test ................................................................................................................... 528 
5.2.3.2.2 Cardiopulmonary Exercise Test ............................................................................................. 528 
5.2.4 EFFECT OF WBVT ON THE MITOCHONDRIAL DISEASE SCALE AND QUALITY OF LIFE ................ 529 
5.2.4.1 WBVT Period ..................................................................................................................................... 529 
5.2.4.2 Follow-up Period .............................................................................................................................. 532 
5.3 LEIGH SYNDROME .......................................................................................................................... 533 
5.3.1 EFFECT OF WBVT ON BONE AND BODY COMPOSITION PARAMETERS .......................................... 533 
5.3.1.1 WBVT Period ..................................................................................................................................... 533 
5.3.1.2 Follow-up Period .............................................................................................................................. 534 
5.3.2 EFFECT OF WBVT ON FORCE PLATE PARAMETERS .......................................................................... 535 
5.3.2.1 WBVT Period ..................................................................................................................................... 535 
5.3.2.2 Follow-up Period .............................................................................................................................. 535 
5.3.3 EFFECT OF WBVT ON EXERCISE CAPACITY ........................................................................................ 536 
5.3.3.1.1 Six-minute Walk Test (6MWT) ............................................................................................... 536 
5.3.3.2 WBVT Period ..................................................................................................................................... 536 
 26 
5.3.3.3 Follow-up Period .............................................................................................................................. 537 
5.3.4 EFFECT OF WBVT ON THE MITOCHONDRIAL DISEASE SCALE AND QUALITY OF LIFE ................ 537 
5.3.4.1 WBVT Period ..................................................................................................................................... 537 
5.3.4.2 Follow-up Period .............................................................................................................................. 537 
6 CONCLUSIONS, LIMITATIONS AND FUTURE DIRECTIONS ............................................. 539 
7 APPENDICES .................................................................................................................................. 544 
8 REFERENCES .................................................................................................................................. 681 
 27 
1 Introduction 
 
 
This study aims to evaluate the effects of six-months home-based whole-body vibration 
training on bone and muscle structure and function in young people with chronic 
diseases. In order to put this study into context, bone structure and function, bone health, 
whole-body vibration training, mitochondrial respiratory chain disorders and cystic 
fibrosis will be discussed. 
 
1.1 Bone structure, function and biology 
 
Bone is a biologically active tissue that is involved in several important physiological 
processes. The adult human body has 206 bones that together form the skeleton. It 
provides a structural scaffold for muscle attachments enabling movement and upright 
locomotion. It also protectively houses the vital organs and, within the marrow 
compartment, is involved in haematopoiesis. It also has an important role in calcium and 
phosphorus mineral homeostasis and acid-base balance and is a reservoir of growth 
factors and cytokines [1]. 
 
Bone is composed of 50-70% mineral, 20-40% organic extra-cellular matrix, 5-10% 
water and less than 3% fat [1]. Bone mineral is predominantly hydroxyapatite 
(Ca5(POD)3OH), this inorganic compound providing the bone with load bearing strength 
and mechanical rigidity [1]. The organic extra-cellular matrix is comprised of 
collagenous and non-collagenous proteins which make up approximately 85% and 15% 
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of all bone protein respectively [1-3]. The collagenous component primarily consists of 
type 1 collagen which provides the structural scaffold upon which bone mineralisation 
occurs and the non-collagenous component is believed to help regulate mineralisation of 
the matrix [1]. This organic extra-cellular matrix gives bone it’s elasticity and flexibility 
[1]. The arrangement of these organic and inorganic components determines bone type 
[4]. The adult skeleton consists of two main bone types, cortical bone which accounts for 
80% of the skeleton, and trabecular bone, which accounts for the remaining 20% [1]. 
Both cortical and trabecular bone are composed of osteons organised in a lamellar 
pattern, where collagen fibres are arranged in alternating directions to give lamellar bone 
its strength [1], however their structure is quite different.  
 
Trabecular osteons are organised into parallel lamellae to form a honeycomb type 
network of plates and rods within the marrow cavity. Trabecular bone is the primary type 
of bone found in the vertebrae and in the metaphyses and epiphyses at the ends of long 
bones e.g. the humerus and tibia. Cortical bone is denser and more solid compared to 
trabecular bone. Cortical osteons form branching networks in cortical bone called 
Haversian systems, the walls of which are formed by concentric lamellae [1]. Haversian 
canals contain a blood vessel which is connected to neighbouring Haversian blood 
vessels by Volkmann’s canals. The walls of the Haversian canals have rectangular shaped 
lacunae embedded within them in which osteocytes reside. Cortical bone forms a thin 
shell around the boundary of trabecular bone and constitutes the shaft or diaphysis of 
long bones [1]. 
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Long bones are designed to have a hollow shaft, or diaphysis, with flared ends that 
participate in articulation with their adjacent bones. The proximal and distal ends of long 
bones are lined with cartilage under which lies the bony epiphysis. Adjacent to the 
epiphysis is the metaphysis which transitions into the diaphysis through metaphyseal in-
wasting. The metaphysis and epiphysis are separate compartments during skeletal growth 
due to the presence of the growth plate, but become fused in the mature adult skeleton. 
Cortical bone in the diaphysis has an outer periosteal surface which is attached to a two-
layered fibrous connective tissue, called the periosteum. This periosteal surface has an 
important role in fracture repair and is the surface upon which appositional growth 
occurs. The inner surface of the hollow diaphysis, adjacent to the marrow cavity, is the 
endosteal surface. It is lined with a vascular connective tissue called the endosteum which 
is in contact with the bone marrow cavity and blood vessels. Endosteum tissue is also 
present in trabecular bone and in Volkmann’s canals [1]. 
 
1.2 Bone Cells 
 
 
1.2.1 Osteoblasts 
 
Osteoblasts are single nucleated cells responsible for the synthesis and mineralisation of 
new extra-cellular bone matrix [1, 3]. During the formation of new bone, osteoblasts 
secrete type 1 collagen which becomes the scaffold upon which mineralisation occurs. 
Osteoblasts also secrete several non-collagenous proteins believed to be integral in 
regulating the mineralisation process [2]. Two of the most abundant non-collagenous 
protein secreted by osteoblasts are osteonectin and osteocalcin which are involved in 
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osteoblast growth and proliferation, and calcium binding and stabilisation of 
hydroxyapatite respectively [1, 3]. Bone matrix mineralisation is achieved by osteoblasts 
through the secretion of specialised vesicles. Alkaline phosphatase in osteoblast 
membranes helps to transport phosphate into the vesicles and create a protected alkaline 
environment in the vesicles allowing the accumulation of calcium and phosphate and the 
precipitation of hydroxyapatite crystals. Together with the non-collagenous proteins, 
alkaline phosphatase is believed to be involved in regulating the amount and size of 
hydroxyapatite crystal formed and it’s ordered deposition in the matrix [1, 5].  
 
Growth and proliferation of the hydroxyapatite crystals eventually ruptures the vesicle, 
exposing the hydroxyapatite crystals to the matrix. Bone mineralisation commences 
approximately two weeks after the release of bone matrix from the osteoblasts. The 
mineralisation process appears to have two stages, primary mineralisation, where nearly 
three quarters of the bone matrix is mineralised within a few days, followed by a 
secondary mineralisation process, which occurs over 6 months [6]. As the bone matures 
the hydroxyapatite crystals enlarge as mineral continues to be added to the matrix 
resulting in crystal growth and aggregation [1]. Vitamin D is an important co-factor in 
bone mineralisation as it is involved in the intestinal absorption of calcium and 
phosphorus and promotes osteoblast differentiation and the expression of osteocalcin, 
osteonectin, alkaline phosphatase, osteoprotegerin (OPG) and other cytokines involved in 
bone formation [1]. Serum concentrations of osteocalcin, secreted by osteoblasts, and 
alkaline phosphatase, released from osteoblast membranes during vesicle rupture, are 
markers of bone formation activity [1]. 
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Osteoblast differentiation and activity is dependent on the Wnt/beta catenin pathway, 
which appears to be controlled by the osteocyte (discussed later) [7, 8]. Osteoblasts from 
the axial and appendicular skeleton differentially express genes and respond differently to 
hormonal, mechanical and cytokine exposure [1]. After completing their role in the 
formation of new bone, the majority of osteoblasts undergo apoptosis with smaller 
percentages becoming osteocytes, trapped within the bone matrix they have laid down, or 
bone lining cells, which form the endosteum in trabecular bone and line the endosteal and 
periosteal surfaces of cortical bone [1, 3, 8, 9]. 
 
1.2.2 Osteoclasts 
 
Osteoclasts are large multinucleated cells capable of resorbing both the organic and 
inorganic components of bone [3]. Bone resorption is achieved by the formation of a 
sealed micro-environment where the osteocyte binds to the bone matrix. This site 
becomes an isolated acidified compartment where resorption can take place [10]. The 
osteocyte secretes the cathepsin K enzyme, which digests the organic matrix consisting 
primarily of type 1 collagen, and hydrogen ions that dissolve the inorganic 
hydroxyapatite crystals [3, 11]. Osteoclast differentiation and activity is dependent on the 
expression of receptor activator of nuclear factor-κB ligand (RANKL). This cytokine is 
expressed by osteocytes, as is its antagonist, osteoprogerin (OPG), which binds to 
RANKL and inhibits its action at the receptor activator of nuclear factor-κB (RANK) 
receptor and thus osteoclast activity [1]. The RANKL/OPG ratio, regulated by the 
osteocyte, ultimately determines osteoclast activity and is integral in the maintenance of 
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bone mass [11]. After bone resorption is completed osteoclasts undergo apoptosis or 
return to an inactive state. 
 
1.2.3 Osteocytes 
 
Osteocytes reside in regularly distributed lacunae within the bone matrix and constitute 
over 90% of all bone cells in the adult skeleton. It is believed that 5-20% of the 
osteoblasts involved in bone formation become entrapped in the bone matrix during bone 
deposition and terminally differentiate into osteocytes. During the process of 
differentiation, changes in gene expression direct a change in osteoblast shape and the 
formation of osteocyte dendritic processes and canaliculi, the channels through which the 
dendritic processes run, which forms a branching system to connect the new osteocyte 
with neighbouring osteocytes, the periosteal and endosteal bone surfaces, bone marrow 
and blood vessel in the marrow compartment and Haversian canals [1, 8, 12, 13]. The 
canaliculi from neighbouring osteocytes are believed to establish intracellular 
communications through gap junctions [8] and the interaction of dendritic processes with 
other bone cells suggest osteocytes may have the ability to direct other bone cell 
functions and regulate mesenchymal stem cell differentiation [12, 14]. Osteocytes have 
major roles in mechano-sensation, maintenance of bone mass and integrity, regulating 
bone mineralisation [12], hormonal interactions with bone [8] as well as detecting micro-
damage and directing the repair process [15, 16]. 
 
Osteocytes are considered to be the primary bone cell responsible for the sensation and 
transduction of mechanical strains imparted on bones [12, 14]. Osteocytes are believed to 
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sense strains in their cell bodies, dendritic processes and cilia [12] due to bone matrix 
tissue deformation, changes in fluid flow dynamic pressure, changes in intramedullary 
cavity pressure [17] or perturbation in canalicular fluid flow causing shear stress [18] in 
response to mechanical loads imparted upon the skeleton [1, 14]. The osteocyte’s 
surrounding bone matrix including osteons, lacunae and canaliculi are involved in 
mechano-sensation, and may be responsible for magnifying strains experienced in the 
bone matrix [19]. Mechano-sensory information from osteocytes is thought to be shared 
between osteocytes and other bone cells via gap junctions between adjacent dendritic 
processes [20]. These gap junctions are integral to osteocyte viability and are comprised 
primarily of gap junction channel protein Connexin 43 (Cx43) which is involved in the 
release of signalling factors for the control of osteoblast and osteoclast activity [21, 22] 
[12, 14].  
 
Osteocytes also seem to have a pivotal role in transducing strain signals and interpreting 
both local strains and the distribution of strains throughout the whole bone to effect a 
response which ultimately controls bone turnover (formation and resorption signals) [1, 
13, 14]. Bone turnover, including preference for bone formation or resorption, appears to 
be achieved through the osteocyte’s expression of sclerostin and resultant modulation of 
the Wnt/β-catenin pathway by the osteocyte [8]. Wnt’s are a family of growth factors 
[23] and the Wnt/β-catenin pathway is important in bone formation and bone 
maintenance and osteocyte viability. Sclerostin, encoded by the SOST gene, is expressed 
and secreted by mature osteocytes in the bone matrix. Sclerostin is a negative regulator of 
the Wnt/β-catenin pathway and thus an inhibitor of bone formation and osteoblast activity 
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[12, 24, 25]. Osteocytes also express Receptor Activator of Nuclear factor-κB ligand 
(RANKL) [26] on dendritic processes which interacts with Receptor Activator of Nuclear 
factor-κB (RANK) receptor to initiate osteoclastogenesis indicating that they are also 
involved in signalling pathways for bone resorption [12]. 
 
Under normal conditions sclerostin expression by the osteocyte keeps the intracellular 
levels of β-catenin low [14]. However, with increased mechanical loading (from 
longitudinal bone growth or weight-bearing physical activity), osteocyte expression of 
sclerostin is reduced [27] and the inhibitory action of sclerostin on the Wnt/ β-catenin 
pathway is alleviated [8, 12, 14] allowing β-catenin to accumulate in the cell. This 
accumulation of β-catenin is integral in the maintenance of osteocyte viability and 
functioning (Bonewald 2011) and influences bone turnover activity. It is involved in the 
activation of the Extracellular signals-Regulated Kinases (ERK) pathway which 
preserves osteocyte viability [28, 29]. It also increases the expression of Cx43 which is 
required for the maintenance of gap junction functioning and osteocyte communication 
[12, 30]. The presence of β-catenin also increases the expression of OPG by osteocytes 
which inhibits RANKL and osteoclast activity [8, 12]. The nuclear translocation of 
accumulated β-catenin influences expression of genes involved in differentiation, 
proliferation, apoptosis and functionality of bone cells as well as bone formation in 
response to the mechanical strains [14, 31-33]. Mechanical loading and their associated 
bone strains are considered to play a significant role in the transport of nutrients and 
oxygen around the osteocyte-canalicular network [34] and in fluid flow, blood flow and 
transport of osteocytic products in the canalicular system [8, 35]. 
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Osteocytes have a long life span [8] and in low bone turn-over states can live in the bone 
for decades [20]. Osteocytes die through apoptosis, which can occur at sites of micro-
damage [12], but is also influenced by the activity of the Wnt/β-catenin pathway, 
whereby increased pathway activity is protective against osteocyte apoptosis. Apoptotic 
osteocytes appear to send signals for the recruitment of osteoclasts and while the exact 
mechanism in which the osteocyte does this is unknown, many mechanisms have been 
postulated including: osteocyte expression of RANKL [8]; osteocyte induced expression 
of RANKL by osteoblasts [8]; down-regulation of OPG, a RANKL antagonist, in the 
dying osteocyte [8];  and signalling from apoptotic bodies released by dying osteocytes 
[36, 37]. Osteocyte apoptosis is considered to be essential for the repair of damaged bone 
and normal bone turnover processes however it can become accelerated in several 
suboptimal conditions including ageing, menopause, glucocorticoid therapy, 
inflammatory cytokines and reduced mechanical loading [12], interrupting the function of 
the osteocyte network and its ability to sense and respond to mechanical strains imparted 
on bone. 
 
Aged bone is characterised by accumulation of micro-damage, reduced osteocyte density, 
accumulation of apoptotic osteocytes and empty lacunae [38, 39]. Hyper-mineralisation 
of the perilacunar matrix with aging, and the presence of longer lived osteocytes [14], 
may adversely affect the function and viability [12, 38] of the osteocyte, by altering the 
flow of fluid through the osteocyte canalicular system and the movement of osteocytic 
products [8, 12], disrupting dendritic gap junctions between osteocytes [40] interfering 
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with communication and interrupting the osteocyte’s ability to respond to stimuli, which 
ultimately results in osteocyte apoptosis. The loss of sex steroids is believed to play a 
significant role in reduced osteocyte viability and increased osteocyte apoptosis with 
aging [1, 41, 42]. A similar pattern of reduced osteocyte viability and increased osteocyte 
apoptosis is also seen during treatment with glucocorticoids [1, 43]. It is also likely that 
the reduced osteocyte density and increased prevalence of apoptotic osteocytes in aging 
bone is related to the decline in physical activity and therefore mechanical loading of the 
skeleton [44]. 
 
Reduction in the mechanical loading of the skeleton, as is seen with reduced weight-
bearing physical activity, ageing, immobility and motor paralysis, is associated with 
decreased osteocyte viability, increased osteocyte apoptosis [44], increased expression of 
sclerostin [27] and reduced activity of the Wnt/ β-catenin pathway [38], and increased 
expression of RANKL by the osteoclast [12, 45], with increased osteoclast activity and 
increased bone resorption [44]. Together these processes are believed to impair the 
osteocyte network’s ability to sense micro-damage, signal for repair [12], transduce 
information from mechanical strains and communicate effectively, culminating in 
reduced integrity of the bone. 
 
It is clear that mechanical loading and unloading of the skeleton influence osteocyte 
expression of key regulators [27] involved in bone turnover including sclerostin, OPG 
and RANKL. Mechanical loading of the skeleton is critical for activation of the Wnt/ β-
catenin pathway which is crucial for bone formation in response to mechanical loading, 
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the maintenance of bone mass, the preservation of osteocyte function and viability and 
inhibition of osteocyte apoptosis [14]. Osteocytes are able to integrate signals from 
mechanical loading with circulating factors e.g. hormones, glucocorticoids and local 
stimuli to regulate bone homeostasis and direct modelling and remodelling processes 
through their ability to regulate bone formation by expression of sclerostin and bone 
resorption by expression of OPG and RANKL [8, 12]. 
 
1.3 Bone Strength 
 
Bone strength refers to the bone’s ability to resist mechanical failure (fracture) and is 
dependent on the interaction between bone quantity and bone quality. Bone quantity 
refers to the mass of bone, which is responsible for 50-70% of bone strength [1]. Across 
the life span, bone mass is determined by the peak bone mass achieved after the pubertal 
growth spurt and the rate and amount of bone loss during adulthood [46].  Bone quality 
includes several bone features including material properties, amount of micro-damage, 
geometry, turnover and tissue quality [1, 46-48]. Material properties of bone refer to the 
quality and assembly of the mineral component (hydroxyapatite) and collagen rich 
organic matrix component. These properties demonstrate minimal variance between 
individuals, and along with the amount of micro-damage present, can only be measured 
using invasive techniques e.g. bone biopsy [47, 48]. The bone’s geometric attributes, 
including longitudinal shape and cross-sectional area, and the distribution of the bone 
tissue in space, also contribute significantly to overall bone strength [47, 48], with greater 
strength achieved if a given amount of material is located further from the centre of the 
structure [49]. Tissue quality refers to the mechanical behaviour of the bone, usually 
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reflecting the combination of bone mass and geometric factors e.g. the stress strain index 
(SSI) [48]. Bone mass, geometric features and parameters of tissue quality can be 
measured non-invasively using densitometric techniques. From a biological perspective, 
bone strength in-vivo is modified throughout life by three important biological processes, 
longitudinal bone growth, modelling and remodelling [35, 47]. Together these processes 
optimise bone strength to habitual mechanical loads imposed on the skeleton to optimise 
function. 
 
1.3.1 Bone remodelling 
 
Bone remodelling is a process that occurs continuously throughout life to maintain bone 
strength and integrity and mineral homeostasis [1].  Remodelling occurs on the periosteal, 
endosteal and Haversian surfaces of cortical bone and on trabecular bone surfaces [35]. 
At the completion of a bone remodelling cycle, bone formation generally exceeds bone 
resorption on the periosteal surface. On Haversian surfaces, bone turnover is equivocal, 
playing a major role in preventing accumulation of microdamage and excessive bone age 
[50]. On endosteal and trabecular surfaces bone resorption exceeds formation [51]. Bone 
remodelling sites may develop randomly, in response to reduced mechanical loading or 
through the identification of old or damaged areas of bone by osteocytes [16, 51, 52]. The 
bone remodelling unit is a tightly coupled group of osteoclasts and osteoblasts that 
remove discrete packets of old bone and synthesis new bone matrix [1, 35, 51, 53]. The 
bone remodelling cycle has 4 stages: (i) activation, where osteoclasts are recruited to the 
site of repair and lift the bone lining cells, under which they create sealed micro-
environments around the site of repair where resorption can take place; (ii) resorption, 
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where osteoclasts take 2-4 weeks to remove the bone matrix, creating Howship’s lacunae 
in trabecular bone and Haversian canals in cortical bone, after which the osteoclasts 
undergo apoptosis; (iii) reversal, where bone resorption is complete and bone formation 
commences; and (iv) formation, where osteoblasts take 4-6 months to synthesise new 
bone matrix and regulate mineralisation, after which osteoblasts undergo apoptosis or 
form osteocytes or bone lining cells [1]. The final outcome of this cycle is the formation 
of a new osteon or partially remodelled trabecular in cortical and trabecular bone 
respectively [1, 53]. Osteocytes regulate the remodelling cycle through expression of 
receptor activator NF-kappaB ligand (RANKL) and OPG [54]. 
 
Bone remodelling continuously occurs throughout life. During childhood and 
adolescence, the growing skeleton is characterised by modelling and remodelling 
processes where bone formation exceeds the rate of bone resorption resulting in a net 
increase in bone [47]. In young healthy adults, after the cessation of growth, remodelling 
becomes the primary process by which bone is adapted to replace old or damaged bone. 
Bone formation is usually coupled closely with bone resorption and there is no net 
change in bone. In post-menopausal and aging bone, as well as pathological bone 
conditions, the rate of bone resorption exceeds bone formation during remodelling cycles 
and a net loss of bone occurs [3]. In healthy aging adults, there are subtle increases in 
periosteal and endosteal circumferences of long bones, due to bone formation exceeding 
bone resorption on periosteal surfaces, and bone resorption exceeding bone formation on 
endosteal surfaces, respectively [1, 35]. The endosteal surface has a higher remodelling 
activity compared to the periosteal surface, so there is also thinning of the cortex and 
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increased cortical porosity with ageing [1]. In adults, cortical bone turnover occurs at a 
rate of 2-3% each year. Trabecular bone turnover is higher as it is more metabolically 
active however it is also believed that the trabecular bone compartment is more involved 
in mineral homeostasis than the cortical compartment [1, 4]. 
 
1.3.2  Bone Modelling 
 
During childhood and adolescence long bones grow in both length and width [1] with 
total skeletal calcium increasing more than 1000g in the first two decades of life [50, 55]. 
This accrual in bone mineral content contributes towards increasing bone size to a far 
greater extent than increasing bone density [3]. Long bones change their length and 
geometry during growth through a process known as bone modelling which acts on 
trabecular surfaces and the periosteal and endosteal surfaces of cortical bone [3, 56]. 
During modelling there is extensive and prolonged bone formation and bone resorption 
occurring on bone surfaces [4] which are not tightly coupled [1, 50, 56]. Bone modelling 
results in the changes in the long bone’s physical dimensions seen between childhood and 
adulthood and ensures the growing bone is adapted to maintain bone strength and optimal 
function of the skeleton, so as it can resist damage caused by strains on bones from 
habitual mechanical loading. Bone modelling occurs during growth in children and 
adolescents, however it subsides in adulthood once skeletal maturity has been reached 
[50, 56, 57]. 
 
Longitudinal bone growth occurs at the growth plate, where endochondral ossification 
replaces cartilage with bone in the metaphyseal region adjacent to the growth plate [58]. 
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The metaphysis is composed primarily of trabecular bone [1, 4, 50]. Newly deposited 
bone along cartilage septa is referred to as primary trabecular bone and exhibits little 
structural difference between individuals [59]. Primary trabecular bone is remodelled into 
secondary trabecular bone which is thicker and exhibits diverse architectural differences 
between individuals depending on mechanical loads applied to the bone. At the distal 
tibial metaphysis, trabecular density (trabecular number and thickness), varies very little 
in females during growth [60, 61], however males have an increase in trabecular density 
during puberty due to an increase in trabecular thickness but not trabecular number [62]. 
This increased trabecular thickness in males may provide some protection against 
osteoporosis with ageing and may partially explain why females are more susceptible to 
osteoporosis compared to males in later life. Trabecular bone in vertebral bodies 
demonstrate increases in trabecular volumetric bone mineral density (vBMD) [6, 63] in 
both sexes during puberty due to increased trabecular thickness but not trabecular number 
[64]. Males have larger vertebral bodies compared to females but their density (trabecular 
number and thickness) does not differ to that of females [65].  
 
Longitudinal growth reduces the long bone’s ability to resist mechanical loads, as the 
bending strength of the long bone is inversely related to its length to the third power [66]. 
To accommodate these increasing mechanical loads associated with longitudinal growth, 
the diaphyseal bone adapts its mass and geometry, in particular it’s outer diameter, as the 
bending strength of the long bone is related to its diameter raised to the third power [58, 
66]. The combined activity of periosteal apposition and endosteal resorption influences 
the bone’s mass, width, cross-sectional area and cortical thickness [4, 56, 57], giving the 
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bone its load bearing strength [35, 66-68]. Geometric adaptations of the long bone’s 
width are some of the most important determinants of bone strength throughout life [69]. 
Long bone geometry is also modified in the metaphyseal region, where newly laid down 
bone in the wider metaphyseal region is reshaped as it transitions into the narrower 
diaphysis. This is achieved by a process known as metaphyseal in-wasting, where the 
periosteal surface is resorbed while bone is formed on the endosteal surface by trabecular 
coalescence [70, 71].  
 
Genetics plays a role in the way a long bone’s size and geometry assembles, however 
bones adapt their size, geometry and the distribution of mineralisation in response to the 
mechanical loading of bones during growth [57] in order to optimise strength and 
function [4]. These mechanical loads are a consequence of longitudinal bone growth, 
increased body weight, increased muscle strength and weight-bearing physical activity [4, 
72]. The processes by which the bone adapts its mass and geometry to mechanical loads 
throughout life, during modelling and remodelling processes are governed by 
physiological principles including Wolff’s Law, the Mechanostat Theory and the Utah 
Paradigm. 
 
1.3.3 Wolff’s Law, the Mechanostat Theory and the Utah Paradigm 
 
Bones adapt their structure including mass, size and geometry, to withstand mechanical 
loads placed upon them from muscle contractions [73], generated during habitual weight-
bearing, body movements and physical activity, to resist mechanical failure (fracture), 
prevent pain and allow optimal function, a light, yet strong skeletal scaffold that does not 
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limit mobility or result in excessive energy consumption [74]. This forms the basis of the 
Mechanostat Theory [47, 75]. The first documentation indicating a link between 
mechanical loading and bone geometry was proposed by Wolff’s Law in 1892 [57]. This 
law underpinned the development of the Mechanostat Theory proposed by Frost in 1964 
and The Utah Paradigm of Skeletal Physiology proposed by Frost in 1998 [75]. 
 
The Mechanostat Theory assumes that humans are born with a blueprint of basic skeletal 
structure and are equipped with biological activities that can effect changes in bone 
architecture in response to mechanical loading of the skeleton after birth [48, 75]. The 
Mechanostat Theory postulates that there is a threshold level of minimally effective 
strains (MES) that determine the osteocyte’s response to mechanical loads imposed on 
bones [35, 72, 76]. There appears to be a higher and lower MES threshold, with an 
optimal range of MES between the two thresholds. It is believed that these MES 
thresholds are genetically determined at birth and persist throughout life. The osteocyte 
directs modelling processes during growth and remodelling processes throughout life to 
keep bone strains imposed by mechanical loading within the threshold range [35, 56, 72]. 
Habitual mechanical loading resulting in bone strains within the MES thresholds do not 
elicit a response from the osteocyte and the bone is considered to be biomechanically 
adapted to its habitual mechanical loads [57]. However, when the habitual mechanical 
loading exceeds the MES threshold (overloading), e.g. with longitudinal bone growth or 
increased weight-bearing physical activity, the osteocyte initiates an adaptive response to 
make the bone stronger. In contrast, if habitual mechanical loading is consistently below 
the MES thresholds e.g. reduced weight-bearing physical activity, the osteocyte initiates 
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remodelling cycles, with bone resorption rates exceeding bone formation rates [35, 47, 
51, 56, 57, 72]. 
 
The Mechanostat Theory therefore explains how long bones adapt to the more than 50-
fold increase in mechanical loads imparted on bones between birth and skeletal maturity 
in adulthood [35], as well as how bones maintain their shape while increasing over 5-fold 
in size between birth and adulthood [57]. During growth, modelling increases bone mass, 
usually on the periosteal surface, and changes geometry (increases cross-sectional area 
and adapts cortical thickness) to accommodate increasing mechanical loads, and to 
reduce bone strains so they fall within the acceptable MES thresholds [50, 57, 72, 73]. 
The Mechanostat Theory also explains the development of age-related and secondary 
disuse osteoporosis, where bones adapt their mass and strength to the reduced muscle 
strength and weight-bearing physical activity associated with both conditions [51]. 
 
The Mechanostat Theory forms a large part of the Utah Paradigm, however the Utah 
Paradigm considers the Mechanostat Theory in the context of other biological process 
and non-mechanical factors that influence bone physiology [47, 75]. The mechanical and 
biological aspects of the mechanostat together with non-mechanical factors ultimately 
determine skeletal health. Non-mechanical factors include gender, genetics, growth and 
sex hormones, nutrition, cytokines, circulating systemic agents, drugs and disease 
processes [35, 51, 66, 75]. Some non-mechanical factors are required for proper 
functioning of bone physiological processes and are believed to modulate the mechanical 
factors acting on bone [73], helping or hindering mechanical control, however non-
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mechanical factors cannot replace the function of the mechanical factors and the 
mechanical factors ultimately guide the biological mechanisms in time and space [75] 
[47, 66]. 
 
1.3.4 The Functional Muscle-Bone Unit 
 
Muscle activity from regular locomotion and weight-bearing physical activity are crucial 
to bone growth and development and the maintenance of bone health throughout life as 
their contractions apply the most frequent and greatest mechanical loads to the underlying 
bone [35, 47, 77-81]. The forces generated by muscles are therefore major determinants 
of bone strength [68]. This intimate relationship between muscle force and bone strength 
was coined the “functional muscle-bone unit” [78]. Normal muscle development and the 
ability of the muscle to generate force therefore has a pivotal role in bone mass accrual 
and geometric adaptations of bone during growth and the maintenance of bone health 
throughout adult life. 
 
The measurement of this relationship in a clinical setting requires surrogate 
measurements of bone strength and muscle force at a corresponding skeletal location 
[80]. Such measures can be obtained from bone densitometry measurements using dual-
energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography 
(pQCT). Bone mineral content (BMC) measured in grams (g) or grams/centimetre (g/cm) 
is considered to be a good surrogate for bone strength, and lean tissue mass (LTM) or 
muscle cross-sectional area is considered to be a good surrogate of muscle force, when 
using DXA and pQCT respectively. Strong correlations between total body BMC and 
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total body LTM have been shown in studies using DXA [82-84] and strong linear 
correlations between BMC and muscle cross-sectional area have been illustrated by 
pQCT studies in adults and children at the radius and tibia where muscle cross-sectional 
area is greatest, the 65% and 66% site for the radius and tibia respectively [61, 78, 85].  
 
A two-step diagnostic algorithm using the functional muscle-bone unit was proposed to 
determine whether the bone is optimally adapted to muscle activity [78], and to aid in the 
interpretation of bone disease in individuals by dividing them into 4 groups: normal, 
primary bone defect, secondary bone defect and mixed bone defect [78]. The first step is 
to determine whether muscle mass is adequate for height, using LTM for height 
calculations from DXA measurements and muscle cross-sectional area calculations from 
pQCT measurements. If the muscle mass is adequate for height, the second step is to 
determine if BMC is adequate for muscle mass, using BMC for LTM calculations from 
DXA measurements and the BMC for muscle cross-sectional area ratio from pQCT 
measurements. If the BMC is adequate for muscle mass the individual has normal bone 
health. If the BMC is inadequate for the muscle mass, the individual has a primary bone 
defect. Going back to the first step, if muscle mass is inadequate for height however 
BMC is adequate for muscle mass, the individual has a secondary bone defect. If muscle 
mass is inadequate for height and BMC is inadequate for muscle mass the individual is 
considered to have a mixed bone defect [78]. 
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1.4 Optimising Bone Health 
 
1.4.1 Peak bone Mass 
 
Genetic factors play a major role in determining an individual’s potential bone size and 
mass [3]. Peak bone mass is achieved by the third decade of life [86-89] and 60-80% of 
the variance in peak bone mass can be genetically explained [55]. Peak bone mass is 
maintained in the mature adult skeleton while remodelling processes continue to produce 
a neutral balance, usually till the fifth decade of life, after which bone turnover begins to 
favour resorption [89] and bone mass begins to decline. Puberty and adolescence is a 
crucial period of time for the attainment of peak bone mass and the foundation of long 
term bone health [90]. It is believed that over 50% of peak bone mass is attained during 
the adolescent growth spurt [50] with peak height velocity a particularly salient stimulus, 
as 25% of peak bone mass is attained in the two years surrounding this period of rapid 
growth [91]. Childhood and adolescent years are therefore critical in establishing the 
foundations of long term bone health and the bone mass acquired during the pubertal 
growth spurt is believed to be similar to the amount of bone lost in later life [90-92], so it 
is an important factor in the lifetime risk of developing osteoporosis [86]. 
 
Successful attainment of peak bone mass to reach an individual’s genetic potential, and 
the maintenance of bone mass throughout life, is only possible when environmental and 
other factors are favourable [4, 55]. Any disturbances in the ability to provide optimal 
nutrition, to participate in regular weight-bearing physical activity, or exposure to 
endocrine regulating factors and hormones, the presence of a chronic illness and/or the 
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medical management of that illness can compromise the attainment of peak bone mass 
and interfere with long term bone health, with increased risk of developing osteoporosis 
[4, 55, 89].  
 
1.4.2 Nutrition 
 
Lifestyle factors including optimising nutrition and participating in weight-bearing 
physical activity are important influences on bone health throughout life [55]. Adequate 
nutrition and normal body weight, including the proportion of muscle and fat mass, is 
essential for normal growth and the development of bone health during childhood and 
adolescence and the maintenance of bone health throughout life [3, 93, 94]. Adequate 
caloric and protein intake, as well as optimal calcium, vitamin D and vitamin K intake, 
are particularly crucial for bone health. The nutritional requirements for these key dietary 
factors peaks during the adolescent growth spurt, when bone mass accrual is at its 
greatest but they are also important in preventing bone loss during adulthood [3, 95]. 
Calcium is integral for bone mineralisation [94] and vitamin D facilitates intestinal 
absorption of calcium [3]. Vitamin D also works together with vitamin K, which is 
involved in the gamma carboxylation of osteocalcin, to improve BMD [96]. 
 
1.4.3 Weight-bearing Physical Activity 
 
Weight-bearing physical activity is recognised as the most effective non-pharmacological 
intervention to optimise bone health across the lifespan, by promoting bone mass accrual 
during the pubertal growth spurt, reducing bone loss during adulthood, and stimulating 
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bone mass accrual if bone loss has occurred [88, 97-99]. The type of weight-bearing 
physical activity employed, and in particular, the mechanical strains imparted on the 
underlying bone generated by the activity, impact on the adaptation of the bone to the 
activity. Weight-bearing physical activities that have a high strain magnitude, apply the 
strain at a rapid rate, have fast acceleration, are multidirectional in nature and produce 
ground reaction forces in excess of those produced during normal activities of daily 
living, aiming for 3-9 times body weight, convey the best osteogenic effects. Examples 
include skipping, hopping, dancing, jumping. Shorter, multiple sessions with rest periods 
interspersed, which restores the mechano-sensitivity of the osteocytes, that have a 
cumulative duration of 10-45 minutes and are performed on 3-5 occasions per week 
appear to result in superior bone adaptations [97, 98, 100]. Bone adaptations in bone 
mass, geometry and strength are site specific and occur at the sites loaded during the 
weight-bearing physical activity interventions [97, 100-102]. 
 
Weight-bearing physical activity, as explained by the mechanostat theory, increases 
BMC, BMD and bone strength and therefore makes it an effective strategy in preventing 
the development of osteoporosis [98, 102]. A meta-analysis conducted by Behringer et al 
in 2014, including 27 randomised controlled trials in children and adolescents with a 
mean age of 10 years and mean intervention period of 47 weeks found that weight-
bearing physical activity interventions significantly increased BMC and BMD, with 
effect sizes of 0.17 and 0.26 respectively [103]. The effect sizes in pre-pubertal children 
were larger at 0.28 for BMC and 0.33 for BMD but only remained significant for BMC 
[103]. In a systematic review and meta-analysis by Nikander et al in 2010, investigating 
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the effect of weight-bearing physical activity interventions of at least 6 months duration 
on bone strength across the lifespan, it was found that lumbar spine and femoral neck 
BMD was up to 6% higher in pre-pubertal children and 2% higher in adolescents in the 
intervention group [97, 102]. Pre-pubertal boys in the intervention group also 
demonstrated significant improvements in bone strength with an effect size of 0.17 [97, 
104]. In the children and adolescents investigated, the weight-bearing physical activity 
interventions improved cortical bone strength by optimising cortical geometry through 
periosteal apposition and trabecular bone strength by increasing trabecular number and 
thickness [97]. 
 
In adults, Nikander et al 2010, also found benefits of weight-bearing physical activity 
interventions on BMD and bone strength [97]. In pre-menopausal women, high intensity, 
progressive resistance training and high impact weight-bearing activities improved 
lumbar spine and femoral neck BMD 1-2%, with resistance training having a more 
beneficial effect on lumbar spine BMD and high impact training having a larger effect on 
femoral neck BMD. There was no significant improvement identified in bone strength, 
however women who were most compliant with their intervention had greater 
improvements in bone strength and cortical thickness compared to the women who were 
least compliant [97]. In post-menopausal women, high intensity, progressive resistance 
training improved lumbar spine BMD by 2%, and a combination of resistance training 
and mixed impact exercise including walking, jogging and stair climbing, maintained 
femoral neck and lumbar spine BMD [97]. Modest, non-significant, site-specific 
improvements in cortical bone strength were achieved only when adequate exercise 
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intensity was performed, and maintenance of these improvements required continued 
participation [97, 105]. In middle aged and older men, high intensity progressive 
resistance training and moderate intensity weight-bearing activities improved femoral 
neck BMD and strength by 2% [97, 106]. In another study, older men in the most 
physically active quartile had greater bone strength, due to larger total bone area, than 
men in the least active quartile [107]. In another study of adults, physical activity levels 
in adulthood had a positive linear relationship with BMD measured by DXA, and was 
associated with higher BMD in later life [108]. Furthermore, healthy adults in the most 
physically active quartile had significantly lower sclerostin levels than adults in the 
lowest physical activity quartile [109].  In these adults, weight-bearing physical activity 
interventions likely improved BMD and bone strength through reduced endosteal bone 
resorption, rather than changes in bone geometry, as seen in children and adolescents 
[97]. 
 
The bone adaptations that occur during childhood and adolescence appear to be 
maintained into young adulthood with high levels of weight-bearing physical activity 
during growth resulting in sustained skeletal benefits in adult bone mass, size and 
geometry [101]. More physically active adolescents demonstrated an up to 17% greater 
bone mass accrual during peak height velocity compared to their less active peers [91], 
and in young adulthood, active adolescent males and females had 10% more bone mass 
in the total body, total hip and femoral neck measured by DXA [110]. In young 
adulthood, active adolescent males also demonstrated a 10% larger total area and 13% 
greater strength at the 66% tibial pQCT site compared to inactive adolescent males, and 
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active adolescent females had 12% greater cortical BMC and 10% greater cortical area 
compared to their less active counterparts [101]. These adaptations in bone mass, 
geometry and strength were independent of the young adult level of weight-bearing 
physical activity [101, 111, 112]. 
 
It is clear, weight-bearing physical activity during growth enhances bone mass accrual, 
bone geometry and strength, influencing both bone quantity and quality [100], and is an 
optimal time to introduce interventions to maximise bone health as the skeleton adapts 
very efficiently, with the capability of producing large effects over a short time period, 
and establish the foundations for lifelong bone health [50, 97, 98, 101-103, 113]. Once 
skeletal maturity has been reached, the influence of weight-bearing physical activity on 
bone health is blunted, with effects primarily maintaining bone health and preventing 
age-related bone loss, resulting in minimal changes in bone mass and geometry, which 
are much slower to take effect [50, 55]. These bone health benefits associated with 
regular weight-bearing physical activity during childhood and adolescence have the 
capacity to impact on lifelong bone health, the development of osteoporosis and fracture 
risk [101]. Children and adolescents who are unable to participate in normal weight-
bearing activities are at heightened risk of having poor bone health and developing 
osteoporosis early in life due to the absence of the osteogenic effects of weight-bearing 
physical activity on bone mass, geometric adaptations and contribution to bone strength 
during growth. Similarly, adults who are unable to participate in normal habitual weight-
bearing activities are at risk of accelerated bone loss and the early development of 
osteoporosis. Improving participation in weight-bearing physical activity, muscle 
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strength, mobility and functional outcomes in people unable to participate in normal 
habitual weight-bearing activities will have beneficial effects on their bone health by 
improving bone adaptations during growth, minimising bone loss and slowing the 
progression towards osteoporosis [114]. 
 
1.4.4 Endocrine Factors 
 
Timely and adequate exposure to several endocrine factors are crucial in optimising bone 
heath during the paediatric years, and for maintaining bone health throughout adulthood 
[50]. These factors include thyroid and parathyroid hormone, growth hormone, 
glucocorticoids and sex hormones [3, 50, 55, 66, 114, 115]. 
 
Differential exposure to androgens and estrogens during puberty and adolescence, affects 
skeletal development in males and females with ramifications for lifelong bone health. In 
males, androgens promote skeletal muscle development and periosteal apposition in the 
cortical diaphysis of long bones, with its effects lasting much later in adolescence 
compared to females, resulting in a higher bone mass, larger cortical area and more 
geometrically efficient distribution of cortical bone mass compared to females, 
culminating in better bone strength indicated by higher cross-sectional moment of inertia 
(CSMI) and polar stress-strain index (pSSI) values [61, 66, 116-118]. Trabecular bone in 
the metaphyseal region of long bones also has a greater trabecular thickness compared to 
females [62] at the end of puberty and this, along with the more favourable geometric 
attributes of the male skeleton may provide some protection against age-related 
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osteoporosis, and may partially explain why females are more susceptible to age-related 
osteoporosis compared to males. 
 
In females, estrogens do not have the same effect on skeletal muscle development as is 
seen in males, and the majority of puberty associated bone changes are reached by, mid-
adolescence at 15-16 years of age [117, 119], explaining the differences in bone mass and 
cortical area which are closely associated with muscle mass development [120]. 
However, after puberty, females demonstrated greater bone mass accrual for a similar 
muscle mass, reduced endosteal expansion and higher volumetric bone mineral density 
compared to males [61, 81, 82, 116, 117, 119, 120], which persists into adulthood in pre-
menopausal women [118]. These differences are considered to be due to the effects of 
estrogen which may exert several influences on bone turnover. Estrogen is believed to 
alter the sensitivity of the mechanostat, lowering the MES set point for the endosteal 
surfaces, allowing greater bone mass accrual on the endosteal surface [121, 122] by 
inhibiting intra-cortical and endosteal remodelling [117, 118, 123, 124], and is considered 
to reduce osteoclast activity [3] and promote osteoblast activity by upregulating OPG 
expression [125]. These estrogen-mediated effects are likely in preparation for pregnancy 
and lactation [61], however the higher vBMD and therefore intrinsic stiffness of the bone, 
reduces bone strength as measured by CSMI in females in comparison to males [126]. 
During menopause, when endogenous estrogen production reduces dramatically, the 
MES set point for the endosteal surfaces is believed to be increased, resulting in a rapid 
increase of remodelling activity on endosteal and trabecular bone surfaces, with 
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consequent loss of bone mass and development of post-menopausal osteoporosis [35, 48, 
121]. 
 
1.5 Osteoporosis 
 
Osteoporosis is defined as “a skeletal disorder characterised by compromised bone 
strength predisposing to an increased risk of fracture” [46]. In children osteoporosis is 
diagnosed when age, gender and body size adjusted BMC or BMD z-scores are more 
than two standard deviations below the mean and there is a clinically relevant fracture 
history, which requires two or more long bone fractures under 10 years of age, three or 
more long bone fractures up to 19 years of age, or a vertebral compression fracture [127]. 
In adults, osteoporosis is diagnosed if the BMD T-score is more than 2.5 standard 
deviations below the mean, however pre-menopausal females and males under 50 years 
of age should have their BMD evaluated using z-scores, and a result more than two 
standard deviations below the mean indicates BMD is below the expected range for age. 
In this cohort, osteoporosis should not be diagnosed on BMD results alone [128]. 
 
Bone loss is an unavoidable result of the aging process and begins around the 5
th
 decade 
of life, accelerating thereafter in both males and females [129]. Loss of bone that can be 
attributed to the natural aging process or hormonal consequences of aging, and are 
responsible for age-related and post-menopausal osteoporosis [46]. Age-related 
osteoporosis is associated with decreased muscle mass and strength, increased fat mass 
[100] and reduced responsiveness of the bone tissue to mechanical loading, resulting in 
reduced BMD and changes in bone geometry, including endosteal resorption, increased 
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cortical porosity and periosteal expansion to maintain bone strength [130, 131]. 
Diminishing postural stability with aging results in increased falls risk which in turn 
increases fracture risk [100, 130]. The decline in sex hormones in both males and females 
causes increased bone remodelling and loss of bone mass, and therefore plays an 
important role in the development of age-related and post-menopausal osteoporosis 
[130]. The rapid loss of bone mass associated with menopause in females is not seen in 
males, and they exhibit more trabecular thinning and less trabecular loss in comparison to 
females [130]. The presence of underlying medical conditions, use of medications, 
nutritional status and participation in weight-bearing physical activity also impacts on the 
development of age-related osteoporosis [130]. 
 
Secondary osteoporosis refers to bone loss that occurs due to mechanisms independent of 
aging [46]. It is usually an adverse consequence of an underlying chronic illness, that is 
not primarily skeletal in nature, or the medical management of that illness, which has 
negative ramifications on bone mass and bone turnover activity, and may be associated 
with increased risk of fracture [46, 132]. Secondary causes of osteoporosis are common 
in paediatrics and were found in two thirds of men, more than one half of pre-menopausal 
women and one fifth of post-menopausal women diagnosed with osteoporosis [129]. In 
paediatrics, secondary osteoporosis prevents children from attaining their genetically 
determined peak bone mass potential [4] and in adulthood it accelerates bone loss. 
Chronic illness is associated with several factors that may contribute towards the 
development of secondary osteoporosis, including pubertal delay and hormonal 
deficiencies, poor nutrition, malabsorption and low body weight, elevated levels of 
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inflammatory cytokines, bone marrow diseases, immobility and exposure to osteotoxic 
drugs including glucocorticoids, anticonvulsants and proton pump inhibitors [93, 132].  
 
Primary osteoporosis occurs when an intrinsic skeletal defect is present which can be 
genetic or idiopathic in origin [94, 114]. The most common genetic cause of primary 
osteoporosis is Osteogenesis Imperfecta, which occurs due to mutations in the genes 
encoding the type 1 collagen alpha chains, resulting in bone fragility [133]. The origin of 
idiopathic Juvenile Osteoporosis is not clear and the mechanisms causing this disease are 
unknown. It has been proposed that such idiopathic presentations may be due to the 
inability of the osteocyte to competently perform mechanosensation and 
mechanotransduction, or due to a disturbance in the Wnt/β-catenin signalling pathway, 
culminating in abnormal bone turnover and ultimately osteoporosis [114]. 
 
1.6 Assessment of Bone Health  
 
1.6.1 Bone Mineral Density and Bone Geometry 
 
The evaluation of bone mineral density (BMD) requires a measurement of the mass of 
inorganic mineral present in a bone section, and the volume of the bone section 
measured. In human bone, BMD can be measured at three different levels: material 
BMD, which directly measures the amount of mineral in the bone matrix; compartment 
BMD, which measures the amount of mineral in the trabecular or cortical bone 
compartments; and total BMD, which measures the amount of mineral within the 
periosteal envelope of a bone or defined section of bone [6]. Material BMD is calculated 
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by dividing the mass of the extracellular bone matrix by the volume of the bone matrix 
occupied by inorganic mineral, thus excluding Haversian canals, marrow spaces, lacunae 
and cancaliculi [6]. Material BMD increases with periosteal expansion during bone 
modelling, and as the age of the bone matrix increases and is reduced when bone 
remodelling activity is increased [6]. Material BMD cannot be measured non-invasively 
using densitometric techniques and requires invasive procedures to obtain bone biopsies 
which can measure material density using backscattered electron microscopy or the 
relative ash weight of dried bone [6]. 
 
Compartment BMD is calculated by dividing the mass of the extracellular bone matrix by 
the total volume of the bone matrix [6]. In this calculation the mass is identical to the 
mass used in the calculation of material BMD, however the volume is larger as it includes 
both bone and non-bone tissue. As a result, compartment BMD will always be lower than 
material BMD. In trabecular bone, compartment BMD depends on trabecular number and 
thickness which is determined by remodelling activity and remodelling balance [6, 64]. In 
cortical bone, compartment BMD is influenced by the number and size of Haversian 
canals, which are increased when intra-cortical remodelling activity is high [6]. During 
childhood, trabecular and cortical compartment BMD increases by ~40%. In the 
trabecular compartment this is due to increased material BMD and trabecular thickness, 
and in the cortical compartment, due to increased material density and changes in the 
relative bone volume [6]. Compartment BMD can be measured non-invasively by 
peripheral quantitative computed tomography (pQCT), which is able to analyse the 
trabecular and cortical compartments separately [6]. 
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Total BMD is calculated by dividing the mass of the extracellular matrix, including 
trabecular and cortical bone, by the total volume of trabecular and cortical bone [6]. Total 
BMD increases during childhood at sites where the relative cortical area increases, and 
decreases with increased remodelling activity resulting in endosteal and trabecular 
resorption [6]. Total BMD can be measured non-invasively using DXA, which generates 
an areal BMD calculated by dividing the mass of bone by the projection area, and also by 
pQCT [6]. 
 
1.6.1.1 DXA Scans 
 
The measurement of bone mineral density by DXA was introduced in the 1980s for the 
evaluation of bone density in post-menopausal women [4]. Since this time, it has evolved 
into one of the most commonly used densitometric methods to assess bone health across 
the life span. Its popularity is due to the fact it is a commonly available, low cost, non-
invasive, relatively fast and highly reproducible investigation with low radiation exposure 
[4, 114, 134, 135]. Furthermore, many of the common scanning sites, including total 
body, lumbar spine and proximal hip have age and sex-specific standard deviation scores 
available for interpretation [114]. DXA scans can be used to identify an individual at risk 
of impaired bone health, the degree to which their bone health is compromised and 
consequent skeletal fragility, as well as monitoring the effects of treatment regimens 
[135]. 
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DXA scans utilise two different x-ray energies, which are attenuated differently by bone 
and soft tissue, allowing the machine to distinguish between these two tissue types. This 
process yields parameters of bone mineral density (BMD), bone mineral content (BMC), 
bone area (BA), lean tissue mass (LTM) and fat mass for the total body, lumbar spine and 
other regions of interest. Total body and lumbar spine scans are the preferred scan sites 
for investigations in children, and give information about cortical and trabecular bone 
respectively [136, 137]. Highly reproducible information can be obtained from these sites 
in children and adults, with coefficients of variation for total body scans 0.66-1.20% in 
children [138] and 0.7% in adults [139], and at the lumbar spine 0.64-1.03% in children 
[138] and 0.7-1.7% in adults [139]. The effective radiation dose of these scans in children 
range between 1.5-10μSv [140]. 
 
DXA derived parameters can also be used for evaluation of the functional muscle-bone 
unit [135, 141]. In healthy children lean tissue mass (LTM) is strongly correlated with 
bone size, height and pubertal stage [135]. To determine whether bone mass is adequately 
adapted to LTM Crabtree et al 2004 [141], following the algorithm of Schoneau et al  
[78], used LTM for height and BMC for LTM to identify any deficits in bone health. 
They were able identify that children with spinal muscular atrophy had a secondary bone 
defect, and children with OI, a primary bone defect, and in a group of children with 
fragility fractures they found that the mean BMC for LTM z-score was -1.9, indicating 
that low BMC for LTM is associated with increased risk of fracture [141]. 
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The use of DXA scanning in the assessment of bone health does have some 
disadvantages. DXA provides a two-dimensional analysis of a three-dimensional 
structure, with a major limitation being the inability to account for the depth of the bone, 
making BMD measures size dependent [136]. This results in individuals with larger 
bones appearing to have greater BMD [4] and smaller, shorter individuals with 
underestimated BMD [142]. This is especially pertinent in the paediatric years, where 
bone size is continually changing, potentially impacting on the interpretation of serial 
measurements. Another limitation is the inability to distinguish between trabecular and 
cortical bone compartments or provide information about the geometric attributes of the 
bone [137]. Furthermore, reference data can only be utilised for scans performed using 
the same scanning hardware and software used to develop the reference data set. 
 
1.6.1.2 pQCT scans 
 
Peripheral quantitative computed tomography (pQCT) is another densitometric 
measurement that can be used to evaluate BMD. It was first developed in Switzerland in 
1976 [143] and while to date it is used predominantly in the research arena, it has several 
advantages over DXA measurements and its clinical utility is being increasingly 
recognised. pQCT is a three dimensional technique that evaluates a cross-section of bone 
in the peripheral skeleton, providing a true volumetric bone mineral density (vBMD) 
which is independent of bone size [3, 4, 114, 144]. It also allows separate evaluation of 
the trabecular and cortical bone compartments reflecting their individual tissue properties 
and response to mechanical forces, drugs and disease processes [3, 114, 144]. 
Furthermore, it can evaluate the geometric attributes of the bone, as well as 
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biomechanical properties, by deriving the bone’s strength and ability to resist bending 
and torsion from pQCT measurements [114, 118, 144, 145]. It can also be used to 
provide information about muscle mass and muscle cross-sectional area for evaluation of 
the functional muscle-bone unit [145].  
 
pQCT measurements are most commonly performed at the radius and tibia, two long 
bones commonly affected by fractures in healthy children and individuals with limited 
mobility [144]. Common scan sites include 4%, 14%, 20%, 38% and 66% of the bone 
length measured from the bone’s distal end. Scans are fast, taking approximately one 
minute per slice and have low effective radiation doses of <1uSv per slice [4, 118]. 
Highly reproducible measurements can be obtained from these sites in children and 
adults, with coefficients of variation for tibial trabecular vBMD and total and cortical 
CSA at the 4% and 66% sites in adults being less than 1%, cortical vBMD at the 66% site 
in adults being 2.5% [61], and for periosteal circumference and cortical thickness at the 
20% tibial site in adults being 0.5% and 1.2% respectively [146]. 
 
During pQCT scanning, thresholds are nominated to distinguish between the different 
tissue types in the cross-section of the limb being evaluated, including fat tissue, muscle 
tissue, trabecular and cortical bone tissue. This process yields several parameters for the 
investigation of bone health including: bone mass indicators such as total, trabecular and 
cortical BMC, total, trabecular and cortical cross-sectional area (CSA) and total and 
trabecular vBMD; the bone tissue quality indicator, cortical vBMD; diaphyseal design 
indicators, including endosteal and periosteal circumferences, cortical thickness, cross-
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sectional moments of inertia (CSMI) and the stress-strain index (SSI); and the muscle 
strength indicator, muscle cross-sectional area [73, 118].  
 
Analysis of the functional muscle-bone unit can be performed using BMC and muscle 
CSA measured by pQCT at the 65% or 66% site of the radius or tibia respectively, where 
the muscle CSA is largest. Using the algorithm proposed by Schoneau et al 2002 [78], the 
same authors were able to characterise the bone health of children with chronic renal 
failure and after renal transplant. In chronic renal failure, BMC was adequate for muscle 
mass and muscle mass adequate for height, despite such patients being shorter than their 
peers, resulting in normal adaptation of the bone to its mechanical environment. After 
transplant however, BMC was not adequate for muscle mass despite muscle mass being 
adequate for height, and a primary bone defect was identified, possibly as a result of post-
transplant medical management, for example, the use of glucocorticoids [80]. This 
example illustrates he clinical utility of pQCT measurements in the analysis of the 
muscle-bone unit, and the ability of such analysis to distinguish between varying 
alterations in bone health. 
 
In adults, tibial bone length, which increases anterior-posterior bending forces on the 
underlying bone [147], and calf muscle mass, which imparts torsional deformation on the 
underling bone [147], were the strongest influences on the development of cortical bone 
mass, geometry and strength at the 14%, 38% and 66% tibial sites  [73]. In children, 
height, and therefore tibial bone length, also had the greatest influence on cortical bone 
mass, geometry and strength at the 66% tibial pQCT site, with height accounting for 60-
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85% of the variability in these measures, and boys consistently had higher values than 
girls [61]. At the 20% tibial pQCT site in pre-pubertal children, cortical bone mass, 
geometry and strength was highly correlated to muscle mass and muscle performance 
[148]. In adults, measurements of cortical vBMD at several sites along the tibia 
demonstrated that it remained essentially consistent for all cortical sites, was not 
influenced by anthropometric or mechanical factors, and was higher in pre-menopausal 
women compared to men [73, 118]. In children, cortical vBMD at the 66% tibial site was 
most strongly influenced by age, which accounted for 55% of the variability in this 
measure, and was greater in girls than boys, independent of height and Tanner stage [61]. 
In pre-pubertal children cortical vBMD at the 20% tibial pQCT site was not correlated to 
measures of muscle mass or muscle performance [148]. In children, muscle CSA 
measured at the 66% tibial pQCT site increased linearly with height, and was greater in 
boys compared to girls, however, cortical BMC for muscle CSA at this same site, also 
increased with age, but was higher in girls than boys [61].  
 
The main disadvantage of using pQCT in the assessment of bone health is the impact of 
the partial volume effect. The partial volume effect refers to the incomplete filling of 
voxels at the edge of the bone, which results in underestimation of cortical vBMD [123] 
[146]. This effect has its greatest impact when cortical thickness is less than 2mm due to 
the higher surface to volume ratio when cortices are thinner [123]. Presence of the partial 
volume effect also impacts on the interpretation of age-dependent reference values for 
cortical vBMD, which give the most accurate reference values when cortical thickness is 
normal for age [123]. Other disadvantages include the need to remain still, especially 
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when multiple sites are being scanned, and the reproducibility of locating the same 
scanning sites on serial measurements and between institutions. 
 
1.6.2 Bone Turnover Markers 
 
Bone turnover markers are peptides released from the bone matrix during bone resorption 
and bone formation processes that are detectable in the blood and urine. These markers, 
including the bone formation markers osteocalcin [149] and alkaline phosphatase [150], 
and the bone resorption marker urinary deoxypyridoline [151], reflect modelling and 
remodelling processes occurring throughout the skeleton [74] and can be used to identify 
abnormalities in bone and mineral metabolism [3]. These markers peak during the 
adolescent growth spurt and decrease once skeletal maturity is reached [74, 151]. Higher 
than expected levels of bone turnover favouring bone resorption is the main cause of 
microarchitectural deterioration in bone, and low bone turnover states result in the 
accumulation of microfractures also impacting on bone health [1]. 
 
1.7 Whole-body Vibration Training  
 
1.7.1 How it Works 
 
Whole body vibration training (WBVT) is an emerging therapeutic modality that has 
gained popularity in recent years for its muscle performance enhancing capabilities and 
rehabilitative potential when muscle mass and performance, bone mass and density and 
physical function are compromised. It was first developed in the 1970s in an effort to 
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counteract the loss of muscle and bone mass of astronauts and to enhance athletic 
performance [152]. There are two types of whole-body vibration platforms commercially 
available, vertical and side-alternating vibration platforms. Vertical vibration platforms 
generate synchronous vertical vibrations where the whole platform moves up and down 
in a vertical direction resulting in symmetrical movement of the lower limbs [153]. Side-
alternating vibration platforms rotate around a central fulcrum, similar to the action of a 
seesaw, generating side-alternating vertical vibrations that are applied alternatively to the 
left and right side of the body [153]. In contrast to the vertical platforms, side-alternating 
platforms produce rotational movements around the pelvis and lumbar spine [154]. The 
training load imposed by WBVT depends on four different parameters: frequency, 
amplitude, acceleration and duration [153]. Frequency refers to the number of vibration 
cycles applied per second, normally applied between 0-45Hz, and amplitude, to the 
displacement height of the oscillation, which is dependent on the distance feet are placed 
away from the central fulcrum in side-alternating vibration, but independent of foot 
position in vertical vibration and generally between 1-12mm [155]. Acceleration refers to 
the product of amplitude and angular velocity, and is proportional to the amount of force 
applied to the body during WBVT, usually ranging between 0-18g [155]. Increasing 
frequency and amplitude increases acceleration [156].  Duration refers to the amount of 
time exposed to the vibration stimulus, and is commonly applied intermittently for 30-60s 
intervals or continuously for 3-5 minutes [153, 157, 158]. The best settings for each of 
these parameters to achieve optimal gains in muscle performance, bone adaptations and 
functional ability is unknown, and likely differs between individuals [155]. 
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Vibration platforms generate a forced oscillation, sinusoidal in shape, that is transferred 
from the platform to the human body carrying with it mechanical energy which results in 
acceleration of the body, eliciting reactive forces in muscles [159]. The sinusoidal 
oscillation causes rapid changes of direction that shorten and stretch the lower limb and 
trunk muscles and their tendons [159] resulting in rapid repeated concentric and eccentric 
muscle contractions [159, 160]. The repeated stretching of the muscle during WBVT is 
believed to enhance muscle spindle discharge [161] which in turn elicits excitation of the 
α-motor neurone via primary 1α-afferents, resulting in faster contractions of the 
homonymous muscle units [162], generating a reflex contraction in the muscle known as 
the tonic vibration reflex (TVR) [163]. The TVR may improve neuromuscular 
performance by increasing motor-unit synchronisation [164] and recruitment of 
previously inactive motor units [165] to enhance voluntary muscle contractions as well as 
increasing the efficiency of agonist-antagonist pairs [166]. While the mechanisms are not 
fully understood, it is also believed that the reflex activity of the muscle is acutely 
enhanced immediately after training [159], and may also contribute to heightened muscle 
performance after WBVT. 
 
The effects of WBVT and the TVR on muscle activity can be observed on an 
electromyogram (EMG) of lower limb muscles, including the gastrocnemius, soleus and 
vastis lateralis [160, 167-169]. EMG activity increased as vibration frequency was 
increased from 15-30Hz [170], and the literature suggests that muscle activation is 
greatest at a frequency of 30Hz [168, 171]. EMG activity was higher when a static squat 
position of ~20 degrees of knee flexion was adopted compared to dynamic squatting. 
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Shallower dynamic squatting, up to 15 degrees knee flexion, had greater EMG activity 
than dynamic squats up to 35 degrees knee flexion [167], and shallow single leg squats 
increased EMG activity more than two leg squats [172]. Side-alternating vibration 
platforms increased EMG activity of the vastis lateralis and gastrocnemius muscles 
significantly more than vertical vibration platforms, however vertical vibration elicited 
greater EMG activity in the tibialis anterior muscles compared to side-alternating 
vibration [167]. There was lower transmission of the vibration stimulus to the upper body 
and head with side-alternating vibration compared to vertical vibration, and this was 
considered to be due to significant absorption of vibration with rotation of the pelvis and 
lumbar spine in side-alternating vibration [154]. 
 
The mechanical dampening properties of human muscles, which is individualised and 
dependent on the compliance of the lower limb joints [167], absorbs the mechanical 
energy, or force, generated during WBVT, and determines how it is dissipated and 
transmitted cephalad in the body [159, 173]. The greatest force and acceleration occurs in 
the muscles closest to the vibration platform and are dissipated as the vibration stimulus 
travels cephalad up the body [174]. The greatest absorption of force in the lower limbs 
occurred when WBVT was performed in 10-15 degrees of knee flexion [167], and when 
side-alternating vibration platforms were used [154]. Due to the influence of individual 
characteristics on EMG responses during WBVT, it is unlikely that a “one size fits all” 
approach can be taken when participating in WBVT. A study comparing WBVT 
performed at a frequency determined by optimal EMG activity compared to WBVT at 
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30Hz found jumping performance to be increased by 18% when the frequency was 
individually tailored [175]. 
 
The muscular contractions elicited by WBVT and the TVR impact on energy metabolism 
in the muscle [153]. ATP consumption in the muscle is increased and this is associated 
with a decrease in intracellular PCr levels [176] and small increases in oxygen uptake, 
which increases as frequency and amplitude are increased [177], but is less pronounced in 
older adults [178]. The increased muscle metabolism also increases intramuscular 
temperature, which increased more rapidly with WBVT than cycle exercise [179], and 
together these effects increase muscle perfusion [180, 181], which appears to be 
frequency dependent [182], and more marked when using side-alternating vibration 
platforms compared to vertical platforms [183, 184]. Skin blood flow in the lower limbs 
is also enhanced during WBVT and along with the increased muscle perfusion is likely to 
be responsible for the erythema and itching, which is commonly described with WBVT 
[185]. WBVT during a static squat did not elicit any changes in heart rate, or blood 
pressure [180], however performing exhaustive squatting exercise during WBVT induces 
muscle deoxygenation [186], an increase in heart rate (~30%), proportional to the 
increase in oxygen uptake [187], an increase in systolic blood pressure, and decrease in 
diastolic blood pressure, indicating arterial vasodilation and increased muscle perfusion 
[180, 185]. 
  
WBVT is therefore believed to influence muscle performance through the generation of 
the TVR, which improves neuromuscular performance and voluntary muscle contraction 
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as evidenced by augmented EMG activity and changes in muscle energy metabolism. 
WBVT may improve balance and functional ability due to the repeated, rapid 
displacements that immediately challenge balance [159] and changes in joint stiffness 
[188]. Improved neuromuscular performance results in enhanced agonist-antagonist 
pairing [189, 190], which positively effects joint stiffness [191, 192], resulting in 
improvements in joint stabilisation, particularly of the ankle and knee [189, 193, 194] and 
which is likely to contribute to improved balance and function [189, 190, 195]. 
 
WBVT is thought to induce its effects on bone indirectly, through mechanical loading of 
the skeleton by skeletal muscle contractions which have improved neuromuscular 
efficiency and performance, and directly by mechanical deformation of the underlying 
bone causing perturbations in canalicular fluid flow and stimulation of the osteocyte and 
the WNT/β-catenin pathway [196].  
 
1.7.2 Effects on Bone 
 
The first group to investigate the effects of WBVT on bone in children was Ward et al in 
2004 [197]. A randomised controlled trial (RCT) was performed in 20 children and 
adolescents with disabling conditions and motor impairment, including cerebral palsy and 
muscular dystrophy, with half receiving low magnitude WBVT performed 10 minutes a 
day, 5 times per week for 26 weeks as part of a standing program [197]. Proximal tibial 
and spine trabecular vBMD measured by QCT increased 6.27mg/ml (6.3%) and 
7.29mg/ml (5.5%) respectively with the control group demonstrating reductions in both 
parameters. Tibial cortical bone parameters including cross-sectional area, periosteal 
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circumference, vBMD, pSSI, cortical thickness and muscle area were not altered with 
WBVT [197]. In a study of 20 children with cerebral palsy randomised to WBVT, 9 
minutes a day, 5 times a week for 26 weeks, or conventional physiotherapy, lumbar spine 
BMD measured by DXA increased slightly more in the WBVT group, and lateral distal 
femur BMD decreased in the WBVT group compared to the physiotherapy group, 
however these differences between groups were not statistically different [198]. In a 
randomised cross-over study of 30 children with cerebral palsy participating in a daily  
standing program with or without the addition of WBVT, pQCT measures of tibial 
cortical bone area and moment of inertia increased significantly after WBVT however 
trabecular vBMD in the tibia and lumbar spine did not differ between groups [199]. In a 
third study of children with CP using WBVT as part of an intensive physiotherapy 
program also utilising resistance training and treadmill walking, total body BMD and 
BMC increased 2.3% and 5.74% after 6 months training respectively, and improvements 
were greater in children less than 10 years of age compared to children over 10 years of 
age [200]. In a more recent study, 30 children with spastic diplegic CP, 10-13 years of 
age were randomised to either a conventional exercise program or the same program with 
the addition of WBVT, 10 minutes a day, 5 times a week for 24 weeks. Children in the 
WBVT group significantly increased their lumbar spine BMD by 0.16mg/cm
2
 and femur 
BMD by 0.27mg/cm
2
, these improvements significantly greater than the improvements 
seen in the children participating in the conventional training alone [201]. A recent 
systematic review and meta-analysis for the effectiveness of WBVT for bone density in 
children and adolescents with cerebral palsy found that femur bone density was increased 
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significantly with WBVT, reporting a standardised mean difference of 1.32, however 
there was no significant improvements in lumbar spine bone density with WBVT [202]. 
 
WBVT has also been found to have beneficial effects on bone in other cohorts of 
children. In children with Osteogenesis Imperfecta, 6 months of WBVT, 9 minutes a day, 
as part of an intensive physiotherapy program also utilising resistance training and 
treadmill walking, resulted in significant increases in total body BMD and BMC however 
their corresponding z-scores did not show significant changes [203].  In 6 ambulant boys 
with Duchenne Muscular Dystrophy, 3 months of WBVT, 6 minutes a day, demonstrated 
a significant improvement in total body BMC measured by DXA, but no significant 
improvements in parameters measured by tibial pQCT at the 4% and 66% sites [204]. In 
eight girls with endocrine disorders, WBVT for 30 minutes, 3 times a week for 8 weeks 
improved trabecular vBMD of the spine and cortical vBMD of the femur [205], and in 
adolescent girls with idiopathic scoliosis randomised to WBVT for 20 mins, 5 times a 
week for 52 weeks, or control, femoral neck BMD and lumbar spine BMC improved 
significantly with WBVT compared to controls, however no differences between groups 
in distal tibial high resolution pQCT parameters were found [206]. In young women with 
low BMD measured by DXA and a history of at least one fracture, WBVT 10 minutes 
daily for 52 weeks compared to controls showed significant improvements in lumbar 
spine trabecular vBMD, femoral cortical bone area measured by QCT in those in the 
WBVT group [207]. In adults, 19-38 years, randomised to WBVT 4 minutes, 3-5 times a 
week for 8 months or control, there were no significant differences in any lumbar spine or 
hip DXA parameters or tibial pQCT parameters between groups [208]. 
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In post-menopausal women, a systematic review and meta-analysis including five RCTs 
[209-213], found a statistically significant treatment effect of WBVT for hip BMD with a 
standard mean difference of 0.015g/cm
2
, however there were no treatment effects of 
WBVT on lumbar spine BMD or tibial trabecular vBMD [214]. When total hip and 
femoral neck analyses were analysed separately, the results remained significant for the 
total hip only with a standard mean difference of 0.014g/cm
2
, and the effects of WBVT 
on hip BMD were significant when WBVT was compared to sham or no treatment, but 
lost significance when compared to an exercise intervention [214]. In a more recent trial 
of osteopoenic post-menopausal women randomised to WBVT, 10 minutes, 2-3 times a 
week for 12 months, or control, there were no differences between groups in femoral 
neck or lumbar spine BMD or on bone architecture measured by high-resolution pQCT 
[215]. 
 
In the older adult population, recent systematic reviews and meta-analyses found that 
WBVT significantly improved femoral neck BMD in comparison to conventional 
exercise interventions with standard mean difference of 0.04g/cm
2
 [216], however there 
were no differences between WBVT and control or exercise intervention groups for total 
hip BMD [217] and lumbar spine BMD [216, 217], even when osteoporosis was 
diagnosed [218]. A study investigating the effects of WBVT in older adults using tibial 
pQCT also found no changes in any pQCT parameters after WBVT [212]. WBVT also 
does not appear to impact on bone turnover markers in older adults [219], after stroke 
[220], in healthy young adults [208], and in postmenopausal women [211, 221]. 
 74 
However, another study in post-menopausal women found a reduction in bone resorption 
markers after 8 weeks of WBVT, and 12 weeks of WBVT in older adults increased bone 
formation and resorption markers [222]. 
 
The lack of consensus in the literature regarding the effects of WBVT on bone mass, 
geometry and strength is largely due to the widely varying treatment protocols utilised, 
however it does appear that the bone-related benefits of WBVT are greatest in children 
and potentially most effective in the pre-pubescent age range when the ability of the 
skeleton to adapt to mechanical stimuli is at its peak. It is also apparent from the literature 
that adherence to the training regime influences outcomes in bone parameters, with 
greater adherence associated with better outcomes at the femoral neck [211] and lumbar 
spine [207]. A systematic review by Matute-Llorente et al in 2014 investigating WBVT 
in children and adolescents, suggested that WBVT would be most osteogenic when it was 
performed for 10-20 minutes, more than 3 times a week, for a minimum of 26 weeks with 
a frequency of 25-35Hz and an amplitude of 4mm [205]. 
 
1.7.3 Effects on Muscle  
 
Several systematic reviews and meta-analysis have been conducted into the effects of 
WBVT on muscle performance. When compared with a control group performing no 
additional exercise, WBVT had a significant positive effect on jump height with a 
standardised mean difference of 0.77, with effects greater in non-athletes, when 
interventions lasted longer than 3 months, when frequency was over 30Hz, amplitude 
greater than 3mm, and the duration of exposure each treatment session more than 10 
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minutes [223]. When compared to an exercise intervention, WBVT had a significant 
positive effect on jump height with a standardised mean difference of 0.63, with side 
alternating platforms showing a greater standardised mean difference of 0.81 compared to 
the average [223]. In another study, WBVT was also found to have a significant influence 
on jump height, with a standardised mean difference of 0.87, which was greater in the 
young adult group, (standardised mean difference of 1.00), compared to the older age 
group, (standardised mean difference of 0.60), likely due the fact the young adult group 
generally performed exercises during the WBVT, and that in the elderly, a longer training 
period is required for the same improvements in muscle performance [224]. WBVT 
frequencies greater than 30Hz had a significant additional effect with a standardised 
mean difference of 1.38 and amplitudes less than or equal to 4 mm had significant effects 
on muscle power, with a standardised mean difference of 1.25 [224]. A third systematic 
review also found long-term WBVT to have a significant effect on muscular power 
production, with an effect size of 0.99 that was larger in older adults, (2.24) than younger 
adults (0.43), greater when dynamic exercises where performed during the WBVT, effect 
size 1.16 compared to 0.72 during isometric exercise, and larger when the WBVT was 
progressive, with increases in amplitude and frequency during the training period, with an 
effect size of 1.19, compared to 0.39 with.no progression [225]. This study also found 
frequencies over 30Hz to be most effective, however they also found amplitudes greater 
than 6mm to be most effective, with 6-12 minutes of training with shorter training 
intervals and vertical platforms to be more effective [225]. 
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The addition of WBVT to a conventional training program significantly increased knee 
extensor strength with a standardised mean difference of 0.76 [224]. When the young 
adult and older adult groups were analysed separately, the effects on knee extensor 
strength were not significant for the young adult population but remained significant in 
the older adult population with a standardised mean difference of 0.47 [224]. WBVT 
frequencies greater than 30Hz had a greater effect on knee extensor strength compared to 
frequencies less than 30Hz, with standardised mean differences of 1.12 and 0.41 
respectively, and amplitudes up to 4mm had a significant effect on knee extensor 
strength, with a standardised mean difference of 1.08, whereas amplitudes greater than 4 
mm did not have a significant influence [224]. In another study, chronic WBVT 
significantly improved knee extension strength, with an effect size of 1.24 which, was 
smaller in young adults compared to older adults, with effect sizes of 1.18 and 1.83 
respectively [225]. Females demonstrated greater effect sizes than men (1.53 compared to 
0.75), untrained participants had greater effect sizes than trained participants (1.78 and 
0.54 respectively), and WBVT protocols including dynamic exercises had a greater effect 
size, (1.40), in comparison to isometric muscle contraction, (0.78) [225]. Effect sizes 
increased with higher frequencies, amplitudes and dose, with 12-15 minutes of WBVT 
each session associated with maximum gains in knee extensor strength [225]. These 
improvements in knee extensor strength associated with WBVT are considered to be 
similar to those seen in conventional resistance training programs, however these effects 
appear to only occur with vertical platforms and not side-alternating platforms [225]. 
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The effects of WBVT on muscle in children has been investigated in several disease 
cohorts including Cerebral Palsy (CP), Osteogenesis Imperfecta (OI), Duchenne 
Muscular Dystrophy (DMD), Spinal Muscular Atrophy (SMA), Down syndrome and 
Cystic Fibrosis. In children with CP who undertook 6 months of WBVT, nine minutes a 
day, as part of an intensive physiotherapy program also utilising resistance training and 
treadmill walking, total body lean tissue mass increased 3.11% [200]. In another study of 
children with CP randomised to WBVT, 18 minutes, 3 times a week for 8 weeks, or 
control, tibialis and soleus muscle thickness increased significantly in the WBVT group 
[226]. In contrast, WBVT did not increase lean tissue mass or muscle cross sectional area 
in children with disabilities [197], CP [199], DMD [204] and Down syndrome [227].  
 
The effects of WBVT on muscle strength in children have also demonstrated variable 
results. In boys with DMD, three months of WBVT, 6 minutes, 2-3 times a week, did not 
improve knee extensor, plantar flexion or dorsiflexion strength [204], and another study 
of children with DMD and SMA, WBVT 9 minutes a day, 5 times a week for 8 weeks, 
also found no improvement in leg muscle strength after WBVT [228]. A similar result 
was seen for leg muscle strength after 4 weeks of WBVT, 10-15 minutes, 3 times a week, 
in children with cystic fibrosis [229], and in children with CP no difference in calf muscle 
strength was found between groups after 6 months of WBVT for 10 minutes daily or a 
standing program [199]. In contrast, muscle force increased significantly after six months 
of WBVT, 18 minutes daily, in children with OI [230, 231] and in young adults with 
cystic fibrosis, 6 minutes of daily WBVT for six months significantly increased muscle 
force during one-leg hopping [232], however in another study of WBVT, 6 minutes, 5 
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times a week for three months, in young adults with cystic fibrosis muscle force during 
one-leg hopping did not improve [233]. In both of these studies in young adults with 
cystic fibrosis, jump performance increased significantly after WBVT [232, 233]. Muscle 
force also increased in children with CP who performed WBVT, 9 minutes a day for six 
months, as part of an intensive physiotherapy program also utilising resistance training 
and treadmill walking [200], and significantly more in children with CP who participated 
in WBVT, 9 minutes, 5 times a week for three months, compared to children 
participating in a conventional physiotherapy program [234]. In young adults with CP, 
WBVT for 2-6 minutes, or resistance training 3 times a week for eight weeks 
significantly improved muscle strength, however there was no difference between groups 
[235]. A recent systematic review and meta-analysis investigating the effects of WBVT 
in CP in children did not find that WBVT had a significant effect on muscle strength 
when compared with a control group [202]. Much of the divergence in strength outcomes 
after WBVT in children and young adults can be attributed to the small number of 
studies, their small sample sizes, the lack of RCTs and the variability in vibration training 
protocols, including type of plate, frequency of training, intensity and volume. A 
systematic review of the effects of WBVT for strength in children and adolescents 
suggests that muscle strength gains occur when WBVT is performed daily for 10-20 
minutes, at a frequency of 15-30Hz, an amplitude of 1-4mm and a duration of 26 weeks 
[205]. 
 
In healthy young adults, a progressive WBVT protocol for 4 minutes, 3-5 times a week 
for four [236] and eight months [208] duration, in comparison to a control group, showed 
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no improvement in isometric knee extension strength, however jumping performance 
improved significantly in the WBVT groups in both studies, with jump height increasing 
8.5% [236] and 7.8% [208] respectively. In young adult women, 12 weeks of WBVT, 3 
times a week with knee extension exercises compared to the same exercises without 
vibration, a lower limb resistance training group and control, found that jump 
performance increased significantly in the WBVT training group only, with a 7.6% 
increase in jump height, and knee extension strength increased significantly in the WBVT 
and resistance training group compared to placebo and control groups, however there 
were no differences in the effects of training between these two groups [169]. In a study 
of young men comparing the effects of nine weeks of training, 2-3 times a week, between 
WBVT with weighted squatting exercises, WBVT and unweighted squatting exercises, 
and floor based weighted squatting exercises, similar improvements in leg strength and 
jump performance were demonstrated in all groups [237]. In two further studies of 
physically fit students, WBVT for 5-8 minutes, 3 times a week for 11 weeks compared to 
control demonstrated no changes in muscle strength or jump performance after WBVT or 
between groups [238], and WBVT with progressive exercises compared to the same 
exercises performed on the floor 3 times a week for four weeks, found no differences in 
jump performance after the intervention in either group, however muscle endurance 
increased significantly in the WBVT group compared to the conventional training group 
[188]. These studies suggest that WBVT may be equivalent to conventional resistance 
training in young healthy adults, but does not appear to consistently provide an additive 
effect to conventional training programs. 
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In post-menopausal women, WBVT for 3-6 mins, 2 times a week for 24 weeks compared 
to control significantly improved jump performance by ~5%, due to increases in power 
but not force [212]. In another study, 24 weeks of progressive WBVT with exercises for 
3-20mins, 3 times a week compared to conventional resistance training and control 
demonstrated significant improvements in jump performance (~20%) and knee extensor 
strength (~15%) in both the WBVT and resistance training groups, but not in the control 
groups, with the majority of the improvement seen in the first three months of WBVT 
[239]. A similar study comparing WBVT for 30 minutes, 3 times a week for 24 weeks, 
with conventional resistance training and control also found significant improvements in 
knee extensor strength for the WBVT and resistance training groups but not the control 
group [213]. WBVT, 6 minutes, 3 times a week for eight months compared to a 60 
minute walking program at 70% maximum heart rate did not find any improvements in 
knee strength in either group, however vertical jump performance improved significantly 
(~7%) in the WBVT group [240]. In a more recent study, WBVT 5 mins, 2-3 times a 
week for twelve months vs control did not show any improvements in jump height or 
knee extensor strength after WBVT [215]. Similar to the studies in young adults, WBVT 
in post-menopausal women indicate that WBVT may be as effective as conventional 
resistance training protocols in improving knee extensor strength and jump performance, 
however the improvements with WBVT appear to be accomplished with much shorter 
time requirement compared to conventional training regimes [213]. 
 
In older adults, two recent systematic reviews and meta-analyses have sown that when 
WBVT was compared to conventional exercise programs there were no between group 
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differences in the improvements in knee extensor muscle strength of jump performance 
[217, 241]. However, when WBVT was compared to the control state, isometric knee 
extension strength was significantly improved with WBVT, with a standardised mean 
difference of 2.15 [241], and dynamic knee extension strength was also significantly 
improved with WBVT, with a standardised mean difference of 0.63 [217]. Power 
generated during dynamic exercises was also significantly higher after WBVT, with a 
mean difference of 10W [241], and leg press performance improved significantly after 
WBVT, with a standardised man difference of 0.57 [242]. In a study of  older men, 
WBVT with execises for 40 minutes, 3 times a week compared to 90 minutes of 
conventional exercise, including cardiovascular, resistance and balance exercises,  or 
control, femoral muscle mass increased ~3% in both the exercise and WBVT groups but 
not in the control group [243]. A more recent study, comparing WBVT to sham in 
combination with a falls prevention program in elderly participants at risk of falling, 
found that leg power increased significantly with WBVT compared to control [222]. 
Another study WBVT in older adults reported that standing position on the platform and 
posture adopted likely influences the response to WBVT, as improvements in muscle 
strength and power appeared to be greater when participants stood on the plate with 
flexed knees [244]. The same authors also reported that significant gains in muscle 
performance occurred when studies were a minimum of eight weeks duration and used 
side-alternating platforms with frequencies of 26-28Hz [244]. 
 
The effects of WBVT on muscle function have also been investigated in neuromuscular 
diseases including stroke and multiple sclerosis. A systematic review and meta-analysis 
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in stroke patients found that WBVT compared to control or another intervention did not 
have a significant treatment effect on knee extensor muscle strength [245]. Another 
systematic review [246] found that when WBVT in stroke patients was compared to an 
identical program without WBVT there were no significant treatment effects for knee 
extension strength [247] and there was no change in rectus femoris, vastus lateralis or 
medial gastrocnemius thickness [248], however, when WBVT was compared to 
convention physiotherapy, WBVT induced significantly greater improvements in knee 
extension strength [249, 250]. In multiple sclerosis, a systematic review [251] found that 
progressive WBVT, 50 sessions over 20 weeks, 2.5-16.5 minutes, compared to control, 
did not improve knee extension strength [252], whilst four weeks of WBVT, 3 times a 
week for 7 minutes, compared to the same exercises without WBVT significantly 
improved knee extensor strength, however there was no difference between groups [253]. 
In a case report of the use of WBVT in a young adult with late onset Pompe disease, 4 
minutes, 3 times a week for 15 weeks, resulted in increased jump performance, and was a 
favourable alternative to conventional exercise regimes which cause fatigue and shortness 
of breath and require high levels of motivation and effort [254]. 
 
1.7.4 Effects on Function 
 
In children with CP, a systematic review and meta-analysis [202] of two studies [198] 
[255] found that WBVT significantly increased performance in the Gross Motor Function 
Measure (GMFM) walking, running and jumping domain, with a mean difference of 2.97 
[202], however the improvement in the standing domain did not reach significance [202]. 
Another study in children with CP using six months of WBVT, 9 minutes a day, as part 
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of an intensive physiotherapy program also utilising resistance training and treadmill 
walking, a 10% improvement in the GMFM sitting domain was found, which remained 
significant in children less than 10 years but not over 10 years of age, a 14% increase in 
the crawling and kneeling domain, a 35% increase in the standing domain, which was 
only significant in children under 10 years of age, and an 8% improvement in the 
walking, running and jumping domain [200]. WBVT was found to significantly improve 
gait speed by 0.13m/s in a systematic review and meta-analysis [202] of two studies 
[198] [226], however in young adults with CP, a progressive WBVT 4-6 minutes, 3 times 
a week for eight weeks, compared to resistance training, did not improve gait function 
measured by the six minute walk test and timed up and go and there was no improvement  
seen in the GMFM [235]. In children with CP randomised to WBVT, 9 minutes, 5 times 
a week for three months, as well as routine physiotherapy or routine physiotherapy alone, 
the children receiving the WBVT had significantly more improvement in their stability 
indices in the anterio-posterior and medio-lateral directions as well as overall [234]. 
 
In children with OI participating in six months of WBVT, 9 minutes a day, as part of an 
intensive physiotherapy program also utilising resistance training and treadmill walking, 
one-minute walking distance increased 43% [203]. Other studies in children with OI have 
also found improvements in walking ability and independence [256, 257]. In children 
with spina bifida, WBVT for 9 minutes twice a day, 5 times a week for six months with 
ongoing physiotherapy intervention improved gait speed by 0.11m/s, and demonstrated 
significant improvements in the GMFM total score, and in the standing and walking, 
running and jumping domains [258]. In children with DMD and SMA, WBVT 9 minutes 
 84 
twice daily, 5 times a week for four weeks demonstrated improvements in the distance 
walked in the six-minute walk test, however this was only significant in the children with 
SMA, who had an 8% improvement [228]. Another study of WBVT in DMD, 2 minutes, 
3 times a week for four weeks, also found no improvement in mobility [259]. In young 
adults with cystic fibrosis, WBVT 6 minutes a day, 5 times a week for three months 
significantly improved chair rise test performance [233].  
 
In older adults, a systematic review and meta-analysis comparing WBVT to conventional 
exercise or control did not find a significant effect of WBVT for the timed up and go test 
[241], however another systematic review and meta-analysis found that when WBVT was 
compared to control, timed up and go performance was significantly improved after 
WBVT, with a standardised mean difference of 0.34, but there was no difference between 
WBVT and conventional exercise programs in improving timed up and go performance 
[260].  Similarly, another group found that chair rise test performance was significantly 
improved after WBVT compared to control, with a standardised mean difference of 0.72, 
however WBVT compared to an exercise intervention had equivalent effects [217]. 
Conflicting results for the effect of WBVT on walking speed were found in a systematic 
review and meta-analysis [260].  
 
The effect of WBVT on function has also been investigated in neuromuscular diseases 
including Parkinson’s Disease (PD), Multiple Sclerosis (MS) and stroke. A Cochrane 
review on the effect of WBVT for PD found no difference in disease score, balance or 
gait performance between WBVT and exercise interventions [261], and this was 
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supported by another systemic review [262]. PD patients randomised to WBVT, 30 
minutes, 5 days a week for three weeks or balance training, demonstrated significant 
improvements in balance, however these improvements were not significantly different to 
the conventional balance training group [263]. There is some evidence in the literature 
that long term WBVT may have an impact on health related quality of life in patients 
with PD [263, 264]. In MS, WBVT did not demonstrate a superior effect on gait [262] 
when compared to an exercise program [265] or control [252], and no differences in 
quality of life were found when WBVT was compared to an exercise intervention [252]. 
However, eight weeks of WBVT in patients with MS resulted in significant 
improvements in 10m walk test, timed up and go and standing balance [266]. A 
systematic review and meta-analysis of the effects of WBVT on muscle function after 
stroke found that long term WBVT significantly improved timed up and go performance 
in comparison to a control or exercise intervention, however there was no difference in 
the improvements between WBVT and other interventions for the 10m and six-minute 
walk tests [245]. The same authors did not find any benefit of WBVT in comparison to 
control or exercise interventions on balance, measured by the Berg Balance Scale, after 
stroke [245], however another systematic review [246] suggested that WBVT compared 
to no intervention significantly improved postural control [250], but this superior effect 
of WBVT was not maintained when WBVT was compared to an exercise intervention 
[247, 267]. When WBVT with exercises was compared to the same exercises without 
WBVT after stroke, there were no between group differences in the incidence of falls 
[268]. Furthermore, WBVT in polio sufferers, 10 minutes, twice a week for five weeks, 
did not improve timed up and go or six-minute walk performance [269]. 
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In summary, WBVT appears to be equally effective in improving muscle strength and 
mobility as conventional exercise interventions, however it has the benefits of achieving 
these outcomes in less time [262, 270, 271], in a small space and without requiring 
technical abilities [272], making it an alternative treatment strategy for improving muscle 
performance, balance and function, and optimising bone health in exercise intolerant or 
mobility limited individuals who are unable to participate in more conventional high 
impact, high intensity exercise interventions [260, 270, 273-275]. WBVT is easily 
integrated into daily life [228], simultaneously exercises muscles in the lower limbs and 
trunk, does not generate the fatigue and lack of motivation associated with participating 
in conventional aerobic and resistance interventions [271], and as a result is an attractive 
modality for use as an adjunct in physical rehabilitation programs [261]. 
 
1.7.5 Adverse Events 
 
No serious adverse events associated with WBVT have been reported in the literature. 
Common mild adverse effects include muscle soreness [195, 228, 245, 260, 271], itching 
in lower limbs [214, 225, 241, 245, 260, 271], erythema [214, 225, 228, 241, 260, 271], 
foot, groin and knee pain [195, 225, 241, 245, 260, 271], joint effusion [195, 225, 260], 
headache [195, 241, 260, 271] and mild dizziness [245]. These adverse effects are 
generally mild and transient, subsiding after the first few sessions as training progresses 
[195, 228, 241, 260]. 
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1.8 Mitochondrial structure, function and genetics 
 
Mitochondria are small, cytoplasmic, membrane bound organelles, measuring 0.5-1.0μm 
in diameter, found in the majority of eukaryotic cells [276]. A primary role of the 
mitochondria is the generation of cellular adenosine triphosphate (ATP) from the 
metabolic substrates, glucose and fatty acids, through oxidative phosphorylation 
(OXPHOS). The generation of ATP provides eukaryotic cells with a useable form of 
energy that fuels intracellular processes [276-281]. The mitochondrial content of a cell is 
dependent on the tissue’s requirement for ATP [277]. Mitochondria are also involved in a 
number of other processes required for cellular functioning [279, 282, 283] including the 
citric acid cycle (TCA), parts of the urea cycle, calcium homeostasis [284, 285], 
regulation of apoptosis [277, 286], intracellular signalling [287], iron sulphur biogenesis, 
the formation of free radicals [288] and reactive oxygen species [289], and they are 
believed to contain over 1000 proteins [290, 291].  
 
1.8.1 Mitochondrial Genetics 
 
Mitochondria are eukaryotic organelles that are under dual genetic control from both 
nuclear deoxyribonucleic acid (nDNA) as well as mitochondrial DNA (mtDNA), for may 
cellular functions, including OXPHOS [281-283, 292-295]. The origin of this dual 
genetic control dates back nearly two billion years, when early eukaryotic cells were 
colonised by bacteria. These early eukaryotic cells derived their energy from anaerobic 
glycolysis, a much less efficient pathway than the aerobic metabolic pathways utilised by 
the bacterial cells. A symbiotic relationship developed between the eukaryotic cells and 
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the bacteria, and with evolution this relationship became permanent, with bacteria 
evolving into mitochondria, providing a pathway for aerobic metabolism within 
eukaryotic cells [280, 296]. The mitochondria however, retained their own DNA from 
their bacterial origins. Throughout evolution, the mitochondrial genome has lost the 
majority of its genes and autonomy to the nuclear genome. Modern day mitochondria are 
dependent on nuclear genes and their products for all their basic functions including 
mtDNA replication and translation, the synthesis of mitochondrial respiratory chain 
(MRC) subunits, and the synthesis of phospholipids, the structural components of the 
inner mitochondrial membrane in which the MRC resides and where OXPHOS takes 
place [283, 293, 296-298]. 
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Figure 1.1: Mitochondrial genome. 
 
 
The mitochondrial genome (Figure 1.1) was first discovered in 1963 [299, 300] and has 
many features akin to its bacterial heritage [298]. It is a double stranded, circular 
molecule consisting of 16,569 base pairs, predominantly composed of exons, with no 
introns, infrequent non-coding bases between genes and no termination codons [301]. 
There is one small, non-coding region in the outer strand, the displacement loop, where 
mtDNA transcription and replication regulatory factors bind [282, 288]. Replication of 
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the mitochondrial genome, similar to bacterial replication, is bidirectional and 
asynchronous, with the outer, heavy-stand, of the double stranded circular molecule, 
undergoing replication first, followed by replication of the inner, light-strand [290]. The 
mitochondrial genome encodes 37 gene products: 13 MRC subunits contributing to 
complexes I, III, IV and V; 2 ribosomal ribonucleic acids (rRNA), a large one, 16S, and a 
small one, 12S; and 22 transfer RNA (tRNA), with the rRNA and tRNA required for 
mtDNA translation [279, 281, 295-298, 302]. The majority of the mtDNA encoded gene 
products are located on the heavy-strand, however one MRC subunit and 8 of the 22 
tRNA are located on the light-strand. All other MRC subunits, proteins required for the 
maintenance and expression of mtDNA and mitochondrial protein synthesis are encoded 
by the nuclear genome, and are believed to number around 1700 [281, 295, 298, 302-
305], indicating significant interdependence between the mitochondrial and nuclear 
genomes and the importance of competent inter-genomic signalling [290]. Nuclear 
encoded MRC subunits are synthesised in the cell cytoplasm, transported into the 
mitochondria and assembled with mtDNA encoded subunits, synthesised within the 
mitochondrial matrix, to form the MRC complexes [282, 306, 307]. 
 
Mitochondrial genetics, like mitochondrial replication, transcription and translation, also 
have characteristics of their bacterial ancestors and differ from mendelian genetics and 
nDNA mechanisms [290, 295, 304]. In contrast to the laws of mendelian genetics, all 
mtDNA is maternally inherited [308], thousands of copies of mtDNA coexist in a single 
cell and not all copies of mtDNA are identical [281, 283, 288, 297, 309, 310]. The 
coexistence of wild-type and mutant mtDNA is known as heteroplasmy [311], and next 
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generation sequencing has suggested that heteroplasmy exists in low levels, 0.2-2%, in all 
individuals [312], and only becomes pathogenic when a critical threshold of mutant 
mtDNA accumulation is reached, the threshold effect [281, 297, 309, 313]. Disease 
manifestation usually occurs when mutant mtDNA constitute in excess of 80% of all 
mtDNA in a cell [297], however the pathogenic threshold varies between tissue types 
depending on their utilisation of OXPHOS and dependence on aerobic metabolism [281, 
282] and provides an explanation for tissue selectivity in MRCD [314]. Paradoxically, 
mutation load, and therefore genotype and clinical phenotype, can change over time 
[315]. During replicative segregation of the mitochondrial genome, the allocation of 
wild-type or mutant mtDNA to daughter cells is random, resulting in fluctuations around 
the pathogenic threshold, explaining pathologic variation within and between tissues. 
Variation in mutant load also underpins the clinical variability seen in individuals with 
the same disease [281, 282, 288, 297, 309, 316]. Finally, shifts in the frequency of 
pathogenic mtDNA mutations between generations may be explained by the bottleneck 
theory. This theory postulates that during oogenesis, a bottleneck occurs which may 
cause the segregation of a subsample of mtDNA carrying a high mutation load, resulting 
in increased frequency of pathogenic disease in the subsequent generation despite 
absence of disease in the previous generations [278, 317-319]. 
 
1.8.2 Mitochondrial Structure 
 
Mitochondria are divided into four compartments, the outer membrane, the inner 
membrane, the inter-membrane space and the matrix. The outer membrane is smooth and 
is separated from the inner membrane by the inter-membrane space. The inner membrane 
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encapsulates the matrix and contains many folds, known as cristae, which protrude into 
the matrix. The mitochondrial respiratory chain and enzymes required for OXPHOS are 
embedded in the inner mitochondrial membrane. The matrix contains enzymes required 
for the citric acid cycle, the pyruvate dehydrogenase complex and β-oxidation of fatty 
acids as well as chaperones for mitochondrial protein import and the assembly of 
OXPHOS enzymes and finally, mtDNA [276, 279]. Each compartment and their 
respective functions have critical roles in ATP generation. 
 
1.8.3 ATP Generation - The Mitochondrial Respiratory Chain 
 
The majority of cellular ATP is generated by OXPHOS, which is achieved through a 
series of biochemical events that occur along the mitochondrial respiratory chain (MRC) 
[296, 302]. The MRC is comprised of five functionally coupled multimeric protein 
complexes (Figure 1.2). Four of these complexes and two mobile electron carriers make 
up the electron transport chain, which provides links to the TCA and access to reducing 
equivalents from intermediary metabolism, and catalyses electron transfer to oxygen to 
form water, creating with it a proton gradient which is used by the fifth and final complex 
to generate ATP [276, 278, 281, 297, 298].  
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Figure 1.2: Mitochondrial Respiratory Chain. Source: www.bioscience.org/2009/v14/ 
af/3509/fig5.jpg. 
 
1.8.3.1 Complex I 
 
Complex I, reduced nicotinamide adenine-dinucleotide (NADH) dehydrogenase-
ubiquinone (CoQ10) reductase, is the largest and heaviest of the 5 MRC complexes and 
consist of at least 46 subunits, 7 or which are encoded by mtDNA, ND1-4, ND4L, ND5 
and ND6 [280, 292, 302]. Pyruvate, generated from the glycolysis of glucose in the 
cytoplasm of the eukaryotic cell, is carried into the mitochondrial matrix where it is 
converted into acetyl-CoA by the pyruvate dehydrogenase complex. In another pathway, 
cytoplasmic fatty-acyl-CoA is carried into the mitochondrial matrix and converted into 
acetyl-CoA via β-oxidation. The acetyl-CoA then enters the TCA and NADH is 
generated [279]. NADH enters complex I which catalyses the transfer of electrons from 
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NADH to CoQ10 and expels protons across the inner mitochondrial membrane into the 
inter-membrane space [290, 320]. The electron carrier CoQ10 is encoded solely by 
nDNA [280, 298]. 
 
1.8.3.2 Complex II 
 
Complex II, succinate-ubiquinone reductase, is the smallest of all the MRC complexes, 
consisting of only 4 subunits which are all located on the matrix side of the inner 
mitochondrial membrane functioning as part of the TCA as well as the electron transport 
chain, with all subunits are encoded by nDNA. Reduced flavin adenine-dinucleotide 
(FADH2), generated in the TCA, enters complex II which catalyses the transfer of 
electrons from FADH2 to CoQ10 via the complex’s iron-sulphur cluster. As Complex II 
does not span the inner mitochondrial membrane, it is the only complex of the electron 
transport chain that does not expel protons from the matrix to the inter-membrane space 
[280, 290, 292, 298, 302, 320-322]. 
 
1.8.3.3 Complex III 
 
Complex III, ubiquinone-cytochrome c reductase, consists of 11 subunits of which only 
one is encoded by mtDNA, cytochrome b. Electrons transferred from complexes I and II 
to CoQ10, are transferred from the fully reduced CoQ10 to cytochrome c via the catalytic 
action of complex III. Energy from the transfer of these electrons expels protons from the 
matrix to the inter-membrane space [280, 290, 292, 298, 302, 321]. 
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1.8.3.4 Complex IV 
 
Complex IV, cytochrome c oxidase, consists of 13 subunits, 3 of which are encoded by 
mtDNA, COX I, COX II and COX III, which contribute to the catalytic core. Complex 
IV is the final complex in the electron transport chain and catalyses the transfer of 
electrons, from cytochrome c, to oxygen to form water, producing energy which expels 
protons from the matrix to the inter-membrane space [280, 292, 302, 320-322]. The 
electron carrier cytochrome c is encoded by nDNA [280, 298]. 
 
1.8.3.5 Complex V 
 
Complex V, ATP synthase, consists of 16 subunits, 2 of which are encoded by mtDNA, 
ATPase 6 and ATPase 8 [280, 292, 302]. The protons expelled from the matrix to the 
inter-membrane space by complexes I, III and IV create a proton gradient which is then 
used by complex V to generate ATP as the protons flow back into the matrix, driven by 
the proton gradient, through this complex [280, 281, 292, 297, 298, 302].  
 
1.9 Mitochondrial Respiratory Chain Disorders 
 
Mitochondrial respiratory chain disorders (MRCD) occur when the ability of the 
mitochondria to perform OXPHOS and generate ATP is impaired [296, 304]. MRCD can 
be caused by mutations in either the mitochondrial or nuclear genomes due to the bi-
genomic regulation of the MRC. Pathogenic mutations in mtDNA can be sporadic large-
scale deletions, or maternally inherited point mutations, affecting mitochondrial protein 
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synthesis. Mutations in nDNA follow mendelian genetics and can be autosomal 
dominant, autosomal recessive or X-linked. Nuclear DNA mutations causing MRCD 
include mutations in genes encoding MRC subunits, genes encoding MRC assembly 
proteins, genes associated with mtDNA translation, genes involved in the structural 
composition of the inner mitochondrial membrane, genes affecting mitochondrial 
dynamics and genes interfering with mitochondrial DNA maintenance [281, 290, 296, 
297, 302, 305, 309, 321, 323-325]. 
 
1.9.1 Mutations in mtDNA 
 
Mutations in mtDNA were first identified in 1988 [311, 326] and since then over 120 
large-scale deletions, 260 pathogenic point mutations and numerous non-pathogenic 
polymorphisms have been identified [281, 282, 288, 298, 321, 327]. MRCD caused by 
mutations in mtDNA are generally heteroplasmic, with pathogenic features and severity 
reflective of the tissues affected, their pathogenic thresholds and dependence on oxidative 
metabolism and the individual’s mutation load [282]. Mutations in mtDNA are the most 
common cause of adult onset mitochondrial disease [328]. 
 
1.9.1.1 Large-scale deletions 
 
Large-scale deletions, or rearrangements, in mtDNA are generally sporadic, occurring 
early in foetal development, and involve a single, large deletion, the size and position of 
which can differ, but which appear to occur in regions of the mitochondrial genome 
adjacent to repeated sequences [329]. One proposal is that these single large-scale 
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deletions may occur during the repair of damaged mtDNA [330] and often affect multiple 
genes and their associated proteins. MRCD caused by single large-scale deletions include 
Kearns-Sayre Syndrome (KSS), Pearson Syndrome and Progressive External 
Opthalmoplegia (PEO) [281, 282, 290, 296-298, 321, 324, 325].  
 
1.9.1.2 Point mutations 
 
Point mutations in mtDNA are usually maternally inherited and affect genes responsible 
for the synthesis of proteins essential for the formation of MRC subunits or tRNA and 
rRNA function, resulting in heteroplasmic disorders and multi-system disease [281, 290, 
296, 297, 309, 323, 331]. Point mutations in mtDNA are 10 fold higher than that seen in 
nDNA [281, 332, 333] and this increased frequency of mutations is considered to be due 
to an increased susceptibility of the mitochondrial genome to damage as a result of: the 
proximity of the mitochondrial genome to the MRC which generates reactive oxygen 
species [296, 332]; the low repair capacity of mtDNA [296]; the absence of histone-
mediated protection [281, 333]; and the accumulation of mutations with age [281]. 
Pathogenic point mutations have been found in all of the mtDNA encoded MRC subunits 
in complexes I, III, IV and V, with over 100 different mutations currently identified 
[281]. In complex I, point mutations in the mtDNA encoded subunits are the most 
numerous of all the MRC complexes, accounting for 50 of the known mtDNA point 
mutations in MRC subunits [296] and cause Leber Hereditary Optic Neuropathy (LHON) 
[326, 331, 334, 335], Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like 
episodes (MELAS) and Leigh Syndrome (LS) [296]. In complex III, point mutations in 
mtDNA encoded subunit cytochrome b, account for 20 of the known mtDNA MRC 
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subunit point mutations, the largest number in any single subunit, and cause LS, MELAS 
and myopathy. Complex IV subunits are the second most common site for mtDNA point 
mutations accounting for 23 of the known point mutations, which cause myopathy. The 
two mtDNA encoded subunits of in complex V account for 15 of the known pathogenic 
mtDNA point mutations and cause LS, LHON, Neuropathy, Ataxia and Retinitis 
Pigmentosa (NARP) and encephalopathy [281, 296, 298, 305, 321, 324, 325]. More than 
160 pathogenic point mutations have been found in mtDNA encoding rRNA and tRNA 
and over 50% of all identified pathogenic point mutations are located in the 
mitochondrial tRNA genes, despite these genes comprising less than 5% of the 
mitochondrial genome [282]. Pathogenic point mutations in mitochondrial rRNA and 
tRNA genes result in impaired overall mitochondrial protein synthesis [281, 282]. Point 
mutations in the mtDNA genes encoding the small rRNA, 12S, cause deafness, and in the 
large rRNA, 16S, point mutations cause cardiomyopathy. Pathogenic point mutations 
have also been identified in all of the 22 tRNA genes, with the most common sites 
involving the tRNA Leu, tRNA Ile and tRNA Lys genes [296]. These pathogenic point 
mutations cause various clinical presentations including myopathy, encephalomyopathy, 
Myoclonus Epilepsy and Ragged-Red Fibers (MERRF), deafness, cardiomyopathy, PEO, 
LS, MELAS, LHON and epilepsy [281, 298, 305, 321]. 
 
1.9.2 Mutations in nDNA 
 
There are approximately 1500 mitochondrial proteins encoded by nDNA [336-338] and 
mutations in these nuclear encoded proteins likely account for the majority of MRCD 
[321]. The first pathogenic nDNA mutation was identified in a nuclear encoded subunit 
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of the MRC complex II in 1995 [339]. Since then, more than 220 pathogenic nDNA 
protein encoding genes have been identified [279], with the majority following an 
autosomal recessive inheritance pattern and parental consanguinity increasing the 
incidence of autosomal recessive inheritance of MRCD [296, 321, 337, 340]. Many of 
these disorders are multi-systemic with disease onset in infancy and childhood [302, 
328]. Adult onset MRCDs caused by nDNA mutations are generally caused by the 
progressive loss of mtDNA integrity [328]. 
 
1.9.2.1 Mutations in genes encoding MRC subunits 
 
Mutations in nDNA genes encoding MRCD subunits have been identified in all of the 5 
MRC complexes, however they are most common in complex I, where mutations in at 
least 16 nDNA encoded subunits have been identified [296, 328]. These nDNA mutations 
in complex I are often associated with autosomal recessive LS [328, 341]. Nuclear 
mutations in the structural subunits of complexes II, III, IV and V are also most 
commonly associated with LS which have similar clinical presentations causing severe 
infantile disease [281, 296, 297, 323, 328]. 
 
1.9.2.2 Mutations in genes encoding MRC assembly or ancillary proteins 
 
MRC assembly and ancillary proteins are essential in the synthesis of both nuclear and 
mitochondrial encoded MRC subunits, the transport of nuclear encoded MRC subunits 
and other essential nuclear encoded proteins required for mitochondrial functioning from 
the cell cytoplasm into the mitochondria, and assembly of mitochondrial and nuclear 
 100 
encoded subunits into the MRC multimeric complexes. They are responsible for proper 
protein folding, the addition of co-factors, protein stabilisation and quality control, 
ensuring optimised structural integrity and function [290, 321]. Mutations in any of the 
genes involved in these processes cause MRCD and are known to effect the proper 
functioning of complexes I, III, IV, V and CoQ10 [281, 296, 297]. To date, few 
mutations in genes involved with protein transport into the mitochondria have been 
identified, however one such mutation in the TIMM8A gene causes Mohr-Tranebjaerg 
deafness-dystonia syndrome [296]. The first mutation in a nuclear encoded MRC 
assembly gene, SURF1, was identified in 1998 [342, 343]. There are now over 30 known 
mutations in the SURF1 gene [344], which is associated with assembly of MRC complex 
IV, and one of the most common causes of LS. More recently, mutations in at least seven 
more genes associated with complex IV assembly have been identified [296]. Mutations 
in assembly genes associated with complex III were first identified in 2002 in the BCS1L 
gene, which encodes a mitochondrial chaperone involved in the assembly of the Rieske 
iron-sulphur subunit into complex III as well as complexes I and II. Mutations in this 
nDNA encoded protein is associated with defects in multiple MRC complexes and causes 
Growth Retardation, Aminoaciduria, Cholestasis, Iron overLoad, and Early death 
(GRACILE) syndrome [345]. More recently, mutations in complex I assembly factors 
have been identified causing LS [346]. LS caused by mutations in nuclear encoded 
assembly and ancillary proteins commonly present as multi-systemic disorders in infancy 
with leukodystrophy and cardiomyopathy and more diverse clinical pathology compared 
to LS due to mutations in MRC subunits [296, 347]. Mutations in nuclear encoded genes 
causing CoQ10 deficiency were identified in 2006 [348, 349] and cause cerebellar 
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atrophy, stroke like lesions, encephalomyopathy and nephrosis [283, 296, 297, 347] 
which manifests as 5 predominant phenotypes: encephalomyopathy with recurrent 
myoglobinuria, seizures, ataxia, mental retardation and ragged red fibers; severe infantile 
multisystemic disease; cerebellar ataxia; LS; and isolated myopathy [350]. 
 
1.9.2.3 Mutations in genes associated with mtDNA translation 
 
Mitochondrial DNA encodes 9 monocistronic and 2 bicostronic messenger RNA 
(mRNA) that are translated by mitochondrial ribosomes into the 13 mtDNA encoded 
subunits of the MRC. The synthesis of functioning MRC subunit proteins requires the 
correct and co-ordinated functioning of the mitochondrial ribosome, mitochondrial rRNA 
and tRNA and each of the 4 phases of mitochondrial mRNA translation (initiation, 
elongation, termination and recycling), as well as the ancillary factors involved in each 
phase, translational activators and tRNA and rRNA modifiers [281, 290, 296, 297, 304, 
321, 351-353]. All of these components involved in mtDNA translation are nuclear 
encoded and mutations in any of these genes can cause MRCD, generally characterised 
by multiple MRC complex defects, with severe neurological involvement, often 
presenting as LS in infancy, however clinical heterogeneity in these disorders has been 
reported [297, 298, 304, 328, 354]. Mutations in ribosomal protein assembly genes, e.g. 
MRPS16 and RMND1, causes fatal neonatal lactic acidosis and mutations in nuclear 
encoded elongation factors cause infantile hepatocerebral syndrome (GFM1 gene) and 
infantile encephalomyopathy (TUFM gene). Nuclear mutations in translational activator 
genes, e.g.TACO1, cause LS and nDNA mutations in tRNA modifying genes, e.g. 
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YARS2, cause Myopathy, Lactic Acidosis and Sideroblastic Anaemia (MLASA) [296, 
297, 355]. 
 
1.9.2.4 Mutations in genes involved in the structural composition of the 
inner mitochondrial membrane 
 
The phospholipid inner mitochondrial membrane is composed primarily of cardiolipin 
and acts a scaffold upon which the multimeric complexes of the MRC embed themselves. 
It has an active role in the formation of the MRC complexes, interacts with them, actively 
participates in OXPHOS and depends on intact MRC functioning for the synthesis of 
cardiolipin. The inner mitochondrial membrane is also in physical contact with matrix-
dwelling endoplasmic reticulum via the mitochondrial-associated endoplasmic reticulum 
membrane. This functional association is believed to have a role in the phospholipid 
composition of the inner mitochondrial membrane and impact on mitochondrial dynamics 
[281, 296, 297, 309, 323]. Nuclear mutations in genes involved in phospholipid 
composition impair the integrity of the inner mitochondrial membrane and alter MRC 
architecture and function. The first mutations in phospholipid composition were 
identified in 2000 and 2002 and involved the TAZ gene causing cardiolipin deficiency 
and Barth Syndrome, an X-linked disorder characterised by myopathy, growth 
retardation, neutropenia and cardiomyopathy [356, 357]. Another gene, AGK, encoding a 
phospholipid precursor to cardiolipin, causes Sengers Syndrome, characterised by 
myopathy, cardiomyopathy, lactic acidosis and congenital cataracts [358]. Mutations in 
the SERAC1 gene, whose protein is involved in phospholipid transfer across the 
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mitochondrial-associated endoplasmic reticulum membrane, caused alterations in the 
composition of cardiolipin and MEDGEL syndrome, 3-methylglutaconic aciduria with 
sensorineural deafness, encephalopathy, and Leigh-like syndrome [359, 360]. Mutations 
in the CHKB gene that encodes a phospholipid precursor synthesized in the 
mitochondrial-associated endoplasmic reticulum membrane, causes encephalomyopathy 
with giant displaced mitochondria, the abnormal structure of these mitochondria 
adversely impacting mitochondrial mobility and their ability to distribute normally in 
cells [281, 296, 361]. 
 
1.9.2.5 Mutations in genes affecting mitochondrial dynamics  
 
Mitochondrial dynamics refers to mitochondrial mobility, fusion and fission [281, 296]. 
Mitochondria are constantly moving and undergoing repeated cycles of fission and 
fusion, characteristics related to their bacterial origins. These features allow mitochondria 
to form extensive tubular networks throughout the cell which ensures energy is 
distributed adequately within the cell, and contributes towards mitochondrial quality 
control by providing a mechanism for the elimination of damaged mitochondria [297, 
362] [281]. These tubular networks are especially important in cells of the central and 
peripheral nervous system as mitochondria have to travel along nerve cell axons to 
adequately distribute aerobic energy sources essential for proper neuronal functioning 
[296]. Mitochondrial fission and fusion rely heavily on proper mitochondrial structure, 
function and the maintenance of mtDNA. Fission requires an intact outer mitochondrial 
membrane, several cytosolic proteins e.g. DRP1 and mitochondrial fission factors e.g. 
MFF, and fusion requires coordination between mitofusions of the outer mitochondrial 
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membrane e.g. MFN2 and inner-mitochondrial membrane e.g. OPA1 as well as 
scaffolding proteins of the inner-mitochondrial membrane [296]. Proteins involved in 
mitochondrial dynamics are nuclear encoded and mutations in any of the genes encoding 
these proteins results in mitochondria of abnormal shape and size and alters their 
distribution within cells causing MRCD, inevitably involving the nervous system causing 
neurological sequelae [296, 297]. Mutations in proteins involved in fission are 
uncommon however mutations in the DRP1 and MFF genes have been reported in the 
literature and cause fatal infantile encephalomyopathy [296]. Mutations in mitochondrial 
fusion proteins are more common, with mutations in the OPA1 gene encoding an inner 
mitochondrial membrane mitofusion, crucial for maintaining the inner-mitochondrial 
membrane architecture [363, 364], causing dominant optic atrophy (DOA), and mutations 
in the outer mitochondrial membrane mitofusion MFN2 gene causing multiple mtDNA 
deletions and depletion and multisystemic manifestations [296]. 
 
1.9.2.6 Mutations in genes interfering with mitochondrial DNA 
maintenance 
The nuclear genome encodes the genes responsible for mtDNA maintenance, including 
mtDNA replication and integrity. These genes therefore control the abundance and 
quality of mtDNA, and interference in the inter-genomic signalling between nDNA and 
mtDNA impairs mtDNA maintenance, resulting in mtDNA depletion, multiple mtDNA 
deletions and site-specific mtDNA point mutations thereby causing loss of integrity of the 
mitochondrial genome [281, 296, 309, 328, 365]. Mitochondrial DNA depletion 
syndromes usually follow an autosomal recessive inheritance pattern [302, 321, 366, 
 105 
367], and culminate in quantitative alterations to mtDNA while multiple mtDNA 
deletions often follow an autosomal dominant inheritance pattern and culminate in 
qualitative alterations in mtDNA [297, 309, 323, 347]. Mitochondrial DNA depletion 
syndromes and multiple mtDNA deletions were considered to be two different 
conditions, recently however, whole-genome sequencing has indicated that these 
conditions often co-exist. Furthermore, mutations in the same gene can result in the 
preferential manifestation of mtDNA depletion or multiple mtDNA deletion syndromes 
[296]. Preferential manifestation of mtDNA depletion syndromes often causes infantile 
disease while preferential manifestation of multiple mtDNA deletion syndromes 
generally causes adult-onset disease, with PEO the most common clinical presentation 
[296, 323, 328, 347, 368, 369].  
 
Mitochondrial DNA maintenance can be impaired due to defects in the mtDNA 
replication machinery, the replisome, or due to defects in the intra-mitochondrial pool of 
deoxyribonucleotide triphosphates (dNTPs) [296]. The mtDNA replisome consists of: a 
catalytic subunit of mtDNA polymerase (mtDNA polymerase gamma, encoded by 
POLG) [370, 371]; an accessory subunit encoded by POLG2 [372]; and the replicative 
helicases Twinkle (encoded by PEO1) [373] and DNA2 [296]. POLG encodes 3 domains 
within the catalytic subunit: the polymerase domain involved in mtDNA replication; the 
exo-nuclease domain involved in proofreading; and the linker region that links the 
replication and proofreading domains [296, 297, 309, 370]. Mutations in the POLG gene 
can result in autosomal dominant or recessive inheritance patterns, mtDNA depletion or 
multiple mtDNA deletions and clinical heterogeneity, likely a reflection on which domain 
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of the catalytic subunit has been affected [296, 309]. Mutations in POLG can cause 
Alpers Syndrome, a severe childhood disorder with autosomal recessive inheritance 
causing mtDNA depletion [374], and adult onset disorders due to multiple mtDNA 
deletions including autosomal dominant and autosomal recessive PEO and the multi-
systemic disorder, SANDO, characterised by Sensory Ataxic Neuropathy, Dysarthria and 
Opthalmoparesis [296]. Mutations in POLG2 which encodes the accessory subunit of 
POLG causes multiple mtDNA deletions and adult onset autosomal dominant PEO [372] 
[296]. Mutations in the gene PEO1 which encodes the replicative helicase “Twinkle” 
usually results in multiple mtDNA deletions causing adult onset autosomal dominant 
PEO however it has also been found to result in mtDNA depletion syndromes causing 
infantile hepatocerebral syndrome and infantile onset spinocerebellar ataxia [296]. 
 
Disruption to mtDNA maintenance also occurs due to defects in the intra-mitochondrial 
pool of dNTPs. There are 4 dNTPs whose availability is crucial for the replication and 
resynthesis of mtDNA. The pool of dNTPs is regulated by 6 identified enzymes, and 
defects in these enzymes alter the availability and balance of the dNTP pool, generally 
resulting in mtDNA depletion syndromes, characterised by 4 major syndromes with 
marked tissue specific deficiency in mtDNA: infant or adult onset myopathy caused by 
mutations in the TK2 gene [375]; infantile hepatoencephalopathy caused by mutations in 
the DGUOK gene [376]; infantile encephalomyopathy caused by mutations in the 
SUCLA2 gene [377]; and Mitochondrial NeuroGastroIntestinal Encephalomyopathy 
(MNGIE) caused by mutations in the TYMP gene [296, 378, 379]. Mitochondrial DNA 
maintenance can also be impaired by mutations in the OPA1 gene. As previously 
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discussed, the OPA1 gene encodes an inner mitochondrial membrane mitofusion, which 
when mutated, causes a non-syndromic form of DOA. The OPA1 gene is also involved in 
mtDNA maintenance through its role in tethering nucleotides required for mtDNA 
replication to the inner mitochondrial membrane. Mutations in the OPA1 gene affecting 
this nucleotide tethering role causes multiple mtDNA deletions presenting as DOA-plus, 
a syndrome characterised by optic atrophy, PEO, sensorineural hearing loss, ataxia, 
myopathy and polyneuropathy [296]. Mutations in the MGME1 gene, which encodes 
Mitochondrial Genome Maintenance Exonuclease 1, integral in mtDNA replication, also 
impairs mtDNA maintenance, resulting in mtDNA depletion and multiple deletions in 
muscle causing PEO, emaciation and respiratory failure [296]. 
 
1.9.3 MRCD Clinical Presentation 
 
The first reported case of mitochondrial disease was identified in 1962 by Luft and 
colleagues [380]. Over two decades later the first pathologic mtDNA mutations were 
discovered, large scale mitochondrial deletions causing KSS, and the point mutations 
m.3243A>G and m.1178G>A causing MELAS and LHON respectively [311, 326]. A 
decade later, the first pathogenic nDNA mutation was identified in a nuclear encoded 
subunit of the MRC complex II [339]. Currently there are in excess of 100 known distinct 
MRCD [305] and they are considered to be the most common, and often the most 
complex, of all inherited genetic diseases [295, 381] with the highest incidence of all 
congenital metabolic disorders [336, 382] and the most prevalent of all inherited neuro-
metabolic disorders [283, 383]. As the most common group of inborn errors of 
metabolism, it is believed that 1 in 5000 births will be diagnosed with a MRCD at some 
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point in their lifetime, with approximately 50% having an onset in the first 5 years of life 
and 50% having an onset at some point during their child or adult years [321, 336, 382, 
384, 385].  
 
1.9.3.1 Prevalence of MRCD 
 
The exact prevalence of MRCD is difficult to establish due to difficulties with the 
confirmation of diagnosis, the clinical and genetic heterogeneity characteristic of MRCD, 
and the ever expanding phenotypic spectrum of MRCD [295, 382, 386]. In the largest 
study of the prevalence of MRCDs in an adult population in the UK, 16 years and older, 
performed in a predominantly white cohort, with English ethnicity, and a low rate of 
parental consanguinity, the prevalence of all pathogenic mutations was 23/100,000, and 
the minimum point prevalence of affected adults with MRCD as a result of mtDNA or 
nDNA mutations was 12.5/100,000 [386]. The prevalence of clinically affected adults 
with mtDNA mutations was 9.6/100,000, accounting for over 75% of all clinically 
affected adults [386], consistent with previous reports [387, 388]. Mitochondrial DNA 
encoded point mutations in tRNA accounted for the majority of mtDNA mutations with a 
prevalence of 4.3/100,000, the m.3243A>G mutation being the most common with a 
prevalence of 3.5/100,000 [386]. Mutations in mtDNA causing LHON were the next 
most common with a prevalence of 3.7/100,000, followed by single mtDNA deletions 
with a prevalence of 1.5/100, 000, consistent with a previous report in the adult Finnish 
population of 1.6/100,000 [389], and the mtDNA encoded point mutation m.8993T>C 
with a prevalence of 0.1/100,000 [386]. Individuals at risk of developing MRCD as a 
result of mtDNA mutations had a prevalence of 10.7/100,000 [386]. The prevalence of 
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clinically affected adults with nDNA mutations was 2.9/100,000, accounting for 
approximately 25% of all clinically affected adults, a third of those affected by mtDNA 
mutations, however the prevalence of nDNA mutations is likely to increase in the future 
with improved diagnostic techniques and increased recognition of pathogenic nDNA 
mutations [386]. Some of the most prevalent nDNA mutations were in genes interfering 
with mitochondrial DNA maintenance causing multiple deletions of mtDNA and gradual 
accumulation of mutant mtDNA [296] including: the progressive external 
ophthalmoplegia 1 protein (PEO1) gene with autosomal dominant inheritance resulting in 
a prevalence of 0.7/100,000; the optic atrophy 1 (OPA1) gene with autosomal dominant 
inheritance resulting in a prevalence of 0.4/100,000; and the POLG gene with autosomal 
recessive inheritance resulting in a prevalence of 0.3/100,000 [386]. Individuals at risk of 
developing MRCD as a result of nDNA mutations had a prevalence of 5.9/100,000 [386]. 
 
In contrast to adults, where diagnosis of MRCD is generally made by the identification of 
a recognised pathogenic mtDNA mutation [388], the diagnosis of MRCD in infants and 
children is based on mitochondrial respiratory chain enzyme defects [382] with molecular 
diagnoses only obtained in approximately 20% of patients presenting with MRCD [382, 
390, 391]. MRCDs presenting in childhood are more likely to have nDNA mutations 
[296, 328, 382, 387, 392, 393] with only 10-30% of children presenting with MRCD 
having a mtDNA defect [290, 324, 382, 390, 393, 394], with MELAS the most common 
presentation caused by a mtDNA mutation [393]. The vast majority of these nDNA 
defects follow an autosomal recessive inheritance pattern with a mean age of onset 
between 3 and 4 months, much earlier than those with mtDNA mutations [328, 382, 390, 
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392, 395]. MRCD in childhood are often associated with severe, progressive disease and 
higher mortality, 10-50% per year after diagnosis, compared to diagnosis and clinical 
onset occurring in adulthood, with a mortality of 5-20% per year [279, 321, 384, 385]. In 
children, mitochondrial respiratory chain enzyme defects are most commonly found in 
Complex I (32% of presentations), followed by multiple respiratory chain complexes 
(26% of presentations), Complex IV (19% of presentations), Complex III (16% of 
presentations) and Complex II (7% of presentations) [382, 391, 393]. The minimum birth 
prevalence of childhood onset MRCD in an Australia cohort was found to be between 5-
6.2/100,000 [382], higher than the 3.2/100,00 reported  in British Columbia [396] but 
lower than the 8.9/100,000 reported in Sweden [390]. The Australian study proposed an 
estimate for the prevalence of MRCD presenting in childhood of 10/100,000 [382]. The 
minimum birth prevalence of MRCD among the Lebanese population in the Australian 
study was significantly higher at 58/100,000, likely due to the high parental 
consanguinity in this ethnic group [382]. 
 
1.9.3.2 Tissue Selectivity in MRCD 
 
Mitochondria are considered to be ubiquitous, present in essentially all eukaryotic cells, 
hence MRCD can result in disruption to the function of any tissue in the body [281, 321]. 
Tissues with high metabolic demands and a greater reliance on OXPHOS are more 
commonly and severely affected. These includes the brain, central and peripheral nervous 
systems, skeletal muscle, heart muscle, the retina and optic musculature, the cochlea, 
bone marrow, kidneys, liver, pancreas and gastro-intestinal system [281-283, 298, 305, 
319, 321, 379, 383, 397]. The lack of available ATP from OXPHOS requires increased 
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dependence on the anaerobic generation of ATP through the conversion of pyruvate to 
lactate resulting in systemic lactic acidosis and elevated lactate and pyruvate levels [282]. 
The frequent involvement of the brain, nervous systems and skeletal muscle in MRCD 
highlights the selective vulnerability of these tissues due to their reliance on OXPHOS, 
and in 1977 they were termed “encephalomyopathies” by Shapira et al [398], a 
description still used today to describe many presentations of MRCD [296, 321, 328, 
399]. MRCD appear to target five mains areas of the brain: the cortex; white matter; brain 
stem; cerebellum; and basal ganglia, with many well defined syndromes having 
characteristic lesions within the brain [347]. Individuals with MRCD may present with 
central and/or peripheral neurological features. Central nervous system sequelae include 
stroke like episodes, migraines, seizures, psychomotor regression, ataxia, encephalopathy 
and cognitive impairment [283, 379]. Stroke like episodes generally occur as a result of a 
sudden reduction in ATP availability and are most typically seen in MRCD as a result of 
mtDNA point mutations or nDNA mutations causing mtDNA depletion and multiple 
deletions e.g. POLG mutations [379, 400]. Seizures occur in 35-60% of individuals 
diagnosed with a MRCD and commonly occur in POLG mutations and other mutations 
interfering with mtDNA maintenance, Complex I deficiencies, mutations in genes 
encoding MRC assembly or ancillary proteins, mutations in MRC subunits, especially of 
Complex V, mutations interrupting CoQ10 availability and mutations associated with 
mtDNA translation [401]. Psychomotor regression can be slowly progressive or can 
occur acutely in response to a metabolic stressor, seizure or stroke like episode [379]. 
Ataxia often presents as part of a cerebellar syndrome, also including dysarthria and 
nystagmus, and often in conjunction with seizures, stroke like episodes and other multi-
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systemic manifestations [379]. Cognitive impairment or mitochondrial dementia can be 
slowly progressive, generally starting with specific, focal cognitive deficits, or can be 
triggered acutely by seizures or stroke like episodes. It can cause frank psychosis, 
confusion, behavioural changes, or Alzheimer and Parkinson Disease-like dementias. 
Progressive or acute presentations are often associated with weakness, ataxia, spasticity 
and migraines. Cognitive impairment is often seen in nDNA mutations affecting POLG, 
PEO1, TK2, TYMP and SURF genes [379, 402]. Depression is also a common feature of 
individuals with MRCD and cognitive impairments. Depression was found to be present 
in 42% of those with symptomatic MELAS and occurs frequently in individuals with 
mutations in genes interfering with mitochondrial DNA maintenance including POLG 
and PEO1 [297]. Peripheral nervous system sequelae include myopathy, ophthalmoplegia 
and peripheral neuropathy [283].  
 
The incidence of skeletal muscle involvement in MRCD is common due to the highly 
oxidative nature of this tissue [403-405]. Symptoms include muscle weakness, 
predominantly of the hip and shoulder girdle [406], exercise intolerance, cramps and 
myalgia [407]. The loss of muscle strength can be cause by the impairment of muscle 
function or due to denervation associated with peripheral neuropathy which causes 
muscle atrophy and weakness distally [408]. Exercise intolerance in MRCD was first 
described in the 1960s [409] and is considered to be a hallmark of MRCD with many 
individuals experiencing muscle fatigue, muscle pain, dyspnoea and lactic acidosis with 
minimal exertion, [403, 405, 406, 410-412] impacting significantly on the performance of 
activities of daily living and quality of life [413]. As a consequence of the uncomfortable 
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side effects of exertion, many individuals with MRCD avoid exercise, adopting a 
sedentary lifestyle, which in turn results in deconditioning, reduced aerobic capacity and 
exercise intolerance [406, 414, 415]. Exercise tolerance in MRCD exhibits wide variation 
depending on the level of OXPHOS deficiency between individuals and exercise testing 
is considered to be a useful screening and evaluation tool in the management of MRCD 
[288, 405, 406].  
 
Studies utilising formal cardiopulmonary exercise testing with gas analysis have been 
pivotal in understanding the mechanism underlying exercise intolerance in MRCD. 
Mitochondrial respiratory chain defects interrupt the function of OXPHOS and during 
exercise this is reflected by the exercising muscle’s inability to extract and utilise the 
available oxygen from the circulating blood [288, 412, 416-418]. This impaired oxygen 
extraction is indicated by a low peak arteriovenous oxygen (a-vO2) difference, which 
measures the amount of oxygen that is removed from blood in the capillaries supplying 
the skeletal muscle [416]. Exercise studies in MRCD have found oxygen extraction at 
peak exercise to range between 3-10ml/dl, less than 50% of that seen in matched controls 
[405, 406, 412, 414, 416, 419]. This disruption to the normal close relationship between 
oxygen delivery and utilisation by the exercising muscle, where cardiac output (Q) 
normally increases 5L for every 1L increase in oxygen uptake (VO2) [420], results in 
hyperkinetic circulation, where oxygen delivery relative to oxygen utilisation (Q/VO2) is 
at least 3 fold higher than normal [405, 411, 412, 414, 416, 417, 419, 421, 422]. The 
inability of the muscle to extract and utilise the available oxygen is believed to be sensed 
by metaboreceptors in the exercising muscle which are believed to have a focal role in 
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driving the hyperkinetic circulatory response seen in MRCD [405].  In a study of 40 
adults with MRCDs and age matched controls, the hyperkinetic circulation was 
characterised by a strong negative exponential relationship between peak Q/VO2 and peak 
systemic a-vO2 difference and between peak Q/VO2 and peak VO2, indicating that the 
mismatch increases as the severity of the OXPHOS deficit increases [405]. A study 
investigating capillary area on muscle biopsy found that abnormalities in capillary growth 
in MRCD may help explain the hyperkinetic circulatory response seen in this population 
[416]. Capillary growth, which is considered to be stimulated by hypoxia in exercising 
muscle and closely correlated with peak VO2 and a-vO2 difference in the control 
population, did not follow the same relationship in individuals with mtDNA defects, who 
demonstrated a 3 fold higher capillary area compared to controls, with capillary growth 
correlating highly with Q/VO2 indicating that those with the lowest VO2 had the highest 
levels of capillary growth and that the impairment in OXPHOS stimulates capillary 
growth independent of tissue hypoxia [416]. Furthermore, muscle biopsies showed that 
these capillaries were concentrated around the OXPHOS deficient fibres which 
paradoxically promotes the mismatch between oxygen delivery and oxygen utilisation, as 
more blood is delivered to the most deficient muscle fibres, consequently augmenting the 
hyperkinetic circulation which is a characteristic response to exercise in MRCD [416]. 
 
Peak oxygen uptake is determined by the delivery of oxygen to the exercising muscle and 
extraction of available oxygen by the muscle [408]. In MRCD the delivery of oxygen to 
the muscle is normal [406], however oxygen extraction is significantly impaired and the 
degree of impairment is closely related to the severity of the OXPHOS deficit [405]. 
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Consequently, peak VO2 is dramatically reduced in MRCD and highly correlated with 
peak a-vO2 difference, a relationship that is not seen in healthy controls [405]. Exercise 
studies in MRCD have found peak VO2 ranging between 6 and 22 ml/kg/min, less than 
50% of that seen in matched controls [405, 406, 412, 414, 416, 417, 419, 423]. Peak work 
rate has also been shown to be severely reduced [405, 406]. When activities of daily 
living require a VO2 of between 15-25 ml/kg/min [424, 425], and two thirds of 
individuals with MRCD have a VO2 less than 18ml/kg/min [405], it is clear that many 
individuals with MRCD will be limited in performing their ADLs, and why exercise 
intolerance reduces their quality of life. Studies investigating mutation load and exercise 
capacity found strong negative exponential relationships between mutation load and peak 
VO2 [405, 426], peak work rate [426], and peak a-vO2 difference [405] indicating that the 
more severe the MRC deficit, the more compromised the aerobic capacity. Exercise 
tolerance is further compromised in MRCD due to reduced basal levels of 
Phosphocreatine (PCr) and impaired PCr resynthesis. PCr is a readily mobilised but very 
short lasting source of energy that contributes to the first 10 seconds of exercise, and both 
basal levels of PCr and the speed of resynthesis of PCr may be reduced by over 2/3 
compared to matched controls [288, 414, 427]. 
 
Exertional dyspnoea is a common cause of exercise limitation in MRCD [412, 419, 428]. 
In a small study of 5 adults with mtDNA mutations without respiratory muscle weakness 
and age-matched controls, the mechanisms behind exertional dyspnoea in MRCD were 
investigated [419]. Impairments in OXPHOS caused by the MRCD increase the reliance 
on anaerobic glycolysis during exercise, which causes a rapid increase in the production 
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of lactic acid, the magnitude of which was found to correlate with mtDNA mutation load 
[426]. In turn, blood lactate increases causing a metabolic acidosis and a drop in pH, 
often at low exercise intensities [288, 405, 411, 417, 427, 429]. The elevated blood 
lactate is sensed by the carotid bodies which initiate a ventilatory response to compensate 
for the metabolic acidosis and prevent further decline in pH levels. The resultant 
progressive increase in respiratory drive results in exaggerated ventilatory responses 
during exercise, most evident in the respiratory equivalents of oxygen (VE/VO2) and 
carbon dioxide (VE/VCO2) which demonstrated abnormally steep increases relative to 
workload and at peak exercise were double that seen in matched controls [419]. Another 
study of 40 adult patient with MRCD found a moderate negative exponential relationship 
between peak VE/VO2 and peak systemic a-vO2 difference and between peak VE/VO2 
and peak VO2, indicating that the mismatch increases as the severity of the OXPHOS 
deficit increases [405]. The disproportionate production of carbon dioxide in relation to 
VO2 results in an elevated respiratory exchange ratio (RER) relative to the workload 
[288, 423, 430] casing the anaerobic threshold to be exceeded earlier in exercise [428] 
and grossly exaggerated peak RER, often 50% higher than controls [405, 419]. Blood 
gases during exercise also showed evidence of exaggerated ventilatory responses with 
PaCO2 and HCO3
-
 lower and PaO2 higher than matched controls [419]. Metaboreceptors 
in the exercising muscle are also considered to have a role in the exaggerated ventilatory 
response to exercise, which are independent of metabolic acidosis, but likely induce an 
exaggerated catecholamine response, evidenced by a two fold increase in adrenaline and 
noradrenaline in MRCD compared to controls, which augments the utilisation of intra-
muscular glycogen stores and stimulates ventilatory responses during exercise [405, 417]. 
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This is illustrated by the responses that occur in recovery once exercise has ceased. Blood 
lactate continues to increase and pH decreases, which in the controls, maintained 
respiratory drive resulting in increases in VE/VO2 and RER and a decrease in PaCO2 on 
blood gases. However, the opposite is seen in MRCD where minute ventilation (VE), 
VE/VO2 and RER decrease rapidly and PaCO2 increases when exercise is ceased. This 
paradoxical response can only be explained by withdrawal of input from the exercising 
muscle [419]. An earlier study in 28 adults with MRCD found an association between 
weakened respiratory muscles and participants reporting exertional dyspnoea as their 
limitation to exercise, suggesting that exertional dyspnoea limiting exercise in MRCD 
may be caused by the increased ventilatory response and respiratory muscle weakness in 
some individuals [428]. 
 
Heart muscle can be affected in MRCD causing hypertrophic cardiomyopathy, dilated 
cardiomyopathy, conduction block and arrhythmias [305, 393]. The eyes are also 
commonly affected in MRCD with manifestations including optic nerve atrophy and 
neuropathy, retinal degeneration and pigmentary retinopathy, ptosis and ophthalmoplegia 
[379]. Sensorineural hearing loss with impaired function of the inner hair cells of the 
cochlea commonly occurs in MRCD but rarely in isolation [282]. The bone marrow may 
be affected causing haematological manifestations including anaemia, which is seen in 
mutations of the YARS2 gene associated with mtDNA translation. The renal tubules of the 
kidneys can be affected in MRCD, as can the β-cell of the pancreas resulting in diabetes 
mellitus. Gastro-intestinal dysmotility is another common manifestations of MRCD [282] 
as well as failure to thrive, growth retardation and short stature [305, 383]. 
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1.9.3.3 Clinical Heterogeneity in MRCD 
 
Mitochondrial respiratory chain disorders are not only characterised by genotypic 
variability, with mutations passed from generation to generation by all known inheritance 
patterns, sporadic, mendelian and mitochondrial, they also display diverse phenotypic 
heterogeneity and variability in presentation [278, 283, 290, 295, 305, 326, 336, 337, 347, 
383, 431]. Disease onset can occur at any age from infancy to late adulthood [298, 321, 
379]. Individuals with MRCD may present with tissue specific involvement or multi-
systemic manifestations, which may be analogous with well-defined syndromes or 
largely non-specific disorders, precipitated by metabolic stressor or as a result of 
progressive or recurrent symptoms [281, 282, 295-298, 327, 384]. There is also a large 
spectrum of disease severity with some MRCD being asymptomatic or oligosymptomatic 
and others causing chronic disability, significant morbidity and premature death [283, 
305, 432, 433]. The complexities underlying clinical phenotype are influenced by many 
factors including the differing demand for ATP and rate of OXPHOS that exists between 
different tissues, making some tissues more vulnerable to mitochondrial dysfunction than 
others, and the intricacies of mitochondrial genetics including heteroplasmy and the 
threshold effect, where disease manifestations only become apparent when a certain 
threshold of mutant mitochondria or demand on OXPHOS is exceeded [279, 281]. This 
threshold also varies for different genetic abnormalities, with tRNA point mutations 
causing disease manifestations at a threshold of greater than 90% mutant load compared 
to a threshold of 50-60% mutant load when mtDNA deletions are present [282]. 
Phenotype can change rapidly from normal to abnormal and once the pathogenic 
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threshold is exceeded, small increases in the percentage of mutant DNA present in cells 
can result in significant progression of phenotypic severity [319], however phenotypic 
severity can fluctuate throughout life [305, 379]. MRCD also exhibit poor genotype-
phenotype correlations with identical clinical phenotypes caused by different genetic 
abnormalities and the same genetic abnormality resulting in a spectrum of phenotypes, 
generally attributed to heteroplasmy [296, 297, 305, 379, 434, 435]. Similarly, there can 
be poor correlation between mutation load and symptom and phenotypic severity, 
especially in muscle [305]. 
 
The predominant features of childhood presentation of MRCD were found to be 
myopathy, encephalopathy and cardiomyopathy but also include hearing and visual 
impairments, lactic acidosis, failure to thrive, diabetes, liver and kidney disease [305, 
321, 393, 397, 401]. In a study of over 100 paediatric patients with mitochondrial disease, 
all those presenting with MRCD had moderate to severe developmental delay or motor 
regression at presentation [393] with hypotonia and lethargy other common myopathic 
symptoms [321, 397]. MRI scans of the brain revealed abnormalities in 70% of children 
with MRCD including cerebellar and cortical atrophy, brain stem and basal ganglia 
lesions, white matter abnormalities, agenesis of the corpus callosum, posterior fossa 
abnormalities and cerebellar volume loss [393]. Seizures are the most common 
manifestation of encephalopathy in childhood [401] and were present in 50% of children 
diagnosed with MRCD, 32% had ophthalmologic problems including optic atrophy, 
ptosis, nystagmus, ophthalmoplegia and pigmentary retinopathy, 21% exhibited 
sensorineural hearing loss [393]. Cardiac involvement was identified in 40% of children 
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presenting with MRCD, 60% of these with hypertrophic cardiomyopathy, 30% with 
dilated cardiomyopathy and 10% with arrhythmias [393]. The presence of cardiac 
involvement on presentation is associated with a significantly reduced life expectancy, 
with less than 20% of children having cardiac involvement surviving to 16 years of age 
compared to 95% of children who did not present with cardiac involvement [393]. 
Movement disorders, especially dystonia, were apparent in 12% of children and ataxia in 
6% [393]. Cognitive deficits, while difficult to accurately measure, have been identified 
in 60% of children with MRCD in one study [436], and in another study 75% of children 
with encephalomyopathies were found to have an intellectual disability or cerebral 
dysfunction [437]. Another study found that children with MRCD have reduced visual-
spatial abilities, nonverbal cognitive impairments and low performance and verbal IQ 
[438]. 
 
Adult presentations of MRCD are characterised by exercise intolerance and muscle 
weakness usually affecting the proximal muscles. With more severe disease, muscle 
weakness may also cause dysarthria and dysphagia. Involvement of the central nervous 
system is also common manifesting as seizures, migraines and focal neurological deficits. 
Many will exhibit sensorineural hearing loss, ophthalmologic problems including optic 
atrophy, ptosis, progressive external ophthalmoplegia and pigmentary retinopathy. 
Cardiac involvement is commonly associated with arrhythmias, conduction block and 
hypertrophic cardiomyopathy. Gastrointestinal dysmotility is common causing 
constipation and pseudo-obstruction and endocrine problems include diabetes and short 
stature [305]. 
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1.9.3.3.1 Progressive External Opthalmoplegia (PEO) 
 
Progressive External Opthalmoplegia is an example of a MRCD that exhibits large 
genetic variability such that identical clinical phenotypes are caused by different genetic 
abnormalities. It can be caused by sporadic mutations or mutations in either the nuclear 
or mitochondrial genomes. Sporadic mutations generally cause large-scale deletions of 
mtDNA and maternally inherited PEO is usually associated with tRNA point mutations. 
PEO caused by mutations in nDNA are a result of mutations in gene interfering with 
mtDNA maintenance and can follow an autosomal dominant or autosomal recessive 
inheritance pattern. PEO is the most common clinical presentation when mutations in 
these nuclear encoded genes e.g. POLG, POLG2 and PEO1 cause multiple mtDNA 
deletions [296, 305]. The characteristic features of PEO, including bilateral ptosis and 
reduced eye movements limiting peripheral vision, demonstrate the vulnerability of the 
extra-ocular muscles in MRCD due to their dependence on OXPHOS [296, 439]. Other 
features include slowly progressive skeletal muscle weakness and disease onset in early 
adulthood, generally between 20-30 years of age [321, 439]. 
 
1.9.3.3.2 Mutations in the Nuclear Encoded POLG gene 
 
POLG-related disorders are an example of phenotypic variability and weak genotype-
phenotype correlations seen in MRCD, despite a common underlying genetic cause 
[440]. There are over 150 known mutations in the POLG gene [379] which interfere with 
mtDNA maintenance causing mtDNA depletion or multiple mtDNA deletions [296, 309]. 
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In a review of 38 presentations with POLG mutations, 10% presented with an autosomal 
dominant pattern of inheritance with mutations predominantly affecting the polymerase 
domain, 24% with an autosomal recessive pattern of inheritance, including all children of 
consanguineous parents, and the remaining 66% presenting as sporadic compound 
heterozygotes [440]. Nearly 30% had more than 2 substitutions in POLG and only one 
third had a family history of disease [440]. Half of the cohort presented in childhood and 
half in their teenage and adult years. Over 60% of those presenting in childhood had 
mutations in the linker region, 20% of those being homozygous in nature, with the 
remaining 40% most commonly seen in the polymerase domain and most childhood 
presentations occurring in males [440].  Individuals presenting in their teenage and adult 
years usually had mutations in the exo-nuclease proofreading domain [440]. 
 
Clinical phenotype, age at presentation and disease progression associated with POLG 
mutations is highly variable [379, 440] however POLG-related disorders do cause several 
well defined and overlapping phenotypes including: Alpers Syndrome, childhood Myo-
Cerebro-Hepatopathy Syndrome (MCHS); Myoclonic Epilepsy, Myopathy and Sensory 
Ataxia syndrome (MEMSA); Spino-Cerebellar Ataxia and Epilepsy (SCAE); Sensory 
Ataxic Neuropathy, Dysarthria and Opthalmoparesis (SANDO) and autosomal dominant 
and autosomal recessive PEO [347, 379]. Infant and childhood presentation are generally 
severe and progressive with common symptoms including encephalopathy, seizures, 
cognitive impairment, sensorineural hearing loss, lactic acidosis, myopathy, hepatic 
failure, renal failure, failure to thrive and vomiting [347, 379, 440]. Presentation in the 
teenage and adult years is commonly associated with PEO, ataxia and myopathy [379] 
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and the study by Howarth et al 2006 found that all those presenting at this time had PEO 
and ptosis, 79% had myopathy and 42% ataxia. Other common symptoms in this cohort 
of teen and adult onset disease were dysphagia in 37%, peripheral neuropathy in 32% and 
diabetes, sensorineural hearing loss and dementia in 11% [440]. In adult patients, 
characteristic neuroimaging in those with POLG mutations involved stroke-like lesions, 
basal ganglia involvement and cerebral and cerebellar atrophy [347]. In teenage and adult 
onset disease there was no gender bias towards males as was seen in childhood 
presentations [440]. 
 
1.9.3.4 Mitochondrial Respiratory Chain Complex Involvement in MRCD 
 
The majority of individuals with MRCD present with deficiencies in multiple MRC 
complexes [295], with the literature suggesting these presentations account for 30-51% of 
all presentations, and up to 25% of paediatric presentations [441]. At least 50% of 
presentations involving multiple MRC complex deficiencies are caused by mutations in 
genes interfering with mtDNA maintenance [320, 352, 441] but can be caused by any 
mtDNA or nDNA mutation [395]. In a cohort of children with MRCD involving multiple 
MRC complexes, 24% were due to large scale mtDNA deletions or rearrangements, 19% 
due to mutations in the POLG gene, 18% due to mtDNA depletions, 18% due to 
mutations in the DGUOK gene and 12% due to mutations causing MELAS [395]. Multi-
system disease manifestations are common including encephalopathy, myopathy, 
cardiomyopathy, visual and hearing impairments, kidney and liver disease, hypotonia and 
growth retardation [290]. Deficiencies in Complex I are the most commonly seen 
deficiencies in MRCDs, with pathogenic mutations identified in all of the 7 mtDNA 
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encoded subunits and 16 of the nDNA encoded subunits as well as 6 assembly factors 
[347]. Complex I deficiencies generally occur in combination with other complex 
deficiencies however isolated Complex I deficiencies account for 22% of presentations 
with MRCD [290, 295]. Complex I deficiencies are most commonly associated with LS 
and are the most frequent cause of MRCD in children [321, 347]. Complex I deficiencies 
almost universally present with bilateral, symmetrical brain stem lesions, and necrotising 
leukoencephalopathy is generally found in individuals with nDNA mutations, and 
cerebellar atrophy in those with mtDNA mutations [347]. Clinically, individuals often 
present with developmental delay, hypotonia, seizures, visual sequelae and 
cardiomyopathy [347]. Deficiencies in Complexes II and III are rare, in presentations 
involving multiple MRC complexes and also as isolated complex deficiencies, 
accounting for up to 4% of all presentations of MRCDs [321, 442]. Deficiencies in these 
complexes demonstrate high clinical heterogeneity with Complex II deficiencies 
generally presenting as LS and Complex III deficiencies as LS or encephalomyopathy 
[297, 321]. Complex IV deficiencies are more common and isolated complex IV 
deficiencies account for 13% of MRCD presentations. These deficiencies are generally 
maternally inherited and their heteroplasmic nature results in diverse clinical 
heterogeneity [290]. Pathogenic mutations have been identified in mtDNA and nDNA 
encoded subunits as well as assembly factors for Complex V, however it is considered to 
be a rare cause of MRCD with deficiencies primarily caused by mutations in the mtDNA 
encoded ATP Synthase 6 subunit. Clinically, Complex V deficiencies present as LS, with 
basal ganglia lesions, cerebellar atrophy, brain stem lesions, ataxia, neuropathy and 
retinitis pigmentosa [347]. 
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1.9.3.5 Leigh Syndrome 
 
Leigh Syndrome was first described by Denis Leigh in 1951 [443] and the first 
pathogenic mutation was identified four decades later in 1991 [444]. Leigh Syndrome is 
the most commonly seen paediatric presentation in MRCD and over 80% of all LS cases 
present by 2 years of age [320, 445]. The estimated prevalence of LS is 1/40,000 births 
[446]. Like many MRCD, LS displays marked genetic heterogeneity with over 75 
pathogenic mutations identified in both the nuclear and mitochondrial genomes which are 
transmitted by autosomal recessive, X-linked and maternal inheritance patterns and 
encode structural subunits of the MRC complexes, proteins required for their assembly 
and stability, proteins involved in the mtDNA maintenance or proteins involved in 
mtDNA translation, however structural subunits of the MRC complexes and their 
associated assembly factors are most commonly affected [283, 320, 340]. Mutations in 
the nuclear genome are the most common cause of LS with mutations in the 
mitochondrial genome only accounting for up to a quarter of all LS presentations [446-
448]. Complex I deficiencies are the most common cause of LS with up to 50% of 
individuals with Complex I deficiency presenting with LS [320, 449, 450]. Over one third 
of all pathogenic mutations causing LS affect Complex I [320, 450] and in 80% of 
individuals with Complex I deficiencies, the underlying genetic cause is due to mutations 
in nDNA [451] with mutations in the NADH dehydrogenase iron-sulphur protein 4 
(NDUFS4) subunit the most frequent autosomal recessive cause of Complex 1 
deficiencies resulting in LS [320, 449, 450]. Complex IV deficiencies are the next most 
common cause of LS, accounting for around 15% of LS presentations [320, 446, 447]. 
 126 
Mutations in the Complex IV assembly factor gene SURF1 accounts for 75% of 
presentations with Complex IV deficient LS [320]. Complex V deficiencies cause 5-10% 
of LS syndrome presentations with mutations in the ATP Synthase 6 subunit of Complex 
V the most common cause of maternally inherited LS, the most frequently occurring of 
which is the mt.8993T>G mutation [320, 434, 452, 453]. Deficiencies in complexes II, III 
and CoQ10 are quite rare, causing less than 10% of LS presentations [320, 446, 447]. 
Deficiencies in multiple respiratory chain complexes causing LS are most frequently 
caused by mutations in genes involved in mtDNA translation [450] [320]. 
 
Leigh syndrome is also characterised by clinical heterogeneity with regards to age of 
onset, symptom presentation and progression, severity and life expectancy [320, 450]. 
Individuals with LS will exhibit progressive neurodegeneration which is a hallmark of the 
disease [320, 446, 450]. The neurodegeneration is characterised by subacute necrotising 
encephalomyopathy with episodes of psychomotor regression which may be associated 
with illness or infections where partial recovery may occur, or follow a stepwise 
deterioration with intermittent periods of stability or even improvement of varied 
duration [445]. Neuroradiology reflects characteristic features including bilateral, 
symmetrical lesions in the brainstem and basal ganglia, spinal cord, thalamus and 
cerebellum [296, 297, 320, 328, 347]. Other neurological symptoms reflect brainstem and 
basal ganglia dysfunction and intellectual and motor delay and include pyramidal and 
extrapyramidal symptoms with movement disorders including choreoathetosis, 
dyskinesia, dystonia, tremor and ataxia, hypotonia, spasticity, abnormal tendon reflexes, 
dysphagia, feeding difficulties, vomiting and failure to thrive, central respiratory 
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dysfunction including apnoeas, hypo- or hyper-ventilation neuro-ophthalmological 
problems including nystagmus, optic atrophy, ptosis, retinitis pigmentosa, 
ophthalmoparesis, neuropathy, myopathy and thermoregulation [290, 296, 320, 347, 
379]. Other non-neurological symptoms include cardiac abnormalities including 
hypertrophic or dilated cardiomyopathy, arrhythmias, conduction block, anaemia, kidney 
and liver disease, gastrointestinal immotility, diabetes and short stature, [320]. Infantile 
onset LS is most commonly associated with hypotonia, developmental delay, vomiting 
and failure to thrive [445]. Presentation during the toddler years are characterised by 
gross motor delay, especially in walking, dystonia and dysarthria while presentation 
during the later childhood and adolescent years is characterised by ataxia and 
extrapyramidal features including dystonia and rigidity [320].  Adult onset LS does not 
follow a typical presentations and can be associated with headaches, hallucination, 
memory loss, intellectual deterioration, ataxia, spasticity, dysarthria, dyspnoea or 
ophthalmological problems [320].  Almost half of all individuals with LS will be 
hospitalised during acute episodes, primarily due to infections or respiratory compromise 
[320]. Peak mortality occurs prior to 3 years of age with death a consequence of 
respiratory dysfunction [447] or cardiac failure [445]. 
 
1.9.3.6 Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-
like episodes (MELAS) Syndrome 
 
MELAS was first discovered in 1991 by Tanaka et al [454] and is one of the most 
common MRCD. MELAS is caused by maternally inherited pathogenic point mutations 
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in mtDNA genes encoding MRC subunits and tRNA [281, 290, 296-298, 309, 321, 323, 
331, 455]. Pathogenic mtDNA point mutations encoding MRC subunits are most 
commonly found in the subunits of Complex I and Complex III [296, 455] however the 
most frequent pathogenic mtDNA point mutation associated with MELAS is the 
m.3243A>G transition of the gene encoding the mitochondrial Leucine tRNA
(UUR)
 which 
is identified in around 80% of individuals presenting with MELAS symptoms [281, 298, 
321, 455-460]. This specific mutation, along with other pathogenic point mutations in 
mitochondrial tRNA genes, results in impaired overall mitochondrial protein synthesis 
[281, 282]. The minimum point prevalence of MELAS in the adult population caused by 
the m.3243A>G mutation was found to be 3.5/100,000 in a recent UK study [386], 
however earlier reports suggest a much higher point prevalence of 16.3/100,000 [461, 
462]. 
 
MELAS displays features of mitochondrial genetics with replicative segregation, 
heteroplasmy and the threshold effect underlying the phenotypic heterogeneity 
characteristic of the disease [280, 281, 296, 298, 321]. Symptoms usually manifest once 
mutant mtDNA exceed the 90% threshold, however symptoms can be transient or 
recurrent with approximately 70% if individuals experiencing their initial symptoms 
between the age of 2 and 20 years, after a period of normal development [281, 296, 455, 
463]. MELAS is multisystemic in nature and a hallmark of the disease is progressive 
neurodegeneration that has devastating cumulative effects [281, 290, 305, 455]. Common 
neurological symptoms include repeated stroke like cerebral episodes commonly 
affecting the temporal, parietal and occipital lobes, often causing migraines, seizures, 
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hemiparesis, hemianopia, cortical blindness, ptosis, ophthalmoplegia, dementia, 
encephalopathy, ataxia and sensorineural hearing loss [281, 298, 321, 455]. 
Neuroimaging reflects lesions in the basal ganglia, cerebellar and cortical atrophy, 
neuronal loss and stroke like episodes [282, 347]. Other symptoms include systemic 
lactic acidosis, myopathy and proximal muscle weakness, fatigue, myalgia, peripheral 
neuropathy, vomiting and other gastro-intestinal disturbances, cardiomyopathy and 
cardiac conduction defects, renal impairment, diabetes and short stature [281, 290, 305, 
347, 455, 456, 459, 464].   
 
1.9.3.7 Kearns-Sayre Syndrome (KSS) 
 
Kearns-Sayre Syndrome is a multisystemic disorder caused by mtDNA deletions of 
various sizes in over 90% of presentations [439, 465]. The vast majority of these 
deletions occur between the two origins of replication on the circular mtDNA, which 
includes over two thirds of the mitochondrial genome. These mitochondrial DNA 
deletions can remove between 9-50% of the genome, with the accumulation of deletions 
within tissues underlying the progressive nature of the syndrome [290, 315]. KSS is 
characterised by a diagnostic triad of disease onset during childhood, progressive external 
ophthalmoplegia and pigmentary retinopathy. This triad generally occurs with other at 
least one of the following: a cardiac conduction defect; cerebellar syndrome; or elevated 
protein content in cerebrospinal fluid [290, 321, 439, 465]. Other symptoms include 
cognitive impairment, seizures, sensorineural deafness, gastrointestinal dysmotility, short 
stature, diabetes, endocrine and renal impairments, myopathy with predominant proximal 
and bulbar weakness, dysphagia, sensory and motor neuropathies, ptosis, optic atrophy, 
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hypertrophic or dilated cardiomyopathy, cardiac arrhythmias and lactic acidosis [290, 
305, 321, 347, 465]. Hallmark features on neuroimaging include symmetrical lesions 
white matter regions of the spinal cord, brainstem, thalamus, globus pallidus, cerebrum 
and cerebellum reflecting severe spongiform degeneration [290, 347]. 
 
1.9.4 Treatment of MRCD 
 
The treatment of MRCD poses a major challenge to the multidisciplinary teams involved 
in the management of individuals with these disorders. There is currently no known cure 
or established treatment regimens as no clear evidence for effective interventions have 
been identified [283, 295, 386, 466-468] which imposes significant costs on the 
healthcare system as the burden of MRCD is usually extensive with multisystem 
derangements requiring medical management [386]. Therapeutic approaches are aimed at 
managing secondary complications, ameliorating symptoms and improving quality of life 
[295, 321, 468, 469]. Symptomatic therapy includes the management of epilepsy with 
anticonvulsants, diabetes with insulin and/or dietary modification, the insertion of a 
pacemaker for conduction block and cochlear implants for sensorineural hearing loss and 
the surgical correction of ptosis [468]. The use of small molecule therapies and metabolic 
manipulation, along with dietary and exercise regimes have been focused on enhancing 
the capacity for ATP synthesis, bypassing the mitochondrial defect, stimulating 
mitochondrial biogenesis and reducing the levels of reactive oxygen species [279]. These 
therapies include pharmacological adjuncts that attempt to boost the level of metabolites 
and co-factors including carnitine, creatinine, thiamine, riboflavin, succinate, CoQ10, 
vitamin E, vitamin C and folic acid [283, 295, 321, 468]. Aerobic exercise training has 
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been shown to increase work and oxidative capacity by up to 30%, oxygen extraction by 
up to 16%, and the activity of some MRC enzymes up to 50% as well as stimulating 
mitochondrial proliferation and improving quality of life by up to 28%, so it is an 
effective treatment to improve exercise tolerance and prevent deconditioning [292, 407, 
411, 414, 415, 468, 470-475]. Resistance exercise training has also been shown to 
increase leg strength by up to 25%, upper limb strength by 60%, improve oxygen 
extraction and the activity of some MRC enzymes [474, 476]. In a study of five children 
with MRCD, exercise time and oxygen uptake remained stable after six months of 
physical therapy incorporating aerobic and resistance training[477]. Many individuals 
with MRCD experience muscle pain, fatigue and dyspnoea with exercise making the 
motivation to participate in and adhere to exercise interventions difficult, especially in 
children where behavioural difficulties may also interfere with optimal training [476, 
477]. While exercise interventions and pharmacological adjuncts have been successful in 
isolated cases and small clinical trials, the efficacy of these interventions in larger cohorts 
have not been investigated to provide clear evidence of their usefulness in the 
management of MRCD [283]. Such studies are often difficult to conduct due to the 
genetic and phenotypic heterogeneity that is characteristic of MRCD making it difficult 
to compare the efficacy of interventions between participants [283, 295, 320, 321, 478]. 
Supportive and preventative therapy involves the provision of prognostic education, 
genetic counselling and where possible prenatal diagnoses [283, 468]. 
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1.10 Cystic Fibrosis 
 
Cystic fibrosis (CF) is the most common life-limiting inherited disorder in the Caucasian 
population [479] with an incidence of 1 in every 3700 babies born in Australia [480]. 
This multi-system disease was first described in 1938 By Dr Dorothy Andersen [481]. 
Over a decade later,  CF was found to be associated with an abnormality in the epithelial 
glands [482] which triggered studies into sweat electrolyte levels and the development of 
the sweat test which is widely used as a diagnostic tool [483]. Alteration to chloride 
permeability and conductance was established in sweat glands [484-486] and later 
confirmed in the pancreas [487] and airway epithelia cells [488-491].  
 
A decade after being first described, researchers suspected a single-gene defect was 
responsible for CF due to the autosomal recessive pattern of inheritance [492] and in 
1985 it was found to be located on chromosome 7 [493, 494], the gene discovered a few 
years later in 1989 [495, 496] along with the mutation in F508Del that encoded the cystic 
fibrosis transmembrane conductance regulator (CFTR) [497]. Over 2000 mutations have 
since been discovered, with just over 10% considered to be disease-causing [498]. 
Despite this diversity in mutation type, 85% of Caucasians  with CF have at least one 
F508Del mutation [498, 499]. 
 
The CFTR is an ATP binding cassette transport-class protein [498, 500] located in the 
apical membrane of epithelial cells in the lung, liver, pancreas, intestines, sweat glands 
and reproductive tract, among others [479, 501]. It is responsible for the transport of 
chloride ions across the apical membrane, regulating trans-epithelial salt and water flow 
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via an osmotic gradient [500, 502]. The CFTR is composed of 5 domains [497, 500, 503, 
504]: two membrane spanning domains that form the channel pore [505, 506]; two 
nuclear binding domains that interact with ATP to modulate channel activity; and a 
regulatory domain that directs the channel to open/close [506-508].  
 
In CF the trans-epithelial transport is disrupted as a result of altered CFTR synthesis 
and/or function. Six classes of gene mutations have been identified [479, 498, 499, 509-
513] and their effects on the CFTR are summarised in Table 1.1. These mutations result 
in the production of abnormally thick and sticky mucus causing multi-system disease 
affecting the airway, pancreas, gut, sweat glands and male fertility [513] leading to 
chronic dysfunction, disability, and a reduced life expectancy [514]. Morbidity and 
mortality is most commonly caused by lung disease [515, 516], where defective chloride 
transport causes a reduction in the airway surface liquid layer [517-519] and impaired 
muco-ciliary clearance, resulting in mucous retention that causes airway obstruction, 
inflammation and infection [520, 521] and eventually irreversible, fibrotic damage to the 
surrounding lung parenchyma [479, 500]. Progressive suppurative pulmonary disease, 
recurrent bronchopulmonary infections and declining lung function are hallmarks of CF 
[515, 516]. Around 90% of CF patients are pancreatic insufficient due to pancreatic 
obstruction, requiring pancreatic enzyme replacement therapy to improve protein and fat 
absorption [479]. 
 
While no cure is available, improvements in the clinical management of CF to treat end-
organ sequelae [498], including early detection of the disease through newborn screening, 
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Table 1.1: CFTR gene mutation classes. 
 
Class Function Interrupted Consequence 
I No synthesis 
Truncation of transcribed mRNA resulting in absent, non-functional or unstable 
CFTR protein 
II Processing/Trafficking 
Mis-folded CFTR protein degraded/removed by intracellular quality control 
mechanisms while migrating to cell surface 
III Gating 
CFTR present at cell surface however regulation disrupted interrupting normal 
flow of chloride ions 
IV Conductance 
CFTR present at cell surface however altered conductivity of the channel pore, 
resulting in abnormal chloride permeability 
V Low synthesis/reduced expression 
Reduced number of CFTR at cell surface however those at the cell surface have 
normal function 
VI High turnover 
CFTR present at cell surface however stability reduced resulting in high 
turnover 
Note: mRNA, messenger ribonucleic acid; CFTR, cystic fibrosis transmembrane conductance regulator.
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advances in antibiotic therapy [522-524], attempts to reduce inflammation [525-528], 
more aggressive management of gastro-intestinal complications and targeted, specialised 
physiotherapy to optimise secretion removal [529-531], has culminated in increases in the 
average life expectancy of individuals with CF. In Australia, the average life expectancy 
is now well into the fourth decade of life [480]. This increase in survival, along with 
improved screening, has seen the emergence of previously under-recognised extra-
pulmonary complications including CF bone disease (CFBD) [532-544]. Second to cystic 
fibrosis related diabetes, CFBD is the second most common extra-pulmonary 
complication [545] and its prevalence is increasing [532, 546, 547].  
 
CFBD is characterized by low bone mass, compromised bone quality (density, geometry 
and strength), increased risk of fragility fractures and exaggerated thoracic kyphosis, and 
un-coupled bone turnover. The underlying pathophysiology is multifactorial involving 
multiple risk factors [532, 548-552]. Awareness of CFBD as a significant co-morbidity 
impacting on the effectiveness of airway clearance techniques, exercise participation, 
health status, quality of life, suitability for transplant, pain and ultimately mortality, was 
not fully recognised till the 1990s [532, 536, 539, 542-545, 547, 549-569]. Despite 
advancement in multidisciplinary CF care, a recent study of CF adults found bone density 
of the lumbar spine and radius to be similar to that seen in a historic cohort 15 years 
prior, despite significant improvements in lung function and vitamin D status [550], 
indicating further interventions need to be investigated to optimize CF bone health. The 
Australian Cystic Fibrosis Data Registry Report, found an overall prevalence of 
osteopenia of 16% and osteoporosis of 5.9% in Australians with CF of all ages. Children 
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aged 6-11 years and 12-17 years had a prevalence of osteopenia and osteoporosis of 2.5% 
and 1.4%, and 15.1% and 5.6% respectively, indicating that CFBD can occur in young 
Australian children with CF, and that prevalence increases with age [480]. 
 
1.10.1 Characteristics of CFBD 
 
 
1.10.1.1 Bone Density in Cystic Fibrosis 
 
Low bone mineral density in CF was first described in 1979 [570, 571] and has been 
found at multiple skeletal sites in both children and adults with CF. Studies investigating 
lumbar spine bone mass across the lifespan in CF, found lumbar spine bone density to be 
significantly reduced [545, 557, 559, 563, 572-574]. Most studies have found deficits 
becoming more prevalent in adolescents and adults [563, 574], however others have 
found similar prevalence across the lifespan [557, 559]. Three longitudinal studies 
demonstrated minimal overall changes in lumbar spine bone density after 2 years [559, 
572, 575]. One study reported changes in lumbar spine bone density to be smaller than 
expected for age and gender matched controls [559] and two studies reported decreases in 
lumbar spine bone density in 38% [559] and 35% [572] of their cohorts. 
 
In CF adults, lumbar spine bone density was significantly lower compared to their 
healthy counterparts [547, 548, 552, 557, 563, 574-588]. Several studies measuring 
lumbar spine bone density by DXA, found standard deviation scores (SDS) to be at least 
2 standard deviations below the norm in 6-41% of their cohorts [548, 552, 553, 559, 569, 
576, 581-583, 586-589] and osteopoenia at the lumbar spine ranged between 10-69% 
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[548, 576, 582, 583, 589], the lowest scores seen in cohorts with end-stage disease 
referred for transplant [552, 569]. A study measuring lumbar spine bone density using 
quantitative commuted tomography (QCT) found 25% of the cohort had SDS at least 2 
SDS below the norm [590]. Longitudinal studies in CF adults did not find lumbar spine 
bone density measured by DXA [583, 591, 592] or quantitative commuted tomography 
(QCT) [591], to be significantly changed over follow-up periods up to 24 months [583, 
591, 592]. In contrast, two studies reported significant annual declines in lumbar spine 
bone density of 0.86% [580] and 0.18% [543].  
 
In paediatric cohorts lumbar spine bone density was significantly reduced when measured 
by DXA [557, 559, 563, 567, 574, 575, 593-603] and quantitative commuted tomography 
[604]. Lumbar spine bone density SDS were in the osteopoenic range in 25-62% of the 
cohorts studied [559, 567, 600, 602, 605-607] and more than 2 SDS below the norm in 9-
27% [563, 567, 594, 596, 600, 602, 607]. Longitudinal studies in paediatric cohorts with 
CF found significant reductions lumbar spine bone density in females but not males 
[592]. Another study, with a follow-up period of two years, found lumbar spine bone 
density in children to decrease by 0.18 SDS in males, mean age 13 years, and to increase 
0.23 SDS in females [572]. In another cohort of children with CF, lumbar spine bone 
density decreased 0.15 SDS annually [595]. Longitudinal follow-up of two years in 
females, found no lumbar spine bone density SDS [605]. Despite the lack of significance, 
50% of the cohort demonstrated declining SDS over the follow-up period [605]. 
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Total body bone density SDS [547, 559, 563, 576-578, 585, 608, 609] and T-scores [543, 
606] were found to be significantly reduced in the majority of the adult literature. Total 
body bone density at least one SDS below the norm occurred in 12-67% of adults studied 
[606, 608, 610] and over two SDS below the norm occurred in 12-38% [553, 563, 608]. 
No significant change in total body bone density was found in follow-up studies [543, 
580, 592]. In CF children, total body bone density was generally found to be normal 
[563, 564, 593, 594, 598, 601, 611-614], however others found significant reductions 
compared to control populations [559, 592, 615], particularly in adolescents [563] and 
females [608, 612]. Longitudinal follow-up did not find any change in total body bone 
density after 2 years [559, 592]. 
 
Bone density measured at the hip was significantly reduce in CF adults [539, 552, 553, 
563, 573, 575-581, 585, 606] with 28-53% of cohorts with bone density at least one SDS 
below the norm [552, 573, 576, 582, 586, 606] and 7-41% reporting bone density two 
SDS below the norm [552, 553, 576, 581, 582, 586]. The literature on CF children was 
divided with some reporting significantly reduced hip bone density [575, 593, 595], and 
others no deficits [564, 616, 617]. Longitudinal follow-up studies reported decreases in 
hip bone density [539, 580] [543, 595], however others found no change [572, 575, 592]. 
 
Analysis of the distal radius using high resolution peripheral quantitative computed 
tomography (HR-pQCT) demonstrated significantly reduced trabecular thickness [561], 
this was in contrast to pQCT findings at the 4% distal radius sit where trabecular 
volumetric bone mineral density (vBMD) was found to be normal [615, 618, 619], 
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however total vBMD was found to be significantly reduced [545, 615]. At the 66% radius 
site cortical vBMD was found to be normal [545, 618] however cortical cross-sectional 
area (CSA) and thickness were significantly reduced [545, 618] as was muscle CSA 
[545] and polar stress-strain index (SSI) [615]. Another study found bone mass to be 
significantly reduced at the mid-shaft [571] and bone density measured by DXA was 
found to be significantly reduced at the radius [552, 570, 620]. 
 
Analysis of the tibia by HR-pQCT found adults with CF to have significantly reduced 
total vBMD and trabecular thickness in the distal tibia [561]. Similar deficits were seen at 
the 4% tibial pQCT site with significantly decreased total and trabecular vBMD in female 
children and adolescents [621]. Another study found BMC to be significantly reduced at 
the 4% and 66% pQCT sites in pubertal females [622]. Muscle CSA was found to be 
decreased in males and females in one study [621] but only pubertal males and females in 
another [622]. Cortical CSA was reduced at the 20% pQCT site in males and females 
[621] and at the 66% site in pubertal females [622] and cortical polar SSI was decreased 
in pubertal females [622].  
 
These studies indicate that in CF children with well-preserved lung function and 
nutritional status, bone health is preserved and does not deviate from their healthy 
counterparts. However, impairments in bone health emerge during adolescent with 
deficiencies in bone mass accrual and geometric adaptations during bone modelling. 
Deficits in bone density are established in adults with CF and accelerated bone loss is 
seen. 
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1.10.1.2 Increased risk of fragility fractures 
 
 
In adults with CF, most studies have reported elevated rates of fractures, with 13-50% of 
cohorts reporting a previous fracture [561, 582, 586, 623, 624], and a pooled prevalence 
of non-vertebral fractures of 20% [544]. Vertebral fractures were also reported with 
increased frequency in CF adults, with 5-53% of cohorts having vertebral fractures [539, 
540, 543, 547, 552-554, 561, 575, 576, 588, 623-625], and a pooled prevalence of 14% 
[544]. These rates are similar to those seen in older adults and untreated post-menopausal 
women [544, 547]. The majority of vertebral fractures occurred in the thoracic spine 
[544, 553, 554, 575, 623], and were mild in nature [588]. Multiple vertebral fractures 
were found in 8-17% [543, 553, 588]. The presence of vertebral fractures was associated 
with increasing age [543] and lower lung function [588, 625, 626]. Vertebral fracture 
incidence was found to be between 5-8.5% [543, 588] and those with new fractures were 
found to have a greater rate of bone loss compared to those without new fractures [543]. 
Rib fractures were found in 8-15% of adult CF cohorts [547, 623] and one study found 
fractures to be associated with lower bone density [623]. The majority of studies found 
that bone density was unable to distinguish between those with a fracture history and 
those without [539, 540, 547, 552, 553, 561, 575, 582, 623, 625, 627]. Similarly, high-
resolution pQCT studies of the distal radius in adults with CF found no difference in 
trabecular bone architecture between those with and without fractures [561, 566]. These 
findings indicate that fractures are not solely a consequence of low bone mass, and that 
bone quality, including geometric attributes of the bone, are likely involved in the 
increased fracture rates described in adults with CF [544, 554, 625].  
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There are conflicting reports in the literature about fracture rates in children. In general 
fracture rates have been found to be similar between CF children and controls [563, 565, 
594, 628, 629], however some studies have found increased rates compared to control 
[545, 629, 630]. While some studies have shown no difference in bone density between 
those with fractures and those without [563, 565], others have found that children with a 
previous fracture had significantly lower total body bone mineral content for height SDS 
[594], had bone density values in the osteopenia range [606], and in those with more than 
one fracture, total body and lumbar spine bond density and trabecular vBMD measured at 
the forearm were significantly lower than those with only one fracture [545]. 
 
In CF adults, exaggerated thoracic kyphosis has been reported at rates between 22-62% 
[547, 625, 631, 632], in adolescents between 15-31% [576, 606, 629, 633], and in 
children younger than 10 years, less than 15% [631], indicating that the prevalence of 
thoracic kyphosis increases with age [629, 631, 633]. In general the development of 
thoracic kyphosis was associated with the presence of vertebral fractures [547, 625]. 
Some studies found the presence of a thoracic kyphosis to be positively correlated with 
bone density [547, 606] however others did not [625, 627]. No correlation between the 
presence of a thoracic kyphosis and lung function was found by some studies [631, 632] 
however other studies found thoracic kyphosis to be negatively correlated with lung 
function [625, 633] and weight-bearing physical activity (WBPA) [625]. The 
development and progression of a thoracic kyphosis imparts abnormal stresses on the 
spine [634, 635] further increasing the risk of future vertebral fractures [636]. The 
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development of thoracic kyphosis and presence of vertebral and rib fractures has negative 
ramifications on effectiveness of airway clearance, pulmonary function tests and 
participation in WBPA. 
 
1.10.1.3 Un-coupled bone turnover 
 
 
Both paediatric and adult studies have found an imbalance in bone turnover. In studies of 
children with CF, bone resorption markers have in most cases remained within normal 
limits [574, 575, 600, 616, 617, 637-639], however some studies have reported elevated 
resorption [592, 601, 607, 630] that was correlated with age [607] and inversely 
correlated with bone density [559, 601, 607]. In contrast, few paediatric studies found 
bone formation to be normal [574, 639], the majority finding bone formation markers, 
especially osteocalcin, to be significantly lower than expected [575, 598, 600, 601, 603, 
607, 616, 617, 630, 638] and often found to be significantly correlated with lung function 
[574, 598, 603] but not bone density [559, 598, 603]. One study also found significantly 
reduced amounts of OPG and a significant reduction in the OPG:RANKL ratio [638], 
providing further evidence of reduced bone formation activity. This un-coupling of 
normal bone turnover in the paediatric years provides support for the failure to accrue 
peak bone mass that becomes apparent during the pubertal growth spurt in adolescent 
with CF [539, 540, 547, 549, 552, 556, 557, 559, 560, 563, 570-572, 576, 585, 590, 592, 
595, 596, 604-606, 613, 619, 623, 630, 640-643] with ramifications for long term bone 
health. 
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A slightly different disruption to bone turnover was seen in CF adults. Markers of bone 
resorption were increased in the vast majority of studies [539, 553, 568, 574-576, 579, 
582, 586, 623, 630, 640, 644], with only a few studies reporting normal bone resorption 
[550]. There was a positive correlation between bone resorption markers and age [574] 
and a negative correlation with lung function [640] and bone mineral density [550, 601, 
624], however others found no correlation with bone density [553, 566, 574, 586].  One 
study found osteoprotegerin (OPG) to be significantly reduced compared to control [645], 
which would have contributed to increased osteoclast activity providing further support 
for the increased bone resorption seen in the adults with CF. Most studies found bone 
formation markers to be in the normal range [550, 624, 630], however levels were found 
to be reduced by some [582, 630].  No association between bone formation markers and 
bone density was found [553, 568, 574], however others found significant correlations 
between the two [540, 548, 566, 586] and some significant negative correlations between 
bone formation markers and bone density [539, 589, 601, 624] suggesting a higher rate of 
bone turnover in those with lower bone density.  This un-coupling in bone turnover in the 
CF adults provides support for the accelerated bone loss seen [576, 591, 592, 630, 646, 
647].  
 
Bone histomorphometry studies in adults have also found evidence of interruptions to 
normal bone turnover. In post-mortem lumbar spine bone specimens, there was a 
significant reduction osteoblast activity reflected by reduced osteoblast number and 
biosynthetic potential as well as increased osteoclast activity, evidenced by increased 
osteoclast number and resorptive activity [558]. Another study of rib bone specimens 
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taken during transplant compared to healthy specimens taken from donors, bone 
formation activity was significantly reduced however osteoblast numbers were normal 
suggesting a problem with osteoblast function or maturation [569] consistent with animal 
studies [648]. Histomorphometry of trans-iliac crest biopsies found significant reductions 
in osteoblast activity and bone formation rate due to a shortened lifespan and impaired 
function of mature osteoblasts. Osteoclast numbers were not significantly increased, 
suggesting bone deficits due to reduced formation rate and not increased resorption [579]. 
 
 
1.10.2 Risk factors involved in the pathogenesis of CFBD 
 
 
1.10.2.1 Influence of the CFTR protein 
 
 
In 2007 Shead et al [649] identified the presence of CFTR in osteocytes, osteoblast and 
osteocytes [649], which was supported by later studies [648-655] indicating that CFBD 
could be directly related to abnormal CFTR function in bone cells. When compared to 
control samples, the expression of OPG [533, 653] and prostaglandin E2 receptor (PGE2) 
[653] was significantly decreased however receptor activator for nuclear factor kappa-B 
ligand (RANKL) [533, 653] and the RANKL:OPG ratio [653] expression was 
significantly increased in human F508Del osteoblasts, indicating that bone loss in CF is 
likely caused by a reduction in osteoblastic bone formation and increased 
osteoclastogenesis and resorption [653]. These alterations to the expression of bone mass 
regulators were found to be associated with reduced chloride transport in the CFTR [533, 
653]. There did not appear to be an effect of CFTR dysfunction on osteoblast 
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differentiation however osteoblasts did not progress through maturation processes 
normally, delaying mineralisation of the extracellular matrix [533]. 
 
When human F508Del osteoblasts were treated with a corrector, PGE2 [656] and OPG 
[533] production was increased, and RANKL [657] and the RANKL:OPG ratio was 
decreased [533, 656]. Furthermore, when CFTR activity was inhibited in normal human 
osteoblast cultures, there was a significant reduction in OPG production [652] and a 
significant increase in the RANKL:OPG ratio [533]. These findings confirm a 
pathological link between the CFTR, reduced osteoblast activity and increased bone 
resorption and that CFTR function has a role as a negative regulator in the expression of 
RANKL and the RANKL:OPG ratio. 
 
In CFTR-null mice, histomorphometry revealed significantly reduced trabecular bone 
volume [650, 658], [655], cortical thickness [650, 658], cortical bone density[655] and 
bone apposition rate [650, 655] compared to heterozygous and wild-type litter mates 
[650], these findings consistent with impairments seen in humans with CF, indicating that 
loss of CFTR activity has direct actions on bone. Similar impairments in trabecular and 
cortical bone were seen in the F508Del mouse model [654]. 
 
Osteoblasts from CFTR-null and F508Del mice demonstrated significantly reduced 
number [648], impaired differentiation [648], function [654, 655, 659] and WNT-
signalling [648], significantly reduced OPG expression [648, 659] and β-catenin [659], 
resulting in depressed WNT-signalling [659], a significantly elevated RANK expression 
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[659], RANKL:OPG ratio [648] and significantly increased osteoclasts [648, 654] and 
bone resorption [654], [648]. When given a F508Del corrector, trabecular bone volume 
and bone formation and apposition rate increased significantly and osteoclast number and 
activity significantly decreased [654], and in another study OPG expression significantly 
increased [659]. These finding supporting a direct effect of altered CFTR function on 
bone health in CF. 
 
Furthermore, some studies found that F508Del homozygotes had significantly lower bone 
density compared to other genotypes in adults [538, 572] and children [559, 621] and 
adults with homozygous of heterozygous for  F508Del had significantly lower bone 
density compared to other genotype [624]. However others have found no correlation 
with genotype in CF adults [539, 540, 550, 560, 561, 563, 566, 568, 573, 581, 602, 606, 
623, 627] or children [563, 594, 595, 602, 603, 612, 614]. 
 
 
1.10.2.2 Disease severity and chronic inflammation 
 
 
Several studies have found a strong correlation between bone density and measures of 
disease severity including lung function, disease severity scores, chest radiograph scores 
and bone mass index (BMI). The majority of studies in adults with CF have found bone 
density to be significantly associated with lung function [539, 540, 548, 553, 554, 560, 
563, 566, 568, 572, 573, 581, 584-587, 589, 595, 606, 608, 609, 614, 620, 623-625, 627, 
640, 660] and that bone density changes over time are significantly correlated to lung 
function [583], however some studies found no association between bone density and 
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lung function [547, 550, 552, 561, 578, 585, 590, 599]. Similar finding were found in 
children and adolescents, with the majority of the existing literature reporting significant 
associations between bone density and lung function  [556, 557, 559, 563, 565, 567, 572, 
573, 594, 595, 597, 600, 602, 603, 606, 608, 621, 661-665] however, some studies in well 
children with mild disease did not [575, 578, 598, 613]. 
 
Disease scores were found to be correlated with bone density in adult [560, 592, 627, 
630]and paediatric cohorts [557, 575, 594, 600, 602, 604, 606, 661, 665], however others 
found no correlation [575, 578, 585, 590]. Similarly chest radiograph scores were 
commonly associated with bone density in both children [594, 595, 602, 606, 661] and 
adults [587, 627, 630] with CF, however a few studies found no link [590, 598, 614]. 
BMI was also found to be significantly correlated with bone density in CF adults [539, 
540, 547, 548, 550, 552-554, 559-561, 563, 572, 576-578, 581, 584, 586, 587, 595, 597, 
606, 608, 623-625, 666] and children [557, 559, 563, 567, 572, 594, 597, 600, 602, 605, 
607, 608, 611, 621, 661, 664, 665], with few studies finding no correlation [552, 585, 
599, 613, 616, 624]. 
 
Worsening disease severity is accompanied by chronic pulmonary infection and 
inflammation [667-669]. Recurrent pulmonary exacerbations cause further spikes in pro-
inflammatory cytokines, including interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour 
necrosis factor (TNF) alpha [561, 645, 669-671], establishing a climate for 
osteoclastogenesis and increased bone resorption [672]. Despite intravenous antibiotic 
treatment for infective exacerbations, there is often only partial resolution of elevated 
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pro-inflammatory cytokines [669, 673, 674], suggesting a role of inflammation in CFBD. 
To further support this, the inhibition of CFTR activity in normal human osteoblast 
cultures in induced inflammatory conditions, significantly increased RANKL and the 
RANKL:OPG ratio [533]. Human F508Del osteoblasts also demonstrated significantly 
increased RANKL expression [533] and production [657] and significantly lower OPG 
expressions [533] compared to control osteoblasts, under inflammatory conditions. 
However, when treated with a corrector the F508Del osteoblasts demonstrated significant 
reductions in RANKL [657], the RANKL:OPG ratio [533] and significant increases in 
OPG [533]. These studies confirm a direct link between inflammation and bone 
resorption and an exaggerated response of this pathway in the presence of CFTR 
dysfunction.  
 
In adults with CF inverse correlations with pro-inflammatory cytokines and bone density 
have been found for IL-1 [582], IL-6 [669, 670, 675], TNF-alpha [669, 670] as well as C-
reactive protein (CRP) [539, 640], number of antibiotic courses [572, 623], number of 
hospital days [563, 584] and exacerbations [609]. IL-6 was found to be negatively 
correlated with bone formation [589] and IL-1 significantly associated with bone 
resorption [644]. In CF children, TNF-alpha, IL-6 and CRP were found to have an 
inverse relationship with bone density [615] as did the number of intravenous antibiotic 
days [572, 594] and number of hospital days [563]. 
 
Oral and inhaled glucocorticoids are often used with increasing disease severity, however 
they adversely affect bone health by inhibiting osteoblast activity, promoting bone 
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resorption and suppressing intestinal calcium absorption and the secretion of gonadal and 
growth hormones [9, 676]. Most studies found oral glucocorticoid use to be correlated 
with bone density in CF adults, particularly at the lumbar spine [540, 547, 553, 560, 577, 
586, 623, 624], however other did not find correlations [550, 566, 578, 585]. In children 
there was no consensus in the literature, with some studies finding a correlation [597, 
621] [557, 559, 603, 606] and others not [538, 564, 594, 595, 608, 614, 665]. There was 
also no consensus in the existing literature in regards to the effect on inhaled 
glucocorticoids on bone density with some studies finding a correlation [563, 603, 606, 
624] but the majority not [538, 550, 564, 578, 584, 586, 594, 602, 623, 627, 630, 661]. 
 
 
1.10.2.3 Pubertal delay and hypogonadism 
 
 
Pubertal delay, with a late and blunted increase in sex hormones and delayed peak height 
velocity is reported in adolescents with CF [564, 677-679] and has been associated with 
impaired peak bone mass accrual [532, 536, 547, 560, 575, 641]. In paediatric CF 
populations, the majority of studies have not found a correlation between tanner stage and 
bone density [594, 630, 663, 665], however others have found significantly reduced bone 
density in the setting of delayed puberty [605, 607]. In adults with CF, several studies 
found that bone density was inversely correlated with age at puberty [547, 553, 560, 590, 
620, 630] and age at menarche [560, 624], however other studies have not found a 
correlation between age at menarche and bone density [552, 606, 623]. One study found 
testosterone to be significantly correlated with bone density [623] however several others 
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have not [547, 553, 564, 582, 586]. Despite this, hypogonadism is considered to be 
associated with accelerated bone loss in CF adults [532, 560, 575, 606]. 
 
1.10.2.4 Nutritional factors 
 
 
Calcium, vitamin D and vitamin K play important roles in bone modelling and 
remodelling processes. Serum calcium, calcium intake or calcium supplementation was 
not found to be correlated with bone density in children or adults with CF [540, 559, 560, 
572, 574, 584, 595, 606, 614, 624]. Similarly, few studies found evidence of a correlation 
with parathyroid hormone [553, 574, 581, 582, 584, 586, 589, 598, 624, 640], however 
those that did found significant negative correlations with bone density [539, 566, 568]. 
Despite sub-optimal vitamin D level being frequently reported in CF [539, 540, 547, 552, 
576, 606, 640, 641], no causal link with bone density has been found in adults [548, 552, 
595], [539, 540, 547, 553, 560, 561, 572-574, 576, 581, 582, 584-586, 590, 606, 620, 
623, 624, 640] or children [559, 596, 598, 600, 607, 613, 614, 617, 665], with few studies 
reporting a correlation [548, 552, 557, 566, 594, 595, 624, 666]. Similarly no correlation 
has been found between vitamin K and bone density [600], however a study of high 
Vitamin K supplementation found significantly higher concentration of carboxylated 
osteocalcin and significantly lower concentrations of the under-carboxylated form [637], 
a climate favourable for bone health. 
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1.10.2.5 Weight bearing physical activity and lean tissue 
 
 
Weight bearing physical activity is similar to controls in prepubescent CF children, 
however from the onset of puberty there is a divergence in reported physical activity 
between boys and girls with CF, with girls being less active than boys [680, 681], and 
adults with CF spend significantly less hours performing physical activity compared to 
their healthy counterparts [563]. In adults with CF bone density was found to be 
correlated with peak exercise watts [666], peak oxygen uptake [581, 625, 627], peak 
working capacity [572, 573], time spent in moderate and vigorous activity [583, 666] and 
other measures of daily physical activity [539, 568, 606, 623] [560]. Time spent in 
moderate and vigorous activity as well as peak exercise watts were also associated with 
bone formation markers [666]. In CF children bone density was significantly correlated 
with peak working capacity [572, 573] and an activity score [563]. 
 
Lean tissue mass is often reported to be significantly decreased in CF cohorts compared 
to controls [559, 576, 614, 619, 621, 663], with negative ramifications on bone health. 
Positive correlations between leant tissue mass and bone density have been reported in 
both children [559, 602, 603, 612, 614, 621, 639, 661, 663, 677] and adults [566, 578, 
582, 610, 618, 624, 660, 666] with CF, and is positively correlated to bone formation 
markers [666].
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1.11 Summary 
 
 
Mitochondrial respiratory chain disorders and cystic fibrosis are two chronic diseases that 
demonstrate impairments in bone mass and density, muscle mass and function, exercise 
capacity and quality of life. Participating in conventional exercise programs is often 
difficult due to functional restrictions imposed by their underlying disease. Whole-body 
vibration training does not elicit a significant cardiovascular response or require a high 
level of musculoskeletal competency. It has been found to be well tolerated and 
beneficial in improving bone mass and density as well as muscle mass and performance 
across the lifespan and in people with underlying respiratory and neuromuscular diseases. 
Whole-body vibration training may therefore be an effective training modality to improve 
impairments in bone, muscle, exercise and quality of life parameters commonly seen in 
people with MRCD and CF. 
 
1.12 Aims 
 
 
To evaluate whether a six-month home-based whole-body vibration training program in 
people with MRCD or CF influences:  
1. Bone mass, density and geometry 
2. Bone biochemistry and markers of bone turnover 
3. Muscle mass 
4. Muscle force, power and efficiency 
5. Exercise capacity  
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6. Quality of Life 
 
1.13 Hypotheses 
 
 
Six-months home-based whole-body vibration training in children with MRCD or CF 
will improve musculoskeletal structure, function and quality of life. 
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2 Methods 
 
2.1 Ethics 
 
The studies presented in this thesis were approved by the Human Research Ethics 
Committee at The Children’s Hospital at Westmead (CHW). Vibration training in 
children with cystic fibrosis: function, power, bone (Ethics Code: 2007/018) and Whole-
body vibration training for Mitochondrial Respiratory Chain Disorders and Rett 
Syndrome (Ethics Code: 08/CHW/89). Informed, written consent was obtained from all 
participants and their care-givers. 
 
2.2 Participant Recruitment 
 
In the CF cohort, participant recruitment occurred between April 2010 and August 2011. 
Patients attending the Cystic Fibrosis Clinic at CHW were approached and invited to 
participate in the study. In the MRCD cohort, participant recruitment occurred between 
June 2009 and February 2012. Patients referred to the Western Sydney Genetic Program 
(WSGP) at the CHW were identified by investigators as potential participants. During 
management clinics held at the CHW, potential participants and their families were 
approached and invited to participate in the study. 
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Families showing interest in participating were provided with child and parent 
information sheets and a follow-up phone call was made to families allowing the 
opportunity for detailed discussion about the study protocol and to have any queries 
addressed. If they wished to participate in the study a mutually convenient time was 
scheduled for their baseline visit. 
 
In the MRCD cohort, ethics was initially sought for participants aged between 8-18 years 
however early in the recruitment process it became evident that we would not reach our 
recruitment goal of 25 participants with this age restriction. An ethics amendment was 
submitted to recruit children and adults referred to the WSGP from other health services 
who were interested in participating in the study. Several adult participants were recruited 
from the Neurogenetics Clinic at Royal North Shore Hospital under the care of Professor 
Carolyn Sue. These amendments to the original protocol allowed for more timely 
recruitment and completion of the study. 
 
2.3 Inclusion Criteria 
 
 Age > 6 years  
 Baseline FEV1 > 25% in the CF cohort 
 Proven mitochondrial respiratory chain disorder based on positive enzymology in 
muscle biopsies or known pathogenic variant of a relevant nuclear or mitochondrially 
encoded gene 
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2.4 Exclusion Criteria 
 
 Long bone or vertebral fracture within the last 6 months 
 Past or present history of arthritis 
 CF liver disease with portal hypertension 
 Co-existent neuropathy or myopathy preventing participants being able to stand on a 
vibration platform for at least 10 minutes 
 Cognitive impairment which would impede the ability of participants to comply with 
testing 
 Untreated vitamin D deficiency (25-hydroxyvitamin D Level < 50nmol/L)  
 History of using any of the following medications known to interfere with bone 
metabolism, regardless of dose, for at least 1 month, within 3 months of enrolment: 
o Anabolic agents 
o Oestrogen (except contraceptives) 
o Progestogens (except contraceptives) 
o Calcitriol 
o Calcitonin 
o Fluoride (except dental health products) 
o Bisphosphonates 
o Growth hormone 
o Parathyroid hormone (PTH) 
o Strontium 
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2.5 Study Design 
 
The studies were divided into three periods: observation, WBVT and follow-up.  During 
the observation period participants were monitored to gauge the progression of their 
chronic illness, each acting as their own control to compare with the WBVT and follow-
up periods. This design was chosen due to the significant phenotypic variability displayed 
in both MRCD and CF and due to the relatively small pool of eligible participants. A 
design where each participant acted as their own control was considered optimal as the 
likelihood of being able to successfully recruit for a randomised-controlled study able to 
compensate for phenotypic variability was minimal. In the MRCD cohort, the 
observation period was 3 months in duration and in the CF cohort, 6 months.  
 
The WBVT period was 6 months in duration in both the MRCD and CF cohorts. This 
duration was chosen for WBVT as significant improvements in tibial trabecular bone 
density had previously been found using this duration of WBVT in ambulant children 
with disabling conditions [197]. During this phase of the study participants were provided 
with a Galileo
®
 Home vibration platform (Stratec, Pforzheim, Germany), which provided 
a side-alternating vibration stimulus. Participants were asked to complete three 3-minute 
sessions of vibration training daily. A minimum of 3 minutes rest was required between 
each session to allow the muscles of the lower limbs and trunk to rest. This training 
protocol was chosen as it had been previously used and well tolerated in children and 
adolescents with motor impairments and bone fragility [256, 257], and in adults with 
cystic fibrosis [233], with favourable results on mobility and muscle function 
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respectively. The participant was allowed to structure their daily training to best fit in 
with their daily activities e.g. all in the morning or some in the morning and some at 
night. Vibration training was only conducted under the direct supervision of a responsible 
adult and was for the sole use of the study participant. 
 
Participants were instructed to stand on the platform with their feet between markers “2” 
and “3” on the vibration platform (Figure 2.1) corresponding to an amplitude between 4-
6mm. They were asked to adopt a static semi-squat position by standing with a slight 
knee bend during training sessions. If desired they could place their hands on their knees. 
In this position the knees were comfortably bent between 10-45 degrees, a 
recommendation of a previous study [257] to optimise absorption of the vibration 
stimulus to the legs and trunk and minimise caudal transmission of the vibration to the 
head which could limit tolerability. Some participants in the MRCD cohort who felt they 
would be unable to maintain their balance on the vibration platform were provided with a 
pick-up frame (Figure 2.1) to use for stability during training. These participants were 
instructed to use the frame only when absolutely necessary and to try and limit the 
amount of weight transferred to the frame through the upper limbs so as to maximise the 
amount of weight through the lower limbs to enhance the effectiveness of the vibration 
training. 
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Figure 2.1: Child on Galileo
®
 Home vibration platform (left). Pick-up frame with 
Galileo
®
 Home vibration platform (right). 
 
Participants trained at a vibration frequency of 20Hz for the duration of the study. This 
frequency was chosen as it should theoretically promote the maintenance of, and 
potentially augment, muscle mass as the vibration stimulus at this frequency does not 
allow the muscle to fully relax between vibration cycles resulting in a tonic contraction of 
the muscle [682, 683]. This frequency had also been previously used and well tolerated in 
children and adolescents with motor impairments and bone fragility [256, 257], and in 
adults with cystic fibrosis [232, 233], with favourable results on mobility and muscle 
function. The initial training session was performed under the supervision of the research 
physiotherapist. This allowed for the identification of any safety concerns, potential 
adverse events and to ensure the participant was competent in the use of the vibration 
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platform. Participants were slowly built up to a vibration frequency of 20Hz over the first 
week of training and the speed at which they reached this frequency was participant-
driven. The research physiotherapist was in regular telephone contact with participants 
during the WBVT period. 
 
The follow-up period was 6 months in duration in both the cohorts. This phase allowed 
for the assessment of any de-training effects or whether benefits persisted after 
completion of the intervention period. 
 
Throughout the study, participants continued to receive their standard treatments. 
Nutritional and physiotherapy reviews were performed at least annually with more 
frequent follow-up attended as clinically indicated on an individualised basis. 
 
2.5.1 Visit Structure 
 
All participants attended The Children’s Hospital at Westmead on 4 occasions for study 
visits: baseline; 3-6 months later (Start WBVT); after 6 months of WBVT (End WBVT); 
and after 6 months follow-up (Follow-up). At each visit participants underwent 
assessments of bone density, blood and urine analysis, muscle function, exercise capacity 
and Quality of Life, as well as pulmonary function testing in the CF cohort. The order in 
which assessments were performed at the first visit were recorded and every effort was 
made to keep the order of assessments, especially those requiring physical exertion, in a 
similar order at subsequent visits. 
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2.6 Outcome measures 
 
2.6.1 Anthropometric Measures 
 
Height and weight were measured to the nearest 0.1cm and 0.1kg respectively, in light 
clothing without shoes, using a stadiometer (Seca Model 220, Seca GmbH, Germany) 
and digital scale (Seca Model 703, Seca GmbH, Germany). LMSgrowth software version 
2.74 was used to calculate height, weight and BMI standard deviation scores (SDS).  
 
2.6.2 Bone Parameters 
 
2.6.2.1 DXA 
 
DXA scans of the total body and lumbar spine were performed in the Nuclear Medicine 
Department at the Children’s Hospital at Westmead (CHW) using the Lunar Prodigy (GE 
Lunar Radiation Corp, Madison, Wisconsin, USA). Total body (Figure 2.2) and 
posterior-anterior lumbar spine (Figure 2.2) scans were performed using positioning and 
scanning procedures recommended by the manufacturer and analysed using software 
version 8.6. Effective radiation from the DXA scans is <1 microSv. The DXA scans 
directly measured bone mineral content (g) and the bones’ two-dimensional projection 
area (cm
2
). Areal bone mineral density was then calculated from these parameters. The 
total body scan was also used to assess the body composition variables, lean tissue and fat 
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mass, and to perform analysis on skeletal subregions (arms, trunk, legs) to assess the site-
specificity of any changes. Lumbar spine vertebrae 1-4 volumetric bone density was 
calculated as described by Carter et al [684]. DXA parameters are shown in Table 2.1. 
Age, height and sex-matched SDS for children were calculated using normative data 
from CHW, based on extended data of published work [685-687]. Total body and lumbar 
spine bone mineral density SDS for adults were calculated from a reference data set 
provided with the Lunar software, which included Australian normative data [688]. 
 
  
Figure 2.2: Child having total body DXA scan (left). Adult having lumbar spine DXA 
scan (right).
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Table 2.1: DXA parameters, their definitions and associated coefficients of variation. 
 
Parameter Definition CV 
Total Body DXA Scans 
TBMC (g) Total Body Bone Mineral Content 1.81%
†
 
TBA (cm
2
) Total Body Bone Area - 
TBMD (g/cm
2
) Total Body Bone Mineral Density 1.55%
†
; 1.7%
‡
 
 
LTM (g) Total Body Lean Tissue Mass 0.80%
†
 
Fat (%) Total Body percentage Fat (calculated by fat/soft tissue) - 
Ancillary Parameters 
LTM for Height SDS LTM as predicted by Height SDS - 
TBA for Height SDS Total BA as predicted by Height SDS - 
TBMC for LTM SDS Total Body BMC as predicted by Lean Tissue Mass SDS - 
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TBMC for TBA SDS Total Body BMC as predicted by Bone Area SDS - 
Parameters of Segmental Analysis of Total Body DXA Scans 
Trunk BMD (g/cm
2
) Bone Mineral Density of the Trunk - 
Arms BMD (g/cm
2
) Bone Mineral Density of the Arms - 
Legs BMC (g) Bone Mineral Content of the Legs - 
Legs BA (cm
2
) Bone Area of the Legs - 
Legs BMD (g/cm
2
) Bone Mineral Density of the Legs - 
Legs LTM (g) Legs Lean Tissue Mass - 
Legs Fat (%) Legs percentage Fat (calculated by fat/soft tissue) - 
Lumbar Spine DXA Parameters 
LS BMC (g) Lumbar spine vertebrae 2-4 bone mineral content  0.48%
†
 
LS BMD (g/cm
2
) Lumbar spine vertebrae 2-4 bone mineral density  0.43%
†
; 1.7%
‡
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L14 BMC (g) Lumbar spine vertebrae 1-4 bone mineral content - 
L14 BA (cm
2
) Lumbar spine vertebrae 1-4 bone area - 
L14 vBMD (g/cm
3
) Lumbar spine vertebrae 1-4 volumetric bone mineral density - 
 
Note: CV, coefficient of variation; DXA, dual-energy x-ray absorptiometry; 
†
based on paediatric data from the department of Nuclear 
Medicine at CHW; 
‡
 based on adult data from Crabtree et al 2009 [134].
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2.6.2.2 pQCT 
 
pQCT scans were performed on the non-dominant tibia using the XCT-2000 scanner 
(Stratec Medizintechik, GmbH, Pforzheim, Germany). Tibial length was measured from 
the medial malleolus to the superior margin of the medial condyle using a tape measure 
while the patient rested their non-dominant ankle on the opposite knee. This length was 
entered into the scanner software version 6.0B and used to calculate relative distances of 
the three analysis sites, 4%, 20% and 66% of the tibial length. The participant’s leg was 
extended into the machine and secured distally to a footplate and proximally by a clamp 
just above the knee (Figure 2.3). Participants were asked to remain as still as possible for 
the duration of the scan. Young children were given a portable DVD player to help 
distract them and keep them still during the scan. 
 
 
Figure 2.3: pQCT scanner showing distal end (left) and proximal end (right). 
 
Once positioned correctly in the scanner, a scout scan was performed to identify the distal 
tibial growth plate, or end plate if final height had been reached. The proximal boundary 
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of this growth plate/endplate was considered the reference line. The scanner software 
then re-positioned the gantry to scan the three analysis sites. Each slice took about 2 
minutes to complete and incurred minimal radiation to the participant (<0.2microSv/ 
slice). Scans were acquired with a voxel size of 0.4mm and scanning speed of 20mm/s 
with a slice thickness of 2.4mm. To avoid errors due to the “partial volume effect”, only 
images with a cortical thickness greater than three times the voxel size were analysed. All 
measurements were performed by the same experienced technician. The scan generated a 
cross-sectional image of the bone and surrounding tissues at the 4% distal metaphyseal 
site and 20% and 66% diaphyseal sites (Figure 2.4). Parameters at each of these sites and 
their corresponding analysis settings are shown in Table 2.2. 
 
Reference data for the 4%, 20% and 66% sites for adult and children have been sourced 
from available published papers and personal communications. In children, reference data 
for the 4% and 66% sites was obtained from the published height interval data of Moyer-
Mileur et al [61] and used to generate SDS. Dr Teresa Binkley (South Dakota State 
University, USA) kindly provided her paediatric reference data for the 20% site and this 
was prepared in height intervals (Table 2.3), similar to the Moyer-Mileur et al [61] data, 
and SDS were calculated. pQCT data for the adult MRCD cohort was sent to Dr Ferretti 
(National University of Rosario, Argentina) who analysed parameters from the 4%, 20% 
and 66% sites, using his reference database of healthy adults. 
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Figure 2.4: pQCT cross-sections at the 4%, 20% and 66% site in a MRCD patient (top) 
and CF patient (bottom). 
 
2.6.2.3 Bone Turnover Markers 
 
Bone mineral homeostasis and turnover markers were assessed at each visit. Parameters 
and their analysis methods can be found in Table 2.4. Blood samples were collected at 
the Children’s Hospital at Westmead Pathology Department and urine samples were 
collected from the second void of the day on the day of their visit, wrapped in foil and 
refrigerated till their review. 
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Table 2.2: pQCT settings for bone and muscle parameters at the 4%, 20% and 66% tibial sites. 
 
Site Variable Analysis 
parameter 
Threshold mg/cm
3
 Mode CVs 
    Contour Peel CORT  
4% 
Total BMC 
CALCBD
 
180
a
; 169
b
 1 1 - 
 
Total CSA 1%
d
 
Total vBMD  
Trabecular BMC 
NB: Trabecular parameters calculated on inner 45% of the cross-section 
 
Trabecular CSA  
Trabecular vBMD 1%
d
 
20% 
Total BMC 
CALCBD 180
a
; 169
b
 1 2 - 
 
Total CSA <2%
e
 
Total vBMD  
Total SSIp CALCBD 280 1 1 - <5%
e
 
Cortical BMC CORTBD 711
a
; 700
b
 - - 1  
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Cortical CSA <2%
e,f
 
Cortical vBMD <2%
e,f
 
Cortical thickness 
Determined using circular ring model described by Louis 1995 in Binkley 2000 
1.2%
c
 
Periosteal circumference 0.5 - 1.4%
c,f
 
Cortical CSMIp 
     
 
Cortical  SSIp  
66% 
Total BMC 
CALCBD 180
a
; 169
b
 1 2 - 
 
Total CSA 1%
d
 
Total vBMD  
Cortical BMC 
CORTBD 711 - - 1 
 
Cortical CSA 1%
d
 
Cortical vBMD 2.5%
d
 
Cortical thickness 
Determined using circular ring model described by Louis 1995 in Binkley 2000 
 
Periosteal circumference  
Cortical CSMIp       
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Cortical SSIp  
Muscle CSA 
CALCBD 50 3 1   
Filter F03F05 used for analysis  
Fat CSA CALCBD -51 3 1   
 
 
Note: BMC, bone mineral content; CSA, cross-sectional area; vBMD, volumetric bone mineral density; SSIp, polar stress-strain 
index; CSMIp, polar cross-sectional moment of inertia; CVs, coefficients of variation; 
a
paediatric parameters; 
b
adult parameters; 
c
Binkley et al [146]; 
d
Moyer-Mileur et al [61]; 
e
Binkley et al [148]; 
f
Binkley et al [117]. 
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Table 2.3: Reference ranges for bone mass, geometry, density and strength by height intervals for boys and girls. 
 
Height 
(cm) 
N Age (years) Cortical 
BMC 
Cortical 
CSA 
Cortical 
vBMD 
Periosteal 
Circumference 
Cortical 
Thickness 
Polar SSI 
Females 
105 – 114 3 5.4 + 0.3 58.1 + 14.7 60.1 + 13.2 961.9 + 35.5 53.0 + 1.9 1.2 + 0.3 293.3 + 80.7 
115 – 124  9 7.1 + 0.6 80.7 + 7.1 82.3 + 7.1 981.3 + 29.6 52.6 + 4.1 1.8 + 0.3 386.1 + 50.5 
125 – 134  21 8.5 + 1.3 91.1 + 13.7 91.3 + 12.8 996.5 + 22.4 56.8 + 3.3 1.8 + 0.3 478.8 + 71.0 
135 – 144  12 10.2 + 1.1 105.1 + 18.1 103.8 + 16.2 1010.6 + 42.7 60.5 + 3.6 1.9 + 0.3 605.1 + 113.6 
145 – 154  15 11.4 + 2.1 139.7 + 26.2 134.7 + 20.7 1033.9 + 52.5 63.8 + 5.0 2.4 + 0.5 803.7 + 141.7 
155 – 164  26 15.4 + 2.8 179.8 + 32.4 163.3 + 23.0 1095.1 + 61.8 66.8 + 5.7 2.9 + 0.7 1033.6 + 176.7 
165 – 174  18 15.9 + 2.6 210.3 + 28.1 187.8 + 22.5 1118.1 + 35.6 69.4 + 5.1 3.2 + 0.5 1265.9 + 216.9 
175 – 184  4 17.2 + 1.9 214.4 + 21.7 188.2 + 18.7 1139.3 + 32.6 75.0 + 5.4 2.9 + 0.3 1479.5 + 193.9 
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Males 
115 – 124  9 6.5 + 1.1 73.4 + 15.9 74.5 + 14.2 967.5 + 44.2 52.8 + 4.0 1.6 + 0.3 364.9 + 87.5 
125 – 134  12 8.3 + 1.6 98.4 + 15.7 100.1 + 13.5 980.0 + 42.2 58.1 + 3.4 1.9 + 0.3 527.6 + 84.7 
135 – 144  17 9.6 + 1.4 113.7 + 12.7 114.0 + 12.8 998.2 + 27.3 61.9 + 5.1 2.1 + 0.3 656.3 + 114.3 
145 – 154  15 10.9 + 1.4 139.9 + 21.5 139.4 + 19.3 1001.8 + 35.9 66.2 + 4.9 2.4 + 0.5 825.5 + 128.5 
155 – 164  8 13.3 + 1.2 188.5 + 38.7 184.9 + 35.9 1017.7 + 37.1 73.8 + 3.9 2.9 + 0.5 1249.8 + 259.6 
165 – 174  10 14.7 + 2.9 207.5 + 52.4 194.2 + 38.4 1058.6 + 66.6 72.3 + 5.9 3.2 + 0.6 1341.5 + 363.6 
175 – 184  9 16.5 + 1.5 246.7 + 30.5 224.2 + 26.2 1100.7 + 44.6 77.2 + 5.7 3.4 + 0.7 1627.2 + 241.9 
185 – 194  6 18.0 + 1.4 272.9 + 34.7 253.9 + 28.2 1073.2 + 45.0 82.2 + 5.1 3.6 +0.6 1840.9 + 260.2 
 
Note: BMC, bone mineral content; CSA, cross-sectional area; vBMD, volumetric bone mineral density; SSI, stress-strain index. Data 
provided by Dr Teresa Binkley. 
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Table 2.4:  Bone mineral homeostasis and turnover markers, analysis methods and reference data used. 
Parameter Unit Analysis Method Reference Data 
Alkaline Phosphatase  (U/L) 
“Dry chemistry” technique (Vitros Fusion 5.1, Ortho-
Clinical Diagnostics) 
Tate et al [689] Calcium  (mmol/L) 
Phosphate  (mmol/L) 
Osteocalcin  (nmol/L) 
Sold phase chemiluminescent immunoassays (Immulite 
1000, Siemens, Los Angeles, USA) 
As per the Children’s 
Hospital at Westmead 
Endocrine Laboratory Policy 
and Procedures Manual  
Parathyroid Hormone  (ng/l) 
Two site chemiluminescent enzyme labelled 
immunometric assay (Immulite, DPC, California, USA) 
Urinary 
Deoxypyridinoline: 
Creatine Ratio  
(nmol/mmol 
creatinine) 
Pyrilinks-D assay (Immulite, DPC, California, USA) 
25-hydroxyvitamin D  (pmol/L) Radioimmunoassay (Diasorin, Stillwater, Minn, USA) Normal range > 50  
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2.6.3 Muscle Function Testing 
 
Functional muscle testing was performed on the Leonardo Mechanography Ground 
Reaction Force Plate (Novotec, Medical GmbH, Pforzheim, Germany) (Figure 2.5). Two 
adjacent force plates (left and right), each with four strain gauge force sensors and a 
resonance frequency of 150Hz, measure vertical ground reaction forces exerted on the 
platform. Signals from the platform are sampled at a frequency of 800Hz and connected 
to a computer by a USB 2.0 connection. The platform was calibrated according to the 
manufacturers recommendations and zeroed prior to the performance of each test. 
Leonardo Mechanography GRFP Research Editions software was used to analyse 
manoeuvres performed on the plate. 
 
Three commonly used mechanographic tests measuring force and their derivatives were 
chosen due to their proven correlation with motor capacity that is relevant to activities of 
daily living and functional decline [690-694]:  the multiple one-leg jump, single two-leg 
jump and chair-rise test. These manoeuvres allowed for a range of functional abilities 
among participants [692]. They have established validity and reliability and reference 
data exists for both paediatric and adult populations [692, 694-696]. Prior to each test, 
participants stood stationary on the platform with one foot on each of the force plates to 
measure body mass. After a single-tone, participants commenced the manoeuvre, the 
vertical force applied to the platform used to calculate vertical acceleration and thus 
power. After completing the manoeuvre, participants stood stationary on the platform till 
a double tone was heard, indicating test completion. At least 3 trials of each manoeuvre 
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were completed. Parameters, reference data and coefficients of variation (CV) are 
presented in Table 2.5.
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Table 2.5:  Force plate parameters, reference data and coefficients of variation. 
Parameter Cohort Unit Definition Reference Data for 
SDS calculation 
CV
a
 
Multiple One-leg Jump (M1LJ) 
F max Paediatrics  
kN Maximum voluntary ground reaction force  
4.7-5.9%  
 Adults 3.7-4.8%  
F max rel Paediatrics  
g 
Maximum ground reaction force in relation to 
body weight 
Lang et al [695] 4.2-6.4%  
 Adults 
Leonardo Software 
Package 
3.8-5.2%  
Single Two-leg Jump (S2LJ)  
EFI  
Paediatrics 
and Adults 
% 
Esslinger Fitness Index - Maximum relative 
power as a percentage of the mean value of the 
gender- and age-matched reference group. 100% 
is equivalent to the 50
th
 centile 
Maximum relative 
power normalized to 
age and gender - 
Tsubaki et al [697]  
 
FE 
Paediatrics 
and Adults 
% 
Force Efficiency of movement pattern – 
maximum relative power output in relation to 
normalized maximum force 
Leonardo Software 
Package 
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P max 
Paediatrics 
kW 
Maximum power during the lift-off phase 
(combined right and left legs) 
 
3.6%  
Adults 5.5%  
P max rel 
Paediatrics 
W/kg Maximum power in relation to body mass 
Busche et al [696] 3.4%  
Adults Dietzel et al [694] 5.5%  
F max 
Paediatrics 
kN 
Maximum ground reaction force during lift off 
phase (combined right and left legs) 
 
12.7% 
Adults 6.0%  
F max rel 
Paediatrics g Maximum force in relation to body weight Busche et al [696] 13.1%  
Adults N/kg Maximum force per kg body mass Dietzel et al [694] 6.6%  
Chair-Rise Test (CRT)  
Time per test 
Paediatrics 
s Average time per repetition 
Busche et al [696] 
 
Adults  
V max Adults m/s 
Average maximum vertical velocity during rise 
of all repetitions 
Dietzel et al [694] 6.2%  
P max Paediatrics W Maximum power (combined right and left legs)  14%  
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Adults 8.1%  
P max rel 
Paediatrics W/kg 
Average maximum power during the rise phase 
of each repetition in relation to body mass 
Busche et al [696] 15.6%  
Adults W/kg 
Maximum power during the rise phase of each 
repetition per kg body mass 
Dietzel et al [694] 8%  
F max 
Paediatrics 
kN 
Maximum ground reaction force during the rise 
phase of each repetition per kg body mass 
 
7%  
Adults 8.3%  
F max rel 
Paediatrics g 
Average maximum ground reaction force during 
the rise phase of each repetition as a multiple of 
body weight 
Busche et al [696] 7.9%  
Adults N/kg 
Maximum force during the rise phase of each 
repetition per kg body mass 
Dietzel et al [694] 7.9%  
 
Note: SDS, standard deviation score; CV, coefficient of variation; 
a
Referring to CVs from Veilleux et al [692]; F, force; EFI, Esslinger 
Fitness Index; FE, force efficiency; P, power; V, velocity. 
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Figure 2.5: Muscle function testing on the Leonardo Mechanography Ground Reaction 
Force Plate. 
 
2.6.3.1 Multiple One-leg Jump (M1LJ) 
 
Participants were instructed to perform 10 consecutive hops as high as possible on the 
ball of the non-dominant foot, trying to keep the heel off the ground by keeping the knee 
stiff (Figure 2.5). The trial with the highest maximum force was selected for analysis 
(Figure 2.6). This manoeuvre allows quantification of maximal ground reaction forces a 
participant can generate and is a surrogate measure for the maximum forces the tibia is 
exposed during habitual physical activity. Performance has been correlated with tibial 
bone parameters assessed using pQCT [698, 699]. 
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Figure 2.6: Multiple one-leg jump output. 
 
2.6.3.2 Single Two-leg Jump (S2LJ) 
 
Participants were instructed to perform one jump as high as possible using both legs 
(Figure 2.5). Three trials were performed and the trial with the highest maximum power 
was selected for analysis (Figure 2.7). This manoeuvre requires muscle coordination and 
balance and allows quantification of maximal power generated by the lower limbs, a 
surrogate measure of anaerobic capacity [700]. 
 
 182 
 
Figure 2.7: Single two-leg jump output. 
 
2.6.3.3 Chair-rise Test (CRT) 
 
Participant were instructed to perform 5 repetitions of a sit-to-stand as fast as possible, 
ensuring a full standing position is achieved with each repetition. A specifically designed 
bench (34 or 46cm) was anchored to the Ground Reaction Force Plate for this 
manoeuvre, at a height aiming for hips and knees to be near 90 degrees when in the 
seated position (Figure 2.5). The same height chair was used on all testing occasions. The 
trial with the highest maximum power was selected for analysis (Figure 2.8). This 
manoeuvre is relevant for daily activities and provides a measurement of power when 
jumping manoeuvres are unable to be performed [692]. 
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Figure 2.8: Chair-rise test output. 
 
2.6.4 Exercise Testing 
 
 
2.6.4.1 Six Minute Walk Test 
 
This test was performed by all participants in the MRCD cohort. It was not performed by 
the CF cohort. The six minute walk test (6MWT) was performed on a 25m track 
according to ATS criteria [701]. Prior to the test participants were seated alongside the 
walking track. Systolic and diastolic blood pressure, heart rate and oxygen saturations 
were recorded using a digital sphygmomanometer (Vital Signs Monitor 300 Series, 
Welch Allyn, USA). A modified rate of perceived exertion (RPE) scale (Cox ref) was 
used to get participants to subjectively rate their degree of physical exhaustion. 
Participants were given instructions about the test according to ATS criteria [701]. In 
brief, participants were asked to walk as far as possible in the 6 minutes and given the 
option to take standing rests if they became exhausted or out of breath however they were 
encouraged to start walking again as soon as possible. The total distance completed was 
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recorded. After completion of the test participants were seated alongside the track. Repeat 
measurements of blood pressure, heart rate, oxygen saturations and RPE were performed 
and recorded. After a five-minute rest period these were collected again. Reference data 
for children was sourced from Ulrich et al [702], for adults < 40 years of age from Chetta 
et al [703] and for adults > 40 years from Enright et al [704].  
 
2.6.4.2 Formal Cardiopulmonary Exercise Testing  
 
All children in the CF cohort and capable children and young adults in the MRCD cohort  
performed formal exercise testing in the Respiratory Function Unit at the Children’s 
Hospital at Westmead using the Bruce Protocol [705] on an electronic treadmill (TMX 
55, Trackmaster Treadmills, Newton, USA) and breath-by-breath gas analysis (Vmax 
Encore 229, Care Fusion, CA, USA) by a soft facemask (7900 Series Silicone Facemask, 
Hans Rudolph, Missouri, USA). Using Vmax Series Version 21-1A software 
(CareFusion, CA, USA), breath-by-breath gas analysis was used to determine
 
peak 
oxygen uptake (VO2), exercise ventilation (VE), carbon dioxide production (VCO2), 
ventilatory equivalents of oxygen (VE/VO2) and carbon dioxide (VE/VCO2) and the 
respiratory exchange ratio (RER). Heart rate and oxygen saturations were measured 
throughout the test using a 4 lead ECG (Cardiosoft 12-Lead ECG, GE Healthcare, 
Chicago, USA) and pulse oximeter (Massimo Radical, Irvine, Canada) respectively, and 
was integrated into the Care Fusion Vmax system. Equipment was calibrated according 
to the American Thoracic Society guidelines prior to each test. 
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Once participants were set up and breath-by-breath data acquisition had commenced a 
baseline period of 2-5 minutes was recorded. During this time participants had blood 
pressure measured using a digital sphygmomanometer (Vital Signs Monitor 300 Series, 
Welch Allyn, USA) and rated their degree of physical exhaustion using the Borg scale 
[706]. After the baseline measurement period the Bruce Treadmill Protocol was 
commenced (Figure 2.9). Every three minutes the speed and incline of the treadmill 
increased according to the Bruce Protocol. At the end of each stage participants were 
asked to rate their degree of physical exhaustion on the Borg scale. The test was 
terminated when the participant reported physical exhaustion or was unable to maintain a 
safe cadence on the treadmill. Participants were seated and blood pressure and RPE were 
recorded. Recovery data were collected for 5 minutes. A final measure of blood pressure 
and RPE was recorded and the participant disconnected from the equipment. 
 
Adults in the MRCD cohort capable of performing a formal exercise test had their tests 
performed at Royal North Shore Hospital (RNSH), an accredited Pulmonary Function 
Laboratory for adults. These participants had breath-by-breath analysis during exercise 
using the same equipment, hardware and software however they performed their tests on 
an electronically braked cycle ergometer (CareFusion, MS-CPX, CA, USA) using a 10 
Watt/minute protocol. These participants underwent the same baseline and recovery 
conditions however during the exercise test they were instructed to cycle at a cadence of 
60 revolutions per minute. Cycle ergometry testing was terminated when the participant 
reported physical exhaustion or was unable to maintain the required cadence of 60 
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revolutions per minute. All exercise tests at both CHW and RNSH were performed with 
at least two people present and under the supervision of a Respiratory Physician. 
 
Reported values for each variable at baseline, anaerobic threshold (AT), peak exercise 
and recovery were calculated by taking an average of the breath-by-breath data over a 30 
second time frame. Anaerobic threshold was identified using the ventilatory equivalents 
method [707], peak exercise was when peak VO2 was achieved and recovery data were 
the last 30-second interval of the 5-minute recovery period. AT and Peak VO2 were 
selected under the guidance of a Respiratory Physician. Reference data for children was 
obtained from Cooper et al [708], and for adults, from a reference data set provided with 
the CareFusion software using data recommended by the American Thoracic Society and 
European Thoracic Society. Maximum predicted heart rate was calculated by subtracting 
the participant’s age from 220. 
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Figure 2.9: Child performing CPET (left) and pulmonary function (right). 
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2.6.5 Disease Specific Quality of Life Questionnaire 
 
 
2.6.5.1 Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) and 
Newcastle Mitochondrial Disease Scale (NMDS) 
 
The quality of life of child participants in the MRCD group was assessed using the 
Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) [709]. This rating scale 
addresses different aspects of mitochondrial disease with 4 domains: Current Function; 
System Specific Involvement; Current Clinical Assessment and Quality of Life. Most 
questions were rated using a four-point scale from 0-3: 0 representing normal, 1- mild, 2- 
moderate and 3- severe, with examples of each given. Higher scores indicating more 
severe disease and poorer quality of life.  Two age-specific versions of the NPMDS were 
used: 2 – 11 years and 12 – 18 years.  Adult participants in the MRCD group completed 
the Newcastle Mitochondrial Disease Adult Scale (NMDAS) [710]. It included the 
Current Function; System Specific Involvement; Current Clinical Assessment domains 
used in the NPMDS, however most questions were rated using a six-point scale from 0-5, 
higher scores indicating more severe disease.  Quality of Life was measured using the 
validated SF12v2 and QualityMetric Health Outcomes Scoring Software 3.0 
(QualityMetric Incorporated, Lincoln, USA) which generates SDS for 8 quality of life 
domains: Physical Functioning; Role Physical; Bodily Pain; General Health; Vitality; 
Social Functioning; Role Emotional; and Mental Health, as well as physical and mental 
component scores. Both the NPMDS and NMDAS have excellent inter-rater reliability 
and established validity with higher scores correlated with greater disease severity in both 
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adult [710, 711] and paediatric [709] patients. Designed primarily to assess the natural 
history of mitochondrial disease and monitor progression in patients [709, 710], no 
meaningful clinically important difference has been identified, however studies have 
found correlations between disease progression measured by the NMDAS and muscle 
mitochondrial DNA heteroplasmy, DNA deletion location and size [711] and increases in 
cerebral blood flow correlated with improvements in NMDAS and NPMDS scores [712]. 
 
2.6.5.2 The Cystic Fibrosis Questionnaire (CRQ-R) 
 
The quality of life of participants in the CF cohort was assessed using the CFQ-R. The 
CFQ-R is a disease specific, health related quality of life measure for individuals with 
CF. The questionnaire has developmentally appropriate versions; Child, for children aged 
6-13 years, with an interviewer format for those aged 6-11 years and a self-report format 
for those 12-13 years; Parent, for parents of children with CF aged 6-13 years; and a 
Teen/adult for those 14 years and older. The questionnaire encompasses general domains 
of health-related quality of life: physical functioning, role functioning, vitality, health 
perception, emotional functioning and social functioning, as well as domains specific to 
CF: body image, eating disturbances, treatment burden, respiratory and digestive 
symptoms. Most questions were rated using a four-point scale that was standardised to a 
100-point scale, with higher scores reflecting better quality of life. The teen/adult version 
of the questionnaire has been validated as a reliable measure of health related quality of 
life for individuals with CF [713]. Domain scores were generated using the CFQ-R 
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Scoring Calculator (Version 2.0). Normative means for each domain the three versions 
have been published [714]. The questionnaire takes about 10 minutes to complete. 
 
2.6.6 Adherence to training 
 
The Galileo® Home Vibration Platform has an inbuilt counter that measured the time that 
the platform was operating. This was used to calculate the treatment time and expressed 
as a percentage of perfect adherence (9 minutes daily for 6 months). 
 
2.6.7 Cystic Fibrosis Specific Outcome Measures 
 
2.6.7.1 Pulmonary Function Tests 
 
Spirometry, Body Plethysmography and Multiple Breath Nitrogen Washout (MBNW) 
test were performed by the CF cohort (Figure 2.9). All tests were performed according to 
standard ATS techniques and at least 3 satisfactory tests were recorded for each measure, 
the best result used for analysis. Spirometry was measured using the Vmax Encore 229 
equipment (Care Fusion, CA, USA) and body plethysmography by the V62J Autobox 
(Care Fusion, CA, USA) using Vmax Series Version 21-1A software (CareFusion, CA, 
USA) in accordance with American Thoracic Society Guidelines [715]. Children sat 
upright with a nose peg (SureGuard nose clip, BIRD Healthcare, Port Melbourne, 
Australia and mouthpiece with a bacterial filter (SureGuard bacterial viral filter, BIRD 
Healthcare, Port Melbourne, Australia). Spirometry parameters included forced vital 
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capacity (FVC), forced expiratory volume in one second (FEV1), the ration of FEV1/FVC 
and forced expiratory flow (FEF25-75%). The ratio of residual volume (RV) and total lung 
capacity (TLC) was used from plethysmography. Results were expressed as a percentage 
of predicted values with the use of reference data from Wang et al [716].  
 
 MBNW allowed the calculation of the lung clearance index (LCI), a measure of 
abnormal ventilation distribution. Children were encouraged to adopt a regular, 
comfortable breathing pattern, and once this was achieved, the patient began to breathe 
100% oxygen. Expired volume was recorded until the nitrogen concentration was 1/40
th
 
of the starting concentration, and LCI was calculated by dividing this expired volume by 
functional residual capacity (FRC). Tests were separated by at least twice the washout 
time. Studies in healthy children have demonstrated that the upper limit for normal LCI is 
7.77 with higher values indicating more severe dysfunction. Tests were performed in the 
same order at every visit, MBNW – spirometry – plethysmography – CPET. 
 
2.6.8 Search Strategy 
 
Key search terms (Table 2.6) were entered into the Medline and Pubmed Databases. 
Articles available in full text and the English language, investigating the effects of at least 
4 weeks of vibration training in standing in humans were reviewed. 
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Table 2.6: Key search terms used in search strategy. 
Participants Intervention Outcome Measures 
Humans 
Paediatric 
Child 
Adult 
Neuromuscular 
Cystic fibrosis 
Respiratory disease 
Mitochondrial disease 
Mitochondrial respiratory chain 
disorders 
Mitochondrial myopathy 
 
 
 
 
 
 
Vibration 
Vibration training 
Whole-body 
vibration 
Oscillating 
Side-alternating 
Vertical  
 
 
 
 
 
 
 
 
 
 
DEXA/DXA 
pQCT/QCT 
Bone 
Bone density 
Bone mass/bone mineral 
content 
Bone loss 
Bone area 
Bone strength 
Bone turnover markers 
Function  
Muscle  
Muscle area 
Muscle mass/lean mass 
Muscle force 
Muscle power 
Muscle strength 
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Hop/Jump  
Single-leg jump/One-leg 
jump 
Chair-rise test/Sit-to-stand 
Force plate 
Walk test 
Six-minute walk test 
Exercise 
Exercise test 
Exercise capacity 
Oxygen uptake 
Quality of life 
Lung function 
Spirometry/FEV1 
Lung volumes/ 
plethysmography 
Lung clearance index 
Nitrogen multiple-breath 
washout 
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2.6.9 Power Calculation 
 
To detect a 0.75 standard deviation difference in the primary outcome measure (bone 
mass) with a significance of 95% and power of 80%, 16 subjects would be required.  The 
aim was to recruit 20 participants into the CF study and 25 into the MRCD study. 
 
2.6.10 Statistical Analysis 
 
To estimate whether between time point differences were statistically significant, a linear 
mixed model [717] with an autoregressive covariance matrix was used for each outcome 
measure. An autoregressive covariance structure provided the best fit for the main 
outcomes as indicated by the lowest -2 log likelihood ratio. This structure allows data 
closer together in time to be more correlated than data points further apart. Least 
significant difference (LSD) tests were used to test whether there were significant 
differences between the follow-up time points. A P value of <0.05 was considered 
statistically significant. The mean differences and 95% confidence intervals (95% CI) 
reported are predicted mean values from the model. The residuals from each linear mixed 
model were plotted to verify that they were approximately normally distributed and to 
confirm that there were no influential outliers. For parameters were SDS were calculated, 
one sample t-tests were used to examine for differences from zero. Statistical analysis 
was performed using IBM SPSS Statistics Version 25 (IBM Corporation). 
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3 CF Results 
 
 
3.1 Participants 
 
 
Nineteen participants, 10 male, 7-18 years of age were recruited in to the study (Table 
3.1). Two participants were withdrawn from the study during the observation period due 
to the development of septic arthritis in one patient and the development of allergic 
broncho-pulmonary aspergillosis (ABPA), requiring medium-term oral steroid use, in the 
other. A third participant was lost to follow-up. 
 
The remaining 16 participants, 10 males, had a mean (SD) age of 12.8 (3.5) years and 
presented with Class I, II, III and V mutations (Table 3.2). Pancreatic insufficiency was 
seen in 14/16 participants (87.5%), which was reflective of Australian CF population, in 
which 82.2% are pancreatic insufficient [480]. The F508del mutation was present in 
15/16 participants (93.8%) with 9/16 (56.3%) being homozygous for this mutation. These 
figures were also consistent with the Australian CF population, where 92.1% carry the 
F508del mutation and 50.2% are homozygous for this mutation [480]. 
 
Participants attended the hospital for four research visits. The observation period 
occurred between Visits 1 and 2. The mean (SD) time elapsed between these visits was 
6.5 (1.0) months. The whole-body vibration training (WBVT) period occurred between 
Visits 2 and 3. The mean (SD) time between visits was 6.6 (0.7) months. The follow-up 
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period occurred between visits 3 and 4. The mean (SD) time periods between these visits 
was 6.6 (1.3) months. 
 
 
 
Figure 3.1: Flow diagram of participant recruitment. 
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3.2 Anthropometric Parameters 
 
 
The baseline anthropometric data for the cohort are presented in Table 3.2. The CF cohort 
has a mean (SD) height of 155.5 (16.8) cm and a mean (SD) height standard deviation 
score (SDS) of 0.0 (0.9), mean (SD) weight of 43.8 (13.3) kg and mean (SD) SDS -0.5 
(0.9) which was significantly lower than the reference population (Figure 3.1). BMI and 
BMI SDS were also low with a mean (SD) of 17.6 (2.3) kg/m
2
 and -0.7 (0.9) which was 
also significantly different to the reference population (Figure 4.1). The lower weight and 
BMI compared to the reference population a common presentation in CF, especially in 
those with pancreatic insufficiency. 
 
Analysis of anthropometric variables can be found in Appendix H, Table H.1. There were 
significant increases in height, weight and BMI during the observation period of 2.6cm, 
p<0.001, 2.7kg, p<0.001, and 0.5kg/m
2
, p=0.005 respectively. However, there were no 
significant changes in their corresponding SDS, indicating that the growth trajectory was 
not altered. After WBVT, height increased significantly by 2.2cm, p<0.001, however 
there was no significant change in its corresponding SDS or in weight, BMI, or their 
corresponding SDS. Height, weight and BMI increased significantly during the follow-up 
period by 2.2cm, p<0.001, 2.1kg, p<0.001 and 0.4kg/m2, p=0.041 respectively. There 
were no significant changes in the SDS scores. Anthropometric variables were unaffected 
during the study, as there were no significant changes in height, weight or BMI SDS. 
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Table 3.1. Participant characteristics. 
 
Patient Gender Age  Pancreatic Mutation 1 Mutation 2 Status 
  (years) Status Type Class Type Class  
1  Male 7 PI F508del II F508del II  
2  Female 17 PI 1898+1G>A I Unknown   
3  Male 14 PI F508del II F508del II  
4 Female 14 PI F508del II F508del II WITHDRAWN - septic arthritis 
5  Male 15 PS F508del II Unknown   
6  Female 13 PI F508del II F508del II  
7 Male 15 PI F508del II F508del II  
8 Male 16 PI F508del II Unknown  WITHDRAWN - ABPA 
9 Female 18 PS F508del II Unknown   
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10 Male 17 PI F508del II F508del II  
11  Male 12 PI F508del II W79X I  
12  Female 8 PI F508del II F508del II  
13  Male 8 PI F508del II F508del II  
14  Female 14 PI F508del II G551D III  
15  Male 11 PI F508del II L1077P II  
16 Female 11 PI F508del II F508del II  
17 Female 12 PI F508del II 3849+10kbC>T V  
18 Male 10 PI F508del II I508del II WITHDRAWN - lost to follow-up 
19 Female 8 PI F508del II F508del II  
 
Note: PI, pancreatic insufficient: PS, pancreatic sufficient.
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Table 3.2. Baseline anthropometric data. 
Patient Gender Age 
(years) 
Height 
(cm) 
Height 
SDS 
Weight 
(kg) 
Weight 
SDS 
BMI 
(kg/m
2
) 
BMI 
SDS 
1  Male 7 126.10 0.17 26.50 0.55 16.67 0.63 
2  Female 17 166.20 0.44 54.00 -0.39 19.55 -0.56 
3  Male 14 172.10 0.47 50.70 -0.42 17.12 -1.10 
5  Male 15 169.80 0.04 57.40 0.14 19.91 0.22 
6  Female 13 153.60 -0.22 43.00 -0.28 18.23 -0.22 
7 Male 15 170.40 0.03 51.30 -0.57 17.67 -0.89 
9 Female 18 174.30 1.77 64.70 0.79 21.30 0.03 
10 Male 17 179.80 0.44 54.60 -1.39 16.89 -2.10 
11  Male 12 140.40 -1.39 32.00 -1.34 16.23 -0.79 
12  Female 8 133.10 0.40 27.00 -0.16 15.24 -0.55 
13  Male 8 130.00 0.20 23.10 -0.89 13.67 -1.67 
14  Female 14 144.30 -2.38 34.10 -2.56 16.38 -1.48 
15  Male 11 141.20 -0.50 29.80 -1.10 14.95 -1.30 
16 Male 16 142.50 -0.35 41.50 0.64 20.44 1.07 
17 Female 12 152.40 -0.09 33.20 -1.51 14.29 -2.37 
19 Female 8 130.00 0.43 24.70 -0.33 14.62 -0.84 
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Note: SDS, standard deviation score; BMI, body mass index. 
 
3.3 Bone Parameters 
 
 
3.3.1 DXA 
 
 
3.3.1.1  Baseline 
 
 
 
Baseline DXA parameters are presented in Table 3.3 and Figure 3.1. This includes: total 
body DXA scan parameters, segmental analysis of the trunk, arms and legs from the total 
body scans; and analysis of the lumbar spine (LS), including lumbar vertebrae 2-4; and 
analysis of the lumbar vertebrae 1-4 (L14). Total body DXA parameters were further 
analysed to obtain ratios between measures of BMC, BA, LTM, and height: LTM for 
height SDS; TBA for height SDS; TBMC for LTM SDS; and TBMC for TBA SDS.  
 
The baseline SD scores for total body BMC, arms BMD, trunk BMD, lean tissue mass for 
height, total bone area for height and lumbar vertebrae 1-4 vBMD were significantly 
reduced compared to the reference population, however total body BMD, BMC for lean 
tissue mass and bone area, legs BMD and lumbar spine BMD and BMC were not  (Figure 
4.1). These findings were generally consistent with the existing literature. The height-
adjusted total body BMC SDS was found to be significantly reduced in other child and 
adolescent CF populations [559, 663, 677] but not significantly different to the reference 
or control populations in others [594, 605, 639, 663].  The height-adjusted total body 
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BMD SDS was not different to the reference or control populations in all [564, 594, 611] 
but one [559] of the previous studies, consistent with that seen in the CF cohort. Total 
body BMD SDS were < -1 in 4/16 (25%) and less < -2 in 2/16 (13%) of the CF cohort, 
similar to that seen in the current literature for young people with CF with 4-28% having 
a SDS <-1 [598, 608] and 4-27% having a SDS <-2 [563, 594]. One study has previously 
investigated the segmental analysis of the total body DXA scans, and similar to that seen 
in the CF cohort, height- and weight-adjusted SDS for the arms and trunk BMD were 
significantly reduced in children and adolescents. They also found a significantly reduced 
BMD SDS in the legs, which was contrary to that seen in the CF cohort, however their 
cohort was much larger, and likely a more representative sample [559]. The significant 
reduction in lean tissue mass for height SDS was consistent with several previous studies 
[559, 603, 614, 621, 663], however others have found no significant difference between 
CF patients and controls [612, 619, 639]. Similarly, the significantly reduced bone area 
for height SDS has also been widely seen in the existing literature [594, 608, 612], with 
only one existing publication finding bone area to be similar between CF patients and 
controls matched for height, weight and pubertal status [611]. The SDS for BMC for lean 
tissue was not significantly different to the reference population, consistent with previous 
reports [612, 619], however others have reported this SDS to be significantly reduced in 
children and adolescents [559] and in pubertal females with CF [612]. The BMC for bone 
area SDS was slightly elevated, but not significantly different to the reference population. 
One previous study found this SDS to significantly increased in its CF children and 
adolescents [608]. 
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Similar to that seen in the CF cohort, height-adjusted lumbar spine vBMD was found to 
be significantly reduced in previous studies of CF children and adolescents [559, 593, 
602]. Lumbar spine BMD SDS was not significantly reduced in the CF cohort, which was 
consistent with an earlier Australian study that adjusted for height and lean tissue mass 
[564], however in contrast to two international studies which adjusted for height and 
found lumbar spine BMD to be significantly reduced [559, 603]. Lumbar spine BMD 
SDS were < -1 in 6/16 (38%) and < -2 in 2/16 (13%) which were similar to the ranges 
seen in the current literature with 22-52% of CF child and adolescent populations having 
a SDS <-1 [567, 598, 603, 605, 607] and 9-35% having a SDS < -2 [559, 563, 567, 594, 
596, 603, 607].  The lumbar spine BMC SDS was also not significantly reduced 
compared to the reference population. This was in contrast to the one published study 
using height- and weight-adjusted SDS that found the same parameter to be significantly 
reduced in children and adolescents with CF [559].  
 
These findings indicate compromised bone health in both the cortical and trabecular bone 
compartments. When considering the cortical compartment, analysis of the total body 
DXA scan using the 4-step algorithm of Hogler et al [687], indicates that the low bone 
mass seen in the CF cohort is secondary to the significantly reduced lean tissue mass for 
height. This reduction in lean mass, imparts less muscle pull on the underlying bone, 
reducing the mechanical stimulus required for optimal bone modelling and in particular, 
geometric adaptations. This caused the significant reduction in bone area for height, as 
the required mechanical stimulus did not surpass the threshold required for geometric 
adaptations to be elicited and deposition of new bone at the same rate as their healthy 
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counterparts. The normal adaptation of BMC to both lean tissue mass and bone area 
further supports the reduced lean tissue mass in the CF cohort being the primary culprit 
for the low bone mass phenotype described.   
 
Table 3.3. Baseline dual-energy x-ray absorptiometry parameters for scans of the total 
body, lumbar spine and distal femur. Mean (SD). 
Total Body DXA Parameters  
TBMC (g) 1611.8 (613.3) 
TBMC SDS -0.7 (1.1) 
TBA (cm
2
) 1615.6 (452.1) 
TBMD (g/cm
2
) 0.974 (0.109) 
TBMD SDS -0.5 (1.1) 
LTM (g) 31407.1 (10401.5) 
Fat (%) 18.6 (7.1) 
Fat (%) SDS -0.2 (0.7) 
LTM for Height SDS -0.7 (0.9) 
TBA for Height SDS -0.9 (1.0) 
TBMC for LTM SDS -0.2 (1.1) 
TBMC for TBA SDS 0.1 (1.1) 
Parameters of Segmental Analysis of Total Body DXA Scans 
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Trunk BMD (g/cm
2
) 0.763 (0.097) 
Trunk BMD SDS -0.3 (0.4) 
Arms BMD (g/cm
2
) 0.694 (0.010) 
Arms BMD SDS -0.7 (1.0) 
Legs BMC (g) 599.3 (272.2) 
Legs BA (cm
2
) 576.2 (173.0) 
Legs BMD (g/cm
2
) 0.998 (0.182) 
Legs BMD SDS -0.3 (1.2) 
Legs LTM (g) 10114.3 (4001.4) 
Legs Fat (%) 24.1 (8.7) 
Lumbar Spine DXA Parameters  
LS BMC (g) 29.5 (11.8) 
LS BMC SDS -0.3 (1.1) 
LS BMD (g/cm
2
) 0.863 (0.189) 
LS BMD SDS -0.4 (1.2) 
L14 BMC (g) 36.9 (14.8) 
L14 BA (cm
2
) 42.5 (9.0) 
L14 vBMD (g/cm
3
) 0.291 (0.059) 
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L14 vBMD SDS -0.9 (1.0) 
 
Note: DXA, dual-energy x-ray absorptiometry; TBMC, total body bone mineral content; 
TBA, total body bone area; TBMD, total body bone mineral density; SDS, standard 
deviation score; LTM, lean tissue mass; BMD, bone mineral density; BMC, bone mineral 
content; BA, bone area; LS, lumbar spine vertebrae 2-4; L14, lumbar spine vertebrae 1-4; 
vBMD, volumetric bone mineral density. 
 
 
 
Figure 3.2. Standard deviation (SD) scores for anthropometric and DXA parameters in 
the paediatric cohort. Mean and 95% confidence intervals. Parameters shown in red were 
significantly different to the reference population on one-sample t-tests, p<0.05. 
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3.3.1.2  Observation Period 
 
The observation period occurred between Visit 1 (Baseline) and Visit 2 (Start WBVT). 
Full analysis data for all DXA parameters for the observation period in the CF cohort can 
be found in Appendix A, Table A.1. There were significant changes in parameters of the 
total body DXA scan, segmental analysis of the total body DXA scan and the lumbar 
spine DXA scan (Table 3.4 and Appendix A, Table A.1). Total body BMC, bone area, 
bone density and lean tissue mass increased significantly from: 1611.8 – 1713.6g 
(p<0.001); 1615.6 – 1689.2 cm2 (p<0.001); 0.974 – 0.992g/cm2 (p<0.001); and 31407.1 – 
32653.7g (p<0.001) respectively. However, there were no significant changes in the SDS 
for BMC or BMD or the bone area for height and LTM for height SDS, indicating these 
changes were associated with normal growth. On segmental analysis, trunk BMD and 
arms BMD increased significantly from 0.763 – 0.779g/cm2 (p=0.001) and 0.694 – 
0.717g/cm
2
 (p<0.001), however their corresponding SDS did not change significantly, 
again indicating normal skeletal development with growth. Legs BMC, BA, LTM and 
BMD increased significantly:  599.3 – 632.8g (p<0.001); 576.2 – 597.6cm2 (p<0.001); 
10114.3 – 10629.5g (p<0.001); and 0.998 – 1.021g/cm2 (p<0.001) respectively. There 
was no significant change in the legs BMD SDS, indicating that the changes in the leg 
bone parameters were likely associated with bone modelling during growth. Similarly, 
lumbar spine BMC and BMD increased significantly from 29.5 – 31.7g (p<0.001) and 
0.863 – 0.891g/cm2, however there were no significant changes in their corresponding 
SDS. In keeping with growth related increases in bone parameters, the BMC and BA of 
lumbar spine vertebrae 1-4 increased significantly: 36.9 – 39.8g (p<0.001) and 42.5 – 
44.3cm2 (p<0.001) respectively.
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Table 3.4. DXA parameters for the CF cohort at each visit, changes between visits and p values. *p<0.05. 
  TBMC (g) TBMC SDS TBA (cm
2
) TBMD (g/cm
2
) TBMD SDS 
Visit 1 Value 1611.809 -0.683 1615.616 0.974 -0.452 
 Δ in Observation 101.744 -0.011 73.575 0.018 -0.011 
 p 0.000* 0.855 0.000* 0.000* 0.820 
Visit 2 Value 1713.553 -0.693 1689.192 0.992 -0.463 
 Δ with WBVT 78.243 -0.086 45.105 0.020 0.032 
 p 0.000* 0.144 0.000* 0.000* 0.501 
Visit 3 Value 1791.796 -0.779 1734. 296 1.011 -0.431 
 Δ in Follow-up 88.182 0.031 77.600 0.007 -0.089 
 p 0.000* 0.600 0.000* 0.059 0.078 
Visit 4 Value 1879.978 -0.748 1811.897 1.018 -0.520 
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  TLTM (g) TLTM:Ht SDS TBA:Ht SDS TBMC:TBA SDS 
Trunk BMD 
(g/cm
2
) 
Visit 1 Value 31407.062 -0.664 -0.906 0.047 0.763 
 Δ in Observation 1246.666 -0.112 0.027 -0.068 0.016 
 p 0.000* 0.172 0.730 0.205 0.001* 
Visit 2 Value 32653.729 -0.776 -0.879 -0.021 0.779 
 Δ with WBVT 1026.258 -0.134 -0.169 0.121 0.018 
 p 0.001* 0.103 0.034* 0.027* 0.000* 
Visit 3 Value 33679.986 -0.910 -1.048 0.100 0.796 
 Δ in Follow-up 1110.143 -0.043 0.186 -0.264 0.004 
 p 0.001* 0.611 0.024* 0.000* 0.400 
Visit 4 Value 34790.129 -0.953 -0.862 -0.165 0.800 
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  Trunk BMD SDS 
Arms BMD 
(g/cm
2
) 
Arms BMD SDS Legs BMC (g) Legs BA (cm
2
) 
Visit 1 Value -0.285 0.694 -0.681 599.273 576.178 
 Δ in Observation -0.018 0.023 0.085 33.543 21.401 
 p 0.496 0.000* 0.144 0.000* 0.000* 
Visit 2 Value -0.303 0.717 -0.597 632.816 597.579 
 Δ with WBVT -0.002 0.009 -0.108 35.089 16.488 
 p 0.946 0.045* 0.065 0.000* 0.000* 
Visit 3 Value -0.304 0.726 -0.705 667.905 614.067 
 Δ in Follow-up -0.061 0.004 -0.122 24.584 17.830 
 p 0.025* 0.355 0.044* 0.001* 0.000* 
Visit 4 Value -0.366 0.730 -0.826 692.489 631.897 
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Legs BMD 
(g/cm
2
) 
Legs BMD SDS Legs LTM (g) LS BMC (g) LS BMC SDS 
Visit 1 Value 0.998 -0.304 10114.26 29.501 -0.270 
 Δ in Observation 0.024 -0.051 515.272 2.233 -0.024 
 p 0.000* 0.414 0.000* 0.000* 0.727 
Visit 2 Value 1.021 -0.355 10629.541 31.734 -0.294 
 Δ with WBVT 0.031 0.047 283.020 1.711 -0.065 
 p 0.000* 0.448 0.034* 0.000* 0.342 
Visit 3 Value 1.051 -0.307 10912.560 33.445 -0.359 
 Δ in Follow-up 0.016 -0.053 381.908 1.431 -0.067 
 p 0.012* 0.410 0.007* 0.003* 0.341 
Visit 4 Value 1.068 -0.360 11294.468 34.877 -0.426 
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  LSBMD (g/cm2) LS BMD SDS L14 BMC (g) L14 BA (cm2)  
Visit 1 Value 0.863 -0.409 36.928 42.531  
 Δ in Observation 0.027 -0.095 2.882 1.769  
 p 0.004* 0.256 0.000* 0.000*  
Visit 2 Value 0.891 -0.504 39.810 44.300  
 Δ with WBVT 0.023 -0.060 2.062 1.353  
 p 0.015* 0.470 0.000* 0.001*  
Visit 3 Value 0.913 -0.564 41.873 45.653  
 Δ in Follow-up 0.006 -0.147 1.720 1.532  
 p 0.533 0.090 0.004* 0.001*  
Visit 4 Value 0.919 -0.711 43.592 47.185  
Note: Δ, change; TBMC, total bone mineral content; TBA, total bone area; TBMD, total bone mineral density; SDS, standard 
deviation score; TLTM, total body lean tissue mass; TFat, total body fat; BMD, bone mineral density; BMC, bone mineral content; 
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BA, bone area; LTM, lean tissue mass; LS, lumbar spine vertebrae 2-4; L14, lumbar spine vertebrae 1-4; vBMD, volumetric bone 
mineral density. 
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3.3.1.3 WBVT Period 
 
 
The WBVT period occurred between Visit 2 (Start WBVT) and Visit 3 (End WBVT). 
Full analysis data for all DXA parameters for the WBVT period for the CF cohort can be 
found in Appendix A, Table A.1. During the WBVT period there were significant 
improvements in several parameters for the total body DXA scan, segmental analysis of 
the total body DXA scan, and the lumbar spine DXA scan (Table 3.4 and Appendix A, 
Table A.1). 
 
Total body BMC, BA, BMD and LTM increased significantly from: 1713.6 – 1791.8g 
(p<0.001); 1689.2 – 1734.3cm2 (p<0.001); 0.992 – 1.0g/cm2 (p<0.001); and 32653.7 – 
33680.0g (p=0.001) respectively. Similar to the observation period there were no 
significant changes in the SDS for BMC or BMD or the LTM for height SDS, indicating 
the above changes were consistent with bone modelling during growth, however the BA 
for height SDS, decreased significantly from -0.9 to -1.1 (p=0.034), suggesting that the 
geometric adaptations of bone area were progressing more slowly than expected. As a 
consequence, the total BMC for BA SDS increased significantly from 0.0 – 0.1 
(p=0.027). 
 
Segmental analysis of the total body DXA scan demonstrated similar changes as those 
seen during the observation period. Trunk BMD and arms BMD increased significantly 
from 0.779 – 0.796g/cm2 (p<0.001) and 0.717 – 0.726g/cm2 (p=0.045). Legs BMC, BA, 
LTM and BMD increased significantly: 632.8 – 667.9g (p<0.001); 597.6 – 614.1cm2 
(p<0.001); 10629.5 – 10912.6g (p=0.034); and 1.021 – 1.051g/cm2 (p<0.001) 
 215 
respectively. The lack of significant change in the trunk, arms and legs BMD SDS, likely 
indicate that the changes in these parameters were associated with skeletal modelling. 
 
Lumbar spine scans also mirrored changes seen during the observation period. Lumbar 
spine BMC and BMD increased significantly from 31.7 – 33.4g (p<0.001) and 0.891 – 
0.913g/cm
2
, with no significant changes in their corresponding SDS. BMC and BA of 
lumbar spine vertebrae 1-4 also increased significantly: 39.8 – 41.9g (p<0.001) and 44.3 
– 45.7cm2 (p=0.001) respectively. 
 
3.3.1.4 Follow-up Period 
 
 
 
The follow-up period occurred between Visit 3 (end WBVT) and Visit 4 (follow-up). 
Analysis data for all DXA parameters for the CF cohort can be found in Appendix A, 
Table A.1. During the follow-up period, the CF cohort demonstrated significant 
improvements in several parameters for the total body DXA scan, segmental analysis of 
the total body DXA scans and the lumbar spine DXA scans (Table 3.4 and Appendix A, 
Table A.1). 
 
Total body BMC, BA and LTM increased significantly from: 1791.8 – 1880.0g 
(p<0.001); 1734.3 – 1811.9cm2 (p<0.001); and 33680.0 – 34790.1g (p=0.001) 
respectively. There were no significant changes in the corresponding SDS for BMC and 
LTM however the BA for height SDS increased significantly from -1.1 to-0.9 (p=0.024), 
indicating that the cohort made geometric adaptations to bone are more rapidly than 
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expected, and returning the cohort to the same status as seen at baseline. In response, the 
total BMC for BA SDS decreased significantly from 0.1 to -0.2 (p<0.001). 
 
Segmental analysis of the total body DXA scans did not find any significant changes in 
trunk and arm BMD however their corresponding SDS decreased significantly from -0.3 
to -0.4 (p=0.025) and -0.7 to -0.8 (p=0.044), likely indicating a reduction in the accrual 
rate of bone mass in these areas during the follow-up period, the first representing 
trabecular bone and the second a non-weight bearing limb. Similar to the observation and 
WBVT periods, legs BMC, BA, LTM and BMD, but not legs BMD SDS, increased 
significantly: 667.9 – 692.5g (p<=.001); 614.1 – 631.9cm2 (p<0.001); 10912.6 – 
11294.5g (p=0.007); and 1.051 – 1.068g/cm2 (p<0.001) respectively, indicating changes 
associated with growth. 
 
Bone parameters in the lumbar spine demonstrated similar changes to those seen in the 
observation and WBVT periods. Lumbar spine BMC, but not the SDS, increased 
significantly from 33.4 – 34.9g (p=0.003). Significant increases were seen in the BMC 
and BA of lumbar spine vertebrae 1-4: 41.9 – 43.6g (p=0.004) and 45.7 – 47.2cm2 
(p=0.001) respectively. 
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3.3.2 Tibial pQCT 
 
 
3.3.2.1 Baseline 
 
 
Bone parameters for the 4% and 20% sites and bone and composition parameters for the 
66% site are presented in Table 3.5 and Figure 3.2. At the 4% site, trabecular vBMD was 
significantly reduced compared to the reference population, with 8/16 (50%) having a 
SDS < -1.0 and 4/16 (25%) with a SDS < -2.0. The significantly reduced trabecular 
vBMD is consistent with findings in child and adolescent females with CF, but not males 
in one study [621], and contrary to the findings in a second study, which did not find 
significantly reduced trabecular vBMD at the 4% tibial pQCT site in pre-pubertal or 
pubertal males or females with CF [622]. Two 20% site parameters also reflected 
compromised bone health in the CF cohort. Cortical vBMD was significantly elevated 
compared to the reference population, with 9/16 (56%) having a SDS >1 and 5/16 (31%) 
having a SDS >2. This is in contrast to the findings of Kelly et al [621], who did not find 
elevated cortical vBMD at the 20% pQCT site in their CF males or females compared to 
controls adjusted for age, race, height and pubertal stage [621]. The same study found 
cortical cross sectional area at the 20% pQCT site to be reduced compared to their control 
population in males and females [621], which was not consistent with the findings in the 
CF cohort. However, females but not males had a significantly reduced periosteal 
circumference compared to controls [621], which supported the findings of significantly 
lower periosteal circumference in the CF cohort compared to the reference population. 
These findings indicate a potentially lower rate of bone turnover and compromised 
geometric attributes in the CF cohort, respectively.  
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At the 66% site, bone and composition parameters were significantly different to the 
reference population, providing further evidence of compromised bone health. Cortical 
BMC was significantly reduced, similar to the findings of Brookes et al [622] in their 
pubertal females. The cortical bone’s geometric attributes, cortical CSA and cortical 
thickness were also significantly reduced. However, the CSA of the total bone was not 
significantly different to the reference population at the 66% site, consistent with the 
findings in pre-pubertal males and females and pubertal males in the study by Brookes et 
al [622]. In keeping with that seen at the 20% site in the CF cohort, cortical vBMD was 
significantly higher than the reference population with 7/16 (44%) having a SDS >1 and 
2/16 (13%) having a SDS >2 however 1/16 (6%) had a SDS < -1. This was in contrast to 
the study by Brookes et al [622] where cortical vBMD was not elevated compared to 
controls [622]. To confirm the impact of the compromised cortical geometry, polar CSMI 
of the cortical bone was significantly reduced, indicating sub-optimal distribution of bone 
mass around the bone’s central axis. This, together with the elevated cortical bone density 
resulted in significantly reduced cortical bone strength measured by polar SSI. This 
significant reduction in polar SSI at the 66% site was consistent with the findings of 
Brookes et al [622] in pubertal females. 
 
Calf muscle CSA in the CF cohort was significantly reduced compared to the reference 
population, in keeping with the findings of Brookes et al [622] in their pubertal males and 
females. This finding likely contributed to the impairments in bone mass, geometry and 
strength seen in tibial pQCT analysis of the CF cohort, as bone adapts these physical 
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attributes to the muscle forces applied to it. Despite the significantly reduced cortical 
CSA, the cortical CSA to muscle CSA is normally adapted at 5.1%, indicating that the 
thinner bone seen in the CF cohort was due to the reduced muscle CSA. The ratio of 
cortical BMC to muscle CSA was significantly increased and together with the 
significantly increased cortical vBMD, suggests that the rate of bone turnover is likely 
reduced in this cohort, potentially as a result of reduced muscle forces not eliciting the 
geometric adaptations, and hence bone turnover and modelling, seen in the healthy 
reference population as part of normal increases in stature and lean tissue mass 
development. 
 
Table 3.5. Baseline peripheral quantitative computed tomography parameters for the 
tibial 4%, 20% and 66% sites. Mean (SD). 
4% Site Parameters  
Total BMC (mg/mm) 226.3 (70.4) 
Total CSA (mm
2
) 765.4 (249.9) 
Total vBMD (mg/cm
3
) 300.200 (39.071) 
Trabecular BMC (mg/mm) 71.9 (26.0) 
Trabecular CSA (mm
2
) 344.3 (112.5) 
Trabecular vBMD (mg/cm
3
) 210.406 (34.436) 
Trabecular vBMD SDS -1.0 (1.4) 
Periosteal Circumference (mm) 97.2 (15.5) 
 220 
20% Site Parameters  
Total BMC (mg/mm) 192.1 (51.9) 
Total CSA (mm
2
) 318.4 (101.9) 
Total vBMD (mg/cm
3
) 615.081 (78.494) 
Cortical BMC (mg/mm) 162.7 (44.4) 
Cortical BMC SDS 0.2 (0.9) 
Cortical CSA (mm
2
) 147.3 (37.6) 
Cortical CSA SDS -0.3 (0.9) 
Cortical vBMD (mg/cm
3
) 1099.694 (42.172) 
Cortical vBMD SDS 1.3 (1.3) 
Cortical Thickness (mm) 2.7 (0.4) 
Cortical Thickness SDS 0.4 (1.1) 
Periosteal Circumference (mm) 62.5 (9.9) 
Periosteal Circumference SDS -0.9 (1.0) 
Cortical CSMI p (mm
4
) 11337.3 (6734.4) 
Cortical SSI p (mm
3
) 877.4 (384.9) 
Total CSMI p (mm
4
) 14490.0 (8603.3) 
Total SSI p (mm
3
) 951.2 9427.7) 
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Total SSI p SDS -0.4 (0.8) 
66% Site Parameters  
Total BMC (mg/mm) 271.4 (80.4) 
Total CSA (mm
2
) 472.9 (146.2) 
Total CSA SDS 0.1 (0.9) 
Total vBMD (mg/cm
3
) 579.400 (73.893) 
Cortical BMC (mg/mm) 227.9 (71.6) 
Cortical BMC SDS -0.6 (1.0) 
Cortical CSA (mm
2
) 212.6 (62.7) 
Cortical CSA SDS -0.8 (0.9) 
Cortical CSA: Total CSA (%) 3.3 (0.5) 
Cortical vBMD (mg/cm
3
) 1067.406 (43.708) 
Cortical vBMD SDS 0.8 (1.1) 
Cortical Thickness (mm) 3.2 (0.6) 
Cortical Thickness SDS -1.1 (0.9) 
Periosteal Circumference (mm) 76.3 (11.6) 
Cortical CSMI p (mm
4
) 26296.4 (15681.3) 
Cortical CSMI p SDS -1.3 (0.7) 
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Cortical SSI p (mm
3
) 1417.3 (637.5) 
Cortical SSI p SDS -0.6 (0.9) 
Soft Tissue Total CSA (mm
2
) 6538.1 (2148.8) 
Muscle CSA (mm
2
) 4272.6 (1432.1) 
Muscle CSA SDS -0.8 (1.1) 
Fat CSA (mm
2
) 1773.1 (761.8) 
Fat CSA: Muscle CSA (%) 42.1 (12.1) 
Muscle CSA: Soft Tissue Total CSA (%) 65.4 (4.9) 
Cortical CSA: Muscle CSA (%) 5.1 (0.6) 
Cortical BMC: Muscle CSA (mg/mm
2
) 0.1 (0.0) 
Cortical BMC: Muscle CSA SDS 4.3 (6.5) 
Note: BMC, bone mineral content; CSA, cross sectional area; vBMD, volumetric bone 
mineral density; SDS, standard deviation score; CSMI, cross sectional moment of inertia; 
p, referring to the polar measurement; SSI, stress strain index. 
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Figure 3.3. Standard deviation (SD) scores for peripheral quantitative computed 
tomography (pQCT) parameters in the paediatric cohort. Mean and 95% confidence 
interval. Parameters shown in red were significantly different to the reference population 
on one-sample t-tests, p<0.05. 
 
3.3.2.2 Observation Period 
 
During the observation period there were significant changes in parameters at the 20% 
and 66% distal tibial pQCT sites, but not the 4% site. (Table 3.6 and Appendix B, Table 
B.1). At the 20% site, total bone BMC, CSA and vBMD increased significantly: 192.1 – 
199.3mg/mm, p<0.001; 318.4 – 325.9mm2, p<0.001; and 615.081 – 622.294mg/cm3, 
p=0.013 respectively. Cortical BMC and vBMD and their corresponding SDS also 
increased significantly: 162.7 – 170.3mg/mm, p<0.001; 0.2 – 0.4, p<0.001; 1099.694 – 
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1107.644mg/cm
3
, p=0.004; and 1.3 – 1.5, p=0.007 respectively. Geometric attributes of 
the cortical bone at the 20% site as well as their corresponding SDS were increased 
significantly. Cortical CSA increased from 147.3 – 153.1mm2, p<0.001 and -0.3 to 0.0, 
p<0.001, cortical thickness from 2.7 – 2.8mm, p<0.001 and 0.4 – 0.5, p=0.003, and 
periosteal circumference from 62.5 – 63.3mm, p<0.001 and -0.9 to -0.8, p<0.001. 
Improved BMC and geometrical attributes of the 20% site cortical bone resulted in 
significant increases in parameters of bone strength, polar CSMI and SSI of 11337.3 – 
11997.7mm
4
, p<0.001 and 877.4 – 924.3mm3, p<0.001 respectively. Total bone measures 
of polar CSMI and SSI as well as the SDS for polar SSI also increased significantly: 
14490.0 – 15127.4mm4, p<0.001; 951.2 – 1002.1mm3, p<0.001 and -0.4 to 0.0, p<0.001 
respectively. 
 
Analysis at the 66% site demonstrated significant changes in total bone, cortical bone and 
composition parameters. Total bone BMC increased significantly from 271.4 – 
282.7mg/mm, p<0.001, and total bone CSA and its corresponding SDS increased 
significantly from 472.9 – 492.6mm2, p<0.001 and 0.1 – 0.4, p<0.001. Cortical BMC and 
CSA and their corresponding SDS as well as periosteal circumference also increased 
significantly from: 227.9 – 236.1mg/mm, p<0.001 and -0.6 to -0.3, p<0.001; 212.5 – 
219.1mm
2
, p=0.001 and -0.8 to -0.6, p=0.001; and 76.3 – 77.9mm, p<0.001 respectively. 
Significant increases were also seen in cortical bone measures of strength, polar CSMI 
and SSI and their corresponding SDS: 26296.3 – 28134.5mm4, p<0.001 and -1.3to -1.1, 
p<0.001; 1417.3 – 1505.6mm3, p<0.001 and -0.6 to -0.3, p<0.001 respectively. Total soft 
tissue CSA increased significantly from 6538.1 – 6721.9mm2, p=0.022, however this was 
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due to a significant increase in fat CSA from 1773.1 – 1854.5mm2, p=0.042, with no 
significant change seen in muscle CSA or its corresponding SDS. 
 
3.3.2.3 WBVT Period 
 
During the WBVT period there were significant improvements in parameters at the 4%, 
20% and 66% distal tibial pQCT sites (Table 3.6 and Appendix B, Table B.1). At the 4% 
site, total bone BMC and vBMD increased significantly from 229.1 – 236.6mg/mm, 
p=0.005 and 298.187 – 304.244mg/cm3, p=0.040, however there were no significant 
changes in trabecular bone parameters after WBVT. These increases in total bone 
parameters were not seen during the observation period. 
 
At the 20% site, significant changes were seen in total and cortical bone parameters after 
WBVT. Total bone BMC, CSA and vBMD increased significantly: 199.3 – 
207.3mg/mm, p<0.001; 325.9 – 333.3mm2, p<0.001; and 622.294 – 632.056mg/cm3, 
p=0.001 respectively. Cortical BMC and vBMD and their corresponding SDS also 
increased significantly: 170.3 – 177.6mg/mm, p<0.001; 0.4 – 0.7, p<0.001; 1107.644 – 
1114.713mg/cm
3
, p=0.011; and 1.5 – 1.6, p=0.013 respectively. Cortical CSA and its 
SDS increased from 153.1 – 158.7mm2, p<0.001 and 0.0 – 0.3, p<0.001, cortical 
thickness and its SDS from 2.8 – 2.9mm, p<0.001 and 0.5 – 0.7, p=0.001, and periosteal 
circumference and its SDS from 63.3 – 64.1mm, p<0.001 and -0.8 to -0.6, p<0.001, 
indicating improved geometric attributes after WBVT. Improvements in bone mass and 
geometry resulted in significant increases in cortical and total bone strength after WBVT. 
Cortical bone polar CSMI and SSI increased 11997.7 – 12647.2mm4, p<0.001 and 924.3 
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– 967.9mm3, p<0.001, and total bone measures of polar CSMI and SSI as well as the 
SDS for polar SSI increased 15127.4 – 15935.3mm4, p<0.001; 1002.1 – 1048.3mm3, 
p<0.001 and 0.0 – 0.3, p<0.001 respectively. 
 
Analysis at the 66% site demonstrated significant changes in total and cortical bone 
parameters as well as composition parameters. Consistent with changes seen in the 
observation and WBVT periods, total bone BMC and total bone CSA and its 
corresponding SDS increased significantly from: 293.4 – 301.7mg/mm, p<0.001; 511.6 – 
522.0mm
2
, p=0.041; and 0.7 – 0.9, p=0.027 respectively. Cortical BMC and CSA and 
their corresponding SDS as well as periosteal circumference again demonstrated 
significant increases: 244.5 – 252.0mg/mm, p<0.001 and -0.1 to 0.2, p<0.001; 225.9 – 
230.7mm
2
, p=0.012 and -0.3 to -0.2, p=0.008; and 79.4 – 80.2mm, p=0.043 respectively. 
Cortical vBMD and its corresponding SDS increased significantly during the follow-up 
period from 1077.144 – 1086.686mg/cm3, p=0.009 and 1.1 – 1.3, p=0.021. Significant 
increases were also seen in cortical bone measures of strength, polar CSMI and SSI and 
their corresponding SDS: 30101.5 – 31303.2mm4, p=0.017 and -0.9 to -0.7, p=0.004; 
1583.3 – 1650.8mm3, p=0.001 and 0.0 – 0.3, p=0.001 respectively.  
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Table 3.6. pQCT parameters for the CF cohort at each visit, changes between visits and p values. *p<0.05. 
  4% Total BMC 
(mg/mm) 
4% Total vBMD 
(mg/cm
3
) 
20% Total BMC 
(mg/mm) 
20% Total CSA 
(mm
2
) 
20% Total vBMD 
(mg/cm
3
) 
Visit 1 Value 226.3 300.200 192.1 318.4 615.081 
 Δ in Observation 2.8 -2.013 7.3 7.5 7.213 
 p 0.268 0.486 0.000* 0.000* 0.013* 
Visit 2 Value 229.1 298.187 199.3 325.9 622.294 
 Δ with WBVT 7.5 6.056 8.0 7.4 9.762 
 p 0.005* 0.040* 0.000* 0.000* 0.001* 
Visit 3 Value 236.6 304.244 207.3 333.3 632.056 
 Δ in Follow-up 4.4 2.582 6.6 6.2 7.393 
 p 0.098 0.387 0.000* 0.000* 0.014* 
Visit 4 Value 241.0 306.826 213.9 339.5 639.450 
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20% Cortical 
BMC (mg/mm) 
20% Cortical 
BMC SDS 
20% Cortical CSA 
(mm
2
) 
20% Cortical 
CSA SDS 
20% Cortical 
vBMD (mg/cm
3
) 
Visit 1 Value 162.7 0.2 147.3 -0.3 1099.694 
 Δ in Observation 7.6 0.3 5.8 0.3 7.950 
 p 0.000* 0.000* 0.000* 0.000* 0.004* 
Visit 2 Value 170.3 0.4 153.1 0.0 1107.644 
 Δ with WBVT 7.3 0.3 5.6 0.3 7.069 
 p 0.000* 0.000* 0.000* 0.000* 0.011* 
Visit 3 Value 177.6 0.7 158.7 0.3 1114.713 
 Δ in Follow-up 6.2 0.3 4.2 0.2 9.332 
 p 0.000* 0.000* 0.000* 0.001* 0.001* 
Visit 4 Value 183.8 1.0 162.9 0.6 1124.045 
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20% Cortical 
vBMD SDS 
20% Cortical 
Thickness (mm) 
20% Cortical 
Thickness SDS 
20% Periosteal 
Circumference 
(mm) 
20% Periosteal 
Circumference 
SDS 
Visit 1 Value 1.3 2.7 0.4 62.5 -0.9 
 Δ in Observation 0.2 0.1 0.2 0.8 0.2 
 p 0.007* 0.000* 0.003* 0.000* 0.000* 
Visit 2 Value 1.5 2.8 0.5 63.3 -0.8 
 Δ with WBVT 0.2 0.1 0.2 0.8 0.2 
 p 0.013* 0.000* 0.001* 0.000* 0.000* 
Visit 3 Value 1.6 2.9 0.7 64.1 -0.6 
 Δ in Follow-up 0.2 0.1 0.1 0.6 0.2 
 p 0.011* 0.009* 0.018* 0.000* 0.002* 
Visit 4 Value 1.8 2.9 0.9 64.7 -0.4 
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20% Cortical 
CSMI p (mm
4
) 
20% Cortical 
SS1p (mm
3
) 
20% Total CSMI 
p (mm
4
) 
20% Total SS1p 
(mm
3
) 
20% Total SS1p 
SDS 
Visit 1 Value 11337.3 877.4 14490.0 951.2 -0.4 
 Δ in Observation 660.2 47.0 637.4 50.9 0.4 
 p 0.000* 0.000* 0.000* 0.000* 0.000* 
Visit 2 Value 11997.5 924.3 15127.4 1002.1 0.00 
 Δ with WBVT 649.7 43.6 807.9 46.2 0.3 
 p 0.000* 0.000* 0.000* 0.000* 0.000* 
Visit 3 Value 12647.2 967.9 15935.3 1048.3 0.3 
 Δ in Follow-up 457.2 44.5 519.4 41.1 0.3 
 p 0.001* 0.000* 0.002* 0.000* 0.000* 
Visit 4 Value 13104.4 1012.4 16454.6 1089.4 0.6 
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66% Total BMC 
(mg/mm) 
66% Total CSA 
(mm
2
) 
66% Total CSA 
SDS 
66% Cortical 
BMC (mg/mm) 
66% Cortical 
BMC SDS 
Visit 1 Value 271.4 472.9 0.1 227.9 -0.6 
 Δ in Observation 11.3 19.7 0.3 8.2 0.3 
 p 0.000* 0.000* 0.000* 0.000* 0.000* 
Visit 2 Value 282.7 492.6 0.4 236.1 -0.3 
 Δ with WBVT 10.7 19.0 0.3 8.3 0.3 
 p 0.000* 0.000* 0.000* 0.000* 0.000* 
Visit 3 Value 293.4 511.6 0.7 244.5 -0.1 
 Δ in Follow-up 8.3 10.4 0.2 7.6 0.2 
 p 0.000* 0.041* 0.027* 0.000* 0.000* 
Visit 4 Value 301.7 522.0 0.9 252.0 0.2 
 232 
  
66% Cortical CSA 
(mm
2
) 
66% Cortical CSA 
SDS 
66% Cortical 
vBMD (mg/cm
3
) 
66% Cortical 
vBMD SDS 
66% Periosteal 
Circumference 
(mm) 
Visit 1 Value 212.6 -0.8 1067.406 0.8 76.3 
 Δ in Observation 6.5 0.2 5.363 0.2 1.6 
 p 0.001* 0.001* 0.118 0.135 0.000* 
Visit 2 Value 219.1 -0.6 1072.769 1.0 77.9 
 Δ with WBVT 6.8 0.2 4.375 0.1 1.5 
 p 0.000* 0.000* 0.201 0.361 0.000* 
Visit 3 Value 225.9 -0.3 1077.144 1.1 79.4 
 Δ in Follow-up 4.8 0.2 9.543 0.3 0.8 
 p 0.012* 0.008* 0.009* 0.021* 0.043* 
Visit 4 Value 230.7 -0.2 1086.686 1.3 80.2 
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66% Cortical CSMI p 
(mm
4
) 
66% Cortical CSMI p 
SDS 
66% Cortical SSI p 
(mm
3
) 
66% Cortical SSI p 
SDS 
Visit 1 Value 26296.4 -1.3 1417.3 -0.6 
 Δ in Observation 1838.2 0.2 88.3 0.3 
 p 0.000* 0.000* 0.000* 0.000* 
Visit 2 Value 28134.5 -1.1 1505.6 -0.3 
 Δ with WBVT 1967.0 0.2 77.7 0.3 
 p 0.000* 0.000* 0.000* 0.000* 
Visit 3 Value 30101.5 -0.9 1583.3 0.0 
 Δ in Follow-up 1201.6 0.2 67.5 0.2 
 p 0.017* 0.004* 0.001* 0.001* 
Visit 4 Value 31303.2 -0.7 1650.8 0.3 
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66% Soft Tissue Total 
CSA (mm
2
) 
66% Muscle CSA 
(mm
2
) 
66% Muscle CSA SDS 66% Fat CSA (mm
2
) 
Visit 1 Value 6538.1 4272.570 -0.8 1773.1 
 Δ in Observation 183.8 82.530 0.1 81.4 
 p 0.022* 0.204 0.125 0.042* 
Visit 2 Value 6721.9 4355.100 -0.7 1854.5 
 Δ with WBVT 64.6 57.010 0.1 -9.1 
 p 0.407 0.378 0.166 0.815 
Visit 3 Value 6786.500 4412.1 -0.7 1845.4 
 Δ in Follow-up 281.510 186.8 0.2 77.5 
 p 0.001* 0.007* 0.004* 0.060 
Visit 4 Value 7068.010 4598.9 -0.5 1922.8 
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Note: Δ, change; 4%, referring to 4% tibial pQCT site; BMC, bone mineral content; CSA, cross-sectional area; vBMD, volumetric 
bone mineral density; SDS, standard deviation score; 20%, referring to the 20% tibial pQCT site; CSMI, cross-section moment of 
inertia; p, referring to the polar measurement; SSI, stress strain index; 66%, referring to the 66% tibial pQCT site. 
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3.3.2.4 Follow-up Period 
 
During the follow-up period there were no significant changes in any parameters at the 
4% pQCT site. Significant changes were seen in total and cortical bone parameters at the 
20% and 66% sites and in composition parameters at the 66% site (Table 3.6, Appendix 
B, Table B.1). 
 
At the 20% site, similar to the observation and follow-up periods, significant changes 
were seen in total bone BMC, CSA and vBMD: 207.3 – 213.9mg/mm, p<0.001; 333.3 – 
339.5mm
2
, p<0.001; and 632.056 – 639.450mg/cm3, p=0.014 respectively. Cortical BMC 
and vBMD and their corresponding SDS also increased significantly: 177.6 – 
183.8mg/mm, p<0.001; 0.7 – 1.0, p<0.001; 1114.713 – 1124.1mg/cm3, p=0.001; and 1.6 
– 1.8, p=0.011 respectively. Cortical bone geometric attributes and their corresponding 
SDS increased significantly: cortical CSA increased from 158.7 – 162.9mm2, p<0.001 
and 0.3 – 0.6, p=0.001; cortical thickness from 2.9 – 2.9mm, p<0.009 and 0.7 – 0.9, 
p=0.018, and periosteal circumference from 64.1 – 64.7mm, p<0.001 and -0.6 to -0.4, 
p<0.002 respectively. Significate improvement s were also seen in parameters of bone 
strength: cortical bone polar CSMI and SSI increased 12647.2 – 13104.4mm4, p=0.001 
and 967.9 – 1012.3mm3, p<0.001; and total bone measures of polar CSMI and SSI as 
well as the SDS for polar SSI increased 15935.3 – 16454.6mm4, p=0.002; 1048.3 – 
1089.4mm
3
, p<0.001 and 0.3 – 0.6, p<0.001 respectively. Total soft tissue CSA increased 
significantly from 6786.5 – 7068.0mm2, p=0.001, and was associate with significant 
increases in muscle CSA and its SDS, 4412.1 – 4598.9mm2, p=0.007 and -0.7 to -0.5, 
p=0.004.  
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3.3.3 Serum Biochemistry and Bone Turn-over Markers 
 
Table 3.7. Baseline Serum Biochemistry and Bone Turnover Marker Parameters. Mean 
(SD). 
Alkaline Phosphatase (U/L) 213.2 (65.3) 
Calcium (mmol/L) 2.32 (0.1) 
Phosphate (mmol/L) 1.5 (0.2) 
Parathyroid Hormone (ng/l) 4.5 (2.6) 
Osteocalcin (nmol/L) 6.1 (1.9) 
Vitamin D (pmol/L) 70.7 (13.9) 
Urinary Deoxypyridinoline: Creatine Ratio 
(nmol/mmol creatinine) 
17.8 (9.4) 
 
3.3.3.1 Baseline 
 
Baseline parameters for the serum biochemistry are presented in Table 3.7. Calcium, 
magnesium and phosphate were within normal reference ranges in all participants over 
the course of the study, except for participant number 10 who had one low calcium value 
at visit 3. Parathyroid hormone was transiently lower than the reference range in 
participants 10 and 17, and transiently higher than the reference range in participants 16 
and 19, however all other participants had levels within the normal reference range. 
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Vitamin D was transiently lower than 50pmol/L in 5 participants (participants 2, 7, 10, 11 
and 16) at one time-point during the study, which coincided with the winter months. 
Serum alkaline phosphatase was within normal reference ranges for all participants for 
the duration for the study except for one, number 10, who had a high level at his baseline 
visit. Osteocalcin was outside of the reference range for at least one time-point in 11 of 
the 16 participants. Osteocalcin was below the reference range at least once in 
participants 1, 2, 5, 6, 9 and 10, and was lower than the reference range at all time points 
in participants 2 and 9. Osteocalcin was above the reference range at least once over the 
study duration in participants 3, 5, 11, 14, 15 and 17, with participants 14 and 17 
recording elevated levels at 3 of the 4 time-points. The urinary deoxypyridinoline: 
creatinine ratio was higher than the normal reference range at least once in 7 participants, 
2, 7, 10, 12, 13, 14 and 19 with participant 10 demonstrating elevated levels at all visits. 
Participant 15 had a low at one of the times he was tested. The finding that the bone 
formation marker, osteocalcin, was below the reference range at least once in 6/16 (38%) 
of participants and consistently below the reference range in 2/16 (13%), as well as the 
bone resorption marker, urinary deoxypyridinoline: creatinine ratio, being increased at 
least once in 7/16 (44%) and at all visits in one participant, is consistent with reduced 
bone formation and increased bone resorption. This indicates an uncoupling of normal 
bone turnover in the CF cohort and is consistent with the compromised bone health found 
on DXA and pQCT analysis. 
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3.3.3.2 Study Periods 
 
Analysis data for bone turnover markers and serum biochemistry during the observation, 
WBVT and follow-up periods can be found in Table 3.7 and Appendix C Table C.1. 
During the observation period osteocalcin decreased significantly, and considering this 
marker of bone formation was decreased in 38% of the CF cohort at baseline, it may 
indicate a further reduction in the rate of bone formation. Calcium and magnesium 
decreased significantly after WBVT, however they also remained within their normal 
reference ranges. In the follow-up period, calcium increased significantly but remained 
within its normal reference range. 
 
Table 3.8. Serum biochemistry and bone turn-over marker parameters for the CF cohort 
at each visit, changes between visits and p values. *p<0.05. 
  Calcium 
(mmol/L) 
Magnesium Osteocalcin 
(nmol/L) 
Visit 1 Value 2.3 0.8 6.1 
 Δ in Observation 0.0 0.0 -2.4 
 p 0.714 0.078 0.013* 
Visit 2 Value 2.3 0.9 3.8 
 Δ with WBVT -0.1 -0.1 0.8 
 p 0.003* 0.001* 0.383 
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Visit 3 Value 2.2 0.8 4.6 
 Δ in Follow-up 0.1 0.0 -0.4 
 p 0.000* 0.177 0.661 
Visit 4 Value 2.4 0.8 4.2 
Note: Δ, change; WBVT, whole body vibration training. 
 
3.4 Force-plate Parameters 
 
3.4.1 Baseline 
 
 
Baseline parameters for the M1LJ, S2LJ and CRT performed on the force plate are 
presented in Table 3.9 and Figure 3.3. Maximum force produced by the leg muscles was 
derived from the M1LJ, maximum power generated derived from the S2LJ and the 
functional performance of leg muscles was derived from the CRT. The force SDS from 
the M1LJ was significantly reduced compared to the reference population, -1.8, p<0.001. 
The force SDS from the S2LJ was also significantly reduced compared to the reference 
population, -0.5, p=0.037, however there was no impact on the ability of the muscles to 
generate power from the force produced and the power, Esslinger Fitness Index and force 
efficiency SDS were not significantly different to the reference population. The CRT 
speed, power and force SDS were not significantly different to the reference population 
indicating good functional performance of the leg muscles. These results indicate that 
during dynamic manoeuvres, the peak force generated by leg muscle is significantly 
 241 
reduced in the CF cohort compared to their healthy peers. While the magnitude of this 
impairment is not impacting on function, it gives some insight to the reduced bone mass 
and density as well as compromised geometry and strength seen on DXA and pQCT 
analysis. In the CF cohort, the peak forces imparted on the underlying bone during 
dynamic manoeuvres are of a significantly reduced magnitude compared to their healthy 
counterparts. Considering these forces play a central role in directing bone modelling 
processes, and particularly optimising geometric adaptations to increase strength, these 
deficiencies in muscle force likely explain some aspects of the compromised bone health 
seen in the CF cohort. 
 
Table 3.9. Baseline force plate parameters. Mean (SD). 
Multiple One-leg Hop (M1LH) Parameters 
F max (kN) 10.9 (3.4) 
F max rel (g) 2.8 (0.3) 
Force SDS -1.8 (0.9) 
Single Two-leg Jump (S2LJ) Parameters  
EFI (%) 95.9 (14.2) 
EFI SDS -0.3 (1.2) 
Force Efficiency (%) 103.6 (12.2) 
Force Efficiency SDS 0.3 (1.2) 
P max (kW) 1.7 (0.8) 
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P max rel (W/kg) 41.3 (7.7) 
Power SDS -0.4 (1.1) 
F max (kN) 0.9 (0.3) 
F max rel (g) 2.3 (0.3) 
Force SDS -0.5 (0.9) 
Chair Rise Test (CRT) Parameters  
Time per test (s) 1.1 (0.2) 
Speed SDS 0.3 (0.9) 
P max (W) 558.1 (188.6) 
Ave P max rel (W/kg) 12.6 (1.9) 
Power SDS -0.4 (1.0) 
F max (kN) 1.6 (0.2) 
Ave F max rel (g) 1.5 (0.1) 
Force SDS 0.1 (0.9) 
 
Note: F max, maximum force; F max rel, maximum relative force per force equivalent to 
body weight; SDS, standard deviation score; EFI, Esslinger Fitness Index; P max, 
maximum power; P max rel, maximum power in relation to body weight; Ave P max rel, 
average maximum power in relation to body weight; Ave F max rel, average maximum 
relative force per force equivalent to body weight.  
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Figure 3.4. Standard deviation (SD) scores for force plate parameters in the paediatric 
cohort. Mean and 95% confidence interval. Parameters shown in red were significantly 
different to the reference population on one-sample t-tests, p<0.05. 
 
3.4.2  Observation Period 
 
 
Analysis data for the M1LJ, S2LJ and CRT performed on the force-plate are presented in 
Table 3.10 and Appendix D, Table D.1. During the observation period, the maximum 
relative force and force SDS for the M1LJ decreased significantly, 2.8 – 2.6g, p=0.004 
and -1.8 to -2.2, p=0.004. Maximum power in the S2LJ increased significantly from 1.7 – 
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1.9kW, p=0.010, however the maximum relative power and power SDS did not change 
significantly, indicating that this increase in power was associated with normal 
musculoskeletal development. The time taken to perform the chair rise test decreased 
significantly by 0.1s, p=0.025 and the speed SDS increased from -0.3 – 0.00, p=0.025. 
 
3.4.3  WBVT Period 
 
 
After WBVT, maximum force in the M1LJ increased by 0.5kN, p=0.050, however there 
was no significant change in the maximum relative force of force SDS, suggesting this 
increase was associated with normal musculoskeletal development. The maintenance of 
the latter two parameters was in contrast to the significant decline seen during the 
observation period and may indicate that WBVT hindered the decline in force production 
during the M1LJ in the CF cohort. Maximum force also increased significantly in the 
S2LJ by 0.1kN (10%), p=0.027 however the maximum relative force and force SDS did 
not change significantly, indicating this increase was likely associated with 
musculoskeletal development. The time to complete the CRT and the speed SDS 
improved significantly after WBVT. Time per test decreased 0.1s (9.1%), p=0.001 and 
the speed SDS increased from 0.0 – 0.5, p=0.001, a larger improvement than that seen 
during the observation period. The maximum force generated during the CRT also 
increased significantly after WBVT by 0.1kN (6.7%), p=0.028, however there was no 
significant change in the maximum relative force or force SDS, indicating a change likely 
associated with musculoskeletal development.  
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Three previous studies have investigated muscle function on a force plate in CF 
populations. In 10 CF adults, 22-27 years, 3 months of progressive home-based side-
alternating WBVT (20-25Hz, 0.6mm, 18 minutes, 5 times a week), found a non-
significant increase in M1LJ force of 72N (~5%) [233], similar in magnitude to the 
increase in the CF cohort. There was a significant reduction in maximum S2LJ force of 
122N (9%), which correlated to a 0.43 reduction in the force SDS [233]. This significant 
reduction in maximum force occurred without a significant change in maximum power or 
its corresponding SDS [233] indicating that the efficiency of muscle function during the 
S2LJ was significantly improved after WBVT, as less force was required to generate an 
equivalent amount of power [718]. These improvements in S2LJ muscle efficiency were 
not seen in the CF cohort, perhaps due to the lower vibration frequency used. There was 
also a significant reduction in the time to perform the CRT of 1.05 seconds (15%), 
significant increase in force of 438N or 7N/kg (41%) and significant increase in power 
output of 135W or 2.38W/kg (19%) during the CRT [233]. The increases in CRT speed 
and force larger than those seen in the CF cohort. In the second study of young adults 
with CF, 21-41 years, 6 months of home-based side-alternating WBVT (12Hz, 6 minutes 
with trunk bends, rotations and extensions, 5 times a week, as well as 26Hz, 6 minutes, 
with the progressive addition of weights up to 9kg, 3 times a week), increased M1LJ 
force by a median of 6.7%, however no statistics were performed due the small size of 
the cohort [232], again similar in magnitude to the CF cohort. Maximum S2LJ force 
decreased by a median of 4.3%, and maximum power increased by a median of 4.7%, 
[232], again indicate improved muscle efficiency after WBVT which was not seen in the 
CF cohort, perhaps due to the higher frequency and use of additional weights in the Roth 
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et al [232] study. A third study in children with CF, 8-18 years, S2LJ power parameters 
did not significantly change after 4 weeks of side-alternating WBVT (20-22Hz, 1mm, 10-
15 minutes, 3 times a week) [229], consistent with the results seen in the CF cohort. 
 
3.4.4 Follow-up Period 
 
 
In the follow-up period, maximum relative force and force SDS in the M1LJ decreased 
significantly from 2.7 – 2.5g, p=0.002 and from -2.2 to -2.7, p=0.002. These changes 
were similar in magnitude to the decreases seen in the observation period and provide 
further evidence to support a beneficial role of WBVT in interrupting the decline in 
muscle force produced during the L1LJ in the CF cohort. There were no significant 
changes in any of the S2LJ or CRT parameters during the follow-up period. 
 
3.5 Exercise Tests 
 
Table 3.10. Baseline Cardiopulmonary Exercise Test Parameters. Mean (SD). 
 
CPET - Pre-Exercise Parameters  
Pre-exercise VO2 (L/min) 0.3 (0.1) 
Pre-exercise VO2 (ml/kg/min) 7.1 (1.8) 
Pre-exercise HR (bpm) 96.8 (17.3) 
Pre-exercise HR (% Predicted) 46.7 (8.2) 
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Pre-exercise O2 Pulse (ml/beat) 3.0 (1.1) 
Pre-exercise VCO2 (L/min) 0.3 (0.1) 
Pre-exercise RQ 1.0 (0.2) 
Pre-exercise VE (L/min) 10.3 (2.9) 
Pre-exercise VE/VO2 40.3 (10.9) 
Pre-exercise VE/VCO2 41.3 (7.9) 
Pre-exercise Borg Score 0.6 (0.6) 
Pre-exercise SBP (mmHg) 106.9 (8.3) 
Pre-exercise DBP (mmHg) 66.8 (8.1) 
Pre-exercise Oxygen Saturations (%) 97.5 (1.5) 
CPET - Anaerobic Threshold (AT) Parameters  
AT VO2 (L/min) 1.7 (0.7) 
AT VO2 (ml/kg/min)  39.4 (7.4) 
AT VO2 (% Predicted) 133.4 (36.6) 
AT VO2 (% Predicted VO2) 95.9 (22.1) 
AT VO2 (% of Peak VO2) 81.5 (10.7) 
AT HR (bpm) 174.6 (13.9) 
AT HR (% Predicted) 84.7 (6.9) 
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AT O2 Pulse (ml/beat) 9.7 (3.8) 
AT VCO2 (L/min) 1.7 (0.7) 
AT RQ 1.0 (0.0) 
AT VE (L/min) 47.7 (20.0) 
AT VE/VO2 28.3 (2.3) 
AT VE/VCO2 28.8 (2.1) 
CPET - Peak Exercise Parameters  
Peak VO2 (L/min) 1.9 (0.8) 
Peak VO2 (ml/kg/min) 45.7 (7.3) 
Peak VO2 (% Predicted) 114.9 (22.5) 
Peak HR (bpm) 181.6 (15.1) 
Peak HR (% Predicted) 87.7 (8.1) 
Peak O2 Pulse (ml/beat) 10.4 (4.3) 
Peak O2 Pulse (% Predicted) 111.9 (26.4) 
Peak VCO2 (L/min) 1.9 (0.8) 
Peak RQ 1.0 (0.1) 
Peak VE (L/min) 55.2 (23.1) 
Peak VE/VO2 29.7 (3.3) 
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Peak VE/VCO2 29.2 (2.0) 
CPET Time (mins) 11.9 (1.9) 
Peak Borg Score 7.0 (3.1) 
Peak SBP (mmHg) 123.9 (16.7) 
Peak DBP (mmHg) 68.3 (10.6) 
Peak Oxygen Saturation (%) 95.9 (1.7) 
CPET - Recovery Parameters  
Recovery VO2 (L/min) 0.4 (0.1) 
Recovery VO2 (ml/kg/min) 8.5 (2.0) 
Recovery HR (bpm) 108.5 (12.2) 
Recovery HR (% Predicted) 2.5 (6.3) 
Recovery O2 Pulse (ml/beat) 53.3 (1.2) 
Recovery VCO2 (L/min) 0.4 (0.2) 
Recovery RQ 1.1 (0.2) 
Recovery VE (L/min) 13.4 (5.1) 
Recovery VE/VO2 40.0 (7.1) 
Recovery VE/VCO2 38.5 (5.0) 
Recovery Borg Score 3.1 (2.2) 
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Recovery SBP (mmHg) 111.8 (12.2) 
Recovery DBP (mmHg) 64.7 (11.1) 
Recovery Oxygen Saturation (%) 96.9 (1.1) 
 
Note: CPET, Cardiopulmonary Exercise Test; VO2, oxygen uptake; HR, heart rate; O2, 
oxygen; VCO2, carbon dioxide production; RQ, respiratory quotient; VE, minute 
ventilation; VE/VO2, ventilatory equivalent of oxygen; VE/VCO2, ventilatory equivalent 
of carbon dioxide; SBP, systolic blood pressure; DBP, diastolic blood pressure; AT, 
anaerobic threshold. 
 
3.5.1  Baseline 
 
Baseline parameters for the CPET are presented in Table 3.10. All 16 participants had 
pre-exercise, peak and recovery parameters recorded however only 8 of the participants 
had a clear ventilatory AT identified. The pre-exercise VO2 was elevated at 
7.1ml/kg/min. The pre-exercise Borg Score of 0.6 indicated that the participants were 
experiencing minimal physical exertion prior to commencing the exercise test. Pre-
exercise measurements of systolic and diastolic blood pressure and oxygen saturations 
were within normal limits. The anaerobic threshold occurred at 81.5% of the peak VO2 
and the VO2 at which AT occurred was 133.4% of that predicted by the reference 
population, indicating good aerobic metabolism.  
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Peak exercise parameters demonstrated well preserved exercise capacity with a mean 
VO2 of 45.7 ml/kg/min, 114.9% of predicted. Oxygen pulse at peak exercise was also 
normal with a peak value of 10.4 ml/beat, 111.9% of predicted. The ventilatory 
equivalents for oxygen and carbon dioxide were within normal limits. At peak exercise 
the mean heart rate was 87.7% of predicted, respiratory quotient 1.0 and Borg Score 7.0, 
all indicating that a peak test had been performed. Systolic and diastolic blood pressures 
were increased compared to pre-exercise values indicating increased physical effort, and 
oxygen saturations remained within normal limits. The recovery data indicated that all 
CPET parameters were returning towards pre-exercise measures.
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Table 3.11. Cardiopulmonary exercise test parameters for the CF cohort at each visit, 
changes between visits and p values. *p<0.05. 
  Pre-exercise 
HR (bpm) 
Pre-exercise HR % 
Predicted (%) 
AT VO2 
(ml/kg/min) 
Visit 1 Value 96.8 46.7 36.5 
 Δ in Observation  4.8 2.5 -5.3 
 p 0.253 0.226 0.075 
Visit 2 Value 101.6 49.2 31.2 
 Δ with WBVT -7.3 -3.4 -0.4 
 p 0.086 0.095 0.900 
Visit 3 Value 94.3 45.7 30.8 
 Δ in Follow-up  -9.0 -4.2 -0.2 
 p 0.039* 0.045* 0.954 
Visit 4 Value 85.2 41.5 30.7 
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AT VO2 % 
Predicted VO2 
(%) 
AT RQ 
Peak VO2 
(ml/kg/min) 
Visit 1 Value 89.2 1.0 45.7 
 Δ in Observation  -8.8 0.0 -4.3 
 p 0.223 0.019* 0.030* 
Visit 2 Value 80.4 1.0 41.4 
 Δ with WBVT -4.9 0.0 0.2 
 p 0.509 0.432 0.925 
Visit 3 Value 75.5 1.0 41.6 
 Δ in Follow-up  1.3 0.0 -1.3 
 p 0.857 0.395 0.495 
Visit 4 Value 76.8 1.0 40.3 
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Peak VO2 % 
Predicted (%) 
Peak RQ  
Peak 
VE/VO2  
Visit 1 Value 114.9 1.0 29.7 
 Δ in Observation  -9.8 0.1 2.7 
 p 0.035* 0.020* 0.001* 
Visit 2 Value 105.0 1.1 32.4 
 Δ with WBVT 0.3 -0.0 -0.6 
 p 0.940 0.093 0.468 
Visit 3 Value 105.4 1.0 31.8 
 Δ in Follow-up  -3.8 0.0 0.2 
 p 0.419 0.795 0.817 
Visit 4 Value 101.6 1.0 32.0 
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  Peak VE/VCO2  Recovery VE/VCO2  
Visit 1  29.2 38.5  
 Δ in Observation  1.4 -0.1  
 p 0.011* 0.916  
Visit 2 Value 30.6 38.4  
 Δ with WBVT 0.6 1.6  
 p 0.236 0.204  
Visit 3 Value 31.2 40.0  
 Δ in Follow-up  -0.2 2.6  
 p 0.758 0.047*  
Visit 4 Value 32.0 42.6  
 
Note: Δ, change; WBVT, whole body vibration training; VO2, oxygen uptake; HR, heart 
rate; bpm, beats per minute; O2, oxygen; VCO2, carbon dioxide production; RQ, 
respiratory quotient; VE, minute ventilation; VE/VO2, ventilator equivalent of oxygen; 
VE/VCO2, ventilator equivalent of carbon dioxide; AT, anaerobic threshold. 
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3.5.2 Observation Period 
 
 
During the observation period there were significant changes in CPET parameters at AT 
and peak-exercise, however there were no significant changes in pre-exercise or recovery 
parameters (Table 3.11 and Appendix E, Table E.1). The respiratory quotient at AT 
increased significantly, however the magnitude of the change was <0.1 points and is 
unlikely to be clinically relevant. There was a non-significant decrease in VO2 at AT of 
5.3ml/kg/min (15%), p=0.075, which while not statistically significant, would be 
considered clinically significant. This was associated with a non-significant decrease of 
the percent-predicted VO2 at AT of 8.8%, p=0.223, which would also be considered 
clinically significant. The percent-predicted heart rate at which AT occurred did not 
change significantly, indicating that AT occurred at a similar cardiovascular effort. 
Together these finding indicate that a clinical deterioration in the VO2 at AT occurred 
during the observation period, suggesting loss of aerobic fitness. 
 
Consistent with the reduction in VO2 seen at the AT, peak measures of VO2 and its 
percent-predicted value decreased significantly, 45.7 – 41.4 ml/kg/min, p=0.030, and 
114.9 – 105.0%, p=0.035. There were also significant increases in the respiratory 
quotient and ventilatory equivalents of oxygen and carbon dioxide at peak exercise: 1.0 – 
1.1, p=0.020; 29.7 – 32.4, p=0.001; and 29.2 – 30.6, p=0.011 respectively. There was no 
significant change in the percent-predicted heart rate at peak exercise. These findings 
show that in the context of a similar cardiovascular effort, carbon dioxide production and 
the ventilatory response at peak exercise was significantly increased, while peak oxygen 
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uptake was significantly reduced, indicating a clinically significant reduction in aerobic 
capacity. 
 
3.5.3  WBVT Period 
 
 
During the WBVT period there were no significant changes in any CPET parameter. The 
significant reduction in peak VO2, and clinically significant reduction in VO2 at AT seen 
during the observation period was not seen after WBVT suggesting that WBVT may 
have slowed the rate of decline in aerobic capacity in young people with CF (Table 3.11 
and Appendix E, Table E.1). 
 
3.5.4  Follow-up Period 
 
 
Significant changes in pre-exercise and recovery CPET parameters, but not AT or peak-
exercise CPET parameters, were seen during the follow-up period (Table 3.11 and 
Appendix E, Table E.1). Pre-exercise heart rate and its percent-predicted value decreased 
significantly during the follow-up period from 94.3 – 85.2 beats/minute, p=0.039 and 
from 45.7 – 41.5% predicted, p=0.045. The recovery ventilatory equivalent for carbon 
dioxide increased significantly from 40.0 – 42.6, p=0.047. In contrast to the WBVT 
period, where peak VO2 remained stable, there were no-significant reductions in peak 
VO2 and its percent-predicted value in the follow-up period which were smaller in 
magnitude than the decreases seen during the observation period.  
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3.6 Revised Cystic Fibrosis Questionnaire (CFQ-R) 
 
 
3.6.1 Baseline 
 
 
Baseline parameters for the CFQ-R are presented in Table 3.12. The shared child and 
adult CFQ-R eating and treatment burden domains were below their corresponding 
normative means [714] indicating that the CF cohort had more eating disturbances and a 
greater treatment burden compared to the norm. All other domains were above their 
corresponding normative scores indicating better Quality of Life in these domains 
compared to the normative data [714]. When considering the adult only CFQ-R domains, 
the role and weight domains were lower than their normative means [714] indicating that 
the CF cohort found their disease to have a larger impact on their role functioning and 
ability to gain weight compared to the norm. Parent CFQ-R domains for eating and 
weight were lower than their normative means [714], consistent with that seen in the 
child CFQ-R domains, indicating greater impact on weight and eating problems in the CF 
cohort compared to the norm. 
 
Table 3.12. Baseline CFQ-R Domain Scores. Mean (SD). 
 
Child and Adult CFQ-R Domains (n=16) 
Physical 81.9 (18.9) 
Emotion 80.5 (15.3) 
Eating 81.3 (21.0) 
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Body 82.0 (16.7) 
Treatment Burden 61.1 (23.0) 
Respiratory 73.4 (16.8) 
Digestion 79.2 (23.3) 
Social 73.7 (14.7) 
Adult Only CFQ-R Domains (n=7) 
Health Perceptions 69.9 (22.0) 
Role 69.0 (24.9) 
Weight 57.2 (31.7) 
Parent CFQ-R Domains (n=9) 
Physical 92.6 (6.1) 
Emotion 91.1 (11.0) 
Vitality 74.1 (12.7) 
School 80.3 (14.5) 
Eating 70.4 (32.0) 
Body Image 82.7 (23.7) 
Treatment Burden 72.8 (26.1) 
Health Perceptions 86.4 (10.8) 
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Respiratory 87.011 (9.191) 
Digestion 74.1 (27.8) 
Weight 51.9 (37.7) 
 
3.6.2 Observation Period 
 
 
Analysis data for CFQ-R parameters can be found in Appendix F, Table F.1. During the 
observation period, the child and adult digestion domain increased significantly from 
79.2 – 89.6, p=0.017, indicating improved digestive symptoms. There was also a 
significant decrease in the parent reported respiratory domain from 87 – 76.5, p=0.046, 
indicating worsening of respiratory symptoms (Table 3.13 and Appendix F, Table F.1). 
One previous study has monitored quality of life during an observation period prior to a 
WBVT intervention in children with CF. Using the same questionnaire, there was no 
significant change in health-related quality of life during a 4 week observation period 
[229]. 
 
3.6.3 WBVT Period 
 
 
After WBVT there were no significant changes in the child or adult domains, however 
parent domains for emotion and school increased significantly from 86.7 – 92.5, p=0.026 
and from 71.6 – 90.7, p=0.043 (Table 3.13 and Appendix F, Table F.1).  
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3.6.4 Follow-up Period 
 
 
During the follow-up period there were no significant changes in any child or adult 
domain scores, however there was a non-significant increase in the child and adult 
respiratory domain of 4.9 points, p=0.262, however this change is greater than the 
minimally clinically important different for this domain [714] and therefore indicates a 
clinically relevant improvement. The parent domains for emotion and respiratory 
increased significantly from 92.5 – 99.7, p=0.026 and from 74.3 – 87.9, p=0.037 (Table 
3.13 and Appendix F, Table F.1) 
 
3.7 Pulmonary Function Tests 
 
 
3.7.1 Baseline 
 
Baseline pulmonary function test are presented in Table 3.13. The percent predicted 
values for FEV1, FVC and FEF25-75 from spirometry, the RV/TLC ratio from 
plethysmography and the lung clearance index all indicate the CF cohort had generally 
mild lung disease.  
 
3.7.2 Study Periods 
 
 
Analysis data for pulmonary function test parameters can be found in Appendix ?. During 
the observation period, the FEV1/FVC ratio and FEF25-75 percent predicted value 
decreased significantly from 79.2 – 76.6%, p=0.041 and from 73.5 – 64.6%, p=0.007  
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Table 3.13. Pulmonary function test parameters. Mean (SD). 
 
Spirometry (n=13) 
FEV1 (L) 2.4 (0.7) 
FEV1 (% Predicted) 84.4 (18.6) 
FVC (L) 3.0 (0.9) 
FVC (% Predicted) 92.3 (13.8) 
FEV1/FVC ratio (%) 79.2 (8.9) 
FEF25-75 2.3 (1.0) 
FEF25-75 (% Predicted) 73.5 (28.5) 
Plethysmography (n=12) 
RV/TLC (%) 27.5 (6.5) 
Nitrogen Multiple-Breath Washout (n=16) 
Lung Clearance Index 7.8 (2.4) 
 
Note: FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; 
FEF25-75, forced expiratory flow over the middle half of the FVC; RV, residual volume; 
TLC, total lung capacity. 
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Table 3.14. Pulmonary function test parameters at each visit, changes between visits and 
p values. *p<0.05. 
  FEV1/FVC (%) FEF25-75 (% 
predicted) 
Visit 1 Value 79.2 73.5 
 Δ in Observation -2.6 -8.9 
 p 0.041* 0.007* 
Visit 2 Value 76.6 64.6 
 Δ with WVBT  0.2 2.4 
 p 0.809 0.443 
Visit 3 Value 76.8 67.0 
 Δ in Follow-up -1.0 -0.9 
 p 0.298 0.785 
Visit 4 Value 75.8 66.2 
 
Note: FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; 
FEF25-75, forced expiratory flow over the middle half of the FVC. 
 
(Table 3.14 and Appendix G, Table G.1), however there was no significant change in 
FEV1 the RV/TLC ratio or lung clearance index, making the clinical significance of this 
difficult to interpret. After WBVT and during the follow-up period there were no 
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significant changes in any pulmonary function test parameters indicating that the CF 
cohort remained stable for a pulmonary function perspective for the duration of the study. 
These findings are consistent with a previous study in children with CF [229] which did 
not find any significant change in FEV1, FVC or FEF25-75 after 1 month side-alternating 
WBVT of after 1 month follow-up and two studies in young adults with CF that found no 
significant changes in FEV1 after and 3 [233] and 6 [232] months side-alternating 
WBVT. 
 
3.8 Adherence 
 
 
Adherence was measured a counter in the vibration plate. Vibration plate counters were 
available for analysis in 15/16 participants (94%) and indicated adherence to treatment of 
48%. Using the vibration plate counters 11/15 participants (73%) trained at least twice a 
week, 8/15 (53%) trained at least 3 times a week, 4/15 (27%) trained at least 4 times a 
week, and 2/15 (13%) trained at least 5 times a week. This level of adherence to vibration 
training is similar to the rate of adherence seen with other aspects of CF care (enzymes, 
airway clearance techniques and nebulisers) measured objectively in children with CF 
which was below 50% [719]. 
 
3.9 Summary of Findings 
 
3.9.1 Baseline 
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The CF cohort presented with mild lung disease measured by spirometry, body 
plethysmography and nitrogen multiple-breath washout. Weight and BMI SDS were 
significantly reduced compared to the reference population however height SDS was 
preserved. The difficulty in maintaining weight and BMI was reflected in the CFQ-R 
child- and adult-reported eating domain, adult-reported weight domain, and parent-
reported eating and weight domains, that were all lower than their corresponding 
normative means. Consistent with significantly reduced weight and BMI SDS, the total 
body lean tissue mass for height SDS measured by DXA and the muscle CSA SDS 
measured at the 66% tibial pQCT site were significantly reduced compared to the 
reference population, indicating that the lean tissue compartment was compromised in the 
CF cohort. A ramification of the significantly reduced lean tissue mass, was the 
significantly lower muscle force SDS produced during the M1LJ and S2LJ, however, 
peak oxygen uptake corrected for body weight was normal. The significant reductions in 
lean tissue mass and maximum forces produced during dynamic manoeuvres, compared 
to their healthy counterparts, would play a dominant role in the compromised bone health 
in both the trabecular and cortical bone compartments seen in the CF, cohort consistent 
with the mechanostat theory [35, 47, 72, 75]. Disturbances to the trabecular compartment 
were evidenced by significantly reduced SDS for vBMD of the lumbar vertebrae 1-4 and 
trunk BMD on the lumbar spine, and segmental analysis of total body DXA scans 
respectively, as well as the significant reduction in trabecular vBMD at the 4% tibial 
pQCT site. Compromised bone health in the cortical bone compartment was reflected in 
cortical bone mass, density, geometry and strength. Bone mass SDS were significantly 
reduced in the total body DXA scan and the cortical measurement at the 66% tibial pQCT 
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site. However, the SDS for BMC for LTM and BMC for muscle CSA were not 
significantly different to the reference population indicating that BMC was appropriately 
adapted for lean mass. Abnormal bone density was demonstrated by the significantly 
reduced arms BMD SDS, a non-weight-bearing site, and the significantly increased 
cortical vBMD at the 20% and 66% tibial pQCT weight-bearing sites. Sub-optimal 
geometric adaptations were evidenced by a significantly reduced DXA derived bone area 
for height SDS, periosteal circumference SDS at the 20% pQCT site and cortical CSA 
and cortical thickness SDS at the 66% pQCT site. Compromised bone strength was 
shown by the significantly reduced SDS for cortical measurements of polar CSMI and 
SSI at the 66% pQCT site. An uncoupling of normal bone turn-over in the CF cohort 
provided further support for the compromised bone health seen in the CF cohort, with 
38% having the bone formation marker, osteocalcin below normal levels, and 44% 
having the bone resorption marker, urinary deoxypyridinoline: creatinine ratio, above 
normal levels, indicating reduced bone formation and increased bone resorption 
respectively. 
 
3.9.2 Observation Period 
 
 
The CF cohort followed their anthropometric trajectories, with no significant changes in 
SDS for height, weight or BMI demonstrated. The lean tissue compartment also remained 
unchanged, however fat CSA at the 66% pQCT site increased significantly, indicating 
that weight gains may have preferentially been in the fat and not lean tissue compartment. 
Pulmonary function tests demonstrated significant deterioration in the FEV1/FVC ratio 
and FEF25-75 measurements and this was associated with significant reductions in the 
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parent-reported respiratory domain of the CFQ-R. Peak oxygen uptake and its percent-
predicted value decreased significantly as did the relative maximum force and force SDS 
for the M1LJ, indicating a deterioration in muscle functional capacity in the setting of 
significantly reduced lean tissue mass. These deteriorations would have had further 
negative impacts on the functional muscle-bone unit in the CF cohort. To support this, the 
bone formation marker, osteocalcin, decreased significantly. The characteristics of the 
trabecular bone compartment remained effectively unchanged with no significant 
changes in SDS at the lumbar spine or 4% pQCT site. Cortical BMC SDS at the 20% and 
66% pQCT sites increased, as did cortical density SDS at the 20% pQCT site. Cortical 
geometry demonstrated improvements measured by the SDS for cortical CSA, cortical 
thickness and periosteal circumference at the 20% pQCT site and for total and cortical 
CSA at the 66% site. Similarly, cortical strength SDS at the 20% and 66% pQCT sites 
increased. 
 
3.9.3 WBVT Period 
 
The CF cohort continued to follow their anthropometric trajectories, however the 
significant increase in fat CSA was not seen after WBVT, potentially indicating an 
improved distribution of weight gains to both the fat and lean tissue compartments. There 
was no further deterioration in pulmonary function or in the child-, adult- or parent-
reported respiratory domain of the CFQ-R. The reduction in muscle functional capacity 
seen in the observation period was arrested with both peak oxygen uptake and force 
parameters in the M1LJ demonstrating non-significant increases after WBVT. To affirm 
beneficial effects of WBVT on the functional muscle bone-unit, bone turnover markers 
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remained stable and there were significant improvements in parameters of the trabecular 
bone compartment. Total bone mass and density at the 4% pQCT site increased 
significantly, a change not seen in the observation period and a beneficial outcome as 
trabecular density at the 4% pQCT site was significantly reduced at baseline. WBVT did 
not have the same effect on the cortical bone compartment. Bone mass in the cortical 
compartment showed some favourable changes with the total body DXA derived BMC to 
bone area SDS increasing significantly, however total and cortical bone BMC at the 20% 
and 66% pQCT sites showed similar changes to that seen in the observation period. Bone 
density in the cortical compartment remain largely unchanged with no changes seen at 
the 66% pQCT site, and similar changes to that seen during observation in total and 
cortical bone density at the 20% pQCT site. However, legs BMD increased 50% more 
than the increase seen in the observation period and the SDS showed a non-significant 
increase in contrast to a decrease seen in the observation period. Cortical bone geometry 
did not improve after WBVT. The DXA derived total bone area to height SDS decreased 
significantly however total and cortical bone CSA, cortical thickness and periosteal 
circumference had similar increases to those seen in the observation period. Similarly, 
total and cortical bone strength measures at the 20% and 66% pQCT sites demonstrated 
similar changes to those seen in the observation period. Improvements seen in the 
trabecular, but not the cortical bone compartment, is likely a reflection of the more 
metabolically active trabecular compartment, which would reflect changes more rapidly 
than the cortical bone compartment. Another consideration when interpreting the effect of 
WBVT on bone parameters is the adherence to the training protocol. Overall adherence 
was poor in the CF cohort, just shy of 50%, with only half the cohort training at least 
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three times a week. This amount of training appears to hinder the deterioration in muscle 
functional capacity seen in the CF cohort, and improve some bone parameters in the 
trabecular compartment, however this level of training stimulus was not adequate to elicit 
changes in the cortical bone compartment. 
 
3.9.4 Follow-up Period 
 
The CF cohort continued to follow their anthropometric trajectories, however there was a 
significant increase in muscle CSA and its corresponding SDS measured at the 66% 
pQCT site, indicating preferential distribution of weight gain to the lean tissue 
compartment. Pulmonary function and peak oxygen uptake remained stable with 
significant improvements in the parent-reported respiratory domain and clinically 
relevant improvements in the child- and adult-reported respiratory domain of the CFQ-R. 
Despite the significant increase in calf muscle CSA, the maximum relative force and 
force SDS for the M1LJ decreased significantly, once again impacting negatively on the 
functional muscle bone unit, with ramifications for the trabecular and cortical bone 
compartments. Gains in trabecular bone mass at the lumbar spine were smaller than those 
seen in the WBVT and observation periods there were no improvements in bone mass at 
the 4% pQCT site. Lumbar spine bone density also demonstrated smaller increases 
compared to the WBVT and observation periods and trunk BMD from segmental analysis 
of the total body DXA scan decreased significantly. In the cortical compartment, BMC 
for bone area decreased significantly and the significant improvements in total and 
cortical bone mass at the 20% and 66% pQCT sites were smaller in magnitude than those 
seen in the WBVT and observation periods. Cortical density was significantly reduced in 
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the arms BMD parameter, a non-weight bearing site, and the significant increase in legs 
BMD was smaller than that seen in the WBVT period and similar to that seen in the 
observation period. The increases in total and cortical bone vBMD at the 20% pQCT site 
were similar in magnitude to the WBVT period, however cortical vBMD at the 66% 
pQCT site increased significantly, perhaps indicating a reduced rate of bone turn-over, an 
unfavourable outcome as this parameter was significantly higher than the reference 
population at baseline. Cortical bone geometry also appeared to be negatively affected in 
the follow-up period. While total bone area to height SDS increased significantly, total 
and cortical bone CSA, cortical thickness and periosteal circumference had smaller 
increases compared to those seen in the WBVT and observation periods. Cortical bone 
strength measures at the 20% and 66% pQCT sites also demonstrated smaller increases 
compared to those seen in the WBVT and observation periods. Taken together, these 
findings suggest a subtle de-training effect in the follow-up period with significant 
reductions or smaller magnitude increases in trabecular and cortical bone parameters 
compared to the WBVT and observation periods. 
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4 MRCD Results 
 
4.1 Participants 
 
 
 
 
 
 
Figure 4.1: Flow diagram of Participant recruitment. 
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Twenty-three participants, 13 male, aged 5-77 years were recruited into the study (Table 
4.1). Thirteen of these participants were recruited through the Children’s Hospital at 
Westmead and the remainder from Royal North Shore Hospital. Four participants were 
later withdrawn: Participants 7 and 11 were found to have Congenital Myasthenia Gravis 
on whole exome sequencing; Participant 9 did not have a confirmed MRCD on muscle 
biopsy; and Participant 10 elected to withdraw from the study after his baseline visit to 
pursue alternative health care options to which WBVT training may have been 
detrimental. 
 
Table 4.1. Participant Characteristics. 
Patient Gender Age Diagnosis 
1  Male 17 Kearns-Sayre Syndrome  
2  Female 16 MLASA 
3  Male 24 Leigh Syndrome 
4  Male 21 Leigh Syndrome 
5  Female 8 Leigh Syndrome 
6  Male 5 Leigh Syndrome 
7  Male 6 WITHDRAWN - Congenital Myasthenia Gravis 
8  Female 22 POLG 
9  Female 77 WITHDRAWN - Unconfirmed MRCD 
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10 Male 43 WITHDRAWN - Pursued alternative treatment option 
11  Male 8 WITHDRAWN - Congenital Myasthenia Gravis 
12  Male 32 MELAS 
13  Female 65 Mitochondrial Myopathy 
14  Male 13 Kearns-Sayre Syndrome 
15  Female 47 CPEO 
16  Female 65 Mitochondrial Myopathy 
17  Female 38 MELAS 
18 Female 20 Complex I Deficiency 
19  Male 11 MELAS 
20 Female 62 MELAS 
21  Male 55 Mitochondrial Myopathy 
22  Male 31 MELAS 
23  Male 11 Leigh Syndrome 
 
Note: MLASA, mitochondrial myopathy, lactic acidosis and sideroblastic anaemia; 
POLG, DNA Polymerase Gamma; MELAS, Mitochondrial encephalomyopathy, lactic 
acidosis ad stroke like episodes; CPEO, Chronic progressive external ophthalmoplegia. 
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The remaining 19 participants, 10 male, with a mean (SD) age of 30.3 (20.1) years, 
presented with diverse genetic and phenotypic manifestations typical of mitochondrial 
respiratory chain disorders (Table 2.2) [278, 281, 283, 290, 295-297, 302, 305, 309, 321, 
323-326, 336, 337, 347, 383, 431]. The bi-genomic regulation of the MRC and the ability 
of pathogenic mutations of both the mitochondrial and nuclear genomes to cause MRCD 
were represented in the cohort. Two participants had genetic mutations originating in the 
nuclear genome, one with childhood MLASA caused by a mutation in the nuclear 
encoded YARS2 gene, a tRNA modifying gene important for mtDNA translation [296, 
297, 355], and the other with adult onset mitochondrial disease due to a POLG mutation 
which interferes with mtDNA maintenance causing mtDNA depletion or multiple 
mtDNA deletions [296, 309, 370, 371]. The remaining six paediatric and eleven adult 
participants had genetic mutations originating in the mitochondrial genome.  
 
The cohort of participants with MRCD in this study displayed diverse phenotypic 
heterogeneity and variability in the presentations in keeping with the literature [278, 283, 
290, 295, 305, 326, 336, 337, 347, 383, 431]. There was a wide variation in age at 
presentation, spanning from the early childhood years to late in adult life. There was also 
a large spectrum in disease severity, with participants being oligosymptomatic with tissue 
specific involvement, while others had multisystemic manifestations causing chronic 
disability, significant morbidity and reduced quality of life. Some participants had 
symptoms that aligned with well-defined syndromes including LS, MELAS, PEO, KSS 
and MLASA, while others had largely non-specific disorders, these features also 
consistent with the literature [281-283, 295-298, 305, 327, 384, 432, 433]. As described 
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in the literature [296, 297, 305, 379, 434, 435], there were poor genotype-phenotype 
correlations within our cohort. The phenotypes consistent with MELAS in our cohort 
were caused by different mtDNA gene mutations, and MELAS caused by the same 
genetic mutation resulted in both child and adult onset disease. Similarly, the five 
participants in our cohort with LS due to the identical m.8993T>C mutation demonstrated 
significant variability in phenotypic severity. In keeping with the literature [281-283, 298, 
305, 319, 321, 379, 383, 397], the participants in our cohort presented with symptoms in 
tissues highly reliant on OXPHOS including the brain, central and peripheral nervous 
systems, skeletal muscle, heart muscle, the retina and optic musculature, the cochlea, 
bone marrow, pancreas and gastro-intestinal system. The majority of participants in our 
cohort presented with features consistent with encephalomyopathy as described by 
Shapira et al in 1977 [398], including central nervous system sequelae such as stroke like 
episodes, migraines, seizures, psychomotor regression, ataxia, encephalopathy and 
cognitive impairment, as previously described [283, 379, 401], as well as skeletal muscle 
involvement, with common symptoms including muscle weakness, predominantly of the 
hip and shoulder girdle, and exercise intolerance, that are well recognised in the literature 
[403-407]. Exercise intolerance is considered to be a hallmark of MRCD [403, 405, 406, 
410-412] and was universally manifested in our cohort. 
 
Two-thirds of our cohort had MRCD involving multiple MRC complexes, three quarters 
of the adult participants and half of the paediatric participants, higher than that reported 
in the literature [295, 382, 391, 393, 395, 441]. These included participants with KSS and 
PEO caused by large-scale mtDNA deletions, mtDNA point mutations including those 
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causing MELAS and nDNA mutations in the POLG and YARS2 genes as recognised in 
the literature [320, 352, 395, 441], [296, 297, 355]. The vast majority of participants with 
deficits in multiple MRC complexes presented with multisystem disease manifestations 
(Table 2.2) consistent with those reported in the literature for KSS [290, 321, 439, 465], 
PEO [321, 439], MELAS  [281, 290, 298, 305, 321, 347, 455, 456, 459, 464], POLG 
gene mutations [296, 309, 440] and YARS2 gene mutations [296, 297, 355]. The five 
participants with LS affecting the ATP synthase 6 subunit of Complex V of the MRC 
also presented with multisystemic disease manifestations which are in keeping with those 
reported in the literature [290, 296, 320, 347, 379, 445, 446, 450]. 
 
The cohort comprised of 7 paediatric and 12 adult participants. These cohorts were 
analysed separately due to the different biological process occurring in the immature 
musculoskeletal system during growth compared to the mature adult musculoskeletal 
system. Paediatric participants presented with more severe, progressive disease as is often 
reported in the literature [279, 321, 384, 385]. The majority of the paediatric MRCD 
cohort presented with mtDNA mutations, despite the literature suggesting that only 10-
30% of paediatric presentations are due to mtDNA defects [290, 324, 382, 390, 393, 
394]. This is likely due to the fact that the paediatric population of MRCD due to nDNA 
mutations have a disease onset much earlier than those with mtDNA mutations [328, 382, 
390, 392, 395] and a more severe clinical course [279, 321, 384, 385] which would have 
precluded them from being enrolled in the study. As a result, the paediatric cohort in our 
study comprised the lesser-affected children with mtDNA mutations. The propensity 
toward nuclear gene mutations in the paediatric population accompanied by their earlier 
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onset and more severe clinical progression may also explain why we were unable to find 
enough eligible paediatric participants for the study. Half of the paediatric participants 
with mtDNA mutations presented with LS, not surprising as LS is the most commonly 
seen paediatric presentation in MRCD [320, 445]. All three of these paediatric 
participants had LS as a result of the point mutation m.8993T>C affecting the formation 
of the ATP Synthase 6 subunit of Complex V of the mitochondrial respiratory chain, one 
of the most common causes of maternally inherited LS [320, 434, 452, 453]. Two of the 
other paediatric participants with mtDNA mutations had KSS, both caused by large-scale 
deletions in mtDNA, the most common cause of KSS [439, 465]. The final paediatric 
participant with a mtDNA mutation had MELAS caused by the mtDNA point mutation 
m.3243A>G which is the most frequent pathogenic mtDNA point mutation associated 
with MELAS [281, 298, 321, 455-460] and the most common paediatric presentation 
caused by a mtDNA mutation [393]. 
 
The majority of adult participants also had mtDNA mutations, this pattern similar to that 
seen in the literature where mutations in mtDNA are the most common cause of adult 
onset mitochondrial disease [328, 386-388]. Eight of the eleven adults with mtDNA 
mutations were found in mitochondrial genes encoding tRNA consistent with the 
literature which has found that over 50% of all identified pathogenic mtDNA point 
mutations are located in the mitochondrial tRNA genes [282]. Furthermore, seven of 
these adults had mutations in the gene encoding the mitochondrial tRNA
Leu(UUR)
, one of 
the most common sites for point mutations in tRNA genes [296]. Four of these adult 
participants presented with MELAS, caused by the m.3243A>G mutation in three, which 
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accounts for around 80% of individuals presenting with MELAS symptoms [281, 298, 
321, 455-460], and by the less common m.3256C>T mutation in the fourth participant. 
The remaining four adult participants with mutations in mitochondrial genes encoding 
tRNA did not fulfil the criteria for well-defined syndromes. Three of these participants 
presented with largely non-specific mitochondrial myopathy, as is often seen in MRCD 
presentations [281, 282, 295-298, 327, 384], and the fourth had an isolated Complex I 
deficiency, which accounts for around a quarter of all MRCD presentations [290, 295]. 
Of the three remaining adult participants with mtDNA mutations, two had the point 
mutation m.8993T>C affecting the formation of the ATP Synthase 6 subunit of Complex 
V of the mitochondrial respiratory chain causing maternally inherited LS, which was the 
same point mutation seen in the three paediatric participants with LS. The last adult 
participant with a mtDNA mutation had Progressive External Ophthalmoplegia (PEO), 
most likely due to a single mtDNA deletion, a common cause of PEO in the literature 
[296, 305], although this was not genetically confirmed. Adult participants in our cohort 
presented with exercise intolerance and muscle weakness usually affecting the proximal 
muscles, seizures, migraines, cognitive impairment, sensorineural hearing loss, 
ophthalmologic problems including optic atrophy, ptosis, progressive external 
ophthalmoplegia and pigmentary retinopathy, cardiac arrhythmias, gastrointestinal 
symptoms. Three of the adult participants, 3, 4 and 18, were diagnosed during their 
paediatric years and had the most severe presentations of all the adult participants, 
supporting the greater disease severity and faster disease progression seen in paediatric 
diagnosed MRCD. 
al dysmotility, diabetes and short stature, as previously reported in MRCD [305]. 
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Within the cohort two distinct clinical cohorts could be identified: 5 participants, 4 male, 
aged 5-24 years with Leigh Syndrome; and 5 participants, 3 male, aged 11-62 years with 
MELAS. The Leigh Syndrome cohort consisted of paediatric and young adult 
participants all affected by the same mutation, m.8993T>C. This sub-cohort was analysed 
independently. The MELAS cohort was predominantly adult and comprised of different 
mutations, including the m.3251A>G mutation and the common m.3243A>G mutation. 
Due to the small number of participants in this cohort and the heterogeneous genetic 
mutations, this sub-cohort was not analysed independently. 
 
Participants attended the hospital for four research visits. The observation period 
occurred between visits 1 and 2. The mean (SD) time elapsed between these visits was 
4.3 (2.0) months. The WBVT period occurred between visits 2 and 4. The mean (SD) 
time between visits was 6.5 (0.6) months. The follow-up period occurred between visits 4 
and 6. The mean (SD) time periods between these visits was 6.3 (0.9) months. 
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Table 4.2. Participant diagnoses, genetic mutations and clinical manifestations. 
Patient Diagnosis Genome 
Affected 
Mutation Interrupted 
Function 
Clinical Manifestations 
1  KSS mtDNA mtDNA deletion  
Sensorineural hearing loss requiring hearing aids, 
moderate - severe ptosis/ophthalmoplegia, dysphagia, 
intention tremor, muscle weakness (proximal > distal), 
exercise intolerance, community mobility in wheelchair 
2  MLASA nDNA 
YARS2, 
homozygous for 
p.Phe52Leu   
tRNA Tyr 
synthetase  
Transfusion dependent sideroblastic anaemia, muscle 
weakness (proximal > distal), dysphagia requiring 
gastrostomy, community mobility in wheelchair, 
exercise intolerance 
3  
Leigh 
Syndrome 
mtDNA m.8993T>C 
ATP Synthase 
subunit 6 
Mild ptosis/ ophthalmoplegia, dysarthria, cerebellar 
ataxia, exercise intolerance, community mobility in 
wheelchair 
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4  
Leigh 
Syndrome 
mtDNA m.8993T>C 
ATP Synthase 
subunit 6 
Proximal muscle weakness, bulbar dysfunction, 
dysarthria, mild tremor and cerebellar ataxia, exercise 
intolerance, community mobility in wheelchair 
5  
Leigh 
Syndrome 
mtDNA m.8993T>C 
ATP Synthase 
subunit 6 
Mild ataxia, dysarthria, action tremor, dysphagia, 
proximal muscle weakness, exercise intolerance, 
community mobility in wheelchair 
6  
Leigh 
Syndrome 
mtDNA m.8993T>C 
ATP Synthase 
subunit 6 
Mild ataxia and dysarthria, exercise intolerance 
8  POLG nDNA 
POLG, with 
mutations of 
p.Pro163Ser, and 
p.Thr851Ala  
mtDNA 
replication and 
stability 
Seizures, peripheral neuropathy, cerebellar and sensory 
ataxia, mild ptosis/ ophthalmoplegia, GI dysmotility, 
insulin resistance, severe generalised sensorimotor 
polyneuropathy, exercise intolerance 
12  MELAS mtDNA m.3256C>T 
tRNA Leu 
(UUR) 
Exercise intolerance 
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13  
Mitochondrial 
Myopathy 
mtDNA m.3251A>G 
tRNA Leu 
(UUR) 
Sensorineural hearing loss, mild neuropathy, mild ptosis, 
impaired glucose tolerance, headaches, exercise 
intolerance, Sjorgens Syndrome 
14  KSS mtDNA mtDNA deletion  
Moderate-severe ptosis/ ophthalmoplegia/ retinitis 
pigmentosa, sensorineural deafness, mild 
dysdiadochokinesia, action tremor, ataxic gait, exercise 
intolerance 
15  CPEO mtDNA   
Proximal muscle weakness, moderate to severe ptosis/ 
ophthalmoplegia, diplopia, exercise intolerance, 
depression, slow processing 
16  
Mitochondrial 
Myopathy 
mtDNA m.3251A>G 
tRNA Leu 
(UUR) 
Moderate ptosis/ ophthalmoplegia, optic neuropathy, 
sensorineural hearing loss, proximal muscle weakness, 
dysphagia, insulin resistance, respiratory muscle 
weakness and type 2 respiratory failure, depression, 
 283 
exercise intolerance 
17  MELAS mtDNA m.3243A>G 
tRNA Leu 
(UUR) 
Mild ptosis, migraines, GI dysmotility, fibromyalgia, 
insulin resistance, exercise intolerance 
18 
Complex I 
Deficiency 
mtDNA 
tRNA-Leu 
mutation 
tRNA Leu 
(UUR) 
Ataxia, muscle weakness (proximal > distal), exercise 
intolerance 
19  MELAS mtDNA m.3243A>G 
tRNA Leu 
(UUR) 
Headaches, seizures, stroke like episodes, dysarthria, 
ptosis, reduced visual acuity, reduced muscle strength, 
anxiety, exercise intolerance 
20 MELAS mtDNA m.3243A>G 
tRNA Leu 
(UUR) 
Sensorineural hearing loss, migraines, proximal muscle 
weakness, GI dysmotility, exercise intolerance 
21  
Mitochondrial 
Myopathy 
mtDNA m.4269A>G tRNA 
Mild retinopathy/ ptosis/ ophthalmoplegia, sensorineural 
hearing loss, dysarthria, proximal muscle weakness, 
mild peripheral neuropathy, GI dysmotility, cognitive 
impairment, exercise intolerance 
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22  MELAS mtDNA m.3243A>G 
tRNA Leu 
(UUR) 
Sensorineural hearing loss, pigmentary retinopathy, 
seizures, stroke like episodes, exercise intolerance 
23 
Leigh 
Syndrome 
mtDNA m.8993T>C 
ATP Synthase 
subunit 6 
Ataxia, proximal muscle weakness, dysarthria, 
dysdiadochokinesia, exercise intolerance, wheelchair for 
community mobility 
 
Note: KSS, Kearns-Sayre Syndrome; MLASA, mitochondrial myopathy, lactic acidosis and sideroblastic anaemia; POLG, DNA 
Polymerase Gamma; MELAS, Mitochondrial encephalomyopathy, lactic acidosis ad stroke like episodes; CPEO, Chronic progressive 
external ophthalmoplegia; mtDNA, mitochondrial DNA; nDNA, nuclear DNA; tRNA, transfer RNA; Tyr, tyrosine; Leu, leucine; 
ATP, adenosine triphosphate; GI, gastrointestinal. 
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4.2 Anthropometric Parameters 
 
 
Analysis data for all anthropometric parameters can be found in Appendix H. 
 
4.2.1 Paediatric Cohort 
 
 
The baseline anthropometric data for the cohort are presented in Table 4.3 and Figure 4.1. 
The paediatric cohort, mean (SD) age of 12.1 (4.1) years, had a mean (SD height of 134.7 
(18.7) cm and a mean (SD) height standard deviation score (SDS) of -2.1 (0.7) which was 
significantly lower than the reference population indicating growth retardation. Weight 
also indicated failure to thrive with mean (SD) 29.4 (8.5) kg and mean (SD) SDS -2.3 
(1.8), which was also significantly lower than the reference population. BMI and BMI 
SDS were also low with a mean (SD) of 16.0 (2.5) kg/m
2
 and -1.4 (2.1) respectively, 
however this was not significantly different to the reference population. These findings 
are consistent with the literature, which have found failure to thrive, growth retardation 
and short stature to be common manifestations in MRCD [305, 383].  
 
During the observation period there was a significant increase in height from 134.7 to 
136.4 cm (p=0.001), however there was no significant change in height SDS, indicating 
normal linear growth. Weight, weight SDS, BMI and BMI SDS did not change 
significantly in the observation period (Appendix H, Table H.2). 
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Height and weight increased significantly during the WBVT period, by 1.8cm, p=0.017 
and 1.3kg, p=0.045, however their corresponding SDS were not altered significantly. 
There were no significant changes in BMI or BMI SDS indicating that the tracking of 
anthropometric measures was not altered during the WBVT period (Appendix H, Table 
H.2.). 
 
Height increased significantly in the follow-up period from 138.2 to 139.8 cm (p=0.033), 
however there was no significant change in the height SDS. Weight, weight SDS, BMI 
and BMI SDS demonstrated no significant changes during the follow-up period 
indicating tracking of anthropometric variables (Appendix H, Table H.2.). 
 
4.2.2 Adult Cohort 
 
Baseline anthropometric data for the cohort are presented in Table 4.3. The adult cohort, 
mean (SD) age 40.9 (17.8) years, had normal nutritional status with a mean (SD) height, 
weight and BMI of 166.8 (9.8) cm, 64.3 (14.4) kg and 23.2 (5.0) kg/m
2
 respectively. 
There was however a range of BMIs with two young adult females with low BMIs 
(<18kg/m
2
) and two middle-aged females with high BMIs (>30kg/m
2
).  
 
There were no significant changes in the height, weight or BMI in the adult cohort during 
the observation, WBVT or follow-up periods (Appendix H, Table H.3). 
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4.2.3 Leigh Syndrome Cohort 
 
Baseline anthropometric data for the cohort are presented in Table 4.3. The Leigh 
Syndrome cohort, mean (SD) age of 14.4 (8.1) years, had a mean (SD) height, weight and 
BMI of 144.8 (35.5) cm, 47.6 (31.0) kg and 20.2 (4.1) kg/m
2
 respectively.  
During the observation period, there were no significant changes in height, weight or 
BMI. Weight increased significantly by 1.7kg, p=0.019, after WBVT, consistent with the 
increase in weight seen in the paediatric cohort. There were no significant changes in 
height or BMI after WBVT or during the follow-up period. Weight significantly 
increased again in the follow-up period by 2.3kg, p=0.004, a change that was not seen in 
either the paediatric of adult cohorts (Appendix H, Table H.4). 
 
Table 4.3. Baseline anthropometric data 
Patient Gender Age 
(years) 
Height 
(cm) 
Height 
SDS 
Weight 
(kg) 
Weight 
SDS 
BMI 
(kg/m
2
) 
BMI 
SDS 
1  Male 17 160.8 -2.1 36.1 -4.7 13.96 -4.5 
2  Female 16 151.6 -1.9 38.4 -2.8 16.71 -1.8 
3  Male 24 188.5  92.6  26.06  
4  Male 21 173.5  64.6  21.46  
5  Female 8 119.0 -2.0 24.9 -0.6 17.58 0.7 
6  Male 5 105.0 -1.9 17.0 -1.4 15.42 -0.1 
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8  Female 22 168.7  49.6  17.43  
12  Male 32 178.5  62.8  19.71  
13  Female 65 156.2  68.2  27.95  
14  Male 13 134.3 -3.5 25.7 -4.0 14.25 -3.0 
15  Female 47 158.3  80.3  32.04  
16  Female 65 167.0  54.2  19.43  
17  Female 38 154.8  73.2  30.55  
18 Female 20 161.2  38.2  14.70  
19  Male 11 134.0 -1.6 24.3 -2.7 13.53 -2.5 
20 Female 62 166.0  57.0  20.69  
21  Male 55 167.7  71.0  25.25  
22  Male 31 161.0  59.8  23.07  
23  Male 11 138.0 -1.4 39.1 0.2 20.53 1.2 
 
Note: SDS, standard deviation score; BMI, body mass index. 
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4.3 Bone Parameters 
 
 
4.3.1 DXA 
 
 
4.3.1.1 Baseline 
 
Baseline DXA parameters for the three cohorts are presented in Table 4.4. This includes: 
total body DXA scan parameters, segmental analysis of the trunk, arms and legs from the 
total body scans; and analysis of the lumbar spine (LS), including lumbar vertebrae 2-4; 
and analysis of the lumbar vertebrae 1-4 (L14). 
 
 
Table 4.4. Baseline dual-energy x-ray absorptiometry parameters for scans of the total 
body and lumbar spine. Mean (SD). 
Cohort Paediatric (n=7) Adult (n=12) Leigh Syndrome 
(n=5) 
Total Body DXA Parameters 
TBMC (g) 1022.1 (379.0) 2378.3 (358.5) 1562.5 (1063.2) 
TBMC SDS -0.8 (1.1)   
TBA (cm
2
) 1199.0 (354.4) 2177.4 (246.0) 1603.1(893.5) 
TBMD (g/cm
2
) 0.839 (0.069) 1.090 (0.105) 0.916 (0.144) 
TBMD SDS -0.8 (1.4) -0.4 (1.5) -0.7 (1.5) 
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LTM (g) 20422.5 (5159.3) 38771.7 (8086.7) 29565.6 (17975.6) 
Fat (%) 24.6 (11.8) 35.9 (11.9) 31.8 (9.3) 
Fat (%) SDS 0.9 (1.5) 
 
LTM for Ht SDS -1.5 (1.2) 
TBA for Ht SDS -1.0 (1.1)  
TBMC for LTM SDS 0.9 (1.5) 
TBMC for TBA SDS -0.3 (1.2) 
Parameters of Segmental Analysis of Total Body DXA Scans 
Trunk BMD (g/cm
2
) 0.636 (0.072) 0.868 (0.108) 0.728 (0.179) 
Trunk BMD SDS -0.4 (0.4)  
Arms BMD (g/cm
2
) 0.591 (0.073) 0.817 (0.106) 0.733 (0.185) 
Arms BMD SDS -0.7 (1.6)   
Legs BMC (g) 300.8 (147.8) 846.5 (149.0) 469.8 (354.9) 
Legs BA (cm
2
) 393.3 (135.8) 741.0 (75.8) 492.8 (284.5) 
Legs BMD (g/cm
2
) 0.735 (0.116) 1.139 (0.159) 0.856 (0.232) 
Legs BMD SDS -1.5 (1.5)   
Legs LTM (g) 6077.4 (1837.9) 12140.9 (260.9.7) 8884.3 (5849.7) 
Legs Fat (%) 31.0 (12.3) 38.8 (11.4) 37.3 (6.78) 
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Lumbar Spine DXA Parameters 
LS BMC (g) 18.7 (8.6) 51.4 (9.2) 31.8 (25.5) 
LS BMC SDS -0.4 (0.6)   
LS BMD (g/cm
2
) 0.672 (0.152) 1.123 (0.841) 0.785 (0.296) 
LS BMD SDS -0.9 (1.0) -0.4 (1.4) -1.1 (0.8) 
L14 BMC (g) 23.8 (11.0) 64.3 (11.1) 39.2 (31.0) 
L14 BA (cm
2
) 34.6 (8.2) 58.6 (6.7) 44.8 (22.1) 
L14 vBMD (g/cm3) 0.248 (0.046) 0.323 (0.067) 0.256 (0.055) 
L14 vBMD SDS -1.0 (1.1)   
 
Note: DXA, dual-energy x-ray absorptiometry; TBMC, total body bone mineral content; 
TBA, total body bone area; TBMD, total body bone mineral density; SDS, standard 
deviation score; LTM, lean tissue mass; Ht, height; BMD, bone mineral density; BMC, 
bone mineral content; BA, bone area; TF, tibia and fibula; LS, lumbar spine vertebrae 2-
4; L14, lumbar spine vertebrae 1-4; vBMD, volumetric bone mineral density. 
 
4.3.1.1.1  Paediatric Cohort 
 
 
In addition to the baseline DXA parameters presented in Table 4.4, further analysis of 
DXA parameters in the paediatric cohort was obtained by investigating ratios between 
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total body DXA derived measures of BMC, BA, LTM, and height: LTM for height SDS; 
TBA for height SDS; TBMC for LTM SDS; and TBMC for TBA SDS.  
  
The baseline SD scores for legs BMD, trunk BMD, LTM:Height, LS BMD and L14 
BMD were significantly reduced compared to the reference population (Figure 4.1). Total 
body BMD SDS were < -1 in 5/7 (71%) and less < -2 in 1/7 (14%) of the paediatric 
cohort. At the lumbar spine, BMD SDS were < -1 in 3/7 (43%) and < -2 in 1/7 (14%).  
The mean total body fat percent was 24.6% with a SDS of 0.9 (Table 2.4), however this 
was not found to be significantly different to the reference population (Figure 4.1). 
Considering the paediatric cohort had a weight SDS significantly lower than the reference 
population, a much larger percentage of their weight is likely to be comprised of fat mass. 
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Figure 4.2. Standard deviation (SD) scores for anthropometric and DXA parameters in 
the paediatric cohort. Mean and 95% confidence intervals. Parameters shown in red were 
significantly different to the reference population on one-sample t-tests, p<0.05. 
 
4.3.1.1.2  Adult Cohort 
 
 
TBMD and LS BMD SDS were not significantly different to the reference population, -
0.4, p=0.389 and -0.4, p=0.306 respectively. Total body BMD SDS were <-2 in 3/12 
(25%) and lumbar spine BMD SDS were <-1 in 4/12 (33%) and <-2 in 1/12 (8%) of the 
adult cohort. Mean total body fat percent for the adult cohort was 35.9% (Table 4.4), the 
upper limit of the normal range for adult females but higher than that expected for adult 
males. 
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4.3.1.1.3  Leigh Syndrome Cohort 
 
 
Consistent with the Leigh Syndrome cohort being a mixed adult and paediatric cohort all 
total body DXA scan parameters were lower than the adult cohort but higher than the 
paediatric cohort. However, the LS BMD SDS was lower than values seen in the other 
cohorts and significantly reduced compared to the reference population (p=0.035), with 
4/5 (80%) having a SDS <-1. These results suggest this site may be more severely 
affected in Leigh Syndrome compared to other MRCD. Total body BMD SDS were <-1 
in 2/5 (40%) and <-2 in 1/5 (20%) of the Leigh Syndrome cohort. Mean total body fat 
percent was 31.8% (Table 4.4), higher than that expected for adult males and children of 
either gender. 
 
4.3.1.2 Observation Period 
 
The observation period occurred between Visit 1 (Baseline) and Visit 2 (Start WBVT). 
Full analysis data for all DXA parameters for the observation period for each of the 3 
cohorts can be found in Appendix A.  
 
4.3.1.2.1 Paediatric Cohort 
 
Analysis revealed significant changes in parameters of the total body DXA scan, 
segmental analysis of the total body DXA scan and the lumbar spine scan (Table 4.5 and 
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Appendix A, Table A.2). Total body LTM increased significantly from 20422.5 – 
21258.9g (p=0.007) however the LTM for height SDS did not change significantly 
indicating this increase was associated with normal growth. Legs BA increased 
significantly, 393.3 – 406.5 cm2 (p=0.008). Total body bone area (TBA) demonstrated a 
non-significant increase and TBA for height SDS did not change significantly, again 
indicating increases associated with normal growth. However, legs BMD SDS decreased 
significantly during the observation period falling from -1.5 to -1.7 (p=0.013), this 
decrease representing a quarter of a SDS. Lumbar spine scans revealed a significant 
increase in L14 BMC from 23.8g to 24.7g (p=0.039). 
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Table 4.5. DXA parameters for the paediatric MRCD cohort at each visit, changes between visits and p values. *p<0.05. 
  TBMC (g) TBMC SDS TBA (cm
2
) TBMD (g/cm
2
) TBMD Ht SDS 
Visit 1 
Value 1022.120 -0.776 1199.002 0.839 -0.772 
Δ in Observation 25.488 -0.168 24.203 0.006 -0.087 
p 0.124 0.195 0.149 0.238 0.328 
Visit 2 
Value 1047.608 -0.944 1223.205 0.845 -0.859 
Δ with WBVT 46.778 0.019 37.931 0.012 0.026 
p 0.008* 0.883 0.029* 0.020* 0.771 
Visit 3 
Value 1094.368 -0.925 1261.136 0.858 -0.833 
Δ in Follow-up 15.264 -0.149 22.821 -0.002 -0.185 
p 0.347 0.250 0.172 0.671 0.048* 
Visit 4 Value 1109.650 -1.074 1283.957 0.856 -1.018 
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  TLTM (g) TLTM:Ht SDS TBA:Ht SDS TBMC:TLTM 
SDS 
TBMC:TBA 
SDS 
Visit 1 
Value 20422.481 -1.504 -0.963 0.850 -0.286 
Δ in Observation 836.461 -0.006 -0.198 -0.248 0.017 
p 0.007* 0.959 0.299 0.191 0.869 
Visit 2 
Value 21258.941 -1.510 -1.160 0.602 -0.286 
Δ with WBVT 364.642 -0.155 0.031 0.266 0.079 
p 0.199 0.215 0.870 0.162 0.463 
Visit 3 
Value 21623.584 -1.665 -1.130 0.868 -0.190 
Δ in Follow-up 503.938 -0.062 -0.174 -0.112 -0.133 
p 0.082 0.612 0.360 0.549 0.220 
Visit 4 Value 22127.521 -1.727 -1.304 0.756 -0.323 
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  Trunk BMD 
(g/cm
2
) 
Trunk BMD 
SDS 
Legs BMC (g) Legs BA (cm
2
) Legs BMD SDS 
Visit 1 
Value 0.636 -0.387 300.766 393.342 -1.461 
Δ in Observation -0.002 -0.076 7.894 13.110 -0.250 
p 0.780 0.151 0.131 0.008* 0.013* 
Visit 2 
Value 0.634 -0.463 308.660 406.452 -1.711 
Δ with WBVT 0.018 0.077 11.778 12.737 -0.073 
p 0.008* 0.146 0.030* 0.009* 0.429 
Visit 3 
Value 0.652 -0.386 320.438 419.189 -1.784 
Δ in Follow-up -0.006 -0.105 8.635 6.031 -0.039 
p 0.364 0.052 0.101 0.184 0.672 
Visit 4 Value 0.646 -0.491 3.29.073 425.220 -1.823 
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  LS BMC (g) LS BMC SDS LSBMD (g/cm
2
) LS BMD SDS L14 BMC (g) 
Visit 1 
Value 18.654 -0.358 0.672 -0.937 23.800 
Δ in Observation 0.579 -0.058 0.008 -0.045 0.883 
p 0.109 0.600 0.587 0.761 0.039* 
Visit 2 
Value 19.233 -0.416 0.679 -0.981 24.682 
Δ with WBVT 1.406 0.173 0.050 0.407 1.731 
p 0.001* 0.133 0.002* 0.012* 0.000* 
Visit 3 
Value 20.639 -0.244 0.729 -0.575 26.413 
Δ in Follow-up -0.118 -0.221 -0.016 -0.278 -0.033 
p 0.735 0.059 0.272 0.071 0.935 
Visit 4 Value 20.521 -0.464 0.713 -0.853 26.381 
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Note: Δ, change; TBMC, total bone mineral content; TBA, total bone area; TBMD, total bone mineral density; SDS, standard 
deviation score; TLTM, total body lean tissue mass; TFat, total body fat; BMD, bone mineral density; BMC, bone mineral content; 
BA, bone area; LTM, lean tissue mass; TF, tibia and fibula; LS, lumbar spine vertebrae 2-4; L14, lumbar spine vertebrae 1-4; vBMD, 
volumetric bone mineral density
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4.3.1.2.2  Adult Cohort 
 
On analysis, there were no significant changes in lumbar spine DXA scans, however 
there were significant decreases in parameters of the total body DXA scan and segmental 
analysis of the total body DXA scans (Table 4.6 and Appendix A, Table A.3). Total body 
LTM and legs LTM decreased significantly during the observation period: 38771.7 g to 
38159.0 g (p=0.048); and 12141.0 g to 11889.1 g (p=0.033) respectively. Legs BMD 
decreased significantly from 1.139 g/cm
2
 to 1.133 g/cm
2
 (p=0.049), however falls within 
the CV for BMD measured by total body DXA scans reported in the adult literature 
[134], and that reported from our laboratory (Table 2.1),.  
 
4.3.1.2.3 Leigh Syndrome Cohort 
 
Investigation revealed significant changes in total body DXA scans and segmental 
analysis of total body DXA scans but not in lumbar spine scans (Table 4.7 and Appendix 
A, Table A.4). Total body BMD increased significantly during the observation period 
from 0.916 g/cm
2
 to 0.925 g/cm
2
 (p=0.025). Legs BMC increased significantly from 
469.8 g to 480.7 g (p=0.022). The improvement in total body BMD was within the CV 
from our laboratory (Table 2.1), and of questionable clinical significance as the 
corresponding SDS did not change significantly. The increase in legs BMC was above 
the CV from our laboratory (Table 2.1) and in contrast to the significant decreases in legs 
BMD seen in both the paediatric and adult MRCD cohorts. This may reflect the small 
sample size or may indicate that in individuals with Leigh Syndrome, bone health is 
affected differently when compared to other MRCD.
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Table 4.6. DXA parameters for the adult MRCD cohort at each visit, changes between 
visits and p values. *p<0.05. 
  TLTM (g) Legs BMD 
(g/cm
2
) 
Legs LTM (g) 
Visit 1 
Value 38771.665 1.139 12140.954 
Δ in Observation -612.627 -0.006 -251.861 
p 0.048* 0.049* 0.033* 
Visit 2 
Value 38159.038 1.133 11889.093 
Δ with WBVT -415.315 0.007 -188.452 
p 0.173 0.036* 0.106 
Visit 3 
Value 37743.722 1.140 11700.640 
Δ in Follow-up 118.572 -0.008 6.224 
p 0.531 0.019* 0.957 
Visit 4 Value 37932.295 1.132 11706.864 
 
Note: Δ, change; WBVT, whole body vibration training; TLTM, total body lean tissue 
mass; BMD, bone mineral density. 
 303 
Table 4.7. DXA parameters for the Leigh Syndrome MRCD cohort at each visit, changes 
between visits and p values. *p<0.05. 
  TBMD 
(g/cm
2
) 
TBMD SDS Legs BMC 
(g) 
Legs BA 
(cm
2
) 
Visit 1 
Value 0.916 -0.702 469.760 492.843 
Δ in Observation 0.010 -0.003 10.984 9.518 
p 0.025* 0.976 0.022* 0.111 
Visit 2 
Value 0.925 -0.705 480.744 502.361 
Δ with WBVT 0.004 -0.123 15.056 14.367 
p 0.316 0.250 0.004* 0.023* 
Visit 3 
Value 0.929 -0.829 495.800 516.728 
Δ in Follow-up 0.004 -0.088 11.732 10.981 
p 0.263 0.406 0.016* 0.070 
Visit 4 Value 0.934 -0.917 507.532 527.709 
 
Note: Δ, change; WBVT, whole body vibration training; TBMD, total bone mineral 
density; SDS, standard deviation score; BMC, bone mineral content; BA, bone area. 
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4.3.1.3 Whole Body Vibration Training (WBVT) Period 
 
The WBVT period occurred between Visit 2 (Start WBVT) and Visit 4 (End WBVT). 
Full analysis data for all DXA parameters for the WBVT period for each of the 3 cohorts 
can be found in Appendix A. 
 
4.3.1.3.1 Paediatric Cohort 
 
Total body DXA scans in the paediatric cohort showed significant increases in TBMC 
TBMD and TBA, 1047.6 g to 1094.4 g (p=0.008), 0.845 to 0.858 g/cm
2
 (p=0.020) and 
1223.2 to 1261.1cm
2
 (p=0.029) respectively (Table 4.5). TBMC and TBMD SDS scores 
also increased but did not reach significance. Total body LTM did not increase 
significantly during the WBVT period as it did in the observation period and the 
magnitude of the increase was less than 50% of that seen during the observation period, 
however the LTM for height SDS did not change significantly, suggesting LTM 
acquisition was not significantly altered during WBVT (Appendix A, Table A.2). 
 
On segmental analysis of the total body scan, legs BMC and legs BA increased 
significantly from 308.7 g to 320.4 g (p=0.030) and 406.5 to 419.2 cm
2
 (p=0.009) 
respectively. Legs BMD SDS continued to decrease in the WBVT period however the 
decrease was not significant and was 70% less than the significant reduction in legs BMD 
SDS seen in the observation period. Legs LTM increased with WBVT however did not 
reach significance, p=0.059 (Table 4.5 and Appendix A, Table A.2). 
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Trunk BMD from the segmental analysis of the total body DXA scan increased 
significantly from 0.634 g/cm
2
 to 0.652 g/cm
2
 (p=0.008). The trunk BMD SDS score also 
increased with WBVT however this did not reach significance. Analysis of the lumbar 
spine scans demonstrated significant increases in both LS BMD and LS BMD SDS: 
0.679 g/cm
2
 to 0.729 g/cm
2
 (p=0.002); and -1.0 to -0.6 (p=0.012). The mean absolute 
increase in the LS BMD SDS was close to half a SDS. LS BMC and L14 BMC also 
increased significantly from 19.2 to 20.6g (p=0.001) and from 24.7 to 25.4g (p<0.001) 
respectively (Table 2.5 and Appendix B, Table B.1).  
 
4.3.1.3.2 Adult Cohort 
 
There were no significant changes in the total body DXA scans (Appendix A, Table A.3). 
On segmental analysis of the total body DXA scan, legs BMD increased significantly 
from 1.133 g/cm
2
 to 1.140 g/cm
2
 (p=0.036). This result was in contrast to the significant 
decrease in legs BMD seen in the observation period and was slightly larger in value, a 
0.007 g/cm
2
 increase compared to a 0.006 g/cm
2
 decrease. Legs LTM continued to 
decrease in the WBVT period with a mean reduction of 188.5 g however this was not 
significant and 25% less than the significant decrease of 251.9 g seen in the observation 
period. Similarly, the total body LTM continued to decline in the WBVT period however 
this decline was not significant and 32% lower than the significant decline observed in 
the observation period, 415.3 g compared to 612.6 g respectively (Table 4.6).  
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4.3.1.3.3 Leigh Syndrome Cohort 
 
There were no significant changes in the total body DXA scans (Appendix A, Table A.4). 
Segmental analysis of the total body DXA scans demonstrated a significant increase in 
legs BMC and legs BA with WBVT: 480.7 to 495.8g (p=0.004), which was 50% greater 
than the significant increase seen in the observation period; and 502.4 to 516.7 cm
2 
(p=0.023). The significant increases in total body BMD seen in the observation period 
did not continue during WBVT (Table 4.7). No significant changes in any parameters of 
the lumbar spine scans were seen (Appendix A, Table A.4). 
 
4.3.1.4 Follow-up Period 
 
The follow-up period occurred between Visit 3 (end WBVT) and Visit 4 (follow-up). 
Analysis data for all DXA parameters for the 3 sub-cohorts for the follow-up period can 
be found Appendix A. 
 
4.3.1.4.1  Paediatric Cohort 
 
Total body DXA scans demonstrated a significant decrease in TBMD SDS, -0.8 to -1.0 
(p=0.048). This decrease was approximately twice the magnitude of the non-significant 
decrease seen in the observation period and in contrast to the significant increase seen 
with WBVT. TBMC acquisition also slowed in the follow-up period with a non-
significant increase of 15.3g, one third of the magnitude of the significant increase seen 
in the WBVT period (Table 4.5).  
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On segmental analysis of the total body DXA scans, trunk BMD demonstrated a non-
significant decrease which was equivalent to one third of the value gained during WBVT, 
and 3-fold greater than the decline seen in the observation period. Trunk BMD SDS 
decreased from -0.4 to -0.5, but did not reach significance (p=0.052). A similar trend was 
seen for LS BMD and LS BMD SDS which decreased from -0.6 to -0.9 (p=0.071). There 
was also a non-significant decrease in LS BMC and the LS BMC SDS decreased from -
0.2 to -0.5 (p=0.059). The SDS decreases for LS BMD and LS BMC indicating a mean 
loss of over a quarter of a SDS in 6 months (Appendix A, Table A.2). 
 
4.3.1.4.2  Adult Cohort 
 
There were no significant changes in any parameters of the total body DXA scans 
(Appendix A, Table A.3). Although not significant, there was a mean increase in the total 
body LTM seen in the follow-up period which is in contrast to the mean decreases in total 
body LTM seen in the observation and WBVT periods. Segmental analysis of the total 
body DXA scans revealed a significant decrease in legs BMD, from 1.140 to 1.132 g/cm
2
 
(p=0.019) (Table 2.6). Similar to that seen in total body LTM, legs LTM also 
demonstrated non-significant mean increases in the follow-up period which was again in 
contrast to the mean decreases in these parameters seen in the observation and WBVT 
periods. The lumbar spine DXA scans found no significant changes in any parameters 
(Appendix A, Table A.3). 
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4.3.1.4.3  Leigh Syndrome Cohort 
 
 
There were no significant changes in the total body DXA scans (Appendix A, Table A.4). 
Segmental analysis of the total body DXA scans demonstrated a significant increase in 
legs BMC from 495.8 to 507.5g (p=0.016) and non-significant increases in legs BA and 
legs LTM, p=0.079 and 0.061 respectively (Table 4.7 and Appendix A, Table A.4). The 
increases in legs BMC and legs BA were approximately two thirds of the increases seen 
with WBVT however the increase in legs LTM was approximately double that seen 
during the WBVT period. Analysis of the lumbar spine did not reveal any significant 
changes in any parameters (Appendix A, Table A.4).  
 
4.3.2 Tibial pQCT 
 
 
4.3.2.1 Baseline 
 
The pQCT scans were not performed at Visit 1 (baseline) so baseline pQCT parameters 
were collected at Visit 2 (Start WBVT). Baseline pQCT parameters for the 3 cohorts are 
presented in Table 2.8. 
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Table 4.8. Baseline peripheral quantitative computed tomography parameters for the tibial 4%, 20% and 66% sites. Mean (SD). 
 Paediatric (n=6) Adult (n=12) Leigh Syndrome (n=5) 
4% Site Parameters 
Total BMC (mg/mm) 119.8 (25.4) 273.6 (53.6) 178.1 (94.6) 
Total CSA (mm
2
) 514.1 (181.8) 1076.8 (151.6) 654.8 (374.8) 
Total vBMD (mg/cm
3
) 246.800 (56.278) 257.550 (58.467) 278.580 (37.618) 
Trabecular BMC (mg/mm) 32.5 (10.7) 94.4 (23.0) 48.3 (31.7) 
Trabecular CSA (mm
2
) 231.2 (81.8) 484.5 (68.2) 294.6 (168.6) 
Trabecular vBMD (mg/cm
3
) 146.120 (35.076) 197.250 (50.746) 163.380 (42.853) 
Trabecular vBMD SDS -2.8 (1.1)   
Periosteal Circumference (mm) 79.3 (14.4) 116.1 (8.1) 87.78(25.7) 
20% Site Parameters 
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Total BMC (mg/mm) 119.8 (19.0) 225.7 (34.8) 160.5 (62.4) 
Total CSA (mm
2
) 227.8 (71.7) 341.7 (46.2) 248.4 (106.7) 
Total vBMD (mg/cm
3
) 560.133 (149.659) 663.750 (82.917) 654.920 (59.221) 
Cortical BMC (mg/mm) 100.4 (19.2) 207.0 (33.3) 144.7 (62.4) 
Cortical BMC SDS -0.3 (1.4)   
Cortical CSA (mm
2
) 91.7 (16.1) 175.9 (27.8) 126.9 (49.3) 
Cortical CSA SDS -1.1 (1.3)   
Cortical vBMD (mg/cm
3
) 1092.717 (26.841) 1176.358 (27.336) 1122.740 (57.253) 
Cortical vBMD SDS 3.4 (1.4)   
Cortical Thickness (mm) 2.0 (0.5) 3.2 (0.5) 2.7 (0.5) 
Cortical Thickness SDS 0.141 (2.302)   
Periosteal Circumference (mm) 52.9 (8.4) 65.4 (4.5) 54.8 (11.9) 
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Periosteal Circumference SDS -1.5 (1.5)   
Cortical CSMI p (mm
4
) 4688.5 (1963.0) 15026.9 (390.6) 8267.3 (7024.0) 
Cortical SSI p (mm
3
) 454.7 (140.8) 1182.1 (225.3) 725.3 (505.4) 
Total CSMI p (mm
4
) 6277.5 (2728.7)   
Total SSI p (mm
3
) 501.3 (159.9)   
Total SSI p SDS -0.9 (0.7)   
66% Site Parameters 
Total BMC (mg/mm) 149.9 (25.3) 341.7 (55.0) 212.8 (105.0) 
Total CSA (mm
2
) 293.2 (75.7) 582.3 (97.0) 389.2 (223.0) 
Total CSA SDS -0.8 (0.4)   
Total vBMD (mg/cm
3
) 525.100 (82.078) 594.992 (96.813) 565.240 (67.949) 
Cortical BMC (mg/mm) 120.8 (22.1) 289.8 (56.3) 173.3 (86.7) 
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Cortical BMC SDS -2.0 (1.0)   
Cortical CSA (mm
2
) 113.6 (19.9) 251.8 (48.3) 158.4 (70.2) 
Cortical CSA SDS -2.3 (0.8)   
Cortical CSA: Total CSA (%) 40.0 (7.8) 43.8 (8.1) 43.0 (6.5) 
Cortical vBMD (mg/cm
3
) 1063.083 (58.076) 1151.100 (24.954) 1072.260 (67.828) 
Cortical vBMD SDS 2.0 (2.0)   
Cortical Thickness (mm) 2.3 (0.4) 3.6 (0.7) 2.7 (0.5) 
Cortical Thickness SDS -1.8 (1.4)   
Periosteal Circumference (mm) 57.6 (0.1) 82.5 (7.1) 64.9 (19.6) 
Cortical CSMI p (mm
4
) 8084.9 (3118.9) 37210.9 (11711.5) 18037.2 (17297.7) 
Cortical CSMI p SDS -2.2 (0.2)   
Cortical SSI p (mm
3
) 617.6 (202.1) 2016.3 (456.1) 1086.9 (866.1) 
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Cortical SSI p SDS -1.8 (0.5)   
Soft Tissue Total CSA (mm
2
) 4801.2 (546.9) 8726.3 (1435.1) 6364.1 (2455.1) 
Muscle CSA (mm
2
) 2686.1 (513.3) 5225.4 (1017.4) 3784.6 (1886.7) 
Muscle CSA SDS -1.0 (0.6)   
Fat CSA (mm
2
) 1815.3 (408.5) 2874.0 (1122.5) 2171.7 (540.0) 
Fat CSA: Muscle CSA (%) 70.3 (21.6) 56.7 (22.6) 66.6 (26.1) 
Muscle CSA: Soft Tissue Total 
CSA (%) 
55.8 (7.3) 60.3 (8.8) 57.5 (8.8) 
Cortical CSA: Muscle CSA (%) 4.3 (0.8) 4.9 (0.8) 4.3 (0.7) 
Cortical BMC: Muscle CSA 
(mg/mm
2
) 
0.046 (0.009) 0.056 (0.009) 0.046 (0.007) 
Cortical BMC: Muscle CSA 
SDS 
-3.1 (8.1)   
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Note: BMC, bone mineral content; CSA, cross sectional area; vBMD, volumetric bone mineral density; SDS, standard deviation 
score; CSMI, cross sectional moment of inertia; p, referring to the polar measurement; SSI, stress strain index.
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4.3.2.1.1  Paediatric Cohort 
 
Baseline pQCT parameters for 6 of the 7 paediatric participants are presented in Table 
4.8 and Figure 4.2. At the 4% site, vBMD of the trabecular bone was abnormally low, 
with a SDS of -2.8, which was significantly reduced compared to the reference 
population and indicated that the trabecular compartment at the 4% site was osteoporotic 
in the paediatric cohort. All participants had a SDS <-1 and 2/6 (33%) had a SDS <-2. 
 
Analysis of the 20% site found that the mean cortical bone SDS were within the normal 
range for BMC and the bone’s geometric attributes including CSA, cortical thickness and 
periosteal circumference, and not significantly different to the reference population.  The 
SDS for cortical vBMD was abnormally high at 3.4 and significantly higher than the 
reference population. The SDS was >1 in 2/6 (33%), >2 in 1/6 (17%) and <-1 in 1/6 
(17%) of the paediatric cohort. Analysis of bone strength at the 20% tibial site found that 
the SDS for the polar measurement of SSI was significantly lower than the reference 
population. 
 
At the 66% site, the SDS for cortical BMC, -2.0, was outside the normal range and 
significantly lower than the reference population. Bone geometry was also compromised 
with the SDS for cortical CSA (-2.3) and cortical thickness (-1.8) falling outside of the 
normal range and significantly lower than the reference population. Furthermore, the 
SDS for total bone CSA (-0.8) was also significantly reduced compared to the reference 
population. The SDS for cortical vBMD, 2.0, was abnormally high compared to the 
reference population but did not reach significance, p=0.055. The SDS was >1 in 5/6 
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(83%) and > 2 in 3/6 (50%) of the paediatric cohort. As a consequence of compromised 
geometry and elevated cortical vBMD, bone strength was impaired at the 66% site. The 
SDS for the polar CSMI and polar SSI were abnormally low at -2.2 and -1.8 respectively, 
and significantly lower than the reference population. Compositional analysis revealed 
that the muscle CSA SDS was within normal limits at -1.0 but was significantly lower 
than the reference population. The SDS for the cortical BMC: muscle CSA ratio was 
abnormally low at -3.1, but not significantly reduced compared to the reference 
population. 
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Figure 4.3. Standard deviation (SD) scores for peripheral quantitative computed 
tomography (pQCT) parameters in the paediatric cohort. Mean and 95% confidence 
interval. Parameters shown in red were significantly different to the reference population 
on one-sample t-tests, p<0.05. 
 
4.3.2.1.2  Adult Cohort 
 
Baseline pQCT parameters for the 12 adult participants are presented in Table 4.5. All 
4% site parameters were greater in magnitude in the adult cohort compared to the 
paediatric cohort, consistent with bone modelling during childhood and adolescence. 
Comparison of the 4% site total vBMD of MRCD adults with control data from Dr 
Ferretti and colleagues found that the values for MRCD males but not females were 
significantly reduced compared to healthy controls (Figure 4.3). 
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Figure 4.4. Total volumetric bone mineral density (vBMD) at the 4% tibial site for 
control and MRCD adult males and females. Mean and SD. PreMP, pre-menopausal; 
PostMP, post-menopausal. *** p<0.005. Graph prepared by Dr Ferretti and colleagues. 
 
Analysis of the 20% site found that all pQCT parameters were greater in the adult cohort 
compared to the paediatric cohort, consistent with bone modelling during growth. When 
comparing the data from the adult cohort to that of the healthy control data from Dr 
Ferretti and colleagues for the 20% site, it was found that cortical BMC was significantly 
reduced in MRCD males but not females (Figure 4.4). Cortical bone geometry, including 
CSA, cortical thickness and periosteal circumference, were significantly smaller in both 
MRCD males and females compared to healthy controls (Figures 4.5 - 4.7). Cortical 
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vBMD was significantly increased in all MRCD participants (Figure 4.8). When 
exploring the correlation between cortical CSA and cortical BMC at the 20% site, a site 
that is not influenced by any allometric associations [126], the MRCD adult cohort had 
significantly higher cortical BMC for CSA compared to controls indicating a 
significantly greater vBMD (Figure 4.9).   
 
 
 
Figure 4.5. Cortical bone mineral content at the 20% tibial site for control and MRCD 
adult males and females. Mean and SD. **p<0.01. Graph prepared by Dr Ferretti and 
colleagues. 
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Figure 4.6. Cortical bone cross sectional area at the 20% tibial site for control and 
MRCD adult males and females. Mean and SD. **p<0.01, ***p<0.005. Graph prepared 
by Dr Ferretti and colleagues. 
 
   
Figure 4.7. Cortical thickness at the 20% tibial site for control and MRCD adult males 
and females. Mean and SD. PreMP, pre-menopausal; PostMP, post-menopausal. *** 
p<0.005, **p<0.01. Graph prepared by Dr Ferretti and colleagues. 
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Figure 4.8. Periosteal circumference at the 20% tibial site for control and MRCD adult 
males and females. Mean and SD.*** p<0.005. Graph prepared by Dr Ferretti and 
colleagues. 
 
Figure 4.9. Cortical volumetric bone mineral density (vBMD) at the 14-20% tibial site 
for control and MRCD adult males and females. Mean and SD. PreMP, pre-menopausal; 
PostMP, post-menopausal. *** p<0.005. Graph prepared by Dr Ferretti and colleagues. 
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Figure 4.10. Cortical cross-sectional area (CSA) and cortical bone mineral content 
(BMC) at the 20% tibial site for control and MRCD adult males and females. Mean and 
SD. PreMP, pre-menopausal; PostMP, post-menopausal. Dashed line represents controls 
and solid line represents the MRCD cohort. ANCOVA analysis of the two equations 
indicated they were significantly different, p<0.0001. Graph prepared by Dr Ferretti and 
colleagues. 
 
 
Similar to that seen in the paediatric MRCD cohort, smaller bone geometry and increased 
cortical vBMD caused reduced bone strength in MRCD adults. Polar CSMI at the 20% 
site was significantly reduced in MRCD men and pre-menopausal women compared to 
controls but not in post-menopausal women (Figure 4.10). CSMI were further 
investigated using distribution-mass and distribution-quality curves which also reflect the 
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functioning of an individual’s mechanostat [118, 126]. In the reference population, the 
distribution mass curves did not differ according to gender or weight-bearing physical 
activity status, indicating a consistent physiological adaptation of the bone to the 
mechanical loads to which it is exposed [126], a response governed by the intact 
mechanostat. The distribution-mass curves at the 20% tibial pQCT site for the adult 
MRCD cohort demonstrate that this relationship was disrupted and there was a clear 
disadvantage, compared to reference population, in how well the mechanostat used the 
available cortical bone mass (Figure 4.11) and CSA (Figure 4.12) to optimise cross-
sectional geometry and achieve the greatest CSMI. The equations representative of the 
MRCD cohort were shifted downwards but remained essentially parallel to the equations 
representative of the reference population, indicating the polar CSMI for the same 
cortical CSA and BMC in MRCD adults was significantly reduced compared to their 
healthy counterparts. When the MRCD data were plotted on the distribution-quality 
curve, which demonstrates the inverse relationship between cortical vBMD, or bone 
stiffness, and the ability to resist torsion forces [126] at the 20% pQCT site, the MRCD 
data plotted within the normal relationship for both males and females, albeit in the lower 
right hand corner, indicating that their abnormally high cortical vBMD values reduces the 
polar CSMI values and therefore the ability of their bone cortices to resist torsion forces 
(Figure 4.13). The data points do however follow the reference curves indicating that the 
mechanostat is directing the geometric distribution of cortical bone tissue in accordance 
with the stiffness of the diaphyseal bone and that the behaviour of the mechanostat is 
congruent with the reference population, albeit below the lower limits seen in the 
reference population. Bone strength at the 20% site was further investigated using the 
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buckling ratio, a reflection of the bone’s ability to resist compressive stress. It is the ratio 
of the bone’s outer radius and cortical thickness, a higher ratio indicating greater 
likelihood of failure in buckling. The ratio in the adult MRCD cohort was significantly 
increased compared to the reference population (Figure 4.14), likely due to their reduced 
cortical thickness compared to the reference population. Furthermore, the risk of fracture 
in the adult cohort will be significantly increased as cortical thickness decreases. 
 
 
Figure 4.11. Polar CSMI at the 20% tibial site for control and MRCD adult males and 
females. Mean and SD. PreMP, pre-menopausal; PostMP, post-menopausal. *** 
p<0.005, **p<0.01. Graph prepared by Dr Ferretti and colleagues. 
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Figure 4.12. Distribution-mass curve: Cortical cross-sectional area and polar cross-
sectional moment of inertia (CSMI) at the 20% tibial site for control and MRCD adult 
males and females. PreMP, pre-menopausal; PostMP, post-menopausal. ANCOVA 
analysis found the control and MRCD equations were significantly different, p=0.04. 
Graph prepared by Dr Ferretti and colleagues. 
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Figure 4.13. Distribution-mass curve: cortical bone mineral content and polar cross-
sectional moment of inertia (CSMI) at the 20% tibial site for control and MRCD adult 
males and females. PreMP, pre-menopausal; PostMP, post-menopausal. ANCOVA 
analysis found the control and MRCD equations were significantly different, p=0.009. 
Graph prepared by Dr Ferretti and colleagues. 
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Figure 4.14. Distribution-quality curve: cortical volumetric bone mineral density 
(vCtBMD) and polar cross-sectional moment of inertia (CSMI) at the 20% tibial site for 
control and MRCD adult males and females. PreMP, pre-menopausal; PostMP, post-
menopausal. Graph prepared by Dr Ferretti and colleagues. 
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Figure 4.15. Buckling ratio at the 20% tibial site for control and MRCD adult males and 
females. Mean and SD. PreMP, pre-menopausal; PostMP, post-menopausal. *** 
p<0.005, **p<0.01. Graph prepared by Dr Ferretti and colleagues. 
 
At the 66% site, all total and cortical bone and composition parameters were greater in 
the adult cohort compared to the paediatric cohort, as would be expected for the mature 
adult musculoskeletal system compared to the evolving child and adolescent 
musculoskeletal system. The only exception was the ratio of fat CSA: muscle CSA, 
which was lower in the adult cohort. The adult cohort had a mean fat CSA of 28.74cm
2
 
(Table 4.5) which is between the mean values seen in healthy adult males, 18.2cm
2
, and 
adult females 34.2cm
2
 [720], however fat CSA as a percentage of muscle CSA had a 
mean value of 56.7% (Table 2.5), much higher than the 20% and 47% seen in the healthy 
 329 
adults [720]. When comparing the adult MRCD cohort to the healthy control data for the 
66% site provided by Dr Ferretti and colleagues, cortical CSA was significantly reduced 
in males but not females (Figure 4.15) and muscle CSA was significantly reduced in 
males and post-menopausal females but not pre-menopausal females (Figure 4.16).  
When analysing the correlation between muscle CSA and cortical CSA at the 66% site 
(Figure 4.17), the MRCD data plotted within 2 standard deviations of the mean of the 
reference population, indicating preserved muscle bone proportions and an intact 
anthropometric and biomechanical relationship between muscle and bone. 
 
 
Figure 4.16. Cortical cross-sectional area at the 66% tibial site for control and MRCD 
adult males and females. Mean and SD. PreMP, pre-menopausal; PostMP, post-
menopausal. ***p<0.005. Graph prepared by Dr Ferretti and colleagues. 
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Figure 4.17. Muscle cross-sectional area at the 66% tibial site for control and MRCD 
adult males and females. Mean and SD. PreMP, pre-menopausal; PostMP, post-
menopausal. **p<0.01, *p<0.05. Graph prepared by Dr Ferretti and colleagues. 
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Figure 4.18. Muscle cross-sectional area and cortical cross-sectional area of the tibia and 
fibula at the 66% tibial site for control and MRCD adult males and females. Bands 
indicate 1, 2 and 3 standard deviation score units around either side of the regression line. 
PreMP, pre-menopausal; PostMP, post-menopausal. Graph prepared by Dr Ferretti and 
colleagues. 
 
4.3.2.1.3 Leigh Syndrome Cohort 
 
Baseline pQCT parameters for the 5 Leigh Syndrome participants are presented in Table 
4.5. At all three tibial pQCT sites, all bone and composition parameters were larger than 
the paediatric but smaller than the adult sub-cohorts, indicating the mixed nature of the 
Leigh Syndrome Cohort, comprised of both paediatric and adult participants. One 
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exception was total bone vBMD at the 4% pQCT site, which was highest in the Leigh 
Syndrome cohort. As trabecular bone vBMD in the paediatric cohort and total bone 
vBMD in the adult cohort were significantly reduced compared to reference populations 
at this site, this result may indicate that bone deficits in the trabecular compartment may 
not be as severe in Leigh Syndrome compared to other MRCD. 
 
4.3.2.2 Whole Body Vibration Training (WBVT) Period 
 
Analysis data for all tibial pQCT parameters for the 3 sub-cohorts during the WBVT 
period, Visit 2 to Visit 3, can be found in Appendix B.  
 
4.3.2.2.1 Paediatric Cohort 
 
Analysis data for the 4%, 20% and 66% tibial pQCT sites for the paediatric cohort can be 
found in (Table 4.9 and Appendix B, Table B.2). After WBVT there was a significant 
increase in total bone BMC at the 4% site from 126.0-135.2 mg/mm, p=0.009. No other 
total bone or trabecular bone parameters at the 4% site changed significantly after 
WBVT. 
 
Analysis of the 20% site demonstrated significant improvements in total and cortical 
bone parameters. Total bone BMC and vBMD increased significantly: 119.8 - 126.9 
mg/mm, p<0.000; and 560.133 - 587.017 mg/cm
3
, p=0.005 respectively. In the cortical 
compartment at the 20% site there were significant improvements in: BMC and BMC 
SDS from 100.4 - 109.2 mg/mm, p<0.000 and -0.3 - 0.4, p=0.001 respectively; CSA and 
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CSA SDS of 91.7 - 98.5 mm
2
, p<0.000 and -1.1 to -0.5, p=0.002 respectively; vBMD 
from 1092.717 - 1106.150 mg/cm
3
, p=0.049; and cortical thickness and cortical thickness 
SDS from 2.0 - 2.2 mm, p=0.001 and 0.1 - 0.7, p=0.008 respectively. Bone strength also 
increased significantly after WBVT. Polar CSMI and polar SSI of the cortical bone 
increased from 4688.5 - 4997.5 mm
4
, p=0.017, and from 454.7 - 490.1 mm
3
, p=0.002 
respectively. Polar SSI of the total bone and its corresponding SDS also increased 
significantly from 501.3 - 532.8 mm
3
, p=0.002, and -1.0 to -0.6, p=0.002 respectively. 
The improvement in the total bone polar SSI SDS representing nearly half a SDS. 
 
WBVT also resulted in significant changes to the total, and cortical bone compartments 
as well as composition parameters at the 66% site. Total bone BMC increased from 149.9 
- 156.7 mg/mm, p<0.000. Cortical bone BMC and CSA and their corresponding SD 
scores increased significantly from: 120.8 - 126.3 mg/mm, p=0.036; -2.0 to -1.7, 
p=0.029; 113.6 - 117.3 mm
2
, p=0.020; and -2.3 to -2.1, p=0.021 respectively. The 
favourable geometric adaptation in cortical bone CSA after WBVT, resulted in 
improvements in bone strength parameters. The polar measurements of cortical CSMI 
and SSI as well as their corresponding SDS increased significantly from: 8084.9 - 8801.3 
mm
4
, p=0.021; -2.2 to -1.1, p=0.010; 617.6 - 662.7 mm
3
, p<0.001; and -1.7 to -1.4, 
p<0.001 respectively. Muscle CSA, muscle CSA SDS and total soft tissue CSA also 
increased significantly during the WBVT period: 2686.1 - 2831.7 mm
2
, p=0.014; -1.0 to -
0.8, p=0.014; and 4801.2 - 5024.8 mm
2
, p=0.017 respectively.
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Table 4.9. pQCT parameters for the paediatric cohort MRCD cohort at each visit, changes between visits and p values. *p<0.05 
  4% Total 
BMC 
(mg/mm) 
20% Total 
BMC 
(mg/mm) 
20% Total 
vBMD 
(mg/ccm) 
20% Cortical 
BMC 
(mg/mm) 
20% Cortical 
BMC SDS 
20% Cortical 
CSA (mm
2
) 
Visit 2 
Value 125.989 119.797 560.133 100.440 -0.321 91.707 
Δ with WBVT 9.238 7.083 26.883 8.718 0.692 6.827 
p 0.009* 0.000* 0.005* 0.000* 0.001* 0.000* 
Visit 3 
Value 135.227 126.880 587.017 109.158 0.371 98.533 
Δ in Follow-up -1.348 2.388 0.967 1.993 0.119 1.840 
p 0.610 0.068 0.901 0.190 0.437 0.202 
Visit 4 Value 133.878 129.268 587.983 111.152 0.490 100.373 
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20% Cortical 
CSA SDS 
20% Cortical 
vBMD 
(mg/ccm) 
20% Cortical 
Thickness 
(mm) 
20% Cortical 
Thickness SDS 
20% Cortical 
CSMI p 
(mm
4
) 
20% Cortical 
SS1p (mm
3
) 
Visit 2 
Value -1.065 1092.717 2.039 0.141 4688.530 454.669 
Δ with WBVT 0.562 13.433 0.155 0.561 308.982 35.442 
p 0.002* 0.049* 0.001* 0.008* 0.017* 0.002* 
Visit 3 
Value -0.504 1106.150 2.194 0.702 4997.512 490.111 
Δ in Follow-up 0.123 1.000 0.020 0.057 183.673 16.132 
p 0.363 0.871 0.567 0.728 0.118 0.081 
Visit 4 Value -0.381 1107.150 2.214 0.759 5181.185 506.243 
        
        
 336 
        
  
20% Total 
SS1p (mm
3
) 
20% Total 
SS1p SDS 
66% Total 
BMC 
(mg/mm) 
66% Total 
CSA (mm
2
) 
66% Total 
CSA SDS 
66% Cortical 
BMC 
(mg/mm) 
Visit 2 
Value 501.269 -0.992 149.850 293.173 -0.839 120.813 
Δ with WBVT 31.561 0.319 6.840 15.307 0.259 5.528 
p 0.002* 0.002* 0.000* 0.133 0.161 0.036* 
Visit 3 
Value 532.830 -0.603 156.690 308.480 -0.580 126.342 
Δ in Follow-up 1.470 0.008 1.807 19.440 0.383 0.443 
p 0.851 0.911 0.172 0.065 0.049* 0.850 
Visit 4 Value 534.3 -0.594 158.497 327.920 -0.198 126.785 
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20% Total 
SS1p (mm
3
) 
20% Total 
SS1p SDS 
66% Total 
BMC 
(mg/mm) 
66% Total 
CSA (mm
2
) 
66% Total 
CSA SDS 
66% Cortical 
BMC 
(mg/mm) 
Visit 2 
Value 501.269 -0.992 149.850 293.173 -0.839 120.813 
Δ with WBVT 31.561 0.319 6.840 15.307 0.259 5.528 
p 0.002* 0.002* 0.000* 0.133 0.161 0.036* 
Visit 3 
Value 532.830 -0.603 156.690 308.480 -0.580 126.342 
Δ in Follow-up 1.470 0.008 1.807 19.440 0.383 0.443 
p 0.851 0.911 0.172 0.065 0.049* 0.850 
Visit 4 Value 534.3 -0.594 158.497 327.920 -0.198 126.785 
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20% Total 
SS1p (mm
3
) 
20% Total 
SS1p SDS 
66% Total 
BMC 
(mg/mm) 
66% Total 
CSA (mm
2
) 
66% Total 
CSA SDS 
66% Cortical 
BMC 
(mg/mm) 
Visit 2 
Value 501.269 -0.992 149.850 293.173 -0.839 120.813 
Δ with WBVT 31.561 0.319 6.840 15.307 0.259 5.528 
p 0.002* 0.002* 0.000* 0.133 0.161 0.036* 
Visit 3 
Value 532.830 -0.603 156.690 308.480 -0.580 126.342 
Δ in Follow-up 1.470 0.008 1.807 19.440 0.383 0.443 
p 0.851 0.911 0.172 0.065 0.049* 0.850 
Visit 4 Value 534.3 -0.594 158.497 327.920 -0.198 126.785 
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66% Cortical 
BMC SDS 
66% Cortical 
CSA (mm
2
) 
66% Cortical 
CSA SDS 
66% 
Periosteal 
Circumference 
(mm) 
66% Cortical 
CSMI p 
(mm
4
) 
66% Cortical 
CSMI p SDS 
Visit 2 
Value -2.023 113.600 -2.263 57.610 8084.868 -2.209 
Δ with WBVT 0.298 3.680 0.192 1.350 716.471 0.115 
p 0.029* 0.020* 0.021* 0.133 0.021* 0.010* 
Visit 3 
Value -1.725 117.280 -2.072 58.960 8801.340 -2.094 
Δ in Follow-up 0.053 1.600 0.099 1.906 778.948 0.145 
p 0.662 0.256 0.190 0.044* 0.014* 0.003* 
Visit 4 Value -1.672 118.880 -1.973 60.866 9580.288 -2.209 
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66% Cortical 
SSI p (mm
3
) 
66% Cortical 
SSI p SDS 
66% Soft 
Tissue Total 
CSA (mm
2
) 
66% Muscle 
CSA (mm
2
) 
66% Muscle 
CSA SDS 
66% Fat 
CSA (mm
2
) 
Visit 2 
Value 617.598 -1.746 4801.227 2686.133 -1.029 1815.253 
Δ with WBVT 45.146 0.333 223.573 145.573 0.248 61.920 
p 0.000* 0.002* 0.017* 0.014* 0.015* 0.267 
Visit 3 
Value 662.744 -1.413 5024.800 2831.707 -0.781 1877.173 
Δ in Follow-up 25.420 0.168 149.760 2.187 0.041 129.120 
p 0.009* 0.060 0.084 0.965 0.636 0.034* 
Visit 4 Value 688.164 -1.245 5174.560 2833.893 -0.739 2006.293 
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66% Fat 
CSA:Muscle 
CSA (%) 
66% Muscle 
CSA:Total 
CSA (%) 
 
Visit 2 
Value 70.277 55.820 
Δ with WBVT -2.364 0.631 
p 0.292 0.329 
Visit 3 
Value 67.913 56.451 
Δ in Follow-up 4.939 -1.570 
p 0.043* 0.029* 
Visit 4 Value 72.852 54.881 
 
Note: Δ, change; 4%, referring to 4% tibial pQCT site; BMC, bone mineral content; CSA, cross-sectional area; vBMD, volumetric 
bone mineral density; 20%, referring to the 20% tibial pQCT site; CSMI, cross-section moment of inertia; p, referring to the polar 
measurement; SSI, stress strain index; 66%, referring to the 66% tibial pQCT site.   
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4.3.2.2.2 Adult Cohort 
 
In the adult cohort there were no significant changes in any parameters for the total or 
trabecular bone compartments at the 4% site. Similarly, there were no significant changes 
in any total or cortical bone parameters at the 20% and 66% sites (Appendix B, Table 
B.3). 
 
4.3.2.2.3 Leigh Syndrome Cohort 
 
Analysis data can be found in Table 4.10 and Appendix B, Table B.4. During the WBVT 
period, there were no significant changes in any parameters at the 4% site. At the 20% 
site the Leigh Syndrome cohort demonstrated significant changes in the cortical bone 
compartment after WBVT. Cortical BMC and cortical thickness increased significantly: 
144.8 - 149.6 mg/mm, p=0.027; and 2.66 - 2.75 mm, p=0.040 respectively. There was 
also a significant increase in the polar measurement of cortical SSI, 725.3 - 757.0 mm
3
, 
p=0.029. Analysis of the 66% site revealed significant increases in total and cortical bone 
BMC of 212.8 - 218.1 mg/mm, p=0.035 and 173.3 - 178.6mg/mm, p=0.033, respectively. 
Cortical CSA also increased significantly from 158.4 - 161.4 mm
2
, p=0.038. There were 
no other significant changes in any composition parameters. 
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Table 4.10. pQCT parameters for the Leigh Syndrome cohort at each visit, changes between visits and p values. *p<0.05. 
  20% Cortical BMC 
(mg/mm) 
20% Cortical 
Thickness (mm) 
20% Cortical SS1p 
(mm
3
) 
66% Total BMC 
(mg/mm) 
Visit 2 
Value 144.767 2.657 725.271 212.832 
Δ with WBVT 4.894 0.088 31.765 5.236 
p 0.027* 0.040* 0.029* 0.035* 
Visit 3 
Value 149.570 2.745 757.036 218.068 
Δ in Follow-up 0.506 0.017 6.004 2.688 
p 0.786  0.643 0.628 0.230 
Visit 4 Value 150.076 1125.100 763.040 220.756 
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66% Cortical BMC 
(mg/mm) 
66% Cortical CSA 
(mm
2
) 
66% Cortical CSMI 
p (mm
4
) 
 
Visit 2 
Value 173.260 158.400 18037.238 
Δ with WBVT 5.298 2.976 323.269 
p 0.033* 0.038* 0.100 
Visit 3 
Value 178.558 161.376 18360.507 
Δ in Follow-up 2.054 2.240 405.134 
p 0.347 0.099 0.048* 
Visit 4 Value 180.612 163.616 18765.640 
 
Note: Δ, change; BMC, bone mineral content; CSA, cross-sectional area; vBMD, volumetric bone mineral density; 20%, referring to 
the 20% tibial pQCT site; CSMI, cross-section moment of inertia; p, referring to the polar measurement; SSI, stress strain index; 66%, 
referring to the 66% tibial pQCT site.
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4.3.2.3 Follow-up Period 
 
4.3.2.3.1 Paediatric Cohort 
 
There were no significant changes in any parameters at the 4% site. All parameters 
demonstrated either a reduction in absolute value or the gains were blunted in comparison 
to gains seen during the WBVT period. At the 20% site, the significant improvements 
seen during the WBVT period were not maintained during the follow-up period and no 
significant changes occurred in any parameter. Analysis of the 66% site found continued 
significant changes in total bone, cortical bone and composition parameters. Total bone 
CSA showed a non-significant increase from 308.5 - 327.9 mm
2
, p=0.065 however the 
corresponding SDS increased significantly from -0.6 to -0.2, p=0.049. Associated with 
this increase in total bone CSA the periosteal circumference also increased significantly 
from 59.0 - 60.9 mm, p=0.044. The ongoing improvements in the geometric attributes of 
the tibia at the 66% resulted in further significant improvements in bone strength 
parameters. Polar CSMI and its corresponding SDS increased significantly from: 778.9 - 
9580.3 mm
4
, p=0.014; and -2.1 to -1.9, p=0.003 respectively. Polar SSI increased 
significantly, 662.7 - 688.2 mm
3
, p=0.009, however its corresponding SDS increase did 
not reach significance, -1.4 to -1.2, p=0.060. Fat CSA and the ratio of fat CSA: muscle 
CSA increased significantly in the follow-up period: 1877.2 - 2006.3 mm
2
, p=0.034; and 
67.9 - 72.8%, p=0.043 respectively. In contrast the ratio of muscle CSA: total soft tissue 
CSA decreased significantly from 56.5 - 54.9%, p=0.029 (Table 4.9 and Appendix B, 
Table B.2). 
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4.3.2.3.2  Adult Cohort 
 
There were no significant changes in any parameters at the 4% or 20% tibial pQCT sites. 
At the 66% site there were significant decreases in cortical CSA, cortical thickness and 
the ratio of cortical CSA: total bone CSA: 252.7 - 251.0 mm
2
, p=0.033; 3.6 - 3.5 mm, 
p=0.015; and 43.9 - 43.5%, p=0.019 respectively (Table 4.13 and Appendix B, Table 
B.3). 
 
Table 4.11. pQCT parameters for the adult MRCD cohort at each visit, changes between 
visits and p values. *p<0.05. 
  66% Cortical 
CSA (mm
2
) 
66% Cortical 
CSA:Total 
CSA (%) 
66% Cortical 
Thickness 
(mm) 
Visit 2 
Value 251.773 43.808 3.556 
Δ with WBVT 0.947 0.105 0.008 
p 0.220 0.497 0.529 
Visit 3 
Value 252.720 43.913 3.564 
Δ in Follow-up -1.707 -0.387 -0.031 
p 0.033* 0.019* 0.015* 
Visit 4 Value 251.013 43.526 3.532 
Note: Δ, change; 66%, referring to the 66% tibial pQCT site; CSA, cross-sectional area. 
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4.3.2.3.3 Leigh Syndrome Cohort 
 
Analysis did not reveal significant changes in any parameters at the 4% or 20% tibial 
pQCT sites. At the 66% site, there was a significant increase in polar CSMI from 18360.5 
- 18765.6 mm
3
, p=0.048 (Appendix B, Table B.4). 
 
4.3.3 Bone Turnover Markers and Serum Biochemistry 
 
 
4.3.3.1 Baseline 
 
 
Baseline parameters for serum biochemistry and bone turn-over markers are presented in 
Table 2.12. Serum alkaline phosphatase (ALP) was within normal reference ranges for all 
participants except for one paediatric participant, number 14, who had ALP levels below 
the normal reference range throughout the study. The paediatric and Leigh Syndrome 
cohorts had higher ALP levels than the adult cohort, consistent with bone modelling. 
Calcium and phosphate were within normal reference ranges in all participants and did 
not differ between cohorts. Thirteen of the 19 participants registered lactate levels above 
the normal reference range at least once during the study period, and 6 of these 
participants (participants 1, 2, 16, 18, 19 and 21) had consistently high lactate levels. Ten 
of the 13 patients with high lactate levels had at least one pyruvate reading above the 
normal reference range, with 3 of these participants (participants 18, 19 and 21) 
consistently registering high pyruvate levels. Mean lactate levels were above the normal 
reference range in the adult and paediatric cohorts indicating OXPHOS dysfunction, with 
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the adult cohort having the greatest mean lactate level. In contrast, the mean lactate in the 
Leigh Syndrome cohort was lower and within the normal reference range.  
 
Osteocalcin levels were transiently higher than the normal reference range in 4 paediatric 
participants (participants 1, 2, 5 and 19) and transiently lower than the normal reference 
range in one paediatric participant (participant 5). All adult participants had at least one 
osteocalcin level lower than normal reference range. In three adult participants 
(participants 3, 4 and 8) the low levels were transient however the remaining 9 adult 
participants had consistently low osteocalcin levels throughout the study period. Mean 
osteocalcin levels were highest in the paediatric cohort and lowest in the adult cohort, 
again consistent with bone modelling in the paediatric cohort. Vitamin D levels were 
maintained above 50 pmol/L for the duration of the study in all participants except for 
participants 14 and 20 who had levels of 47 and 48 pmol/L respectively at visit 4 which 
occurred during the winter months. The urinary deoxypyridinoline:creatinine ratio was 
higher than the normal reference range at least once in 13 of the 19 participants 
(participants 2-6, 8, 12, 15-18, 20 and 21), and 8 of these participants had values higher 
than the normal range at least 3 of the 4 times they were tested. One paediatric participant 
(participant 17) had one urinary deoxypyridinoline:creatinine ratio that was below the 
normal reference range. The paediatric cohort had the highest urinary 
deoxypyridinoline:creatinine ratio, more than double that of the adult cohort that had the 
lowest urinary deoxypyridinoline:creatinine ratio, indicating higher bone turnover during 
the paediatric years reflecting bone modelling. 
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4.3.3.2 Study Periods 
 
 
Analysis data for bone turnover markers and serum biochemistry in the three cohorts 
during the observation, WBVT and follow-up periods can be found in Appendix C. 
 
4.3.3.2.1 Paediatric Cohort 
 
During the observation period, serum vitamin D decreased significantly from 106.0 - 83.4 
pmol/L, p=0.018 however this level was still well within the normal reference range, and 
above the minimum accepted value of 50pmol/L. Osteocalcin levels decreased 
significantly during the WBVT period from 6.9 - 4.0nmol/L, p=0.002, and phosphate 
decreased significantly during the follow-up period from 1.532 - 1.427mmol/L, p=0.042, 
however these remained within the normal reference ranges (Table 4.13). There were no 
statistically significant changes in any other bone turnover markers or serum 
biochemistry parameters in any of the study periods (Appendix C, Table C.2). 
 
4.3.3.2.2 Adult Cohort 
 
There were no statistically significant changes in bone turnover markers or serum 
biochemistry during the observation, WBVT or follow-up periods (Appendix C, Table 
C.3). 
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Table 4.12. Baseline Serum Biochemistry and Bone Turnover Marker Parameters. Mean (SD). 
 Paediatric (n=7) Adult (n=12) Leigh Syndrome (n=5) 
Alkaline Phosphatase (U/L) 155.3 (61.5) 74.9 (16.0) 155.8 (78.5) 
Calcium (mmol/L) 2.4 (0.1) 2.4 (0.1) 2.4 (0.1) 
Phosphate (mmol/L) 1.5 (0.1) 1.2 (0.2) 1.3 (0.2) 
Lactate (mmol/L) 3.4 (2.5) 3.6 (4.9) 1.5 (0.9) 
Osteocalcin (nmol/L) 6.4 (3.8) 1.6 (1.3) 4.6 (2.0) 
Vitamin D (pmol/L) 106.0 (36.2) 78.9 (17 7) 93.0 (31.8) 
Urinary Deoxypyridinoline: Creatine 
Ratio (nmol/mmol creatinine) 
17.2 (11.0) 8.0 (2.9) 13.4 (5.8) 
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Table 4.13. Bone turn-over markers and serum biochemistry parameters for the 
paediatric cohort at each visit, changes between visits and p values. *p<0.05. 
  Vitamin D 
(pmol/L) 
Osteocalcin 
(nmol/L) 
Phosphate 
(mmol/L) 
Visit 1 Value 106.0 6.4 1.5 
 
Δ in Observation -22.6 0.5 0.1 
p 0.018* 0.553 0.061 
Visit 2 Value 83.4 6.9 1.5 
 
Δ with WBVT -3.7 -2.8 -0.0 
p 0.670 0.002* 0.698 
Visit 4 Value 79.7 4.0 1.5 
 
Δ in Follow-up -8.0 -0.3 -0.1 
p 0.364 0.678 0.042* 
Visit 6 Value 71.7 3.7 1.4 
Note: Δ, change; WBVT, whole body vibration training. 
 
4.3.3.2.3  Leigh Syndrome Cohort 
 
During the observation period, phosphate increased significantly from 1.3 - 1.4mmol/L, 
p=0.006. There were no significant changes after WBVT, however, in the follow-up 
period, phosphate also decreased significantly 1.5 - 1.3mmlo/L, p<0.000 (Table 2.14). 
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Despite these changes, phosphate remained within the normal reference range throughout 
the study. There were on other statistically significant changes in bone turnover markers 
or serum biochemistry in any of the study periods (Appendix C, Table C.4). 
 
 
Table 4.14. Bone turn-over markers and serum biochemistry parameters for the Leigh 
Syndrome cohort at each visit, changes between visits and p values. *p<0.05. 
  Phosphate (mmol/L) 
Visit 1 Value 1.3 
 
Δ in Observation 0.1 
p 0.006* 
Visit 2 Value 1.4 
 
Δ with WBVT 0.0 
p 0.291 
Visit 4 Value 1.5 
 
Δ in Follow-up -0.2 
p 0.000* 
Visit 6 Value 1.3 
 
Note: Δ, change; WBVT, whole body vibration training. 
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4.4 Force Plate Parameters 
 
 
4.4.1 Baseline 
 
 
4.4.1.1 Paediatric Cohort 
 
 
Baseline parameters for the M1LJ, S2LJ and CRT performed on the force plate are 
presented in Table 2.12 and Figure 2.18. The M1LJ gives information about the 
maximum force the leg muscles of an individual can produce, the S2LJ gives information 
about the maximum power the leg muscles of an individual can generate, and the CRT 
gives information about functional performance of the leg muscles in an everyday task. 
Only 2 paediatric participants were able to perform the M1LH and only 4 the S2LJ. This 
data has been presented to provide information about muscle function in the paediatric 
MRCD cohort in relation to the adult MRCD cohort and the reference population. No 
further analysis was performed on the data as the sample size was too small.   
 
It is clear the ability of the leg muscles to produce force in the paediatric cohort was 
severely impaired as only 2 of 7 participants could perform the manoeuvre. The force 
SDS for the 2 participants able to perform the test was abnormal and significantly 
reduced compared to the reference population, -2.6, p=0.040 (Table 4.15 and Figure 
4.18). Information from the S2LJ demonstrates that the ability of the leg muscles to 
generate power was also adversely affected in the paediatric cohort, impacting on muscle 
performance and efficiency. In the four paediatric participants able to perform the S2LJ, 
the SDS for EFI, FE and power were significantly lower than the reference population, 
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however the force SDS demonstrated a non-significant reduction: -5.3, p=0.001; -4.6, 
p=0.001; -4.7, p<0.000; and -1.6, p=0.119 respectively (Figure 2.18). These findings 
indicate inefficiency of muscle function and movement during the S2LJ. This dynamic 
manoeuvre demonstrates the inability of children with MRCD to use muscle force to 
generate power, superimposed on a reduced ability to produce normal muscle force. All 
S2LJ SDS parameters were lesser in value than the adult cohort indicating a greater 
functional impairment in this cohort of children with MRCD compared to adults with 
MRCD.  
 
The findings from the M1LH and S2LJ help to inform the observations seen when 
investigating a functional movement, the CRT. All 7 paediatric participants were able to 
perform this test. The SDS for CRT speed, power and force were found to be abnormally 
low and significantly lower than the reference population at: -6.4, p=0.036; -2.5, 
p<0.000; and -2.2, p=0.003 respectively. The compromised ability of children with 
MRCD to generate muscle force and power culminated in grossly abnormal performance 
in the CRT as reflected in the speed SDS. 
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Figure 4.19. Standard deviation (SD) scores for force plate parameters in the paediatric 
cohort. Mean and 95% confidence interval. Parameters shown in red were significantly 
different to the reference population on one-sample t-tests, p<0.05. 
 
4.4.1.2 Adult Cohort 
 
 
Baseline force plate parameters are presented in Table 4.12 and Figure 4.19. All but one 
of the adult participants was able to perform the M1LJ. The force SDS was abnormal and 
significantly decreased compared to the reference population, -4.4, p<0.001 (Figure 
4.19). This outcome is consistent with that seen in the paediatric MRCD cohort and 
indicates the leg muscles are unable to produce force normally in adults with MRCD. All 
of the adult participants were able to perform the S2LJ. The EFI, FE, power and force 
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SDS were all significantly lower than the reference population: -2.8, p<0.000; -3.4, 
p<0.000; -3.0, p<0.000; and -1.2, p=0.002 respectively (Figure 4.19), demonstrating 
similar impairments to those seen in the smaller paediatric cohort, confirming 
inadequacies of the muscle to produce force and generate power resulting in poor muscle 
efficiency in performing dynamic movements. All adult participants were also able to 
perform the CRT. The SDS for CRT speed, power and force were all significantly 
different to the reference population (Figure 4.19). The speed at which the CRT was 
significantly reduced, -3.4, p<0.001, however this was not as drastically reduced as the 
paediatric MRCD cohort. Power generated during the CRT was also significantly reduced 
compared to the reference population and more severely affected compared to the 
paediatric MRCD cohort, -2.7, p<0.001. The amount of force required to generate power 
during the CRT was significantly increased compared to the reference population, 2.9, 
p=0.016, indicating inefficiency in the ability of the leg muscles to perform the CRT. In 
contrast to the paediatric MRCD cohort, where force SDS indicated an inability of the leg 
muscles to produce adequate force during the CRT, the adult MRCD cohort was able to 
generate adequate force, however the amount of force required to perform this functional 
movement was significantly elevated compared to the reference population, a reflection 
of the poor efficiency of muscle work in adults with MRCD, as significantly more force 
was required to generate the power to perform the CRT. These results suggest that 
muscle function is more severely affected in the paediatric MRCD cohort compared to 
the adult MRCD cohort, reinforcing the more severe clinical presentations and disease 
progression often seen in children compared to adults with MRCD [279, 321, 384, 385]. 
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Figure 4.20. Standard deviation (SD) scores for force plate parameters in the adult 
cohort. Mean and 95% confidence interval. Parameters shown in red were significantly 
different to the reference population on one-sample t-tests, p<0.05. 
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Table 4.15. Baseline Force-plate parameters. Mean (SD). 
Multiple One-Leg Jump (M1LJ) Parameters 
 Paediatric (n=2) Adult (n=11) Leigh Syndrome (n=1) 
F max (kN) 5.9 (0.0) 11.8 (3.4)   10.4 
F max rel (g) 2.5 (0.1) 2.0 (0.5) 1.7 
Force SDS -2.6 (0.2) -4.4 (1.7) -5.4 
Single Two-Leg Jump (S2LJ) Parameters  
 Paediatric (n=4) Adult (n=12) Leigh Syndrome (n=2) 
EFI (%) 40.9 (8.3)  53.8 (20.0)  33.8 (1.7) 
EFI SDS -5.3 (0.9) -2.8 (1.4) -4.8 (0.1) 
FE (%) 53.0 (8.6) 65.8 (22.0) 47.8 (0.0) 
FE SDS -4.6 (0.8) -3.4 (2.2) -5.2 (0.0) 
P max (kW) 0.6 (0.1) 1.5 (0.8) 1.6 (0.3) 
P max rel (W/kg) 19.2 (3.9) 23.4 (11.4) 20.3 (1.0) 
Power SDS -4.7 (0.5) -3.0 (1.8) -5.3 (0.2) 
F max (kN) 0.6 (0.1) 1.3 (0.3) 1.3 (0.2) 
F max rel (N/kg) 19.2 (4.9) 20.0 (3.4) 17.3 (0.9) 
Force SDS -1.6 (1.5) -1.2 (1.0) -2.7 (0.3) 
Chair Rise Test (CRT) Parameters 
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 Paediatric (n=7) Adult (n=12) Leigh Syndrome (n=5) 
Time per test (s) 2.5 (1.3) 2.8 (1.2) 2.7 (1.2) 
V max (m/s) 0.7 (0.2) 0.7 (0.2) 0.6 (0.2) 
Speed SDS -6.4 (6.3) -3.4 (1.9) -4.1 (0.5) 
P max (W) 234.1 (90.0) 473.5 (14.9) 326.4 (203.7) 
P max rel (W/kg) 8.2 (2.4) 7.3 (3.1) 7.2 (2.1) 
Ave P max rel (W/kg) 7.1 (2.4) 6.8 (2.8) 6.4 (1.9) 
Power SDS -2.5 (0.8) -2.7 (1.3) -2.6 (0.8) 
F max (kN) 1.3 (0.2) 1.2 (0.1) 1.2 (0.2) 
F max rel (N/kg) 49.5 (2.1) 19.7 (5.7) 39.9 (33.0) 
Ave F max rel (g) 1.3 (0.1) 1.2 (0.1) 1.2 (0.1) 
Force SDS -2.2 (1.2) 2.9 (3.6) -1.8 (1.4) 
 
Note: SDS, standard deviation score; V max, maximum velocity; P max, maximum 
power; P max rel, maximum power in relation to body weight; F max, maximum force; F 
max rel, maximum relative force in relation to body weight; EFI, Esslinger Fitness Index; 
FE, Force Efficiency.  
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4.4.1.3  Leigh Syndrome Cohort 
 
 
Baseline force-plate parameters are presented in Table 4.12 and Figure 4.20. Only 1 
participant with Leigh Syndrome was able to perform the M1LH and only 2 the S2LJ. 
This data has been presented to provide information about muscle function in this cohort 
in relation to the paediatric and adult cohorts and the reference population. The one 
young adult able to perform the M1LH had a force SDS well below the reference 
population and lower than the mean of the adult cohort, suggesting that the muscle’s 
ability to produce force may be more affected in Leigh Syndrome than other MRCD. The 
two participants able to perform the S2LJ had EFI, FE, power and force SDS 
significantly lower than the reference population: -4.8, p=0.012; -5.2, p<0.000; -5.3, 
p=0.014; and -2.7, p=0.044 respectively. The SDS for FE, power and force were lower 
than the paediatric and adult cohorts, again suggesting that muscle force, power and 
efficiency are more affected in Leigh Syndrome than other MRCD. All participants were 
able to perform the CRT. Speed, power and force SDS during the CRT were all lower 
than the reference population (Figure 4.20), the SDS for speed and power were 
significantly reduced compared to reference population: -4.1, p<0.000 and -2.6, p=0.002, 
however the force SDS did not reach significance, -1.8, p=0.050. As a mixed paediatric 
and adult cohort, the values for the CRT SDS were between those seen in the paediatric 
and adult cohorts. This finding does not support the theory that muscle force, power and 
co-ordination are more affected in Leigh Syndrome compared to other MRCD. 
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Figure 4.21. Standard deviation (SD) scores for force plate parameters in the Leigh 
Syndrome cohort. Mean and 95% confidence interval. Parameter in blue represent one 
participant. Parameters shown in red were significantly different to the reference 
population on one-sample t-tests, p<0.05. 
 
4.4.2 Observation Period 
 
 
Statistical analysis was performed on the M1LJ, S2LJ and CRT parameters for the adult 
cohort but only on the CRT parameters for the paediatric and Leigh Syndrome cohorts. 
There were no significant changes in any force plate parameters for the paediatric, adult 
or Leigh Syndrome cohorts during the observation period (Appendix D, Table D.2-D.4).  
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4.4.3 WBVT Period 
 
 
4.4.3.1 Paediatric Cohort 
 
 
Statistical analysis was only performed on the CRT parameters in the paediatric cohort. 
The speed at which the CRT was performed and the power required to perform the 
manoeuvre did not change significantly after WBVT (Appendix D, Table D.2). The force 
required to generate power however, decreased significantly (Table 2.13). Maximum 
force decreased from 1.3 – 1.2kN, p=0.037, and maximum relative force decreased from 
47.6 – 41.3N/kg, p=0.019. The force SDS did not decrease significantly however it 
decreased by half a SDS from -2.4 to -2.9, p=0.160. These results may indicate that the 
force generating capacity of the muscle has worsened, however it may also indicate that 
the efficiency of movement may have improved after WBVT, as less force was required 
to generate similar power and speed.  
 
Table 4.16. CRT parameters for the paediatric MRCD cohort at each visit, changes 
between visits and p values. *p<0.05. 
  F max (kN) F max rel 
(N/kg) 
Ave F max 
rel (g) 
Force SDS 
Visit 1 
Value 1.288 49.458 1.250 -2.201 
Δ in Observation 0.013 -1.878 -0.021 -0.196 
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p 0.804 0.452 0.609 0.567 
Visit 2 
Value 1.302 47.580 1.230 -2.397 
Δ with WBVT -0.119 -6.278 -0.054 -0.492 
p 0.037* 0.019* 0.196 0.160 
Visit 4 
Value 1.182 41.302 1.176 -2.889 
Δ in Follow-up  0.079 1.749 0.081 0.632 
p 0.153 0.482 0.058 0.076 
Visit 4 Value 1.261 43.052 1.257 -2.257 
 
Note: Δ, change; F max, maximum force; F max rel, maximum relative force; Ave F max 
rel, average maximum relative force; SDS, standard deviation score. 
 
4.4.3.2 Adult Cohort 
 
 
There were no significant changes in any M1LH or S2LJ parameters after WBVT 
(Appendix D, Table D.3). Analysis of the CRT parameters demonstrated a significant 
decrease in the time to perform each chair rise from 2.6 – 2.4s, p=0.030 (Table 2.14). 
However, there was no significant change in the corresponding speed SDS. Power and 
force parameters did not change significantly (Appendix D, Table D.2). These results 
likely indicate improved leg muscle agonist/antagonist co-ordination as the same force 
and power was required to perform each chair-rise in a faster time.  
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Table 4.17. CRT parameters for the adult sub-cohort at each visit, changes between visits 
and p values. *p<0.05. 
  Time per 
test (s) 
P max (W) P max rel 
(W/kg) 
Power SDS 
Visit 1 Value 2.806 437.484 7.329 -2.684 
 Δ in Observation -0.162 24.854 0.411 0.226 
 p 0.179 0.491 0.398 0.343 
Visit 2 Value 2.644 498.338 7.741 -2.458 
 Δ with WBVT -0.269 -29.499 -0.203 -0.057 
 p 0.030* 0.414 0.675 0.811 
Visit 3 Value 2.375 468.839 7.537 -2.515 
 Δ in Follow-up -0.201 75.600 1.093 0.506 
 p 0.099 0.042* 0.030* 0.038* 
Visit 4 Value 2.174 544.440 8.630 -2.009 
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  F max (kN) 
F max rel 
(N/kg) 
Ave F max 
rel (g) 
Force SDS 
Visit 1 Value 1.205 19.652 1.205 2.924 
 Δ in Observation 0.001 -0.103 -0.001 -0.025 
 p 0.950 0.796 0.963 0.935 
Visit 2 Value 1.206 19.549 1.204 2.898 
 Δ with WBVT 0.034 0.696 0.032 0.346 
 p 0.142 0.088 0.110 0.266 
Visit 3 Value 1.240 20.245 1.236 3.244 
 Δ in Follow-up 0.063 1.155 0.039 0.732 
 p 0.009* 0.006* 0.052 0.022* 
Visit 4 Value 1.303 21.400 1.275 3.976 
 
Note: Δ, change; P max, maximum power; P max rel, maximum relative power;  F max, 
maximum force; F max rel, maximum relative force; Ave F max rel, average maximum 
relative force; SDS, standard deviation score. 
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4.4.3.3 Leigh Syndrome Cohort 
 
Statistical analysis was only performed on the CRT parameters. There were no significant 
changes in any CRT speed, power of force parameters after WBVT (Appendix D, Table 
D.4). 
 
4.4.4 Follow-up Period 
 
 
4.4.4.1  Paediatric Cohort 
 
 
Analysis of the CRT parameters did not demonstrate any significant changes (Appendix 
D, Table D.2). In contrast to the WBVT period, there were non-significant increases in 
CRT average relative force and the force SDS: 1.2 – 1.3g, p=0.058; and -2.9 to -2.3, p-
0.076, respectively, the latter over half a SDS which would be considered clinically 
relevant (Table 4.13). As the changes in CRT speed and power were not of the same 
magnitude as the changes seen in CRT force, these results may indicate worsening of 
muscle efficiency after withdrawal of WBVT as more force was required to achieve the 
same speed and power during the CRT.  
 
4.4.4.2 Adult Cohort 
 
 
During the follow-up period, there were no significant changes in any M1LJ or S2LJ 
parameters (Appendix D, Table D.3). Significant increases were seen in CRT power and 
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force parameters but not speed parameters. Maximum power, maximum relative power 
and the power SDS increased significantly: 468.8 – 544.4W, p=0.042; 7.5 – 8.6W/kg, 
p=0.030; and -2.5 to -2.0, p=0.038 respectively. Maximum force, maximum relative force 
and force SDS also increased significantly: 1.2 – 1.3kN, p=0.009; 20.2 – 21.4N/kg, 
p=0.006; and 3.2 – 4.0, p=0.022 respectively (Table 4.14). The further increase in the 
amount of force required to generate power to perform the CRT, coupled with the 
increased amount of power required to perform the test at the same speed, indicates 
worsening of muscle efficiency, an aspect which appears to have been hindered during 
the WBVT period. 
 
4.4.4.3 Leigh Syndrome Cohort 
 
 
Analysis of the CRT parameters revealed significant changes in CRT force parameters 
but not speed or power parameters (Appendix D, Table D.4). Maximum force, average 
relative force and force SDS increased significantly: 1.1 – 1.3kN, p=0.033; 1.1 – 1.2g, 
p=0.002; and -2.4 to -1.3, p=0.009 respectively (Table 2.15). These results would suggest 
that the ability of the Leigh Syndrome cohort to generate force improved during the 
follow-up period, however that lack of follow-on improvement in the power and speed 
parameters of the CRT, do not indicate improve muscle efficiency. 
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Table 4.18. CRT parameters for the Leigh Syndrome cohort at each visit, changes 
between visits and p values. *p<0.05. 
  F max (kN) Ave F max rel (g) Force SDS 
Visit 1 Value 1.217 1.182 -1.776 
 Δ in Observation -0.029 -0.036 -0.228 
 p 0.617 0.373 0.536 
Visit 2 Value 1.188 1.146 -2.004 
 Δ with WBVT -0.064 -0.047 -0.364 
 p 0.275 0.245 0.329 
Visit 3 Value 1.124 1.098 -2.369 
 Δ in Follow-up 0.136 0.151 1.106 
 p 0.033* 0.002* 0.009* 
Visit 4 Value 1.260 1.249 -1.263 
 
Note: Δ, change; F max, maximum force; Ave F max rel, average maximum relative 
force; SDS, standard deviation score. 
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4.5 Exercise Parameters 
 
 
4.5.1 Six Minute Walk Test (6MWT) 
 
 
4.5.1.1 Baseline 
 
Baseline 6MWT parameters are presented in Table 4.19. Baseline, post and recovery 
measures of heart rate, systolic and diastolic blood pressure and oxygen saturations were 
all within normal boundaries indicating that the 6MWT was safely performed in this 
population.   
 
4.5.1.1.1 Paediatric Cohort 
 
 
Baseline 6MWT parameters for the 7 paediatric participants are presented in Table 4.19. 
The distance covered during the 6MWT, 319.2m, 52.2% of that predicted by the 
reference population, indicated moderate to severely impaired exercise capacity. The 
paediatric cohort also demonstrated the worst exercise capacity of the 3 cohorts. Borg 
scores and blood pressure parameters were increased at the post measurement compared 
to the baseline measurement and decreased toward baseline levels at the recovery 
measurement, however heart rate increased at the post measurement but did not show any 
decrease at the recovery measurement, indicating poor cardiovascular recovery after 
physical effort. 
 
 370 
Table 4.19. Baseline 6MWT parameters. Mean (SD). 
 Paediatric (n=7) Adult (n=12) Leigh Syndrome (n=5) 
Six Minute Walk Test (6MWT) Parameters 
Distance (m) 319.2 (156.0) 413.0 (139.9) 341.6 (76.8) 
Distance % Predicted (%) 52.2 (27.4) 71.3 (24.7) 56.8 (18.7) 
Baseline HR (bpm) 94.0 (10.1) 86.0 (18.6) 83.7 (18.7) 
Baseline Borg Score 0.6 (1.0) 1.2 (1.0) 0.4 (0.9) 
Baseline SBP (mmHg) 104.6 (9.8) 126.1 (9.5) 114.3 (18.9) 
Baseline DBP (mmHg) 66.6 (9.6) 83.2 (5.2) 77.8 (8.7) 
Baseline SpO2 (%) 98.7 (1.8) 97.6 (1.7) 99.2 (1.8) 
Post HR (bpm) 107.7 (9.1) 106.8 (20.2) 120.0 (2.0) 
Post Borg Score 3.0 (1.4) 2.7 (1.1) 2.8 (1.3) 
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Post SBP (mmHg) 115.5 (13.9) 140.8 (14.1) 116.5 (17.7) 
Post DBP (mmHg) 73.5 (12.9) 85.7 (11.5) 74.5 (13.4) 
Post SpO2 (%) 98.6 (1.3) 97.7(1.4) 99.0 (1.4) 
Recovery HR (bpm) 108.7 (9.7) 86.9 (19.6) 98.3 (16.3) 
Recovery Borg Score 1.9 (1.3) 1.5 (1.1) 1.2 (0.8) 
Recovery SBP (mmHg) 108.4 (11.5) 127.7 (11.2) 124.8 (21.8) 
Recovery DBP (mmHg) 66.6 (10.9) 78.9 (7.2) 75.0 (16.9) 
Recovery SpO2 (%) 98.3 (1.6) 97.2 (1.9) 98.6 (1.5) 
 
Note: HR, heart rate; bpm, beats per minute; mmHg, millimeters of mercury; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; SpO2, oxygen saturations.
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4.5.1.1.2 Adult Cohort 
 
 
 
Baseline 6MWT parameters for the 12 adult participants are presented in Table 4.19. The 
adult cohort covered the greatest distance in the 6MWT, compared to the other cohorts, 
and demonstrated a higher percent-predicted value of 71.3%, indicating moderately 
impaired exercise capacity. Baseline Borg scores were slightly higher than the other 
cohorts, however post and recovery scores were similar across all cohorts. Heart rate, 
Borg score and blood pressure parameters were all increased at the post measurement 
compared to the baseline measurement, indicating increased physical effort, and then 
dropped to near baseline levels at the recovery measurement. 
 
4.5.1.1.3 Leigh Syndrome Cohort 
 
 
Baseline 6MWT parameters for the 5 Leigh Syndrome participants are presented in Table 
4.19. The Leigh Syndrome cohort covered a greater distance than the paediatric cohort 
but a shorter distance than the adult cohort. The percent-predicted value for the distance 
covered was also between the paediatric and adult cohorts and demonstrated a moderate 
to severely impaired exercise capacity. Heart rate, Borg score and blood pressure 
parameters increased between baseline and post measurements.  At the recovery 
measurement, blood pressure had increased further and the recovery in heart rate was 
slow, indicating poor cardiovascular recovery, similar to that seen in the paediatric 
cohort. 
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4.5.1.2 Observation Period 
 
 
Analysis data for all 6MWT parameters for the observation period can be found in 
Appendix E. Safety measures, including blood pressure and oxygen saturations, for each 
of the 3 cohorts, will not be discussed.  
 
4.5.1.2.1 Paediatric Cohort 
 
 
There were no significant changes in 6MWT distance or Borg scores at baseline, post or 
recovery measurements. However, the heart rate post the 6MWT increased by 26.8 bpm, 
p=0.037 indicating greater cardiovascular effort to achieve a similar 6MWT distance 
(Table 4.20 and Appendix E, Table E.2). 
 
4.5.1.2.2  Adult Cohort 
 
 
There were no significant changes in 6MWT distance, heart rate or Borg scores at 
baseline, post or recovery measurements in the adult cohort (Appendix E, Table E.3). 
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Table 4.20. Six-minute walk test parameters for the paediatric cohort at each visit, 
changes between visits and p values. *p<0.05. 
  Baseline HR 
(bpm) 
Post HR (bpm) Recovery Borg 
Score 
Visit 1 Value 96.040 106.7 1.8 
 Δ in Observation 7.817 26.8 0.3 
 p 0.149 0.037* 0.569 
Visit 2 Value 103.857 133.429 2.1 
 Δ with WBVT  -10.429 -27.9 -1.3 
 p 0.011* 0.015* 0.018* 
Visit 3 Value 93.429 105.571 0.9 
 Δ in Follow-up  10.259 23.0 0.3 
 p 0.017* 0.038* 0.569 
Visit 4 Value 103.668 129 1.1 
 
Note: Δ, change; WBVT, whole body vibration training; HR, heart rate; bpm, beats per 
minute. 
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4.5.1.2.3 Leigh Syndrome Cohort 
 
 
There were significant decreases in the 6MWT distance and the percent-predicted value 
during the observation period: 341.6 - 274.9m, p=0.035; and 56.8 – 46.0%, p=0.023 
respectively (Table 4.21). Significant decreases in 6MWT distance were not seen in the 
paediatric or adult MRCD cohorts during the observation period. These findings suggest 
that in comparison to other MRCD, Leigh Syndrome may exhibit a more accelerated 
decline in muscle endurance. There were no significant changes in heart rate or Borg 
scores at baseline, post or recovery measurements (Appendix E, Table E.4). 
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Table 4.21. 6MWT parameters for the Leigh Syndrome cohort at each visit, changes between visits and p values. *p<0.05. 
  Distance (m) Distance % Predicted (%) Post Borg Score Recovery Borg Score 
Visit 1 Value 341.580 56.765 2.8 1.2 
 Δ in Observation -66.700 -10.794 -0.6 0.2 
 p 0.035* 0.023* 0.068 0.584 
Visit 2 Value 274.880 45.971 2.2 1.4 
 Δ with WBVT  24.020 3.306 0.8 -1.0 
 p 0.408 0.439 0.020* 0.016* 
Visit 3 Value 298.900 49.278 3.0 0.4 
 Δ in Follow-up  18.500 2.753 -0.6 0.4 
 p 0.521 0.518 0.068 0.283 
Visit 4 Value 317.400 52.031 2.4 0.8 
Note: Δ, change; WBVT, whole body vibration training.  
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4.5.1.3 WBVT Period 
 
 
Analysis data for all 6MWT parameters for the WBVT period can be found in Appendix 
E. 
 
4.5.1.3.1  Paediatric Cohort 
 
 
There were no significant changes in 6MWT distance after WBVT (Appendix E, Table 
E.2). Heart rate at baseline was significantly reduced by 10.5 bpm, p=0.011, after WBVT. 
There was also a significant reduction in heart rate post the 6MWT of 27.9 bpm, p=0.015, 
indicating less cardiovascular effort to achieve a similar 6MWT distance. To further 
support an improved response to exercise after WBVT, the recovery Borg score 
decreased significantly by 1.3 points, 0.018 (Table 4.20). 
 
4.5.1.3.2  Adult Cohort 
 
 
There were no significant changes in any of the 6MWT parameters after WBVT 
(Appendix E, Table E.3). The 6MWT distance did increase non-significantly by 19.2m 
(4.8%) compared to an 11.2m decrease during the observation period. 
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4.5.1.3.3  Leigh Syndrome Cohort 
 
 
After WBVT there was a non-significant increase in 6MWT distance of 24.0m (8.7%) 
and a 3.3% increase in the percent-predicted value. This is in contrast to the significant 
decrease in 6MWT distance seen in the observation period. The post measurement for the 
Borg score was significantly increased by 0.8, p=0.020, indicating greater perceived 
physical effort required to perform the 6MWT. The recovery measurement of the Borg 
score was significantly decreased after WBVT by 1.0, p=0.016, indicating improved 
recovery, despite a greater effort to perform the test (Table 4.21). There were no 
significant changes in baseline, post or recovery measures of heart rate (Appendix E, 
Table E.4). 
 
4.5.1.4 Follow-up Period 
 
 
Analysis data for all 6MWT parameters for the Follow-up period can be found in 
Appendix E. 
 
4.5.1.4.1 Paediatric Cohort 
 
 
There were no significant changes in 6MWT distance or the baseline, post or recovery 
measurements for Borg score during the follow-up period (Appendix E, Table E.2). 
Baseline heart rate increased significantly by 10.3 bpm, p=0.017. Hear rate post the 
 379 
6MWT also increased significantly by 23.0 bpm, p=0.038, indicating increased 
cardiovascular effort to cover a similar 6MWT distance. 
 
4.5.1.4.2 Adult Cohort 
 
 
There were no significant changes during the follow-up period for 6MWT distance or 
heart rate and Borg scores at baseline, post or recovery measurements (Appendix E, 
Table E.3). 
 
4.5.1.4.3 Leigh Syndrome Cohort 
 
 
After WBVT there were no significant changes in any of the 6MWT parameters 
(Appendix E, Table E.4). The 6MWT distance demonstrated a non-significant increase of 
18.5m which was similar to the improvement seen during the WBVT period and in 
contrast to the significant reduction in 6MWT distance seen during the observation period 
(Appendix E, Table E.4). 
 
4.5.2 Cardio-pulmonary Exercise Testing (CPET) 
 
 
CPET data were available for 2 paediatric and 7 adult participants. The paediatric 
participants performed the exercise tests on a treadmill using the Bruce Treadmill 
Protocol, as did two of the young adult participants. The 5 remaining adult participants 
performed the exercise tests on a cycle ergometer using a 10-watt ramp protocol. 
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4.5.2.1 Baseline 
 
 
Baseline CPET parameters are presented in Table 4.22. The limited paediatric data has 
presented to provide information about their response to exercise compared to the adult 
cohort and the reference population. The pre-exercise VO2 was elevated in both the 
paediatric and adult cohorts at 7.6 and 4.5 ml/kg/min respectively, compared to that seen 
in the healthy adult reference population at rest of 3.5 ml/kg/min. The pre-exercise Borg 
Score of 1.0 and 2.8, in the paediatric and adult cohorts respectively, indicates that the 
participants were experiencing a mild level of physical exertion prior to commencing the 
exercise test. Pre-exercise measurements of systolic and diastolic blood pressure were 
within normal limits in both cohorts. 
 
The anaerobic threshold occurred abnormally early in exercise in the adult cohort as 
demonstrated by a mean percent predicted VO2 of 30.9% and percent predicted Watts of 
23.9% which indicated severely impaired oxidative pathways. This was not as 
pronounced in the paediatric cohort, however the VO2 at which AT occurred was 80.5% 
of that predicted by the reference population. This indicated mild-moderate impairment 
of the oxidative pathways in the paediatric cohort. The ventilatory equivalents for oxygen 
(VE/VO2) and carbon dioxide (VE/VCO2) were abnormally high at the anaerobic 
threshold in the adult cohort with mean values of 36.0 and 36.7 respectively, greater than 
their corresponding reference maximums of 28 and 32, indicating an exaggerated 
ventilatory response. These parameters were not elevated to the same degree in the 
 381 
paediatric cohort. At AT, participants were already experiencing moderate to high 
muscular and cardiovascular effort. In the paediatric cohort, AT occurred at 48.3% of 
total exercise time, with a percent-predicted heart rate of 79.1% and VO2 at 92.9% of its 
peak. In the adult cohort, AT occurred at 55.5% of total exercise time and 57.4% of peak 
Watts, when heart rate was at 72.2% predicted and VO2 was at 70.6% of its peak. 
 
Peak exercise parameters demonstrated moderate-severely reduced oxidative and exercise 
capacity with a mean VO2 of 28.0 ml/kg/min, 61.0% of predicted in the paediatric cohort 
and a mean VO2 of 15.4ml/kg/min, 45.0% of predicted, and mean power output of 
63.2W, 45.2% of predicted, in the adult cohort. Oxygen pulse at peak exercise was also 
moderately-severely restricted with a peak value of 3.5ml/beat, 53.5% of predicted and 
5.8ml/beat, 32.9% of predicted, in the paediatric and adult cohorts respectively. The 
ventilatory equivalent for oxygen was also high at peak exercise with a mean value of 
48.0 in the paediatric cohort and 46.0 in the adult cohort. These findings at peak exercise, 
together with the findings at AT, reflect the inability of the exercising muscle to use the 
oxygen provided to it by the circulating blood. Consequently, the arterial-mixed venous 
oxygen difference does not progressively increase at it should, forcing a prematurely 
exaggerated response of the cardiovascular system to increase cardiac output in an 
attempt to increase VO2. Concurrently, the working muscle is forced to use anaerobic 
pathways that produce lactic acid, the buffering of this increased lactic acid by 
bicarbonate, resulting in a rapid increase in VCO2 causing exaggerated ventilatory 
responses. These exaggerated responses in the cardiovascular and respiratory systems, 
causing them to rapidly escalate toward their physiological maximums, culminated in 
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significantly reduced exercise capacity.  At peak exercise the mean heart rate was 89.0 
and 87.2% of predicted, respiratory quotient 1.4 and Borg Score 7.0 and 7.4 in the 
paediatric and adult cohorts respectively, all indicating that a peak test had been 
performed. Systolic and diastolic blood pressures were increased compared to pre-
exercise values also indicating increased physical effort. 
 
The recovery data were only available for the adult cohort and indicates that all CPET 
parameters were returning towards baseline levels except for the ventilatory equivalent 
for oxygen which remained high at 47.8, a likely reflection of elevated minute ventilation 
in response to the increased VCO2. 
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Table 4.22. Baseline Cardiopulmonary Exercise Test Parameters. Mean (SD). 
 
 Paediatric Cohort (n=2) Adult Cohort (n=7) 
CPET - Pre-Exercise Parameters 
Pre-exercise VO2 (L/min) 0.2 (0.1) 0.2 (0.1) 
Pre-exercise VO2 (ml/kg/min) 7.6 (3.7) 4.5 (2.4) 
Pre-exercise HR (bpm) 101.5 (3.5) 91.4 (21.5) 
Pre-exercise HR (% Predicted) 49.0 (1.2) 52.6 (7.5) 
Pre-exercise O2 Pulse (ml/beat) 1.9 (0.8) 2.6 (1.1) 
Pre-exercise VCO2 (L/min) 0.2 (0.1) 0.2 (0.1) 
Pre-exercise RQ 0.8 (0.1) 0.9 (0.1) 
Pre-exercise VE (L/min) 7.6 (4.5) 9.9 (5.4) 
Pre-exercise VE/VO2 39.0 (5.8) 42.4 (11.2) 
Pre-exercise VE/VCO2 46.1 (3.0) 46.3 (13.4) 
Pre-exercise Borg Score 1.0 (0.0) 2.8 (2.6) 
Pre-exercise SBP (mmHg) 109.5 (0.7) 121.6 (10.4) 
Pre-exercise DBP (mmHg) 73.0 (8.5) 84.0 (9.4) 
CPET - Anaerobic Threshold (AT) Parameters 
AT VO2 (L/min) 0.7 (0.1) 0.6 (0.3) 
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AT VO2 (ml/kg/min) 26.1 (4.0) 10.9 (5.5) 
AT VO2 (% Predicted) 80.5 (14.8)  
AT VO2 (% Predicted VO2) 56.6 (1.6) 30.9 (11.1) 
AT VO2 (% of Peak VO2) 92.9 (7.3) 70.6 (17.7) 
AT HR (bpm) 164.0 (12.7) 125.0 (21.3) 
AT HR (% Predicted) 79.1 (6.9) 72.2 (6.5) 
AT O2 Pulse (ml/beat) 4.0 (0.5) 4.8 (2.4) 
AT VCO2 (L/min) 0.7 (0.1) 0.6 (0.3) 
AT RQ 1.0 (0.0) 1.0 (0.0) 
AT VE (L/min) 20.1 (0.1) 20.2 (8.8) 
AT VE/VO2 31.2 (6.1) 36.0 (13.4) 
AT VE/VCO2 30.9 (5.8) 36.7 (14.1) 
AT (% of CPET Time) 48.3 (12.7) 55.51 (29.0) 
AT Watts (W) 
 
33.6 (19.2) 
AT Watts (% Predicted) 23.9 (10.6) 
AT Watts (W/kg) 0.6 (0.3) 
AT Watts (% of Peak Watts) 57.4 (26.7) 
CPET - Peak Exercise Parameters 
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Peak VO2 (L/min) 0.7 (0.1) 0.9 (0.5) 
Peak VO2 (% Predicted) 61.0 (2.9) 45.0 (16.3) 
Peak VO2 (ml/kg/min) 28.0 (2.1) 15.4 (7.3) 
Peak HR (bpm) 184.5 (3.5) 150.0 (14.2) 
Peak HR (% Predicted) 89.0 (2.6) 87.2 (7.0) 
Peak O2 Pulse (ml/beat) 3.5 (0.1) 5.8 (2.7) 
Peak O2 Pulse (% Predicted) 53.5 (1.5) 32.9 (13.0) 
Peak VCO2 (L/min) 0.9 (0.1) 1.1 (0.7) 
Peak RQ 1.4 (0.2) 1.4 (0.2) 
Peak VE (L/min) 30.1 (10.2) 38.0 (20.12) 
Peak VE/VO2 48.0 (15.6) 46.0 (12.3) 
Peak VE/VCO2 34.5 (6.4) 36.8 (14.1) 
Peak Watts (W) 
 
63.2 (32.2) 
Peak Watts (% Predicted) 45.2 (19.1) 
Peak Watts (W/kg) 1.1 (0.5) 
CPET Time (mins) 5.9 (2.0) 5.4 (3.5) 
Peak Borg Score 7.0 (2.8) 7.4 (2.5) 
Peak SBP (mmHg) 124.5 (12.0) 169.4 (16.0) 
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Peak DBP (mmHg) 89.5 (2.1) 90.0 (9.7) 
CPET - Recovery Parameters 
Recovery VO2 (L/min) 
 
0.4 (0.2) 
Recovery VO2 (ml/kg/min) 6.4 (3.9) 
Recovery HR (bpm) 107.6 (23.5) 
Recovery HR (% Predicted) 62.0 (9.2) 
Recovery O2 Pulse (ml/beat) 3.2 (1.6) 
Recovery VCO2 (L/min) 0.4 (0.3) 
Recovery RQ 1.1 (0.1) 
Recovery VE (L/min) 16.2 (8.7) 
Recovery VE/VO2 47.8 (8.2) 
Recovery VE/VCO2 47.0 (12.6) 
Recovery Borg Score 3.0 (1.4) 2.8 (2.2) 
Recovery SBP (mmHg) 115.5 (12.0) 137.8 (12.4) 
Recovery DBP (mmHg) 84.0 (2.8) 82.6 (11.7) 
 
Note: CPET, Cardiopulmonary Exercise Test; VO2, oxygen uptake; HR, heart rate; O2, 
oxygen; VCO2, carbon dioxide production; RQ, respiratory quotient; VE, minute 
ventilation; VE/VO2, ventilator equivalent of oxygen; VE/VCO2, ventilator equivalent of 
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carbon dioxide; SBP, systolic blood pressure; DBP, diastolic blood pressure; AT, 
anaerobic threshold. 
 
4.5.2.2 Observation Period 
 
 
Analysis data for CPET parameters in the adult cohort for the observation period can be 
found in Appendix E. No longitudinal analysis was performed on the paediatric data. 
 
4.5.2.2.1 Adult Cohort  
 
 
Pre-exercise Borg score decreased significantly by 1.7 points, p=0.005 during the 
observation period. There were no other significant changes in pre-exercise, AT or peak 
exercise parameters. Heart rate at 5-minutes recovery decreased significantly by 
12.9bpm, p=0.013. (Table 4.23 and Appendix E, Table E.5). These findings perhaps 
suggest that anxiety associated with the unfamiliarity of the testing environment and 
procedures, increased fatigue prior to the test on the first study visit, and heightened heart 
rate during recovery. 
 
4.5.2.3 WBVT Period 
 
 
Analysis data for CPET parameters can be found in Appendix E. 
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4.5.2.3.1  Adult Cohort 
 
After WBVT, there were no statistically significant changes in any of the pre-exercise 
parameters. Similarly, at the anaerobic threshold, no parameters demonstrated statistically 
significant changes. Despite this, several anaerobic threshold parameters registered their 
highest values after WBVT. This included the percent-predicted values for VO2 and 
power output as well as the oxygen pulse parameter. The peak exercise parameters did 
not reflect any significant changes during the WBVT period. However, peak VO2 
(ml/kg/min) increased 5% after WBVT, with 2 of the 7 participants improving their VO2 
by greater than 10% during the WBVT period. The ventilatory equivalent for oxygen at 
5-minutes recovery increased significantly after WBVT, however there were no other 
significant changes in recovery parameters. (Table 4.23 and Appendix E, Table E.5). 
 
4.5.2.4 Follow-up Period 
 
 
Analysis data for CPET parameters can be found in Appendix E. 
 
4.5.2.4.1 Adult Cohort 
 
During the follow-up period, there were no significant changes in any of the pre-exercise, 
AT, peak exercise or recovery parameters. However, several anaerobic threshold 
parameters demonstrated non-significant decreases in the follow-up period. The VO2 at 
AT decreased 0.2L/min (25%), p=0.076, and 2.5ml.kg/min (18%), p=0.068, 
corresponding to a 5.3% decrease in the percent-predicted value and a 5.7% decrease in 
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the AT VO2 as a percentage of the peak VO2. AT occurred 8.4% earlier when considering 
total exercise time. Oxygen pulse also decreased 1.1ml/beat (18%), p=0.076. The 
magnitude of these reductions would be considered clinically relevant. Taken together 
these results indicate that there was a clinical de-training effect on anaerobic threshold 
parameters during follow-up (Appendix E, Table E.5). A non-significant decrease in peak 
VO2 of 1.5mlkg/min (8%), p=0.278 was also seen, with no change in power output at 
peak exercise and a non-significant reduction in exercise time of only 3%. These results 
also suggest a clinical de-training effect on peak oxygen uptake. 
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Table 4.23.  CPET parameters for the adult MRCD cohort at each visit, changes between visits and p values. *p<0.05. 
  Pre-exercise Borg Score AT VO2 (L/min) AT VO2 % Predicted (%) 
Visit 1 Value 3.1 0.7 34.9 
 Δ in Observation -1.7 0.1 5.7 
 p 0.005* 0.275 0.257 
Visit 2 Value 1.4 0.8 40.5 
 Δ with WBVT  -0.3 0.0 2.0 
 p 0.533 0.814 0.630 
Visit 3 Value 1.1 0.8 42.6 
 Δ in Follow-up -0.4 -0.2 -5.3 
 p 0.440 0.076 0.246 
Visit 4 Value 0.8 0.6 37.2 
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  AT VO2 (ml/kg/min) AT VO2 % of Peak VO2 (%) AT O2 Pulse (ml/beat) 
Visit 1 Value 12.2 69.8 5.0 
 Δ in Observation 1.7 5.4 0.9 
 p 0.247 0.480 0.170 
Visit 2 Value 13.8 75.2 5.9 
 Δ with WBVT  -0.1 2.1 0.2 
 p 0.929 0.760 0.755 
Visit 3 Value 13.7 77.3 6.1 
 Δ in Follow-up -2.5 -5.7 -1.1 
 p 0.068 0.424 0.076 
Visit 4 Value 11.2 71.5 5.0 
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  AT Watts (% Predicted) AT % Exercise Time (%) Peak VO2 (ml/kg/min) 
Visit 1 Value 24.9 56.0 17.8 
 Δ in Observation 5.5 -2.5 -0.3 
 p 0.164 0.818 0.842 
Visit 2 Value 30.4 53.5 17.5 
 Δ with WBVT  0.2 -0.4 0.9 
 p 0.944 0.964 0.519 
Visit 3 Value 30.6 53.1 18.4 
 Δ in Follow-up -3.2 -8.4 -1.5 
 p 0.365 0.410 0.278 
Visit 4 Value 27.4 44.7 16.9 
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  Recovery HR (bpm) Recovery HR % predicted (%) Recovery VE/VO2 
Visit 1 Value 111.3 62.7 48.1 
 Δ in Observation -12.9 -7.3 -2.6 
 p 0.013* 0.009* 0.376 
Visit 2 Value 98.4 55.4 45.6 
 Δ with WBVT  0.4 0.7 5.9 
 p 0.915 0.730 0.029* 
Visit 4 Value 98.9 56.2 51.4 
 Δ in Follow-up 1.0 0.7 -0.1 
 p 0.804 0.738 0.954 
Visit 6 Value 99.9 56.9 51.3 
Note: Δ, change; WBVT, whole body vibration training; VO2, oxygen uptake; HR, heart rate; bpm, beats per minute; O2, oxygen; VE, 
minute ventilation; VE/VO2, ventilator equivalent of oxygen; AT, anaerobic threshold. 
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4.6 Disease Scale and Quality of Life Parameters 
 
 
4.6.1 Baseline 
 
 
4.6.1.1 Paediatric Cohort 
 
 
The baseline Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Scores are 
presented in Table 4.24. Section 1, reflecting the patient and care-giver perspective of 
current function, demonstrated mild impact of disease on function. Section 2, reflecting 
system specific involvement, indicated minimal serious systemic manifestations of the 
disease. Section 3, reflecting the clinician’s clinical assessment, indicated mild-moderate 
impact of the disease on current status. Section 4, reflecting patient and care-giver 
perspectives on Quality of Life, indicated mildly affected quality of life. 
 
 
Table 4.24. Baseline Disease Scale and Quality of Life Scores for the paediatric and 
Leigh Syndrome cohorts. Mean (SD). 
Newcastle Mitochondrial Paediatric Disease Scale Scores 
 Paediatric Cohort (n=5) Leigh Syndrome Cohort (n=5) 
Section 1 4.7 (2.6) 4.0 (2.1) 
Section 2 1.1 (1.1) 0.6 (0.9) 
Section 3 10.1 (4.3) 9.6 (3.4) 
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Section 4 9.2 (3.1) 8.0 (2.7) 
 
 
4.6.1.2 Adult Cohort 
 
 
The baseline Newcastle Disease Adult Scale (NMDAS) and Quality of Life Scores are 
presented in Table 4.25. Section 1, reflecting the patient’s perspective of current function, 
demonstrated minimal impact of disease on function, however they are aware of minor 
changes to what would be considered normal function. The patient’s perception of their 
current function was affected to a similar extent in the paediatric and adult cohorts. 
Section 2, reflecting system specific involvement, indicated minimal serious systemic 
manifestations of the disease, similar to that seen in the paediatric cohort. Section 3, 
reflecting the clinician’s clinical assessment, indicated mild impact of the disease on 
current status. The paediatric cohort was more adversely affected in this area compared to 
the adult cohort. Quality of Life, measured by the SF-12v2, was significantly reduced in 
the physical functioning, role physical, bodily pain and general health domains, but not in 
the vitality, social function, role emotional and mental health domains. The physical 
component score, but not the mental component score was also significantly reduced 
compared to the reference population (Figure 4.21). While different quality of life 
measurement shave been utilised, it would appear that the adult cohort had more severely 
affected Quality of Life compared to the paediatric cohort. 
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Table 4.25. Baseline Disease Scale and Quality of Life Scores for the adult cohort. Mean 
(SD). 
 Adult Cohort (n=10) 
Newcastle Mitochondrial Disease Adult Scale Scores 
Section 1 9.8 (6.5) 
Section 2 5.0 (3.1) 
Section 3 10.2 (6.3) 
SF-12v2 Domain Standard Deviation Scores 
Physical Functioning  -1.5 (0.8) 
Role Physical -1.1 (0.9) 
Bodily Pain  -1.0 (0.8) 
General Health  -1.3 (1.2) 
Vitality  -0.6 (1.1) 
Social Function  -0.6 (1.2) 
Role Emotional  -0.1 (0.6) 
Mental Health  0.2 (0.7) 
Physical Component Score  -1.7 (0.9) 
Mental Component Score  0.3 (0.6) 
 
 397 
 
 
Figure 4.22. Standard deviation (SD) scores for Quality of Life Domains in the adult 
cohort. Mean and 95% confidence interval. Parameters shown in red were significantly 
different to the reference population on one-sample t-tests, p<0.05. 
 
4.6.1.3 Leigh Syndrome Cohort 
 
 
The baseline NPMDS Scores are presented in Table 4.24. Scores for each section were 
slightly lower than those seen in the paediatric cohort, indicating a higher current 
function, less system specific involvement, better clinical performance and more 
desirable Quality of Life, respectively. Similar to the paediatric cohort, the Leigh 
Syndrome cohort appears to be more affected on clinical assessment compared to the 
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adult cohort, however the adult cohort appears to have the lowest Quality of Life of the 
three cohorts. 
 
4.6.2 Study Periods 
 
 
All data analysis for disease scale and Quality of Life parameters for the three cohorts 
over the observation, WBVT and follow-up periods are presented in Appendix F, Table 
F2-4. 
 
4.6.2.1 Paediatric Cohort 
 
During the observation period, the NPMDS Section 1 score increased significantly by 1.9 
points, p<0.000, indicating patient and care-giver perception of current function had 
worsened (Table 2.26, Appendix F.2). There was also a non-significant increase in the 
NPMDS Section 3 score of 1.3 points, p=0.076, indicating that the clinician’s clinical 
assessment also demonstrated some deterioration. There were no significant changes in 
any of the NPMDS sections during the WBVT or follow-up periods. The progression of 
mitochondrial disease identified by an increase in the disease scores for current function 
and current clinical assessment during the observation period appears to have been 
interrupted by the WBVT intervention in the paediatric MRCD cohort and was not seen 
during the follow-up period, perhaps suggesting a latent effect of WBVT on 
mitochondrial disease progression measured by the NPMDS after cessation of the WBVT 
intervention in the paediatric MRCD cohort. 
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Table 4.26. Newcastle Paediatric Mitochondrial Disease Scale parameters for the 
paediatric cohort at each visit, changes between visits and p values. *p<0.05. 
  Section 1 Section 3 
Visit 1 Value 4.7 10.1 
 Δ in Observation 1.9 1.3 
 p 0.000* 0.077 
Visit 2 Value 6.6 11.4 
 Δ with WBVT -0.3 -0.6 
 p 0.484 0.415 
Visit 3 Value 6.3 10.9 
 Δ in Follow-up 0.0 1.0 
 p 1.000 0.161 
Visit 4 Value 6.3 11.9 
 
Note: Δ, change; WBVT, whole body vibration training; NPMDS, Newcastle Paediatric 
Mitochondrial Disease Scale. 
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4.6.2.2 Adult Cohort 
 
The NMDAS and SF12v2 scores did not change significantly during the observation 
period. After WBVT the NMDAS Section 3 score decreased significantly by 1.7 points, 
p=0.010, indicating improvement in the clinician’s clinical assessment (Table 2.27, 
Appendix F, Table F.3). There was a non-significant decrease in the NMDAS Section 1 
score of 1.8 points, p=0.083, indicating that the patients perceived their current function 
to have improved after WBVT. There were no significant changes in Quality of Life 
parameters, however a non-significant increase in the role physical domain, 0.5 SDS, 
p=0.074, was consistent with the significant improvements seen in the NMDAS Section 
3, and encouraging as this domain was significantly reduced compared to the reference 
population at baseline. There were no significant changes in the NMDAS or SF-12v2 
parameters during the follow-up period. 
 
Table 4.27. Newcastle Mitochondrial Disease Adult Scale and Quality of Life parameters 
for the adult cohort at each visit, changes between visits and p values. *p<0.05. 
  NMDAS  
Section 1 
NMDAS  
Section 3 
Role Physical 
SDS (SF-12v2) 
Visit 1 Value 9.8 10.2 -1.1 
 Δ in Observation 1.5 -0.5 -0.3 
 p 0.145 0.423 0.275 
Visit 2 Value 11.3 9.7 -1.4 
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 Δ with WBVT -1.8 -1.7 0.5 
 p 0.083 0.010* 0.074 
Visit 3 Value 9.5 8.0 -0.9 
 Δ in Follow-up 0.7 0.9 -0.2 
 p 0.490 0.155 0.361 
Visit 4 Value 10.2 8.9 -1.1 
 
Note: Δ, change; WBVT, whole body vibration training; NMDAS, Newcastle 
Mitochondrial Disease Adult Scale. 
 
4.6.2.3 Leigh Syndrome Cohort 
 
There were no significant changes in the NPMDS section scores during the observation 
or WBVT periods. However, Section 3 of the NPMDS increased significantly by 1.8 
points, p=0.008, during the follow-up period indicating deterioration on the clinician’s 
clinical assessment. 
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Table 4.28. Newcastle Paediatric Mitochondrial Disease Scale parameters for the Leigh 
Syndrome cohort at each visit, changes between visits and p values. *p<0.05. 
  NPMDS Section 3 
Visit 1 Value 9.6 
 Δ in Observation 0.4 
 p 0.493 
Visit 2 Value 10.0 
 Δ with WBVT  -0.6 
 p 0.310 
Visit 3 Value 9.4 
 Δ in Follow-up  1.8 
 p 0.008* 
Visit 4 Value 11.2 
 
Note: Δ, change; WBVT, whole body vibration training; NPMDS, Newcastle Paediatric 
Mitochondrial Disease Scale. 
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4.7 Adherence 
 
 
Adherence was measured a counter in the vibration plate. Vibration plate counters were 
available for analysis in 14/19 participants (74%) and indicated overall adherence to 
treatment of 63%. Using the vibration plate counters 12/14 participants (86%) trained at 
least twice a week, 11/14 (79%) trained at least 3 times a week, 9/14 (64%) trained at 
least 4 times a week, and 5/14 (36%) trained at least 5 times a week. 
 
4.8 Summary of Findings 
 
 
This is the first study investigating bone health in individuals with MRCD. 
4.8.1 Paediatric Cohort 
 
 
4.8.1.1 Baseline 
 
 
The paediatric MRCD cohort presented with mild-moderate impact of their disease on 
current status as measured by the NPMDS. Height and weight SDS as well as the total 
body lean tissue mass for height SDS measured by DXA and the muscle CSA SDS 
measured at the 66% tibial pQCT site were significantly reduced compared to the 
reference population. The proportion of lean and fat mass also appears to be disrupted 
with the SDS for total body fat measured by DXA towards the upper end of normal and 
the ratio of fat CSA for muscle CSA at the 66% pQCT site elevated at 70.3%. These 
abnormalities in nutritional indices, including longitudinal growth, body weight, lean 
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tissue and the proportion of muscle and fat mass [3, 93, 94], are risk factors that 
negatively impact bone health, as they compromise achievement of peak bone mass, 
ultimately impacting long-term bone health [4, 55, 89].  
 
The paediatric cohort also demonstrated impairments in muscle performance during 
functional activities and evidence of reduced habitual WBPA, further risk factors for the 
attainment of genetically determined peak bone mass and the maintenance of bone mass 
throughout life [4, 55]. The force SDS in the M1LJ and CRT and force efficiency SDS in 
the S2LJ were significantly reduced. Functional muscle performance was also 
significantly impaired with significantly increased time to perform the CRT, a 6MWT 
distance of 52% of predicted and peak oxygen uptake corrected for body weight of 61% 
predicted. The limitations in muscle performance, ability to perform functional tasks and 
aerobic capacity have ramifications on the paediatric MRCD cohort’s ability to 
participate in regular WBPA, especially the types of activities that promote optimal bone 
adaptations. Such activities have a high strain magnitude, apply strain at a rapid rate, 
have fast acceleration, are multidirectional in nature and produce ground reaction forces 
in excess of those produced during normal daily activities [97, 98, 100]. These activities 
would be particularly difficult for the paediatric MRCD cohort as few were able to jump 
and hop. As WBPA has been shown to significantly increase BMC, BMD and bone 
strength in children and adolescents [97, 102, 103], with the benefits impacting on bone 
health in later life [91, 101, 108, 110-112], the inability to particpate in the appropriate 
WBPA and generate normal muscle forces, reducing the strain magnitude and frequency 
imparted on the underlying bone, will impact on their life-long bone health. This is 
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especially pertinent to the paediatric MRCD cohort as the foundations of long term bone 
health are established in the childhood and adolescent years which represents an optimal 
time for skeletal adaptation [50, 90, 97, 98, 101-103, 113].  
 
Compromised bone health was evident in both the trabecular and cortical bone 
compartments. Trabecular bone density SDS were significantly reduced at the lumbar 
spine, the vBMD measurement for lumbar vertebrae 1-4 and at the 4% tibial pQCT site. 
Impairments were also seen in cortical bone mass, density, geometry and strength. 
Cortical bone mass SDS at the 66% pQCT site was significantly reduced. Compromised 
cortical density was evidenced by significantly reduced legs BMD SDS measured by 
DXA, but significantly increased cortical vBMD at the 20% and 66% pQCT sites. Sub-
optimal geometric attributes were demonstrated by significantly reduced SDS for cortical 
CSA, cortical thickness and total bone CSA at the 66% pQCT site. Compromised bone 
strength was evident at both the 20% and 66% pQCT sites. A further risk factor for 
compromised bone health was the uncoupling of normal bone turn-over, with half of the 
cohort having an increased level of the bone resorption marker, urinary 
deoxypyridinoline: creatinine ratio.  
 
In summary, the paediatric MRCD cohort presented with short, narrow diaphyses, 
reduced cortical bone mass and strength but increased cortical density. Paradoxically, 
bone density in the trabecular bone compartment was low. The mechanostat theory 
proposes a feedback system that regulates the stiffness of the diaphyseal bone through the 
regulation of modelling and remodelling processes by the osteocyte in response to strains 
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imposed on the bone from mechanical loading [35, 47, 72, 75]. A functional mechanostat 
requires intact mechanical and biological aspects and a disruption to either of these 
aspects can affect the bone’s mass and geometric adaptation to mechanical loading [35]. 
The mechanical aspect of the mechanostat can be investigated by analysing the functional 
muscle-bone unit using total body DXA derived parameters [687] and pQCT derived 
parameters [78]. Using the algorithm by Hogler et al [687], BMC for height was at the 
lower end of the normal range, LTM for height was significantly reduced, however BMC 
was appropriately adapted for LTM, indicating low bone mass was secondary to reduced 
lean mass, a secondary bone defect. The significantly reduced LTM and inadequate 
muscle forces imparted on the skeleton during habitual mechanical loading, resulting in 
lower magnitude bone strains, would not activate osteocytes to elicit accrual of bone 
mass, periosteal apposition and geometric bone adaptations as seen in their healthy 
counterpart, and would cause bone losses in the trabecular bone compartment and on the 
endosteal surfaces of cortical bone [35, 56, 72]. Furthermore, in the setting of reduced 
WBPA, intra-cortical remodelling is reduced culminating in the accumulation of older 
bone which becomes hyper-mineralised, increasing the bone’s material density [6]. This 
increased density, further reduces tissue strains generated in the bone from mechanical 
loading. Older bone also has reduced osteocyte density and empty lacunae, which impairs 
the ability of the osteocyte network to sense and communicate strains, adversely affecting 
their viability and function [12, 38, 39], again interfering with the normal modelling and 
remodelling processes of the bone. 
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Using the algorithm by Schoenau et al [78], muscle CSA for height at the 66% tibial 
pQCT site was significantly reduced and bone mass was not appropriately adapted for 
muscle CSA indicating a mixed bone defect, and disruptions to the mechanical and 
biological aspects of the mechanostat. To provide further evidence of a mixed bone 
defect, bone-muscle proportions were also disrupted when considering the ratio of 
cortical CSA to muscle CSA at the 66% pQCT site, which was reduced at 4.3%, 5% 
indicating normal adaptation of the muscle and bone compartments. The significantly 
elevated cortical vBMD also supports a mixed bone defect. Cortical vBMD is linearly 
correlated with the intrinsic stiffness of bone tissue [126], a material property [6], and is 
tightly controlled to remain within a narrow optimal range which varies minimally 
between individuals [47, 48, 126]. The elevated cortical vBMD indicates the cortical 
bone tissue is stiffer than normal. This increase in stiffness means that when the bone is 
subjected to mechanical challenges form increasing bone length during growth and 
increased muscle force from WBPA, bone deformation will be reduced in comparison to 
the same mechanical load being applied to a bone with normal cortical vBMD [721]. This 
reduction in deformation culminates in diminished generation of tissue strains within the 
cortical bone tissue, and if it falls below the optimal minimally effective strains (MES) 
threshold range, the strain is not perceived by the osteocytes to require alterations in bone 
mass and geometry, and so the osteocyte does not direct bone cells to increase bone mass 
or optimise bone modelling during growth. This ultimately culminates in narrow 
diaphyses and reduced cortical bone mass, these inadequacies adversely affecting bone 
strength which is dependent on both bone quantity (mass) [1], and bone quality, which 
includes the geometric attributes of the bone [47, 48] . Furthermore, persistent absence of 
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strains in the MES threshold range, results in the osteocyte perceiving bone in the cortical 
compartment to be superfluous, directing the removal of cortical bone mass by endosteal 
resorption in an attempt to thin the bone so it will bend more easily with the application 
of mechanical loading, with the resultant associated bone strains then falling within the 
desired MES threshold range [35, 56, 72], but adversely affecting cortical thickness. This 
same mechanism drives bone resorption in the trabecular bone compartment, resulting in 
reduced trabecular BMD. This paradoxically high cortical vBMD but low trabecular 
vBMD also described in osteogenesis imperfecta [721]. 
 
A disruption in the biological aspect of the mechanostat could involve a genetic alteration 
to components of the organic extra-cellular matrix or an abnormality in the 
hydroxyapatite crystal size, shape or speed of the mineralisation process, either of which 
could result in hyper-mineralisation of the bone matrix [722], altered MES thresholds 
[35, 56, 72, 76], the inability of the osteocyte to correctly sense and interpret bone strains, 
interruptions to osteocyte communication with osteoblasts and osteoclasts and their 
ability to direct modelling and remodelling processes [12, 14, 21, 22], or a problem in the 
function of osteoblasts and osteoclasts themselves [114, 723-725].  
 
4.8.1.2 Observation Period 
 
The paediatric MRCD cohort reported significant reductions in patient and care-giver 
perceptions of current function as measured by the NPMDS. They followed their 
anthropometric trajectories, with no significant changes in SDS for height, weight or BMI 
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demonstrated nor were there significant changes in body composition SDS parameters. 
There were no changes in muscle functional performance measured by the CRT and 
6MWT. In the trabecular bone compartment, bone mass of lumbar spine increased 
significantly (3.7%), which was above the reported CV at our laboratory  (Table 2.1). 
however there were no changes in bone density. In the cortical compartment there were 
no changes bone mass however the SDS for legs BMD decreased significantly. This 
decline in leg BMD can be explained by the significant increases in leg bone area, which 
was not matched by increases in BMC of similar magnitude. It would appear that the rate 
of bone mineral accrual did not match the rate of bone area expansion, and this is a likely 
consequence of reduced habitual weight-bearing physical activity and progressive decline 
in muscle strength and function associated with MRCD in childhood [403-407, 410-412]. 
This mechanism is consistent with the mechanostat theory [47, 75] where bones adapt 
their structure, including bone mass, to withstand mechanical loads placed upon them 
from muscle contractions [73]. These findings are consistent with those previously 
documented, where impaired muscle activity or reduced weight-bearing physical activity 
has been linked to compromised bone mass accrual during skeletal growth [35, 56, 72]. 
Bone turnover markers remained stable indicating an ongoing state of increased bone 
resorption. In the paediatric MRCD cohort, bone density in the lower limbs was 
adversely affected during the observation period. 
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4.8.1.3 WBVT Period 
 
Patient, care-giver and clinician assessment found the impact of disease to have remained 
stable as measured by the NPMDS. The paediatric MRCD cohort continued to follow 
their anthropometric trajectories, however there was a significant increase in soft tissue 
CSA at the 66% pQCT site which was accompanied by a significant increase in the 
muscle CSA, indicating a preferential distribution of weight gain into the lean tissue 
compartment. There was a significant reduction in the amount of force required to 
perform the CRT, indicating improved muscle efficiency, however performance in the 
6MWT was unchanged. There were also significant improvements in parameters of both 
the trabecular and cortical bone compartments. Bone mass in the trabecular compartment 
increased significantly at the lumbar spine and 4% pQCT site and bone density at the 
lumbar spine after WBVT. In the cortical bone compartment, bone mass increased 
significantly on total body DXA and at the 20% and 66% pQCT sites. Cortical bone 
density measured by DXA and at the 20% pQCT site also demonstrated significant 
increases after WBVT. The significant reduction in leg BMD seen in the observation 
period was also attenuated. There were also significant increases in parameters of cortical 
bone geometry and strength at both the 20% and 66% pQCT sites. There was no 
significant change in the bone resorption marker, however osteocalcin, a bone formation 
marker, significantly decreased, but remained within its reference range. These 
favourable improvements in trabecular bone mass and density, cortical bone mass, 
density, geometry and strength, appear to be a result of the WBVT as they were not seen 
during the observation period. Adherence to the WBVT protocol in the paediatric MRCD 
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cohort was 62%. This amount of WBVT appears to be successful in improving trabecular 
and cortical bone health and muscle CSA in the calf of children with MRCD. 
 
 
4.8.1.4 Follow-up period 
 
 
Patient, care-giver and clinician assessment found the impact of disease to have remained 
stable as measured by the NPMDS. The paediatric MRCD cohort continued to follow 
their anthropometric trajectories, however there was a significant increase in fat CSA at 
the 66% pQCT site which was accompanied by a significant increase in the ratio of fat to 
muscle CSA and in the ratio of muscle CSA to total soft tissue CSA, indicating a 
preferential distribution of weight gain into the fat compartment. There was a significant 
increase in the amount of force required to perform the CRT, indicating worsening 
muscle efficiency, and performance in the 6MWT remained unchanged. Bone mass and 
density in the trabecular bone compartment demonstrated non-significant reductions. 
Cortical bone mass remained stable however the total body bone density decreased 
significantly. Cortical bone geometric attributes and strength demonstrated significant 
increases at the 66% pQCT site. There were no significant changes in bone turnover 
markers. These findings suggest a de-training effect in the follow-up period with 
particular effects in the trabecular bone compartment and soft tissue composition of the 
calf. 
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4.8.2 Adult Cohort  
 
 
4.8.2.1 Baseline 
 
 
The adult MRCD cohort presented with mild impact of their disease on current status as 
measured by the NMDAS. The mean BMI of the cohort was within the normal range 
however the muscle CSA measured at the 66% tibial pQCT site was significantly reduced 
compared to the reference population in males and post-menopausal females, indicating 
that the lean tissue compartment was compromised. Furthermore, total body fat percent 
for the adult MRCD cohort was 35.9%, the upper limit of normal for adult females but 
higher than that expected for adult males, and at the 66% pQCT site, fat CSA was 
28.74cm
2
, between the mean values seen in healthy adult males, 18.2cm
2
, and females 
34.2cm
2
 [720], however fat CSA as a percentage of muscle CSA had a mean value of 
56.7%), much higher than the 20% and 47% seen in their healthy counterpart [720]. The 
reduced lean mass and increased proportion of fat to muscle are important factors in the 
maintenance of bone health and these abnormalities may cause accelerated bone loss and 
the early development of osteoporosis [3, 95]. 
 
Consistent with the paediatric MRCD cohort, the adult MRCD cohort had impairments in 
muscle performance during functional activities and reduced habitual WBPA, further risk 
factors the maintenance of bone health [4, 55]. Force SDS in the M1LJ, S2LJ and CRT 
and force efficiency SDS in the S2LJ were significantly reduced. Functional muscle 
performance was also impaired with significantly increased time to perform the CRT, a 
 413 
6MWT distance of 71% of predicted and peak oxygen uptake corrected for body weight 
and peak power output of 45% predicted. The inadequacies in lean mass, functional 
muscle performance and habitual WBPA were reflected in significantly reduced physical 
function related domains of the SF12v2. These limitations in muscle performance and 
ability to participate in regular WBPA, that is osteogenic or osteo-protective in nature 
[97, 98, 100], would have negative ramifications on the maintenance of bone health in 
adulthood. 
 
Similar to the paediatric MRCD cohort, compromised bone health was seen in both the 
trabecular and cortical bone compartments. In the trabecular compartment, bone density 
at the 4% tibial pQCT site was significantly reduced compared to the reference 
population in males. Impairments were also seen in cortical bone mass, density, geometry 
and strength. Cortical bone mass at the 20% pQCT site was significantly reduced in 
males. Compromised cortical density was evidenced by significantly increased cortical 
vBMD at the 20%. Cortical bone geometric attributes were also significantly reduced at 
the 20% and 66% pQCT sites and compromised bone strength was evident at the 20% 
site. A further risk factor for compromised bone health was seen by the uncoupling of 
normal bone turnover, with the majority of the adult cohort having a decreased level of 
the bone formation marker, osteocalcin and an increased level of the bone resorption 
marker, urinary deoxypyridinoline: creatinine ratio, indicating that bone remodelling in 
the adult MRCD cohort favoured bone resorption and accelerated loss of bone, a 
suboptimal climate for the maintenance and preservation of long term bone health. In 
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adult medicine, bone turnover markers have been used to predict the presence and 
development of osteoporosis [726, 727] and risk of fracture [727, 728]. 
 
In summary, the adult MRCD cohort presented with a remarkably similar bone 
phenotype to the paediatric MRCD cohort, with narrow diaphyses, reduced cortical bone 
mass and strength, increased cortical density and reduced trabecular density. Total BMC 
for muscle CSA was not significantly different to the reference population, indicating that 
BMC was appropriately adapted to muscle CSA, suggesting the low bone mass 
phenotype seen in the adult cohort was secondary to reduced lean mass, a disruption to 
the mechanical aspect of the mechanostat. The preservation of the bone-muscle 
proportions when considering the ratio of cortical CSA to muscle CSA at the 66% pQCT 
site, also supports a secondary bone defect. The disruption to the mechanical aspect of the 
mechanostat was impacting on the magnitude and frequency of bone tissue strains 
generated, as well as the viability and function of the osteocytes [12, 38, 39] in their 
ability to sense and respond to bone strains, and altering the bone tissue environment by 
reducing intra-cortical remodelling resulting in older, more dense bone [6] and directing 
bone losses in the trabecular bone compartment and on the endosteal surfaces of cortical 
bone [35, 56, 72]. 
 
The significantly elevated cortical vBMD, cortical BMC for CSA ratio and distribution-
mass curves at the 20% provide evidence for a mixed bone defect and an additional 
disruption to the biological aspect of the mechanostat. This is further supported by the 
findings in the distribution-quality curve at the 20% pQCT site that demonstrates reduced 
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cortical CSMI was a direct consequence of the elevated cortical density as the normal 
relationship of the mechanostat was preserved. The significantly reduced bone CSA in 
the MRCD adult cohort also supports an interruption to the biological aspect of the 
mechanostat. Any of the biological disruptions causing increased cortical density, 
described for the paediatric MRCD cohort, are likely to have been present since birth and 
could explain the small bone size seen in the adult MRCD cohort, as bone mass accrual, 
periosteal apposition and geometric adaptations would have been hindered during growth 
impacting on the size and integrity of the mature adult bone. This is an interesting 
finding, as only three of the twelve adult participants reported symptoms in their 
paediatric years, and despite the remaining nine adult participants describing symptom 
onset and diagnosis in their adult years, there appears to have been a disruption to normal 
bone modelling during the paediatric years.  
 
4.8.2.2 Observation Period 
 
 
Patient and clinician assessment found the impact of disease to have remained stable as 
measured by the NMDAS. There were no significant changes in anthropometric variables 
however total body LTM and legs LTM measured by DXA decreased significantly, a 
clinically concerning outcome due to the already reduced baseline LTM in this cohort 
seen at the 66% pQCT measured by muscle CSA. The loss of lean tissue mass was 
greater in the legs compared to the total body indicating that this area of the body is most 
sensitive to disease progression in MRCD. This is likely a consequence of the progressive 
decline in muscle strength, function, weight bearing physical activity and exercise 
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tolerance that is reported in MRCD [403-407, 410-412].  There were no changes in 
muscle force parameters or functional measures and physical domains of the SF12v2 
remained stable. There were no changes to bone mass or density in the trabecular 
compartment or to bone mass or geometry in the cortical compartment, however legs 
BMD decreased significantly, likely associated with the significant decrease in legs 
LTM. According to the mechanostat theory [47, 75], bones adapt their structure, to 
withstand mechanical loads placed upon them from muscle contractions [73], to resist 
mechanical failure [74]. The reduction in LTM during the observation period would have 
likely reduced the magnitude of the habitual forces imposed on the underlying bones 
resulting in the reduced bone density seen in the adult MRCD cohort. Bone turnover 
markers did not change significantly, consistent with one previous study [729], and 
continued to reflect un-coupled bone turnover, with remodelling of the adult skeleton 
continuing to favour bone resorption and accelerated bone loss, consistent with the 
significant loss of BMD in the legs. In the adult MRCD cohort, lean tissue mass and bone 
density in the lower limbs demonstrated deterioration in the observation period. 
 
 
4.8.2.3 WBVT Period 
 
 
After WBVT, patient and clinician assessment found the impact of disease to have 
improved as measured by the NMDAS. There were no significant changes in 
anthropometric variables however the significant decline in total body LTM and legs 
LTM seen during the observation period was hindered. There were no significant changes 
in muscle force parameters however chair rise test speed increased significantly and there 
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was a non-significant increase on the 6MWT distance of 5%. A similar magnitude non-
significant increase was also seen in peak VO2 corrected for body weight. The role 
physical domain of the SF12v2 also demonstrated a non-significant increase of half a 
SDS. The trabecular bone compartment did not demonstrate any significant changes after 
WBVT however in the cortical compartment, legs bone density measured by DXA 
increased significantly. No changes in bone mass, geometry or strength were seen in the 
cortical bone compartment. Bone turnover markers remained unchanged, in a state of un-
coupled bone turnover. Adherence to the WBVT protocol in the adult MRCD cohort was 
64%. This amount of WBVT appears to have a beneficial effect of WBVT on physical 
function, lean tissue mass and bone density of the legs, counteracting deficits seen during 
the observation period. 
 
 
4.8.2.4 Follow-up Period 
 
 
Patient and clinician assessment found the impact of disease to have remained stable as 
measured by the NMDAS. There were no significant changes in anthropometric variables 
or lean mass. Maximum force and power in the CRT increased significantly, however 
6MWT distance did not change significantly. There was a non-significant reduction in 
peak VO2 corrected for body weight of 8% and several parameters at the anaerobic 
threshold also demonstrated clinically relevant reductions, indicating a deterioration in 
oxidative capacity. Physical domains of the SF12v2 remained stable. There we no 
significant changes in the trabecular bone compartment or in bone mass or strength in the 
cortical compartment. However, cortical density and geometry demonstrated significant 
reductions. Bone turnover markers did not change significantly with the persistence of 
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uncoupled bone turnover favouring bone resorption. When considering all outcomes, 
there appears to have been a detraining effect in the follow-up period with particular 
effects on muscular performance and the cortical bone compartment. 
 
4.8.3 Leigh Syndrome Cohort 
 
 
4.8.3.1 Baseline 
 
 
The Leigh Syndrome cohort presented with mild impact of their disease on current status 
as measured by the NPMDS. The mean BMI of the cohort was at the lower end of the 
normal range. The distribution of soft tissue in the lean and fat compartments was unable 
to be analysed due to the mixed paediatric and adult nature of the cohort. Muscle force 
SDS were significantly reduced in the M1LJ and S2LJ, dynamic manoeuvres, however 
the force SDS for the CRT, a functional test, was significantly elevated, indicating 
adversely affected force production and muscle efficiency. Functional muscle 
performance was also impaired with a significantly increased time to perform the CRT 
and a 6MWT distance of 57% of predicted. The only bone parameters available to assess 
the cohort compared to a reference population were the total body and lumbar spine 
BMD SDS. The total body SDS was not significantly different to the reference 
population but the lumbar spine SDS was significantly reduced and lower than both the 
paediatric and adult cohorts, suggesting that the trabecular bone compartment may be 
more affected in Leigh Syndrome compared to other MRCD. Bone turnover markers 
indicated an increased level of the bone resorption marker, urinary deoxypyridinoline: 
creatinine ratio. Deficits in muscle force production and functional muscle performance 
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as well as the uncoupled bone turnover favouring bone resorption in the Leigh Syndrome 
would have contributed to the compromised bone health seen in the trabecular bone 
compartment. 
 
4.8.3.2 Observation Period 
 
 
Patient, care-giver and clinician assessment found the impact of disease to have remained 
stable as measured by the NPMDS. There were no significant changes in anthropometric 
variables or in muscle force parameters. However, the 6MWT distance and its percent of 
predicted decreased significantly indicating worsening of functional exercise capacity. 
There were no changes to bone mass or density in the trabecular compartment measured 
by DXA. In the cortical bone compartment, legs BMC and total body BMD increased 
significantly.  Bone turnover markers did not change significantly, continuing to reflect 
increased bone resorption. Functional exercise capacity demonstrated the most prominent 
changes during the observation period. 
 
4.8.3.3 WBVT Period 
 
 
After WBVT, the impact of the disease on current function remained stable according to 
patient, care-giver and clinician assessment measured by the NPMDS. Weight increased 
significantly, a change that was not seen in the paediatric or adult cohorts. Muscle force 
parameters measured by the CRT did not change, however there was a non-significant 
9% increase in the 6MWT distance, which contrasts to the significant decline seen in the 
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observation period. There were no changes to bone mass or density in the trabecular 
compartment measured by DXA or pQCT. In the cortical bone compartment, bone mass 
increased in the legs DXA measurement and at the 20% and 66% pQCT sites. There were 
no significant changes in bone density, however geometric attributes demonstrated 
significant increases in the legs DXA measurement and at the 20% and 66% pQCT sites. 
Bone strength increased significantly at the 20% pQCT site.  Bone turnover markers did 
not change significantly, with an uncoupling of bone turnover favouring bone resorption 
persisting. Adherence to the WBVT protocol in the Leigh Syndrome cohort was 61%. 
This amount of WBVT appears to have been beneficial in slowing the decline in 
functional exercise capacity and in promoting changes in bone mass, geometry and 
strength in the cortical bone compartment. 
 
 
4.8.3.4 Follow-up Period 
 
 
Clinician assessment of current status measured by the NPMDS increased significantly 
during follow-up indicating worsening of clinical manifestations. Significant increases in 
weight were again seen, in contrast to that seen in the paediatric and adult cohorts. 
Muscle force parameters in the CRT increased significantly indicating further progression 
of abnormal muscle efficiency. There was not a significant change in the 6MWT 
distance. Similar to the observation and WBVT periods, there were no significant 
changes in bone mass or density in the trabecular bone compartment. In the cortical bone 
compartment, legs BMC measured by DXA increased significantly as did bone strength 
at the 66% pQCT site. There were no significant changes in bone turnover markers with 
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bone resorption measured by the urinary deoxypyridinoline: creatinine ratio remaining 
higher than the reference range. There does not appear to be a de-training effect after 
removal of the WBVT stimulus in the Leigh Syndrome cohort. 
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5 Discussion 
 
 
The discussion regarding the effect of WBVT on chronic disease will be presented from 
the paediatric perspective, considering the CF cohort and the paediatric MRCD cohort, 
followed by the adult perspective, considering the adult MRCD cohort. Finally, the 
findings for the Leigh Syndrome cohort, a genetically identical, mixed adult and 
paediatric MRCD cohort will be presented. This approach is consistent with the existing 
literature in WBVT which predominantly reports paediatric or adult cohorts, and allows 
the investigation of the effects of WBVT on the immature growing skeleton as well as the 
mature adult skeleton, which may respond differently to WBVT. 
 
5.1 Paediatric Perspective 
 
 
5.1.1 Effect of WBVT on Bone and Body Composition Parameters 
 
5.1.1.1 WBVT Period 
 
5.1.1.1.1 Trabecular Bone Compartment 
 
The trabecular bone compartment was investigated using lumbar spine DXA scans and 
pQCT at the 4% tibial site. 
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5.1.1.1.1.1 Bone Mass 
 
The CF cohort and paediatric MRCD cohort demonstrated significant improvements in 
bone mass in the trabecular compartment measured by lumbar spine DXA and pQCT at 
the 4% site after WBVT. In the CF cohort, lumbar spine BMC increased significantly by 
1.7g (5.4%), as did the BMC of lumbar vertebrae 1-4 by 2.1g (5.2%) In the paediatric 
MRCD cohort, lumbar spine BMC increased significantly by 1.4g (7.3%), as did the 
BMC of lumbar vertebrae 1-4 by 1.7g (7.0%). These increases in both cohorts were well 
above the reported CV at our laboratory (Table 2.1). The lumbar spine BMC SDS did not 
show a significant change after WBVT in either cohort indicating that these changes were 
likely consistent with normal growth. In the CF cohort, the improvements seen after 
WBVT were slightly smaller than the improvements seen during the observation period, 
suggesting no effect of WBVT on bone mass in the trabecular compartment. Previous 
studies have also suggested a negligible effect of WBVT on trabecular bone mass. In a 
study of adolescent females, mean age 17 years, with low bone density and a history of 
fracture, randomised to home-based low-magnitude vertical WBVT (30Hz, 0.3g, 10 
minutes a day) or control, lumbar spine BMC significantly increased after WBVT by 
2.1g (2%), however these improvements were not significantly different to their control 
group [207]. In another study of osteopoenic adolescent girls with idiopathic scoliosis, 
mean age 18 years, randomised to home-based low-magnitude vertical WBVT (32-37Hz, 
0.3g, 20 minutes, 5 times a week for 12 months) or control, lumbar spine BMC increased 
by 1.2g (3.5%), p=0.05, after WBVT, however this was not significantly difference to the 
control group [206]. The smaller improvement in lumbar spine BMC seen in these 
studies, compared to the CF and MRCD cohorts, may be due to the use of low-magnitude 
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WBVT in comparison to the higher magnitude vibration used in the CF cohort. Another 
study of 19 children, 5-16 years of age, with cerebral palsy and other neurological 
conditions, using school-based low-magnitude vertical WBVT (40-42Hz, 0.2mm, 5 -15 
minutes, at least twice a week for 6 months) improved lumbar spine BMC by 1.2g (7%). 
This improvement, however, was not found to be significantly different to their baseline 
measures [730]. 
 
In the paediatric MRCD cohort, as the observation and WBVT periods cannot be directly 
compared due to the varying lengths of the two periods, 4.3 months compared to 6.5 
months respectively, the rates of increase in DXA parameters were calculated accounting 
for the disparity in the length of the two research periods. The rate of increase in lumbar 
spine BMC and the BMC of lumbar vertebrae 1-4 was 63%, 32% higher than the rate of 
increase seen during the observation period respectively. These improvements in bone 
mass support a beneficial effect of WBVT in the paediatric MRCD cohort, which has 
some support in the existing literature. Healthy children and children with Down 
Syndrome, 12-18 years of age, significantly increased lumbar spine (L1-4) BMC in both 
the Down Syndrome and healthy groups by 2.5g (6.6%), and by 3.4g (8.0%) after vertical 
WBVT (25-30Hz, 2mm, 5-10 minutes, 3 times a week, for 20 weeks) [731]. The percent 
changes in L1-4 BMC were similar in value to the increases seen in the paediatric MRCD 
cohort, despite the higher vibration frequency used. In another study of adolescents and 
young adults, mean age 16 years, with cerebral palsy GMFCS levels II and III, side-
alternating WBVT (20Hz, 9 minutes a day, 4 times a week for 20 weeks) significantly 
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increased lumbar spine BMC by 2.7g (5.1%) [732], similar in magnitude to the results 
seen in both the CF and paediatric MRCD cohorts with a similar training stimulus. 
 
Significant improvements in bone mass were also seen at the 4% pQCT site 
in the CF and paediatric MRCD cohorts after WBVT. In the CF Cohort, total bone BMC 
increased significantly by 7.5mg/mm (3.3%), much larger than the non-significant 
increase seen during the observation period in the CF cohort.  Total bone BMC increased 
by 9.2mmg/mm (7.3%) in the paediatric MRCD cohort. Neither cohort demonstrated a 
significant improvement in trabecular BMC at the 4% tibial pQCT site which is 
calculated on the inner 45% of the 4% site cross-section. These results indicate that at the 
4% pQCT site, WBVT appears to have improved bone mass from the outer perimeter 
inwards rather than the central area of the cross-section outwards. There are no reports in 
the existing literature of the effects of WBVT on bone mass at the 4% pQCT site. 
 
5.1.1.1.1.1.1 Summary  
 
 
Bone mass in the trabecular bone compartment, measured at different sites using two- 
and three-dimensional imaging techniques demonstrated significant increases after 
WBVT in the CF and paediatric MRCD cohorts. In the CF cohort, increases seen in the 
lumbar spine were very similar to those seen during the observation period and appears to 
be consistent with normal growth, however the increases seen at the 4% pQCT site were 
larger than those seen during the observation period in the CF cohort suggesting a benefit 
of WBVT on trabecular bone mass. The paediatric MRCD cohort demonstrated increases 
at the lumbar spine of greater magnitude compared to those seen during the observation 
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period as well as a significant increase at the 4% pQCT site, supporting a beneficial effect 
of WBVT on trabecular bone mass. Despite the lack of consensus, in the limited existing 
literature, on the effect of WBVT on trabecular bone mass in children, the increases seen 
in bone mass in the trabecular bone compartment, particularly at the 4% tibial pQCT site, 
will contribute beneficially towards improving trabecular BMD which was significantly 
reduced compared to the reference population prior to the commencement of WBVT at 
this site in both cohorts. 
 
5.1.1.1.1.2 Bone Density 
 
During the WBVT period, there were significant increases in trabecular bone density in 
the CF and paediatric MRCD cohorts. In the CF cohort, lumbar spine BMD increased 
significantly by 0.023g/cm
2
 (2.6%), and trunk BMD from the segmental analysis of the 
total body DXA scan increased significantly by 0.018g/cm
2
 (2.3%), similar in magnitude 
to the improvements seen during the observation period and above the CVs of our 
laboratory. The lumbar spine BMD SDS did not change significantly after WBVT, 
suggesting these changes in BMD were associated with normal growth, and suggest no 
effect of WBVT on trabecular bone density. Other studies have found similar outcomes. 
In a study of children with cerebral palsy and other neurological conditions, low-
magnitude vertical vibration increased lumbar spine BMD by 0.016g/cm
2
 (3%), however 
this improvement was not statistically different to the baseline value in this cohort and 
there was no corresponding change in the lumbar spine BMD SDS [730]. In children with 
Osteogenesis Imperfecta (OI), with a mean age 9 years, using side-alternating WBVT 
with a tilt-table (15-20Hz, 9 minutes twice a day for 6 months) as part of a 12-month 
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intensive physiotherapy program, lumbar spine BMD increased significantly by 
0.05g/cm
2
 (12%), however there was no change in the corresponding SDS [203]. These 
improvements in lumbar spine BMD were much larger than those seen in the CF cohort, 
perhaps due to the longer daily training, 18 minutes compared to 9 minutes, or the 
concurrent intensive physiotherapy program. In another study of adolescent females, 
home-based low-magnitude vertical WBVT  improved lumbar spine BMD by 0.02g/cm
2
 
(2.3%), however this improvement was not significantly different to the control group 
[207]. This study also measured spinal volumetric BMD by quantitative computed 
tomography and found a 2.1% increase in this measure after WBVT, however, did not 
hold its significance when compared to the control group [207]. Two other studies 
investigating the effect of WBVT on spinal volumetric BMD using quantitative 
computed tomography. Six months low-magnitude vertical WBVT (90Hz, 0.3g, 10 
minutes, 5 times a week) during a standing program in children with disabling conditions 
and motor impairment, with a mean age 9 years, found a signifincat increase of 5.5% in 
spinal vBMD, however this was not signifncatly different to the untreated group  [197]. A 
second study in children with cerebral palsy, with a mean age 9 years, investigating the 
same intervention (low-magnitude vertical WBVT 30Hz, 0.3g, 10 minutes a day) using a 
randomised cross-over design, did not find any improvements in spine vBMD over time 
or compared to the control group [199]. Two previous studies have investigated the effect 
of WBVT on lumbar spine vertebrae 1-4 BMAD. The first, a shorter duration study of 
side-alternating WBVT (16-24Hz, 4mm, 2-6 minutes, 2-3 times a week for 3 months) in 
boys with Duchenne Muscular Dystrophy (DMD), mean age 7 years, found BMAD of 
the lumbar vertebrae 1-4 and its corresponding SDS did not change significantly after 
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WBVT [204], consistent with the results seen in the CF and paediatric MRCD cohorts. In 
contrast, adolescents with Down Syndrome and age-matched healthy controls, had 
significant improvements in lumbar vertebra 1-4 BMAD of 0.023g/cm
2
 (2.9%) in those 
with Down Syndrome and 0.028g/cm
2
 (3.5%) in the healthy controls after 20 weeks of 
vertical WBVT [731]. 
 
In the paediatric MRCD cohort, lumbar spine BMD increased 0.050g/cm
2
 (7.4%), and the 
lumbar spine BMD SDS also increased significantly by 0.4. There was also a significant 
increase in trunk BMD of 0.018g/cm
2
 (2.8%), however the corresponding SDS did not 
change significantly. The rate of increase in lumbar spine BMD was over 300% greater 
than the rate of increase seen in the observation period and the significant increase in 
trunk BMD was in contrast to a reduction in trunk BMD seen during the observation 
period. The increase in lumbar spine BMD and trunk BMD supports a beneficial role of 
WBVT in this cohort of children with MRCD, as the lumbar spine BMD SDS as well as 
the trunk BMD SDS were significantly reduced compared to the reference population 
prior to the commencement of WBVT. These increases in lumbar spine BMD seen in the 
paediatric MRCD cohort are consistent with the findings of previous studies investigating 
the effects of WBVT in other paediatric cohorts. Lumbar spine BMD increased 
significantly by 0.013g/cm
2
 in children with cerebral palsy, 6-12 years of age, 
randomised to side-alternating WBVT with a tilt-table (12-18Hz, 2-4mm, 9 minutes, 5 
times a week for 6 months) in addition to conventional physiotherapy, however this 
improvement was not significantly greater than the improvement seen in those 
randomised to conventional physiotherapy alone [198]. The magnitude of this 
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improvement was less than that seen in the paediatric MRCD cohort, and may be due to 
any of the following difference between the MRCD study and the Ruck et al [198] study: 
daily compared to 5 times a week WBVT; the vibration frequency of 20Hz compared to 
18Hz; the use of shoes in the Ruck et al [198] study which dampens the transmission of 
the vibration stimulus to the legs; foot placement further away from the central fulcrum in 
the MRCD cohort resulting in greater amplitude displacement and therefore a greater 
vibration stimulus; and the use of a tilt table in the Ruck et al [198] study which reduces 
the amount of weight perpendicular to the vibration platform, again reducing the 
magnitude of the vibration stimulus delivered to the legs [198]. Another study in children 
with CP, utilising WBVT in addition to a conventional exercise training, found that 
lumbar spine BMD increased 0.16g/cm
2
 after a similar intervention period [201]. The 
larger results seen in this study compared to the paediatric MRCD cohort may be due to 
additional benefit of the conventional exercise training in addition to the WBVT. In 
adolescents and young adults with cerebral palsy, 20 weeks of side-alternating WBVT 
significantly increased lumbar spine BMD by 0.014g/cm
2
 (1.3%) [732], smaller than the 
improvements seen in the paediatric MRCD cohort despite a similar training protocol. 
However, the paediatric MRCD cohort had a younger mean age, which may have 
allowed greater improvements in the trabecular bone compartment in response to WBVT.  
 
WBVT also had a significant effect on total vBMD measured by pQCT at the 4% site in 
the CF cohort, which increased by 6.056mg/cm
3
 (2.0%), larger than the reported CV 
reported in the current literature [61], and no significant changes in these measures were 
seen during the observation period, suggesting the WBVT is having a beneficial effect on 
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vBMD in the trabecular bone compartment. Similar to the finding for BMC at the 4% 
pQCT site, there were no significant changes in trabecular vBMD, which measures the 
inner 45% of the pQCT cross-section, indicating that improvements in vBMD are 
occurring from the outer perimeter inwards. However, this increase in total vBMD will 
contribute beneficially towards improving trabecular bone density which was 
significantly reduced compared to the reference population at baseline at the lumbar spine 
and 4% pQCT site. In the paediatric MRCD cohort there was no effect of WBVT on total 
or trabecular vBMD at the 4% pQCT site. The results seen in the CF and paediatric 
MRCD cohorts for trabecular vBMD at the 4% pQCT site were consistent with a 
previous study in 6 ambulant boys with DMD, 7 years of age, where there was no 
significant change in trabecular vBMD at the 4% pQCT site after 3 months of side-
alternating WBVT (16-24Hz, 4mm, 2-6 minutes, 2-3 times a week for 3 months) [214]. 
Two other studies investigated the effects of 6 months low-magnitude vertical WBVT 
during a standing program on proximal tibial trabecular vBMD measured by quantitative 
computed tomography. The first study involving children and adolescents, with disabling 
conditions, found a significant increase in proximal tibial trabecular vBMD of 6.27mg/ml 
(6.3%) in those using low-magnitude WBVT compared to a decrease in the same 
measure in the untreated group [197]. The second study in children with cerebral palsy, 
found no significant changes in proximal tibial trabecular vBMD with the addition of 
low-magnitude WBVT to a daily standing program using a randomised cross-over design 
[199]. The difference in results between these studies may be due to the higher vibration 
frequency used by Ward et al [197], 90Hz, compared to 30Hz in the Wren et al [199] 
study. Another study in adolescent girls, with idiopathic scoliosis, did not find an effect 
 431 
of 12 months home-based low-magnitude vertical WBVT on distal tibial vBMD 
measured by high-resolution pQCT over time or compared to controls [206]. 
 
5.1.1.1.1.2.1 Summary  
 
 
The greatest improvements in bone density in the trabecular bone compartment after 
WBVT occurred at the 4% distal tibial pQCT site in the CF cohort. The effects of WBVT 
may have been more pronounced at the 4% distal pQCT site compared to the lumbar 
spine, due to the proximity of this trabecular bone site to the vibration platform, which 
would have received the greatest vibration stimulus, before the acceleration was 
dissipated as it travelled caudally towards the lumbar spine. In contrast, the greatest 
improvements occurred in the lumbar spine in the paediatric MRCD cohort. The effects 
of WBVT may have been more pronounced in the lumbar spine compared to the 4% 
distal pQCT site, due to the side-alternating nature of the vibration stimulus which 
produces rotational movements around the pelvis and lumbar spine [154], the rapid 
repeated concentric and eccentric muscle contractions [159, 160] in this area having a 
more profound effect on the trabecular bone in the spine than the effect of the vibration 
stimulus on the distal tibia.  
 
There are conflicting results in the current literature as to whether WBVT has a beneficial 
effect on bone density in the trabecular bone compartment measured by both two-
dimension and three-dimensional techniques. This is likely a consequence of the variation 
in analysis sites and analysis methods described, the variable WBVT intervention 
protocols employed and the different patient groups investigated, whose underlying 
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conditions may cause bone to behave differently in response to WBVT. Larger studies, 
investigating different paediatric cohorts with factors compromising the attainment or 
maintenance of optimal bone health are required, and need to utilise similar analysis 
techniques to elucidate the effect of WBVT on the trabecular bone compartment centrally 
in the spine and peripherally in the metaphyseal regions of long bones. 
 
5.1.1.1.2 Cortical Bone Compartment 
 
The cortical bone compartment was investigated using total body DXA scans, segmental 
analysis of these scans, and the 20% and 66% sites of the tibial pQCT scans. 
 
5.1.1.1.2.1 Bone Mass 
 
Bone mass increased in the cortical bone compartment after WBVT in the CF cohort on 
analysis of total body DXA scans and pQCT scans at the 20% and 66% sites. Total body 
BMC increased significantly by 78.2g (4.6%), above the reported CV for this measure 
from our laboratory (Table 2.1), however this increase was smaller than the increase seen 
during the observation period and the corresponding SDS did not change significantly, 
suggesting normal increase with growth. The total body BMC for total body bone area 
SDS increased significantly during the WBVT period by 0.1, indicating that bone mass 
was being accrued at a greater rate than bone area expansion. Similar changes were seen 
in the paediatric MRCD cohort after WBVT. Total body BMC increased significantly by 
46.8g (4.5%), however the corresponding SDS did not change significantly. The rate of 
increase in total body BMC during the WBVT period was 23% greater than the rate of 
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increase in BMC seen during the observation period and occurred in the context of 
equivalent increases in height in the two time periods, so cannot be accounted for by 
skeletal growth alone, supporting a beneficial effect of WBVT in the paediatric MRCD 
cohort. Furthermore, while not statistically significant, total body BMC SDS and the total 
BMC to total LTM SDS increased during the WBVT period, in contrast to reductions in 
these parameters seen during the observation period, and total body BMC to total body 
bone area SDS showed larger improvements during the WBVT period than during the 
observation period. 
 
The improvements in total body BMC seen in the CF and paediatric MRCD cohort after 
side-alternating WBVT are similar to those reported in existing studies investigating the 
effects of side-alternating WBVT in other paediatric populations. In a study of children 
with bilateral spastic cerebral palsy, GMFCS I-V, with a mean age 9.8 years, using side-
alternating WBVT with a tilt-table (5-25Hz, up to 9mm, 9 minutes twice a day for 6 
months) as part of an intensive physiotherapy program (including resistance training, 
treadmill walking and hydrotherapy), total body BMC significantly increased 5.7% after 
6 months of WBVT [200]. A similarly designed study in children with OI reported 
significant improvements in total body BMC of 63.1g (21%), but no significant change in 
the corresponding SDS, after side-alternating WBVT as part of a 12 month intensive 
physiotherapy program [203]. The larger increases seen in these studies compared to the 
CF cohort, likely attributable to the physiotherapy intervention which was concurrently 
performed, the higher amplitude used or longer training times. Another study using side-
alternating WBVT in adolescents and young adults with cerebral palsy, found a 
 434 
significant improvement in total body BMC after WBVT of 48g (2.3%) [732]. This 
improvement was slightly smaller than the one seen in the CF and paediatric MRCD 
cohorts, despite a very similar training protocol. In another study, 6 months vertical 
WBVT in children with cerebral palsy and other neurological conditions, significantly 
increased total body BMC by 33.5g (7%), a slightly larger percentage increase than that 
seen in the CF and paediatric MRCD cohorts, perhaps a reflection of the different 
vibration stimulus employed, vertical compared to side-alternating. Another study 
investigating the effect of side-alternating WBVT in children with DMD, found that 3 
months of WBVT increased total body BMC by 47g (6.6%) [204], a slightly greater 
percentage increase compared to that seen in the CF  and paediatric MRCD cohorts, 
perhaps due to the younger mean age in the Soderpalm et al [204] study. In a study of 
adolescent females, with a mean age 17 years, with low bone density and a history of 
fracture, randomised to low-magnitude vertical WBVT (30Hz, 0.3g, 10 minutes a day for 
12 months) or control, total body BMC significantly increased by 53.5g (3.5%) however 
this was not significantly different to the control group [207]. Another study utilising 
vertical WBVT in adolescents with Down Syndrome and age-matched healthy controls, 
12-18 years, demonstrated significant improvements in total body BMC of 51.7g (3.7%) 
in the Down syndrome group and 145.8g (8.0%) in the control group after 20 weeks of 
WBVT (25-30 Hz, 5-10 minutes, 3 times a week) [731]. The improvements seen in the 
Down Syndrome cohort were similar in magnitude to those seen in the CF cohort but 
smaller than the improvements seen in the control group, an indication that healthy 
adolescents with no musculoskeletal compromise may have a larger benefit from WBVT. 
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Improvements in bone mass were also seen when segmental analyses of the total body 
DXA scans were performed. In the CF cohort there was a statistically significant 
increases in legs BMC, of 35.1g (5.5%), above the reported CV from our laboratory, but 
similar in magnitude to the increases seen in these measures during the observation 
period, indicating that WBVT is unlikely to have influenced bone mass accrual.  
In the paediatric MRCD cohort, legs BMC increased significantly by 11.8g (3.8%), 
however, the rate of increase in legs BMC during the WBVT period was similar to the 
rate of increase seen during the observation period again indicating no effect of  WBVT 
on bone mass accrual. These findings were similar to those seen in the existing literature. 
Lower limb BMC significantly improved by 13g (2%) in adolescents and young adults 
with cerebral palsy, GMFCS II and III, with a mean age 16 years, after 20 weeks of side-
alternating WBVT (20Hz, 406mm, 9 minutes, four times a week) [732], slightly smaller 
than the increases seen in the CF and paediatric MRCD cohorts despite the similar 
vibration training protocol. Another study using vertical WBVT (25-30Hz, 5-10 minutes, 
3 times a week) in adolescents with Down Syndrome and age-matched healthy controls, 
12-18 years, found that 20 weeks of WBVT, significantly increased lower limb BMC in 
those with Down Syndrome by 26.7g (6.0%) and in the healthy controls by 46.7g (6.9%) 
[731]. The gains in both these cohorts were greater than the gains seen in the CF and 
paediatric MRCD cohorts and may be a reflection of the WBVT stimulus used, vertical 
compared to side-alternating, or alternatively due to the adolescent age group studied by 
Matute-Llorente et al [731] where gains in BMC are likely to have been enhanced by the 
adolescent growth spurt [733]. One previous study, investigated the effect of WBVT on 
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femoral BMC and it did not find significant improvements in BMC of the femur after 
side-alternating WBVT in adolescents and young adults with cerebral palsy [732]. 
 
At both the 20% 66% tibial pQCT sites, significant increases in BMC were seen after 
WBVT in the CF cohort.  Total bone and cortical BMC at the 20% pQCT site increased 
significantly by 8.0mg/mm (4.0%) and 7.3mg/mm (4.3%) respectively. The SDS for 
cortical BMC also increased significantly by 0.3. At the 66% pQCT site significant 
increases in total and cortical BMC of 7.3mg/mm (3.8%) and 7.6 mg/mm (3.5%), and the 
cortical BMC SDS increased significantly by 0.3. These improvements in BMC 
parameters at the 20 and 66% pQCT site were similar in magnitude to those seen during 
the observation period and are most likely associated with growth and not a direct 
consequence of the WBVT. In contrast the paediatric MRCD cohort demonstrated 
increases that would support a beneficial effect of WBVT. The largest increase in BMC 
in the paediatric MRCD cohort was seen in cortical bone at both the 20% and 66% pQCT 
sites. At the 20% site BMC significantly increased 8.7 mg/mm (8.7%) and the 
corresponding SDS increased 0.7, and at the 66% site BMC significantly increased 
5.5mg/mm (4.6%) with a 0.3 standard deviation increase. Total bone BMC also increased 
significantly at the both pQCT sites. At the 20% site BMC increased by 7.1mg/mm 
(5.9%) and at the 66% site BMC increased by 6.8mg/mm (4.6%). There is no pQCT data 
for the observation period in the paediatric MRCD cohort so comparison between the two 
periods cannot be performed for parameters at the 20% and 66% pQCT sites. 
 
 437 
All increases in BMC were larger in the 20% site cross-section than the 66% site cross-
section in both cohorts. While the forces imparted to the underlying bone from the effects 
of the WBVT on the overlying muscle bulk should be greatest at the 66% site where the 
calf muscle has a larger cross-section and thus greater bulk and the capacity to generate 
larger forces to the underlying bone, greater increase in BMC was seen at the 20% site. 
This may be explained by the slightly closer proximity of the 20% site to the vibration 
platform in comparison to the 66% site. Due to this closer proximity greater force and 
acceleration occurs in the muscles at the 20% site compared to the 66% site, which are 
dissipated as the vibration stimulus travels in a cephalad direction [174]. However, the 
large disparity in muscle bulk between the two sites and the small distance between the 
two sites in the same long bone, suggests that the larger increases seen at the 20% tibial 
pQCT site in comparison to the 66% site may not be predominantly due to the effect of 
the vibration stimulus acting through the muscle, but rather a direct action of the 
vibration stimulus on the underlying bone. This mechanism has previously been 
described, where the WBVT acts directly on the bone by inducing mechanical 
deformation of the bone causing perturbations in canalicular fluid flow and stimulation of 
the osteocyte and the WNT/β-catenin pathway [196]. 
 
The existing literature does not report on the effects of WBVT on cortical bone mass in 
the peripheral skeleton measured by pQCT. While there is little evidence to support a 
beneficial role of WBVT for cortical bone mass in the CF cohort, the paediatric cohort 
with MRCD consistently demonstrated significant increases in cortical bone mass in the 
total body DXA scans, segmental analysis of these scans as well as at both the 20% and 
 438 
66% pQCT sites after WBVT, which would support a beneficial role of WBVT in 
improving cortical bone mass. The significant increases in cortical bone mass are of 
particular importance for the bone health of children with MRCD as their cortical BMC 
SDS at the 66% pQCT site was significantly reduced compared the reference population 
prior to the commencement of WBVT and their cortical BMC SDS at the 20% tibial 
pQCT site as well as their total body BMC SDS were also below zero, though not 
significantly different to the reference population. 
 
5.1.1.1.2.2 Bone Density 
 
WBVT had a beneficial effect on the bone density in the cortical bone compartment when 
measured by both two- and three-dimensional analysis techniques. In the CF cohort total 
body BMD measured by DXA increased significantly by 0.020g/cm
2
 (2.0%), larger than 
the CV for our laboratory (Table 2.1), but similar in magnitude to the increase seen 
during the observation period and not large enough to elicit a corresponding significant 
increase in the total body BMD SDS. In the paediatric MRCD cohort, total body BMD 
measured by DXA increased significantly by 0.012g/cm
2
 (1.0%), and rate of increase was 
34% larger than the rate of increase seen during the observation period, however the 
magnitude of this increase was within the CV for our laboratory (Table 2.1), and while 
statistically significant, cannot conclusively be attributed to WBVT. While there was no 
corresponding significant increase in the total body BMD SDS during the WBVT period, 
this parameter did increase during the WBVT period, in contrast to a reduction during the 
observation period.  
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The increases in total body BMD in the CF and paediatric MRCD cohorts was similar to 
that reported in existing studies investigating the effects of side-alternating WBVT in 
other paediatric cohorts. In a study of children with bilateral spastic cerebral palsy, 
GMFCS I-V, mean age 9.8 years, using side-alternating WBVT with a tilt-table, (5-25Hz, 
up to 9mm, 9 minutes twice a day) as part of an intensive physiotherapy program, total 
body BMD significantly increased by 2.3% after 6 months of WBVT [200]. This increase 
was as slightly larger in magnitude than the increases seen in the CF and paediatric 
MRCD cohorts however their intervention also involved resistance training and treadmill 
walking [200], which would have contributed to the BMD improvements. A similarly 
designed study in children with Osteogenesis Imperfecta, with a mean age 9 years, 
reported significant improvements in total body BMD of 0.01g/cm
2
 (2%) after side-
alternating WBVT with a tilt-table (15-20Hz, up to 9mm, 9 minutes twice a day for 6 
months) as part of an intensive 12 month physiotherapy program [203]. There was no 
significant improvement in the total body BMD SDS [203]. These findings are similar to 
those seen in the CF and paediatric MRCD cohorts however they were measured after 12 
months, indicating a faster improvement in the CF and MRCD cohorts as it occurred in 
half the time. Another study using side-alternating WBVT (20Hz, 4-6mm, 9 minutes, 4 
times a week) in adolescents and young adults with cerebral palsy, GMFCS II and III, 
with a mean age 16 years, found a significant increase in total body BMD of 0.008g/cm
2
 
(0.8%) after 20 weeks of training [732]. The smaller increase in BMD in the Gusso et al 
[732] study compared to the CF and paediatric MRCD cohorts, despite the similar 
training protocol, is likely due to the younger mean age of the CF and paediatric MRCD 
cohort and greater capacity for optimisation of bone density in the short intervention 
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period. In a study of children with cerebral palsy and other neurological conditions, with 
a mean age 12.5 years, 6 months vertical WBVT (40-42Hz, 0.2mm, 2-15 minutes, twice a 
week for 6 months) significantly improved total body less head BMD by 0.014g.cm
2 
(2%)
 
[730], similar in magnitude to the improvement seen in the CF and paediatric 
MRCD cohorts. Furthermore, this same study did not find any improvement in the total 
body BMD SDS score after 6 months of WBVT [730]. Another study investigating the 
effect of WBVT in children with Duchenne Muscular Dystrophy, mean age 7 years, 
found that 3 months of side-alternating WBVT (16-24Hz, 4mm, 2-6 minutes, 2-3 times a 
week) did not result in any significant improvement in total body BMD [204] perhaps 
due to the lower training volume and shorter intervention time compared to the CF and 
paediatric MRCD cohorts. In a study of adolescent females with low bone density and a 
history of fracture, with a mean age 17 years, home-based, low-magnitude vertical 
WBVT (30Hz, 0.3g, 10 minutes a day for 12 months) increased total body BMD by 
0.01g/cm
2
 however this increase was not significantly different to baseline or the control 
group, a likely consequence of the absence of limitations in the muscle function, mobility 
or participation in weight-bearing physical activity of the cohort [207]. Vertical WBVT 
(25-30Hz, 5-10 minutes, 3 times a week for 20 weeks), in adolescents with Down 
Syndrome and age-matched healthy controls found significant improvements in total 
body BMD in the healthy controls of 0.037g/cm
2
 (3.7%), however there was no 
significant change in total body BMD in the Down Syndrome group [731]. The 
improvements in total body BMD in the control group likely reflect the greater capacity 
of able-bodied adolescents without musculoskeletal impairments to improve their BMD 
with WBVT during adolescence. 
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In the CF cohort, bone density significantly improved during the WBVT period when the 
segmental analyses of the total body DXA scans were analysed. Arms BMD increased 
significantly by 0.009g/cm
2
 (1.3%), however there was no significant change in the 
corresponding SDS and this improvement fell within the CV reported by our laboratory 
(Table 2.1). Legs BMD increased significantly after WBVT by 0.031g/cm
2
 (3.0%), 
demonstrating a larger improvement compared to the observation period, indicating that 
while only small in magnitude, these improvements in BMD in the lower limbs may be 
associated with WBVT.  
 
Several existing studies support a beneficial effect of WBVT on the lower limbs in 
paediatric populations.  A study in adolescents and young adults with cerebral palsy, 
GMFCS II and III, with a mean age 16 years, which demonstrated significant 
improvements in BMD of the legs by 0.023g/cm
2
 (2.2%) after 20 weeks of side-
alternating WBVT (20 Hz, 4-6mm, 9 minutes, 4 times a week) [732]. Another study in 
children with cerebral palsy found a significant improvement in femur BMD of 
0.27g/cm
2
, following WBVT in addition to conventional exercise compared to exercise 
alone [201]. This improvement was much larger than the improvement seen in the current 
study any may be a reflection of the additional benefit of the conventional exercise 
training in conjunction with WBVT. The benefit of vertical WBVT (25-30Hz, 5-10 
minutes, 3 times a week) in improving legs BMD was also demonstrated in adolescents 
with Down Syndrome and age-matched healthy controls after 20 weeks of WBVT, with 
legs BMD significantly increasing in the Down Syndrome and healthy control groups by 
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0.052g/cm
2
 (2.7%) and 0.064g/cm
2
 (3.1%) respectively [731], similar in magnitude to 
that seen in the CF cohort. Arms BMD also increased significantly in the healthy control 
by 0.029g/cm
2
 (2.4%), larger than the increase seen in the CF cohort, however there was 
no significant improvement in arms BMD in the Down Syndrome group [731]. A study 
investigating the effect of home-based low-magnitude, vertical WBVT (32-37Hz, 0.3g, 
20 minutes, 5 times a week, for 12 months) in adolescent girls (mean age 18 years) with 
idiopathic scoliosis, femoral neck BMD improved significantly by 0.015g/cm
2
 (2.2%) on 
those randomised to the WBVT and this was significantly greater than the control group 
[206].  
 
In children with MRCD, bone density on segmental analyses of the total body DXA did 
not change significantly after WBVT. However, the significant reduction in leg BMD 
SDS seen during the observation period did not continue during the WBVT period and 
the rate of decline in this parameter was hindered. These results are encouraging and 
support a benefit of WBVT for improving bone health in children with MRCD through 
the maintenance of BMD. The lack of significant improvements in lower limb BMD in 
the paediatric MRCD cohort compared to the existing literature [731, 732], despite a 
similar training protocol [732] suggests the differences in effects are likely due to the 
underlying disease processes, or may be explained by the different WBVT stimulus used, 
vertical [731] compared to side-alternating respectively. Ruck et al [198] did not find any 
significant changes in femur BMD after 6 months of side-alternating WBVT with a tilt-
table (12-18Hz, 2-4mm, 9 minutes a day, 5 times a week for 6 months) and conventional 
physiotherapy, compared to conventional physiotherapy alone [198].  
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Volumetric BMD increased significantly at the 20% but not at the 66% pQCT site in both 
the CF and paediatric MRCD cohorts. In the CF cohort, the vBMD of the total and 
cortical sectors at the 20% site increased by 9.8g/cm
3
 (1.6%), and 7.1g/cm
3
 (0.6%) 
respectively, and the SDS for cortical vBMD increased significantly by 0.2. These 
increase in vBMD of the cortical sector were above the CV reported in the literature 
[117] (Table 2.2), however the improvements in all these parameters were similar to 
those seen during the observation period and are unlikely to be attributable to the WBVT 
intervention. In the paediatric MRCD cohort, the vBMD of the total and cortical sectors 
at the 20% site increased by 26.9mg/cm
3
 (4.8%), and 13.4mg/cm
3
 (1.2%), however there 
was no change in the cortical vBMD SDS.  Despite the lack of significant increases in 
vBMD at the 66% pQCT site, there was a non-significant increase in the cortical vBMD 
SDS of 0.60 after WBVT, a clinically relevant improvement. There is no pQCT data for 
the observation period in the paediatric MRCD cohort so comparison between the two 
periods cannot be made. 
 
Previous studies have not found significant improvements in bone density measured by 
three-dimensional techniques after WBVT. A study investigating the effect of side-
alternating WBVT (20Hz, 4-6mm, 9 minutes, 4 times a week) on vBMD at the 20% 
pQCT site in adolescents and young adults with cerebral palsy, GMFCS II and III, with a 
mean age 16 years, and they did not find a significant increase after 20 weeks of WBVT 
[732] despite a similar training protocol, a difference which may be related to the 
younger age of the CF and paediatric MRCD cohorts compared to the cerebral palsy 
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cohort. A study investigating the effect of 6 months low-magnitude vertical WBVT 
(90Hz, 0.3g, 10 minutes, 5 times a week) during a standing program in children with 
disabling conditions and motor impairment, with a mean age 9 years, did not find a 
significant improvement in cortical vBMD measured between 25-50% of proximal tibial 
length using quantitative computed tomography in those randomised to the WBVT or 
placebo groups [197]. Another study using side-alternating WBVT (16-24Hz, 4mm, 2-6 
minutes, 2-3 times a week) in boys with Duchenne Muscular Dystrophy, mean age 7 
years, did not find significant changes in cortical vBMD at the 66% pQCT site after 3 
months of training [214]. The difference on the current outcomes compared to these 
studies may be explained by the difference in the vibration platforms used [197], the 
different analysis site [197] and shorter intervention period [214]. 
 
5.1.1.1.2.3 Bone Area and Geometry 
 
In the cortical bone compartment, WBVT in the CF and paediatric MRCD cohorts was 
associated with significant increases in bone area measured by DXA and the long bone’s 
geometric attributes measured by pQCT at the 20% and 66% pQCT sites. Total body 
bone area significantly increased by 45.1cm
2
 (2.8%), however this improvement was less 
than that seen during the observation period, and the total bone area for height SDS 
decreased significantly during the WBVT by 0.2. Segmental analysis of the total body 
DXA scans also revealed significant improvements in legs bone area of 16.5cm
2
 (2.8%) 
after WBVT, slightly smaller in magnitude compared to the change seen during the 
observation period. The results in the CF cohort suggest that WBVT did not appear to be 
beneficial in improving bone area measured by DXA.  
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In the paediatric MRCD cohort, total body bone area significantly increased 37.9cm
2
 
(3.1%). The rate of increase in total bone area was 5% greater in the WBVT period than 
the rate of increase seen during the observation period and occurred in the context of 
equivalent increases in height in the two study periods so cannot be attributed to growth 
alone. Furthermore, while there was no significant increase in the total bone area to 
height SDS during the WBVT period, this parameter did increase, which was in contrast 
to a reduction in this parameter during the observation period. Segmental analysis of the 
total body DXA scans revealed significant improvements in leg bone area after WBVT of 
12.7cm
2
 (3.1%). In contrast to the total body DXA scan where the rate of expansion of 
total bone area was greater during the WBVT period, the rate of expansion of the legs 
bone area was greater during the observation period. The results in the paediatric MRCD 
cohort suggest that WBVT may be beneficial in improving bone area measured by DXA. 
There are no published data on the effect of WBVT on bone area measured by DXA.  
 
The effect of WBVT on bone geometry in the cortical bone compartment was further 
investigated with pQCT scans of the 20% and 66% pQCT sites which allows a three-
dimensional analysis of the bone’s geometric attributes. WBVT was associated with 
significant increases in CSA and cortical thickness at both the 20% and 66% pQCT sites. 
At the 20% tibial pQCT site, CSA of the total and cortical bone sectors increased 
significantly after WBVT in the CF cohort by 7.4mm
2
 (2.3%) and 5.6mm
2
 (3.6%), and 
the total and cortical bone CSA SDS increased significantly by 0.3 and 0.2 respectively. 
These increases were larger than the reported CV in the existing literature (Table 2.2) and 
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the changes in the total and cortical bone CSA and their corresponding SDS changed with 
similar magnitude to the observation period. Cortical thickness and periosteal 
circumference and their corresponding SD scores also increased significantly after 
WBVT at the 20% pQCT site in the CF cohort by 0.1mm (2.7%) and 0.2, and 0.8mm 
(1.2%) and 0.2, the magnitude of all these improvements being similar to those seen 
during the observation period. Total bone CSA at the 66% pQCT site increased 
significantly by 19.0mm
2
 (3.9%) and 0.3 SDS, cortical bone CSA increased significantly 
by 6.8mm
2
 (3.1%) and by 0.2 in the corresponding SDS, and periosteal circumference 
increased significantly by 1.5mm (1.9%), these changes also similar in magnitude to the 
changes seen during the observation period. There were no significant changes in cortical 
thickness at the 66% pQCT site. 
 
In the paediatric MRCD cohort, there were no significant changes in total bone CSA at 
the 20% or 66% pQCT sites however, cortical CSA at the 20% site increased 
significantly by 6.8mm
2
 (1.1%) and the corresponding SDS increased significantly by 
0.6. The percentage improvement in cortical CSA may fall within the reported CV for 
this measure [117, 148], however the corresponding significant increase in the SDS of 
over half a standard deviation confirms the clinical relevance of this improvement. 
Cortical CSA at the 66% tibial pQCT site increased significantly by 3.7mm
2
 (3.2%) with 
a significant increase of 0.2 in the associated SDS. The percentage improvement in 
cortical CSA was greater than the CV reported in the literature [61]. Cortical thickness 
also increased significantly after WBVT at the 20% pQCT site by 0.2mm (7.6%) with an 
associated significant increase in the SDS of 0.6. There were no significant changes in 
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periosteal circumferences seen after WBVT at either the 20% of 66% pQCT sites. While 
there is no pQCT data for the observation period in the paediatric MRCD cohort to make 
comparisons, it appears that in contrast to the CF cohort where WBVT did not seem to 
have a beneficial effect on bone geometry, WBVT appears to have been beneficial in the 
paediatric MRCD cohort, especially in the cortical bone sector. 
 
Few studies have investigated the effect of WBVT on the geometric attributes of the 
cortical bone compartment in children using three-dimensional analyses. The study by 
Ward et al [197] using low-magnitude vertical WBVT (90Hz, 0.3g, 10 minutes 5 times a 
week for 6 months) during a standing program in children with disabling conditions and 
motor impairment, with a mean age 9 years, did not find a significant improvement in 
cortical CSA, cortical thickness or periosteal circumference measured between 25-50% 
of proximal tibial length using QCT over time or between those randomised to the 
WBVT or placebo groups [197]. In another study investigating the effects of low-
magnitude vertical WBVT (30Hz, 0.3g, 10 minutes a day for 6 months) with a 
randomised cross-over study in children with cerebral palsy GMFCS I-IV, with a mean 
age 9 years, QCT of the tibial mid-shaft found an 8.5% increase in cortical CSA after 
WBVT which was significantly greater than the control group [199]. This improvement 
was much larger than that seen in the CF cohort. The disparity in the results reported in 
these studies compared to the current study,  is likely a reflection of the different type of 
WBVT used, low magnitude and high frequency, generating a much lower acceleration 
compared to the WBVT used in the current study, the different analysis site and 
technique used, 25-50% of tibial length measured from the proximal end using QCT 
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compared to pQCT measured from the distal end in the current study, or the different 
paediatric populations investigated [197, 199].  
 
Consistent with DXA findings in the paediatric MRCD cohort, results from pQCT at the 
20% and 66% distal tibial sites in this cohort support a beneficial effect of WBVT in 
improving bone geometry in paediatric patients with MRCD. The significant 
improvements seen in the paediatric MRCD cohort are of particular benefit to their bone 
health, as the SD scores for total bone CSA and cortical CSA at the 66% tibial pQCT site 
were significantly reduced compared to the reference population prior to the 
commencement of WBVT, and the SD score for cortical CSA at the 20% tibial pQCT site 
was reduced at  -1.07 but not significantly different to the reference population (Table 2.5 
and Figure 2.18). The small magnitude of the significant improvements in bone geometry 
seen in the current study, along with the paucity of data in the in the existing body of 
research and the conflicting results in that body of evidence, indicate that larger studies, 
with a longer WBVT intervention period are required to fully understand the effects of 
WBVT on bone geometry in children. 
 
5.1.1.1.2.4 Bone Strength 
 
Surrogate measures for bone strength, including cross-sectional moment of inertia 
(CSMI), section modulus and stress-strain index (SSI), increased significantly in the 
cortical bone compartment at both the 20% and 66% tibial pQCT sites after WBVT in the 
CF and paediatric MRCD cohorts. In the CF cohort, the polar measurement of cortical 
CSMI at the 20% site increased significantly by 649.7mm
4
 (5.4%), with similar results 
 449 
seen for the polar measurement of cortical SSI of 43.5mm
3
 (4.7%). Total bone polar 
CSMI also increased significantly after WBVT by 807.9mm
4
 (5.3%), as did total bone 
polar SSI and its corresponding SDS by 46.2mm
3
 (4.6%) and 0.3 respectively. The CV 
reported in the current literature for polar SSI at the 20% tibial pQCT site is less than 5% 
[148], so caution should be used when interpreting clinical relevance of these results. At 
the 66% site, the polar measurement of cortical CSMI and its corresponding SDS 
increased significantly by 1967.0mm
4
 (7.0%) and 0.2, as did the polar measurement for 
cortical SSI and its corresponding SDS by 77.7mm
3
 (5.2%) and 0.3. The increases in 
these 20% and 66% site parameters were similar in magnitude to the increases seen in the 
observation period, indicating that WBVT may not have had a beneficial effect on bone 
strength in the CF cohort. 
 
In the paediatric MRCD cohort, cortical polar CSMI increased significantly at the 20% 
by 309.0mm
4
 (6.6%) and at the 66% site, by 716.4mm
4
 (8.9%) with a significant 
improvement in its corresponding SDS score of 0.1. Cortical polar SSI significantly 
increased at the 20% site by 35.4mm
3
 (7.8%) and at the 66% site by 45.1mm
3
 (7.3%) 
with the SDS of the latter parameter also increasing significantly by 0.3. Significant 
improvements were also seen in the total bone polar SSI and the corresponding SDS 
score at the 20% site of 31.6mm
3
 (6.3%) and 0.3 respectively. These findings were larger 
than the CV reported for polar SSI in the literature [148]. There was no pQCT data for 
the observation period in the paediatric MRCD cohort to make comparisons, however all 
increases were larger in magnitude than those seen in the CF cohort, and were in keeping 
with the significant improvements in CSA and cortical thickness seen in the paediatric 
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MRCD cohort which reflect an enhancement of the geometric attributes of the cortical 
bone cross-section at these two analysis sites. These favourable geometric adaptations, 
along with the significant increases in bone mass, played a focal role in the significant 
improvements in bone strength seen in the cortical bone compartment after WBVT.  
  
Three previous studies have investigated the effect of WBVT on cortical bone strength in 
children. The study by Ward et al 2004 [197] did not find a significant improvement in 
polar CSMI measured between 25-50% of proximal tibial length using QCT after WBVT 
[197]. Gusso et al 2016 [732] did not find any significant improvements in polar SSI at 
the 20% tibial pQCT site in adolescents and young adults with cerebral palsy [732] 
despite a very similar training protocol to that used in the CF and MRCD cohorts, 
however the significant increases seen may be due the younger mean age of participants 
and a greater ability of the developing skeleton to respond to the WBVT. The study by 
Wren et al 2010 [199] found significant improvements in the polar measurement of 
CSMI in the tibial mid-shaft, which increased ~17% after WBVT, significantly larger 
than the control group [199] and also the increases seen in the CF and MRCD cohorts. 
The differences between the results reported in the current literature and the CF and 
MRCD cohorts are likely a consequence of different study populations, vibration 
platforms used, analysis sites and techniques performed [197, 199]. 
 
5.1.1.1.2.5 Body composition 
 
WBVT in the CF cohort was also associated with significant increases in lean tissue 
mass. Total body LTM measured by DXA increased significantly by 1026.3g (3.1%), 
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above the CV reported by our laboratory (Table 2.1), however there was no significant 
change in the LTM for height SDS indicating that the improvement seen during the 
WBVT was not likely to be attributed to the WBVT but rather normal growth.  
Segmental analysis of the total body DXA scans found significant improvements in legs 
LTM of 283.0g (2.7%) after WBVT. These increases in LTM were smaller increase 
compared to that seen during the observation period, suggesting WBVT did not have a 
beneficial effect on LTM in the CF cohort. Two previous studies investigating the effect 
of WBVT on LTM measured by total body DXA scans found similar responses to those 
seen in the CF cohort. In a study of children with cerebral palsy using side-alternating 
WBVT as part of an intensive physiotherapy program, total body LTM measured by 
DXA significantly increased 3.1% after 6 months of WBVT [200], similar in magnitude 
to the increase seen in the CF cohort, despite the addition of resistance training and 
treadmill walking during the WBVT intervention, which would have contributed to the 
improvement seen in LTM [200]. Another study found 6 months of side-alternating 
WBVT in adolescents and young adults with cerebral palsy significantly increased LTM 
of the total body and legs by 2.1% and 2.2% respectively [732], slightly smaller than the 
increases seen in the CF cohort.  
 
The paediatric MRCD cohort did not reveal any significant increases in total body LTM, 
the LTM to height SDS or LTM of the legs. This area however did have the greatest non-
significant improvement in LTM during the WBVT period compared to the observation 
and follow-up periods. Three previous studies also found no effect of WBVT on LTM 
measured by DXA. In a study of children with cerebral palsy and other neurological 
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conditions, 6 months of vertical WBVT did not significantly increase total body LTM 
[730]. In adolescents with Down Syndrome, 20 weeks of vertical WBVT did not 
significantly increase total body LTM or LTM of the lower limbs [227]. The use of 
vertical WBVT in adolescent females with low bone density and a history of fracture, did 
not significantly increase total body LTM measured by DXA after 12 months of WBVT 
[207]. 
 
Analysis of the soft tissue compartment at the 66% pQCT site did not show any 
significant changes after WBVT in the CF cohort, however the increase in fat CSA seen 
during the observation period was ablated, a potentially beneficial effect of WBVT. 
These findings are consistent with two previous studies. pQCT analysis of muscle CSA at 
the 66% tibial site in boys with Duchenne Muscular Dystrophy did not find a significant 
increase in muscle CSA after 3 months of side-alternating WBVT [214], and the study by 
Ward et al [197] using low magnitude, high frequency WBVT during a standing program 
in children with disabling conditions and motor impairment did not find a significant 
improvement in muscle CSA measured between 25-50% of proximal tibial length using 
QCT [197].  
 
When the 66% pQCT site was analysed in the paediatric MRCD cohort, significant 
increases were found after WBVT in total soft tissue CSA, muscle CSA and the muscle 
CSA SDS. These parameters increased significantly by 223.6mm
2
 (4.7%), 145.6mm
2
 
(5.4%) and 0.2 respectively. One previous study supports these findings. After 20 weeks 
of side-alternating WBVT in adolescents and young adults with cerebral palsy, muscle 
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CSA at the 50% tibial pQCT site increased significantly by 3.8% [732], a result similar to 
that seen in the paediatric MRCD cohort. The improvements in LTM may only have been 
significant at the 66% pQCT site in the paediatric MRCD cohort as this analysis 
technique can measure true muscle CSA [145], a more accurate measure than DXA 
scanning techniques allow.  
 
The current study, with some support from the existing literature, would suggest a 
positive benefit of WBVT for increasing LTM in the paediatric cohorts, especially the 
paediatric MRCD cohort. The significant improvements in muscle CSA is of particular 
importance to the paediatric MRCD cohort as their muscle CSA SDS was significantly 
reduced compared to the reference population prior to the commencement of WBVT, and 
likely played an important role in the significantly reduced bone mass seen at the 66% 
pQCT site, as well as the compromised geometric attributes (cortical CSA, total CSA and 
cortical thickness), and reduced bone strength (polar SSI and polar CSMI) at the 20% and 
66% pQCT sites also seen prior to commencement of WBVT (Table 4.5 and Figure 
4.18). The significant improvements in muscle CSA after WBVT may have been focal in 
the significant improvements in bone mass, geometry and strength seen after WBVT. The 
close interaction between LTM and bone mineral content is known as the functional 
muscle-bone unit [78], and strong correlations between total body BMC and total body 
LTM have been shown in studies using DXA [82-84] and between BMC and muscle 
cross-sectional area in studies using pQCT [61, 78, 85]. The functional muscle-bone unit 
is also involved in the changes in long bone geometry observed during growth, whereby 
the geometry of the bone is adapted to the mechanical loads habitually applied to it to 
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maintain its strength [1, 51, 64]. As previously suggested, the effect of WBVT on the leg 
muscles, generating rapid muscular contractions and increasing muscle tone [159, 160], 
along with the subsequent transmission of muscle forces generated to the underlying bone 
[196], cannot be recreated through the normal movements of children with MRCD due to 
their compromised muscle strength and function and impaired ability to participate in 
normal locomotion and weight-bearing physical activities [403-407, 410-412]. Therefore, 
we can propose that WBVT has a beneficial effect on LTM, the accrual of bone mass and 
promotes favourable geometric adaptations of long bones in children with MRCD during 
growth directly through its actions on muscles and the underlying bone, which in turn 
precipitated improvements in cortical bone strength parameters. In conclusion, WBVT 
appears to have significantly improved many aspects of the cortical bone compartment, 
including those significantly compromised compared to their peers prior to 
commencement of WBVT, culminating in generally improved bone health in children 
with MRCD. 
 
5.1.1.1.2.6 Bone Biochemistry and Turnover Markers 
 
After WBVT, there were no significant changes in bone turnover markers in the CF 
cohort. Bone biochemistry, demonstrated significant decreases in calcium and 
magnesium however they remained within their corresponding normal reference ranges. 
There was a significant decrease in osteocalcin in the paediatric MRCD cohort, which is 
of questionable clinical significance as improvements in bone health were seen during the 
WBVT period. These results were consistent with those of a paediatric study 
investigating the effect of WBVT on a dynamic platform with a mean of 22 minutes a 
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week at 40-42Hz, in patients with severe motor disabilities including cerebral palsy 
[730]. After 6 months of training, there were no significant differences in calcium, 
phosphate, parathyroid hormone, vitamin D, osteocalcin, PINP, bone specific alkaline 
phosphatase or CTX [730].  
 
The WBVT period was associated with several favourable adaptations in the trabecular 
bone compartment for bone mass and density and also in the cortical bone compartment 
for bone mass, density, area and geometry, and strength in the paediatric MRCD cohort. 
The magnitude and diversity of the response to WBVT seen in these bone parameters 
measured by DXA and pQCT were much larger than those seen in the observation period 
however there were not any changes in the bone turnover markers to reflect this. This 
may be explained by the fact that the bone turnover markers used have wide reference 
ranges and large inter-individual variation, resulting in no discernible difference between 
the two study periods despite the difference in bone response. Alternatively, the bone 
turnover markers used in the paediatric MRCD cohort may not have been sensitive 
enough to identify a difference with WBVT. Markers of bone formation including bone 
specific alkaline phosphatase [734] and PINP [735] are considered to be more robust 
measures than osteocalcin and alkaline phosphatase due to confounding influences on 
these measures, including the sample instability and susceptibility to processing and 
storage practices for osteocalcin as well as it being non-homogenously distributed in the 
circulation and having high individual variability [736], and the influences from gut, 
liver, kidney and brain when alkaline phosphatase is used [736]. Bone specific alkaline 
phosphatase, an osteoblast ectoenzyme that helps to regulate bone mineralisation, more 
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specifically assesses osteoblast function compared to alkaline phosphatase, and the 
production of bone specific alkaline phosphatase has been found to positively correlate 
with bone formation measured by histomorphometry [736, 737]. PINP is released during 
the synthesis of type I collagen from procollagen, reflecting a different aspect of 
osteoblast activity and bone formation compared to osteocalcin, a protein synthesised by 
osteoblasts that assists in the regulation of bone mineralisation, and bone specific alkaline 
phosphatase, an osteoblast enzyme which also assists in the regulation of bone 
mineralisation [736-738]. Age-specific reference ranges are available for the analysis of 
BAP [727, 738, 739] and PINP [735, 738] in paediatric patients.  Serum-derived markers 
of bone resorption are also preferred over urinary-derived measures as there is less 
variability [727, 736, 740-742] due to difficulties with serial measurements [738, 743, 
744], susceptibility to UV exposure [736], the effect of changing muscle mass and age 
when expressed relative to creatinine [727, 740, 745] and large variations between 
individuals [741, 746] that are associated with urinary-derived measures. Age and 
gender-specific references ranges for CTX are available in the paediatric population [727, 
738] 
 
5.1.2 Follow-up Period 
 
5.1.2.1 Trabecular bone compartment 
 
5.1.2.1.1 Bone Mass and Density 
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During the follow-up period, the CF cohort demonstrated significant increases in BMC of 
the lumbar spine and lumbar vertebra 1-4 of 1.4g (4.3%) and 1.7g (4.1%), both smaller in 
magnitude than the increases seen during the WBVT period. There were no significant 
changes in the corresponding SDS of these two parameters however the trunk BMD SDS 
for segmental analysis of the total body DXA scan decreased significantly by 0.1. The 
paediatric MRCD cohort did not demonstrate any significant changes in trabecular bone 
parameters measured by DXA at the lumbar spine. However, in contrast to the significant 
increases seen after WBVT and relative stability of these parameters in the observation 
period, the lumbar spine BMC SDS and BMD SDS decreased by 0.2 and 0.3 of a 
standard deviation respectively, and these decreases neared significance, p=0.059 and 
p=0.071 respectively. There were no significant changes in bone mass or density at the 
4% pQCT site in either cohort. This finding was similar to that seen in the observation 
period for the CF cohort but in contrast to the significant increases in total BMC seen 
after WBVT in both cohorts and the significant increase in total vBMD in the CF cohort.  
 
Two previous studies have investigated the effects of WBVT after completion of training. 
In children with cerebral palsy, 6 months after completing a 6 month side-alternating 
WBVT intervention, lumbar spine BMC, BMD and the BMD SDS had not signifincatly 
changed from their post WBVT values [730]. In 6 boys with Duchenne Muscular 
Dystrophy, followed for nine months after completion of their 3 months side-alternating 
WBVT intervention, total body and lumbar spine DXA scans and distal tibial pQCT at 
the 4% and 66% sites were performed 3 and 9 months after completion of WBVT. 
Lumbar spine BMD and its associated SDS did not change significantly during follow-
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up. Trabecular vBMD measured at the 4% tibial pQCT site demonstrated progressive 
non-significant reductions at 3 and 9 month follow-up after a non-significant increase 
seen with WBVT [214]. The results of the Soderpalm et al 2013 study [214], as well as 
the results in the paediatric MRCD cohort, suggest a benefical effect of WBVT in 
maintaining or potentially increasing trabecular bone mass and density. While there is no 
pQCT data for the observation period to help deduce whether the effects seen during the 
WBVT period in the paediatric MRCD cohort are a direct response of the WBVT, the 
follow-up data supports a beneficial role of WBVT for improving trabecular bone mass 
and density in children with MRCD. The significant improvements seen in DXA and 
pQCT measures of trabecular bone mass and density at multiple sites during the WBVT 
period, including DXA analysis of the lumbar spine, and pQCT analysis of the 4% distal 
pQCT site, were not reproduced during the follow-up period of similar duration. In fact, 
during the follow-up period, all DXA and pQCT measures of the trabecular bone 
compartment demonstrated mean decreases, and while non-significant, contrast with the 
significant increases in bone mass and density seen across both analysis modalities and at 
multiple analysis sites during the WBVT period. These differences between the WBVT 
and follow-up periods support a benefical effect of side-alternating WBVT in improving 
trabecular bone mass and density in the paedaitric MRCD cohort. These beneficial effects 
are particularly pertinent to this cohort of children as their baseline data demonstrate that 
the health of the trabecular bone compartment is compromised with trunk BMD, lumbar 
spine BMD and lumbar spine vertebrae 1-4 vBMD standard deviation scores all 
significantly reduced compared to the reference population (Table 4.4 and Figure 4.1), as 
well as the mean trabecular vBMD SDS at the 4% tibial pQCT site (Table 4.5 and Figure 
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4.18). Despite the short six-month intervention period used, considering a primary bone 
outcome, significant improvements in trabecular bone health were demonstrated. A 
longer study with greater durations of all study periods, that are equal in length to allow 
direct comparison between study periods, as well as the use of pQCT analysis for the 
duration of the study in a larger cohort of children with MRCD would help to further 
define the benefit of WBVT as well as any detraining effects after completion of WBVT 
on the trabecular bone compartment. 
 
5.1.2.2 Cortical bone compartment 
 
5.1.2.2.1 Bone Mass 
 
In the cortical bone compartment, there were significant changes in bone mass in the CF 
cohort measured by DXA and pQCT during the follow-up period. Total body BMC 
increased significantly by 88.2g (4.9%), similar in magnitude to the increase seen in the 
WBVT period. There was no significant change in the total body BMC SDS however the 
total body BMC for total body bone area SDS decreased significantly by 0.3, which is in 
contrast to the significant improvement in this parameter seen in the WBVT period. Legs 
BMC, also increased significantly during the follow-up period by 24.6g (3.7%), smaller 
than those seen during the WBVT period. Total and cortical BMC at the 20% tibial 
pQCT site increased significantly during the follow-up period by 6.6mg/mm (3.2%) and 
6.2mg/mm (3.5%), and the cortical BMC SDS increased significantly by 0.3. At the 66% 
tibial pQCT site, total BMC and cortical BMC increased significantly during the follow-
up period by 8.3mg/mm (2.8%) and 7.7mg/mm (3.1%). The cortical BMC SDS increased 
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significantly by 0.2. These significant increases at the 20% and 66% pQCT sites were 
smaller than the increases seen during the WBVT period. These significant changes were 
consistent with Kilebrant et al [730] who found a significant increase in total body BMC 
of 20g in the 6 months following completion of WBVT in children with cerebral palsy 
and other neurological conditions [730], this change being smaller in magnitude 
compared to the increase seen in the CF cohort. 
 
In the paediatric MRCD cohort, there were no significant changes in bone mass measured 
by DXA or pQCT during the follow-up period. This contrasts to the significant 
improvements in total body and legs BMC seen after WBVT as well as the significant 
improvement in total and cortical bone sectors on analysis at the 20% and 66% pQCT 
sites. Similarly,  Soderpalm et al [214] did not find significant improvements in total 
body BMC in the follow-up period. 
 
5.1.2.2.2 Bone Density 
 
The CF cohort did not demonstrate any significant changes in bone mineral density 
measured by total body DXA during the follow-up period, however segmental analysis of 
these scans demonstrated significant improvments in legs BMD of 0.016g/cm2 (1.5%), 
smaller in magnitude than the improvements seen in the WBVT period. In the paediatric 
MRCD cohort, there was a significant decrease in the total body BMD SDS during the 
follow-up period of 0.2 standard deviations, opposite to the significant increase in total 
body BMD documented during the WBVT period. Furthermore, the significant decrease 
in leg BMD SDS seen in the observation period, was not seen in the follow-up period, 
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instead the decline in this parameter continued to be hindered in the follow-up period . 
There is no conistenncy in the current literature regarding changes in BMD measured by 
DXA after cmpletion of a WBVT intervention. In children with cerebral palsy and other 
neurological conditions, total body BMD and its associated SDS did not significnatly 
change 6 month after completing a WBVT intervention [730], however there was a 
significant increase in total body BMD at 9 months follow-up in boys with DMD [214]. 
 
At the 20% pQCT site, total and cortical vBMD increased significantly during the follow-
up period in the CF cohort by 7.4g/cm
3
 (1.2%) and 9.3g/cm
3
 (0.8%), and the cortical 
vBMD SDS increased significantly by 0.2. These improvements were similar in 
magnitude to those seen during the WBVT period, however they fall within the reported 
CV for this measure (Table 2.2). At the 66% distal tibial pQCT site, total bone vBMD did 
not change significantly during the follow-up period in the CF cohort, however cortical 
bone vBMD and its corresponding SDS increased significantly by 9.543mg/cm
3
 (0.9%) 
and 0.3. This change falls within the CV reported in the literature for cortical vBMD at 
the 66% tibial pQCT site (Table 2.2). While the clinical relevance of this change is 
questionable, a further increase in the already elevated cortical vBMD at the 66% site 
would indicate a likely reduction in the rate of intra-cortical bone turnover, an 
unfavourable change as this would result in the accumulation of older bone that less 
effectively responds to bone strains resulting in sub-optimal geometric adaptations. There 
were no significant changes in BMD measured by pQCT at the 20% or 66% sites during 
the follow-up period in the paediatric MRCD cohort. These results are in contrast to the 
significant improvements in vBMD seen in the total bone and cortical bone sectors at the 
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20% pQCT site during the WBVT period. No significant changes in cortical vBMD 
measured at the 66% pQCT site were found at 3 or 9 months follow-up in boys with 
DMD [214]. 
 
5.1.2.2.3 Bone Area and Geometry 
 
In the CF cohort, bone area measured by total body DXA and the segmental analysis of 
those scans demonstrated significant improvements in bone area during the follow-up 
period. Total bone area increased by 77.6cm
2
 (4.5%), legs bone area by 17.8cm
2
 (2.9%), 
and the total bone area for height SDS increased significantly by 0.2, all larger in 
magnitude than the changes seen during the WBVT period, indicating favourable bone 
geometric adaptations during the follow-up period. Cortical bone geometry at the 20% 
and 66% tibial pQCT sites demonstrated enhancements during the follow-up period. At 
the 20% pQCT site, total CSA, cortical CSA and the cortical CSA SDS increased 
significantly during the WBVT period by 6.2mm
2
 (1.9%), 4.2mm
2 
(2.6%) and 0.2 
respectively. Cortical thickness and periosteal circumference as well as their 
corresponding SDS also significantly improved during the WBVT period by 0.1mm 
(1.9%) and 0.1, and by 0.6mm (1.0%) and 0.2 respectively. Increases in these parameters 
were smaller than the increases seen in during the WBVT period, and close to the CVs 
reported for these measures in the current literature (Table 2.2). At the 66% tibial pQCT 
site, cortical CSA and its corresponding SDS increased significantly by 4.8mm
2
 (2.1%) 
and 0.2, however these improvements were smaller than those seen during the WBVT 
period. 
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In the paediatric MRCD cohort there were no significnat changes in cortical bone 
geometry on DXA or at the 20% pQCT site during the follow-up period. Total bone CSA 
SDS at the 66% pQCT site increased significantly by 0.4 and this was accompanied by a 
significant increase in the periosteal circumference at the 66% pQCT site of 1.9mm 
(3.2%). These significant increases occurred in different parameters to the significant 
increases seen during the WBVT period, which occurred in cortical CSA and its 
associated SDS at the 66% pQCT site. It appears that periosteal apposition may have 
been more active in the follow-up period, culminating in the significnant increases in 
total bone CSA and periosteal circumference seen at the 66% tibial pQCT site, two 
parameters associated with long bone strength [1, 51, 58, 64].  
 
5.1.2.2.4 Bone Strength 
 
During the follow-up period, bone strength in the cortical bone compartment increased 
significantly in the CF cohort. At the 20% pQCT site, cortical polar CSMI and polar SSI 
increased significantly by 457.2mm
4
 (3.6%) and 44.5mm
3
 (4.6%) as did total polar CSMI 
and polar SSI by 519.4mm
4
 (3.3%) and 41.0mm
3
 (3.9%) All these improvements were 
smaller than those seen during the WBVT period. At the 66% pQCT site, significant 
increases were seen in the polar measurements for cortical CSMI and SSI and their 
corresponding SDS of 1201.6mm
4
 (4.0%) and 0.2 and by 67.5mm
3
 (4.3%) and 0.3, these 
changes smaller than those seen during the WBVT period. 
In the paediatric MRCD cohort there were no significant changes in total or cortical bone 
strength parameters at the 20% tibial pQCT site. At the 66% pQCT site, cortical polar 
CSMI significantly increased by 778.9mm
4
 (8.9%) with its associated SDS significantly 
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increasing by 0.1, similar increases to those seen during the WBVT period.  Cortical 
polar SSI also increased significantly by 25.4mm
3
 (3.8%), a smaller improvement than 
that seen during the WBVT period which did not elicit a change in the polar SSI SDS, as 
seen in the WBVT period. No previous studies have investigated bone strength indicators 
after completion of a WBVT intervention. 
 
5.1.2.2.5 Body Composition 
 
During the follow-up period, the CF cohort demonstrated significant alterations in their 
body composition. Total body and legs LTM increased significantly by 1110.1g (3.3%), 
381.9g (3.5%) similar in magnitude to the changes seen during the WBVT period. There 
was also a significant increase in muscle CSA and its corresponding SDS measured at the 
66% tibial pQCT site, of 186.8mm
2
 (4.2%) and 0.2. this finding only reported in the 
follow-up period and beneficial for the CF cohort as muscle CSA at the 66% site was 
significantly reduced at baseline. This is also more favourable than the increase in fat 
CSA at the 66% site seen during the observation period, perhaps indicating preferential 
enhancement of the lean tissue compartment after the WBVT intervention.  
 
The paediatric MRCD cohort demonstrated significant alterations in their body 
composition. Fat CSA measured at the 66% pQCT site significantly increased 129.1mm
2
 
(6.9%) and was associated with a significant increase in the ratio of fat CSA to muscle 
CSA, of 4.9%. These increases in fat CSA also had an adverse effect on the muscle CSA 
to total soft tissue CSA ratio which significantly decreased by 1.6%. These finding are 
similar to those found in children with cerebral palsy and other neurological conditions 
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who demonstrated no changes in total body lean tissue mass but significantly increased 
their total body fat mass, measured by total body DXA, 6 months after completion of a 
WBVT intervention [730]. 
 
These alterations in body composition are concerning as the fat % SDS measured by 
DXA was elevated in the paediatric MRCD cohort with a value of 0.92, prior to 
commencement of WBVT. Furthermore, the increases in fat CSA seen on analysis of the 
66% tibial pQCT site appears to be impacting on the proportion of muscle at the 66% 
tibial pQCT site. Reductions in the proportion of muscle CSA are particularly alarming 
for the paediatric MRCD cohort as their muscle CSA SDS at the 66% tibial pQCT site 
was significantly reduced compared to the reference population at baseline (Figure 4.5 
and Table 4.18) and this reduction in muscle CSA was postulated to be closely involved 
in compromising other aspect of bone health in the cortical bone compartment of the 
paediatric MRCD cohort as discussed above. The significant increases in fat CSA as well 
as the significant reduction in the proportion of muscle CSA in the cross-section could 
negatively impact on the bone health of the paediatric MRCD cohort. 
 
5.1.2.2.6 Bone Biochemistry and Turnover Markers 
 
During the follow-up period there were no significant changes in bone turnover markers 
in either cohort. The CF cohort demonstrated a small but significant reduction in calcium 
and the paediatric MRCD cohort a reduction in phosphorus, however these measures 
remained well within their reference ranges. Despite ongoing significant increases in the 
geometry and strength of the cortical bone compartment measured by tibial pQCT, the 
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bone turnover markers remained unchanged. It may be that these markers were not 
sensitive enough to reflect such changes or that more specific, stable and sensitive 
markers including the bone formation markers, bone specific alkaline phosphatase and 
PINP, and the bone resorption marker, CTX, are required to elucidate the ongoing effects 
after completion of WBVT in the paediatric patients with MRCD.  
 
5.1.3 Effect of WBVT on Force Plate Parameters 
 
M1LJ and S2LJ analysis was only performed in the CF cohort due to the limited number 
of participants in the paediatric MRCD cohort able to perform these manoeuvres. CRT 
parameters were analysed in both cohorts.  
 
 
5.1.3.1 WBVT Period 
 
After WBVT, maximum force in the M1LJ increased in the CF cohort by 0.5kN (4.6%), 
p=0.050, however there were no corresponding changes in relative force or the force SDS 
and this change fell within the CV reported in the literature (Table 2.5), indicating the 
change is likely physiological. This finding is however, in contrast to the significant 
reduction in relative force and the force SDS seen during the observation period, 
suggesting the WBVT had a beneficial effect on preserving the force producing 
capability of the lower limb muscles during the M1LJ.  Three previous studies have 
investigated the effects of WBVT on force generating capacity in paediatric cohorts. In 
children with OI, mean age 9 years, participating in a paired randomised controlled trial 
of side-alternating WBVT (24Hz, 4-6mm, 9 minutes twice a day, with exercises 
 467 
including squats and weight shifts for 20 weeks) or control, there was no significant 
change in M1LJ maximum relative force after WBVT or compared to the control group 
[747]. Two other studies using a tilt-table to provide WBVT have also shown 
improvements in maximum force after WBVT. Significant improvements in maximum 
relative force, corresponding the increased ground reaction force required to keep the 
patient upright as the angle of the tilt table was increased, were seen in children with OI 
types III and IV, and mobility impairments, 5-15 years, after side-alternating WBVT (15-
25Hz, 1-2mm, 9 minutes twice a day) [257] and in children with bilateral spastic cerebral 
palsy, GMFCS classification I-V, with a mean age 9.8 years, after side-alternating 
WBVT 9 minutes twice a day for 6 months as part of an intensive physiotherapy program 
including resistance training hydrotherapy and treadmill walking [748]. 
 
During the WBVT period, the CF cohort did not demonstrate any significant changes in 
efficiency or power parameters during the S2LJ, however, maximum force increased 
significantly by 0.1kN (10%), well above the reported CV (Table 2.5). There were no 
significant changes in relative force or the force SDS, likely indicating increases 
associated with normal musculoskeletal growth and development. However, considering 
the SDS for this parameter was significantly reduced at baseline and significant increases 
in force during the S2LJ were not seen in the observation or follow-up periods, this may 
indicate a beneficial effect of WBVT on preserving normal increases in force production 
in the CF cohort. This would be consistent with the beneficial effects of WBVT in 
preserving force production in the M1LJ. 
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Previous studies have investigated the effects of WBVT on S2LJ performance in 
paediatric cohorts in good health and with underlying disease. Similar to the result seen 
in the CF cohort, S2LJ power parameters did not significantly change after 4 weeks of 
side-alternating WBVT (20-22Hz, 1mm, 10-15 minutes, 3 times a week) in children with 
CF [229], after 20 weeks of side-alternating WBVT (20 Hz, 4-6mm, 9 minutes, 4 times a 
week) in children with cerebral palsy, mean age 16.2 years [732], or after side-alternating 
WBVT (24Hz, 4-6mm, 9 minutes twice a day, with exercises including squats and weight 
shifts for 20 weeks) in children with OI, mean age 9 years, and matched controls [747]. 
In two studies of elite adolescent female basketball players, jump height parameters, 
which are closely correlated to power parameters, significantly increased by 2.6% after 
vertical WBVT (35Hz, 4mm, 3-6 minutes with exercises including squats and heel raises, 
twice a week for 14 weeks) in addition to normal aerobic, resistance and basketball 
training [749] and by 2.9cm (10%) after vertical WBVT (25-35Hz, 4mm, 5 minutes with 
exercises including squats and lunges for 15 weeks) prior to routine resistance training 
[750]. In the former study, increases were not significantly different to the those 
randomised to the control group (normal training without WBVT) [749] perhaps a 
reflection of an inadequate training stimulus as only 6 minutes of WBVT was performed 
twice a week, or that the elite status of the participants left little room for improvement. 
The latter study demonstrated an improvement that was larger in magnitude and 
significantly greater than those randomised to control (resistance training only) [750]. 
One previous study found no significant changes in maximum relative force after side-
alternating WBVT, or compared to the control group, in children with OI [747], 
consistent with the results of the CF cohort. 
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The CF cohort demonstrated significant changes in CRT speed and force parameters after 
WBVT. Time per test decreased significantly by 0.1s (9.1%), and the corresponding SDS 
increased significantly by 0.5, indicating improve muscle efficiency and co-ordination 
after WBVT, however was similar in magnitude to improvements in CRT performance 
seen in the observation period. CRT time also decreased significantly by 1.5s (18%) after 
20 weeks of side-alternating WBVT (20 Hz, 4-6mm, 9 minutes, 4 times a week) In 40 
children with cerebral palsy, GMFCS II and III, mean age 16.2 years [732], a larger 
improvement than that seen in the CF cohort using a similar vibration training protocol, 
however CRT performance at baseline was much better in the CF cohort compared to the 
cerebral palsy cohort so they may not have had the same capacity to improve. 
Alternatively, Gusso et al [732] used a higher amplitude, 6mm, compared to 4 mm in the 
CF cohort, which may have impacted on the outcome and this should be considered in 
future studies. However, an RCT of side-alternating WBVT (24Hz, 4-6mm, 9 minutes 
twice a day, with exercises including squats and weight shifts for 20 weeks) or no 
intervention, in 20 children with Osteogenesis Imperfecta (OI) types I-IV and controls 
paired for gender and pubertal status, mean age 9 years, found no significant 
improvements in time per test [747].  
 
There were no significant changes in CRT power parameters in the CF or paediatric 
MRCD cohorts, similar to that reported in the existing literature in children with cerebral 
palsy [732] and children with OI [747]. Maximum force during the rising phase of the 
CRT increased significantly by 0.1kN (6.7%) in the CF cohort, however relative force 
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and force SDS did not change significantly, indicating increases associated with normal 
musculoskeletal growth and development, consistent with the increased maximum force 
seen during the S2LJ in the CF cohort. The paediatric MRCD cohort demonstrated 
significant decreases in maximum force and maximum relative force of 0.1kN (7.7%) and 
6.3N/kg (13.2%) respectively, larger than the reported CV for maximum force (Table 
2.5) and a non-significant decrease in force SDS of 0.5, a clinically relevant 
improvement. The significant reduction in muscle force without significant changes in 
power or speed parameters indicates improved muscle efficiency as less force is required 
to generate a similar power and speed [718]. No previous studies have reported on CRT 
force parameters. 
 
5.1.3.2 Follow-up Period 
 
 
After 6 months follow-up, the CF cohort demonstrated significant reductions in relative 
force and force SDS of 0.2g (7.4%) and 0.5. These reductions were larger than the 
reductions seen in the observation period and indicate that WBVT was effective in 
preserving and perhaps improving the force producing capacity of the lower limb muscles 
during M1LJ in the CF cohort. This is especially pertinent as the M1LJ force SDS was 
significantly reduced at baseline and further deterioration would have negative 
ramifications on long term bone health. No previous studies have investigated the effects 
of WBVT removal on muscle force parameters. 
 
The CF cohort did not demonstrate any significant changes in any of the efficiency, 
power or force parameters measured by the S2LJ during the follow-up period. One 
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previous study investigated the effects of cessation of WBVT in a cohort of paediatric 
patients with CF. Four weeks after the withdrawal of side-alternating WBVT (20-22Hz, 
1mm, 10-15 minutes, 3 times a week for 4 weeks), there were no significant changes in 
power parameters during the S2LJ [229]. 
 
During the follow-up period, there were no significant changes in speed, power or force 
parameters during the CRT in the CF cohort. These finding indicating that the significant 
improvements in muscle efficiency and co-ordination gained during the WBVT were not 
lost in the first 6 months after cessation of the WBVT intervention. The paediatric 
MRCD cohort also did not demonstrate any significant changes in CRT force, power or 
speed parameters in the follow-up period, however, average relative force and the force 
SDS demonstrated non-significant increases of 0.1g (8.3%), p=0.058 and 0.6, p=0.076 
respectively. As this increase occurred in the absence of other significant changes in 
power and speed parameters, this indicates a worsening of muscle function, as a 
significantly larger amount of force was required to maintain the same muscle power and 
velocity. No previous studies have evaluated the effect of WBVT cessation on CRT 
performance. 
 
5.1.4 Effect Of WBVT on Exercise Capacity 
 
 
Exercise capacity in the CF cohort was investigated using formal cardio-pulmonary 
exercise testing (CPET) with the Bruce Treadmill Protocol. In the paediatric MRCD 
cohort, exercise capacity was measured using the six-minute walk test (6MWT) and 
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CPET. There is a complete dataset for the six-minute walk test, however, only data for 
two paediatric participants were available for CPET and thus statistical analysis was not 
performed due to the small size of the sample. 
 
5.1.4.1 WBVT Period 
 
 
After WBVT there were no significant changes in any CPET parameters at baseline, AT, 
peak exercise or recovery in the CF cohort. This is contrast to the significant declines in 
peak VO2 and its percent-predicted value and a non-significant, but clinically relevant 
decline in VO2 at AT in the observation period. Similar to the pattern seen in maximum 
relative force and force SDS in the M1LJ, WBVT appears to have been beneficial in 
hindering the decline in peak VO2 and in preserving the submaximal VO2
 
kinetics at AT. 
One previous study has investigated the effects of WBVT on peak VO2 using an 
incremental treadmill test in children with CF and did not find any significant changes 
after WBVT [229], consistent with the findings in the CF cohort. 
 
The paediatric MRCD cohort did not demonstrate any significant changes in the 6MWT 
distance after WBVT. Post-6MWT heart rate decreased significantly by 27.9 
beats/minute (20.9%), suggesting an improved cardiovascular response to the 6MWT, 
especially as 6MWT distance had not significantly changed. It was also in contrast to a 
significant increase in this parameter in the observation period of 25.1%. The Borg Score, 
measured after 5 minutes of seated recovery, was also significantly reduced after WBVT 
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by 1.3 points, also indicating an improved aerobic efficiency, as recovery after this 
endurance test was attained at a more rapid rate. 
 
The effect of WBVT on walking performance has been investigated in the existing 
literature in paediatric cohorts with underlying medical conditions including CP, DMD, 
SMA, OI and SB. Consistent with the paediatric MRCD cohort, two previous studies 
have found no effect of WBVT on 6MWT distance in children with DMD after 
progressive side-alternating WBVT (10-24Hz, 4mm, 9 minutes twice a day, 5 times a 
week for 8 weeks) [228] and in in four boys with DMD and two boys with Becker 
Muscular Dystrophy after 6 months of low-magnitude vertical WBVT (30-90Hz, 0.4g, 10 
minutes daily) [751]. In contrast, 6MWT distance was found to be significantly improved 
by 44m (11%) in GMFCS II and by 40m (35%) in GMFCS III, after 20 weeks of side-
alternating WBVT (20 Hz, 4-6mm, 9 minutes, 4 times a week) [732]. The larger 
improvements seen in this study compared to the paediatric MRCD cohort may be due to 
the higher peak vibration amplitude used during training, 6mm compared to 4mm. 
6MWT distance also increased significantly by 31.5m (8%) in children with SMA, mean 
age 10 years, after progressive side-alternating WBVT (10-24Hz, 4mm, 9 minutes twice 
a day, 5 times a week for 8 weeks)  [228]. The higher peak amplitude, 24Hz compared to 
20Hz and the longer daily training duration, 18 minutes compared to 9 minutes, may have 
contributed to the improvements in 6MWT performance seen in the SMA group that 
were not seen in the paediatric MRCD cohort. In children with OI, mean age 9 years, 
participating in an intensive functional physical therapy program (including resistance 
trailing, treadmill walking and neurodevelopmental therapy) for 12 months in addition to 
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side-alternating WBVT with a tilt-table (15-20Hz, 9 minutes twice a day, for 6 months), 
the one-minute walk test increased significantly by 43% after 6 months of WBVT [203]. 
Children with cerebral palsy, 6-12 years of age, receiving twice weekly physical therapy 
sessions, were randomised to progressive side-alternating WBVT with a tilt-table (12-
18Hz, 2-4mm, 5 times a week for 6 months) or control [198]. Walking speed in the 10m 
walk test significantly increased by 38% in the WBVT group which was significantly 
larger than the control group [198]. Side-alternating WBVT (using individualised 
frequency and amplitude setting, 9 minutes twice a day, 5 days a week for 6 months) in 
addition to an intensive physical therapy program (including resistance training, treadmill 
walking and hydrotherapy), resulted in a 39% increase in self-selected 6m gait speed, in 
children with spina bifida, mean age 8.7 years [258]. Another study in children with 
bilateral spastic cerebral palsy, mean age 10 years, participating in a conventional 
physical therapy program (including massage, stretching and balance training), found a 
significant improvement in common gait pattern speed measured by 3D gait analysis of 
30% in those randomised to progressive side-alternating WBVT (5-25Hz, 2-6mm, 18 
minutes, with dynamic squats, 3 times a week for 8 weeks), which was significantly 
larger than the control group [226]. A systematic review and meta-analysis investigating 
the effects of WBVT in children with cerebral palsy found that compared to control, 
WBVT significantly increased gait speed by 34% [202]. 
 
5.1.4.2 Follow-up Period 
 
 
After 6 months follow-up, there were no significant changes in CPET parameters at AT 
or peak exercise in the CF cohort, similar to that seen one moth post withdrawal of 
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WBVT in a study of children with CF [229]. The significant reductions in peak VO2 seen 
in the CF cohort during the observation period did not continue in the follow-up period, 
perhaps due to a latent effect of the WBVT. 
 
There were no significant changes in the 6MWT distance during the follow-up period in 
the paediatric MRCD cohort. The maintenance of 6MWT distance during the follow-up 
period in the paediatric MRCD cohort is consistent with the current literature which has 
not shown any significant changes in walking test performance during a follow-up period 
after cessation of WBVT. In 8 ambulant children with spinal muscular atrophy, mean age 
10 years, and 14 ambulant children with Duchenne Muscular Dystrophy, mean age 9 
years, there was a non-significant decrease in 6MWT distance of 2% 4 weeks after 
ceasing progressive side-alternating WBVT (10-24Hz, 4mm, 9 minutes twice a day, 5 
times a week for 8 weeks) [228]. Six months after completing low-magnitude vertical 
WBVT (30-90Hz, 0.4g, 10 minutes daily, for 6 months), in four boys with Duchenne 
Muscular Dystrophy and two boys with Becker Muscular Dystrophy, 6-22 years of age, 
there was a non-significant increase in 6MWT distance of 0.8m (0.2%) [751]. In children 
with OI, mean age 9 years, there was no change in one-minute walk distance 6 months 
after completing side-alternating WBVT with a tilt-table (15-20Hz, 9 minutes twice a 
day, for 6 months), however participants continued to receive an intensive functional 
physical therapy program (including resistance training, treadmill walking and 
neurodevelopmental therapy) during the 6 month follow-up after cessation of the WBVT 
intervention [203]. Self-selected 6m gait speed in children with spina bifida, mean age 
8.7 years, did not change significantly, 6 month after completing side-alternating WBVT 
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(using individualised frequency and amplitude setting, 9 minutes twice a day, 5 days a 
week for 6 months) in addition to an intensive physical therapy program [258]. 
 
The post-6MWT heart rate increased significantly by 23.0 beats/minute (21.8%) 
indicating a deterioration in the cardiovascular response to the endurance test, especially 
considering this increase in heart rate occurred without a significant increase in 6MWT 
performance, and may indicate worsening OXPHOS capacity. 
 
5.1.5 Effect of WBVT on Quality of Life 
 
 
Quality of life in the CF cohort was measured using a disease-specific questionnaire, the 
CFQ-R. In the paediatric MRCD cohort, Quality of Life was measured using section IV 
of the NPMDS. 
 
5.1.5.1 WBVT Period 
 
 
After WBVT, the CF cohort did not demonstrate any significant changes in child- and 
adult-reported domains, however the parent-reported emotion and school domains 
increased significantly, indicating better quality of life in emotional regulation and school 
attendance and participation. Importantly, participants did not perceive the home-based 
WBVT intervention as an increased treatment burden, as there were no significant 
changes in this domain after WBVT. This is especially important as the treatment burden 
domain was below the normative mean at baseline. There were no significant changes in 
quality of life in the paediatric MRCD cohort. Two previous studies have investigated the 
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effects of WBVT on quality of life in paediatric cohorts. In children with cystic fibrosis, 
with a mean age of 11.7 years, participating in a randomised cross-over trial of side-
alternating WBVT (20-22Hz, 1mm, 10-15 minutes, 3 times a week for 4 weeks), health-
related quality of life measured by the CFQ-R did not change significantly after WBVT 
[229]. In children with cerebral palsy, GMFCS II and III, mean age 16.2 years, quality of 
life measured by the Cerebral Palsy Quality of Life Questionnaire did not find any 
significant changes in patient-reported health-related quality of life, however caregivers 
reported significant improvements in school well-being, general well-being and 
participation, perceived pain and impact of disability and global quality of life scores, 
after 20 weeks of side-alternating WBVT (20 Hz, 4-6mm, 9 minutes, 4 times a week) 
[732], sharing some similarities with the results in the CF cohort. 
 
5.1.5.2 Follow-up Period 
 
 
After 6 months follow-up, there were no significant changes in child- or adult-reported 
domains however parent-reported emotion and respiratory domains increased 
significantly, indicating improvements in emotions and respiratory symptoms. There was 
also a non-statistically significant, but clinically relevant improvement in the child- and 
adult-reported respiratory domain. The paediatric MRCD cohort did not demonstrate any 
significant changes in quality of life during the follow-up period. No previous studies 
have investigated health-related quality of life after cessation of a WBVT intervention. 
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5.2 Adult Perspective 
 
 
5.2.1 Effect of WBVT on Bone and Body Composition Parameters 
 
 
5.2.1.1 WBVT Period 
 
 
5.2.1.1.1 Trabecular Bone Compartment 
 
 
The trabecular bone compartment was investigated using lumbar spine DXA scans and 
pQCT at the 4% tibial site. 
 
5.2.1.1.1.1 Bone Mass 
 
 
In the adult MRCD cohort, 6 months WBVT did not have a significant impact on lumbar 
spine bone mass or density. These results are consistent with systematic reviews and 
meta-analyses in postmenopausal women [214] and in the older adult population [216, 
217], which found no treatment effects of WBVT on lumbar spine BMD when compared 
to a control group performing no intervention or an active exercise group. However, a 
more recent systematic review and meta-analysis in post-menopausal women found a 
significant treatment effect of WBVT on lumbar spine BMD when compared to control, 
sham and active exercise interventions, however this was only preserved when low-
magnitude WBVT (<1g) was used [752]. The use of high magnitude WBVT in the adult 
MRCD cohort may explain why we did not find significant improvements in lumbar 
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spine BMD. However, the four low magnitude studies [211, 753-755] in the meta-
analysis [752] utilised WBVT for 12-18 months, compared to 6-12 months in the high 
magnitude studies [209, 210, 221, 756], the longer intervention period likely contributing 
to the difference in outcomes. 
 
Five studies using side-alternating vibration platforms in post-menopausal women have 
reported lumbar spine BMD outcomes [209, 210, 215, 754, 757]. Gusi et al [209] and 
Liphardt et al [215] did not find any improvements in lumbar spine BMD after 8 months 
WBVT (12Hz, 3mm, 3-6 minutes, 3 times a week) and 12 months WBVT (20Hz, 3-
4mm, 10 minutes, 2-3 times a week) respectively, these findings consistent with those 
seen in the adult MRCD cohort. The results of one study suggested a bone-sparing effect 
of 8 months WBVT (12Hz, 2mm, 6 minutes, twice a week) with no significant effect on 
lumbar spine BMD, BMC or area seen after WBVT compared to significant reductions in 
the control group [757]. The combination of dynamic exercises including squats and heel 
raises, with 12 months WBVT (12Hz, 12mm, 10 minutes, 3 times a week) significantly 
increased lumbar spine BMD 0.007g/cm
2
 (0.7%), significantly larger than the control 
group [754]. Iwamoto et al [210] found a significant increase in lumbar spine BMD in 
post-menopausal women after 12 months of WBVT at 20Hz, however the participants in 
the were also receiving alendronate, and this may have contributed to the positive 
response in lumbar spine BMD seen. 
 
Several studies using vertical vibration platforms have reported lumbar spine BMD 
outcomes. Four studies using low-magnitude vertical vibration in post-menopausal 
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women and community dwelling elderly for 12-24 months [211, 753, 758, 759] and four 
using high-magnitude vertical vibration in post-menopausal women, older adults and 
healthy, young adults for 3-8 months [208, 221, 760, 761] did not find a beneficial 
treatment effect of WBVT for lumbar spine BMD and BMC, which is consistent with the 
results of the adult MRCD cohort. Two studies demonstrated a potential bone 
preservation effect of vertical WBVT on the lumbar spine in post-menopausal women 
when compared to control groups after 8 months low-magnitude WBVT (30Hz, 0.3g, 15 
minutes, twice a week) [757] and 6 months of high-magnitude WBVT (35-40Hz, 1.5mm, 
7-12 minutes, 3 times a week) [762]. Three studies in post-menopausal women found 6-
18 months of vertical WBVT to have a significant improvement on lumbar spine BMD 
[208, 754-756]. 
 
The existing literature suggests high-magnitude vibration [210, 754-756, 762] with 
amplitudes up to 12mm [754], frequency >25Hz [754-757, 762, 763], >12 months in 
duration [210, 754, 755, 763], progressive nature of the vibration training with dynamic 
exercises [754, 755], and the combination of WBVT with a conventional exercise 
intervention [755], may contribute to the improvements in lumbar spine bone mass and 
density after WBVT.  Larger improvements in lumbar spine bone mass and density may 
have been found in the adult MRCD cohort if the duration of the study was prolonged, 
ideally to at least 12 months, and if the WBVT protocol used a frequency > 25Hz. 
Progressing the intensity of the vibration training by increasing frequency, amplitude or 
adding in some dynamic exercises may also improve lumbar spine bone mass and density 
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outcomes. The effects of high and low-magnitude vibration training should also be 
investigated in adults with MRCD. 
 
In the adult MRCD cohort, there were no significant changes in bone mass and density 
parameters measured at the 4% tibial pQCT site after WBVT. These results are consistent 
with the existing literature. In healthy, young adults, 8 months of vertical WBVT (25-
45Hz, 2mm, 2-8g, 2-4 minutes, 3 times a week) with dynamic exercises, showed no 
changes in distal tibial trabecular vBMD measured by pQCT [208]. Side-alternating 
WBVT (12-28Hz, 2-6 minutes, twice a week) for 6 months in post-menopausal women 
did not change trabecular vBMD at the 4% pQCT site compared to controls [212]. In 
another study of post-menopausal women, randomised to 12 months side alternating 
WBVT (20Hz, 2-4mm, 10 minutes, 2-3 times a week) or control, there was no significant 
differences in total or trabecular bone vBMD at the distal tibia measured by high 
resolution pQCT [215]. In another study using high resolution pQCT of the distal tibia, 
12 months of home-based low-magnitude vertical vibration in post-menopausal women 
found no significant changes in total and trabecular vBMD [759]. Trabecular vBMD 
measured by QCT of the proximal femur did not significantly differ between low-
magnitude vertical WBVT compared to placebo after 2 years in community-dwelling 
elderly [758]. Another study in older adults found no effect of 11 weeks of vertical 
WBVT (40Hz, 2mm, 7.5 minutes, 3 times a week) on total and trabecular BMC and 
vBMD measured at the 4% tibial pQCT site [761].  
 
 482 
The results reflected in the available literature as well as those found in the adult MRCD 
cohort, investigating the effect of WBVT on trabecular bone mass and density in the 
lower limbs, suggest that WBVT may have limited efficacy in improving bone health in 
trabecular bone. However, all the studies investigating distal tibial vBMD were only up 
to 12 months in duration. It may be that a longer duration intervention period is required 
in adults, especially when bone health is already compromised, to precipitate changes in 
the trabecular bone compartment. Intervention periods of at least 18 months, along with 
progressive, high intensity WBVT are likely required to elicit a beneficial response in 
trabecular bone in the adult MRCD cohort. 
 
5.2.1.1.2  Cortical Bone Compartment 
 
 
5.2.1.1.2.1 Bone Mass 
 
 
After WBVT, no significant changes were seen in bone mass when analysing the total 
body DXA scans or segmental analysis of those scans in the adult MRCD cohort. These 
results are consistent with previous studies. In post-menopausal women, no significant 
differences in total body BMC were found after 8 months side-alternating WBVT (12Hz, 
2mm, 6 minutes, twice a week) [757]. Similar results were found in older adults, after 11 
weeks vertical WBVT (40Hz, 2mm, 7.5 minutes, 3 times a week) with static squats 
[761]. 
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There were no significant changes in bone mass parameters measured at the 20% or 66% 
distal tibial pQCT sites in the adult MRCD cohort during the WBVT period. These 
findings are consistent with one study in the existing literature investigating the effects of 
11 weeks vertical WBVT (40Hz, 2mm, 7.5 minutes, 3 times a week), compared to 
controls, in older adults [761]. Total BMC and cortical BMC at the 38% tibial pQCT site 
did not change significantly after WBVT or between groups however there was a 
significant reduction in total BMC at the 38% tibial pQCT site in the control group [761]. 
These results suggest there may be a bone sparing effect of WBVT at the 38% tibial 
pQCT site in older adults. 
 
5.2.1.1.2.2 Bone Density 
 
 
In the adult MRCD cohort, WBVT did not have an effect on total body bone density. 
These finding are consistent with the existing literature in post-menopausal women using 
side -alternating [757], low-magnitude [757] and vertical [221, 760], WBVT and in older 
adults using vertical WBVT [761].  Segmental analysis of the total body DXA scans in 
the adult MRCD cohort found a significant increase in legs BMD of 0.007g/cm
2
 or 0.6% 
after WBVT. This value is within the CV reported in the adult literature, 0.7% [134], and 
that reported from our laboratory, 1.55% (Table 2.1), and may not be of any clinical 
relevance. The effect of WBVT on legs BMD in the adult cohort cannot be directly 
compared to the literature as previous studies in the adult population used total hip and 
femoral neck DXA scans, however we can make some comparisons. The magnitude of 
the change in legs BMD in the adult MRCD cohort was smaller than the changes 
recorded in recent systematic review and meta-analyses in post-menopausal women 
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where hip BMD significantly increased after WBVT with a standardised mean difference 
of 0.015g/cm
2
 [214]. However it was similar in magnitude to that seen in a meta-analysis 
in older adults where WBVT was found to have a significant treatment effect on femoral 
neck BMD with a mean difference of 0.04g/cm
2
 [216]. Another meta-analysis in post-
menopausal women did not find a significant treatment effect of WBVT on femoral neck 
BMD with an intervention period of at least 6 months [752] and no significant treatment 
effect of WBVT on total hip BMD was found in another meta-analysis in older adults 
[217]. It is obvious that WBVT affects different areas of the skeleton differently, even 
when analysis is performed in areas of close proximity, for example the total hip and 
femoral neck areas. While we cannot directly compare the results of proximal hip 
analysis to that of the segmental analysis of the leg BMD in the adult MRCD cohort, 
improvements in the BMD of the cortical bone in the lower limbs of adults with MRCD 
may be augmented with a longer intervention period and frequencies greater than 25Hz 
[763].  
 
When considering side-alternating vibration platforms, 8 months WBVT (12 Hz, 3mm, 2-
6minutes, 3 times a week), significantly improved femoral neck BMD in post-
menopausal women compared to a walking program [209]. However the same positive 
response in femoral neck BMD in post-menopausal women was not found in three more 
recent studies using side-alternating WBVT for 8-12 months [215, 754, 757]. Studies 
using vertical vibration platforms in post-menopausal women also report conflicting 
results for the effect of WBVT on hip BMD. One study demonstrated a significant 
increase in total hip BMD of 0.008g/cm
2
 (0.93%) after 6 months of WBVT [221], similar 
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in magnitude to the increase in legs BMD seen in the adult cohort despite the addition of 
dynamic exercises during the vibration stimulus and the different anatomical site 
analysed. Other studies investigating the effects of vertical vibration platforms however, 
did not show any beneficial effect of WBVT on hip BMD in post-menopausal women 
[211, 754, 755, 759, 760, 764]. Studies using vertical vibration platforms in older adults 
also did not find a beneficial effect of WBVT on hip BMD [758, 761, 765].  
 
In the adult MRCD cohort, 6 months of WBVT did not have any significant effect on 
bone density measured at the 20% or 66% tibial pQCT sites. These results are similar to 
those seen in healthy, young adults, which showed no change in the cortical vBMD of the 
tibial mid-shaft compared to control after 8 months of progressive vertical WBVT [208]. 
In another study using side-alternating WBVT in post-menopausal women, 6 months of 
progressive WBVT (12-28Hz, 3-6 minutes with increasing amplitude, twice a week), 
cortical vBMD at the 38% tibial site did not change significantly in the WBVT group 
compared to a significant decrease in the control group [212], these results indicating a 
potential bone sparing effect WBVT. In contrast, 11 weeks of vertical WBVT (40Hz, 
2mm, 7.5 minutes, 3 times a week) in older adults resulted in a significant reduction in 
total vBMD and cortical vBMD at the 38% tibial pQCT site, which was significantly 
greater than the decline seen in the control group for total vBMD [761]. The decline in 
vBMD seen in the latter study may be due to the shorter intervention period, older age of 
participants or the non-progressive nature of the WBVT protocol. 
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Side-alternating WBVT [208, 209] appears to be more successful in improving cortical 
bone density in the lower limbs compared to vertical WBVT, which may be explained by 
the rapid alternating displacements at the level where the hip meets the pelvis generated 
during side-alternating WBVT, the resulting muscle action imparting larger site specific 
forces to the underlying bone in the hip and lower limb region during side-alternating 
vibration compared to vertical vibration. High-magnitude vibration training appears to be 
more beneficial than low-magnitude vibration training, which did not elicit any beneficial 
effects on cortical bone density in any of the studies reviewed [211, 753, 758, 759], an 
observation confirmed in a recent meta-analysis in post-menopausal women [752], and 
likely a result of a reduced mechanical stimulus imparted on the hip and lower limb 
region compared to high-magnitude vertical and side-alternating WBVT platforms. 
Vertical vibration appears to have been more beneficial in improving cortical bone 
density when frequencies >30Hz were employed [221, 765], an aspect of vibration 
training protocols which was found to be particularly osteogenic for hip BMD in a recent 
meta-analysis in post-menopausal women [763]. Future studies investigating the effects 
of WBVT in adults with MRCD should involve a larger sample size, exploring the effects 
of different vibration frequencies, as well as the use of proximal hip DXA scans, 
including total hip and femoral neck scans, to elucidate the efficacy of WBVT on cortical 
bone in the lower limbs.  
 
5.2.1.1.2.3 Bone Area and Geometry 
 
There were no significant changes in any parameter of bone area or geometry in either of 
the analysis techniques used in the adult MRCD cohort. These results are consistent with 
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the findings of Russo et al [212] who did find any changes in bone area at the 38% tibial 
site in post-menopausal women compared to controls after 6 months of progressive side-
alternating WBVT (12-28Hz, 3-6 minutes with increasing amplitude, twice a week) 
[212], and Torvinen et al [208] who found no improvements in bone area measured at the 
tibial mid-shaft after 8 months of progressive vertical WBVT (25-45Hz, 2mm, 2-8g, 2-4 
minutes, 3 times a week) with dynamic exercises in healthy young adults [208].  Total 
and cortical bone area at the 38% tibial pQCT site did not change significantly after 11 
weeks of vertical WBVT (40Hz, 2mm, 7.5 minutes, 3 times a week) in older adults, 
however total bone area decreased significantly in the control group [761], suggesting a 
potential bone-sparing effect of WBVT.  
 
5.2.1.1.2.4 Bone Strength 
 
In the adult MRCD cohort there were no significant changes in any parameter of bone 
strength measured at the 20% or 66% tibial pQCT site after WBVT. Two previous 
studies investigating the effect of vertical WBVT on bone strength in the tibia were 
consistent with the findings in the adult MRCD cohort. Progressive vertical WBVT (25-
45Hz, 2mm, 2-8g, 2-4 minutes, 3 times a week) with dynamic exercises in healthy young 
adults found no improvement in bone strength of the tibial mid-shaft after 8 months 
[208]. In older adults, 11 weeks of vertical WBVT (40Hz, 2mm, 7.5 minutes, 3 times a 
week) polar SSI at the 38% tibial pQCT site [761].  
 
Similar to findings in the trabecular bone compartment, 6 months WBVT in adults with 
MRCD did not demonstrate any significant improvements in bone mass, density, 
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geometry or strength in the cortical bone compartment. Analogous to the conclusions 
drawn for the trabecular compartment, it is likely studies with a longer WBVT period 
using progressive protocols may elucidate whether WBVT in adults is beneficial in 
improving bone health in the cortical bone compartment. Furthermore, larger studies 
investigating different vibration platforms, vertical and side-alternating, as well as 
different vibration frequencies are required to determine optimal training protocols for 
enhancing cortical bone parameters. 
 
5.2.1.1.2.5 Body Composition 
 
During the WBVT period, body composition was measured using total body DXA scans, 
segmental analysis of these scans and the measurement of muscle and fat CSA at the 66% 
distal tibial pQCT site. In the adult cohort, WBVT did not have an effect on total body 
lean tissue mass or fat mass. This finding is consistent with the Verscheuren et al [221] 
study which found no change in total body lean tissue mass in post-menopausal women, 
after 6 months of progressive vertical WBVT (35-40Hz, 1.7-2.5mm) with dynamic 
exercises compared to controls [221], however, a significant decreased in fat mass of 
2.3% was found [221]. Similar results were found by von Stengel et al [766] in post-
menopausal women, where 18 months of conventional training (including aerobic, 
resistance and balance exercises) and progressive vertical WBVT (25-35Hz, 1.7-2.0mm, 
with dynamic exercises including squats and heel raises, twice a week) did not find a 
significant change in LTM over time or compared to the control group, however total 
body fat decreased significantly by 2.2% after WBVT and significantly more than control 
[766]. In older adults, 11 weeks of vertical WBVT (40Hz, 2mm, 7.5 minutes with static 
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squats, 3 times a week) did not significantly change total body lean tissue mass over time 
or compared to controls [767]. Fat free mass, measured by underwater weighing, 
increased significantly after progressive vertical WBVT (35-45Hz, 2.5-5mm, 13-20 
minutes with static and dynamic exercises) in untrained young adult females but was not 
significantly different to the control group [768]. There was no change in body fat over 
time or between groups [768].  
 
There were no significant changes in body composition parameters on segmental analysis 
of the total body DXA scans, however, WBVT appears to have reduced the rate of 
decline and in some cases reversed the significant decline of LTM that was seen in the 
total body and legs during the observation period (Table B.2). The study by Gomez-
Cabello et al [767], in older adults, did not find significantly altered LTM in the legs after 
11 weeks of vertical WBVT (40Hz, 2mm, 7.5 minutes with static squats, 3 times a week) 
[767]. Verschueren et al 2011 [765] did not find a significant change in upper leg muscle 
mass measured by multi-slice CT after 6 months progressive vertical WBVT (30-40Hz, 
1-12 minutes, 1.6-2.2g, with dynamic exercises, 3 times a week) in elderly 
institutionalised females [765]. Using a similar method, Bogaerts et al [769] found a 
significant increase in muscle mass (3.4%) measured by CT of the upper thigh after 12 
months of progressive vertical WBVT (35-40Hz, 5mm, 2-15 mins with dynamic 
exercises) which was significantly greater than control group, in older men, [769]. 
Machado et al [770] found significant increases in the muscle CSA of the vastis medialis 
and biceps femoris measured by CT, which were significantly greater than control, after 
10 weeks of progressive vertical WBVT (20-40Hz, 2-4mm, 1.5-8 minutes, 3-5x/week 
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with dynamic exercises) in community-dwelling older females. Quadriceps muscle CSA 
of the upper third of the thigh, measured by MRI, did not change significantly after 8 
months vertical WBVT (20Hz, 2mm, 3.2g, 3-3.5 minutes, twice a week) in elderly 
women, however, those randomised to the control group demonstrated significant 
reductions in quadriceps muscle CSA, suggesting that WBVT may have a muscle-
preserving effect [771]. 
 
Body composition parameters at the 66% tibial pQCT site in adults with MRCD 
remained stable during the WBVT period. There are no reports in the literature describing 
the effect of WBVT on muscle and fat CSA at the 66% distal pQCT site in adults. In a 
study investigating the effects of 13 weeks of vertical WBVT (12Hz, 1mm, 3 times a 
week) in older adults, mid-calf muscle CSA measured by pQCT did not change 
significantly with WBVT [244]. 
 
The previous literature investigating the effects of WBVT on body composition in adults 
has been focused on vertical vibration platforms. It would appear from the available 
literature that improvements in LTM occur when progressive vertical vibration protocols 
are utilised with frequencies >40Hz, amplitudes of 4-5mm, with dynamic exercises for at 
least 10 minutes duration [768-770]. Future larger studies in adults with MRCD with 
higher training stimulus that are progressive in nature, including amplitude and 
frequency, with the addition of static or dynamic exercises on the platform may improve 
outcomes for body composition, including lean tissue mass and fat mass, in adults with 
MRCD. 
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5.2.1.1.2.6 Bone Biochemistry and Turn-over Markers 
 
There were no significant changes in blood biochemistry or bone turnover markers in the 
adult MRCD cohort during the WBVT period indicating that WBVT did not interrupt the 
accelerated bone loss seen in this cohort due to bone remodelling favouring bone 
resorption. Despite the absence of change in bone turnover markers and the climate 
favouring bone resorption during the WBVT period, bone parameters did not continue to 
decline significantly as seen during the observation period and there was a significant 
improvement in leg BMD, which was of borderline clinical significance. This may be 
explained by the small size of the cohort and the inherent variability of the bone turnover 
markers used. 
 
Elmantaser et al [729] found that 8 weeks of side-alternating WBVT (18-22Hz, 9 
minutes, 3 times a week) in healthy young men, significantly decreased the serum bone 
resorption marker CTX, however there was no change in the other bone resorption 
marker TRACP5b, or the serum bone formation markers BAP and osteocalcin [729]. In 
the same study, men randomised to low magnitude vertical WBVT 32-37Hz, 10-20 
minutes, did not demonstrate any significant changes in markers of bone resorption or 
formation after WBVT [729]. Despite the similarities in the side-alternating training 
protocol used in the MRCD cohort, the favourable reduction in resorptive activity seen in 
healthy young men [729] was not seen in the adult MRCD cohort, however this may be 
due to the different markers of osteoclast activity that were used. The urinary 
deoxypyridinoline:creatine ratio used in the MRCD cohort is not as preferable as the 
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serum measure of CTX utilised in the Elmantaser et al 2012 study [729]. Urinary derived 
measures of bone resorption have several limitations including large variations between 
individuals, the influence of circadian variation [741, 746], difficulty with serial 
measurements [738, 743, 744], susceptibility to UV exposure [736] and the effect of 
changing muscle mass and age when expressed relative to creatinine [727, 740, 745]. 
Consequently, serum derived measurements of bone resorption, such as CTX, are 
preferred [727, 740-742]. 
 
Two other studies investigating vertical WBVT in post-menopausal women found 
WBVT to have a beneficial effect on bone resorption. Low-magnitude vertical WBVT 
(12Hz, 0.3g, 10 mins 3 times a week) had significant reductions in the urinary N-terminal 
telopeptide (Ntx)/creatine ratio, however serum-derived BAP (bone alkaline phosphatase) 
did not change significantly [772]. Progressive vertical WBVT (35-40Hz, 1.5mm, 7-12 
minutes, 3 times a week) for 6 months, found a significant reduction in urinary 
hydroxyproline (29%) compared to a non-significant increase in the control group (55%) 
[762]. 
 
In another study investigating the effects of side-alternating (30Hz, 3mm, 3.6g), vertical 
(30Hz, 1.3mm, 1.5g), or sham WBVT in older adults, a 12 week progressive program 
with 3 training sessions a week, 1-6 minutes, found significant increases in the bone 
formation marker aminoterminal propeptide of type I collagen (P1NP) in the side-
alternating WBVT group (35%) and vertical WBVT group (26%) which were 
significantly greater than sham, however the bone resorption marker CTX did not change 
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significantly over time or between groups [222]. The findings in this study with regard to 
bone resorption support the findings in the adult MRCD cohort despite the different 
markers used, however the significant increase in the bone formation marker P1NP is in 
contrast to the results seen in the adult MRCD cohort, where different markers of bone 
formation, osteocalcin and alkaline phosphatase, did not significantly improve after 
WBVT. The differing results may be explained by the different bone formation markers 
used. In comparison to the bone formation markers osteocalcin and alkaline phosphatase, 
utilised in the adult MRCD cohort, which are released at different stages of 
differentiation and proliferation of the osteoblast [773], PINP estimates the rate of 
synthesis of type I collagen, the most prolific collagen in bone [735]. PINP may be a 
more sensitive measure of bone formation compared to osteocalcin, which is more labile 
with marked diurnal variation and susceptibility to processing and storage practices [734, 
739], and alkaline phosphatase, which lacks specificity to bone due to influences from 
other organs including the gut, liver, kidney and brain [734, 736]. Corrie et al [222] also 
speculated that their study may have found a significant increase in bone formation due to 
the shorter intervention period compared to most of the existing literature, 12 weeks 
compared to at least 6 months. They proposed that bone formation may be increased 
during the initial period of exposure to the WBVT stimulus, but that this increase would 
only be transient, subsiding once adaptations in the skeleton had occurred, hence 
explaining why longer duration studies did not see a similar increase in bone formation 
markers [222]. 
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Several studies in the existing literature did not find a beneficial effect of WBVT on bone 
turnover markers using side-alternating [212], vertical [208, 220, 221, 760], and low-
magnitude [211, 758] WBVT in healthy adults [208], post-menopausal women [211, 212, 
221, 760], older adults [758], and post-stroke [220], consistent with the findings in the 
adult MRCD cohort.  
 
Alterations to bone resorption markers [729, 762, 772] appears to occur more regularly 
than changes in bone formation markers [222] indicating that WBVT may be more 
successful in reducing the rate of bone resorption than stimulating bone formation in 
adult populations. The studies significantly improving bone resorption markers affected a 
variety of markers, CTX [729], urinary NTX/Creatinine ratio [772], and urinary 
hydroxypyroline [762], and utilised different vibration training protocols, progressive 
side-alternating [729], progressive vertical [762], and low-magnitude [772] of varying 
durations, 8 weeks [729], 6 months [762] and 8 months [772] in young adults [729] and 
post-menopausal women [762, 772].  Only one study found significant improvements in 
in bone formation markers, P1NP, after 12 weeks of progressive side-alternating 
vibration in older adults [222]. It is difficult to elucidate the most effective training 
protocol to elicit changes in bone formation and resorption markers. Side-alternating 
WBVT [222, 729] has been successful in reducing bone resorption markers and 
increasing bone formation markers, whereas vertical vibration [762, 772] has only been 
successful in reducing bone resorption markers. Identifying changes in bone formation 
markers may be time-sensitive, with one study speculating that changes in bone turnover 
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occur in the first few months of the training stimulus with a transient change that subside 
once adaptations in bone have occurred [222].  
 
Serum derived measurements of bone resorption, such as CTX, that is released during 
collagen breakdown [736, 737], are preferred [727, 740-742] due to limitations in urinary 
derived measures that increase variability [727, 736, 738, 740, 741, 743-746]. Bone-
specific alkaline phosphatase (BAP), which eliminates confounding influences from other 
organs including the gut, liver, kidney, and brain when alkaline phosphatase is used [734, 
736] and has been found to positively correlate with bone formation measured by 
histomorphometry [736, 737], should also be considered. P1NP, which reflects the rate of 
synthesis of type I collagen [735], a different aspect of bone formation to that measured 
by osteocalcin, a protein synthesised by osteoblasts and alkaline phosphatase, an 
osteoblast ectoenzyme, both of which are involved in the regulation of bone 
mineralisation [736-738, 773] is likely to be a more sensitive measure of bone formation 
compared to osteocalcin [734, 739] and alkaline phosphatase [734, 736] and has been 
utilised in studies of post-menopausal women to assess osteoporosis and assess the 
effects of anti-resorptive agents [734]. Both BAP and PINP are considered to be more 
stable than osteocalcin which exhibits sample instability and susceptibility to processing 
and storage practices as well as it being non-homogenously distributed in the circulation 
and having high individual variability [736]. The international Osteoporosis Foundation 
recommends the use of the bone formation marker PINP and the bone resorption marker, 
CTX, for monitoring osteoporosis in the adult population [774]. The incorporation of 
these more specific, sensitive and stable, serum derived bone turnover markers in future 
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larger and longer-term studies are required to determine whether WBVT has the capacity 
to alter bone turnover markers and improve bone health in adults with MRCD. 
 
5.2.1.2 Follow-up Period 
 
 
5.2.1.2.1  Trabecular Bone Compartment 
 
 
5.2.1.2.1.1 Bone Mass and Density 
 
 
During the follow-up period, there were no significant changes in bone mass parameters 
measured at the lumbar spine or 4% distal tibial pQCT site in the adult MRCD cohort. 
Cheung et al [775] followed-up post-menopausal women, 12 months after completing an 
18 month randomised controlled trial comparing low-magnitude WBVT (35Hz, 0.3g, 5 
times a week) to control. Lumbar spine BMD remained stable during the follow-up 
period and was not significantly different to those randomised to the control group [775], 
their finding consistent with those in the adult MRCD cohort. High-resolution pQCT of 
the distal tibia did not find a significant change in total or trabecular vBMD in the 8 
month follow up period in post-menopausal women, randomised to control or side-
alternating WBVT (20Hz, 3-4mm, 10 minutes, 2-3 times a week) for 12 months [215]. 
This result supports the finding at the 4% distal pQCT site in the adult MRCD cohort.  
 
5.2.1.2.2 Cortical Bone Compartment 
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5.2.1.2.2.1 Bone Mass and Density 
 
 
In the adult MRCD cohort there were no significant changes in bone mass or density 
measured by total body DXA scans or at the 20% and 66% pQCT sites during the follow-
up period. However, on segmental analysis of the total body DXA scans, legs BMD 
decreased significantly by 0.008g/cm
2
 or 0.7%, just within the reported CV in the adult 
literature of 0.7% [134].  The magnitude of this significant decrease was larger than the 
decrease seen in the observation period and the significant increase seen in the WBVT 
period. It could be postulated that the reduction in legs BMD seen in the follow-up period 
may be a result of the withdrawal of the vibration stimulus, which may have improved 
legs BMD through its actions on the leg muscles and the subsequent transfer of forces to 
the underlying bone during the WBVT period. The forces generated during WBVT 
cannot be recreated through the normal movements of adults with MRCD during the 
follow-up period, despite preserved muscle mass seen. Alternatively, the reduced leg 
BMD may be due to the withdrawal of the actions of the vibration stimulus directly on 
the bone where it is postulated to cause mechanical deformation of the underlying bone 
resulting in perturbations in canalicular fluid flow and stimulation of the osteocyte and 
the WNT/β-catenin pathway [196] resulting in the preservation or augmentation of BMD 
as was seen in the WBVT period.  
 
One previous study has followed-up post-menopausal women, 12 months after 
completing an 18 month randomised controlled trial comparing low-magnitude WBVT, 
(35Hz, 0.3g, 5 times a week) to control [775]. Total hip BMD remained stable during the 
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follow-up period and was not significantly different to those randomised to the control 
group [775]. The different anatomic sites measured in the Cheung et al 2016 study [775], 
total hip, in contrast to segmental analysis of the legs from the total body DXA scan in 
the MRCD cohort needs to be considered. The larger surface area covered by segmental 
analysis of the legs from the total body DXA scan may have been more sensitive in 
identifying changes in the entire lower limb BMD than the small region of interest 
investigated when analysing the total hip BMD and may account for differences in 
outcomes. Nevertheless, the adult MRCD cohort may be more susceptible to bone loss 
after withdrawal of the vibration training compared to post-menopausal females as a 
significant reduction in legs BMD was found after just 6 months of follow-up in contrast 
to the non-significant change in post-menopausal women after 12 months follow-up. 
 
 
5.2.1.2.2.2 Bone Area, Geometry and Strength 
 
The adult MRCD cohort did not display any significant changes in bone area measured 
by total body DXA scans or the segmental analysis of those scans during the follow-up 
period. However, there were significant reductions in cortical CSA and cortical thickness 
measured at the 66% pQCT site of 1.7mm
2
 or 0.7% and 0.0mm or 0.9% respectively. 
There was also a significant reduction in the ratio of cortical CSA to total CSA of 0.4%. 
The reported CVs for cortical CSA in adults is less than 1% [61], so the changes in 
cortical CSA and cortical thickness may well be clinically relevant, suggesting endosteal 
resorption. Considering the cohort of adults with MRCD demonstrated significantly 
reduced cortical CSA at the 66% site prior to commencing WBVT (Figure 4.16), further 
reductions in cortical CSA will have negative ramifications on bone health in this cohort. 
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The distribution-mass relationship in the adult MRCD cohort is disrupted with a given 
cortical CSA associated with a lower polar CSMI compared to the reference population 
indicating compromised bone strength (Figure 2.11). Although it did not reach 
significance there was an associated decrease in the polar CSMI at the 66% pQCT site 
with this significant decrease in cortical CSA during the follow-up period. If the cortical 
CSA continues to decline polar CSMI will follow and bone strength will be further 
compromised in this cohort. Furthermore, the significant reductions in cortical thickness 
and the cortical CSA to total CSA ratio are likely to increase the buckling ratio at the 
66% site causing the bone to be at a greater risk of fracture further compromising bone 
health in adults with MRCD. As bone and muscle parameters measured by pQCT in the 
adult MRCD cohort remained stable during the WBVT period, we might speculate that 
the vibration stimulus had a positive effect on the underlying bone, especially at the 66% 
tibial pQCT site where the calf muscle mass is at its greatest. The activation of the 
muscle at this site during WBVT and the associated forces imparted on the underlying 
bone may have prevented the contraction of cortical CSA and cortical thickness, by 
endosteal resorption, seen in the follow-up period when the vibration stimulus was 
withdrawn.  
 
5.2.1.2.2.3 Body Composition 
 
There were no significant changes in any body composition parameters measured using 
total body DXA scans, or at the 66% distal tibial pQCT site during the follow-up period 
in adults with MRCD. One previous study followed-up older men, one year after 
completing a 12 month trial of progressive vertical WBVT (35-40Hz, 5mm, 2-15 mins 
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with dynamic exercises) and found muscle mass, measured by CT of the upper thigh, 
decreased significantly (2.6%) [776]. The maintenance of lean tissue mass in the adult 
MRCD cohort during the follow-up period contrasts to the significant reductions in total 
body and legs LTM and seen during the observation period, which was also shorter in 
duration compared to the follow-up period. It may be that WBVT has had a muscle-
sparing effect on adults with MRCD that has persisted 6 months post-intervention. The 
preservation of LTM during the follow-up period did not prevent the loss of legs BMD in 
the follow-up period as was seen during the WBVT period. These results suggest that the 
beneficial neuromuscular adaptations likely gained during WBVT are no longer having a 
beneficial impact on the underlying bone through muscle contractile activity or that the 
bone was directly stimulated during WBVT, which is postulated to cause mechanical 
deformation of the underlying bone resulting in perturbations in canalicular fluid flow 
and stimulation of the osteocyte and the WNT/β-catenin pathway [196].    
 
5.2.1.2.2.4 Bone Biochemistry and Turnover Markers  
 
In the MRCD cohort there were no significant changes in bone turnover markers in the 
follow-up period indicating continued accelerated bone loss as osteocalcin levels 
remained below the reference range and the urinary deoxypyridinoline:creatinine ratio 
above the reference range. These findings support the adverse consequences of removal 
of the WBVT stimulus on the cortical bone compartment evidenced by significant 
reductions in legs BMD and cortical CSA and thickness measured at the 66% pQCT site. 
One study has investigated bone turnover markers 4 weeks after cessation of a side-
alternating WBVT intervention in adults and found no significant changes in the bone 
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formation markers, BAP or osteocalcin, or the bone resorption marker TRACP5b, 
however CTX, another bone resorption marker, increased significantly [729]. The 
significant increase in CTX seen after one month of removing the WBVT stimulus is 
consistent with the adverse effects seen in the cortical bone compartment in the MRCD 
cohort after removal of the WBVT stimulus. As previously discussed, serum-derived 
CTX is preferred over urinary-derived measures of bone resorption and may have been 
more sensitive in identifying any changes in bone resorption after withdrawal of the 
WBVT in the adult MRCD cohort. 
 
5.2.2 Effect of WBVT on Force Plate Parameters 
 
 
Only 11 of the 12 participants in the adult MRCD cohort were able to perform the 
multiple one-leg hop manoeuvre and many of the remaining participants found this 
outcome measure difficult to perform. 
 
 
5.2.2.1 WBVT Period 
 
 
5.2.2.1.1  Multiple One-leg Jump (M1LJ) 
 
The adult MRCD cohort did not exhibit any significant changes in force parameters 
during the M1LJ after WBVT. Three previous studies have investigated the effects of 
WBVT on force production during the M1LJ, two in young adults with CF and one in 
osteopoenic post-menopausal women. In 10 CF adults, 22-27 years, 3 months of 
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progressive home-based side-alternating WBVT (20-25Hz, 0.6mm, 18 minutes, 5 times a 
week), found a non-significant increase in force of 72N (~5%) [233]. In the second study 
of young adults with CF, 21-41 years, six months of home-based side-alternating WBVT 
(12Hz, 6 minutes with trunk bends, rotations and extensions, 5 times a week, as well as 
26Hz, 6 minutes, with the progressive addition of weights up to 9kg, 3 times a week), 
increased M1LJ force by a median of 6.7%, however no statistics were performed due the 
small size of the cohort [232]. In osteopoenic post-menopausal women, 9 months of 
progressive side-alternating WBVT (22-24Hz, 2-4mm, 4 minutes with squat exercises, 
twice a week) in addition to a conventional aerobic and resistance training program, 
significantly increased peak force and peak relative force ~4% after WBVT [777]. Each 
of these studies saw improvements in force parameters during the M1LJ of between 4-7% 
after WBVT, much larger than the improvements seen in the adult MRCD cohort. The 
lack of improvements seen in the adult MRCD cohort may have been due to a sub-
optimal WBVT protocol. All three studies used a higher frequency than that used in the 
adult MRCD cohort, and a progressive protocol [232, 233, 777]. The addition of weights 
[232] or the performance of squat exercise [777] during WBVT may have also improved 
the effectiveness of the WBVT in improving M1LJ performance. 
 
The M1LJ measures the maximum forces acting through the tibia, making it an attractive 
outcome measure to use in WBVT studies, as it can be correlated directly to bone health 
measurements taken of the tibia using pQCT [698, 699]. The lack of improvement in 
force parameters during the M1LJ may explain the lack of improvements seen in pQCT 
parameters in the adult MRCD cohort as muscle forces are essential for improving and 
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maintaining the underlying bone health. The complexity of the movement pattern 
required to perform the M1LJ with correct technique, made it a difficult outcome 
measure for the adult MRCD cohort. Many participants were unable to perform the hops 
on the ball of the foot, or complete 10 consecutive hops, and most required support to 
maintain balance during the manoeuvre. This, coupled with the severely impaired muscle 
function demonstrated by the adult MRCD cohort at baseline, indicate that it may not 
have been the best measurement to assess peak forces and gauge the efficacy of WBVT, 
perhaps explaining why no changes in force production during the were seen. A study in 
healthy, older adults, used an isokinetic dynamometer to assess ankle plantar-flexor force 
after 8 weeks of progressive side-alternating WBVT (26Hz, 5-8mm, 4-8 minutes, with 
static and dynamic exercises) and found isokinetic ankle plantar-flexion strength 
increased significantly (18.5%) [778]. Force measurements of the ankle plantar-flexor 
using an isokinetic motorised dynamometer should be considered for future studies. 
 
Furthermore, maximal force measurements could be assessed by measuring knee 
extension strength isometrically or isokinetically using a motorised dynamometer or leg 
press dynamometer. Meta-analyses have investigated the effects of WBVT on knee 
extension strength measured in this way. In healthy adolescents and adults, 12-78 years, 
chronic WBVT, compared to the identical training condition without WBVT significantly 
increased maximum knee extensor strength [300, 301, 307, 314, 197, 299, 259, 315, 203, 
262] with a standardised mean difference of 0.76 [224]. A meta-analysis in older adults, 
mean age 68 years, found WBVT [213, 770, 779, 780] significantly increased isometric 
knee extension strength, compared to a control intervention, with a standardised mean 
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difference of 2.15 [216]. However, dynamic knee extension strength [213, 778, 781, 782] 
was not significantly improved after WBVT compared to a control intervention or 
exercise intervention [216]. In contrast, another meta-analysis in older adults, 57-82 years 
of age, found that chronic WBVT [213, 240, 778], significantly improved dynamic knee 
extension strength compared a control intervention, with a standardised mean difference 
of 0.63 [217], however no effect of WBVT was found when compared to an exercise 
intervention [217], the differences in these meta-analyses due to the studies included and 
the analysis methods used.  The latter meta-analysis also found that chronic WBVT [213, 
783] had no significant effect on isometric knee extension strength, measured using a 
motorised isometric dynamometer, when compared to a control intervention or an 
exercise intervention [217], however, isometric leg extension strength, measured using a 
leg press dynamometer [766, 770], significantly increased after WBVT, compared to a 
control intervention ,with a standardised mean difference of 0.57 [217]. These results 
indicated that the method of assessing lower limb muscle strength is important and can 
affect the interpretation of the benefits following WBVT. 
 
A purer measure of knee extension strength, using isometric and/or isokinetic motorised 
dynamometry or leg press dynamometry should be considered in future studies. In fact 
isometric and isokinetic motorised dynamometry have been used to evaluate the 
effectiveness of WBVT on knee extension muscle strength in adult cohorts with 
underlying medical conditions involving movement disorders, including cerebral palsy 
[235], Pompe Disease [254, 784], multiple sclerosis [252, 265, 785], stroke [786], as well 
as post-menopausal women [213, 215, 239, 240, 787] and older adults [765, 769, 775, 
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776, 778, 781-783, 788-792] who often display age-related impairments in 
neuromuscular function and strength. Many of these studies using this method to assess 
knee extension strength demonstrated beneficial effects after side-alternating [254, 778, 
782, 784, 787, 791, 792] and vertical [213, 239, 769, 775, 781, 783, 788] WBVT. The 
type of exercise performed during WBVT (isometric or dynamic) should be taken into 
account when deciding which measurement of knee extension strength (isometric or 
isokinetic) will be utilised as an outcome measure in future studies, with static exercises 
likely to result in better isometric muscle strength, and dynamic exercise, isokinetic 
muscle strength [216]. 
 
Another aspect to consider, when trying to elucidate why we did not find any strength 
benefits after WBVT in the adult MRCD cohort, is the WBVT protocol used. Optimising 
the protocol in future studies may provide an adequate stimulus to elicit the muscle 
morphological or neurological changes required for improvements force production to be 
seen. Two meta-analyses investigated the effect of vibration frequency and amplitude on 
knee extension muscle strength [224, 793]. They both found WBVT to be more 
beneficial in improving muscle strength when frequencies were over 30Hz [224, 272], 
and as high as 50Hz were used [793]. These findings indicate that the frequency in the 
protocol employed by the MRCD cohort was likely inadequate to elicit changes in 
neuromuscular performance. Frequency is an important aspect of training as it activates 
the tonic vibration reflex, which in turn enhances motor unit synchronisation [794], with 
higher frequencies believed to more closely mimic the rate of motor unit discharge during 
more forceful muscle contractions [223]. The meta-analyses were not as consistent in 
 506 
their results for the effect of amplitude on muscle strength, the smaller meta-analysis, 
which derived data from 7 randomised controlled trials, finding an amplitude of up to 
4mm was most beneficial [224], however the larger meta-analysis, deriving data from 18 
randomised controlled trials, finding that amplitudes of 8-10mm [793] were most 
beneficial. This latter meta-analysis also found that amplitude was the vibration training 
parameter most highly correlated with strength improvements [793]. As the amplitude 
increases, larger electromyographic activity is elicited [795], which in turn correlates 
with muscle activation, ultimately impacting on the magnitude of the training stimulus 
delivered. It would appear that the frequency and amplitude used in the adult MRCD 
cohort did not deliver an adequate training stimulus to induce the muscle morphological 
and neuromuscular changes required to improve muscle strength after WBVT. One meta-
analyses investigated the effect WBVT volume during each training session and found 
that 12-15 minutes of WBVT was the most beneficial volume to improve knee extensor 
strength [793]. The delivery of WBVT in the adult MRCD cohort, 3 bouts of 3 minutes, 
interspersed with a minimum 3 minute rest period, may also have impacted on the lack of 
improvement in muscle strength after WBVT, as training intervals of 30-90 seconds, 
interspersed with 60 second rest periods have been suggested to be most beneficial, likely 
because they reflect the work/rest intervals of conventional resistance training programs 
[793]. One meta-analysis found that performing dynamic as well as static exercises 
during the WBVT improved the beneficial effect of WBVT on muscle strength [793]. 
The lack of dynamic exercise during WBVT in the adult MRCD cohort may explain why 
no changes in force generated during the single-two leg jump were seen in the adult 
MRCD cohort, as the single two-leg jump is a measure of dynamic function. The 
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incorporation of dynamic exercises into the WBVT protocol likely improves muscle 
strength outcomes as dynamic exercises demand greater muscle force to be generated 
which increases motor unit recruitment resulting in improved synchronisation and co-
ordination of motor units after WBVT [793]. The majority of studies in this same meta-
analysis were progressive in nature and included squat and other exercises [793]. The 
authors [793] also discuss the potential benefits of including additional weights to WBVT 
as this results in greater acceleration [796]. The incorporation of progressive protocols 
that include dynamic as well as static exercise are likely necessary to optimise benefits 
from WBVT, according to overload principle which is required for favourable muscle 
morphological and neuromuscular adaptations to occur [223]. These aspects of WBVT 
were not incorporated in the protocol used by the adult MRCD cohort. 
 
5.2.2.1.2  Single Two-leg Jump (S2LJ) 
 
 
There were no significant changes in any of the S2LJ power, force, or efficiency 
parameters during the WBVT period in the adult MRCD cohort. Previous studies in side-
alternating WBVT have demonstrated largely beneficial effects of WBVT on S2LJ 
performance. Only studies investigating the effects of chronic WBV, at least 8 weeks in 
duration, have been discussed to align more closely with the 6-month intervention period 
in the adult MRCD cohort. In many studies, jump height was used as a surrogate measure 
for muscle power [223]. 
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When considering side-alternating WBVT, one RCT in healthy, trained young adults, 
mean age 20 years, randomised to 11 weeks of progressive side-alternating WBVT 
(30Hz, 8 mm, 5-8 minutes with exercises) did not demonstrated any significant changes 
in jump height [238]. While consistent with the results in the adult MRCD cohort, the 
capacity of this cohort of healthy young adults to improve their functional muscle 
performance after WBVT may be limited due to their baseline high level of function, in 
contrast to the adult MRCD cohort, who demonstrated significantly impaired muscle 
function at baseline. The remaining studies into the effects of side-alternating WBVT on 
S2LJ performance have demonstrated beneficial effects in cohorts with underlying 
medical conditions, or age-related decline in muscle function, causing impairments in 
muscle function, in keeping with the impaired muscle function seen in the adult MRCD 
cohort. After 3 months of home-based side-alternating WBVT 20-25Hz, 0.6mm, 18 
minutes, 5 time a week, 10 young adults with CF, 24-27 years, maximum S2LJ force 
decreased significantly by 122N (9%), without a significant change in maximum power 
[233] indicating improved efficiency of muscle function as less force was required to 
generate an equivalent amount of power [718]. Similar improvements in muscle 
efficiency were seen in another study of 8 young adults with CF, 21-41 years, after 6 
months of home-based side-alternating WBVT (12Hz for 6 minutes with trunk bends, 
rotations and extensions, 5 times a week, and 26Hz for 6 minutes with additional weights 
up to 9kg, 3 times a week) with a reduction in maximum S2LJ force by a median of 
4.3%, and increase in maximum power by a median of 4.7% [232]. Muscle efficiency 
during the S2LJ was also improved after 4 weeks side-alternating WBVT (20Hz, 20mm, 
combined with exercises for muscle co-ordination, 4 times a week) in middle-aged adults 
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with pulmonary artery hypertension, whose maximum power significantly increased by 
4.4%, and maximum force significantly decreased by 2.7% [797].  Furthermore, in a 
case-study of a 34 year old female with late-onset Pompe Disease, 15 weeks of 
progressive side-alternating WBVT (5-20Hz, 4mm, 2-4 minutes, 3 times a week) 
significantly increased maximum S2LJ power by 64% [254]. Pompe Disease sufferers 
exhibit progressive decline in muscle strength and impaired mobility, similar to that seen 
in MRCD, however the large improvement seen in power generation during the S2LJ in 
this case study is much greater than that seen in the MRCD cohort, despite similar 
features of the training protocol.  
 
Several RCTs in post-menopausal women have found significant improvement in S2LJ 
performance after side-alternating WBVT: 8 months side-alternating WBVT (12.6Hz, 6 
mm, 3-6 minutes, 3 times a week) with a 10 minute stationary bike warm-up significantly 
increased S2LJ height 1.57cm (13%) [240]; 6 months of progressive side-alternating 
WBVT (12-28Hz, 3-6 minutes, twice a week) significantly increased maximum S2LJ 
power by 8.4W (5%) without significant changes in the maximum force [212], indicating 
improved muscle efficiency; progressive side-alternating WBVT (22-24Hz, 2-4mm, 4 
minutes, with static and dynamic squats, twice a week) in addition to conventional 
aerobic and resistance training for 9 months, increased maximum S2LJ power and the 
Esslinger Fitness Index significantly after WBVT by 0.6W/kg (2%) and 4% respectively, 
however, Jump Efficiency Index remained stable in contrast to a significant decline in 
this parameter seen in those randomised to the balance group [777], this study suggesting 
WBVT may provide an additional benefit for muscle efficiency over conventional 
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aerobic, resistance and balance exercise in isolation, as this aspect of jump performance 
was maintained over the 9 months intervention in the WBVT group but not in the balance 
group. A RCT older adults, found 6 months progressive side-alternating WBVT (30Hz, 
3.9mm, 6-18 minutes, with static and dynamic squat exercises, twice a week) 
significantly increased jump height by 18.6% [789].  
 
Individuals with underlying medical conditions, post-menopausal women and older 
adults with disease- or age-related reductions in muscle neuromuscular performance were 
amenable to improvements after WBVT (often delivered and assessed with the same 
devices used in the adult MRCD cohort), however similar improvements were not seen in 
the adult MRCD cohort, despite compromised neuromuscular function at baseline. The 
lack of improvement seen in the adult MRCD cohort may be due to differences in the 
vibration training protocols used. The use of a progressive protocol [212, 777, 789], 
higher vibration frequencies (22-28Hz) [212, 232, 233, 777, 789], higher vibration 
amplitude [240] [797], the longer duration of each training session [233], the addition of 
squat exercises during the vibration stimulus [232, 777, 789, 797], or the addition of 
weights during WBVT [232] may improve the efficacy of the side-alternating WBVT 
protocol in improving S2LJ performance and should be considered in future studies 
investigating the effects of WBVT in adults with MRCD.  
 
The majority of studies investigating the effects of WBVT on S2LJ performance have 
used vertical vibration platforms. A meta-analysis in healthy adults 17-80 years of age, 
including 15 randomised control trials [158, 169, 175, 208, 238, 239, 769, 798-805], 
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showed that compared to a control intervention, WBVT significantly increased jump 
height with a standardised mean difference of 0.77, which was increased to 0.96 when 
considering non-athletes [223]. This result is consistent with another meta-analysis in 
older adults, 57-82 years of age, that found chronic vertical WBVT significantly 
improved jump height with a standardised mean difference of 0.51 [217] when compared 
to a control intervention [239, 769]. Another meta-analysis investigated the effects of 
chronic WBVT with exercises (including squats, lunges and heel raises) performed 
during WBVT compared to the identical training condition without WBVT [169, 212, 
237, 766, 806-808], on muscle power in healthy people 11.8-77.5 years of age and found 
that jump height was significantly increased after WBVT, with a standardised mean 
difference of 0.87 [224]. The authors suggest that the improvements in jump height after 
WBVT are likely due to the effects of WBVT on the stretch reflex, which is believed to 
be an important aspect in enabling increases in muscle stiffness, which underlies the 
effectiveness of the stretch-shortening cycle in generating force to precipitate the jump 
[224]. One of the theories behind the effectiveness of WBVT is that it increases the 
excitability of the stretch reflex via Ia afferents [809].  
 
When WBVT was compared to an exercise intervention [169, 239, 240, 769], including 
conventional aerobic and resistance training and walking programs, in healthy adults, the 
meta-analysis found that WBVT had a significantly greater effect on jump height, with a 
standardised mean difference of 0.63 [223]. This indicates that chronic vertical WBVT is 
at least as effective in improving S2LJ power as conventional exercise interventions, with 
these benefits achieved in a shorter time, 15-30 minutes of WBVT compared to up to 90 
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minutes [769] of conventional training, and with less physical effort, unweighted 
standing exercises during WBVT, compared to aerobic and resistance training. However 
another meta-analysis in older adults, 57-82 years of age, found that when compared to 
an exercise intervention [239, 240, 769], no significant effect of WBVT on jump height 
was found [217], likely a reflection of the fact that younger participants, less than 60 
years [169, 237, 806-808], performed better after WBVT, compared to older participants 
[212, 766] as reported by Osawa et al [224]. 
 
Three studies have investigated the effects of WBVT on single two-leg jump 
performance after both side-alternating and vertical WBVT and no differences were 
found between vertical and side-alternating vibration platforms in their effectiveness at 
improving S2LJ performance in healthy young adult males after 8 weeks of training 
[729], in post-menopausal women, after 12 months of training [754] or in older adults 
after 12 weeks of training [222].  
 
Published meta-analyses [217, 223, 224, 272] consistently report a beneficial effect of 
WBVT S2LJ power parameters healthy adults. The lack of significant improvements in 
power parameters after WBVT in the adult MRCD cohort are disappointing especially 
considering the baseline muscle function of the adult MRCD cohort was significantly 
impaired and it is believed that WBVT may improve muscle function to a larger extent in 
those with poorer baseline muscle function [223, 272, 810]. This may indicate that the 
S2LJ test is not the most appropriate test to investigate power in the adult MRCD cohort 
or that the WBVT protocol used in the adult MRCD cohort was not optimised. As only 
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healthy individuals were included in the meta-analysis, it is difficult to elucidate whether 
similar improvements would be expected in cohorts with underlying medical conditions. 
The few studies that have investigated the effects of WBVT on S2LJ performance in 
cohorts with underlying medical conditions, have all used side-alternating vibration 
platforms and have all shown improvements in after WBVT [232, 233, 254, 797], so it 
would not be unreasonable to expect to see improvements in S2LJ performance in the 
adult MRCD cohort after side-alternating WBVT. 
 
The measurement of muscle power in the adult MRCD cohort, using the S2LJ, may not 
have been the most appropriate method to investigate the effects of WBVT on muscle 
power. The meta-analysis by Marin et al 2010 [272], which included measures of muscle 
power from a motorised isokinetic dynamometer [169, 781, 798, 801, 802, 811] as well 
as jump performance, demonstrated the largest standardised mean difference, 0.99 [272], 
compared to 0.77 [223] and 0.87 [224] for the effect of WBVT on muscle power as well 
as a larger effect in untrained participants 1.52 [272] compared to 0.96 [223] and those 
over 50 years of age, 2.24 [272], compared to 0.6 [224] and 0.51 [217]. These results 
indicate that larger improvements were found in muscle power using methods other than 
jump performance, especially in untrained individuals and those older in age who have 
age-related deficits in neuromuscular function, two aspects consistent with the adult 
MRCD cohort. Future studies should consider using a motorised isokinetic dynamometer 
to measure the effects of WBVT on muscle power. This method has been used 
successfully in more recent studies investigating the effects of WBVT in older adults 
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[222] and stroke patients [220], two cohorts with compromised muscle function and 
mobility, features congruent with the adult MRCD cohort. 
 
It would appear that the WBVT protocol used in the adult MRCD cohort did not provide 
sufficient stimulus for the muscle morphological or neurological changes required for 
improvements in S2LJ performance to occur, and could be optimised in future studies. 
Three of the meta-analyses investigated the effect of vibration frequency and amplitude 
on single two-leg jump performance [223, 224, 272]. They all found WBVT to be more 
beneficial on jump performance when frequencies were over 30Hz [223, 224, 272], 
higher than the 20Hz used in the adult MRCD cohort. The effect of amplitude on jump 
performance was not as consistent, however at least 3mm [223] and as high as 8-10mm 
[272] were found to be the most beneficial. There also appeared to be a beneficial 
interaction between frequency and amplitude on jump performance, higher amplitudes 
(>3mm) combined with higher frequencies (>30Hz) the most beneficial combination 
[223]. While these recommendations are based predominantly on vertical WBVT studies, 
more recent chronic side-alternating WBVT studies, including studies in those with an 
underlying medical condition, that have shown beneficial effects on jump performance 
have used frequencies between 22-28Hz  [212, 232, 233, 777, 789] and amplitudes of at 
least 6mm [240, 797]. Two of the meta-analyses investigated the effect of the volume of 
WBVT performed during each training session [223, 272]. One study found that 6-10 
minutes of WBVT was the most beneficial volume to improve jump performance [272], 
and the other found that over 10 minutes was more beneficial [223]. The way the WBVT 
was delivered in the adult MRCD cohort may also have impacted on the lack of 
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improvement in S2LJ performance after WBVT. The training protocol employed 
delivered the WBVT in three bouts of 3-minutes training, with at least 3 minutes rest 
between bouts. It has been suggested that shorter training intervals, up to 60s in duration, 
will likely to limit neuromuscular fatigue [272], which may have been a factor for the 
adult MRCD cohort who trained for 3-minute durations.  One meta-analysis found that 
WBVT over 12 weeks in duration was more beneficial to jump performance [223]. The 
MRCD cohort trained for 6-months, however longer intervention periods of 12 -18 
months may need to be considered to elicit improvements in muscle function during the 
S2LJ. The beneficial effects of WBVT were also improved with progressive WBVT 
protocols (manipulating frequency, amplitude and volume), when dynamic exercises 
were performed during WBVT, and when exercises other than squats (including lunges 
and heel raises) were performed during WBVT [272]. These aspects of the WBVT 
protocol ensure the overload principle is met which likely optimises neuromuscular 
adaptations for improving power after WBVT [272] and were not used in the adult 
MRCD cohort. 
 
5.2.2.1.3  Chair-rise Test (CRT) 
 
 
After WBVT, the adult MRCD cohort significantly decreased CRT time by 0.2s (7.7%), 
well above the CV reported in the literature [691, 692], however the corresponding SDS 
did not change significantly. There were no significant changes in force or power 
parameters. Three previous studies have investigated the effects of WBVT on the CRT 
using a force platform generating parameters of force, power, velocity and time per test. 
 516 
In young adults with CF, 24-27 years, 3 months of home-based side-alternating WBVT 
(20-25Hz, 0.6mm, 18 minutes, 5 times a week) significantly reduced the time per test by 
1.05 seconds (15%) and significantly increased mean velocity by 0.13m/s (21%), 
maximum force and relative force by 438N and 7N/kg (41%) and maximum power and 
relative power by 135W and 2.38W/kg (19%) [233]. Similar results were found in 
institutionalised elderly, mean age 85 years, randomised to 8 weeks of progressive 
vertical WBVT (30-35Hz, 4mm, 5-10 minutes, with exercises, 3x/week) or control [812]. 
The number of chair-rises performed in 30 seconds significantly increased by 36% and 
this was significantly greater than the control group, however the maximum velocity 
achieved during the chair-rise test did not change significantly over time or between 
groups [812]. There was a significant increase in maximum power of 12%, significantly 
greater than the control group [812]. These increases in force and power parameters were 
not seen in the adult MRCD cohort. The improvement in the time to complete the CRT 
was larger than adult MRCD cohort, perhaps a reflection of the longer duration of each 
training session in the Rietschel et al study [233] or the addition of exercises during 
WBVT in the Alvarez-Barbosa et al study [812]. Conventional aerobic and resistance 
training with progressive side-alternating WBVT (22-24Hz, 2-4mm, 4 minutes, with 
static and dynamic squats, twice a week) or a balance program including proprioceptive 
and balance training for 9 months, in post-menopausal women with osteopenia or 
osteoporosis, significantly decreased the time to perform the CRT by 0.11 seconds (8%), 
and significantly increased the relative force by 0.02g (1.5%) in the WBVT group, 
however no between-group differences were found [777]. There were no significant 
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changes in relative power parameters [777]. Similar magnitude changes in time per test 
were seen in the adult MRCD cohort, despite a much less intensive training regime. 
 
The remaining literature has investigated the effect of WBVT on CRT time parameters. 
There have been several studies investigating the effect of WBVT on the time to 
complete the CRT in older adults, which is used as a surrogate measure of functional 
muscle strength of the lower limbs. A systematic review and meta-analysis found that 
WBVT had a significant treatment effect on the time to complete the CRT or the number 
of CRT completed within a defined time, with a standardised mean difference of 0.72 
when compared to control [778, 813, 814] interventions [217]. 
 
Previous studies investigating the effect of side-alternating WBVT have in general, 
shown beneficial treatment effects in reducing the time to perform the CRT in post-
menopausal women [240, 757], middle aged adults [797], older adults [792, 815, 816]. 
Studies reporting greater improvements in CRT time compared to the adult MRCD 
cohort, performed exercises during the WBVT intervention [797, 816] or utilised a higher 
frequency of 24-26Hz [815, 816]. Progressive side-alternating vibration interventions in 
older adult populations [778, 791, 814, 817-819] have reported larger improvements in 
chair-rise test performance than those seen in the adult MRCD cohort. These studies all 
used higher frequencies, up to 30Hz, and some utilised larger amplitudes of 6-14mm 
[778, 791, 817]. The existing literature in vertical WBVT in patients with Multiple 
Sclerosis [820], post-menopausal women [757] and older adults [222, 244, 771, 820] 
demonstrate conflicting results on the effects of vertical WBVT on CRT time, however 
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the studies demonstrating a beneficial effect of WBVT  [757, 771, 820, 821] were 
generally larger in magnitude compared to the adult MRCD cohort, perhaps due to their 
longer duration [757, 771], higher frequency [820], the addition of squat exercise during 
WBVT [820], or concurrent participation in a multi-disciplinary rehabilitation program 
[820]. In general, progressive vertical WBVT protocols were beneficial in improving 
CRT performance in older adults [813, 822]. The improvements in chair-rise time seen in 
these studies were greater in magnitude compared to the adult MRCD cohort, perhaps a 
consequence of the different vibration stimulus used, the progressive nature of the 
vibration protocol, the higher maximum frequency (25-40Hz) or addition of exercises 
[813, 822] during the WBVT. 
 
5.2.2.1.3.1 Chair-rise Summary 
 
 
There is limited literature exploring the effects of WBVT on power, force and velocity 
parameters during the chair-rise test as few studies have used a force platform during the 
manoeuvre, the vast majority instead performed as field tests with a chair and timing 
device. Despite the paucity of data and variety of cohorts investigated [233, 777, 812], it 
appears that both side-alternating [233] and vertical platforms [812] are able to 
significantly increase the power generated during the CRT. This parameter remained 
unchanged in the adult MRCD cohort after 6 months of WBVT. Force [233, 777] and 
velocity [233] parameters only demonstrated significant changes after side-alternating, 
but not vertical [812] WBVT. This observation should be considered with caution 
however due to the small amount of literature available. Both the side-alternating and 
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vertical WBVT protocols that were successful in improving power parameters in the CRT 
used higher frequencies than those utilised in the adult MRCD cohort, 25Hz [233] and 
35Hz [812] respectively, compared to 20Hz. The side-alternating WBVT protocol with 
beneficial effects on power and velocity also used a smaller amplitude 0.6mm and longer 
training duration, 18 minutes [233], compared to 4mm and 9 minutes in the adult MRCD 
study, two other important aspects that should be considered when designing WBVT 
protocols for future studies. 
 
There is an abundance of literature investigating the effect of WBVT on the time to 
perform the CRT and the number of chair-rises performed in a defined time period. The 
vast majority of these studies have been performed on older adults. Both progressive 
[778, 791, 814, 817-819] and non-progressive [240, 757, 792, 797, 815, 816] side-
alternating and vertical [757, 771, 813, 820-823] WBVT protocols, as well as low-
magnitude vertical WBVT [757], have shown beneficial effects on chair-rise time, side-
alternating protocols more consistently demonstrating beneficial effects compared to 
vertical protocols. The majority of the existing literature has demonstrated that WBVT 
improves CRT time when participants act as their own controls [233, 792, 797] or in 
comparison to a control group [757, 771, 778, 812-815, 817-819, 823], however some 
studies, all using vertical WBVT protocols, did not find an effect of WBVT over control 
[222, 244, 781, 821].  
 
There may be evidence in the existing literature to suggest that progressive WBVT 
protocols [777, 778, 791, 812-814, 817-819, 822, 823], using side-alternating or vertical 
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vibration platforms, result in larger magnitude gains in chair-rise time in shorter time 
periods, compared to non-progressive WBVT protocols [233, 240, 757, 771, 792, 797, 
815, 816, 820, 821], and should be considered when designing WBVT protocols for 
future studies in adults with MRCD. Progressive WBVT protocols in the literature 
generally used higher frequencies, 25-40Hz, than that used in the adult MRCD study, and 
an amplitude of at least 3mm. Two studies investigated the effect of the number of 
training session performed each week on CRT performance [813, 823]. Both studies 
found that a minimum of 2 training sessions a week were required to elicit improvements 
in CRT performance, with improvements increasing with the number of sessions 
performed [813, 823]. 
 
5.2.2.2 Follow-up Period 
 
 
5.2.2.2.1  Multiple One-leg Jump 
 
 
In the follow-up period, there were no significant changes in muscle force parameters 
during the M1LJ in the adult MRCD cohort. No previous studies have investigated the 
effects of WBVT on multiple one-leg hop performance after withdrawal of the WBVT 
stimulus. 
 
5.2.2.2.2  Single Two-leg Jump 
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During the follow-up period, there were no significant changes in any S2LJ force, power 
or efficiency parameters in the adult MRCD cohort. These results are consistent with a 
study of healthy young adults that found no significant changes in S2LJ maximum force 
or power 4 weeks after completing 8 weeks of side-alternating WBVT (18-22Hz, 9 
minutes, 3 times a week) or low-magnitude vertical WBVT (32-37Hz, 10-20 minutes, 3 
times a week) [729]. In another group of young adults, jump height decreased 
significantly by 5% 5 weeks after completing 13 weeks of vertical WBVT (35Hz, 2mm, 9 
minutes, twice a week) with progressive resistance training for the lower limbs and trunk 
[824]. 
 
In older males, jump height decreased significantly by 6.1% 12 months after completing 
a 12 month progressive vertical WBVT (35-40Hz, 5mm, 2-15 minutes with static and 
dynamic exercises, 3 times a week), but remained significantly greater than baseline 
performance [776]. Those in fitness group which combined aerobic, resistance and 
balance training for 90 minutes, and control group demonstrated larger reductions in 
jump height that were not significantly different to their baseline performance [776]. This 
suggest a slower decline in the S2LJ benefits seen after WBVT compared to a 
conventional fitness program. 
 
The persistence of benefits in S2LJ performance after ceasing a WBVT intervention, or 
lack thereof, requires further investigation. It is likely the length of the intervention 
period, the intensity of the WBVT protocol as well as the baseline level of muscle 
 522 
function, age of participants, and the presence of any underlying medical conditions will 
influence the outcome. 
 
5.2.2.2.3  Chair-rise Test 
 
 
During the follow-up period, the adult MRCD cohort demonstrated significant increases 
in CRT force and power parameters. Maximum force increased by 0.1kN (8.3%), 
maximum relative force increased by 1.2N/kg (5.9%) and the SDS increased by 0.7. 
Maximum power increased by 75.6W (16.1%), maximum relative force by 1.1W.kg 
(14.7%) and the SDS increased by 0.5. The significant increases in both force and power 
parameters with any significant improvement in CRT speed parameters indicates 
worsening of muscle efficiency. 
 
Two previous studies in older adults measured CRT after a follow-up period once WBVT 
had ceased. Neither of these studies performed the CRT on a force plate and thus did not 
report on velocity, power or force parameters during the chair-rise test however they did 
investigate time parameters. Six months after a 6 week progressive vertical WBVT with 
exercises, CRT time decreased significantly by 13.25s (44%) institutionalised elderly 
[822]. The ongoing significant improvement in CRT performance in contrast to the lack 
of improvement seen in the adult MRCD cohort and may be due to bi-weekly group 
exercise sessions attended by participants during the follow-up period [822]. In 
community-dwelling older adults, the number of chair-rises completed in 30 seconds 
decreased significantly during a 3-week follow-up period, in those randomised to 
progressive WBVT with exercises twice a week for eight weeks, however those 
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randomised to four times a week did not demonstrate significant differences to their post-
training results [823]. The results of this study indicate that a training threshold may need 
to be attained for maintenance of muscle function improvements during the chair-rise test 
after cessation of WBVT. Both studies also included exercises during their WBVT 
intervention, an aspect that was not incorporated into WBVT for the adult MRCD cohort, 
and which may enhance or extend the benefits of WBVT on muscle function during the 
CRT. 
 
5.2.3 Effect of WBVT on Exercise Capacity 
 
 
5.2.3.1 WBVT Period 
 
 
5.2.3.1.1  Six-minute Walk Test (6MWT) 
 
 
The pre-exercise Borg Score was significantly reduced by 0.4 of a point, which may 
indicate a minor reduction in general fatigue in the adult MRCD cohort after 6 months of 
WBVT, however the clinical relevance of this small change is questionable. After WBVT 
period there were no significant changes in 6MWT distance, however there was an 
improvement of 19.2m (4.8%). This change was slightly larger than the smallest 
meaningful change in 6MWT distance of 20m found in a large cohort of community-
dwelling older adults, sub-acute stroke survivors and older adults with mobility 
impairments [825]. In a smaller cohort of individuals with Alzheimer Disease, affected 
by dementia, mean age 80 years, the minimal detectable change was found to be 33.5m 
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[826], and another small study of individuals with Parkinson Disease, mean age 71 years, 
found the minimal detectable change for the 6MWT distance to be 82m [827], the change 
seen in the adult MRCD cohort smaller than both these cohorts sharing impairments seen 
in adults with MRCD, dementia and movement disorders respectively. Multi-center drug 
trials in other metabolic conditions including mucopolysaccharidosis have demonstrated 
improvement in 6MWT distance of 38m (11%) [828] and 30m (8%) [829] after 26 and 
52 weeks respectively. In another multi-center drug trial, individuals with Pompe Disease 
increased 6MWT distance by 28m (9%) after 78 weeks [830]. The 22m (6%) increase in 
6MWT distance after WBVT in the adult MRCD cohort is similar in magnitude to the 
30m (8%) [829] and the 28m (9%) [830] improvement in 6MWT distances seen after 
drug trials in other metabolic conditions after much longer intervention periods, and 
indicates that while not statistically significant, the improvements seen in the adult 
MRCD cohort may be clinically relevant, suggesting a beneficial effect of WBVT on 
functional capacity. 
 
The effects of side-alternating and vertical WBVT on 6MWT distance have been 
investigated previously. The previous literature investigating the effects of side-
alternating WBVT has shown beneficial effects of WBVT on 6MWT distance in: case 
studies of late-onset Pompe Disease [254, 784]; post lung transplant [831]; middle-aged 
adults with Multiple Sclerosis [785]; middle-aged adults with pulmonary artery 
hypertension [797]; and older adults with COPD [791, 816]. These studies reported 
improvements in 6MWT distance of similar or greater magnitude than that seen in the 
adult MRCD cohort. Those reporting larger increases in 6MWT distance were also 
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participating in a concurrent rehabilitation program [784, 816, 831], used higher 
frequencies 26-40Hz [785, 791, 816], or larger amplitudes of 6-20mm [791, 797, 816], 
used progressive protocols [785, 791, 797], performed exercises during the WBVT [785, 
797, 816], used a training frequency of at least 3 times a week [254, 784, 785, 797, 816, 
831], for at least 12 weeks duration [254, 784, 785, 791]. These aspect of WBVT should 
be considered in future studies to optimise the improvement in 6MWT distance after 
side-alternating WBVT. 
 
Previous literature investigating the effect of vertical WBVT on 6MWT performance 
have shown varied results. Beneficial effects of WBVT on 6MWT distance have been 
seen in: middle aged adults with Multiple Sclerosis [820]; stroke survivors [268, 832]; 
older adults [244, 821, 833]; and older adults with COPD [790, 834], but not in young 
adults with cerebral palsy [235]. No effect of WBVT was found on the two-minute walk 
test distance in middle-aged adults with Multiple Sclerosis [252], however older adults 
demonstrated significant improvement in the shuttle walk test after WBVT [332]. Those 
studies demosntrating improvements of greater magnitude in the 6MWT, to those seen in 
the adult MRCD cohort were concurrently participating in a rehabiitation program [820]; 
used higher frequencies of 25-40Hz [268, 790, 820, 821, 832-834]; used progressive 
protocols [268, 834]; performed squat exercise during the WBVT [790, 820, 821, 832, 
833]; or performed WBVT for 12-15 minutes each session [268, 790, 832], at least 3 
times a week. [788, 790, 820, 821, 834]. These aspects of the WBVT protocol should be 
considered in future studies using vertical platforms. 
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5.2.3.1.2  Cardiopulmonary Exercise Test 
 
 
During the WBVT period there were no significant changes in any anaerobic threshold, 
or peak exercise parameters during CPET in the adult MRCD cohort, however there was 
a non-significant increase in VO2 of 5%, similar in magnitude to the increase in 6MWT 
distance after WBVT. These results are in contrast to two published studies that have 
investigated the effects of WBVT on CPET. In middle-aged adults with pulmonary 
hypertension, oxygen uptake at AT and peak exercise significantly increased by 6% and 
7% respectively, after 4 weeks of side-alternating WBVT (20Hz, 20mm, 4 times a week 
with exercises for muscle co-ordination) [797]. Even larger results were seen in 
community-dwelling older adults, mean age 67 years, randomised to progressive vertical 
WBVT (30-40Hz, 2.5-5mm, 2-15 minutes with exercises including squats, lunges and 
heel raises, 3 times a week for 12 months), significantly increased peak oxygen uptake by 
18% after WBVT [783]. Both these studies included exercise as part of their vibration 
protocols, the former also utilised a larger vibration amplitude compared to the adult 
MRCD study and the latter a higher vibration frequency, longer training duration and 
longer intervention period, all aspects of their respective protocols which may have 
contributed to larger improvements in oxygen uptake after WBVT. 
 
5.2.3.1.3  Summary 
 
The outcome measures used to determine exercise capacity may not have shown any 
significant changes after WBVT as the vibration protocol did not reach a high enough 
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intensity to elicit meaningful cardiovascular work. To improve cardiovascular fitness and 
endurance, as measured by the 6MWT and CPET, the prescribed training should provide 
a workload that is 40-50% of an individual’s peak VO2 and/or 60% of their age-predicted 
maximum heart rate [835]. While these parameters were not directly measured in the 
adult MRCD cohort during WBVT, previous studies have found minimal cardiovascular 
response to WBVT, even when squatting exercises were added during the WBVT 
stimulus [154, 185, 836]. The addition of extra weight during the squatting exercise and 
increasing frequency and amplitude [154, 185] still did not elicit an adequate 
cardiovascular response, the fatigue experienced by the participants driven by the 
neuromuscular system and not the cardiovascular system [185]. 
 
Future studies may consider adding an additional measure of functional mobility that can 
assess maximal gait speed which reflects the ability to adapt to changing environmental 
demands and obstacles [837]. The 10m walk test is most commonly used however 
lengths can vary between 6-12m. Participants are asked to walk at their comfortable or 
fastest walking speeds and the time taken to cover the defined distance is recorded. The 
10m walk test has been used extensively as an outcome measure, with established 
reliability and validity, in neuromuscular disease including Multiple Sclerosis [838], 
children with neuromuscular diseases [839], older adults [825], Parkinson Disease [827], 
stroke [840-842] and normative data exists [841, 843]. The 10m walk test has also been 
used as an outcome measure investigating the effectiveness of WBVT interventions in 
individuals with multiple sclerosis [265, 820, 844], Parkinson Disease [263] and older 
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adults [778, 821, 845-848] and demonstrated improved performance after vertical WBVT 
[820] and side-alternating WBVT [263, 844-847] interventions. 
 
5.2.3.2 Follow-up Period 
 
 
5.2.3.2.1  Six-minute Walk test 
 
 
There were no significant changes in 6MWT distance, heart rate or Borg Score 
parameters during the follow-up period in the adult MRCD cohort. Similar results were 
seen in chronic stroke survivors, where there was no significant change in 6MWT 
distance one month after an eight week progressive vertical WBVT intervention (20-
30Hz, 0.4-0.6mm, 9-15 minutes with exercises including squats, lunges and heel raises, 3 
times a week) [268]. After completing 24 months of side-alternating WBVT (8-18Hz, 
4mm, 6 minutes, 3 times a week), a 72 year old female with late-onset Pompe Disease, 
reduced her 6MWT distance by 42m (9%) at one month follow-up [784]. The more rapid 
decline in 6MWT distance demonstrated in this case-study, compared the adult MRCD 
cohort, may be a reflection of the lower frequency, training volume or frequency of 
training sessions each week used in comparison to the adult MRCD vibration protocol, 
the effect of which may not have been as effectively sustained. 
 
5.2.3.2.2  Cardiopulmonary Exercise Test 
 
During the follow-up period, there were no significant changes in any of the AT or peak 
exercise parameters. However, several anaerobic threshold parameters, including VO2 
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and oxygen pulse, demonstrated non-significant, but clinically relevant decreases of 18% 
in the follow-up period, indicating that the anaerobic threshold occurred earlier in 
exercise, a reflection of worsening aerobic efficiency as the transition to anaerobic 
metabolism during exercise began earlier. There was also a non-significant, but clinically 
relevant decrease in peak VO2 of 8%, indicating that there was a clinical de-training 
effect on anaerobic threshold parameters and peak VO2. These findings would suggest 
that WBVT preserved aerobic capacity in the adult MRCD cohort and in particular, 
aerobic efficiency at submaximal exercise. No previous studies have investigated CPET 
outcomes after cessation of WBVT intervention. 
 
5.2.4 Effect of WBVT on the Mitochondrial Disease Scale and Quality of 
Life 
 
 
5.2.4.1 WBVT Period 
 
 
After WBVT the NMDAS Section 3 score decreased significantly by 1.7 points, 
indicating improvement in the clinician’s assessment of clinical function. There was also 
a non-significant decrease in the NMDAS Section 1 score of 1.8 points, indicating that 
the patients also perceived their current function to have improved after WBVT and a 
non-significant increase in the role physical domain of the SF12v2 of 0.5 SDS. These 
results suggest that while there was minimal improvement in function measured by the 
M1LJ, S2LJ and CRT or endurance measured by the 6MWT and CPET, the adult MRCD 
cohort felt improvements in function, including activities of daily living, gait stability and 
exercise tolerance, that were not reflected in the chosen outcome measures. This finding 
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supports the consideration of additional and/or alternative outcome measures for 
functional mobility and lower limb strength as discussed above.  
 
The effect of WBVT interventions on disease-specific scales have been investigated in 
Parkinson Disease using the Unified Parkinson Disease Rating Scale. After 3 weeks of 
side-alternating WBVT (25Hz, 7-14mm, 15 minutes, twice a day, 5 times a week) as part 
of a multi-component inpatient rehabilitation program, the total score improved 
significantly [263]. After 5 weeks of side-alternating WBVT (6Hz, 13mm, 5 minutes, 2-3 
times a week), there were significant improvements in the total score and motor section 
scores however these improvements were similar to the placebo group [264].  
 
Two previous studies in older adults have used the SF-12 to investigate the effects of 
WBVT on quality of life. Significant improvements in the SF-12 physical component 
score were found after progressive side-alternating WBVT (6-26Hz, 1-3mm, 4-5 minutes, 
3-5 times a week for 8 weeks) [819] and after progressive side-alternating WBVT (15-
30Hz, 2-8mm, 5 minutes, 3 times a week for 8 weeks) in addition to an exercise program 
including strength, balance and functional mobility training [845] in older adults. Neither 
study found significant changes in the mental component score [819, 845] consistent with 
that seen in the adult MRCD cohort. Both these studies demonstrated findings consistent 
with the adult MRCD cohort for the mental component scores, however they found a 
beneficial effect of WBVT on the physical component score which was not seen in the 
adult MRCD cohort. These findings in contrast to the adult MRCD cohort where not 
improvements in the physical component score were seen, perhaps a reflection of the 
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progressive nature of the vibration protocols [819, 845], the higher frequency [819, 845] 
and amplitude [845] used in these studies or the concurrent participation in an exercise 
intervention [845]. 
 
The SF-36, a longer version of the SF-12, has been used more extensively to investigate 
the effect of WBVT on quality of life and demonstrated conflicting results in the 
literature. No effect of WBVT on the SF-36 was found in older adults [222, 753, 823] 
and post-menopausal females [849] using side-alternating, [222] vertical [222, 823, 849] 
and low-magnitude [753] WBVT. In contrast, several studies have found a beneficial 
effect of WBVT on quality of life. Improvements in quality of life measured by the SF-36 
were found in middle-aged adults with pulmonary artery hypertension [797], middle-aged 
adults post lung transplant [831], middle-aged adults with Multiple Sclerosis [844] post-
menopausal women [850], older adults [813, 851, 852] using side-alternating [797, 831, 
844] or vertical [813, 850-852]  WBVT. 
 
Other quality of life measures have also demonstrated conflict in the literature about the 
effect of WBVT on quality of life. Significant increases in quality of life were found after 
vertical WBVT in older adults measured by the EuroQol-5D [812]; after vertical WBVT 
in older males with COPD measured by the St George Questionnaire [834] after side-
alternating  WBVT in older adults with COPD measured by the Chronic Respiratory 
Questionnaire [816]. However, no change in Quality of Life was seen after side-
alternating WBVT in middle-aged females with fibromyalgia measured by the 
Fibromyalgia Impact Questionnaire or 15D [853]; after side-alternating WBVT in older 
adults with COPD measured by the St George Questionnaire [791]; after vertical WBVT 
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in middle-aged adults with Multiple Sclerosis measured by the Multiple Sclerosis Impact 
Scale [265]; after side-alternating WBVT in older adults with Parkinson’s Disease 
measured by the Parkinson Disease Questionnaire [264]. 
 
Studies demonstrating the most beneficial effects on quality of life used vibration 
protocols with different training parameters to those used in the adult MRCD cohort, 
which could be considered in training protocols for future studies. Vibration training 
frequencies of 25-35Hz [812, 813, 834, 844, 850-852] and amplitudes of 6-20mm [797, 
844, 852], combined with exercises including squats, lunges and heel raises [797, 812, 
850], for 10-20 minutes [812, 831, 851] should be incorporated into future protocols to 
improve quality of life. Vibration training alongside balance training [850] or physical 
training [852] programs may also be beneficial. 
 
5.2.4.2 Follow-up Period 
 
There were no significant changes in the NMDAS or SF12v2 during the follow-up period 
in the adult MRCD cohort. One previous study in Parkinson’s Disease has investigated 
the effect of WBVT cessation on a disease-specific scale and found similar results to 
those seen in the adult MRCD cohort. Four weeks after completion of side-alternating 
WBVT (25Hz, 7-14mm, 15 minutes, twice a day, 5 times a week for 3 weeks) as part of a 
multi-component inpatient rehabilitation program, there were no significant changes in 
the Unified Parkinson Disease Rating Scale score in older adults [263].  
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One previous study has investigated the effect of cessation of a WBVT intervention on 
the SF-12. At 6 months follow-up, the physical component score significantly decreased 
in older adults, [845] in contrast to no change seen in the adult MRCD cohort, however, 
consistent with the MRCD cohort, the metal component score did not change 
significantly [845]. Three previous studies have investigated the effects of WBVT on 
quality of life, using the SF-36, after the WBVT intervention has been ceased. There 
were no changes in the SF-36 in post-menopausal women 12 months after completing 
low-magnitude WBVT [775], in community-dwelling older adults 3 weeks after 
completing progressive vertical WBVT [823], or in middle-aged adults with Multiple 
Sclerosis two weeks after completing progressive side-alternating WBVT [775]. 
 
5.3 Leigh Syndrome 
 
 
5.3.1 Effect of WBVT on Bone and Body Composition Parameters 
 
 
5.3.1.1 WBVT Period 
 
 
After WBVT, the Leigh Syndrome cohort did not have any significant changes in 
parameters of the trabecular bone compartment. This was consistent with the findings in 
the adult MRCD cohort but in contrast to the paediatric MRCD cohort that demonstrated 
increases in bone mass in the lumbar spine and at the 4% pQCT site.  
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In the cortical bone compartment the Leigh Syndrome cohort demonstrated significant 
changes in bone mass, area, geometry and strength. Bone mass parameters from 
segmental analysis of total body DXA scans as well as parameters from the 20% and 
66% distal tibial pQCT sites increased significantly after WBVT training. Legs BMC 
increased significantly by 15.1g (3.1%), larger than the reported CV at our laboratory 
(Table 2.1), however the rate of increase slower than that seen during the observation 
period and smaller than increases seen in the paediatric MRCD cohort, reflecting the 
combination of paediatric and adult participants in the cohort. Cortical BMC at the 20% 
pQCT site increased significantly by 3.4% and total and cortical BMC at the 66% pQCT 
site increased significantly by 2.5% and 3.1% respectively. Cortical polar SSI at the 20% 
pQCT site increased significantly by 4.4%. All pQCT parameters were smaller in 
magnitude compared to the significant improvements seen in the corresponding 
parameters in the paediatric cohort, indicating that these changes are likely a reflection of 
responses in the paediatric participants in the Leigh Syndrome cohort. There were no 
significant changes in markers of bone turnover, consistent with both the paediatric and 
adult cohorts. 
 
 
5.3.1.2 Follow-up Period 
 
The Leigh Syndrome cohort did not demonstrate any significant change in the trabecular 
bone compartment during the follow-up period, consistent with the findings of both the 
paediatric and adult MRCD cohorts, however there were significant changes in the 
cortical bone compartment. Legs BMC increased significantly by 2.4% an improvement 
that was not seen when the adult and paediatric cohorts were analysed separately, 
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however the rate of increase in this parameter was slower than that seen in both the 
observation and WBVT periods, and may indicate that WBVT is beneficial in 
maintaining bone mass accrual in the legs of individuals with Leigh Syndrome. Bone 
strength measured by the polar cortical CSMI at the 66% pQCT site increased 
significantly by 2.2%, a quarter of the significant increase seen in the same parameter in 
the paediatric cohort, indicating that the Leigh Syndrome cohort may not have been able 
to maintain improvements in bone strength after WBVT as well as children with other 
MRCD. There were no significant changes in bone turnover markers consistent with the 
findings of the adult MRCD cohort. A much larger cohort of participants with genetically 
identical Leigh Syndrome is needed to confirm any differences in bone health and bone 
responses to WBVT between Leigh Syndrome and other MRCD. 
 
 
5.3.2 Effect of WBVT on Force Plate Parameters 
 
 
5.3.2.1 WBVT Period 
 
 
CRT speed, force and power parameters did not change significantly after WBVT in the 
Leigh Syndrome cohort. In comparison to the paediatric MRCD cohort, this indicated 
maintenance of muscle efficiency during the CRT, however in comparison to the adult 
MRCD cohort, there did not appear to be improved leg muscle agonist/antagonist co-
activation. 
 
5.3.2.2 Follow-up Period 
 
 536 
 
CRT force parameters increased significantly in the Leigh Syndrome cohort during the 
follow-up period. Maximum force by 0.2kN (18.2%), average relative force by 0.1g 
(9.1%) and the force SDS by 1.1. These findings were consistent with adult MRCD 
cohort as well as non-significant changes in the same parameters in the paediatric cohort, 
and indicate a de-training effect and worsening of muscle efficiency during a functional 
task. 
 
5.3.3 Effect of WBVT on Exercise Capacity 
 
 
5.3.3.1.1 Six-minute Walk Test (6MWT) 
 
 
5.3.3.2 WBVT Period 
 
 
In comparison the significant decrease in 6MWT distance and percent-predicted values 
seen during the observation period, there was a non-significant increase in 6MWT 
distance of 24.0m (8.7%) and a 3.3% increase in the percent-predicted value after 
WBVT. This increase in 6MWT distance was larger than the 4.8% increase seen in the 
adult MRCD cohort and in contrast to a reduction in 6MWT distance seen in the 
paediatric MRCD cohort. There was also a significant reduction in the recovery Borg 
Score, indicating less perceived effort and improved recovery, this change also seen in 
the paediatric MRCD cohort. 
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5.3.3.3 Follow-up Period 
 
There was no significant change in 6MWT distance during the follow-up period, which 
was also seen in the paediatric and adult cohorts. This is particularly beneficial for the 
Leigh Syndrome cohort as significant reductions were seen during the observation period, 
suggesting a latent beneficial effect of WBVT in maintaining sub-maximal muscular 
endurance. 
 
5.3.4 Effect of WBVT on the Mitochondrial Disease Scale and Quality of 
Life 
 
 
5.3.4.1 WBVT Period 
 
 
The Leigh Syndrome cohort did not demonstrate any changes in the NPMDS disease 
scales or Quality of Life measure after WBVT, consistent with that seen in the paediatric 
MRCD cohort. 
 
5.3.4.2 Follow-up Period 
 
During the follow-up period, Section 3 of the NPMDS increased significantly, indicating 
deterioration on the clinician’s clinical assessment. The paediatric and adult MRCD 
cohorts did not demonstrate a similar decline in function, consistent with a detraining 
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effect after removal of the WBVT stimulus which was also postulated for reductions in 
CRT performance during the follow-up period in the Leigh Syndrome cohort. 
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6 Conclusions, Limitations and Future Directions 
 
 
The primary aim of this thesis was to determine whether a six-month home-based side-
alternating WBVT intervention influences bone mass, density, geometry and strength in 
children with CF or MRCD. Secondary aims included determining the influences of the 
WBVT intervention on bone turnover markers, muscle mass and function, exercise 
capacity and Quality of Life. The results presented in this thesis have shown that WBVT 
was well tolerated, with contrasting effects on children with different chronic illnesses 
and on children and adults with same chronic illness. WBVT in the CF cohort produced 
increases in trabecular bone mass and density, that were not seen during the observation 
or follow-up periods whereas WBVT in the paediatric MRCD cohort elicited significant 
increases in both the trabecular and cortical bone compartments with the greatest effects 
on cortical bone mass, geometry and strength. In contrast, WBVT in the adult MRCD 
cohort had very little impact on the trabecular or cortical bone compartments, likely a 
reflection of the lower metabolic activity of the adult skeleton compared to the immature 
skeleton of the growing child. When considering the Leigh Syndrome cohort, WBVT had 
no effect on the trabecular bone compartment however cortical bone mass, geometry and 
strength were favourably influenced. There was minimal influence of the WBVT 
intervention on bone turnover markers in any of the cohorts. WBVT augmented muscle 
CSA in the paediatric MRCD cohort and appeared to hinder the rate of decline in LTM in 
the adult MRCD cohort but did not have an impact on muscle mass in the CF or Leigh 
Syndrome cohorts. WBVT appeared to inhibit the deterioration in muscle force and 
exercise capacity in the CF and Leigh syndrome cohorts, provide some subtle benefits to 
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muscle function and exercise capacity in the adult MRCD cohort, but did not appear to 
influence muscle function or functional exercise capacity in the paediatric MRCD cohort. 
WBVT did not influence Quality of Life in any of the three MRCD cohorts however, the 
parent-reported school and emotion domains of the CFQ-R improved significantly in the 
CF cohort. This data is the first to investigate the effects of WBVT in people with MRCD 
and is the first to investigate the effects of WBVT on bone health in children with CF, 
adding to a small body of adult literature in this area. 
 
When analysing the baseline DXA and pQCT scans in the MRCD cohorts, a 
compromised bone phenotype was identified, which could not be completely attributed to 
a secondary bone defect. The underlying mechanism contributing to the mixed nature of 
this bone defect cannot be elucidated with non-invasive measures. Verification of the 
possible mechanisms that may be contributing to the MRCD bone phenotype requires 
further investigation with the use of invasive techniques including but not limited to bone 
biopsies, static and dynamic histomorphometry, quantitative backscattered electron 
imaging, mechanical testing of bone stiffness and toughness, tissue mineralisation, intra-
cortical remodelling rate, osteoblast and osteoclast number and bone turnover rate [6, 80, 
114, 132, 722, 723, 854]. These findings will be instructive in better managing bone 
health in people with MRCD. 
 
When comparing outcomes in the CF and MRCD cohorts to the existing literature, it 
became clear that the WBVT protocol used during the intervention period was likely sub-
optimal, and did not provide sufficient stimulus for the muscle morphological or 
 541 
neurological changes required for improvements in muscle function and bone mass, as 
better improvements were seen in other cohorts with more intensive WBVT protocols. It 
is likely that WBVT protocols will need to be tailored specifically for the desired 
outcome (bone density or muscle function) and the musculoskeletal site where the 
outcome is desired (lumbar spine or total body). Recommendations from the existing 
literature have been summarised at the end of each section, however it is important to 
have a progressive WBVT protocol to meet the requirements of the overload principle. 
Future studies should consider progressing vibration training protocols by increasing 
frequency (25-40Hz), amplitude (6-10mm), training time (12-15 minutes) or adding 
exercises (static/dynamic lunges, squats, heel raises, weight shifts) and/or the addition of 
weights during the vibration-training stimulus. The addition of exercises or using WBVT 
interspersed with short intervals of aerobic training may improve aerobic capacity. 
Shorter training intervals of 30-90 seconds, interspersed with 60-second rest periods, will 
limit neuromuscular fatigue, compared to the 3 minutes intervals used in the CF and 
MRCD cohorts, and may be more beneficial. Training should be performed at least 3 
times a week. The effects of vertical as well as side-alternating WBVT platforms should 
also be investigated. While interventions of at least 12 weeks may be effective in eliciting 
changes in muscle mass and function, it is likely intervention periods of at least 9-18 
months are required to elicit changes in bone parameters, especially in adult populations. 
The de-training effect in muscle and bone parameters seen in the CF cohort, adult MRCD 
and Leigh Syndrome cohort during the follow-up period also indicates that future studies 
designed to incorporate intermittent training periods (6 months WBVT, 3 months off, 6 
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months WBVT, 3 months off) may also be beneficial in preserving muscle and bone 
mass. 
 
The choice of outcome measures should also be reconsidered in future studies. DXA 
scans should include the use of proximal hip DXA scans, including total hip and femoral 
neck scans, to elucidate the efficacy of WBVT on cortical bone in the lower limbs, 
particularly in adult cohorts as a lot of literature exists in this area. pQCT analysis of the 
tibia should consider using more commonly analysed sights including the 14% and 38% 
sites instead of the 20% site. More specific, sensitive and stable, serum derived bone 
turnover markers should be used. The bone formation marker PINP should be used 
instead of osteocalcin and alkaline phosphatase and the bone resorption marker, CTX, 
should be used instead of urinary deoxypyridinoline. Maximum force and power could be 
investigated using isometric and/or isokinetic motorised knee extension dynamometry or 
leg press dynamometry. The 10m walk test should be considered as an additional 
measure of functional mobility that can assess maximal gait speed. A measure of habitual 
physical activity should also be considered as moderate-vigorous activity is important for 
bone modelling during growth and remodelling over the lifespan. 
 
This study had several limitations, including the small sample size, lack of sample-size 
calculations for secondary measures, the large age-range, short intervention period of 6 
months WBVT and lack of direct supervision of daily training routine. Future studies 
should aim for randomised controlled trials, stratifying for gender and pubertal stage in 
paediatric cohorts and by menopausal state in adult females. Intervention periods of at 
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least 12 months comparing vertical and side-alternating vibration platforms using 
progressive or cycling training protocols with more widely used densitometry measures, 
more sensitive bone turnover markers and more easily performed measures of muscle 
force and power. Telemedicine options could be utilised to support adherence to home-
based training protocols. Despite these limitations, the data presented in this thesis 
demonstrates a potential therapeutic role for WBVT in a subset of chronic illnesses 
affecting musculoskeletal function. This intervention is safe but more work is required to 
determine its optimal efficacy. 
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7 Appendices 
 
 
 
 
 
 
 
 
 
 
Appendix A: DXA Parameters 
 
Table A.1 CF Cohort 
Table A.2 Paediatric MRCD Cohort 
Table A.3 Adult MRCD Cohort 
Table A.4 Leigh Syndrome Cohort
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Table A.1. DXA parameters for the CF cohort at each visit with changes between visits and associated p values from linear mixed models 
analysis. *p<0.05. 
  TBMC (g) TBMC SDS TBA (cm
2
) TBMD 
(g/cm
2
) 
TBMD SDS TLTM (g) 
Visit 1 
Value 1611.8 -0.7 1615.6 0.974 -0.5 31407.1 
Δ in Observation 101.7 -0.0 73.6 0.018 0.0 1246.7 
p 0.000* 0.855 0.000* 0.000* 0.820 0.000* 
Visit 2 
Value 1713.6 -0.7 1689.2 0.992 -0.5 32653.7 
Δ with WBVT 78.2 -0.1 45.1 0.020 0.0 1026.3 
p 0.000* 0.144 0.000* 0.000* 0.501 0.001* 
Visit 3 
Value 1791.8 -0.8 1734. 3 1.011 -0.4 33680.0 
Δ in Follow-up 88.2 0.0 77.6 0.007 -0.1 1110.1 
p 0.000* 0.600 0.000* 0.059 0.078 0.001* 
Visit 4 Value 1880.0 -0.748 1811.9 1.018 -0.5 34790.1 
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  TFat (%) TFat % SDS TLTM:Ht 
SDS 
TBA:Ht SDS TBMC:TLTM 
SDS 
TBMC:TBA 
SDS 
Visit 1 
Value 18.6 -0.2 -0.7 -0.9 -0.2 0.0 
Δ in Observation 1.0 0.1 -0.1 0.0 0.1 -0.1 
p 0.106 0.181 0.172 0.730 0.294 0.205 
Visit 2 
Value 19.6 -0.1 -0.8 -0.9 -0.1 -0.0 
Δ with WBVT 0.3 0.0 -0.1 -0.2 0.1 0.1 
p 0.592 0.745 0.103 0.034* 0.661 0.027* 
Visit 3 
Value 20.0 -0.0 -0.9 -1.0 -0.0 0.1 
Δ in Follow-up 0.7 0.1 -0.0 0.2 0.1 -0.3 
p 0.308 0.426 0.611 0.024* 0.236 0.000* 
Visit 4 Value 20.7 0.1 -1.0 -0.9 0.1 -0.2 
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  Legs 
BMD 
(g/cm
2
) 
Legs BMD 
SDS 
Legs LTM (g) Legs Fat (%) LS BMC (g) LS BMC SDS 
Visit 1 
Value 0.998 -0.3 10114.2 24.1 29.5 -0.23 
Δ in Observation 0.024 -0.1 515.3 0.4 2.2 -0.0 
p 0.000* 0.414 0.000* 0.488 0.000* 0.727 
Visit 2 
Value 1.021 -0.4 10629.5 24.5 31.7 -0.3 
Δ with WBVT 0.031 0.0 283.0 0.5 1.7 -0.1 
p 0.000* 0.448 0.034* 0.445 0.000* 0.342 
Visit 3 
Value 1.051 -0.3 10912.6 25.0 33.4 -0.4 
Δ in Follow-up 0.016 -0.1 381.908 0.4 1.4 -0.1 
p 0.012* 0.410 0.007* 0.578 0.003* 0.341 
Visit 4 Value 1.068 -0.4 11294.5 25.3 34.9 -0.4 
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  LSBMD 
(g/cm
2
) 
LS BMD SDS L14 BMC (g) L14 BA (cm
2
) L14 vBMD 
(g/cm3) 
L14 vBMD 
SDS 
Visit 1 
Value 0.863 -0.4 36.9 42.5 0.291 -0.9 
Δ in Observation 0.027 -0.1 2.9 1.8 0.001 -0.1 
p 0.004* 0.256 0.000* 0.000* 0.865 0.446 
Visit 2 
Value 0.891 -0.5 39.8 44.3 0.292 -1.0 
Δ with WBVT 0.023 -0.1 2.1 1.4 0.003 -0.0 
p 0.015* 0.470 0.000* 0.001* 0.553 0.807 
Visit 3 
Value 0.913 -0.6 41.9 45.7 0.295 -1.0 
Δ in Follow-up 0.006 -0.1 1.7 1.5 0.001 -0.1 
p 0.533 0.090 0.004* 0.001* 0.870 0.592 
Visit 4 Value 0.919 -0.7 43.6 47.2 0.296 -1.1 
 
Note: Δ, change; TBMC, total bone mineral content; TBA, total bone area; TBMD, total bone mineral density; SDS, standard deviation score; 
TLTM, total body lean tissue mass; TFat, total body fat; BMD, bone mineral density; BMC, bone mineral content; BA, bone area; LTM, lean 
tissue mass; TF, tibia and fibula; LS, lumbar spine vertebrae 2-4; L14, lumbar spine vertebrae 1-4; vBMD, volumetric bone mineral density; R, 
region of distal femur scan. 
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Table A.2. DXA parameters for the paediatric MRCD cohort at each visit with changes between visits and associated p values from linear mixed 
models analysis. *p<0.05. 
  TBMC (g) TBMC SDS TBA (cm
2
) TBMD 
(g/cm
2
) 
TBMD Ht Z TLTM (g) 
Visit 1 
Value 1022.1 -0.8 1199.0 0.839 -0.8 20422.5 
Δ in Observation 25.5 -0z 24.2 0.006 -0.1 836.5 
p 0.124 0.195 0.149 0.238 0.328 0.007* 
Visit 2 
Value 1047.6 -0.9 1223.2 0.845 -0.9 21258.9 
Δ with WBVT 46.8 0.0 37.9 0.012 0.0 364.6 
p 0.008* 0.883 0.029* 0.020* 0.771 0.199 
Visit 3 
Value 1094.4 -0.9 1261.1 0.858 -0.8 21623.6 
Δ in Follow-up 15.3 -0.1 22.8 -0.002 -0.2 503.9 
p 0.347 0.250 0.172 0.671 0.048* 0.082 
Visit 4 Value 1109.7 -1.1 1284.0 0.856 -1.0 22127.5 
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  TFat (%) TFat % SDS TLTM:Ht 
SDS 
TBA:Ht SDS TBMC:TLTM 
SDS 
TBMC:TBA 
SDS 
Visit 1 
Value 24.6 0.9 -1.5 -1.0 0.9 -0.3 
Δ in Observation 0.1 0.0 -0.0 -0.2 -0.2 0.0 
p 0.850 0.903 0.959 0.299 0.191 0.869 
Visit 2 
Value 24.7 0.9 -1.5 -1.1 0.6 -0.3 
Δ with WBVT 1.5 0.2 -0.2 0.0 0.3 0.1 
p 0.067 0.077 0.215 0.870 0.162 0.463 
Visit 3 
Value 26.2 1.1 -1.7 -1.1 0.9 -0.2 
Δ in Follow-up 0.0 -0.0 -0.1 -0.2 -0.1 -0.1 
p 0.955 0.909 0.612 0.360 0.549 0.220 
Visit 4 Value 26.3 1.1 -1.7 -1.3 0.8 -0.3 
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  Trunk BMD 
(g/cm
2
) 
Trunk BMD 
SDS 
Arms BMD 
(g/cm
2
) 
Arms BMD 
SDS 
Legs BMC 
(g) 
Legs BA 
(cm
2
) 
Visit 1 
Value 0.636 -0.4 0.591 -0.7 300.8 393.3 
Δ in Observation -0.002 -0.1 0.004 -0.1 7.9 13.1 
p 0.780 0.151 0.401 0.204 0.131 0.008* 
Visit 2 
Value 0.634 -0.5 0.595 -0.8 308.7 406.5 
Δ with WBVT 0.018 0.1 0.009 0.0 11.8 12.7 
p 0.008* 0.146 0.067 0.893 0.030* 0.009* 
Visit 3 
Value 0.652 -0.4 0.604 -0.8 320.4 419.2 
Δ in Follow-up -0.006 -0.1 0.001 -0.1 8.6 6.0 
p 0.364 0.052 0.812 0.113 0.101 0.184 
Visit 4 Value 0.646 -0.5 0.605 -1.0 329.1 425.2 
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  Legs BMD 
(g/cm
2
) 
Legs BMD 
SDS 
Legs LTM 
(g) 
Legs Fat (%) LS BMC (g) LS BMC SDS 
Visit 1 
Value 0.735 -1.5 6077.4 31.0 18.7 -0.4 
Δ in Observation -0.001 -0.3 113.1 0.6 0.6 -0.1 
p 0.830 0.013* 0.169 0.389 0.109 0.600 
Visit 2 
Value 0.734 -1.7 6210.5 31.7 19.2 -0.4 
Δ with WBVT 0.009 -0.1 187.4 1.1 1.4 0.2 
p 0.168 0.429 0.059 0.147 0.001* 0.133 
Visit 3 
Value 0.743 -1.8 6397.92 32.8 20.6 -0.2 
Δ in Follow-up 0.013   -0.0 156.7 0.0 -0.1 -0.2 
p 0.077 0.672 0.108 0.948 0.735 0.059 
Visit 4 Value 0.756 -1.8 6554.7 32.9 20.5 -0.5 
 
 
 
 
 
 
 
 553 
  LSBMD 
(g/cm
2
) 
LS BMD SDS L14 BMC (g) L14 BA (cm
2
) L14 vBMD 
(g/cm3) 
L14 vBMD 
SDS 
Visit 1 
Value 0.672 -0.9 23.8 34.6 0.248 -1.0 
Δ in Observation 0.008 -0.0 0.9 1.0 0.003 -0.0 
p 0.587 0.761 0.039* 0.052 0.816 0.973 
Visit 2 
Value 0.679 -1.0 24.7 35.6 0.251 -1.0 
Δ with WBVT 0.050 0.4 1.7 0.0 0.001 -0.0 
p 0.002* 0.012* 0.000* 0.956 0.961 0.875 
Visit 3 
Value 0.729 -0.6 26.4 35.6 0.252 -1.1 
Δ in Follow-up -0.016 -0.3 -0.0 0.7 0.000 -0.1 
p 0.272 0.071 0.935 0.172 0.968 0.863 
Visit 4 Value 0.713 -0.9 26.4 36.3 0.252 -1.1 
Note: Δ, change; TBMC, total bone mineral content; TBA, total bone area; TBMD, total bone mineral density; SDS, standard deviation score; 
TLTM, total body lean tissue mass; TFat, total body fat; BMD, bone mineral density; BMC, bone mineral content; BA, bone area; LTM, lean 
tissue mass; TF, tibia and fibula; LS, lumbar spine vertebrae 2-4; L14, lumbar spine vertebrae 1-4; vBMD, volumetric bone mineral density; R, 
region of distal femur scan. 
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Table A.3. DXA parameters for the adult MRCD cohort at each visit with changes between visits and associated p values from linear mixed 
models analysis. *p<0.05. 
  TBMC (g) TBA (cm
2
) TBMD (g/cm
2
) TBMD SDS TLTM (g) TFat % 
Visit 1 
Value 2378.3 2177.4 1.090 -0.4 38771.7 35.9 
Δ in Observation 21.1 23.8 -0.003 -0.0 -612.6 0.6 
p 0.260 0.174 0.296 0.817 0.048* 0.251 
Visit 2 
Value 2399.4 2201.2 1.087 -0.4 38159.0 36.5 
Δ with WBVT 6.0 10.4 -0.002 -0.0 -415.3 0.8 
p 0.747 0.548 0.660 0.772 0.173 0.156 
Visit 3 
Value 2405.4 2211.6 1.085 -0.4 37743.7 37.3 
Δ in Follow-up -21.0 -20.0 -0.000 -0.0 118.6 -0.7 
p 0.264 0.251 0.859 0.544 0.531 0.179 
Visit 4 Value 2384.4 2191.5 1.085 -0.461 37932.3 36.6 
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  Trunk BMD 
(g/cm
2
) 
Arms BMD 
(g/cm
2
) 
Legs BMC 
(g) 
Legs BA 
(cm
2
) 
Legs BMD 
(g/cm
2
) 
Legs LTM (g) 
Visit 1 
Value 0.868 0.817 846.5 741.0 1.139 12141.0 
Δ in Observation -0.005 -0.003 -6.6 -2.5 -0.006 -251.89 
p 0.380 0.490 0.100 0.460 0.049* 0.033* 
Visit 2 
Value 0.863 0.814 839.9 738.5 1.133 11889.1 
Δ with WBVT -0.003 0.003 1.5 -2.6 0.007 -188.5 
p 0.551 0.482 0.704 0.436 0.036* 0.106 
Visit 3 
Value 0.860 0.817 841.4 735.9 1.140 11700.6 
Δ in Follow-up 0.000 -0.004 -4.2 1.5 -0.008 6.2 
p 0.939 0.335 0.290 0.661 0.019* 0.957 
Visit 4 Value 0.860 0.813 837.2 737.4 1.132 11706.9 
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  Legs Fat 
(%) 
LSBMC (g) LSBMD 
(g/cm
2
) 
LS SDS L14BMC (g) L14 BA 
(cm
2
) 
L14 vBMD 
(g/cm3) 
Visit 1 
Value 38.8 51.4 1.123 -0.4 64.3 58.6 0.323 
Δ in Observation 0.5 0.1 0.004 0.1 0.1 -0.2 0.007 
p 0.274 0.794 0.694 0.467 0.898 0.646 0.326 
Visit 2 
Value 39.3 51.6 1.126 -0.4 64.4 58.8 0.330 
Δ with WBVT 0.5 -0.6 -0.010 -0.1 -0.3 0.2 -0.011 
p 0.293 0.245 0.246 0.276 0.571 0.617 0.125 
Visit 3 
Value 39.8 51.0 1.116 -0.5 64.1 59.0 0.319 
Δ in Follow-up -0.6 0.4 0.003 0.1 0.5 0.3 0.009 
p 0.237 0.397 0.732 0.461 0.359 0.441 0.235 
Visit 4 Value 39.3 51.4 1.119 -0.4 64.6 59.3 0.327 
Note: Δ, change; TBMC, total bone mineral content; TBA, total bone area; TBMD, total bone mineral density; SDS, standard deviation score; 
TLTM, total body lean tissue mass; TFat, total body fat; BMD, bone mineral density; BMC, bone mineral content; BA, bone area; LTM, lean 
tissue mass; TF, tibia and fibula; LS, lumbar spine vertebrae 2-4; L14, lumbar spine vertebrae 1-4; vBMD, volumetric bone mineral density; R, 
region of distal femur scan. 
 557 
Table A.4. DXA parameters for the Leigh Syndrome MRCD cohort at each visit with changes between visits and associated p values from linear 
mixed models analysis. *p<0.05. 
  TBMC (g) TBA (cm
2
) TBMD 
(g/cm
2
) 
TBMD SDS TLTM (g) TFat (%) 
Visit 1 
Value 1562.5 1603.124 0.916 -0.7 29565.6 31.8 
Δ in Observation 48.8 33.9 0.010 -0.0 -26.6 0.5 
p 0.227 0.348 0.025* 0.976 0.966 0.606 
Visit 2 
Value 1611.3 1637.0 0.925 -0.7 29538.9 32.24 
Δ with WBVT 28.9 32.8 0.004 -0.1 731.3 1.2 
p 0.465 0.363 0.316 0.250 0.252 0.211 
Visit 3 
Value 1640.3 1669.9 0.929 -0.8 30270.2 33.5 
Δ in Follow-up 14.3 13.6 0.004 -0.1 943.6 0.3 
p 0.716 0.702 0.263 0.406 0.146 0.730 
Visit 4 Value 1654 1683.5 0.934 -0.9 31213.8 33.8 
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  Arms BMD 
(g/cm
2
) 
Trunk BMD 
(g/cm
2
) 
Legs BMC 
(g) 
Legs BA 
(cm
2
) 
Legs BMD 
(g/cm
2
) 
Legs LTM 
(g) 
Visit 1 
Value 0.733 0.728 469.8 492.8 0.856 8884.3 
Δ in Observation 0.001 0.004 11.0 9.5 0.006 -188.8 
p 0.885 0.665 0.022* 0.111 0.438 0.312 
Visit 2 
Value 0.734 0.732 480.7 502.4 0.862 8695.5 
Δ with WBVT 0.008 0.007 15.1 14.4 0.012 182.2 
p 0.301 0.424 0.004* 0.023* 0.108 0.3 
Visit 3 
Value 0.742 0.739 495.8 516.7 0.874 8877.743 
Δ in Follow-up -0.002 0.007 11.7 11.0 0.012 369.3 
p 0.815 0.435 0.016* 0.070 0.106 0.061 
Visit 4 Value 0.740 0.746 507.5 527.7 0.887 9247.1 
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  Legs Fat 
(%) 
LS BMC (g) LS BMD 
(g/cm
2
) 
LS BMD 
SDS 
L14 BMC 
(g) 
L14 BA 
(cm
2
) 
L14 vBMD 
(g/cm3) 
Visit 1 
Value 37.3 31.8 0.785 -1.1 39.2 44.8 0.256 
Δ in Observation 1.0 -0.3 0.010 0.0 1.0 0.3 0.004 
p 0.251 0.489 0.462 0.933 0.088 0.582 0.755 
Visit 2 
Value 38.2 32.0 0.795 -1.0 40.2 45.1 0.260 
Δ with WBVT 1.1 0.7 0.23 0.2 0.7 0.6 -0.008 
p 0.199 0.087 0.113 0.252 0.175 0.218 0.550 
Visit 3 
Value 39.3 32.7 0.818 -0.8 40.9 45.8 0.252 
Δ in Follow-up 0.4 0.0 0.005 -0.1 0.4 -0.0 0.007 
p 0.588 0.907 0.736 0.737 0.471 0.967 0.629 
Visit 4 Value 39.8 32.8 0.823 -0.9 41.3 45.8 0.259 
Note: Δ, change; TBMC, total bone mineral content; TBA, total bone area; TBMD, total bone mineral density; SDS, standard deviation score; 
TLTM, total body lean tissue mass; TFat, total body fat; BMD, bone mineral density; BMC, bone mineral content; BA, bone area; LTM, lean 
tissue mass; TF, tibia and fibula; LS, lumbar spine vertebrae 2-4; L14, lumbar spine vertebrae 1-4; vBMD, volumetric bone mineral density; R, 
region of distal femur scan. 
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Table B.1. pQCT parameters for the CF cohort at each visit with changes between visits and associated p values from linear mixed 
models analysis. *p<0.05. 
  4% Total 
BMC 
(mg/mm) 
4% Total CSA 
(mm
2
) 
4% Total 
vBMD 
(mg/cm3) 
4% 
Trabecular 
BMC 
(mg/mm) 
4% 
Trabecular 
CSA (mm
2
) 
4% 
Trabecular 
vBMD 
(mg/cm3) 
Visit 1 
Value 226.3 765.4 300.200 71.9 344.3 210.406 
Δ in Observation 2.8 12.5 -2.013 -0.3 5.6 -3.244 
p 0.268 0.136 0.486 0.850 0.135 0.108 
Visit 2 
Value 229.1 777.9 298.187 71.7 350.0 207.162 
Δ with WBVT 7.5 6.6 6.056 1.2 2.9 0.456 
p 0.005* 0.430 0.040* 0.357 0.431 0.818 
Visit 3 
Value 236.6 784.4 304.244 72.9 352.9 207.619 
Δ in Follow-up 4.4 8.3 2.582 0.5 3.7 -0.654 
p 0.098 0.336 0.387 0.737 0.337 0.750 
Visit 4 Value 241.0 792.689 306.826 73.4 356.6 206.965 
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4% 
Trabecular 
vBMD 
SDS 
4% Periosteal 
Circumference 
(mm) 
20% Total 
BMC 
(mg/mm) 
20% Total 
CSA (mm2) 
20% Total 
vBMD 
(mg/cm3) 
20% Cortical 
BMC 
(mg/mm) 
Visit 1 
Value -1.0 97.2 192.1 318.4 615.081 162.7 
Δ in Observation -0.1 1.1 7.3 7.5 7.213 7.6 
p 0.110 0.548 0.000* 0.000* 0.013* 0.000* 
Visit 2 
Value -1.1 98.3 199.3 325.9 622.294 170.3 
Δ with WBVT 0.0 0.0 8.0 7.4 9.762 7.3 
p 0.744 0.996 0.000* 0.000* 0.001* 0.000* 
Visit 3 
Value -1.1 98.3 207.3 333.3 632.056 177.6 
Δ in Follow-up 0.0 1.2 6.6 6.2 7.393 6.2 
p 0.858 0.533 0.000* 0.000* 0.014* 0.000* 
Visit 4 Value -1.1 99.4 213.9 339.5 639.450 183.8 
 
 
 563 
  20% 
Cortical 
BMC SDS 
20% Cortical 
CSA (mm
2
) 
20% Cortical 
CSA SDS 
20% Cortical 
vBMD 
(mg/cm3) 
20% Cortical 
vBMD SDS 
20% Cortical 
Thickness 
(mm) 
Visit 1 
Value 0.2 147.3 -0.3 1099.694 1.3 2.7 
Δ in Observation 0.3 5.8 0.3 7.950 0.2 0.1 
p 0.000* 0.000* 0.000* 0.004* 0.007* 0.000* 
Visit 2 
Value 0.4 153.1 0.0 1107.644 1.5 2.8 
Δ with WBVT 0.3 5.6 0.3 7.069 0.2 0.1 
p 0.000* 0.000* 0.000* 0.011* 0.013* 0.000* 
Visit 3 
Value 0.7 158.7 0.3 1114.713 1.6 2.9 
Δ in Follow-up 0.3 4.2 0.2 9.332 0.2 0.1 
p 0.000* 0.000* 0.001* 0.001* 0.011* 0.009* 
Visit 4 Value 1.0 162.9 0.6 1124.045 1.8 2.9 
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  20% 
Cortical 
Thickness 
SDS 
20% 
Periosteal 
Circumference 
(mm) 
20% 
Periosteal 
Circumference 
SDS 
20% Cortical 
CSMI p 
(mm
4
) 
20% Cortical 
SS1p (mm
3
) 
20% Total 
CSMI p 
(mm
4
) 
Visit 1 
Value 0.4 62.5 -0.9 11337.3 877.4 14490.0 
Δ in Observation 0.2 0.8 0.2 660.2 47.0 637.4 
p 0.003* 0.000* 0.000* 0.000* 0.000* 0.000* 
Visit 2 
Value 0.5 63.3 -0.8 11997.5 924.3 15127.4 
Δ with WBVT 0.2 0.8 0.2 649.7 43.6 807.9 
p 0.001* 0.000* 0.000* 0.000* 0.000* 0.000* 
Visit 3 
Value 0.7 64.1 -0.6 12647.2 967.9 15935.3 
Δ in Follow-up 0.1 0.6 0.2 457.2 44.5 519.4 
p 0.018* 0.000* 0.002* 0.001* 0.000* 0.002* 
Visit 4 Value 0.9 64.7 -0.4 13104.4 1012.4 16454.6 
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  66% 
Cortical 
vBMD 
SDS 
66% Cortical 
Thickness 
(mm) 
66% Cortical 
Thickness 
SDS 
66% 
Periosteal 
Circumference 
(mm) 
66% Cortical 
CSMI p 
(mm
4
) 
66% Cortical 
CSMI p SDS 
Visit 1 
Value 0.8 3.2 -1.1 76.3 26296.4 -1.3 
Δ in Observation 0.2 0.0 0.1 1.6 1838.2 0.2 
p 0.135 0.208 0.205 0.000* 0.000* 0.000* 
Visit 2 
Value 1.0 3.2 -1.0 77.9 28134.5 -1.1 
Δ with WBVT 0.1 0.0 0.1 1.5 1967.0 0.2 
p 0.361 0.127 0.165 0.000* 0.000* 0.000* 
Visit 3 
Value 1.1 3.2 -0.9 79.4 30101.5 -0.9 
Δ in Follow-up 0.3 0.1 0.1 0.8 1201.6 0.2 
p 0.021* 0.090 0.095 0.043* 0.017* 0.004* 
Visit 4 Value 1.3 3.3 -0.8 80.2 31303.2 -0.7 
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  66% 
Cortical 
SSI p 
(mm
3
) 
66% Cortical 
SSI p SDS 
66% Soft 
Tissue Total 
CSA (mm
2
) 
66% Muscle 
CSA (mm
2
) 
66% Muscle 
CSA SDS 
66% Fat CSA 
(mm
2
) 
Visit 1 
Value 1417.3 -0.6 6538.1 4272.570 -0.8 1773.1 
Δ in Observation 88.3 0.3 183.8 82.530 0.1 81.4 
p 0.000* 0.000* 0.022* 0.204 0.125 0.042* 
Visit 2 
Value 1505.6 -0.3 6721.9 4355.100 -0.7 1854.5 
Δ with WBVT 77.7 0.3 64.6 57.010 0.1 -9.1 
p 0.000* 0.000* 0.407 0.378 0.166 0.815 
Visit 3 
Value 1583.3 0.0 6786.500 4412.1 -0.7 1845.4 
Δ in Follow-up 67.5 0.2 281.510 186.8 0.2 77.5 
p 0.001* 0.001* 0.001* 0.007* 0.004* 0.060 
Visit 4 Value 1650.8 0.3 7068.010 4598.9 -0.5 1922.8 
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  66% Fat 
CSA:Muscle 
CSA (%) 
66% Muscle 
CSA:Total CSA 
(%) 
66% Cortical 
CSA:Muscle 
CSA (%) 
66% Cortical 
BMC:Muscle 
CSA (mg/mm
2
) 
66% Cortical 
BMC:Muscle 
CSA SDS 
Visit 1 
Value 42.1 65.4 5.1 0.1 4.3 
Δ in Observation 0.8 -0.4 0.0 0.0 0.6 
p 0.384 0.415 0.652 0.382 0.358 
Visit 2 
Value 42.9 65.0 5.1 0.1 5.0 
Δ with WBVT -0.5 0.1 0.1 0.0 0.7 
p 0.620 0.886 0.329 0.179 0.290 
Visit 3 
Value 42.4 65.1 5.2 0.1 5.7 
Δ in Follow-up 0.0 0.1 -0.1 0.0 -0.4 
p 0.984 0.798 0.488 0.801 0.587 
Visit 4 Value 42.4 65.2 5.1 0.1 5.3 
Note: Δ, change; 4%, referring to 4% tibial pQCT site; BMC, bone mineral content; CSA, cross-sectional area; vBMD, volumetric 
bone mineral density; SDS, standard deviation score; 20%, referring to the 20% tibial pQCT site; CSMI, cross-section moment of 
inertia; p, referring to the polar measurement; SSI, stress strain index; 66%, referring to the 66% tibial pQCT site. 
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Table B.2. pQCT parameters for the paediatric cohort MRCD cohort at each visit with changes between visits and associated p values 
from linear mixed models analysis. *p<0.05. 
 
  4% Total 
BMC 
(mg/mm) 
4% Total 
CSA (mm
2
) 
4% Total 
vBMD 
(mg/cm3) 
4% 
Trabecular 
BMC 
(mg/mm) 
4% 
Trabecular 
CSA (mm
2
) 
4% 
Trabecular 
vBMD 
(mg/cm3) 
Visit 2 
Value 125.989 549.749 241.935 33.721 247.274 142.427 
Δ with WBVT 9.238 20.011 6.181 1.324 9.046 1.023 
p 0.009* 0.089 0.277 0.406 0.088 0.801 
Visit 3 
Value 135.227 569.760 248.117 35.045 256.320 143.450 
Δ in Follow-up -1.348 11.493 -7.517 -0.430 5.173 -3.550 
p 0.610 0.261 0.158 0.764 0.262 0.350 
Visit 4 Value 133.878 581.253 240.600 34.615 261.493 139.900 
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  4% 
Trabecular 
vBMD SDS 
4% Periosteal 
Circumferenc
e (mm) 
20% Total 
BMC 
(mg/mm) 
20% Total 
CSA (mm
2
) 
20% Total 
vBMD 
(mg/cm3) 
20% Cortical 
BMC 
(mg/mm) 
Visit 2 
Value -2.983 81.860 119.797 227.760 560.133 100.440 
Δ with WBVT 0.027 1.821 7.083 -1.867 26.883 8.718 
p 0.813 0.069 0.000* 0.719 0.005* 0.000* 
Visit 3 
Value -2.956 83.781 126.880 225.893 587.017 109.158 
Δ in Follow-up -0.097 0.955 2.388 3.013 0.967 1.993 
p 0.362 0.267 0.068 0.564 0.901 0.190 
Visit 4 Value -3.053 84.736 129.268 228.907 587.983 111.152 
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  20% Cortical 
BMC SDS 
20% Cortical 
CSA (mm
2
) 
20% Cortical 
CSA SDS 
20% Cortical 
vBMD 
(mg/cm3) 
20% Cortical 
vBMD SDS 
20% Cortical 
Thickness 
(mm) 
Visit 2 
Value -0.321 91.707 -1.065 1092.717 3.396 2.039 
Δ with WBVT 0.692 6.827 0.562 13.433 0.377 0.155 
p 0.001* 0.000* 0.002* 0.049* 0.193 0.001* 
Visit 3 
Value 0.371 98.533 -0.504 1106.150 3.772 2.194 
Δ in Follow-up 0.119 1.840 0.123 1.000 0.045 0.020 
p 0.437 0.202 0.363 0.871 0.869 0.567 
Visit 4 Value 0.490 100.373 -0.381 1107.150 3.818 2.214 
 
 
 
 
 
 
 
 
 
 571 
 
  20% Cortical 
BMC SDS 
20% Cortical 
CSA (mm
2
) 
20% Cortical 
CSA SDS 
20% Cortical 
vBMD 
(mg/cm3) 
20% Cortical 
vBMD SDS 
20% Cortical 
Thickness 
(mm) 
Visit 2 
Value -0.321 91.707 -1.065 1092.717 3.396 2.039 
Δ with WBVT 0.692 6.827 0.562 13.433 0.377 0.155 
p 0.001* 0.000* 0.002* 0.049* 0.193 0.001* 
Visit 3 
Value 0.371 98.533 -0.504 1106.150 3.772 2.194 
Δ in Follow-up 0.119 1.840 0.123 1.000 0.045 0.020 
p 0.437 0.202 0.363 0.871 0.869 0.567 
Visit 4 Value 0.490 100.373 -0.381 1107.150 3.818 2.214 
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  20% Cortical 
Thickness 
SDS 
20% 
Periosteal 
Circumference 
(mm) 
20% 
Periosteal 
Circumference 
SDS 
20% Cortical 
CSMI p 
(mm
4
) 
20% Cortical 
SS1p (mm
3
) 
20% Total 
CSMI p 
(mm
4
) 
Visit 2 
Value 0.141 52.945 -1.499 4688.530 454.669 6277.490 
Δ with WBVT 0.561 -0.114 0.016 308.982 35.442 196.390 
p 0.008* 0.836 0.912 0.017* 0.002* 0.358 
Visit 3 
Value 0.702 52.831 -1.483 4997.512 490.111 6473.880 
Δ in Follow-up 0.057 0.382 0.058 183.673 16.132 167.378 
p 0.728 0.493 0.680 0.118 0.081 0.431 
Visit 4 Value 0.759 53.213 -1.425 5181.185 506.243 6641.258 
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  20% Cortical 
Thickness 
SDS 
20% 
Periosteal 
Circumference 
(mm) 
20% 
Periosteal 
Circumference 
SDS 
20% Cortical 
CSMI p 
(mm
4
) 
20% Cortical 
SS1p (mm
3
) 
20% Total 
CSMI p 
(mm
4
) 
Visit 2 
Value 0.141 52.945 -1.499 4688.530 454.669 6277.490 
Δ with WBVT 0.561 -0.114 0.016 308.982 35.442 196.390 
p 0.008* 0.836 0.912 0.017* 0.002* 0.358 
Visit 3 
Value 0.702 52.831 -1.483 4997.512 490.111 6473.880 
Δ in Follow-up 0.057 0.382 0.058 183.673 16.132 167.378 
p 0.728 0.493 0.680 0.118 0.081 0.431 
Visit 4 Value 0.759 53.213 -1.425 5181.185 506.243 6641.258 
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  66% Cortical 
BMC 
(mg/mm) 
66% Cortical 
BMC SDS 
66% Cortical 
CSA (mm
2
) 
66% Cortical 
CSA SDS 
66% Cortical 
CSA:Total 
CSA (%) 
66% Cortical 
vBMD 
(mg/cm
3
) 
Visit 2 
Value 120.813 -2.023 113.600 -2.263 40.014 1063.083 
Δ with WBVT 5.528 0.298 3.680 0.192 0.157 17.067 
p 0.036* 0.029* 0.020* 0.021* 0.901 0.115 
Visit 3 
Value 126.342 -1.725 117.280 -2.072 39.857 1080.150 
Δ in Follow-up 0.443 0.053 1.600 0.099 -1.252 9.383 
p 0.850 0.662 0.256 0.190 0.332 0.365 
Visit 4 Value 126.785 -1.672 118.880 -1.973 38.604 1070.767 
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  66% Cortical 
vBMD SDS 
66% Cortical 
Thickness 
(mm) 
66% Cortical 
Thickness 
SDS 
66% 
Periosteal 
Circumference 
(mm) 
66% Cortical 
CSMI p 
(mm
4
) 
66% Cortical 
CSMI p SDS 
Visit 2 
Value 2.045 2.275 -1.837 57.610 8084.868 -2.209 
Δ with WBVT 0.597 0.030 0.124 1.350 716.471 0.115 
p 0.118 0.611 0.455 0.133 0.021* 0.010* 
Visit 3 
Value 2.643 2.305 -1.713 58.960 8801.340 -2.094 
Δ in Follow-up -0.339 -0.038 -0.080 1.906 778.948 0.145 
p 0.354 0.521 0.628 0.044* 0.014* 0.003* 
Visit 4 Value 2.304 2.267 -1.793 60.866 9580.288 -2.209 
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  66% Cortical 
SSI p (mm
3
) 
66% Cortical 
SSI p SDS 
66% Soft 
Tissue Total 
CSA (mm
2
) 
66% Muscle 
CSA (mm
2
) 
66% Muscle 
CSA SDS 
66% Fat CSA 
(mm
2
) 
Visit 2 
Value 617.598 -1.746 4801.227 2686.133 -1.029 1815.253 
Δ with WBVT 45.146 0.333 223.573 145.573 0.248 61.920 
p 0.000* 0.002* 0.017* 0.014* 0.015* 0.267 
Visit 3 
Value 662.744 -1.413 5024.800 2831.707 -0.781 1877.173 
Δ in Follow-up 25.420 0.168 149.760 2.187 0.041 129.120 
p 0.009* 0.060 0.084 0.965 0.636 0.034* 
Visit 4 Value 688.164 -1.245 5174.560 2833.893 -0.739 2006.293 
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  66% Fat 
CSA:Muscle 
CSA (%) 
66% Muscle 
CSA:Total 
CSA (%) 
66% Cortical 
CSA:Muscle 
CSA (%) 
66% Cortical 
BMC:Muscle 
CSA 
(mg/mm
2
) 
66% Cortical 
BMC:Muscle 
CSA SDS 
 
Visit 2 
Value 70.277 55.820 4.287 0.046 -3.140  
Δ with WBVT -2.364 0.631 -0.120 -0.001 -0.623  
p 0.292 0.329 0.226 0.561 0.574  
Visit 3 
Value 67.913 56.451 4.167 0.045 -3.763  
Δ in Follow-up 4.939 -1.570 0.082 0.000 0.075  
p 0.043* 0.029* 0.402 0.743 0.946  
Visit 4 Value 72.852 54.881 4.249 0.045 -3.688  
 
Note: Δ, change; 4%, referring to 4% tibial pQCT site; BMC, bone mineral content; CSA, cross-sectional area; vBMD, volumetric 
bone mineral density; SDS, standard deviation score; 20%, referring to the 20% tibial pQCT site; CSMI, cross-section moment of 
inertia; x, referring to the measurement in the x plane y, referring to the measurement in the y plane; p, referring to the polar 
measurement; SSI, stress strain index; 66%, referring to the 66% tibial pQCT site. 
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Table B.3. pQCT parameters for the adult MRCD cohort at each visit with changes between visits and associated p values from linear 
mixed models analysis. *p<0.05. 
 
  4% Total 
BMC 
(mg/mm) 
4% Total 
CSA (mm
2
) 
4% Total 
vBMD 
(mg/cm3) 
4% 
Trabecular 
BMC 
(mg/mm) 
4% 
Trabecular 
CSA (mm
2
) 
4% 
Trabecular 
vBMD 
(mg/cm3) 
Visit 2 
Value 273.630 1076.840 257.550 94.427 484.493 197.250 
Δ with WBVT -1.033 -0.760 -0.075 -0.431 -0.307 -0.125 
p 0.388 0.878 0.938 0.516 0.891 0.875 
Visit 3 
Value 272.597 1076.080 257.475 93.996 484.187 197.125 
Δ in Follow-up 0.843 0.227 0.708 0.170 0.067 0.242 
p 0.480 0.964 0.464 0.797 0.976 0.762 
Visit 4 Value 273.441 1076.307 258.183 94.166 484.253 197.367 
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  4% Periosteal 
Circumferenc
e (mm) 
4% 
Trabecular 
BMC 
(mg/mm) 
20% Total 
BMC 
(mg/mm) 
20% Total 
CSA (mm
2
) 
20% Total 
vBMD 
(mg/cm3) 
20% Cortical 
BMC 
(mg/mm) 
Visit 2 
Value 116.066 94.427 225.665 341.720 663.750 206.971 
Δ with WBVT -0.059 -0.431 -0.280 -0.693 1.092 0.076 
p 0.828 0.516 0.716 0.518 0.617 0.921 
Visit 3 
Value 116.007 93.996 225.385 341.027 660.842 207.047 
Δ in Follow-up 0.003 0.170 -0.430 0.213 -1.892 -0.803 
p 0.990 0.797 0.577 0.842 0.388 0.297 
Visit 4 Value 116.010 94.166 224.955 341.240 662.950 206.243 
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  20% Cortical 
CSA (mm
2
) 
20% Cortical 
vBMD 
(mg/cm3) 
20% Cortical 
Thickness 
(mm) 
20% 
Periosteal 
Circumference 
(mm) 
20% Cortical 
CSMI p 
(mm
4
) 
20% Cortical 
SS1p (mm
3
) 
Visit 2 
Value 175.947 1176.358 3.178 65.390 15026.898 1182.136 
Δ with WBVT -0.480 2.792 -0.001 -0.068 -109.071 -0.187 
p 0.521 0.226 0.951 0.508 0.189 0.984 
Visit 3 
Value 175.467 1179.150 3.177 65.322 14917.827 1181.949 
Δ in Follow-up -0.400 -1.492 -0.011 0.021 -1.628 2.162 
p 0.593 0.512 0.532 0.840 0.984 0.811 
Visit 4 Value 175.067 1177.658 3.166 65.343 14916.199 1184.111 
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  66% Total 
BMC 
(mg/mm) 
66% Total 
CSA (mm
2
) 
66% Total 
vBMD 
(mg/cm3) 
66% Cortical 
BMC 
(mg/mm) 
66% Cortical 
CSA (mm
2
) 
66% Cortical 
CSA:Total 
CSA (%) 
Visit 2 
Value 341.704 582.293 594.992 289.793 251.773 43.808 
Δ with WBVT -0.176 0.307 -0.867 0.237 0.947 0.105 
p 0.807 0.873 0.653 0.740 0.220 0.497 
Visit 3 
Value 341.528 582.600 594.125 290.029 252.720 43.913 
Δ in Follow-up -0.347 1.627 -1.942 -1.013 -1.707 -0.387 
p 0.632 0.400 0.318 0.164 0.033* 0.019* 
Visit 4 Value 341.182 584.227 592.183 289.016 251.013 43.526 
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  66% Cortical 
vBMD 
(mg/cm3) 
66% Cortical 
Thickness 
(mm) 
66% 
Periosteal 
Circumference 
(mm) 
66% Cortical 
CSMI p 
(mm
4
) 
66% Cortical 
SSI p (mm
3
) 
66% Soft 
Tissue Total 
CSA (mm
2
) 
Visit 2 
Value 1151.100 3.556 82.484 37210.932 2016.335 8726.307 
Δ with WBVT -2.875 0.008 0.145 158.897 5.674 -32.413 
p 0.176 0.529 0.202 0.342 0.472 0.776 
Visit 3 
Value 1148.225 3.564 82.629 37369.82 2022.009 8693.893 
Δ in Follow-up 3.242 -0.031 0.073 -135.482 -0.514 -68.280 
p 0.129 0.015* 0.518 0.417 0.948 0.551 
Visit 4 Value 1151.467 3.532 82.702 37234.346 2021.496 8625.613 
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  66% Muscle 
CSA (mm
2
) 
66% Fat CSA 
(mm
2
) 
66% Fat 
CSA:Muscle 
CSA (%) 
66% Muscle 
CSA:Total 
CSA (%) 
66% Cortical 
CSA:Muscle 
CSA (%) 
66% Cortical 
BMC:Muscle 
CSA 
(mg/mm
2
) 
Visit 2 
Value 5225.360 2874.013 56.701 60.252 4.885 0.056 
Δ with WBVT -39.560 6.480 0.448 -0.171 0.016 0.000 
p 0.703 0.927 0.826 0.810 0.875 0.974 
Visit 3 
Value 5185.800 2880.493 57.149 60.081 4.901 0.056 
Δ in Follow-up 61.427 -131.307 -2.824 1.094 -0.053 0.000 
p 0.555 0.074 0.174 0.135 0.599 0.696 
Visit 4 Value 5247.227 2749.187 54.325 61.174 4.848 0.056 
 
Note: Δ, change; 4%, referring to 4% tibial pQCT site; BMC, bone mineral content; CSA, cross-sectional area; vBMD, volumetric 
bone mineral density; 20%, referring to the 20% tibial pQCT site; CSMI, cross-section moment of inertia; x, referring to the 
measurement in the x plane; y, referring to the measurement in the y plane; p, referring to the polar measurement; SSI, stress strain 
index; 66%, referring to the 66% tibial pQCT site.   
 
 584 
Table B.4. pQCT parameters for the Leigh Syndrome cohort MRCD cohort at each visit with changes between visits and associated p 
values from linear mixed models analysis. *p<0.05. 
 
  4% Total 
BMC 
(mg/mm) 
4% Total 
CSA (mm
2
) 
4% Total 
vBMD 
(mg/cm3) 
4% 
Trabecular 
BMC 
(mg/mm) 
4% 
Trabecular 
CSA (mm
2
) 
4% 
Trabecular 
vBMD 
(mg/cm3) 
Visit 2 
Value 178.112 654.816 278.580 48.316 294.560 163.380 
Δ with WBVT 6.326 20.192 3.100 1.926 9.120 4.160 
p 0.071 0.106 0.608 0.145 0.105 0.164 
Visit 3 
Value 184.438 675.008 281.680 50.242 303.680 167.540 
Δ in Follow-up 1.826 4.320 -1.940 0.382 1.952 0.800 
p 0.565 0.707 0.747 0.757 0.706 0.776 
Visit 4 Value 186.264 679.328 279.740 50.624 305.632 168.340 
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  4% Periosteal 
Circumferenc
e (mm) 
20% Total 
BMC 
(mg/mm) 
20% Total 
CSA (mm
2
) 
20% Total 
vBMD 
(mg/cm3) 
20% Cortical 
BMC 
(mg/mm) 
20% Cortical 
CSA (mm
2
) 
Visit 2 
Value 87.760 160.536 248.416 654.920 144.767 126.944 
Δ with WBVT 1.844 3.620 1.728 10.820 4.894 3.712 
p 0.080 0.122 0.562 0.089 0.027* 0.070 
Visit 3 
Value 89.604 164.156 250.144 665.740 149.570 130.656 
Δ in Follow-up 0.571 0.368 2.528 -4.120 0.506 1.408 
p 0.551 0.865 0.402 0.482 0.786  0.450 
Visit 4 Value 90.175 164.524 252.672 661.620 150.076 132.064 
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  4% Periosteal 
Circumferenc
e (mm) 
20% Total 
BMC 
(mg/mm) 
20% Total 
CSA (mm
2
) 
20% Total 
vBMD 
(mg/cm3) 
20% Cortical 
BMC 
(mg/mm) 
20% Cortical 
CSA (mm
2
) 
Visit 2 
Value 87.760 160.536 248.416 654.920 144.767 126.944 
Δ with WBVT 1.844 3.620 1.728 10.820 4.894 3.712 
p 0.080 0.122 0.562 0.089 0.027* 0.070 
Visit 3 
Value 89.604 164.156 250.144 665.740 149.570 130.656 
Δ in Follow-up 0.571 0.368 2.528 -4.120 0.506 1.408 
p 0.551 0.865 0.402 0.482 0.786  0.450 
Visit 4 Value 90.175 164.524 252.672 661.620 150.076 132.064 
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  20% Cortical 
vBMD 
(mg/cm3) 
20% Cortical 
Thickness 
(mm) 
20% 
Periosteal 
Circumference 
(mm) 
20% Cortical 
CSMI p 
(mm
4
) 
20% Cortical 
SS1p (mm
3
) 
66% Total 
BMC 
(mg/mm) 
Visit 2 
Value 1122.740 2.657 54.842 8267.347 725.271 212.832 
Δ with WBVT 7.960 0.088 0.240 216.025 31.765 5.236 
p 0.282 0.040* 0.509 0.177 0.029* 0.035* 
Visit 3 
Value 1130.700 2.745 55.082 8483.372 757.036 218.068 
Δ in Follow-up -5.600 0.017 0.348 143.372 6.004 2.688 
p 0.441 0.643 0.345 0.355 0.628 0.230 
Visit 4 Value 132.064 1125.100 2.762 8626.743 763.040 220.756 
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  66% Total 
CSA (mm
2
) 
66% Total 
vBMD 
(mg/cm3) 
66% Cortical 
BMC 
(mg/mm) 
66% Cortical 
CSA (mm
2
) 
66% Cortical 
CSA:Total 
CSA (%) 
66% Cortical 
vBMD 
(mg/cm3) 
Visit 2 
Value 389.184 565.240 173.260 158.400 42.978 1072.260 
Δ with WBVT 3.968 17.580 5.298 2.976 0.811 21.720 
p 0.452 0.144 0.033* 0.038* 0.402 0.070 
Visit 3 
Value 393.152 582.820 178.558 161.376 43.789 1093.980 
Δ in Follow-up 9.600 -8.060 2.054 2.240 -0.415 -2.540 
p 0.092 0.479 0.347 0.099 0.662 0.813 
Visit 4 Value 402.752 574.760 180.612 163.616 43.374 1091.440 
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  66% Cortical 
Thickness 
(mm) 
66% 
Periosteal 
Circumference 
(mm) 
66% Cortical 
CSMI p 
(mm
4
) 
66% Cortical 
SSI p (mm
3
) 
66% Soft 
Tissue Total 
CSA (mm
2
) 
66% Muscle 
CSA (mm
2
) 
Visit 2 
Value 2.731 64.941 18037.238 1086.900 6364.096 3784.576 
Δ with WBVT 0.058 0.413 323.269 29.749 205.408 28.000 
p 0.179 0.361 0.100 0.056 0.099 0.794 
Visit 3 
Value 2.789 65.354 18360.507 1116.649 6569.504 3812.576 
Δ in Follow-up 0.005 0.855 405.134 20.390 171.552 130.880 
p 0.910 0.080 0.048* 0.164 0.158 0.242 
Visit 4 Value 2.794 66.209 18765.640 1137.039 6741.056 3943.456 
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  66% Fat CSA 
(mm
2
) 
66% Fat 
CSA:Muscle 
CSA (%) 
66% Muscle 
CSA:Total 
CSA (%) 
66% Cortical 
CSA:Muscle 
CSA (%) 
66% Cortical 
BMC:Muscle 
CSA 
(mg/mm
2
) 
 
Visit 2 
Value 2171.680 66.625 57.503 4.289 0.046  
Δ with WBVT 171.264 0.823 -0.422 -0.031 0.000  
p 0.198 0.832 0.747 0.779 0.556  
Visit 3 
Value 2342.944 67.448 57.081 4.259 0.046  
Δ in Follow-up 31.616 2.064 -0.255 0.009 0.000  
p 0.803 0.598 0.845 0.930 0.869  
Visit 4 Value 2374.560 69.511 56.826 4.268 0.046  
 
Note: Δ, change; 4%, referring to 4% tibial pQCT site; BMC, bone mineral content; CSA, cross-sectional area; vBMD, volumetric 
bone mineral density; 20%, referring to the 20% tibial pQCT site; CSMI, cross-section moment of inertia; x, referring to the 
measurement in the x plane y, referring to the measurement in the y plane; p, referring to the polar measurement; SSI, stress strain 
index; 66%, referring to the 66% tibial pQCT site.  
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Appendix C: Bone Turnover Markers 
 
Table C.1 CF Cohort 
Table C.2 Paediatric MRCD Cohort 
Table C.3 Adult MRCD Cohort 
Table C.4 Leigh Syndrome Cohort 
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Table C.1 Serum biochemistry and bone turn-over marker parameters for the CF cohort at each visit with changes between visits and 
associated p values from linear mixed models analysis. *p<0.05. 
  Alkaline Phosphatase (U/L) Calcium (mmol/L) Phosphate (mmol/L) Parathyroid 
Hormone 
Visit 1 
Value 213.2 2.3 1.5 4.6 
Δ in Observation -9.6 0.0 -0.1 -0.2 
p 0.356 0.714 0.140 0.781 
Visit 2 
Value 203.6 2.3 1.4 4.4 
Δ with WBVT -19.7 -0.1 0.0 -0.4 
p 0.063 0.003* 0.740 0.556 
Visit 3 
Value 183.9 2.2 1.4 4.0 
Δ in Follow-up 8.0 0.1 0.0 -0.4 
p 0.458 0.000* 0.582 0.557 
Visit 4 Value 191.8 2.4 1.5 3.6 
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  Osteocalcin 
(nmol/L) 
Vitamin D 
(pmol/L) 
Urinary Deoxypyridoline: 
Creatine Ratio (nmol/mmol 
creatinine) 
Visit 1 
Value 6.1 70.7 17.5 
Δ in Observation -2.4 -8.5 -2.6 
p 0.013* 0.069 0.213 
Visit 3 
Value 3.8 62.2 14.9 
Δ with WBVT 0.8 7.1 -0.6 
p 0.383 0.133 0.774 
Visit 5 
Value 4.6 69.3 14.3 
Δ in Follow-up -0.4 -7.5 1.5 
p 0.661 0.121 0.510 
Visit 7 Value 4.2 61.8 15.8 
 
Note: Δ, change; WBVT, whole body vibration training.  
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Table C.2. Serum biochemistry and bone turn-over marker parameters for the paediatric MRCD cohort at each visit with changes 
between visits and associated p values from linear mixed models analysis. *p<0.05. 
 
  Alkaline 
Phosphatase (U/L) 
Calcium (mmol/L) Phosphate 
(mmol/L) 
Lactate (mmol/L) 
Visit 1 
Value 155.286 2.416 1.453 3.357 
Δ in Observation 7.286 -0.011 0.087 -0.071 
p 0.556 0.753 0.061 0.866 
Visit 2 
Value 162.571 2.404 1.540 3.286 
Δ with WBVT 9.000 0.009 -0.017 0.243 
p 0.468 0.813 0.698 0.567 
Visit 3 
Value 171.571 2.413 1.523 3.529 
Δ in Follow-up 8.571 -0.016 -0.096 -0.257 
p 0.489 0.666 0.042* 0.544 
Visit 4 Value 180.143 2.397 1.427 3.271 
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  Urinary Deoxypyridoline: 
Creatine Ratio (nmol/mmol 
creatinine) 
Osteocalcin (nmol/L) Vitamin D 
(pmol/L) 
Visit 1 
Value 17.229 6.386 106.000 
Δ in Observation 3.800 0.471 -22.571 
p 0.313 0.553 0.018* 
Visit 2 
Value 21.029 6.857 83.429 
Δ with WBVT -4.829 -2.843 -3.714 
p 0.204 0.002* 0.670 
Visit 4 
Value 16.200 4.014 79.714 
Δ in Follow-up 3.014 -0.329 -8.000 
p 0.420 0.678 0.364 
Visit 6 Value 19.214 3.686 71.714 
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Table C.3. Serum biochemistry and bone turn-over marker parameters for the adult MRCD cohort at each visit with changes between 
visits and associated p values from linear mixed models analysis. *p<0.05. 
 
  Alkaline 
Phosphatase (U/L) 
Calcium (mmol/L) Phosphate 
(mmol/L) 
Lactate (mmol/L) 
Visit 1 
Value 74.917 2.426 1.233 3.567 
Δ in Observation -1.333 -0.058 0.028 -1.033 
p 0.669 0.063 0.567 0.153 
Visit 2 
Value 73.583 2.367 1.261 2.533 
Δ with WBVT -3.500 0.002 -0.063 0.550 
p 0.266 0.935 0.206 0.442 
Visit 3 
Value 70.083 2.370 1.198 3.083 
Δ in Follow-up 5.834 0.008 0.047 0.908 
p 0.079 0.784 0.340 0.208 
Visit 4 Value 75.917 2.378 1.245 3.992 
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  Urinary Deoxypyridoline: 
Creatine Ratio (nmol/mmol 
creatinine) 
Osteocalcin (nmol/L) Vitamin D 
(pmol/L) 
Visit 1 
Value 7.950 1.577 78.917 
Δ in Observation -0.950 -0.495 -2.833 
p 0.450 0.070 0.706 
Visit 2 
Value 7.000 1.082 76.083 
Δ with WBVT 0.517 0.101 6.500 
p 0.680 0.691 0.389 
Visit 3 
Value 7.517 1.183 82.583 
Δ in Follow-up -0.846 -0.229 7.000 
p 0.512 0.416 0.354 
Visit 4 Value 6.671 0.954 89.583 
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Table C.4. Serum biochemistry and bone turn-over marker parameters for the Leigh Syndrome MRCD cohort at each visit with 
changes between visits and associated p values from linear mixed models analysis. *p<0.05. 
 
  Alkaline 
Phosphatase (U/L) 
Calcium (mmol/L) Phosphate 
(mmol/L) 
Lactate (mmol/L) 
Visit 1 
Value 155.800 2.432 1.302 1.540 
Δ in Observation -2.200 -0.018 0.132 -0.180 
p 0.833 0.639 0.006* 0.627 
Visit 2 
Value 153.600 2.414 1.434 1.360 
Δ with WBVT 15.400 0.018 0.044 0.320 
p 0.157 0.639 0.291 0.393 
Visit 3 
Value 169.000 2.432 1.478 1.680 
Δ in Follow-up 2.800 -0.002 -0.214 0.120 
p 0.788 0.958 0.000* 0.745 
Visit 4 Value 171.800 2.430 1.264 1.800 
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  Urinary Deoxypyridoline: Creatine Ratio 
(nmol/mmol creatinine) 
Osteocalcin 
(nmol/L) 
Vitamin D 
(pmol/L) 
Visit 1 
Value 13.400 4.560 93.000 
Δ in Observation 6.820 0.100 -5.200 
p 0.099 0.904 0.583 
Visit 2 
Value 20.220 4.660 87.800 
Δ with WBVT -4.600 -1.160 10.400 
p 0.251 0.177 0.282 
Visit 4 
Value 15.620 3.500 98.200 
Δ in Follow-up 3.720 -1.500 -8.800 
p 0.349 0.088 0.359 
Visit 6 Value 19.340 2.000 89.400 
 
Note: Δ, change; WBVT, whole body vibration training. 
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Appendix D: Force plate Parameters 
 
Table D.1 CF Cohort 
Table D.2 Paediatric MRCD Cohort 
Table D.3 Adult MRCD Cohort 
Table D.4 Leigh Syndrome Cohort
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Table D.1. Fore plate parameters for the CF cohort at each visit with changes between visits and associated p values from linear mixed 
models analysis. *p<0.05. 
  CRT Time per 
test (s) 
CRT Time per 
test SDS 
CRT P max 
(W) 
CRT Ave P 
max rel (W/kg) 
CRT Ave P 
max rel SDS 
CRT F max 
(kN) 
Visit 1 
Value 1.1 -0.3 558.1 12.6 -0.4 1.6 
Δ in Observation  -0.1 0.3 46.7 -0.1 -0.1 -0.1 
p 0.025* 0.025* 0.205 0.867 0.732 0.165 
Visit 2 
Value 1.1 0.0 604.8 12.5 -0.5 1.5 
Δ with WVBT  -0.1 0.5 52.0 0.4 0.1 0.1 
p 0.001* 0.001* 0.159 0.539 0.747 0.028* 
Visit 3 
Value 1.0 0.5 656.8 12.9 -0.4 1.6 
Δ in Follow-up  0.0 -0.2 27.5 0.3 0.1 0.0 
p 0.234 0.234 0.465 0.617 0.762 0.907 
Visit 4 Value 1.0 0.3 684.4 13.2 -0.3 1.6 
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  CRT Ave F 
max/g (g) 
CRT Ave F 
max/g SDS 
S2LJ EFI (%) S2LJ EFI SDS S2LJ FE (%) S2LJ FE SDS 
Visit 1 
Value 1.5 0.1 95.9 -0.3 103.6 0.3 
Δ in Observation  0.0 -0.1 -0.4 0.0 -1.9 -0.2 
p 0.707 0.707 0.832 0.805 0.378 0.404 
Visit 2 
Value 1.5 -0.1 95.5 -0.4 101.7 0.2 
Δ with WVBT  0.0 0.3 -0.4 0.0 -4.2 -0.4 
p 0.370 0.371 0.840 0.778 0.053 0.055 
Visit 3 
Value 1.5 0.2 95.2 -0.4 97.5 -0.2 
Δ in Follow-up  0.0 0.1 -1.2 -0.1 1.4 0.1 
p 0.748 0.775 0.532 0.485 0.533 0.543 
Visit 4 Value 1.5 0.3 94.0 -0.5 98.9 -0.1 
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  S2LJ P max (kW) S2LJ P max rel 
(W/kg) 
S2LJ P max rel 
SDS 
S2LJ F max (kN) S2LJ F max/g (g) 
Visit 1 
Value 1.7 41.3 -0.4 0.9 2.3 
Δ in Observation  0.1 0.5 0.0 0.1 0.0 
p 0.010* 0.514 0.874 0.061 0.769 
Visit 2 
Value 1.9 41.8 -0.4 1.0 2.4 
Δ with WVBT  0.1 0.6 0.0 0.1 0.1 
p 0.061 0.495 0.943 0.027* 0.132 
Visit 3 
Value 1.9 42.4 -0.4 1.1 2.5 
Δ in Follow-up  0.1 0.2 -0.1 0.0 -0.1 
p 0.096 0.823 0.699 0.860 0.307 
Visit 4 Value 2.0 42.6 -0.5 1.1 2.4 
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  S2LJ F max/g SDS M1LJ F max (kN) M1LJ F max/g (g) M1LJ F max/g SDS 
Visit 1 
Value -0.5 10.9 2.8 -1.8 
Δ in Observation  0.1 0.1 -0.1 -0.4 
p 0.769 0.827 0.004* 0.004* 
Visit 2 
Value -0.5 10.9 2.6 -2.2 
Δ with WVBT  0.3 0.5 0.0 0.1 
p 0.132 0.050* 0.727 0.727 
Visit 3 
Value -0.1 11.4 2.7 -2.2 
Δ in Follow-up  -0.2 -0.2 -0.2 -0.5 
p 0.307 0.302 0.002* 0.002* 
Visit 4 Value -0.3 11.2 2.5 -2.7 
Note: Δ, change; WBVT, whole body vibration training; CRT, chair rise test; Ave V max, average maximum velocity; P max, maximum power; P 
max rel, maximum power in relation to body weight; Ave P max rel, average maximum power in relation to body weight; F max, maximum force; 
F max rel, maximum relative force in relation to body weight; F max/g, maximum relative force per force equivalent to body weight (Fg); Ave F 
max/g, average maximum relative force per force equivalent to body weight.
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Table D.2. Fore plate parameters for the paediatric MRCD cohort at each visit with changes between visits and associated p values from linear 
mixed models analysis. *p<0.05. 
  CRT Time 
per test (s) 
CRT V max 
(m/s) 
CRT Speed 
SDS 
CRT P max 
(W) 
CRT P max 
rel (W/kg) 
CRT Ave P 
max rel 
(W/kg) 
CRT Power 
SDS 
Visit 1 
Value 2.475 0.678 -6.410 234.059 8.221 7.134 -2.491 
Δ in Observation 0.055 0.045 0.250 42.079 1.290 0.483 0.127 
p 0.765 0.489 0.765 0.256 0.277 0.525 0.630 
Visit 2 
Value 2.530 0.722 -6.660 276.138 9.511 7.617 -2.363 
Δ with WBVT  -0.070 -0.036 -0.320 -27.246 -1.417 -0.696 -0.317 
p 0.703 0.578 0.703 0.457 0.234 0.363 0.238 
Visit 3 
Value 2.460 0.686 -6.341 248.892 8.094 6.921 -2.680 
Δ in Follow-up  -0.097 0.016 -0.440 3.069 -0.053 0.460 0.090 
p 0.601 0.809 0.601 0.933 0.964 0.545 0.733 
Visit 4 Value 2.363 0.702 -5.901 251.961 8.041 7.381 -2.590 
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CRT F max 
(kN) 
CRT F max 
rel (N/kg) 
CRT Ave F 
max rel (g) 
CRT Force 
SDS 
S2LJ EFI 
(%) 
S2LJ EFI 
SDS 
S2LJ FE 
(%) 
Visit 1 
Value 1.288 49.458 1.250 -2.201 38.215 -5.151 52.155 
Δ in Observation 0.013 -1.878 -0.021 -0.196 -1.652 -0.117 -1.813 
p 0.804 0.452 0.609 0.567 0.604 0.546 0.689 
Visit 2 
Value 1.302 47.580 1.230 -2.397 36.564 -5.269 50.342 
Δ with WBVT -0.119 -6.278 -0.054 -0.492 -1.543 -0.070 -4.508 
p 0.037* 0.019* 0.196 0.160 0.591 0.689 0.284 
Visit 3 
Value 1.182 41.302 1.176 -2.889 35.020 -5.338 45.834 
Δ in Follow-up  0.079 1.749 0.081 0.632 2.349 0.108 -2.729 
p 0.153 0.482 0.058 0.076 0.418 0.538 0.510 
Visit 4 Value 1.261 43.052 1.257 -2.257 37.370 -5.231 43.106 
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  S2LJ FE 
SDS 
S2LJ P max 
(kW) 
S2LJ P max 
rel (W/kg) 
S2LJ Power 
SDS 
S2LJ F max 
(kN) 
S2LJ F max 
rel (N/kg) 
S2LJ Force 
SDS 
Visit 1 
Value -4.523 0.475 16.993 -4.798 0.497 18.520 -1.799 
Δ in Observation -0.131 0.007 -0.493 -0.130 0.021 -0.624 -0.186 
p 0.745 0.812 0.672 0.570 0.662 0.787 0.788 
Visit 2 
Value -4.653 0.482 16.500 -4.928 0.518 17.897 -1.985 
Δ with WBVT  -0.391 0.018 -0.059 -0.119 0.019 0.312 0.093 
p 0.293 0.494 0.954 0.568 0.650 0.883 0.910 
Visit 3 
Value -5.045 0.500 16.441 -5.047 0.537 18.209 -1.892 
Δ in Follow-up  -0.311 0.023 1.043 0.172 0.100 4.242 1.272 
p 0.398 0.383 0.326 0.412 0.035* 0.067 0.067 
Visit 4 Value -5.356 0.523 17.485 -4.875 0.637 22.451 -0.620 
Note: Δ, change; WBVT, whole body vibration training; CRT, chair rise test; SDS, standard deviation score; Ave V max, average maximum 
velocity; P max, maximum power; P max rel, maximum power in relation to body weight; Ave P max rel, average maximum power in relation to 
body weight; F max, maximum force; F max rel, maximum relative force in relation to body weight; F max/g, maximum relative force per force 
equivalent to body weight (Fg); Ave F max/g, average maximum relative force per force equivalent to body weight; S2LJ, single two-leg jump; 
EFI, Esslinger Fitness Index; FE, force efficiency; V max, maximum velocity. 
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Table D.3. Fore plate parameters for the adult MRCD cohort at each visit with changes between visits and associated p values from linear mixed 
models analysis. *p<0.05. 
  CRT Time 
per test (s) 
CRT V max 
(m/s) 
CRT Speed 
SDS 
CRT P max 
(W) 
CRT P max 
rel (W/kg) 
CRT Ave P 
max rel 
(W/kg) 
CRT Power 
SDS 
Visit 1 
Value 2.806 0.650 -3.421 437.484 7.329 6.772 -2.684 
Δ in Observation -0.162 0.039 0.244 24.854 0.411 0.391 0.226 
p 0.179 0.283 0.274 0.491 0.398 0.355 0.343 
Visit 2 
Value 2.644 0.688 -3.177 498.338 7.741 7.163 -2.458 
Δ with WBVT  -0.269 -0.012 -0.113 -29.499 -0.203 0.004 -0.057 
p 0.030* 0.732 0.610 0.414 0.675 0.992 0.811 
Visit 3 
Value 2.375 0.676 -3.290 468.839 7.537 7.167 -2.515 
Δ in Follow-up  -0.201 0.046 0.253 75.600 1.093 0.542 0.506 
p 0.099 0.205 0.257 0.042* 0.030* 0.202 0.038* 
Visit 4 Value 2.174 0.722 -3.037 544.440 8.630 7.709 -2.009 
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  CRT F max 
(kN) 
CRT F max rel 
(N/kg) 
CRT Ave F 
max rel (g) 
CRT Force 
SDS 
S2LJ EFI (%) S2LJ EFI SDS 
Visit 1 
Value 1.205 19.652 1.205 2.924 53.775 -2.776 
Δ in Observation 0.001 -0.103 -0.001 -0.025 -1.268 -0.132 
p 0.950 0.796 0.963 0.935 0.506 0.258 
Visit 2 
Value 1.206 19.549 1.204 2.898 52.507 -2.907 
Δ with WBVT  0.034 0.696 0.032 0.346 -0.357 -0.006 
p 0.142 0.088 0.110 0.266 0.854 0.959 
Visit 3 
Value 1.240 20.245 1.236 3.244 52.150 -2.914 
Δ in Follow-up 0.063 1.155 0.039 0.732 1.385 0.109 
p 0.009* 0.006* 0.052 0.022* 0.478 0.359 
Visit 4 Value 1.303 21.400 1.275 3.976 53.535 -2.805 
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  S2LJ FE (%)  S2LJ FE SDS S2LJ P max (kW) S2LJ P max rel 
(W/kg) 
S2LJ Power SDS 
Visit 1 
Value 65.805 -3.419 1.498 23.442 -2.957 
Δ in Observation -0.896 -0.090 -0.082 -0.898 -0.118 
p 0.636 0.636 0.280 0.346 0.439 
Visit 2 
Value 64.909 -3.509 1.416 22.544 -3.075 
Δ with WBVT  -2.429 -0.243 -0.012 -0.083 -0.042 
p 0.214 0.214 0.881 0.932 0.789 
Visit 3 
Value 62.481 -3.752 1.404 22.461 -3.117 
Δ in Follow-up  3.125 0.312 0.42 0.612 0.097 
p 0.113 0.113 0.590 0.529 0.536 
Visit 4 Value 65.606 -3.439 1.446 23.073 -3.020 
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  S2LJ F max 
(kN) 
S2LJ F max rel 
(N/kg) 
S2LJ Force 
SDS 
M1LJ F max 
(kN) 
M1LJ F max 
rel (g) 
M1LJ Force 
SDS 
Visit 1 
Value 1.275 20.044 -1.230 11.895 1.937 -4.545 
Δ in Observation -0.022 -0.244 -0.087 -0.208 -0.057 -0.191 
p 0.622 0.663 0.603 0.632 0.436 0.436 
Visit 2 
Value 1.253 19.800 -1.317 11.686 1.879 -4.736 
Δ with WBVT  0.038 0.689 0.208 -0.127 0.024 0.080 
p 0.416 0.233 0.232 0.761 0.734 0.734 
Visit 3 
Value 1.291 20.490 -1.110 11.560 1.903 -4.656 
Δ in Follow-up  -0.036 -0.630 -0.187 0.874 0.087 0.289 
p 0.438 0.275 0.282 0.051 0.241 0.241 
Visit 4 Value 1.255 19.860 -1.296 12.433 1.990 -4.367 
Note: Δ, change; WBVT, whole body vibration training; CRT, chair rise test; Ave V max, average maximum velocity; SDS, standard deviation 
score; P max, maximum power; P max rel, maximum power in relation to body weight; F max, maximum force; F max rel, maximum relative 
force in relation to body weight; F max/g, maximum relative force per force equivalent to body weight (Fg); S2LJ, single two-leg jump; EFI, 
Esslinger Fitness Index; FE, force efficiency; V max, maximum velocity; M1LH, multiple one-leg hop. 
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Table D.4. Fore plate parameters for the Leigh Syndrome MRCD cohort at each visit with changes between visits and associated p values from 
linear mixed models analysis. *p<0.05. 
  CRT Time per 
test (s) 
CRT V max 
(m/s) 
CRT Speed 
SDS 
CRT P max 
(W) 
CRT P max rel 
(W/kg) 
CRT Ave P 
max rel (W/kg) 
Visit 1 
Value 2.741 0.630 -4.081 326.370 7.190 6.395 
Δ in Observation 0.354 0.010 -0.702 31.759 1.056 0.094 
p 0.098 0.907 0.359 0.650 0.459 0.919 
Visit 2 
Value 3.095 0.640 -4.783 358.129 8.246 6.489 
Δ with WBVT  -0.173 -0.069 0.001 -85.541 -1.675 -0.960 
p 0.398 0.413 0.999 0.235 0.249 0.313 
Visit 3 
Value 2.922 0.570 -4.782 272.589 6.571 5.529 
Δ in Follow-up  -0.196 0.038 0.210 76.034 0.522 0.805 
p 0.341 0.652 0.779 0.288 0.712 0.395 
Visit 4 Value 2.726 0.608 -4.572 348.623 7.093 6.334 
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  CRT Power SDS CRT F max (kN) CRT F max rel 
(N/kg) 
CRT Ave F max 
rel (Fg) 
CRT Force SDS 
Visit 1 
Value -2.572 1.217 39.935 1.182 -1.776 
Δ in Observation 0.085 -0.029 -2.340 -0.036 -0.228 
p 0.804 0.617 0.2490 0.373 0.536 
Visit 2 
Value -2.487 1.188 37.595 1.146 -2.004 
Δ with WBVT  -0.504 -0.064 -4.885 -0.047 -0.364 
p 0.160 0.275 0.163 0.245 0.329 
Visit 3 
Value -2.992 1.124 32.710 1.098 -2.369 
Δ in Follow-up  0.295 0.136 1.941 0.151 1.106 
p 0.398 0.033* 0.566 0.002* 0.009* 
Visit 4 Value -2.697 1.260 34.651 1.249 -1.263 
Note: Δ, change; WBVT, whole body vibration training; CRT, chair rise test; Ave V max, average maximum velocity; SDS, standard deviation score; P max, 
maximum power; P max rel, maximum power in relation to body weight; F max, maximum force; F max rel, maximum relative force in relation to body 
weight; F max/g, maximum relative force per force equivalent to body weight (Fg); S2LJ, single two-leg jump; EFI, Esslinger Fitness Index; FE, force 
efficiency; V max, maximum velocity; M1LH, multiple one-leg hop. 
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Appendix E: Exercise Parameters 
 
Table E.1 CF Cohort 
Table E.2 Paediatric MRCD Cohort 
Table E.3 Adult MRCD 6MWT 
Table E.4 Leigh Syndrome Cohort 
Table E.5 Adult MRCD CPET 
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Table E.1. Cardiopulmonary exercise test parameters for the CF cohort at each visit with changes between visits and associated p values from 
linear mixed models analysis. *p<0.05. 
  Pre-exercise 
VO2 (L/min) 
Pre-exercise 
VO2/kg 
(ml/kg/min) 
Pre-exercise 
HR (bpm) 
Pre-exercise 
HR % 
Predicted (%) 
Pre-exercise O2 
Pulse (ml/beat) 
Pre-exercise 
VCO2 (L/min) 
Visit 1 
Value 0.3 7.1 96.8 46.7 3.0 0.3 
Δ in Observation  0.0 0.3 4.8 2.5 0.5 0.1 
p 0.203 0.629 0.253 0.226 0.116 0.061 
Visit 2 
Value 0.3 7.5 101.6 49.2 3.5 0.3 
Δ with WVBT  0.0 -0.6 -7.3 -3.4 -0.3 0.0 
p 0.567 0.375 0.086 0.095 0.400 0.279 
Visit 3 
Value 0.3 6.9 94.3 45.7 3.2 0.3 
Δ in Follow-up  0.0 -1.2 -9.0 -4.2 -0.2 -0.1 
p 0.123 0.079 0.039* 0.045* 0.522 0.086 
Visit 4 Value 0.3 5.6 85.2 41.5 3.0 0.2 
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  Pre-exercise 
RQ 
Pre-exercise 
VE (L/min) 
Pre-exercise 
VE/VO2 
Pre-exercise 
VE/VCO2 
Pre-exercise 
Borg Score 
AT VO2 
(L/min) 
AT VO2 (% 
Predicted) 
Visit 1 
Value 1.0 10.3 40.3 41.3 0.6 1.6 135.7 
Δ in Observation  0.0 1.0 -0.6 -1.6 0.1 -0.1 -7.4 
p 0.669 0.378 0.831 0.478 0.739 0.425 0.525 
Visit 2 
Value 1.0 11.3 39.6 39.7 0.7 1.5 128.2 
Δ with WVBT  0.0 -0.2 2.3 2.0 0.3 0.0 -11.5 
p 0.836 0.851 0.424 0.365 0.442 0.955 0.346 
Visit 3 
Value 1.0 11.1 41.9 41.8 0.9 1.5 116.7 
Δ in Follow-up  0.0 -1.4 -0.4 1.7 -0.2 0.0 3.4 
p 0.329 0.244 0.881 0.444 0.479 0.949 0.764 
Visit 4 Value 1.0 9.7 41.5 43.5 0.7 1.5 120.2 
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  AT VO2 
(ml/kg/min) 
AT VO2 
(ml/kg/min) % 
Predicted VO2 
(%) 
AT VO2 as a % 
of Peak VO2 
(%) 
AT HR (bpm) AT HR % 
Predicted (%) 
AT O2 Pulse 
(ml/beat) 
Visit 1 
Value 36.5 89.2 80.0 165.9 80.4 9.2 
Δ in Observation  -5.3 -8.8 -0.3 -4.5 -2.0 4.5 
p 0.075 0.223 0.953 0.301 0.350 0.154 
Visit 2 
Value 31.2 80.4 79.7 161.4 78.4 13.8 
Δ with WVBT  -0.4 -4.9 -4.3 -1.8 -0.6 -4.4 
p 0.900 0.509 0.385 0.679 0.777 0.188 
Visit 3 
Value 30.8 75.5 75.5 159.5 77.8 9.4 
Δ in Follow-up  -0.2 1.3 3.4 -0.5 -0.1 -0.2 
p 0.954 0.857 0.466 0.913 0.972 0.995 
Visit 4 Value 30.7 76.8 78.8 159.0 77.7 9.3 
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  AT VCO2 (L/min) AT RQ AT VE (L/min) AT VE/VO2 AT VE/VCO2 
Visit 1 
Value 1.6 1.0 44.1 28.5 28.9 
Δ in Observation  -0.1 0.0 -1.4 1.5 0.7 
p 0.478 0.019* 0.750 0.067 0.286 
Visit 2 
Value 1.5 1.0 42.7 30.0 29.6 
Δ with WVBT  0.0 0.0 -0.8 0.1 0.9 
p 0.869 0.432 0.858 0.866 0.205 
Visit 3 
Value 1.4 1.0 41.9 30.2 30.5 
Δ in Follow-up  0.0 0.0 0.3 -0.5 -0.6 
p 0.989 0.395 0.947 0.542 0.411 
Visit 4 Value 1.4 1.0 42.2 29.7 30.0 
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  Peak VO2 (L/min) Peak VO2 (L/min) % 
Predicted (%) 
Peak VO2 
(ml/kg/min) 
Peak VO2 
(ml/kg/min) % 
Predicted (%) 
Visit 1 
Value 1.9 104.2 45.7 114.9 
Δ in Observation  -0.1 -8.7 -4.3 -9.8 
p 0.169 0.033* 0.030* 0.035* 
Visit 2 
Value 1.8 95.6 41.4 105.0 
Δ with WVBT  0.1 -0.7 0.2 0.3 
p 0.517 0.855 0.925 0.940 
Visit 3 
Value 1.8 94.8 41.6 105.4 
Δ in Follow-up  0.0 -3.2 -1.3 -3.8 
p 0.955 0.430 0.495 0.419 
Visit 4 Value 1.8 91.6 40.3 101.6 
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  Peak HR 
(bpm) 
Peak HR % 
Predicted (%) 
Peak O2 Pulse 
(ml/beat) 
Peak O2 Pulse 
% Predicted 
(%) 
Peak VCO2 
(L/min) 
Peak RQ  
Visit 1 
Value 181.6 87.7 10.4 111.9 1.9 1.0 
Δ in Observation  1.2 0.8 2.6 5.6 0.0 0.1 
p 0.728 0.662 0.315 0.716 0.631 0.020* 
Visit 2 
Value 182.8 88.5 13.0 117.5 1.9 1.1 
Δ with WVBT  -3.7 -1.6 -2.7 -16.5 0.0 -0.0 
p 0.301 0.361 0.305 0.294 0.982 0.093 
Visit 3 
Value 179.1 86.9 10.3 101.0 1.9 1.0 
Δ in Follow-up  1.9 1.2 -0.1 -6.2 0.0 0.0 
p 0.621 0.509 0.968 0.704 0.999 0.795 
Visit 4 Value 181.0 88.1 10.2 94.8 1.9 1.0 
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  Peak VE (L/min) Peak VE/VO2  Peak VE/VCO2  Exercise Time (mins) 
Visit 1 
Value 55.2 29.7 29.2 11.9 
Δ in Observation  0.9 2.7 1.4 -0.3 
p 0.787 0.001* 0.011* 0.312 
Visit 2 
Value 56.1 32.4 30.6 11.6 
Δ with WVBT  0.6 -0.6 0.6 0.2 
p 0.848 0.468 0.236 0.598 
Visit 3 
Value 56.7 31.8 31.2 11.8 
Δ in Follow-up  0.65 0.2 -0.2 0.1 
p 0.890 0.817 0.758 0.707 
Visit 4 Value 57.1 32.0 31.0 11.9 
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  Peak Borg 
Score 
Recovery VO2 
(L/min) 
Recovery VO2 
(ml/kg/min) 
Recovery HR 
(bpm) 
Recovery HR 
% predicted 
(%) 
Recovery O2 
Pulse (ml/beat) 
Visit 1 
Value 7.0 0.4 8.5 108.5 52.5 3.2 
Δ in Observation  0.0 0.0 -1.0 -1.4 -0.7 0.2 
p 0.956 0.252 0.075 0.662 0.671 0.511 
Visit 2 
Value 7.0 0.3 7.6 107.1 51.8 3.5 
Δ with WVBT  0.3 0.0 -0.3 -0.9 -0.3 -0.4 
p 0.658 0.971 0.589 0.778 0.864 0.221 
Visit 3 
Value 7.3 0.3 7.3 106.2 51.5 3.0 
Δ in Follow-up  0.2 0.0 -0.5 1.0 0.6 -0.2 
p 0.727 0.493 0.319 0.746 0.681 0.661 
Visit 4 Value 7.5 0.3 6.8 107.2 52.2 2.9 
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  Recovery 
VCO2 (L/min) 
Recovery RQ Recovery VE 
(L/min) 
Recovery 
VE/VO2 
Recovery 
VE/VCO2 
Recovery Borg 
Score 
Visit 1 
Value 0.4 1.1 13.4 40.0 38.5 3.1 
Δ in Observation  0.0 0.0 -0.1 2.7 -0.1 -0.3 
p 0.783 0.052 0.964 0.164 0.916 0.621 
Visit 2 
Value 0.4 1.1 13.4 42.7 38.4 2.8 
Δ with WVBT  0.0 0.0 0.3 1.6 1.6 -0.1 
p 0.781 0.786 0.767 0.392 0.204 0.809 
Visit 3 
Value 0.4 1.1 13.7 44.3 40.0 2.7 
Δ in Follow-up  0.0 0.0 0.0 2.9 2.6 0.5 
p 0.546 0.682 0.978 0.122 0.047* 0.331 
Visit 4 Value 0.3 1.1 13.7 47.2 42.6 3.2 
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  Pre-exercise 
SBP 
Pre-exercise 
DBP 
Pre-exercise 
SpO2 
Peak SBP Peak DBP Peak SpO2 
Visit 1 
Value 107.1 66.9 97.5 124.5 68.1 95.9 
Δ in Observation  -0.5 -1.8 -0.1 6.2 3/7 0.2 
p 0.793 0.544 0.890 0.089 0.157 0.685 
Visit 2 
Value 106.6 65.1 97.4 130.7 71.8 96.1 
Δ with WVBT  2.2 1.1 -0.1 -2.9 0.5 0.6 
p 0.235 0.711 0.890 0.379 0.842 0.181 
Visit 3 
Value 108.8 66.1 97.4 127.9 72.2 96.7 
Δ in Follow-up  3.2 6.5 -0.1 5.0 2.5 -0.7 
p 0.091 0.031* 0.917 0.132 0.292 0.178 
Visit 4 Value 112.0 72.7 97.3 132.9 74.8 96.0 
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  Recovery SBP Recovery DBP Recovery SpO2 
Visit 1 
Value 110.9 64.7 96.9 
Δ in Observation  2.3 3.4 0.1 
p 0.361 0.273 0.722 
Visit 2 
Value 113.1 68.1 97.1 
Δ with WVBT  2.0 0.2 0.1 
p 0.416 0.942 0.722 
Visit 3 
Value 111.2 68.3 97.2 
Δ in Follow-up  5.8 3.1 -0.1 
p 0.024* 0.297 0.725 
Visit 4 Value 117.0 72.7 97.1 
Note: Δ, change; WBVT, whole body vibration training; VO2, oxygen uptake; HR, heart rate; bpm, beats per minute; O2, oxygen; VCO2, carbon 
dioxide production; RQ, respiratory quotient; VE, minute ventilation; VE/VO2, ventilator equivalent of oxygen; VE/VCO2, ventilator equivalent 
of carbon dioxide; AT, anaerobic threshold. 
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Table E.2. Six-minute walk test parameters for the paediatric MRCD cohort at each visit with changes between visits and associated p values 
from linear mixed models analysis. *p<0.05. 
  6MWT 
Distance (m) 
6MWT Percent 
Predicted (%) 
6MWT 
Baseline HR 
(bpm) 
6MWT 
Baseline Borg 
Score 
6MWT 
Baseline SBP 
(mmHg) 
6MWT 
Baseline DBP 
(mmHg) 
Visit 1 
Value 319.243 52.171 96.040 0.571 104.1 68.1 
Δ in Observation -12.000 -2.685 7.817 0.143 5.0 -5.8 
p 0.380 0.214 0.149 0.700 0.130 0.279 
Visit 2 
Value 307.243 49.485 103.857 0.714 109.1 62.3 
Δ with WBVT  -8.643 -1.754 -10.429 -0.143 -4.6 6.3 
p 0.525 0.411 0.011* 0.700 0.113 0.189 
Visit 3 
Value 298.600 47.731 93.429 0.571 104.6 68.6 
Δ in Follow- 10.443 1.162 10.259 -0.143 2.4 -2.3 
p 0.443 0.584 0.017* 0.700 0.418 0.643 
Visit 4 Value 309.043 48.893 103.668 0.429 107.0 66.3 
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  6MWT 
Baseline SpO2 
(%) 
6MWT Post 
HR (bpm) 
6MWT Post 
Borg Score 
6MWT Post 
SBP (mmHg) 
6MWT Post 
DBP (mmHg) 
6MWT Post 
SpO2 (%) 
Visit 1 
Value 99 106.7 3.0 116.6 71.3 99 
Δ in Observation -1 26.8 -0.3 0.4 7.5 -2 
p 0.486 0.037* 0.437 0.938 0.187 0.276 
Visit 2 
Value 98 133.429 2.7 117.0 78.8 97 
Δ with WBVT  0 -27.9 -0.1 0.0 -5.2 1 
p 0.687 0.015* 0.696 0.998 0.259 0.534 
Visit 3 
Value 98 105.571 2.6 117.0 73.6 98 
Δ in Follow-up  0 23.0 -0.4 -1.8 -3.8 0 
p 0.759 0.038* 0.249 0.663 0.379 0.920 
Visit 4 Value 98 129 2.1 115.2 69.8 98 
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  6MWT Recovery 
HR (bpm) 
6MWT Recovery 
Borg Score 
6MWT Recovery 
SBP (mmHg) 
6MWT Recovery 
DBP (mmHg) 
6MWT Recovery 
SpO2 (%) 
Visit 1 
Value 112.6 1.8 106.2 67.4 98 
Δ in Observation -1.2 0.3 1.9 -2.0 1 
p 0.875 0.569 0.645 0.688 0.755 
Visit 2 
Value 111.4 2.1 108.1 65.4 99 
Δ with WBVT  -7.9 -1.3 0.8 -0.1 0 
p 0.148 0.018* 0.832 0.982 0.854 
Visit 3 
Value 103.6 0.9 108.9 65.3 99 
Δ in Follow-up  3.8 0.3 3.1 -0.8 -1 
p 0.499 0.569 0.385 0.856 0.497 
Visit  4 Value 107.3 1.1 112.0 64.5 98 
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Table E.3. Six-minute walk test parameters for the adult MRCD cohort at each visit with changes between visits and associated p values from 
linear mixed models analysis. *p<0.05. 
  6MWT 
Distance (m) 
6MWT % 
Predicted (%) 
6MWT 
Baseline HR 
(bpm) 
6MWT 
Baseline Borg 
Score 
6MWT 
Baseline SBP 
(mmHg) 
6MWT 
Baseline DBP 
(mmHg) 
Visit 1 
Value 413.042 71.303 86.000 1.177 126.083 83.167 
Δ in Observation -11.225 -1.307 -3.721 -0.093 -6.161 -8.195 
p 0.466 0.588 0.388 0.653 0.057 0.002 
Visit 2 
Value 401.817 69.996 82.279 1.083 119.922 74.972 
Δ with WBVT  19.175 3.258 -4.898 -0.417 5.328 0.028 
p 0.216 0.182 0.356 0.110 0.098 0.991 
Visit 3 
Value 420.992 73.254 77.382 0.667 125.250 75.000 
Δ in Follow-up  4.133 0.641 3.064 0.167 -2.096 1.710 
p 0.787 0.790 0.564 0.519 0.510 0.492 
Visit 4 Value 425.125 73.895 80.446 0.833 123.154 76.710 
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  6MWT 
Baseline SpO2 
(%) 
6MWT Post 
HR (bpm) 
6MWT Post 
Borg Score 
6MWT Post 
SBP (mmHg) 
6MWT Post 
DBP (mmHg) 
6MWT Post 
SpO2 (%) 
Visit 1 
Value 98 106.8 2.7 138.8 84.4 98 
Δ in Observation 0 -1.4 -0.2 -0.4 -2.2 0 
p 0.514 0.797 0.610 0.287 0.193 0.673 
Visit 2 
Value 98 105.4 2.6 138.4 82.3 98 
Δ with WBVT  0 0.7 0.2 5.3 1.8 1 
p 0.259 0.894 0.582 0.134 0.243 0.201 
Visit 3 
Value 98 106.1 2.8 143.7 84.1 99 
Δ in Follow-up  0 -2.2 -0.2 -7.0 -1.6 0 
p 0.300 0.688 0.582 0.045* 0.295 0.653 
Visit 4 Value 98 103.9 2.6 136.7 82.5 99 
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  6MWT Recovery 
HR (bpm) 
6MWT Recovery 
Borg Score 
6MWT Recovery 
SBP (mmHg) 
6MWT Recovery 
DBP (mmHg) 
6MWT Recovery 
SpO2 (%) 
Visit 1 
Value 86.9 1.4 127.7 78.9 97 
Δ in Observation -2.7 0.0 -6.2 -2.8 1 
p 0.410 0.952 0.059 0.386 0.106 
Visit 2 
Value 84.2 1.4 121.5 76.2 98 
Δ with WBVT  0.7 -0.1 1.9 -1.5 0 
p 0.832 0.764 0.547 0.635 0.915 
Visit 3 
Value 84.9 1.3 123.4 74.7 98 
Δ in Follow-up  3.1 -0.3 -1.8 0.5 -1 
p 0.346 0.371 0.580 0.892 0.349 
Visit 4 Value 88.0 1.1 121.7 75.1 97 
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Table E.4. Six-minute walk test parameters for the Leigh Syndrome MRCD cohort at each visit with changes between visits and associated p 
values from linear mixed models analysis. *p<0.05. 
  6MWT 
Distance (m) 
Leigh 
6MWT Percent 
Predicted 
6MWT 
Baseline HR 
(bpm) 
6MWT 
Baseline Borg 
Score 
6MWT 
Baseline SBP 
(mmHg) 
6MWT 
Baseline DBP 
(mmHg) 
Visit 1 
Value 341.580 56.765 94.5 0.4 113.1 78.7 
Δ in Observation -66.700 -10.794 6.1 -0.2 -0.5 14.2 
p 0.035* 0.023* 0.282 0.387 0.906 0.014* 
Visit 2 
Value 274.880 45.971 100.6 0.2 112.6 64.4 
Δ with WBVT  24.020 3.306 -5.4 0.0 -1.8 7.4 
p 0.408 0.439 0.259 1.000 0.628 0.128 
Visit 4 
Value 298.900 49.278 95.2 0.2 110.8 71.8 
Δ in Follow-up  18.500 2.753 3.6 0.0 5.6 1.0 
p 0.521 0.518 0.443 1.000 0.150 0.829 
Visit 6 Value 317.400 52.031 98.8 0.2 116.4 72.8 
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  6MWT 
Baseline SpO2 
(%) 
6MWT Post 
HR (bpm) 
6MWT Post 
Borg Score 
6MWT Post 
SBP (mmHg) 
6MWT Post 
DBP (mmHg) 
6MWT Post 
SpO2 (%) 
Visit 1 
Value 99 123.9 2.8 119.4 74.4 99 
Δ in Observation 0 -13.9 -0.6 -10.6 -3.8 -1 
p 0.781 0.360 0.068 0.342 0.613 0.611 
Visit 2 
Value 99 110.0 2.2 108.8 70.6 98 
Δ with WBVT  0 -10.4 0.8 17.8 1.8 0 
p 1.000 0.413 0.020* 0.071 0.762 0.936 
Visit 3 
Value 99 99.6 3.0 126.6 72.4 98 
Δ in Follow-up  0 20.4 -0.6 0.2 0.0 0 
p 0.781 0.128 0.068 0.974 1.000 0.680 
Visit 4 Value 99 120.0 2.4 126.8 72.4 98 
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  6MWT Recovery 
HR (bpm) 
6MWT Recovery 
Borg Score 
6MWT Recovery 
SBP (mmHg) 
6MWT Recovery 
DBP (mmHg) 
6MWT Recovery 
SpO2 (%) 
Visit 1 
Value 112.6 1.2 122.1 75.6 99 
Δ in Observation -8.0 0.2 -12.0 -7.7 0 
p 0.255 0.584 0.093 0.234 0.441 
Visit 2 
Value 104.6 1.4 110.1 67.9 99 
Δ with WBVT  0.8 -1.0 5.9 -3.1 0 
p 0.880 0.016* 0.373 0.609 0.794 
Visit 3 
Value 105.4 0.4 116.0 64.8 99 
Δ in Follow-up  -0.8 0.4 4.0 0.4 0 
p 0.880 0.283 0.467 0.937 0.794 
Visit 4 Value 104.6 0.8 120.0 65.2 99 
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Table E.5. Cardiopulmonary exercise test parameters for the adult MRCD cohort at each visit with changes between visits and associated p 
values from linear mixed models analysis. *p<0.05. 
  Pre-exercise 
VO2 (L/min) 
Pre-exercise 
VO2/kg 
(ml/kg/min) 
Pre-exercise 
HR (bpm) 
Pre-exercise 
HR % 
Predicted (%) 
Pre-exercise O2 
Pulse (ml/beat) 
Pre-exercise 
VCO2 (L/min) 
Visit 1 
Value 0.249 4.679 96 53.0 2.6 0.233 
Δ in Observation -0.004 -0.388 -9 -3.8 0.2 -0.026 
p 0.889 0.465 0.141 0.273 0.585 0.266 
Visit 2 
Value 0.246 4.292 88 49.2 2.8 0.207 
Δ with WBVT  -0.008 -0.167 -2 -0.3 -0.1 -0.009 
p 0.738 0.714 0.773 0.928 0.723 0.660 
Visit 3 
Value 0.238 4.125 86 49.0 2.7 0.199 
Δ in Follow-up  -0.009 -0.052 1.000 0.9 -0.1 -0.003 
p 0.702 0.909 0.840 0.775 0.761 0.889 
Visit 4 Value 0.229 4.073 87 49.8 2.6 0.196 
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Pre-exercise 
RQ 
Pre-exercise 
VE (L/min) 
Pre-exercise 
VE/VO2 
Pre-exercise 
VE/VCO2 
Pre-exercise 
Borg Score 
AT VO2 
(L/min) 
Visit 1 
Value 0.922 10.344 42.0 45.8 3.1 0.7 
Δ in Observation -0.079 -1.402 -4.4 -1.3 -1.7 0.1 
p 0.053 0.286 0.158 0.684 0.005* 0.275 
Visit 2 
Value 0.843 8.943 37.6 44.5 1.4 0.8 
Δ with WBVT  -0.016 0.129 0.6 1.9 -0.3 0.0 
p 0.651 0.909 0.807 0.484 0.533 0.814 
Visit 3 
Value 0.827 9.071 38.3 46.4 1.1 0.8 
Δ in Follow-up  0.033 -0.071 1.6 0.5 -0.4 -0.2 
p 0.351 0.949 0.543 0.859 0.440 0.076 
Visit 4 Value 0.860 9.000 39.9 46.8 0.8 0.6 
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  AT VO2 % 
Predicted (%) 
AT VO2 
(ml/kg/min) 
AT VO2 as a % 
of Peak VO2 
(%) 
AT HR (bpm) AT HR % 
Predicted (%) 
AT O2 Pulse 
(ml/beat) 
Visit 1 
Value 34.9 12.2 69.8 132.2 73.9 5.0 
Δ in Observation 5.7 1.7 5.4 -6.0 -2.9 0.9 
p 0.257 0.247 0.480 0.289 0.348 0.170 
Visit 2 
Value 40.5 13.8 75.2 126.1 71.0 5.9 
Δ with WBVT  2.0 -0.1 2.1 2.3 1.9 0.2 
p 0.630 0.929 0.760 0.632 0.466 0.755 
Visit 4 
Value 42.6 13.7 77.3 128.4 72.9 6.1 
Δ in Follow-up  -5.3 -2.5 -5.7 -4.2 -2.4 -1.1 
p 0.246 0.068 0.424 0.414 0.390 0.076 
Visit 6 Value 37.2 11.2 71.5 124.2 70.5 5.0 
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  AT VCO2 
(L/min) 
AT RQ AT VE (L/min) AT VE/VO2 AT VE/VCO2 AT Watts (W) 
Visit 1 
Value 0.7 1.0 22.8 36.2 37.0 34.7 
Δ in Observation 0.1 0.0 1.7 -2.6 -3.7 8.7 
p 0.246 0.260 0.623 0.310 0.143 0.144 
Visit 2 
Value 0.8 1.0 24.5 33.6 33.3 43.4 
Δ with WBVT  0.0 0.0 1.7 0.1 0.7 -1.0 
p 0.899 0.428 0.565 0.947 0.724 0.841 
Visit 3 
Value 0.8 1.0 26.2 33.8 34.1 42.4 
Δ in Follow-up  -0.1 0.0 -3.9 3.0 2.4 -6.0 
p 0.079 0.319 0.233 0.212 0.285 0.266 
Visit 4 Value 0.6 1.0 22.3 36.8 36.5 36.4 
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  AT Watts (% 
Predicted) 
AT Watts 
(W/kg) 
AT Watts as a 
% of Peak 
Watts (%) 
AT % Exercise 
Time (%) 
Peak VO2 
(L/min) 
Peak VO2 % 
Predicted (%) 
Visit 1 
Value 24.9 0.7 55.0 56.0 1.0 54.2 
Δ in Observation 5.5 0.1 5.6 -2.5 0.0 1.1 
p 0.164 0.276 0.429 0.818 0.880 0.840 
Visit 2 
Value 30.4 0.8 60.6 53.5 1.0 55.3 
Δ with WBVT  0.2 0.0 2.7 -0.4 0.1 1.2 
p 0.944 0.945 0.650 0.964 0.651 0.788 
Visit 3 
Value 30.6 0.8 63.3 53.1 1.1 56.5 
Δ in Follow-up  -3.2 -0.1 -5.9 -8.4 -0.1 -2.4 
p 0.365 0.314 0.364 0.410 0.215 0.597 
Visit 4 Value 27.4 0.7 57.4 44.7 1.0 54.1 
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  Peak VO2 
(ml/kg/min) 
Peak HR 
(bpm) 
Peak HR % 
Predicted (%) 
Peak O2 Pulse 
(ml/beat) 
Peak O2 Pulse 
% Predicted 
(%) 
Peak VCO2 
(L/min) 
Visit 1 
Value 17.8 154.2 87.7 6.2 37.1 1.2 
Δ in Observation -0.3 -1.8 -1.7 0.2 1.2 0.0 
p 0.842 0.799 0.636 0.721 0.765 0.977 
Visit 2 
Value 17.5 152.4 86.0 6.4 38.3 1.2 
Δ with WBVT  0.9 -3.0 -0.9 0.0 -0.2 0.0 
p 0.519 0.625 0.786 0.937 0.953 0.858 
Visit 3 
Value 18.4 149.4 85.1 6.4 38.1 1.2 
Δ in Follow-up -1.5 2.1 1.0 -0.2 -1.2 -0.0 
p 0.278 0.726 0.748 0.695 0.727 0.945 
Visit 4 Value 16.9 151.6 86.1 6.1 36.9 1.2 
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  Peak RQ  Peak VE 
(L/min) 
Peak VE/VO2  Peak VE/VCO2  Peak Watts 
(W) 
Peak Watts (% 
Predicted) 
Visit 1 
Value 1.3 340.6 42.9 36.7 69.3 50.3 
Δ in Observation 0.0 -1.4 2.8 -3.0 0.9 0.3 
p 0.559 0.791 0.555 0.162 0.744 0.922 
Visit 2 
Value 1.3 39.2 45.7 33.7 70.3 50.6 
Δ with WBVT  0.0 0.4 0.6 1.6 -1.3 -0.5 
p 0.979 0.930 0.887 0.383 0.600 0.839 
Visit 3 
Value 1.3 39.6 46.3 35.3 69.0 50.1 
Δ in Follow-up  0.1 0.3 5.1 1.0 -0.6 0.0 
p 0.261 0.953 0.213 0.576 0.815 0.994 
Visit 4 Value 1.4 39.9 51.4 36.3 68.4 50.1 
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  Peak Watts 
(W/kg) 
Exercise Time 
(mins) 
Peak Borg 
Score 
Recovery VO2 
(L/min) 
Recovery VO2 
(ml/kg/min) 
Recovery HR 
(bpm) 
Visit 1 
Value 1.2 5.7 7.4 0.4 6.4 111.3 
Δ in Observation 0.0 0.4 -0.1 -0.1 -0.7 -12.9 
p 0.684 0.241 0.941 0.263 0.334 0.013* 
Visit 2 
Value 1.2 6.1 7.3 0.3 5.7 98.4 
Δ with WBVT  0.0 0.0 -0.7 0.0 -0.2 0.4 
p 0.918 0.881 0.524 0.847 0.727 0.915 
Visit 3 
Value 1.2 6.1 6.6 0.3 5.5 98.9 
Δ in Follow-up  0.0 -0.2 -0.6 0.0 -0.6 1.0 
p 0.894 0.431 0.626 0.439 0.388 0.804 
Visit 4 Value 1.2 5.9 6.0 0.3 4.9 99.9 
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  Recovery 
HR % 
predicted 
(%) 
Recovery 
O2 Pulse 
(ml/beat) 
Recovery 
VCO2 
(L/min) 
Recovery 
RQ 
Recovery 
VE (L/min) 
Recovery 
VE/VO2 
Recovery 
VE/VCO2 
Recovery 
Borg Score 
Visit 1 
Value 62.7 3.3 0.4 1.1 16.6 48.1 45.9 3.0 
Δ Observation -7.3 0.1 -0.1 0.0 -2.8 -2.6 -2.4 -0.3 
p 0.009* 0.873 0.307 0.824 0.188 0.376 0.272 0.717 
Visit 2 
Value 55.4 3.2 0.3 1.1 13.8 45.6 43.6 2.7 
Δ with WBVT  0.7 -0.1 0.0 0.1 0.7 5.9 1.8 -0.4 
p 0.730 0.822 0.912 0.101 0.687 0.029* 0.321 0.574 
Visit 3 
Value 56.2 3.1 0.3 1.2 14.5 51.4 45.3 2.3 
Δ in Follow-up  0.7 -0.4 0.0 0.0 -0.3 -0.1 0.7 1.1 
p 0.738 0.355 0.531 0.486 0.856 0.954 0.707 0.227 
Visit 4 Value 56.9 2.8 0.3 1.1 14.2 51.3 46.0 3.4 
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  Pre-exercise 
SBP (mmHg) 
Pre-exercise 
DBP (mmHg) 
Peak SBP 
(mmHg) 
Peak DBP 
(mmHg) 
Recovery SBP 
(mmHg) 
Recovery DBP 
(mmHg) 
Visit 1 
Value 120.9 85.2 165.0 89.6 135.5 82.9 
Δ in Observation 0.8 -10.1 -13.4 -7.0 -6.1 -9.1 
p 0.861 0.033* 0.076 0.277 0.261 0.091 
Visit 2 
Value 121.7 75.1 151.6 82.6 129.4 73.9 
Δ with WBVT  -4.4 -1.0 1.1 6.3 -6.7 4.9 
p 0.261 0.741 0.855 0.271 0.164 0.288 
Visit 4 
Value 117.3 74.1 152.7 88.9 122.7 78.1 
Δ in Follow-up  4.8 0.8 -2.5 -1.7 9.2 2.3 
p 0.257 0.816 0.702 0.778 0.097 0.653 
Visit 6 Value 122.0 74.9 150.2 87.2 131.9 81 
Note: Δ, change; WBVT, whole body vibration training; VO2, oxygen uptake; HR, heart rate; bpm, beats per minute; O2, oxygen; VCO2, carbon 
dioxide production; RQ, respiratory quotient; VE, minute ventilation; VE/VO2, ventilator equivalent of oxygen; VE/VCO2, ventilator equivalent 
of carbon dioxide; AT, anaerobic threshold.
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Appendix F: Quality of Life Parameters 
 
Table F.1 CF Cohort 
Table F.2 Paediatric MRCD Cohort 
Table F.3 Adult MRCD Cohort 
Table F.4 Leigh Syndrome Cohort 
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Table F.1. Quality of Life parameters for the CF cohort at each visit with changes between visits and associated p values from linear mixed 
models analysis. *p<0.05. 
  Physical 
Domain 
Emotion 
Domain 
Eating 
Domain 
Body Domain Treatment 
Burden 
Domain 
Respiratory 
Domain 
Visit 1 
Value 81.9 80.5 81.3 82.0 61.1 73.4 
Δ in Observation  -1.1 1.9 5.6 2.1 3.5 2.6 
p 0.664 0.519 0.209 0.675 0.454 0.542 
Visit 2 
Value 80.8 82.4 86.8 84.0 64.6 76.0 
Δ with WVBT  3.0 2.2 0.0 4.9 -2.1 -2.3 
p 0.259 0.451 0.999 0.299 0.655 0.599 
Visit 3 
Value 83.8 84.6 86.8 88.9 62.5 73.8 
Δ in Follow-up  -3.3 0.5 4.5 -4.0 1.5 4.9 
p 0.218 0.857 0.320 0.405 0.757 0.262 
Visit 4 Value 80.4 85.1 91.3 84.9 64.0 78.7 
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  Digestion 
Domain 
Social Domain Health 
Perceptions 
Domain (Adult 
Version) 
Role Domain 
(Adult 
Version) 
Weight 
Domain (Adult 
Version) 
Body Image 
Domain 
(Parent 
Version) 
Visit 1 
Value 79.2 73.7 72.8 71.1 60.3 82.7 
Δ in Observation  10.4 2.4 0.6 6.3 10.2 -4.9 
p 0.017* 0.429 0.917 0.172 0.190 0.500 
Visit 2 
Value 89.6 76.1 73.3 77.5 70.5 77.8 
Δ with WVBT  -4.2 2.5 -4.1 -2.0 0.7 9.6 
p 0.327 0.408 0.453 0.665 0.922 0.215 
Visit 3 
Value 85.4 78.6 69.2 75.5 71.2 87.4 
Δ in Follow-up  3.3 -2.2 -2.6 3.2 -8.3 2.9 
p 0.443 0.490 0.617 0.454 0.252 0.758 
Visit 4 Value 88.8 76.5 66.7 78.7 63.0 90.3 
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  Physical 
Domain 
(Parent 
Version) 
Emotion 
Domain 
(Parent 
Version) 
Vitality 
Domain 
(Parent 
Version) 
School Domain 
(Parent 
Version) 
Eating Domain 
(Parent 
Version) 
Weight 
Domain 
(Parent 
Version) 
Visit 1 
Value 92.6 91.1 74.1 80.3 70.4 51.9 
Δ in Observation  -0.8 -4.5 -5.2 -8.7 -1.9 7.4 
p 0.813 0.067 0.346 0.323 0.834 0.518 
Visit 2 
Value 91.8 86.7 68.9 71.6 68.5 59.3 
Δ with WVBT  0.7 5.8 4.1 19.1 2.8 6.1 
p 0.843 0.026* 0.477 0.043* 0.762 0.611 
Visit 3 
Value 92.5 92.5 72.9 90.7 71.4 65.3 
Δ in Follow-up  -2.9 7.2 5.1 -12.6 19.5 21.4 
p 0.513 0.026* 0.452 0.247 0.099 0.153 
Visit 4 Value 89.6 99.7 78.1 78.2 90.9 86.7 
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  Treatment Burden 
Domain (Parent 
Version) 
Health Perceptions 
Domain (Parent 
Version) 
Respiratory Domain 
(Parent Version) 
Digestion Domain 
(Parent Version) 
Visit 1 
Value 72.8 86.4 87.0 74.1 
Δ in Observation  -9.3 -6.2 -10.5 3.7 
p 0.085 0.194 0.046* 0.570 
Visit 2 
Value 63.6 80.3 76.5 77.8 
Δ with WVBT  7.9 4.6 -2.2 -3.5 
p 0.159 0.350 0.668 0.612 
Visit 3 
Value 71.5 84.9 74.3 74.3 
Δ in Follow-up  2.2 -0.2 13.5 2.0 
p 0.749 0.979 0.037* 0.816 
Visit 4 Value 73.6 84.7 87.9 76.3 
Note: Δ, change; WBVT, whole body vibration training 
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Table F.2: Quality of life parameters for the paediatric MRCD cohort at each visit with changes between visits and associated p values from 
linear mixed models analysis. *p<0.05. 
  NMPDS 1 Total NMPDS 2 Total NMPDS 3 Total NMPDS 4 Total 
Visit 1 
Value 4.7 1.1 10.1 9.2 
Δ in Observation 1.9 0.1 1.3 1.1 
p 0.000* 0.696 0.077 0.115 
Visit 2 
Value 6.6 1.3 11.4 10.3 
Δ with WBVT  -0.3 0.4 -0.6 -1.2 
p 0.484 0.249 0.415 0.104 
Visit 3 
Value 6.3 1.7 10.9 9.2 
Δ in Follow-up  0.0 0.6 1.0 -1.2 
p 1.000 0.129 0.161 0.103 
Visit 4 Value 6.3 2.3 11.9 8.0 
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Table F.3: Quality of life parameters for the adult MRCD cohort at each visit with changes between visits and associated p values from linear 
mixed models analysis. *p<0.05. 
  NMDAS 1 
Total 
NMDAS 2 
Total 
NMDAS 3 
Total 
PF NBS SDS RP NBS SDS BP NBS SDS 
Visit 1 
Value 9.8 5.0 10.2 -1.5 -1.1 -1.0 
Δ in Observation 1.5 0.4 -0.5 -0.1 -0.3 0.5 
p 0.145 0.577 0.423 0.705 0.275 0.116 
Visit 2 
Value 11.3 5.4 9.7 -1.6 -1.4 -0.5 
Δ with WBVT  -1.8 -0.2 -1.7 -0.2 0.5 0.0 
p 0.083 0.780 0.010* 0.440 0.074 1.000 
Visit 3 
Value 9.5 5.2 8.0 -1.8 -0.9 -0.5 
Δ in Follow-up  0.7 0.8 0.9 0.0 -0.2 0.3 
p 0.490 0.269 0.155 1.000 0.361 0.339 
Visit 4 Value 10.2 6.0 8.9 -1.8 -1.1 -0.2 
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  GH NBS 
SDS 
VT NBS SDS SF NBS SDS RE NBS SDS MH NBS 
SDS 
PCS SDS MCS SDS 
Visit 1 
Value -1.3 -0.6 -0.6 -0.1 0.2 -1.7 0.3 
Δ in Observation 0.4 0.3 0.0 0.2 0.1 0.1 0.2 
p 0.175 0.311 1.000 0.460 0.801 0.681 0.497 
Visit 2 
Value -0.9 -0.3 -0.6 0.1 0.2 -1.6 0.503 
Δ with WBVT  -0.2 -0.1 0.0 -0.2 -0.2 0.1 -0.2 
p 0.469 0.7933 1.000 0.327 0.453 0.612 0.376 
Visit 3 
Value -1.1 -0.4 -0.6 -0.2 0.1 -1.5 0.3 
Δ in Follow-up  0.2 -0.3 -0.1 -0.1 -0.1 0.1 -0.2 
p 0.469 0.311 0.735 0.805 0.802 0.704 0.534 
Visit 4 Value -0.9 -0.7 -0.7 -0.2 0.0 -1.4 0.1 
Note: Δ, change; WBVT, whole body vibration training; NMDAS, Newcastle Disease Adult Scale; PF, physical functioning domain; NBS, 
norm-based score; SDS, standard deviation score; RP, role limitation domain; BP, bodily pain domain; GH,  general health. 
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Table F.4: Quality of life parameters for the Leigh Syndrome MRCD cohort at each visit with changes between visits and associated p values 
from linear mixed models analysis. *p<0.05. 
Note: Δ, change; WBVT, whole body vibration training; NMPDS, Newcastle Mitochondrial Paediatric Disease Scale. 
  NMPDS 1 Total NMPDS 2 Total NMPDS 3 Total NMPDS 4 Total 
Visit 1 
Value 4.0 0.6 9.6 8.0 
Δ in Observation 0.2 -0.2 0.4 0.3 
p 0.825 0.670 0.493 0.738 
Visit 2 
Value 4.2 0.4 10.0 8.3 
Δ with WBVT  0.4 -0.4 -0.6 -0.1 
p 0.659 0.401 0.310 0.953 
Visit 3 
Value 4.6 0.0 9.4 8.2 
Δ in Follow-up  0.2 0.4 1.8 0.4 
p 0.825 0.401 0.008* 0.679 
Visit 4 Value 4.8 0.4 11.2 8.6 
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Appendix G: Lung Function Parameters 
 
 
 
Table G.1 CF Cohort 
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Table G.1. Lung function parameters for the CF cohort at each visit with changes between visits and associated p values from linear 
mixed models analysis. *p<0.05. 
  FEV1 (L)  
(n=13) 
FEV1 
(% predicted) 
FVC (L) FVC 
 (% Predicted) 
FEV1/FVC  
(%) 
Visit 1 
Value 2.4 84.4 3.0 92.3 79.2 
Δ in Observation  0.3 -2.4 0.1 0.3 -2.6 
p 0.909 0.329 0.163 0.893 0.041* 
Visit 2 
Value 2.4 82.0 3.1 92.6 76.6 
Δ with WVBT  0.1 0.1 0.2 -0.5 0.2 
p 0.117 0.975 0.114 0.814 0.809 
Visit 3 
Value 2.5 82.1 3.3 92.1 76.8 
Δ in Follow-up  0.0 -1.9 0.0 -2.0 -1.0 
p 0.958 0.449 0.765 0.384 0.298 
Visit 4 Value 2.5 80.2 3.3 90.1 75.8 
 
 656 
  FEF25-75 (L) FEF 25-75 
(% predicted) 
RV/TLC (%) 
(n=12) 
LCI  
(n=16) 
Visit 1 
Value 2.3 73.5 27.5 7.8 
Δ in Observation  -0.2 -8.9 -0.8 0.1 
p 0.060 0.007* 0.669 0.632 
Visit 2 
Value 2.1 64.6 26.8 7.9 
Δ with WVBT  0.2 2.4 2.3 0.3 
p 0.121 0.443 0.188 0.151 
Visit 3 
Value 2.3 67.0 29.1 8.2 
Δ in Follow-up  0.0 -0.9 -0.6 0.2 
p 0.859 0.785 0.739 0.509 
Visit 4 Value 2.3 66.2 28.5 8.4 
Note: Δ, change; WBVT, whole-body vibration training; FEV1, forced expiratory volume in the first second; FVC, forced vital 
capacity; FEF, forced expiratory flow at 25-75% of lung volume; RV, residual volume; TLC, total lung capacity; LCI, lung clearance 
index.
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Appendix H: Anthropometric Parameters 
 
 
 
Table H.1 CF Cohort 
Table H.2 Paediatric MRCD Cohort 
Table H.3 Adult MRCD Cohort 
Table H.4 Leigh Syndrome Cohort 
 658 
 
Table H.1. Anthropometric parameters for the CF cohort at each visit with changes between visits and associated p values from linear 
mixed models analysis. *p<0.05. 
 
  Height (cm) Height SDS Weight (kg) Weight SDS BMI (kg/m
2
) BMI SDS 
Visit 1 
Value 151.6 0.0 40.5 -0.6 17.1 -0.7 
Δ in Observation  2.6 0.0 2.7 0.1 0.5 0.1 
p 0.000* 0.509 0.000* 0.170 0.005* 0.135 
Visit 2 
Value 154.2 0.0 43.2 -0.5 17.6 -0.6 
Δ with WVBT  2.5 0.1 1.0 -0.1 0.0 -0.1 
p 0.000* 0.137 0.064 0.211 0.815 0.148 
Visit 3 
Value 156.7 0.0 44.1 -0.5 17.5 -0.7 
Δ in Follow-up  2.2 0.1 2.1 0.1 0.4 0.1 
p 0.000* 0.145 0.000* 0.369 0.041* 0.503 
Visit 4 Value 158.9 0.1 46.2 -0.5 17.9 -0.7 
Note: Δ, change; SDS, standard deviation score; BMI, body mass index. 
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Table H.2. Anthropometric parameters for the paediatric MRCD cohort at each visit with changes between visits and associated p 
values from linear mixed models analysis. *p<0.05. 
 
  Height (cm) Height SDS Weight (kg) Weight SDS BMI (kg/m
2
) BMI SDS 
Visit 1 
Value 134.7 -2.1 29.4 -2.3 16.0 -1.4 
Δ in Observation 1.8 0.1 0.8 0.1 0.0 0.0 
p 0.017* 0.135 0.183 0.625 0.954 0.997 
Visit 2 
Value 136.4 -1.9 30.2 -2.2 16.0 -1.4 
Δ with WBVT  1.8 -0.1 1.3 -0.1 0.3 0.0 
p 0.017* 0.459 0.045* 0.701 0.366 0.907 
Visit 3 
Value 138.2 -2.0 31.5 -2.3 16.3 -1.4 
Δ in Follow-up  1.6 -0.1 0.8 -0.2 0.1 -0.2 
p 0.030* 0.283 0.190 0.160 0.730 0.421 
Visit 4 Value 139.8 -2.1 32.3 -2.5 16.4 -1.56 
Note: Δ, change; SDS, standard deviation score; BMI, body mass index.
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Table H.3. Anthropometric parameters for the adult MRCD cohort at each visit with 
changes between visits and associated p values from linear mixed models analysis. 
*p<0.05. 
 
  Height (cm) Weight (kg) BMI (kg/m
2
) 
Visit 1 
Value 166.8 64.3 23.2 
Δ in Observation 0.2 0.6 0.2 
p 0.220 0.289 0.429 
Visit 2 
Value 166.9 64.9 23.4 
Δ with WBVT  -0.1 -0.2 -0.1 
p 0.300 0.684 0.651 
Visit 3 
Value 166.8 64.7 23.3 
Δ in Follow-up 0.1 -0.6 -0.3 
p 0.364 0.349 0.181 
Visit 4 Value 166.9 64.1 23.0 
Note: Δ, change; BMI, body mass index.
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Table H.4. Anthropometric parameters for the Leigh Syndrome MRCD cohort at each 
visit with changes between visits and associated p values from linear mixed models 
analysis. *p<0.05. 
 
  Height (cm) Weight (kg) BMI (kg/m
2
) 
Visit 1 
Value 144.8 47.6 20.2 
Δ in Observation 1.6 0.6 -0.1 
p 0.094 0.340 0.680 
Visit 2 
Value 146.4 48.3 20.1 
Δ with WBVT  1.5 1.7 0.4 
p 0.117 0.019* 0.218 
Visit 3 
Value 148.0 50.0 20.5 
Δ in Follow-up  1.6 2.3 0.6 
p 0.101 0.004* 0.090 
Visit 4 Value 149.6 52.3 21.1 
Note: Δ, change; BMI, body mass index. 
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